22	B-CHED
-	I-CHED
oxacalcitriol	I-CHED
suppresses	O
secondary	O
hyperparathyroidism	O
without	O
inducing	O
low	O
bone	O
turnover	O
in	O
dogs	O
with	O
renal	O
failure	O
.	O

BACKGROUND	O
:	O
Calcitriol	B-CHED
therapy	O
suppresses	O
serum	O
levels	O
of	O
parathyroid	O
hormone	O
(	O
PTH	O
)	O
in	O
patients	O
with	O
renal	O
failure	O
but	O
has	O
several	O
drawbacks	O
,	O
including	O
hypercalcemia	O
and	O
/	O
or	O
marked	O
suppression	O
of	O
bone	O
turnover	O
,	O
which	O
may	O
lead	O
to	O
adynamic	O
bone	O
disease	O
.	O

A	O
new	O
vitamin	B-CHED
D	I-CHED
analogue	O
,	O
22	B-CHED
-	I-CHED
oxacalcitriol	I-CHED
(	O
OCT	B-CHED
)	O
,	O
has	O
been	O
shown	O
to	O
have	O
promising	O
characteristics	O
.	O

This	O
study	O
was	O
undertaken	O
to	O
determine	O
the	O
effects	O
of	O
OCT	B-CHED
on	O
serum	O
PTH	O
levels	O
and	O
bone	O
turnover	O
in	O
states	O
of	O
normal	O
or	O
impaired	O
renal	O
function	O
.	O

METHODS	O
:	O
Sixty	O
dogs	O
were	O
either	O
nephrectomized	O
(	O
Nx	O
,	O
N	O
=	O
38	O
)	O
or	O
sham	O
-	O
operated	O
(	O
Sham	O
,	O
N	O
=	O
22	O
)	O
.	O

The	O
animals	O
received	O
supplemental	O
phosphate	B-CHED
to	O
enhance	O
PTH	O
secretion	O
.	O

Fourteen	O
weeks	O
after	O
the	O
start	O
of	O
phosphate	B-CHED
supplementation	O
,	O
half	O
of	O
the	O
Nx	O
and	O
Sham	O
dogs	O
received	O
doses	O
of	O
OCT	B-CHED
(	O
three	O
times	O
per	O
week	O
)	O
;	O
the	O
other	O
half	O
were	O
given	O
vehicle	O
for	O
60	O
weeks	O
.	O

Thereafter	O
,	O
the	O
treatment	O
modalities	O
for	O
a	O
subset	O
of	O
animals	O
were	O
crossed	O
over	O
for	O
an	O
additional	O
eight	O
months	O
.	O

Biochemical	O
and	O
hormonal	O
indices	O
of	O
calcium	B-CHED
and	O
bone	O
metabolism	O
were	O
measured	O
throughout	O
the	O
study	O
,	O
and	O
bone	O
biopsies	O
were	O
done	O
at	O
baseline	O
,	O
60	O
weeks	O
after	O
OCT	B-CHED
or	O
vehicle	O
treatment	O
,	O
and	O
at	O
the	O
end	O
of	O
the	O
crossover	O
period	O
.	O

RESULTS	O
:	O
In	O
Nx	O
dogs	O
,	O
OCT	B-CHED
significantly	O
decreased	O
serum	O
PTH	O
levels	O
soon	O
after	O
the	O
induction	O
of	O
renal	O
insufficiency	O
.	O

In	O
long	O
-	O
standing	O
secondary	O
hyperparathyroidism	O
,	O
OCT	B-CHED
(	O
0	O
.	O
03	O
microg	O
/	O
kg	O
)	O
stabilized	O
serum	O
PTH	O
levels	O
during	O
the	O
first	O
months	O
.	O

Serum	O
PTH	O
levels	O
rose	O
thereafter	O
,	O
but	O
the	O
rise	O
was	O
less	O
pronounced	O
compared	O
with	O
baseline	O
than	O
the	O
rise	O
seen	O
in	O
Nx	O
control	O
.	O

These	O
effects	O
were	O
accompanied	O
by	O
episodes	O
of	O
hypercalcemia	O
and	O
hyperphosphatemia	O
.	O

In	O
animals	O
with	O
normal	O
renal	O
function	O
,	O
OCT	B-CHED
induced	O
a	O
transient	O
decrease	O
in	O
serum	O
PTH	O
levels	O
at	O
a	O
dose	O
of	O
0	O
.	O
1	O
microg	O
/	O
kg	O
,	O
which	O
was	O
not	O
sustained	O
with	O
lowering	O
of	O
the	O
doses	O
.	O

In	O
Nx	O
dogs	O
,	O
OCT	B-CHED
reversed	O
abnormal	O
bone	O
formation	O
,	O
such	O
as	O
woven	O
osteoid	O
and	O
fibrosis	O
,	O
but	O
did	O
not	O
significantly	O
alter	O
the	O
level	O
of	O
bone	O
turnover	O
.	O

In	O
addition	O
,	O
OCT	B-CHED
improved	O
mineralization	O
lag	O
time	O
,	O
(	O
that	O
is	O
,	O
the	O
rate	O
at	O
which	O
osteoid	O
mineralizes	O
)	O
in	O
both	O
Nx	O
and	O
Sham	O
dogs	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
indicate	O
that	O
even	O
though	O
OCT	B-CHED
does	O
not	O
completely	O
prevent	O
the	O
occurrence	O
of	O
hypercalcemia	O
in	O
experimental	O
dogs	O
with	O
renal	O
insufficiency	O
,	O
it	O
may	O
be	O
of	O
use	O
in	O
the	O
management	O
of	O
secondary	O
hyperparathyroidism	O
because	O
it	O
does	O
not	O
induce	O
low	O
bone	O
turnover	O
and	O
,	O
therefore	O
,	O
does	O
not	O
increase	O
the	O
risk	O
of	O
adynamic	O
bone	O
disease	O
.	O

Hypotension	O
,	O
bradycardia	O
,	O
and	O
asystole	O
after	O
high	O
-	O
dose	O
intravenous	O
methylprednisolone	B-CHED
in	O
a	O
monitored	O
patient	O
.	O

We	O
report	O
a	O
case	O
of	O
hypotension	O
,	O
bradycardia	O
,	O
and	O
asystole	O
after	O
intravenous	O
administration	O
of	O
high	O
-	O
dose	O
methylprednisolone	B-CHED
in	O
a	O
73	O
-	O
year	O
-	O
old	O
patient	O
who	O
underwent	O
electrocardiographic	O
(	O
ECG	O
)	O
monitoring	O
throughout	O
the	O
episode	O
.	O

There	O
was	O
a	O
history	O
of	O
ischemic	O
cardiac	O
disease	O
9	O
years	O
earlier	O
.	O

The	O
patient	O
was	O
admitted	O
with	O
a	O
pulmonary	O
-	O
renal	O
syndrome	O
with	O
hemoptysis	O
,	O
rapidly	O
progressive	O
renal	O
failure	O
,	O
and	O
hypoxemia	O
that	O
required	O
mechanical	O
ventilation	O
in	O
the	O
intensive	O
care	O
unit	O
.	O

After	O
receiving	O
advanced	O
cardiopulmonary	O
resuscitation	O
,	O
the	O
patient	O
recovered	O
cardiac	O
rhythm	O
.	O

The	O
ECG	O
showed	O
a	O
junctional	O
rhythm	O
without	O
ventricular	O
arrhythmia	O
.	O

This	O
study	O
reviews	O
the	O
current	O
proposed	O
mechanisms	O
of	O
sudden	O
death	O
after	O
a	O
high	O
dose	O
of	O
intravenous	O
methylprednisolone	B-CHED
(	O
IVMP	B-CHED
)	O
.	O

These	O
mechanisms	O
are	O
not	O
well	O
understood	O
because	O
,	O
in	O
most	O
cases	O
,	O
the	O
patients	O
were	O
not	O
monitored	O
at	O
the	O
moment	O
of	O
the	O
event	O
.	O

Rapid	O
infusion	O
and	O
underlying	O
cardiac	O
disease	O
were	O
important	O
risk	O
factors	O
in	O
the	O
case	O
reported	O
here	O
,	O
and	O
the	O
authors	O
discount	O
ventricular	O
arrhythmia	O
as	O
the	O
main	O
mechanism	O
.	O

Worsening	O
of	O
levodopa	B-CHED
-	O
induced	O
dyskinesias	O
by	O
motor	O
and	O
mental	O
tasks	O
.	O

Ten	O
patients	O
who	O
had	O
Parkinson	O
'	O
s	O
disease	O
with	O
disabling	O
dyskinesia	O
were	O
included	O
in	O
this	O
study	O
to	O
evaluate	O
the	O
role	O
of	O
mental	O
(	O
mental	O
calculation	O
)	O
and	O
motor	O
(	O
flexion	O
/	O
extension	O
of	O
right	O
fingers	O
,	O
flexion	O
/	O
extension	O
of	O
left	O
fingers	O
,	O
flexion	O
/	O
extension	O
of	O
the	O
neck	O
,	O
speaking	O
aloud	O
)	O
tasks	O
on	O
the	O
worsening	O
of	O
peak	O
-	O
dose	O
dyskinesia	O
following	O
administration	O
of	O
an	O
effective	O
single	O
dose	O
of	O
apomorphine	B-CHED
.	O

Compared	O
with	O
the	O
score	O
at	O
rest	O
(	O
1	O
.	O
3	O
+	O
/	O
-	O
0	O
.	O
3	O
)	O
,	O
a	O
significant	O
aggravation	O
of	O
the	O
dyskinesia	O
score	O
was	O
observed	O
during	O
speaking	O
aloud	O
(	O
5	O
.	O
2	O
+	O
/	O
-	O
1	O
.	O
1	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
movements	O
of	O
right	O
(	O
4	O
.	O
5	O
+	O
/	O
-	O
1	O
.	O
0	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
left	O
(	O
3	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
8	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
fingers	O
,	O
movements	O
of	O
the	O
neck	O
(	O
5	O
.	O
1	O
+	O
/	O
-	O
1	O
.	O
0	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
and	O
mental	O
calculation	O
(	O
3	O
.	O
1	O
+	O
/	O
-	O
1	O
.	O
0	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

These	O
results	O
suggest	O
that	O
activation	O
tasks	O
such	O
as	O
"	O
speaking	O
aloud	O
"	O
could	O
be	O
used	O
for	O
objective	O
assessment	O
of	O
dyskinesia	O
severity	O
.	O

Urine	O
N	O
-	O
acetyl	O
-	O
beta	O
-	O
D	O
-	O
glucosaminidase	O
-	O
-	O
a	O
marker	O
of	O
tubular	O
damage	O
?	O

BACKGROUND	O
:	O
Although	O
an	O
indicator	O
of	O
renal	O
tubular	O
dysfunction	O
,	O
an	O
increased	O
urinary	O
N	O
-	O
acetyl	O
-	O
beta	O
-	O
D	O
-	O
glucosaminidase	O
(	O
NAG	O
)	O
activity	O
might	O
reflect	O
increased	O
lysosomal	O
activity	O
in	O
renal	O
tubular	O
cells	O
.	O

METHODS	O
:	O
Puromycin	B-CHED
aminonucleoside	I-CHED
(	O
PAN	B-CHED
)	O
was	O
administered	O
to	O
Sprague	O
Dawley	O
rats	O
to	O
induce	O
proteinuria	O
.	O

Total	O
protein	O
,	O
albumin	O
,	O
NAG	O
activity	O
and	O
protein	O
electrophoretic	O
pattern	O
were	O
assessed	O
in	O
daily	O
urine	O
samples	O
for	O
33	O
days	O
.	O

The	O
morphological	O
appearance	O
of	O
the	O
kidneys	O
was	O
examined	O
on	O
days	O
three	O
,	O
four	O
,	O
six	O
,	O
eight	O
and	O
thirty	O
three	O
and	O
the	O
NAG	O
isoenzyme	O
patterns	O
on	O
days	O
zero	O
,	O
four	O
,	O
eight	O
and	O
thirty	O
three	O
.	O

RESULTS	O
:	O
Following	O
intravenous	O
PAN	B-CHED
urine	O
volume	O
and	O
urine	O
NAG	O
activity	O
increased	O
significantly	O
by	O
day	O
two	O
,	O
but	O
returned	O
to	O
normal	O
by	O
day	O
four	O
.	O

After	O
day	O
four	O
all	O
treated	O
animals	O
exhibited	O
a	O
marked	O
rise	O
in	O
urine	O
albumin	O
,	O
total	O
protein	O
excretion	O
and	O
NAG	O
activity	O
.	O

Electrophoresis	O
showed	O
a	O
generalised	O
increase	O
in	O
middle	O
and	O
high	O
molecular	O
weight	O
urine	O
proteins	O
from	O
day	O
four	O
onwards	O
.	O

Protein	O
droplets	O
first	O
appeared	O
prominent	O
in	O
tubular	O
cells	O
on	O
day	O
four	O
.	O

Peak	O
urine	O
NAG	O
activity	O
and	O
a	O
change	O
in	O
NAG	O
isoenzyme	O
pattern	O
coincided	O
with	O
both	O
the	O
peak	O
proteinuria	O
and	O
the	O
reduction	O
in	O
intracellular	O
protein	O
and	O
NAG	O
droplets	O
(	O
day	O
six	O
onwards	O
)	O
.	O

CONCLUSIONS	O
:	O
This	O
animal	O
model	O
demonstrates	O
that	O
an	O
increase	O
in	O
lysosomal	O
turnover	O
and	O
hence	O
urine	O
NAG	O
activity	O
,	O
occurs	O
when	O
increased	O
protein	O
is	O
presented	O
to	O
the	O
tubular	O
cells	O
.	O

Urine	O
NAG	O
activity	O
is	O
thus	O
a	O
measure	O
of	O
altered	O
function	O
in	O
the	O
renal	O
tubules	O
and	O
not	O
simply	O
an	O
indicator	O
of	O
damage	O
.	O

Cauda	O
equina	O
syndrome	O
after	O
spinal	O
anaesthesia	O
with	O
hyperbaric	O
5	O
%	O
lignocaine	B-CHED
:	O
a	O
review	O
of	O
six	O
cases	O
of	O
cauda	O
equina	O
syndrome	O
reported	O
to	O
the	O
Swedish	O
Pharmaceutical	O
Insurance	O
1993	O
-	O
1997	O
.	O

Six	O
cases	O
of	O
cauda	O
equina	O
syndrome	O
with	O
varying	O
severity	O
were	O
reported	O
to	O
the	O
Swedish	O
Pharmaceutical	O
Insurance	O
during	O
the	O
period	O
1993	O
-	O
1997	O
.	O

All	O
were	O
associated	O
with	O
spinal	O
anaesthesia	O
using	O
hyperbaric	O
5	O
%	O
lignocaine	B-CHED
.	O

Five	O
cases	O
had	O
single	O
-	O
shot	O
spinal	O
anaesthesia	O
and	O
one	O
had	O
a	O
repeat	O
spinal	O
anaesthetic	O
due	O
to	O
inadequate	O
block	O
.	O

The	O
dose	O
of	O
hyperbaric	O
5	O
%	O
lignocaine	B-CHED
administered	O
ranged	O
from	O
60	O
to	O
120	O
mg	O
.	O

Three	O
of	O
the	O
cases	O
were	O
most	O
likely	O
caused	O
by	O
direct	O
neurotoxicity	O
of	O
hyperbaric	O
5	O
%	O
lignocaine	B-CHED
.	O

In	O
the	O
other	O
3	O
cases	O
,	O
direct	O
neurotoxicity	O
was	O
also	O
probable	O
,	O
but	O
unfortunately	O
radiological	O
investigations	O
were	O
not	O
done	O
to	O
definitely	O
exclude	O
a	O
compressive	O
aetiology	O
.	O

All	O
cases	O
sustained	O
permanent	O
neurological	O
deficits	O
.	O

We	O
recommend	O
that	O
hyperbaric	O
lignocaine	B-CHED
should	O
be	O
administered	O
in	O
concentrations	O
not	O
greater	O
than	O
2	O
%	O
and	O
at	O
a	O
total	O
dose	O
preferably	O
not	O
exceeding	O
60	O
mg	O
.	O

Systemic	O
toxicity	O
following	O
administration	O
of	O
sirolimus	B-CHED
(	O
formerly	O
rapamycin	B-CHED
)	O
for	O
psoriasis	O
:	O
association	O
of	O
capillary	O
leak	O
syndrome	O
with	O
apoptosis	O
of	O
lesional	O
lymphocytes	O
.	O

BACKGROUND	O
:	O
Sirolimus	B-CHED
(	O
formerly	O
rapamycin	B-CHED
)	O
is	O
an	O
immunosuppressive	O
agent	O
that	O
interferes	O
with	O
T	O
-	O
cell	O
activation	O
.	O

After	O
2	O
individuals	O
with	O
psoriasis	O
developed	O
a	O
capillary	O
leak	O
syndrome	O
following	O
treatment	O
with	O
oral	O
sirolimus	B-CHED
lesional	O
skin	O
cells	O
and	O
activated	O
peripheral	O
blood	O
cells	O
were	O
analyzed	O
for	O
induction	O
of	O
apoptosis	O
.	O

OBSERVATIONS	O
:	O
A	O
keratome	O
skin	O
specimen	O
from	O
1	O
patient	O
with	O
sirolimus	B-CHED
-	O
induced	O
capillary	O
leak	O
syndrome	O
had	O
a	O
2	O
.	O
3	O
-	O
fold	O
increase	O
in	O
percentage	O
of	O
apoptotic	O
cells	O
(	O
to	O
48	O
%	O
)	O
compared	O
with	O
an	O
unaffected	O
sirolimus	B-CHED
-	O
treated	O
patient	O
with	O
psoriasis	O
(	O
21	O
%	O
)	O
.	O

Activated	O
peripheral	O
blood	O
T	O
cells	O
from	O
patients	O
with	O
psoriasis	O
tended	O
to	O
exhibit	O
greater	O
spontaneous	O
or	O
dexamethasone	B-CHED
-	O
induced	O
apoptosis	O
than	O
did	O
normal	O
T	O
cells	O
,	O
particularly	O
in	O
the	O
presence	O
of	O
sirolimus	B-CHED
.	O

CONCLUSIONS	O
:	O
Severe	O
adverse	O
effects	O
of	O
sirolimus	B-CHED
include	O
fever	O
,	O
anemia	O
,	O
and	O
capillary	O
leak	O
syndrome	O
.	O

These	O
symptoms	O
may	O
be	O
the	O
result	O
of	O
drug	O
-	O
induced	O
apoptosis	O
of	O
lesional	O
leukocytes	O
,	O
especially	O
activated	O
T	O
lymphocytes	O
,	O
and	O
possibly	O
release	O
of	O
inflammatory	O
mediators	O
.	O

Because	O
patients	O
with	O
severe	O
psoriasis	O
may	O
develop	O
capillary	O
leak	O
from	O
various	O
systemic	O
therapies	O
,	O
clinical	O
monitoring	O
is	O
advisable	O
for	O
patients	O
with	O
inflammatory	O
diseases	O
who	O
are	O
treated	O
with	O
immune	O
modulators	O
.	O

Effect	O
of	O
lithium	B-CHED
maintenance	O
therapy	O
on	O
thyroid	O
and	O
parathyroid	O
function	O
.	O

OBJECTIVES	O
:	O
To	O
assess	O
changes	O
induced	O
by	O
lithium	B-CHED
maintenance	O
therapy	O
on	O
the	O
incidence	O
of	O
thyroid	O
,	O
parathyroid	O
and	O
ion	O
alterations	O
.	O

These	O
were	O
evaluated	O
with	O
respect	O
to	O
the	O
duration	O
of	O
lithium	B-CHED
therapy	O
,	O
age	O
,	O
sex	O
,	O
and	O
family	O
history	O
(	O
whether	O
or	O
not	O
the	O
patient	O
had	O
a	O
first	O
-	O
degree	O
relative	O
with	O
thyroid	O
disease	O
)	O
.	O

DESIGN	O
:	O
Prospective	O
study	O
.	O

SETTING	O
:	O
Affective	O
Disorders	O
Clinic	O
at	O
St	O
.	O

Mary	O
'	O
s	O
Hospital	O
,	O
Montreal	O
.	O

PATIENTS	O
:	O
One	O
hundred	O
and	O
one	O
patients	O
(	O
28	O
men	O
and	O
73	O
women	O
)	O
with	O
bipolar	O
disorder	O
receiving	O
lithium	B-CHED
maintenance	O
therapy	O
ranging	O
from	O
1	O
year	O
'	O
s	O
to	O
32	O
years	O
'	O
duration	O
.	O

The	O
control	O
group	O
consisted	O
of	O
82	O
patients	O
with	O
no	O
psychiatric	O
or	O
endocrinological	O
diagnoses	O
from	O
the	O
hospital	O
'	O
s	O
out	O
-	O
patient	O
clinics	O
.	O

OUTCOME	O
MEASURES	O
:	O
Laboratory	O
analyses	O
of	O
calcium	B-CHED
,	O
magnesium	B-CHED
and	O
thyroid	O
-	O
stimulating	O
hormone	O
levels	O
performed	O
before	O
beginning	O
lithium	B-CHED
therapy	O
and	O
at	O
biannual	O
follow	O
-	O
up	O
.	O

RESULTS	O
:	O
Hypothyroidism	O
developed	O
in	O
40	O
patients	O
,	O
excluding	O
8	O
patients	O
who	O
were	O
hypothyroid	O
at	O
baseline	O
.	O

All	O
patients	O
having	O
first	O
-	O
degree	O
relatives	O
affected	O
by	O
thyroid	O
illness	O
had	O
accelerated	O
onset	O
of	O
hypothyroidism	O
(	O
3	O
.	O
7	O
years	O
after	O
onset	O
of	O
lithium	B-CHED
therapy	O
)	O
compared	O
with	O
patients	O
without	O
a	O
family	O
history	O
(	O
8	O
.	O
6	O
years	O
after	O
onset	O
of	O
lithium	B-CHED
therapy	O
)	O
.	O

Women	O
over	O
60	O
years	O
of	O
age	O
were	O
more	O
often	O
affected	O
by	O
hypothyroidism	O
than	O
women	O
under	O
60	O
years	O
of	O
age	O
(	O
34	O
.	O
6	O
%	O
versus	O
31	O
.	O
9	O
%	O
)	O
.	O

Magnesium	B-CHED
levels	O
in	O
patients	O
on	O
lithium	B-CHED
treatment	O
were	O
unchanged	O
from	O
baseline	O
levels	O
.	O

After	O
lithium	B-CHED
treatment	O
,	O
calcium	B-CHED
levels	O
were	O
higher	O
than	O
either	O
baseline	O
levels	O
or	O
control	O
levels	O
.	O

Thus	O
,	O
lithium	B-CHED
treatment	O
counteracted	O
the	O
decrease	O
in	O
plasma	O
calcium	B-CHED
levels	O
associated	O
with	O
aging	O
.	O

CONCLUSIONS	O
:	O
Familial	O
thyroid	O
illness	O
is	O
a	O
risk	O
factor	O
for	O
hypothyroidism	O
and	O
hypercalcemia	O
during	O
lithium	B-CHED
therapy	O
.	O

Severe	O
immune	O
hemolytic	O
anemia	O
associated	O
with	O
prophylactic	O
use	O
of	O
cefotetan	B-CHED
in	O
obstetric	O
and	O
gynecologic	O
procedures	O
.	O

Second	O
-	O
and	O
third	O
-	O
generation	O
cephalosporins	B-CHED
,	O
especially	O
cefotetan	B-CHED
,	O
are	O
increasingly	O
associated	O
with	O
severe	O
,	O
sometimes	O
fatal	O
immune	O
hemolytic	O
anemia	O
.	O

We	O
noticed	O
that	O
10	O
of	O
our	O
35	O
cases	O
of	O
cefotetan	B-CHED
-	O
induced	O
hemolytic	O
anemias	O
were	O
in	O
patients	O
who	O
had	O
received	O
cefotetan	B-CHED
prophylactically	O
for	O
obstetric	O
and	O
gynecologic	O
procedures	O
.	O

Eight	O
of	O
these	O
cases	O
of	O
severe	O
immune	O
hemolytic	O
anemia	O
are	O
described	O
.	O

Effects	O
of	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
on	O
hemostasis	O
in	O
patients	O
with	O
aneurysmal	O
subarachnoid	O
hemorrhage	O
.	O

Platelet	O
function	O
is	O
impaired	O
by	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
with	O
prominent	O
anti	O
-	O
inflammatory	O
properties	O
.	O

Their	O
safety	O
in	O
patients	O
undergoing	O
intracranial	O
surgery	O
is	O
under	O
debate	O
.	O

Patients	O
with	O
aneurysmal	O
subarachnoid	O
hemorrhage	O
(	O
SAH	O
)	O
were	O
randomized	O
to	O
receive	O
either	O
ketoprofen	B-CHED
,	O
100	O
mg	O
,	O
three	O
times	O
a	O
day	O
(	O
ketoprofen	B-CHED
group	O
,	O
n	O
=	O
9	O
)	O
or	O
a	O
weak	O
NSAID	O
,	O
acetaminophen	B-CHED
,	O
1	O
g	O
,	O
three	O
times	O
a	O
day	O
(	O
acetaminophen	B-CHED
group	O
,	O
n	O
=	O
9	O
)	O
starting	O
immediately	O
after	O
the	O
diagnosis	O
of	O
aneurysmal	O
SAH	O
.	O

Treatment	O
was	O
continued	O
for	O
3	O
days	O
postoperatively	O
.	O

Test	O
blood	O
samples	O
were	O
taken	O
before	O
treatment	O
and	O
surgery	O
as	O
well	O
as	O
on	O
the	O
first	O
,	O
third	O
,	O
and	O
fifth	O
postoperative	O
mornings	O
.	O

Maximal	O
platelet	O
aggregation	O
induced	O
by	O
6	O
microM	O
of	O
adenosine	B-CHED
diphosphate	I-CHED
decreased	O
after	O
administration	O
of	O
ketoprofen	B-CHED
.	O

Aggregation	O
was	O
lower	O
(	O
P	O
<	O
.	O
05	O
)	O
in	O
the	O
ketoprofen	B-CHED
group	O
than	O
in	O
the	O
acetaminophen	B-CHED
group	O
just	O
before	O
surgery	O
and	O
on	O
the	O
third	O
postoperative	O
day	O
.	O

In	O
contrast	O
,	O
maximal	O
platelet	O
aggregation	O
increased	O
in	O
the	O
acetaminophen	B-CHED
group	O
on	O
the	O
third	O
postoperative	O
day	O
as	O
compared	O
with	O
the	O
pretreatment	O
platelet	O
aggregation	O
results	O
(	O
P	O
<	O
.	O
05	O
)	O
.	O

One	O
patient	O
in	O
the	O
ketoprofen	B-CHED
group	O
developed	O
a	O
postoperative	O
intracranial	O
hematoma	O
.	O

Coagulation	O
(	O
prothrombin	O
time	O
[	O
PT	O
]	O
,	O
activated	O
partial	O
thromboplastin	O
time	O
[	O
APPT	O
]	O
,	O
fibrinogen	O
concentration	O
,	O
and	O
antithrombin	O
III	O
[	O
AT	O
III	O
]	O
)	O
was	O
comparable	O
between	O
the	O
two	O
groups	O
.	O

Ketoprofen	B-CHED
but	O
not	O
acetaminophen	B-CHED
impaired	O
platelet	O
function	O
in	O
patients	O
with	O
SAH	O
.	O

If	O
ketoprofen	B-CHED
is	O
used	O
before	O
surgery	O
on	O
cerebral	O
artery	O
aneurysms	O
,	O
it	O
may	O
pose	O
an	O
additional	O
risk	O
factor	O
for	O
hemorrhage	O
.	O

Nitric	B-CHED
oxide	I-CHED
synthase	O
expression	O
in	O
the	O
course	O
of	O
lead	B-CHED
-	O
induced	O
hypertension	O
.	O

We	O
recently	O
showed	O
elevated	O
reactive	O
oxygen	B-CHED
species	O
(	O
ROS	O
)	O
,	O
reduced	O
urinary	O
excretion	O
of	O
NO	B-CHED
metabolites	O
(	O
NOx	O
)	O
,	O
and	O
increased	O
NO	B-CHED
sequestration	O
as	O
nitrotyrosine	B-CHED
in	O
various	O
tissues	O
in	O
rats	O
with	O
lead	B-CHED
-	O
induced	O
hypertension	O
.	O

This	O
study	O
was	O
designed	O
to	O
discern	O
whether	O
the	O
reduction	O
in	O
urinary	O
NOx	O
in	O
lead	B-CHED
-	O
induced	O
hypertension	O
is	O
,	O
in	O
part	O
,	O
due	O
to	O
depressed	O
NO	B-CHED
synthase	O
(	O
NOS	O
)	O
expression	O
.	O

Male	O
Sprague	O
-	O
Dawley	O
rats	O
were	O
randomly	O
assigned	O
to	O
a	O
lead	B-CHED
-	O
treated	O
group	O
(	O
given	O
lead	B-CHED
acetate	I-CHED
,	O
100	O
ppm	O
,	O
in	O
drinking	O
water	O
and	O
regular	O
rat	O
chow	O
)	O
,	O
a	O
group	O
given	O
lead	B-CHED
and	O
vitamin	B-CHED
E	I-CHED
-	O
fortified	O
chow	O
,	O
or	O
a	O
normal	O
control	O
group	O
given	O
either	O
regular	O
food	O
and	O
water	O
or	O
vitamin	B-CHED
E	I-CHED
-	O
fortified	O
food	O
for	O
12	O
weeks	O
.	O

Tail	O
blood	O
pressure	O
,	O
urinary	O
NOx	O
excretion	O
,	O
plasma	O
malondialdehyde	B-CHED
(	O
MDA	B-CHED
)	O
,	O
and	O
endothelial	O
and	O
inducible	O
NOS	O
(	O
eNOS	O
and	O
iNOS	O
)	O
isotypes	O
in	O
the	O
aorta	O
and	O
kidney	O
were	O
measured	O
.	O

The	O
lead	B-CHED
-	O
treated	O
group	O
exhibited	O
a	O
rise	O
in	O
blood	O
pressure	O
and	O
plasma	O
MDA	B-CHED
concentration	O
,	O
a	O
fall	O
in	O
urinary	O
NOx	O
excretion	O
,	O
and	O
a	O
paradoxical	O
rise	O
in	O
vascular	O
and	O
renal	O
tissue	O
eNOS	O
and	O
iNOS	O
expression	O
.	O

Vitamin	B-CHED
E	I-CHED
supplementation	O
ameliorated	O
hypertension	O
,	O
lowered	O
plasma	O
MDA	B-CHED
concentration	O
,	O
and	O
raised	O
urinary	O
NOx	O
excretion	O
while	O
significantly	O
lowering	O
vascular	O
,	O
but	O
not	O
renal	O
,	O
tissue	O
eNOS	O
and	O
iNOS	O
expression	O
.	O

Vitamin	B-CHED
E	I-CHED
supplementation	O
had	O
no	O
effect	O
on	O
either	O
blood	O
pressure	O
,	O
plasma	O
MDA	B-CHED
,	O
or	O
NOS	O
expression	O
in	O
the	O
control	O
group	O
.	O

The	O
study	O
also	O
revealed	O
significant	O
inhibition	O
of	O
NOS	O
enzymatic	O
activity	O
by	O
lead	B-CHED
in	O
cell	O
-	O
free	O
preparations	O
.	O

In	O
conclusion	O
,	O
lead	B-CHED
-	O
induced	O
hypertension	O
in	O
this	O
model	O
was	O
associated	O
with	O
a	O
compensatory	O
upregulation	O
of	O
renal	O
and	O
vascular	O
eNOS	O
and	O
iNOS	O
expression	O
.	O

This	O
is	O
,	O
in	O
part	O
,	O
due	O
to	O
ROS	O
-	O
mediated	O
NO	B-CHED
inactivation	O
,	O
lead	B-CHED
-	O
associated	O
inhibition	O
of	O
NOS	O
activity	O
,	O
and	O
perhaps	O
stimulatory	O
actions	O
of	O
increased	O
shear	O
stress	O
associated	O
with	O
hypertension	O
.	O

Glyceryl	B-CHED
trinitrate	I-CHED
induces	O
attacks	O
of	O
migraine	O
without	O
aura	O
in	O
sufferers	O
of	O
migraine	O
with	O
aura	O
.	O

Migraine	O
with	O
aura	O
and	O
migraine	O
without	O
aura	O
have	O
the	O
same	O
pain	O
phase	O
,	O
thus	O
indicating	O
that	O
migraine	O
with	O
aura	O
and	O
migraine	O
without	O
aura	O
share	O
a	O
common	O
pathway	O
of	O
nociception	O
.	O

In	O
recent	O
years	O
,	O
increasing	O
evidence	O
has	O
suggested	O
that	O
the	O
messenger	O
molecule	O
nitric	B-CHED
oxide	I-CHED
(	O
NO	B-CHED
)	O
is	O
involved	O
in	O
pain	O
mechanisms	O
of	O
migraine	O
without	O
aura	O
.	O

In	O
order	O
to	O
clarify	O
whether	O
the	O
same	O
is	O
true	O
for	O
migraine	O
with	O
aura	O
,	O
in	O
the	O
present	O
study	O
we	O
examined	O
the	O
headache	O
response	O
to	O
intravenous	O
infusion	O
of	O
glyceryl	B-CHED
trinitrate	I-CHED
(	O
GTN	B-CHED
)	O
(	O
0	O
.	O
5	O
microg	O
/	O
kg	O
/	O
min	O
for	O
20	O
min	O
)	O
in	O
12	O
sufferers	O
of	O
migraine	O
with	O
aura	O
.	O

The	O
specific	O
aim	O
was	O
to	O
elucidate	O
whether	O
an	O
aura	O
and	O
/	O
or	O
an	O
attack	O
of	O
migraine	O
without	O
aura	O
could	O
be	O
induced	O
.	O

Fourteen	O
healthy	O
subjects	O
served	O
as	O
controls	O
.	O

Aura	O
symptoms	O
were	O
not	O
elicited	O
in	O
any	O
subject	O
.	O

Headache	O
was	O
more	O
severe	O
in	O
migraineurs	O
than	O
in	O
the	O
controls	O
during	O
and	O
immediately	O
after	O
GTN	B-CHED
infusion	O
(	O
p	O
=	O
0	O
.	O
037	O
)	O
as	O
well	O
as	O
during	O
the	O
following	O
11	O
h	O
(	O
p	O
=	O
0	O
.	O
008	O
)	O
.	O

In	O
the	O
controls	O
,	O
the	O
GTN	B-CHED
-	O
induced	O
headache	O
gradually	O
disappeared	O
,	O
whereas	O
in	O
migraineurs	O
peak	O
headache	O
intensity	O
occurred	O
at	O
a	O
mean	O
time	O
of	O
240	O
min	O
post	O
-	O
infusion	O
.	O

At	O
this	O
time	O
the	O
induced	O
headache	O
in	O
6	O
of	O
12	O
migraineurs	O
fulfilled	O
the	O
diagnostic	O
criteria	O
for	O
migraine	O
without	O
aura	O
of	O
the	O
International	O
Headache	O
Society	O
.	O

The	O
results	O
therefore	O
suggest	O
that	O
NO	B-CHED
is	O
involved	O
in	O
the	O
pain	O
mechanisms	O
of	O
migraine	O
with	O
aura	O
.	O

Since	O
cortical	O
spreading	O
depression	O
has	O
been	O
shown	O
to	O
liberate	O
NO	B-CHED
in	O
animals	O
,	O
this	O
finding	O
may	O
help	O
our	O
understanding	O
of	O
the	O
coupling	O
between	O
cortical	O
spreading	O
depression	O
and	O
headache	O
in	O
migraine	O
with	O
aura	O
.	O

Rapid	O
reversal	O
of	O
life	O
-	O
threatening	O
diltiazem	B-CHED
-	O
induced	O
tetany	O
with	O
calcium	B-CHED
chloride	I-CHED
.	O

We	O
describe	O
a	O
patient	O
who	O
developed	O
tetany	O
with	O
sudden	O
respiratory	O
arrest	O
after	O
the	O
infusion	O
of	O
intravenous	O
diltiazem	B-CHED
.	O

The	O
administration	O
of	O
calcium	B-CHED
chloride	I-CHED
rapidly	O
resolved	O
the	O
patient	O
'	O
s	O
tetany	O
with	O
prompt	O
recovery	O
of	O
respiratory	O
function	O
,	O
averting	O
the	O
need	O
for	O
more	O
aggressive	O
airway	O
management	O
and	O
ventilatory	O
support	O
.	O

The	O
emergency	O
physician	O
should	O
be	O
aware	O
that	O
life	O
-	O
threatening	O
tetany	O
may	O
accompany	O
the	O
administration	O
of	O
intravenous	O
diltiazem	B-CHED
and	O
that	O
calcium	B-CHED
chloride	I-CHED
may	O
be	O
a	O
rapid	O
and	O
effective	O
remedy	O
.	O

Predictors	O
of	O
decreased	O
renal	O
function	O
in	O
patients	O
with	O
heart	O
failure	O
during	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
inhibitor	O
therapy	O
:	O
results	O
from	O
the	O
studies	O
of	O
left	O
ventricular	O
dysfunction	O
(	O
SOLVD	O
)	O

BACKGROUND	O
:	O
Although	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
inhibitor	O
therapy	O
reduces	O
mortality	O
rates	O
in	O
patients	O
with	O
congestive	O
heart	O
failure	O
(	O
CHF	O
)	O
,	O
it	O
may	O
also	O
cause	O
decreased	O
renal	O
function	O
.	O

Little	O
information	O
is	O
available	O
to	O
predict	O
which	O
patients	O
are	O
at	O
highest	O
risk	O
for	O
this	O
complication	O
.	O

OBJECTIVE	O
:	O
To	O
quantify	O
specific	O
clinical	O
predictors	O
of	O
reduction	O
in	O
renal	O
function	O
in	O
patients	O
with	O
CHF	O
who	O
are	O
prescribed	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
inhibitor	O
therapy	O
.	O

METHOD	O
:	O
We	O
analyzed	O
data	O
from	O
the	O
Studies	O
of	O
Left	O
Ventricular	O
Dysfunction	O
(	O
SOLVD	O
)	O
,	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
of	O
enalapril	B-CHED
for	O
the	O
treatment	O
of	O
CHF	O
.	O

There	O
were	O
3379	O
patients	O
randomly	O
assigned	O
to	O
enalapril	B-CHED
with	O
a	O
median	O
follow	O
-	O
up	O
of	O
974	O
days	O
and	O
3379	O
patients	O
randomly	O
assigned	O
to	O
placebo	O
with	O
a	O
mean	O
follow	O
-	O
up	O
of	O
967	O
days	O
.	O

Decreased	O
renal	O
function	O
was	O
defined	O
as	O
a	O
rise	O
in	O
serum	O
creatinine	B-CHED
>	O
/	O
=	O
0	O
.	O
5	O
mg	O
/	O
dL	O
(	O
44	O
micromol	O
/	O
L	O
)	O
from	O
baseline	O
.	O

We	O
used	O
time	O
-	O
to	O
-	O
event	O
analysis	O
to	O
identify	O
potential	O
predictors	O
of	O
decrease	O
in	O
renal	O
function	O
including	O
age	O
,	O
baseline	O
ejection	O
fraction	O
,	O
baseline	O
creatinine	B-CHED
,	O
low	O
systolic	O
blood	O
pressure	O
(	O
<	O
100	O
mm	O
Hg	O
)	O
,	O
history	O
of	O
hypertension	O
,	O
diabetes	O
,	O
and	O
use	O
of	O
antiplatelet	O
,	O
diuretic	B-CHED
,	O
and	O
beta	O
-	O
blocker	O
therapy	O
.	O

RESULTS	O
:	O
Patients	O
randomly	O
assigned	O
to	O
enalapril	B-CHED
had	O
a	O
33	O
%	O
greater	O
likelihood	O
of	O
decreased	O
renal	O
function	O
than	O
controls	O
(	O
P	O
=	O
.	O
003	O
)	O
.	O

By	O
multivariate	O
analysis	O
,	O
in	O
both	O
the	O
placebo	O
and	O
enalapril	B-CHED
groups	O
older	O
age	O
,	O
diuretic	B-CHED
therapy	O
,	O
and	O
diabetes	O
were	O
associated	O
with	O
decreased	O
renal	O
function	O
,	O
whereas	O
beta	O
-	O
blocker	O
therapy	O
and	O
higher	O
ejection	O
fraction	O
were	O
renoprotective	O
.	O

Older	O
age	O
was	O
associated	O
with	O
a	O
greater	O
risk	O
of	O
developing	O
decreased	O
renal	O
function	O
in	O
both	O
groups	O
,	O
but	O
significantly	O
more	O
so	O
in	O
the	O
enalapril	B-CHED
group	O
(	O
enalapril	B-CHED
:	O
risk	O
ratio	O
[	O
RR	O
]	O
1	O
.	O
42	O
per	O
10	O
years	O
,	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
1	O
.	O
32	O
-	O
1	O
.	O
52	O
with	O
enalapril	B-CHED
;	O
placebo	O
:	O
RR	O
1	O
.	O
18	O
,	O
95	O
%	O
CI	O
1	O
.	O
12	O
-	O
1	O
.	O
25	O
)	O
.	O

Diuretic	B-CHED
therapy	O
was	O
likewise	O
associated	O
with	O
a	O
greater	O
risk	O
of	O
decreased	O
renal	O
function	O
in	O
the	O
enalapril	B-CHED
group	O
(	O
RR	O
1	O
.	O
89	O
,	O
95	O
%	O
CI	O
1	O
.	O
70	O
-	O
2	O
.	O
08	O
)	O
than	O
in	O
the	O
placebo	O
group	O
(	O
RR	O
1	O
.	O
35	O
,	O
95	O
%	O
CI	O
1	O
.	O
09	O
-	O
1	O
.	O
66	O
)	O
.	O

Conversely	O
,	O
enalapril	B-CHED
had	O
a	O
relative	O
renoprotective	O
effect	O
(	O
RR	O
1	O
.	O
33	O
,	O
95	O
%	O
CI	O
1	O
.	O
13	O
-	O
1	O
.	O
53	O
)	O
compared	O
with	O
placebo	O
(	O
RR	O
1	O
.	O
96	O
,	O
95	O
%	O
CI	O
1	O
.	O
57	O
-	O
2	O
.	O
44	O
)	O
in	O
patients	O
with	O
diabetes	O
.	O

A	O
lower	O
risk	O
of	O
renal	O
impairment	O
was	O
seen	O
in	O
both	O
groups	O
with	O
beta	O
-	O
blocker	O
therapy	O
(	O
RR	O
0	O
.	O
70	O
,	O
95	O
%	O
CI	O
0	O
.	O
57	O
-	O
0	O
.	O
85	O
)	O
and	O
higher	O
baseline	O
ejection	O
fraction	O
(	O
RR	O
0	O
.	O
93	O
per	O
5	O
%	O
increment	O
,	O
95	O
%	O
CI	O
0	O
.	O
91	O
-	O
0	O
.	O
96	O
)	O
.	O

CONCLUSIONS	O
:	O
Enalapril	B-CHED
use	O
caused	O
a	O
33	O
%	O
increase	O
in	O
the	O
risk	O
of	O
decreased	O
renal	O
function	O
in	O
patients	O
with	O
CHF	O
.	O

Diuretic	B-CHED
use	O
and	O
advanced	O
age	O
increased	O
this	O
risk	O
.	O

Diabetes	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
renal	O
impairment	O
in	O
all	O
patients	O
with	O
CHF	O
,	O
but	O
this	O
risk	O
was	O
reduced	O
in	O
the	O
enalapril	B-CHED
group	O
compared	O
with	O
the	O
placebo	O
group	O
.	O

beta	O
-	O
Blocker	O
therapy	O
and	O
higher	O
ejection	O
fraction	O
were	O
renoprotective	O
in	O
all	O
patients	O
regardless	O
of	O
therapy	O
.	O

Hypomania	O
-	O
like	O
syndrome	O
induced	O
by	O
olanzapine	B-CHED
.	O

We	O
report	O
a	O
female	O
patient	O
with	O
a	O
diagnosis	O
of	O
a	O
not	O
otherwise	O
specified	O
psychotic	O
disorder	O
(	O
DSM	O
-	O
IV	O
)	O
who	O
developed	O
hypomania	O
shortly	O
after	O
the	O
introduction	O
of	O
olanzapine	B-CHED
treatment	O
.	O

Acetazolamide	B-CHED
-	O
induced	O
Gerstmann	O
syndrome	O
.	O

Acute	O
confusion	O
induced	O
by	O
acetazolamide	B-CHED
is	O
a	O
well	O
known	O
adverse	O
drug	O
reaction	O
in	O
patients	O
with	O
renal	O
impairment	O
.	O

We	O
report	O
a	O
case	O
of	O
acetazolamide	B-CHED
-	O
induced	O
Gerstmann	O
syndrome	O
in	O
a	O
patient	O
with	O
normal	O
renal	O
function	O
,	O
to	O
highlight	O
predisposing	O
factors	O
that	O
are	O
frequently	O
overlooked	O
.	O

Vasopressin	B-CHED
in	O
the	O
treatment	O
of	O
milrinone	B-CHED
-	O
induced	O
hypotension	O
in	O
severe	O
heart	O
failure	O
.	O

The	O
use	O
of	O
phosphodiesterase	O
inhibitors	O
such	O
as	O
milrinone	B-CHED
in	O
the	O
treatment	O
of	O
severe	O
heart	O
failure	O
is	O
frequently	O
restricted	O
because	O
they	O
cause	O
vasodilation	O
and	O
hypotension	O
.	O

In	O
patients	O
with	O
decompensated	O
heart	O
failure	O
with	O
hypotension	O
after	O
treatment	O
with	O
milrinone	B-CHED
,	O
low	O
doses	O
of	O
vasopressin	B-CHED
restored	O
blood	O
pressure	O
without	O
inhibiting	O
the	O
inotropic	O
effect	O
of	O
milrinone	B-CHED
.	O

Treatment	O
of	O
tacrolimus	B-CHED
-	O
related	O
adverse	O
effects	O
by	O
conversion	O
to	O
cyclosporine	B-CHED
in	O
liver	O
transplant	O
recipients	O
.	O

When	O
tacrolimus	B-CHED
side	O
effects	O
persist	O
despite	O
dose	O
reduction	O
,	O
conversion	O
to	O
cyclosporine	B-CHED
-	O
based	O
immunosuppression	O
(	O
CyA	O
)	O
is	O
necessary	O
.	O

We	O
characterized	O
tacrolimus	B-CHED
side	O
effects	O
that	O
warranted	O
discontinuation	O
of	O
the	O
drug	O
,	O
and	O
outcomes	O
after	O
conversion	O
.	O

Of	O
388	O
liver	O
recipients	O
who	O
received	O
tacrolimus	B-CHED
as	O
primary	O
immunosuppression	O
,	O
70	O
required	O
conversion	O
to	O
CyA	O
.	O

We	O
recorded	O
indication	O
for	O
conversion	O
,	O
whether	O
conversion	O
was	O
early	O
or	O
late	O
after	O
transplantation	O
,	O
tacrolimus	B-CHED
dose	O
and	O
trough	O
blood	O
level	O
at	O
conversion	O
,	O
and	O
incidence	O
of	O
rejection	O
after	O
conversion	O
.	O

Conversion	O
was	O
early	O
in	O
29	O
patients	O
(	O
41	O
.	O
4	O
%	O
)	O
and	O
late	O
in	O
41	O
(	O
58	O
.	O
6	O
%	O
)	O
.	O

Indications	O
for	O
early	O
conversion	O
were	O
neurotoxicity	O
(	O
20	O
)	O
,	O
(	O
insulin	O
-	O
dependent	O
)	O
diabetes	O
mellitus	O
(	O
IDDM	O
)	O
(	O
5	O
)	O
,	O
nephrotoxicity	O
(	O
3	O
)	O
,	O
gastrointestinal	O
(	O
GI	O
)	O
toxicity	O
(	O
6	O
)	O
,	O
and	O
cardiomyopathy	O
(	O
1	O
)	O
,	O
and	O
for	O
late	O
conversion	O
were	O
neurotoxicity	O
(	O
15	O
)	O
,	O
IDDM	O
(	O
12	O
)	O
,	O
nephrotoxicity	O
(	O
3	O
)	O
,	O
GI	O
toxicity	O
(	O
5	O
)	O
,	O
hepatotoxicity	O
(	O
6	O
)	O
,	O
post	O
-	O
transplant	O
lmphoproliferate	O
disease	O
(	O
PTLD	O
)	O
(	O
2	O
)	O
,	O
cardiomyopathy	O
(	O
1	O
)	O
,	O
hemolytic	O
anemia	O
(	O
1	O
)	O
,	O
and	O
pruritus	O
(	O
1	O
)	O
.	O

All	O
early	O
-	O
conversion	O
patients	O
showed	O
improvement	O
/	O
resolution	O
of	O
symptoms	O
.	O

Among	O
late	O
-	O
conversion	O
patients	O
,	O
37	O
(	O
90	O
.	O
2	O
%	O
)	O
had	O
improvement	O
/	O
resolution	O
;	O
in	O
4	O
(	O
9	O
.	O
8	O
%	O
)	O
,	O
adverse	O
effects	O
persisted	O
.	O

The	O
overall	O
rejection	O
rate	O
was	O
30	O
%	O
.	O

Sixty	O
-	O
two	O
patients	O
(	O
88	O
.	O
6	O
%	O
)	O
are	O
alive	O
with	O
functioning	O
grafts	O
686	O
+	O
/	O
-	O
362	O
days	O
(	O
range	O
,	O
154	O
-	O
1433	O
days	O
)	O
after	O
conversion	O
.	O

When	O
tacrolimus	B-CHED
side	O
effects	O
are	O
unresponsive	O
to	O
dose	O
reduction	O
,	O
conversion	O
to	O
CyA	O
can	O
be	O
accomplished	O
safely	O
,	O
with	O
no	O
increased	O
risk	O
of	O
rejection	O
and	O
excellent	O
long	O
-	O
term	O
outcome	O
.	O

Ocular	O
manifestations	O
of	O
juvenile	O
rheumatoid	O
arthritis	O
.	O

We	O
followed	O
210	O
cases	O
of	O
juvenile	O
rheumatoid	O
arthritis	O
closely	O
for	O
eleven	O
years	O
.	O

Thirty	O
-	O
six	O
of	O
the	O
210	O
patients	O
(	O
17	O
.	O
2	O
%	O
)	O
developed	O
iridocyclitis	O
.	O

Iridocyclitis	O
was	O
seen	O
most	O
frequently	O
in	O
young	O
female	O
patients	O
(	O
0	O
to	O
4	O
years	O
)	O
with	O
the	O
monoarticular	O
or	O
pauciatricular	O
form	O
of	O
the	O
arthritis	O
.	O

However	O
,	O
30	O
%	O
of	O
the	O
patients	O
developed	O
uveitis	O
after	O
16	O
years	O
of	O
age	O
.	O

Although	O
61	O
%	O
of	O
patients	O
had	O
a	O
noncontributory	O
ocular	O
history	O
on	O
entry	O
,	O
42	O
%	O
had	O
active	O
uveitis	O
on	O
entry	O
.	O

Our	O
approach	O
was	O
effective	O
in	O
detecting	O
uveitis	O
in	O
new	O
cases	O
and	O
exacerbations	O
of	O
uveitis	O
in	O
established	O
cases	O
.	O

Forty	O
-	O
four	O
percent	O
of	O
patients	O
with	O
uveitis	O
had	O
one	O
or	O
more	O
identifiable	O
signs	O
or	O
symptoms	O
,	O
such	O
as	O
red	O
eye	O
,	O
ocular	O
pain	O
,	O
decreased	O
visual	O
acuity	O
,	O
or	O
photophobia	O
,	O
in	O
order	O
of	O
decreasing	O
frequency	O
.	O

Even	O
after	O
early	O
detection	O
and	O
prompt	O
treatment	O
,	O
41	O
%	O
of	O
cases	O
of	O
uveitis	O
did	O
not	O
respond	O
to	O
more	O
than	O
six	O
months	O
of	O
intensive	O
topical	O
treatment	O
with	O
corticosteroids	B-CHED
and	O
mydriatics	O
.	O

Despite	O
this	O
,	O
there	O
was	O
a	O
dramatic	O
decrease	O
in	O
the	O
50	O
%	O
incidence	O
of	O
blinding	O
complications	O
of	O
uveitis	O
cited	O
in	O
earlier	O
studies	O
.	O

Cataract	O
and	O
band	O
keratopathy	O
occurred	O
in	O
only	O
22	O
and	O
13	O
%	O
of	O
our	O
group	O
,	O
respectively	O
.	O

We	O
used	O
chloroquine	B-CHED
or	O
hydroxychloroquine	B-CHED
in	O
173	O
of	O
210	O
cases	O
and	O
found	O
only	O
one	O
case	O
of	O
chorioretinopathy	O
attributable	O
to	O
these	O
drugs	O
.	O

Systemically	O
administered	O
corticosteroids	B-CHED
were	O
used	O
in	O
75	O
of	O
210	O
cases	O
;	O
a	O
significant	O
number	O
of	O
posterior	O
subcapsular	O
cataracts	O
was	O
found	O
.	O

Typical	O
keratoconjunctivitis	O
sicca	O
developed	O
in	O
three	O
of	O
the	O
uveitis	O
cases	O
.	O

This	O
association	O
with	O
uveitis	O
and	O
JRA	O
was	O
not	O
noted	O
previously	O
.	O

Surgical	O
treatment	O
of	O
cataracts	O
,	O
band	O
keratopathy	O
,	O
and	O
glaucoma	O
achieved	O
uniformly	O
discouraging	O
results	O
.	O

Cyclophosphamide	B-CHED
-	O
induced	O
cystitis	O
in	O
freely	O
-	O
moving	O
conscious	O
rats	O
:	O
behavioral	O
approach	O
to	O
a	O
new	O
model	O
of	O
visceral	O
pain	O
.	O

PURPOSE	O
:	O
To	O
develop	O
a	O
model	O
of	O
visceral	O
pain	O
in	O
rats	O
using	O
a	O
behavioral	O
approach	O
.	O

Cyclophosphamide	B-CHED
(	O
CP	B-CHED
)	O
,	O
an	O
antitumoral	O
agent	O
known	O
to	O
produce	O
toxic	O
effects	O
on	O
the	O
bladder	O
wall	O
through	O
its	O
main	O
toxic	O
metabolite	O
acrolein	B-CHED
,	O
was	O
used	O
to	O
induce	O
cystitis	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
CP	B-CHED
was	O
administered	O
at	O
doses	O
of	O
50	O
,	O
100	O
and	O
200	O
mg	O
.	O
/	O
kg	O
.	O

i	O
.	O
p	O
.	O
to	O
male	O
rats	O
,	O
and	O
their	O
behavior	O
observed	O
and	O
scored	O
.	O

The	O
effects	O
of	O
morphine	B-CHED
(	O
0	O
.	O
5	O
to	O
4	O
mg	O
.	O
/	O
kg	O
.	O
i	O
.	O
v	O
.	O
)	O
on	O
CP	B-CHED
-	O
induced	O
behavioral	O
modifications	O
were	O
tested	O
administered	O
alone	O
and	O
after	O
naloxone	B-CHED
(	O
1	O
mg	O
.	O
/	O
kg	O
.	O
s	O
.	O
c	O
.	O
)	O
.	O

In	O
addition	O
,	O
90	O
minutes	O
after	O
CP	B-CHED
injection	O
,	O
that	O
is	O
,	O
at	O
the	O
time	O
of	O
administration	O
of	O
morphine	B-CHED
,	O
the	O
bladder	O
was	O
removed	O
in	O
some	O
rats	O
for	O
histological	O
examination	O
.	O

Finally	O
,	O
to	O
show	O
that	O
the	O
bladder	O
is	O
essential	O
for	O
the	O
CP	B-CHED
-	O
induced	O
behavioral	O
modifications	O
,	O
female	O
rats	O
also	O
received	O
CP	B-CHED
at	O
doses	O
of	O
200	O
mg	O
.	O
/	O
kg	O
.	O

i	O
.	O
p	O
.	O
and	O
of	O
20	O
mg	O
.	O
by	O
the	O
intravesical	O
route	O
,	O
and	O
acrolein	B-CHED
at	O
doses	O
of	O
0	O
.	O
5	O
mg	O
.	O
by	O
the	O
intravesical	O
route	O
and	O
of	O
5	O
mg	O
.	O
/	O
kg	O
.	O

i	O
.	O
v	O
.	O
RESULTS	O
:	O
CP	B-CHED
dose	O
-	O
relatedly	O
induced	O
marked	O
behavioral	O
modifications	O
in	O
male	O
rats	O
:	O
breathing	O
rate	O
decrease	O
,	O
closing	O
of	O
the	O
eyes	O
and	O
occurrence	O
of	O
specific	O
postures	O
.	O

Morphine	B-CHED
dose	O
-	O
dependently	O
reversed	O
these	O
behavioral	O
disorders	O
.	O

A	O
dose	O
of	O
0	O
.	O
5	O
mg	O
.	O
/	O
kg	O
.	O
produced	O
a	O
reduction	O
of	O
almost	O
50	O
%	O
of	O
the	O
behavioral	O
score	O
induced	O
by	O
CP	B-CHED
200	O
mg	O
.	O
/	O
kg	O
.	O

This	O
effect	O
was	O
completely	O
prevented	O
by	O
pretreatment	O
with	O
naloxone	B-CHED
.	O

At	O
the	O
time	O
of	O
administration	O
of	O
morphine	B-CHED
,	O
histological	O
modifications	O
of	O
the	O
bladder	O
wall	O
,	O
such	O
as	O
chorionic	O
and	O
muscle	O
layer	O
edema	O
,	O
were	O
observed	O
.	O

In	O
female	O
rats	O
,	O
CP	B-CHED
200	O
mg	O
.	O
/	O
kg	O
.	O

i	O
.	O
p	O
.	O
produced	O
the	O
same	O
marked	O
behavioral	O
modifications	O
as	O
those	O
observed	O
in	O
male	O
rats	O
.	O

Administered	O
at	O
the	O
dose	O
of	O
20	O
mg	O
.	O
intravesically	O
,	O
CP	B-CHED
did	O
not	O
produce	O
any	O
behavioral	O
effects	O
,	O
whereas	O
acrolein	B-CHED
at	O
0	O
.	O
5	O
mg	O
.	O
intravesically	O
induced	O
behavioral	O
modifications	O
identical	O
to	O
those	O
under	O
CP	B-CHED
200	O
mg	O
.	O
/	O
kg	O
.	O

i	O
.	O
p	O
.	O
,	O
with	O
the	O
same	O
maximal	O
levels	O
.	O

Conversely	O
,	O
acrolein	B-CHED
5	O
mg	O
.	O
/	O
kg	O
.	O

i	O
.	O
v	O
.	O
did	O
not	O
produce	O
any	O
behavioral	O
effects	O
at	O
all	O
.	O

CONCLUSIONS	O
:	O
Overall	O
,	O
these	O
results	O
indicate	O
that	O
this	O
experimental	O
model	O
of	O
CP	B-CHED
-	O
induced	O
cystitis	O
may	O
be	O
an	O
interesting	O
new	O
behavioral	O
model	O
of	O
inflammatory	O
visceral	O
pain	O
,	O
allowing	O
a	O
better	O
understanding	O
of	O
these	O
painful	O
syndromes	O
and	O
thus	O
a	O
better	O
therapeutic	O
approach	O
to	O
them	O
.	O

Prednisolone	B-CHED
-	O
induced	O
muscle	O
dysfunction	O
is	O
caused	O
more	O
by	O
atrophy	O
than	O
by	O
altered	O
acetylcholine	B-CHED
receptor	O
expression	O
.	O

Large	O
doses	O
of	O
glucocorticoids	O
can	O
alter	O
muscle	O
physiology	O
and	O
susceptibility	O
to	O
neuromuscular	O
blocking	O
drugs	O
by	O
mechanisms	O
not	O
clearly	O
understood	O
.	O

We	O
investigated	O
the	O
effects	O
of	O
moderate	O
and	O
large	O
doses	O
of	O
prednisolone	B-CHED
on	O
muscle	O
function	O
and	O
pharmacology	O
,	O
and	O
their	O
relationship	O
to	O
changes	O
in	O
muscle	O
size	O
and	O
acetylcholine	B-CHED
receptor	O
(	O
AChR	O
)	O
expression	O
.	O

With	O
institutional	O
approval	O
,	O
35	O
Sprague	O
-	O
Dawley	O
rats	O
were	O
randomly	O
allocated	O
to	O
receive	O
daily	O
subcutaneous	O
doses	O
of	O
10	O
mg	O
/	O
kg	O
prednisolone	B-CHED
(	O
P10	O
group	O
)	O
,	O
100	O
mg	O
/	O
kg	O
prednisolone	B-CHED
(	O
P100	O
group	O
)	O
,	O
or	O
an	O
equal	O
volume	O
of	O
saline	O
(	O
S	O
group	O
)	O
for	O
7	O
days	O
.	O

A	O
fourth	O
group	O
of	O
rats	O
was	O
pair	O
fed	O
(	O
food	O
restricted	O
)	O
with	O
the	O
P100	O
rats	O
for	O
7	O
days	O
(	O
FR	O
group	O
)	O
.	O

On	O
Day	O
8	O
,	O
the	O
nerve	O
-	O
evoked	O
peak	O
twitch	O
tensions	O
,	O
tetanic	O
tensions	O
,	O
and	O
fatigability	O
,	O
and	O
the	O
dose	O
-	O
response	O
curves	O
of	O
d	B-CHED
-	I-CHED
tubocurarine	I-CHED
in	O
the	O
tibialis	O
cranialis	O
muscle	O
were	O
measured	O
in	O
vivo	O
and	O
related	O
to	O
muscle	O
mass	O
or	O
expression	O
of	O
AChRs	O
.	O

Rate	O
of	O
body	O
weight	O
gain	O
was	O
depressed	O
in	O
the	O
P100	O
,	O
FR	O
,	O
and	O
P10	O
groups	O
compared	O
with	O
the	O
S	O
group	O
.	O

Tibialis	O
muscle	O
mass	O
was	O
smaller	O
in	O
the	O
P100	O
group	O
than	O
in	O
the	O
P10	O
or	O
S	O
groups	O
.	O

The	O
evoked	O
peak	O
twitch	O
and	O
tetanic	O
tensions	O
were	O
less	O
in	O
the	O
P100	O
group	O
than	O
in	O
the	O
P10	O
or	O
S	O
groups	O
,	O
however	O
,	O
tension	O
per	O
milligram	O
of	O
muscle	O
mass	O
was	O
greater	O
in	O
the	O
P100	O
group	O
than	O
in	O
the	O
S	O
group	O
.	O

The	O
50	O
%	O
effective	O
dose	O
of	O
d	B-CHED
-	I-CHED
tubocurarine	I-CHED
(	O
microg	O
/	O
kg	O
)	O
in	O
the	O
tibialis	O
muscle	O
was	O
smaller	O
in	O
the	O
P10	O
(	O
33	O
.	O
6	O
+	O
/	O
-	O
5	O
.	O
4	O
)	O
than	O
in	O
the	O
S	O
(	O
61	O
.	O
9	O
+	O
/	O
-	O
5	O
.	O
0	O
)	O
or	O
the	O
P100	O
(	O
71	O
.	O
3	O
+	O
/	O
-	O
9	O
.	O
6	O
)	O
groups	O
.	O

AChR	O
expression	O
was	O
less	O
in	O
the	O
P10	O
group	O
than	O
in	O
the	O
S	O
group	O
.	O

The	O
evoked	O
tensions	O
correlated	O
with	O
muscle	O
mass	O
(	O
r	O
(	O
2	O
)	O
=	O
0	O
.	O
32	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
however	O
,	O
not	O
with	O
expression	O
of	O
AChR	O
.	O

The	O
50	O
%	O
effective	O
dose	O
of	O
d	B-CHED
-	I-CHED
tubocurarine	I-CHED
did	O
not	O
correlate	O
with	O
muscle	O
mass	O
or	O
AChR	O
expression	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
neuromuscular	O
dysfunction	O
after	O
prednisolone	B-CHED
is	O
dose	O
-	O
dependent	O
,	O
and	O
derives	O
primarily	O
from	O
muscle	O
atrophy	O
and	O
derives	O
less	O
so	O
from	O
changes	O
in	O
AChR	O
expression	O
.	O

IMPLICATIONS	O
:	O
The	O
mechanisms	O
by	O
which	O
chronic	O
glucocorticoid	O
therapy	O
alters	O
neuromuscular	O
physiology	O
and	O
pharmacology	O
are	O
unclear	O
.	O

We	O
suggest	O
that	O
the	O
observed	O
effects	O
are	O
dose	O
-	O
dependent	O
and	O
derive	O
primarily	O
from	O
muscle	O
atrophy	O
and	O
derive	O
less	O
from	O
changes	O
in	O
acetylcholine	B-CHED
receptor	O
expression	O
.	O

Apomorphine	B-CHED
:	O
an	O
underutilized	O
therapy	O
for	O
Parkinson	O
'	O
s	O
disease	O
.	O

Apomorphine	B-CHED
was	O
the	O
first	O
dopaminergic	O
drug	O
ever	O
used	O
to	O
treat	O
symptoms	O
of	O
Parkinson	O
'	O
s	O
disease	O
.	O

While	O
powerful	O
antiparkinsonian	O
effects	O
had	O
been	O
observed	O
as	O
early	O
as	O
1951	O
,	O
the	O
potential	O
of	O
treating	O
fluctuating	O
Parkinson	O
'	O
s	O
disease	O
by	O
subcutaneous	O
administration	O
of	O
apomorphine	B-CHED
has	O
only	O
recently	O
become	O
the	O
subject	O
of	O
systematic	O
study	O
.	O

A	O
number	O
of	O
small	O
scale	O
clinical	O
trials	O
have	O
unequivocally	O
shown	O
that	O
intermittent	O
subcutaneous	O
apomorphine	B-CHED
injections	O
produce	O
antiparkinsonian	O
benefit	O
close	O
if	O
not	O
identical	O
to	O
that	O
seen	O
with	O
levodopa	B-CHED
and	O
that	O
apomorphine	B-CHED
rescue	O
injections	O
can	O
reliably	O
revert	O
off	O
-	O
periods	O
even	O
in	O
patients	O
with	O
complex	O
on	O
-	O
off	O
motor	O
swings	O
.	O

Continuous	O
subcutaneous	O
apomorphine	B-CHED
infusions	O
can	O
reduce	O
daily	O
off	O
-	O
time	O
by	O
more	O
than	O
50	O
%	O
in	O
this	O
group	O
of	O
patients	O
,	O
which	O
appears	O
to	O
be	O
a	O
stronger	O
effect	O
than	O
that	O
generally	O
seen	O
with	O
add	O
-	O
on	O
therapy	O
with	O
oral	O
dopamine	B-CHED
agonists	O
or	O
COMT	O
inhibitors	O
.	O

Extended	O
follow	O
-	O
up	O
studies	O
of	O
up	O
to	O
8	O
years	O
have	O
demonstrated	O
long	O
-	O
term	O
persistence	O
of	O
apomorphine	B-CHED
efficacy	O
.	O

In	O
addition	O
,	O
there	O
is	O
convincing	O
clinical	O
evidence	O
that	O
monotherapy	O
with	O
continuous	O
subcutaneous	O
apomorphine	B-CHED
infusions	O
is	O
associated	O
with	O
marked	O
reductions	O
of	O
preexisting	O
levodopa	B-CHED
-	O
induced	O
dyskinesias	O
.	O

The	O
main	O
side	O
effects	O
of	O
subcutaneous	O
apomorphine	B-CHED
treatment	O
are	O
related	O
to	O
cutaneous	O
tolerability	O
problems	O
,	O
whereas	O
sedation	O
and	O
psychiatric	O
complications	O
play	O
a	O
lesser	O
role	O
.	O

Given	O
the	O
marked	O
degree	O
of	O
efficacy	O
of	O
subcutaneous	O
apomorphine	B-CHED
treatment	O
in	O
fluctuating	O
Parkinson	O
'	O
s	O
disease	O
,	O
this	O
approach	O
seems	O
to	O
deserve	O
more	O
widespread	O
clinical	O
use	O
.	O

Probing	O
peripheral	O
and	O
central	O
cholinergic	O
system	O
responses	O
.	O

OBJECTIVE	O
:	O
The	O
pharmacological	O
response	O
to	O
drugs	O
that	O
act	O
on	O
the	O
cholinergic	O
system	O
of	O
the	O
iris	O
has	O
been	O
used	O
to	O
predict	O
deficits	O
in	O
central	O
cholinergic	O
functioning	O
due	O
to	O
diseases	O
such	O
as	O
Alzheimer	O
'	O
s	O
disease	O
,	O
yet	O
correlations	O
between	O
central	O
and	O
peripheral	O
responses	O
have	O
not	O
been	O
properly	O
studied	O
.	O

This	O
study	O
assessed	O
the	O
effect	O
of	O
normal	O
aging	O
on	O
(	O
1	O
)	O
the	O
tropicamide	B-CHED
-	O
induced	O
increase	O
in	O
pupil	O
diameter	O
,	O
and	O
(	O
2	O
)	O
the	O
reversal	O
of	O
this	O
effect	O
with	O
pilocarpine	B-CHED
.	O

Scopolamine	B-CHED
was	O
used	O
as	O
a	O
positive	O
control	O
to	O
detect	O
age	O
-	O
dependent	O
changes	O
in	O
central	O
cholinergic	O
functioning	O
in	O
the	O
elderly	O
.	O

DESIGN	O
:	O
Randomized	O
double	O
-	O
blind	O
controlled	O
trial	O
.	O

PARTICIPANTS	O
:	O
Ten	O
healthy	O
elderly	O
(	O
mean	O
age	O
70	O
)	O
and	O
9	O
young	O
(	O
mean	O
age	O
33	O
)	O
volunteers	O
.	O

INTERVENTIONS	O
:	O
Pupil	O
diameter	O
was	O
monitored	O
using	O
a	O
computerized	O
infrared	O
pupillometer	O
over	O
4	O
hours	O
.	O

The	O
study	O
involved	O
4	O
sessions	O
.	O

In	O
1	O
session	O
,	O
tropicamide	B-CHED
(	O
20	O
microL	O
,	O
0	O
.	O
01	O
%	O
)	O
was	O
administered	O
to	O
one	O
eye	O
and	O
placebo	O
to	O
the	O
other	O
.	O

In	O
another	O
session	O
,	O
tropicamide	B-CHED
(	O
20	O
microL	O
,	O
0	O
.	O
01	O
%	O
)	O
was	O
administered	O
to	O
both	O
eyes	O
,	O
followed	O
23	O
minutes	O
later	O
by	O
the	O
application	O
of	O
pilocarpine	B-CHED
(	O
20	O
microL	O
,	O
0	O
.	O
1	O
%	O
)	O
to	O
one	O
eye	O
and	O
placebo	O
to	O
the	O
other	O
.	O

All	O
eye	O
drops	O
were	O
given	O
in	O
a	O
randomized	O
order	O
.	O

In	O
2	O
separate	O
sessions	O
,	O
a	O
single	O
dose	O
of	O
scopolamine	B-CHED
(	O
0	O
.	O
5	O
mg	O
,	O
intravenously	O
)	O
or	O
placebo	O
was	O
administered	O
,	O
and	O
the	O
effects	O
on	O
word	O
recall	O
were	O
measured	O
using	O
the	O
Buschke	O
Selective	O
Reminding	O
Test	O
over	O
2	O
hours	O
.	O

OUTCOME	O
MEASURES	O
:	O
Pupil	O
size	O
at	O
time	O
points	O
after	O
administration	O
of	O
tropicamide	B-CHED
and	O
pilocarpine	B-CHED
;	O
scopolamine	B-CHED
-	O
induced	O
impairment	O
in	O
word	O
recall	O
.	O

RESULTS	O
:	O
There	O
was	O
no	O
significant	O
difference	O
between	O
elderly	O
and	O
young	O
volunteers	O
in	O
pupillary	O
response	O
to	O
tropicamide	B-CHED
at	O
any	O
time	O
point	O
(	O
p	O
>	O
0	O
.	O
05	O
)	O
.	O

The	O
elderly	O
group	O
had	O
a	O
significantly	O
greater	O
pilocarpine	B-CHED
-	O
induced	O
net	O
decrease	O
in	O
pupil	O
size	O
85	O
,	O
125	O
,	O
165	O
and	O
215	O
minutes	O
after	O
administration	O
,	O
compared	O
with	O
the	O
young	O
group	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Compared	O
with	O
the	O
young	O
group	O
,	O
the	O
elderly	O
group	O
had	O
greater	O
scopolamine	B-CHED
-	O
induced	O
impairment	O
in	O
word	O
recall	O
60	O
,	O
90	O
and	O
120	O
minutes	O
after	O
administration	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

CONCLUSION	O
:	O
There	O
is	O
an	O
age	O
-	O
related	O
pupillary	O
response	O
to	O
pilocarpine	B-CHED
that	O
is	O
not	O
found	O
with	O
tropicamide	B-CHED
.	O

Thus	O
,	O
pilocarpine	B-CHED
may	O
be	O
useful	O
to	O
assess	O
variations	O
in	O
central	O
cholinergic	O
function	O
in	O
elderly	O
patients	O
.	O

Pain	O
responses	O
in	O
methadone	B-CHED
-	O
maintained	O
opioid	O
abusers	O
.	O

Providing	O
pain	O
management	O
for	O
known	O
opioid	O
abusers	O
is	O
a	O
challenging	O
clinical	O
task	O
,	O
in	O
part	O
because	O
little	O
is	O
known	O
about	O
their	O
pain	O
experience	O
and	O
analgesic	O
requirements	O
.	O

This	O
study	O
was	O
designed	O
to	O
describe	O
pain	O
tolerance	O
and	O
analgesic	O
response	O
in	O
a	O
sample	O
of	O
opioid	O
addicts	O
stabilized	O
in	O
methadone	B-CHED
-	O
maintenance	O
(	O
MM	O
)	O
treatment	O
(	O
n	O
=	O
60	O
)	O
in	O
comparison	O
to	O
matched	O
nondependent	O
control	O
subjects	O
(	O
n	O
=	O
60	O
)	O
.	O

By	O
using	O
a	O
placebo	O
-	O
controlled	O
,	O
two	O
-	O
way	O
factorial	O
design	O
,	O
tolerance	O
to	O
cold	O
-	O
pressor	O
(	O
CP	O
)	O
pain	O
was	O
examined	O
,	O
both	O
before	O
and	O
after	O
oral	O
administration	O
of	O
therapeutic	O
doses	O
of	O
common	O
opioid	O
(	O
hydromorphone	B-CHED
2	O
mg	O
)	O
and	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
(	O
ketorolac	B-CHED
10	O
mg	O
)	O
analgesic	O
agents	O
.	O

Results	O
showed	O
that	O
MM	O
individuals	O
were	O
significantly	O
less	O
tolerant	O
of	O
CP	O
pain	O
than	O
control	O
subjects	O
,	O
replicating	O
previous	O
work	O
.	O

Analgesic	O
effects	O
were	O
significant	O
neither	O
for	O
medication	O
nor	O
group	O
.	O

These	O
data	O
indicate	O
that	O
MM	O
opioid	O
abusers	O
represent	O
a	O
pain	O
-	O
intolerant	O
subset	O
of	O
clinical	O
patients	O
.	O

Their	O
complaints	O
of	O
pain	O
should	O
be	O
evaluated	O
seriously	O
and	O
managed	O
aggressively	O
.	O

High	O
-	O
dose	O
methylprednisolone	B-CHED
may	O
do	O
more	O
harm	O
for	O
spinal	O
cord	O
injury	O
.	O

Because	O
of	O
the	O
National	O
Acute	O
Spinal	O
Cord	O
Injury	O
Studies	O
(	O
NASCIS	O
)	O
,	O
high	O
-	O
dose	O
methylprednisolone	B-CHED
became	O
the	O
standard	O
of	O
care	O
for	O
the	O
acute	O
spinal	O
cord	O
injury	O
.	O

In	O
the	O
NASCIS	O
,	O
there	O
was	O
no	O
mention	O
regarding	O
the	O
possibility	O
of	O
acute	O
corticosteroid	B-CHED
myopathy	O
that	O
high	O
-	O
dose	O
methylprednisolone	B-CHED
may	O
cause	O
.	O

The	O
dosage	O
of	O
methylprednisolone	B-CHED
recommended	O
by	O
the	O
NASCIS	O
3	O
is	O
the	O
highest	O
dose	O
of	O
steroids	B-CHED
ever	O
being	O
used	O
during	O
a	O
2	O
-	O
day	O
period	O
for	O
any	O
clinical	O
condition	O
.	O

We	O
hypothesize	O
that	O
it	O
may	O
cause	O
some	O
damage	O
to	O
the	O
muscle	O
of	O
spinal	O
cord	O
injury	O
patients	O
.	O

Further	O
,	O
steroid	B-CHED
myopathy	O
recovers	O
naturally	O
and	O
the	O
neurological	O
improvement	O
shown	O
in	O
the	O
NASCIS	O
may	O
be	O
just	O
a	O
recording	O
of	O
this	O
natural	O
motor	O
recovery	O
from	O
the	O
steroid	B-CHED
myopathy	O
,	O
instead	O
of	O
any	O
protection	O
that	O
methylprednisolone	B-CHED
offers	O
to	O
the	O
spinal	O
cord	O
injury	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
discussion	O
considering	O
the	O
possibility	O
that	O
the	O
methylprednisolone	B-CHED
recommended	O
by	O
NASCIS	O
may	O
cause	O
acute	O
corticosteroid	B-CHED
myopathy	O
.	O

Conversion	O
to	O
rapamycin	B-CHED
immunosuppression	O
in	O
renal	O
transplant	O
recipients	O
:	O
report	O
of	O
an	O
initial	O
experience	O
.	O

BACKGROUND	O
:	O
The	O
aim	O
of	O
this	O
study	O
is	O
to	O
evaluate	O
the	O
effects	O
of	O
RAPA	B-CHED
conversion	O
in	O
patients	O
undergoing	O
cyclosporine	B-CHED
(	O
CsA	B-CHED
)	O
or	O
tacrolimus	B-CHED
(	O
Tac	B-CHED
)	O
toxicity	O
.	O

METHODS	O
:	O
Twenty	O
renal	O
transplant	O
recipients	O
were	O
switched	O
to	O
fixed	O
dose	O
rapamycin	B-CHED
(	O
RAPA	B-CHED
)	O
(	O
5	O
mg	O
/	O
day	O
)	O
0	O
to	O
204	O
months	O
posttransplant	O
.	O

Drug	O
monitoring	O
was	O
not	O
initially	O
used	O
to	O
adjust	O
doses	O
.	O

The	O
indications	O
for	O
switch	O
were	O
chronic	O
CsA	B-CHED
or	O
Tac	B-CHED
nephrotoxicity	O
(	O
12	O
)	O
,	O
acute	O
CsA	B-CHED
or	O
Tac	B-CHED
toxicity	O
(	O
3	O
)	O
,	O
severe	O
facial	O
dysmorphism	O
(	O
2	O
)	O
,	O
posttransplant	O
lymphoproliferative	O
disorder	O
(	O
PTLD	O
)	O
in	O
remission	O
(	O
2	O
)	O
,	O
and	O
hepatotoxicity	O
in	O
1	O
.	O

Follow	O
-	O
up	O
is	O
7	O
to	O
24	O
months	O
.	O

RESULTS	O
:	O
In	O
the	O
12	O
patients	O
switched	O
because	O
of	O
chronic	O
nephrotoxicity	O
there	O
was	O
a	O
significant	O
decrease	O
in	O
serum	O
creatinine	B-CHED
[	O
233	O
+	O
/	O
-	O
34	O
to	O
210	O
+	O
/	O
-	O
56	O
micromol	O
/	O
liter	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
at	O
6	O
months	O
]	O
.	O

Facial	O
dysmorphism	O
improved	O
in	O
two	O
patients	O
.	O

No	O
relapse	O
of	O
PTLD	O
was	O
observed	O
.	O

Five	O
patients	O
developed	O
pneumonia	O
(	O
two	O
Pneumocystis	O
carinii	O
pneumonia	O
,	O
one	O
infectious	O
mononucleosis	O
with	O
polyclonal	O
PTLD	O
lung	O
infiltrate	O
)	O
and	O
two	O
had	O
bronchiolitis	O
obliterans	O
.	O

There	O
were	O
no	O
deaths	O
.	O

RAPA	B-CHED
was	O
discontinued	O
in	O
four	O
patients	O
,	O
because	O
of	O
pneumonia	O
in	O
two	O
,	O
PTLD	O
in	O
one	O
,	O
and	O
oral	O
aphtous	O
ulcers	O
in	O
one	O
.	O

RAPA	B-CHED
levels	O
were	O
high	O
(	O
>	O
15	O
ng	O
/	O
ml	O
)	O
in	O
7	O
of	O
13	O
(	O
54	O
%	O
)	O
patients	O
.	O

CONCLUSIONS	O
:	O
RAPA	B-CHED
conversion	O
provides	O
adequate	O
immunosuppression	O
to	O
enable	O
CsA	B-CHED
withdrawal	O
.	O

However	O
,	O
when	O
converting	O
patients	O
to	O
RAPA	B-CHED
drug	O
levels	O
should	O
be	O
monitored	O
to	O
avoid	O
over	O
-	O
immunosuppression	O
and	O
adequate	O
antiviral	O
and	O
Pneumocystis	O
carinii	O
pneumonia	O
prophylaxis	O
should	O
be	O
given	O
.	O

Electro	O
-	O
oculography	O
,	O
electroretinography	O
,	O
visual	O
evoked	O
potentials	O
,	O
and	O
multifocal	O
electroretinography	O
in	O
patients	O
with	O
vigabatrin	B-CHED
-	O
attributed	O
visual	O
field	O
constriction	O
.	O

PURPOSE	O
:	O
Symptomatic	O
visual	O
field	O
constriction	O
thought	O
to	O
be	O
associated	O
with	O
vigabatrin	B-CHED
has	O
been	O
reported	O
.	O

The	O
current	O
study	O
investigated	O
the	O
visual	O
fields	O
and	O
visual	O
electrophysiology	O
of	O
eight	O
patients	O
with	O
known	O
vigabatrin	B-CHED
-	O
attributed	O
visual	O
field	O
loss	O
,	O
three	O
of	O
whom	O
were	O
reported	O
previously	O
.	O

Six	O
of	O
the	O
patients	O
were	O
no	O
longer	O
receiving	O
vigabatrin	B-CHED
.	O

METHODS	O
:	O
The	O
central	O
and	O
peripheral	O
fields	O
were	O
examined	O
with	O
the	O
Humphrey	O
Visual	O
Field	O
Analyzer	O
.	O

Full	O
visual	O
electrophysiology	O
,	O
including	O
flash	O
electroretinography	O
(	O
ERG	O
)	O
,	O
pattern	O
electroretinography	O
,	O
multifocal	O
ERG	O
using	O
the	O
VERIS	O
system	O
,	O
electro	O
-	O
oculography	O
,	O
and	O
flash	O
and	O
pattern	O
visual	O
evoked	O
potentials	O
,	O
was	O
undertaken	O
.	O

RESULTS	O
:	O
Seven	O
patients	O
showed	O
marked	O
visual	O
field	O
constriction	O
with	O
some	O
sparing	O
of	O
the	O
temporal	O
visual	O
field	O
.	O

The	O
eighth	O
exhibited	O
concentric	O
constriction	O
.	O

Most	O
electrophysiological	O
responses	O
were	O
usually	O
just	O
within	O
normal	O
limits	O
;	O
two	O
patients	O
had	O
subnormal	O
Arden	O
electro	O
-	O
oculography	O
indices	O
;	O
and	O
one	O
patient	O
showed	O
an	O
abnormally	O
delayed	O
photopic	O
b	O
wave	O
.	O

However	O
,	O
five	O
patients	O
showed	O
delayed	O
30	O
-	O
Hz	O
flicker	O
b	O
waves	O
,	O
and	O
seven	O
patients	O
showed	O
delayed	O
oscillatory	O
potentials	O
.	O

Multifocal	O
ERG	O
showed	O
abnormalities	O
that	O
sometimes	O
correlated	O
with	O
the	O
visual	O
field	O
appearance	O
and	O
confirmed	O
that	O
the	O
deficit	O
occurs	O
at	O
the	O
retinal	O
level	O
.	O

CONCLUSION	O
:	O
Marked	O
visual	O
field	O
constriction	O
appears	O
to	O
be	O
associated	O
with	O
vigabatrin	B-CHED
therapy	O
.	O

The	O
field	O
defects	O
and	O
some	O
electrophysiological	O
abnormalities	O
persist	O
when	O
vigabatrin	B-CHED
therapy	O
is	O
withdrawn	O
.	O

Myocardial	O
ischemia	O
due	O
to	O
coronary	O
artery	O
spasm	O
during	O
dobutamine	B-CHED
stress	O
echocardiography	O
.	O

Dobutamine	B-CHED
stress	O
echocardiography	O
(	O
DSE	O
)	O
is	O
a	O
useful	O
and	O
safe	O
provocation	O
test	O
for	O
myocardial	O
ischemia	O
.	O

Until	O
now	O
,	O
the	O
test	O
has	O
been	O
focused	O
only	O
on	O
the	O
organic	O
lesion	O
in	O
the	O
coronary	O
artery	O
,	O
and	O
positive	O
DSE	O
has	O
indicated	O
the	O
presence	O
of	O
significant	O
fixed	O
coronary	O
artery	O
stenosis	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
is	O
to	O
examine	O
whether	O
myocardial	O
ischemia	O
due	O
to	O
coronary	O
spasm	O
is	O
induced	O
by	O
dobutamine	B-CHED
.	O

We	O
performed	O
DSE	O
on	O
51	O
patients	O
with	O
coronary	O
spastic	O
angina	O
but	O
without	O
significant	O
fixed	O
coronary	O
artery	O
stenosis	O
.	O

All	O
patients	O
had	O
anginal	O
attacks	O
at	O
rest	O
with	O
ST	O
elevation	O
on	O
the	O
electrocardiogram	O
(	O
variant	O
angina	O
)	O
.	O

Coronary	O
spasm	O
was	O
induced	O
by	O
intracoronary	O
injection	O
of	O
acetylcholine	B-CHED
,	O
and	O
no	O
fixed	O
coronary	O
artery	O
stenosis	O
was	O
documented	O
on	O
angiograms	O
in	O
all	O
patients	O
.	O

DSE	O
was	O
performed	O
with	O
intravenous	O
dobutamine	B-CHED
infusion	O
with	O
an	O
incremental	O
doses	O
of	O
5	O
,	O
10	O
,	O
20	O
,	O
30	O
,	O
and	O
40	O
microg	O
/	O
kg	O
/	O
min	O
every	O
5	O
minutes	O
.	O

Of	O
the	O
51	O
patients	O
,	O
7	O
patients	O
showed	O
asynergy	O
with	O
ST	O
elevation	O
.	O

All	O
7	O
patients	O
(	O
13	O
.	O
7	O
%	O
)	O
had	O
chest	O
pain	O
during	O
asynergy	O
,	O
and	O
both	O
chest	O
pain	O
and	O
electrocardiographic	O
changes	O
were	O
preceded	O
by	O
asynergy	O
.	O

These	O
findings	O
indicate	O
that	O
dobutamine	B-CHED
can	O
provoke	O
coronary	O
spasm	O
in	O
some	O
patients	O
with	O
coronary	O
spastic	O
angina	O
.	O

When	O
DSE	O
is	O
performed	O
to	O
evaluate	O
coronary	O
artery	O
disease	O
,	O
not	O
only	O
fixed	O
coronary	O
stenosis	O
,	O
but	O
also	O
coronary	O
spasm	O
should	O
be	O
considered	O
as	O
a	O
genesis	O
of	O
asynergy	O
.	O

Effect	O
of	O
intravenous	O
metoprolol	B-CHED
or	O
intravenous	O
metoprolol	B-CHED
plus	O
glucagon	O
on	O
dobutamine	B-CHED
-	O
induced	O
myocardial	O
ischemia	O
.	O

STUDY	O
OBJECTIVE	O
:	O
To	O
determine	O
the	O
effect	O
of	O
metoprolol	B-CHED
on	O
dobutamine	B-CHED
stress	O
testing	O
with	O
technetium	B-CHED
-	I-CHED
99m	I-CHED
sestamibi	I-CHED
single	O
-	O
photon	O
emission	O
computed	O
tomography	O
imaging	O
and	O
ST	O
-	O
segment	O
monitoring	O
,	O
and	O
to	O
assess	O
the	O
impact	O
of	O
intravenous	O
glucagon	O
on	O
metoprolol	B-CHED
'	O
s	O
effects	O
.	O

DESIGN	O
:	O
Randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
.	O

SETTING	O
:	O
Community	O
hospital	O
.	O

PATIENTS	O
:	O
Twenty	O
-	O
two	O
patients	O
with	O
known	O
reversible	O
perfusion	O
defects	O
.	O

INTERVENTION	O
:	O
Patients	O
underwent	O
dobutamine	B-CHED
stress	O
tests	O
per	O
standard	O
protocol	O
.	O

Before	O
dobutamine	B-CHED
was	O
begun	O
,	O
no	O
therapy	O
was	O
given	O
during	O
the	O
first	O
visit	O
,	O
and	O
patients	O
were	O
randomized	O
on	O
subsequent	O
visits	O
to	O
receive	O
metoprolol	B-CHED
or	O
metoprolol	B-CHED
plus	O
glucagon	O
1	O
mg	O
.	O

Metoprolol	B-CHED
was	O
dosed	O
to	O
achieve	O
a	O
resting	O
predobutamine	B-CHED
heart	O
rate	O
below	O
65	O
beats	O
/	O
minute	O
or	O
a	O
total	O
intravenous	O
dose	O
of	O
20	O
mg	O
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
:	O
Metoprolol	B-CHED
reduced	O
maximum	O
heart	O
rate	O
31	O
%	O
,	O
summed	O
stress	O
scores	O
29	O
%	O
,	O
and	O
summed	O
difference	O
scores	O
43	O
%	O
versus	O
control	O
.	O

Metoprolol	B-CHED
plus	O
glucagon	O
also	O
reduced	O
the	O
maximum	O
heart	O
rate	O
29	O
%	O
versus	O
control	O
.	O

Summed	O
stress	O
and	O
summed	O
difference	O
scores	O
were	O
not	O
significantly	O
reduced	O
,	O
although	O
they	O
were	O
18	O
%	O
and	O
30	O
%	O
lower	O
,	O
respectively	O
,	O
than	O
control	O
.	O

No	O
significant	O
differences	O
were	O
found	O
in	O
any	O
parameter	O
between	O
metoprolol	B-CHED
and	O
metoprolol	B-CHED
-	O
glucagon	O
.	O

CONCLUSION	O
:	O
During	O
dobutamine	B-CHED
stress	O
testing	O
,	O
metoprolol	B-CHED
attenuates	O
or	O
eliminates	O
evidence	O
of	O
myocardial	O
ischemia	O
.	O

Glucagon	O
1	O
mg	O
,	O
although	O
somewhat	O
effective	O
,	O
does	O
not	O
correct	O
this	O
effect	O
to	O
the	O
extent	O
that	O
it	O
can	O
be	O
administered	O
clinically	O
.	O

Evidence	O
of	O
functional	O
somatotopy	O
in	O
GPi	O
from	O
results	O
of	O
pallidotomy	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
explore	O
the	O
functional	O
anatomy	O
of	O
the	O
globus	O
pallidus	O
internus	O
(	O
GPi	O
)	O
by	O
studying	O
the	O
effects	O
of	O
unilateral	O
pallidotomy	O
on	O
parkinsonian	O
'	O
off	O
'	O
signs	O
and	O
levodopa	B-CHED
-	O
induced	O
dyskinesias	O
(	O
LID	O
)	O
.	O

We	O
found	O
significant	O
positive	O
correlations	O
between	O
the	O
preoperative	O
levodopa	B-CHED
responsiveness	O
of	O
motor	O
signs	O
and	O
the	O
levodopa	B-CHED
responsiveness	O
of	O
scores	O
in	O
timed	O
tests	O
(	O
Core	O
Assessment	O
Program	O
for	O
Intracerebral	O
Transplantations	O
)	O
in	O
the	O
contralateral	O
limbs	O
and	O
the	O
improvement	O
in	O
these	O
scores	O
after	O
surgery	O
,	O
whereas	O
there	O
was	O
no	O
correlation	O
with	O
the	O
improvement	O
in	O
LID	O
.	O

We	O
also	O
found	O
a	O
highly	O
significant	O
correlation	O
(	O
P	O
:	O
<	O
0	O
.	O
0001	O
,	O
r	O
=	O
0	O
.	O
8	O
)	O
between	O
the	O
volume	O
of	O
the	O
ventral	O
lesion	O
in	O
the	O
GPi	O
and	O
the	O
improvement	O
in	O
LID	O
in	O
the	O
contralateral	O
limbs	O
,	O
whereas	O
there	O
was	O
no	O
correlation	O
between	O
the	O
ventral	O
volume	O
and	O
the	O
improvement	O
in	O
parkinsonian	O
'	O
off	O
'	O
signs	O
.	O

The	O
volumes	O
of	O
the	O
total	O
lesion	O
cylinder	O
and	O
the	O
dorsal	O
lesion	O
did	O
not	O
correlate	O
with	O
the	O
outcome	O
of	O
either	O
dyskinesias	O
or	O
parkinsonian	O
'	O
off	O
'	O
signs	O
.	O

The	O
differential	O
predictive	O
value	O
of	O
levodopa	B-CHED
responsiveness	O
for	O
the	O
outcome	O
of	O
parkinsonian	O
'	O
off	O
'	O
signs	O
and	O
LID	O
and	O
the	O
different	O
correlations	O
of	O
ventral	O
lesion	O
volume	O
with	O
dyskinesias	O
and	O
parkinsonian	O
'	O
off	O
'	O
signs	O
indicate	O
that	O
different	O
anatomical	O
or	O
pathophysiological	O
substrates	O
may	O
be	O
responsible	O
for	O
the	O
generation	O
of	O
parkinsonian	O
'	O
off	O
'	O
signs	O
and	O
dyskinesias	O
.	O

Whereas	O
cells	O
in	O
a	O
wider	O
area	O
of	O
the	O
GPi	O
may	O
be	O
implicated	O
in	O
parkinsonism	O
,	O
the	O
ventral	O
GPi	O
seems	O
to	O
be	O
crucial	O
for	O
the	O
manifestation	O
of	O
LID	O
.	O

We	O
suggest	O
that	O
our	O
observations	O
are	O
additional	O
proof	O
of	O
the	O
functional	O
somatotopy	O
of	O
the	O
systems	O
within	O
the	O
GPi	O
that	O
mediate	O
parkinsonism	O
and	O
dyskinesias	O
,	O
especially	O
along	O
the	O
dorsoventral	O
trajectory	O
used	O
in	O
pallidotomy	O
.	O

The	O
outcome	O
of	O
pallidotomy	O
in	O
which	O
the	O
lesion	O
involves	O
the	O
ventral	O
and	O
dorsal	O
GPi	O
could	O
be	O
the	O
net	O
effect	O
of	O
alteration	O
in	O
the	O
activity	O
of	O
pathways	O
which	O
mediate	O
different	O
symptoms	O
,	O
and	O
hence	O
could	O
be	O
variable	O
.	O

Screening	O
for	O
stimulant	O
use	O
in	O
adult	O
emergency	O
department	O
seizure	O
patients	O
.	O

OBJECTIVE	O
:	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
prevalence	O
of	O
positive	O
plasma	O
drug	O
screening	O
for	O
cocaine	B-CHED
or	O
amphetamine	B-CHED
in	O
adult	O
emergency	O
department	O
seizure	O
patients	O
.	O

METHODS	O
:	O
This	O
prospective	O
study	O
evaluated	O
consecutive	O
eligible	O
seizure	O
patients	O
who	O
had	O
a	O
plasma	O
sample	O
collected	O
as	O
part	O
of	O
their	O
clinical	O
evaluation	O
.	O

Plasma	O
was	O
tested	O
for	O
amphetamine	B-CHED
and	O
the	O
cocaine	B-CHED
metabolite	O
benzoylecgonine	B-CHED
using	O
enzyme	O
-	O
mediated	O
immunoassay	O
methodology	O
.	O

Plasma	O
samples	O
with	O
benzoylecgonine	B-CHED
greater	O
than	O
150	O
ng	O
/	O
mL	O
or	O
an	O
amphetamine	B-CHED
greater	O
than	O
500	O
ng	O
/	O
mL	O
were	O
defined	O
as	O
positive	O
.	O

Patient	O
demographics	O
,	O
history	O
of	O
underlying	O
drug	O
or	O
alcohol	B-CHED
-	O
related	O
seizure	O
disorder	O
,	O
estimated	O
time	O
from	O
seizure	O
to	O
sample	O
collection	O
,	O
history	O
or	O
suspicion	O
of	O
cocaine	O
or	O
amphetamine	O
abuse	O
,	O
results	O
of	O
clinical	O
urine	O
testing	O
for	O
drugs	O
of	O
abuse	O
,	O
and	O
assay	O
results	O
were	O
recorded	O
without	O
patient	O
identifiers	O
.	O

RESULTS	O
:	O
Fourteen	O
of	O
248	O
(	O
5	O
.	O
6	O
%	O
,	O
95	O
%	O
CI	O
2	O
.	O
7	O
%	O
-	O
8	O
.	O
5	O
%	O
)	O
plasma	O
samples	O
were	O
positive	O
by	O
immunoassay	O
testing	O
for	O
benzoylecgonine	B-CHED
and	O
no	O
samples	O
(	O
0	O
%	O
,	O
95	O
%	O
CI	O
0	O
-	O
1	O
.	O
2	O
%	O
)	O
were	O
positive	O
for	O
amphetamine	B-CHED
.	O

Positive	O
test	O
results	O
were	O
more	O
common	O
in	O
patient	O
visits	O
where	O
there	O
was	O
a	O
history	O
or	O
suspicion	O
of	O
cocaine	O
or	O
amphetamine	O
abuse	O
(	O
p	O
<	O
0	O
.	O
0005	O
)	O
.	O

CONCLUSIONS	O
:	O
During	O
this	O
study	O
period	O
,	O
routine	O
plasma	O
screening	O
for	O
cocaine	B-CHED
and	O
amphetamines	B-CHED
in	O
adult	O
seizure	O
patients	O
had	O
a	O
low	O
yield	O
.	O

As	O
a	O
result	O
,	O
routine	O
plasma	O
screening	O
would	O
yield	O
few	O
cases	O
of	O
stimulant	O
drug	O
in	O
which	O
there	O
was	O
neither	O
a	O
history	O
nor	O
suspicion	O
of	O
drug	O
abuse	O
in	O
this	O
population	O
.	O

Contribution	O
of	O
sodium	B-CHED
valproate	I-CHED
to	O
the	O
syndrome	O
of	O
inappropriate	O
secretion	O
of	O
antidiuretic	O
hormone	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
62	O
-	O
year	O
-	O
old	O
man	O
who	O
was	O
administered	O
sodium	B-CHED
valproate	I-CHED
(	O
VPA	B-CHED
)	O
and	O
who	O
subsequently	O
developed	O
the	O
syndrome	O
of	O
inappropriate	O
secretion	O
of	O
antidiuretic	O
hormone	O
(	O
SIADH	O
)	O
.	O

He	O
had	O
been	O
taking	O
VPA	B-CHED
for	O
treatment	O
of	O
idiopathic	O
generalized	O
tonic	O
-	O
clonic	O
convulsions	O
since	O
he	O
was	O
56	O
years	O
old	O
.	O

After	O
substituting	O
VPA	B-CHED
with	O
zonisamide	B-CHED
,	O
the	O
serum	O
sodium	B-CHED
level	O
returned	O
to	O
normal	O
.	O

We	O
consider	O
this	O
episode	O
of	O
SIADH	O
to	O
be	O
the	O
result	O
of	O
a	O
combination	O
of	O
factors	O
including	O
a	O
weakness	O
of	O
the	O
central	O
nervous	O
system	O
and	O
the	O
long	O
-	O
term	O
administration	O
of	O
VPA	B-CHED
.	O

Association	O
of	O
nitric	B-CHED
oxide	I-CHED
production	O
and	O
apoptosis	O
in	O
a	O
model	O
of	O
experimental	O
nephropathy	O
.	O

BACKGROUND	O
:	O
In	O
recent	O
studies	O
increased	O
amounts	O
of	O
nitric	B-CHED
oxide	I-CHED
(	O
NO	B-CHED
)	O
and	O
apoptosis	O
have	O
been	O
implicated	O
in	O
various	O
pathological	O
conditions	O
in	O
the	O
kidney	O
.	O

We	O
have	O
studied	O
the	O
role	O
of	O
NO	B-CHED
and	O
its	O
association	O
with	O
apoptosis	O
in	O
an	O
experimental	O
model	O
of	O
nephrotic	O
syndrome	O
induced	O
by	O
a	O
single	O
injection	O
of	O
adriamycin	B-CHED
(	O
ADR	B-CHED
)	O
.	O

METHODS	O
:	O
The	O
alteration	O
in	O
the	O
NO	B-CHED
pathway	O
was	O
assessed	O
by	O
measuring	O
nitrite	B-CHED
levels	O
in	O
serum	O
/	O
urine	O
and	O
by	O
evaluating	O
the	O
changes	O
in	O
vascular	O
reactivity	O
of	O
the	O
isolated	O
perfused	O
rat	O
kidney	O
(	O
IPRK	O
)	O
system	O
.	O

Rats	O
were	O
stratified	O
into	O
control	O
groups	O
and	O
ADR	B-CHED
-	O
induced	O
nephropathy	O
groups	O
.	O

These	O
two	O
groups	O
were	O
then	O
divided	O
into	O
:	O
group	O
1	O
,	O
animals	O
receiving	O
saline	O
;	O
and	O
group	O
2	O
,	O
animals	O
receiving	O
aminoguanidine	B-CHED
(	O
AG	B-CHED
)	O
which	O
is	O
a	O
specific	O
inhibitor	O
of	O
inducible	O
-	O
NO	B-CHED
synthase	O
.	O

On	O
day	O
21	O
,	O
rats	O
were	O
sacrificed	O
after	O
obtaining	O
material	O
for	O
biochemical	O
analysis	O
.	O

RESULTS	O
:	O
Histopathological	O
examination	O
of	O
the	O
kidneys	O
of	O
rats	O
treated	O
with	O
ADR	B-CHED
revealed	O
focal	O
areas	O
of	O
mesangial	O
proliferation	O
and	O
mild	O
tubulointerstitial	O
inflammation	O
.	O

They	O
also	O
had	O
significantly	O
higher	O
levels	O
of	O
proteinuria	O
compared	O
with	O
control	O
and	O
treatment	O
groups	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Urine	O
nitrite	B-CHED
levels	O
were	O
significantly	O
increased	O
in	O
the	O
ADR	B-CHED
-	O
nephropathy	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

In	O
the	O
IPRK	O
phenylephrine	B-CHED
and	O
acetylcholine	B-CHED
related	O
responses	O
were	O
significantly	O
impaired	O
in	O
the	O
ADR	B-CHED
-	O
nephropathy	O
group	O
.	O

Apoptosis	O
was	O
not	O
detected	O
in	O
controls	O
.	O

However	O
,	O
in	O
the	O
ADR	B-CHED
-	O
nephropathy	O
group	O
,	O
numerous	O
apoptotic	O
cells	O
were	O
identified	O
in	O
the	O
tubulointerstitial	O
areas	O
.	O

Double	O
staining	O
revealed	O
numerous	O
interstitial	O
apoptotic	O
cells	O
to	O
stain	O
for	O
ED1	O
,	O
a	O
marker	O
for	O
monocytes	O
/	O
macrophages	O
.	O

Treatment	O
with	O
AG	B-CHED
prevented	O
the	O
impairment	O
of	O
renal	O
vascular	O
bed	O
responses	O
and	O
reduced	O
both	O
urine	O
nitrite	B-CHED
levels	O
and	O
apoptosis	O
to	O
control	O
levels	O
.	O

CONCLUSION	O
:	O
We	O
suggest	O
that	O
interactions	O
between	O
NO	B-CHED
and	O
apoptosis	O
are	O
important	O
in	O
the	O
pathogenesis	O
of	O
the	O
ADR	B-CHED
-	O
induced	O
nephrosis	O
.	O

Dual	O
effects	O
of	O
melatonin	B-CHED
on	O
barbiturate	B-CHED
-	O
induced	O
narcosis	O
in	O
rats	O
.	O

Melatonin	B-CHED
affects	O
the	O
circadian	O
sleep	O
/	O
wake	O
cycle	O
,	O
but	O
it	O
is	O
not	O
clear	O
whether	O
it	O
may	O
influence	O
drug	O
-	O
induced	O
narcosis	O
.	O

Sodium	B-CHED
thiopenthal	I-CHED
was	O
administered	O
intraperitoneally	O
into	O
male	O
rats	O
pre	O
-	O
treated	O
with	O
melatonin	B-CHED
(	O
0	O
.	O
05	O
,	O
0	O
.	O
5	O
,	O
5	O
and	O
50	O
mg	O
/	O
kg	O
)	O
.	O

Melatonin	B-CHED
pre	O
-	O
treatment	O
affected	O
in	O
a	O
dual	O
manner	O
barbiturate	B-CHED
narcosis	O
,	O
however	O
,	O
no	O
dose	O
-	O
effect	O
correlation	O
was	O
found	O
.	O

In	O
particular	O
,	O
low	O
doses	O
reduced	O
the	O
latency	O
to	O
and	O
prolonged	O
the	O
duration	O
of	O
barbiturate	B-CHED
narcosis	O
.	O

In	O
contrast	O
,	O
the	O
highest	O
dose	O
of	O
melatonin	B-CHED
(	O
50	O
mg	O
/	O
kg	O
)	O
caused	O
a	O
paradoxical	O
increase	O
in	O
the	O
latency	O
and	O
produced	O
a	O
sustained	O
reduction	O
of	O
the	O
duration	O
of	O
narcosis	O
,	O
and	O
a	O
reduction	O
in	O
mortality	O
rate	O
.	O

Melatonin	B-CHED
0	O
.	O
5	O
and	O
5	O
mg	O
/	O
kg	O
influenced	O
the	O
duration	O
but	O
not	O
the	O
latency	O
of	O
ketamine	B-CHED
-	O
or	O
diazepam	B-CHED
-	O
induced	O
narcosis	O
.	O

Thus	O
,	O
the	O
dual	O
action	O
of	O
melatonin	B-CHED
on	O
pharmacological	O
narcosis	O
seems	O
to	O
be	O
specific	O
for	O
the	O
barbiturate	B-CHED
mechanism	O
of	O
action	O
.	O

Reduced	O
cardiotoxicity	O
and	O
preserved	O
antitumor	O
efficacy	O
of	O
liposome	O
-	O
encapsulated	O
doxorubicin	B-CHED
and	O
cyclophosphamide	B-CHED
compared	O
with	O
conventional	O
doxorubicin	B-CHED
and	O
cyclophosphamide	B-CHED
in	O
a	O
randomized	O
,	O
multicenter	O
trial	O
of	O
metastatic	O
breast	O
cancer	O
.	O

PURPOSE	O
:	O
To	O
determine	O
whether	O
Myocet	B-CHED
(	O
liposome	O
-	O
encapsulated	O
doxorubicin	B-CHED
;	O
The	O
Liposome	O
Company	O
,	O
Elan	O
Corporation	O
,	O
Princeton	O
,	O
NJ	O
)	O
in	O
combination	O
with	O
cyclophosphamide	B-CHED
significantly	O
reduces	O
doxorubicin	B-CHED
cardiotoxicity	O
while	O
providing	O
comparable	O
antitumor	O
efficacy	O
in	O
first	O
-	O
line	O
treatment	O
of	O
metastatic	O
breast	O
cancer	O
(	O
MBC	O
)	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Two	O
hundred	O
ninety	O
-	O
seven	O
patients	O
with	O
MBC	O
and	O
no	O
prior	O
chemotherapy	O
for	O
metastatic	O
disease	O
were	O
randomized	O
to	O
receive	O
either	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
of	O
Myocet	B-CHED
(	O
M	O
)	O
or	O
conventional	O
doxorubicin	B-CHED
(	O
A	O
)	O
,	O
in	O
combination	O
with	O
600	O
mg	O
/	O
m	O
(	O
2	O
)	O
of	O
cyclophosphamide	B-CHED
(	O
C	O
)	O
,	O
every	O
3	O
weeks	O
until	O
disease	O
progression	O
or	O
unacceptable	O
toxicity	O
.	O

Cardiotoxicity	O
was	O
defined	O
by	O
reductions	O
in	O
left	O
-	O
ventricular	O
ejection	O
fraction	O
,	O
assessed	O
by	O
serial	O
multigated	O
radionuclide	O
angiography	O
scans	O
,	O
or	O
congestive	O
heart	O
failure	O
(	O
CHF	O
)	O
.	O

Antitumor	O
efficacy	O
was	O
assessed	O
by	O
objective	O
tumor	O
response	O
rates	O
(	O
World	O
Health	O
Organization	O
criteria	O
)	O
,	O
time	O
to	O
progression	O
,	O
and	O
survival	O
.	O

RESULTS	O
:	O
Six	O
percent	O
of	O
MC	O
patients	O
versus	O
21	O
%	O
(	O
including	O
five	O
cases	O
of	O
CHF	O
)	O
of	O
AC	O
patients	O
developed	O
cardiotoxicity	O
(	O
P	O
=	O
.	O
0002	O
)	O
.	O

Median	O
cumulative	O
doxorubicin	B-CHED
dose	O
at	O
onset	O
was	O
more	O
than	O
2	O
,	O
220	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
MC	O
versus	O
480	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
AC	O
(	O
P	O
=	O
.	O
0001	O
,	O
hazard	O
ratio	O
,	O
5	O
.	O
04	O
)	O
.	O

MC	O
patients	O
also	O
experienced	O
less	O
grade	O
4	O
neutropenia	O
.	O

Antitumor	O
efficacy	O
of	O
MC	O
versus	O
AC	O
was	O
comparable	O
:	O
objective	O
response	O
rates	O
,	O
43	O
%	O
versus	O
43	O
%	O
;	O
median	O
time	O
to	O
progression	O
,	O
5	O
.	O
1	O
%	O
versus	O
5	O
.	O
5	O
months	O
;	O
median	O
time	O
to	O
treatment	O
failure	O
,	O
4	O
.	O
6	O
versus	O
4	O
.	O
4	O
months	O
;	O
and	O
median	O
survival	O
,	O
19	O
versus	O
16	O
months	O
.	O

CONCLUSION	O
:	O
Myocet	B-CHED
improves	O
the	O
therapeutic	O
index	O
of	O
doxorubicin	B-CHED
by	O
significantly	O
reducing	O
cardiotoxicity	O
and	O
grade	O
4	O
neutropenia	O
and	O
provides	O
comparable	O
antitumor	O
efficacy	O
,	O
when	O
used	O
in	O
combination	O
with	O
cyclophosphamide	B-CHED
as	O
first	O
-	O
line	O
therapy	O
for	O
MBC	O
.	O

The	O
role	O
of	O
nitrergic	O
system	O
in	O
lidocaine	B-CHED
-	O
induced	O
convulsion	O
in	O
the	O
mouse	O
.	O

The	O
effects	O
of	O
N	B-CHED
-	I-CHED
nitro	I-CHED
-	I-CHED
L	I-CHED
-	I-CHED
arginine	I-CHED
-	I-CHED
methyl	I-CHED
ester	I-CHED
(	O
L	B-CHED
-	I-CHED
NAME	I-CHED
)	O
a	O
nitric	B-CHED
oxide	I-CHED
(	O
NO	B-CHED
)	O
synthase	O
inhibitor	O
and	O
L	B-CHED
-	I-CHED
arginine	I-CHED
,	O
a	O
NO	B-CHED
precursor	O
,	O
were	O
investigated	O
on	O
lidocaine	B-CHED
-	O
induced	O
convulsions	O
.	O

In	O
the	O
first	O
experiment	O
,	O
four	O
groups	O
of	O
mice	O
received	O
physiological	O
saline	O
(	O
0	O
.	O
9	O
%	O
)	O
,	O
L	B-CHED
-	I-CHED
arginine	I-CHED
(	O
300	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
,	O
L	B-CHED
-	I-CHED
NAME	I-CHED
(	O
100	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
and	O
diazepam	B-CHED
(	O
2	O
mg	O
/	O
kg	O
)	O
,	O
respectively	O
.	O

Thirty	O
minutes	O
after	O
these	O
injections	O
,	O
all	O
mice	O
received	O
lidocaine	B-CHED
(	O
50	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
.	O

In	O
the	O
second	O
experiment	O
,	O
four	O
groups	O
of	O
mice	O
received	O
similar	O
treatment	O
in	O
the	O
first	O
experiment	O
,	O
and	O
30	O
min	O
after	O
these	O
injections	O
,	O
all	O
mice	O
received	O
a	O
higher	O
dose	O
of	O
lidocaine	B-CHED
(	O
80	O
mg	O
/	O
kg	O
)	O
.	O

L	B-CHED
-	I-CHED
NAME	I-CHED
(	O
100	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
and	O
diazepam	B-CHED
(	O
2	O
mg	O
/	O
kg	O
)	O
significantly	O
decreased	O
the	O
incidence	O
of	O
lidocaine	B-CHED
(	O
50	O
mg	O
/	O
kg	O
)	O
-	O
induced	O
convulsions	O
.	O

In	O
contrast	O
,	O
the	O
L	B-CHED
-	I-CHED
arginine	I-CHED
treatment	O
increased	O
the	O
incidence	O
of	O
lidocaine	B-CHED
(	O
80	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
-	O
induced	O
convulsions	O
significantly	O
.	O

These	O
results	O
may	O
suggest	O
that	O
NO	B-CHED
is	O
a	O
proconvulsant	O
mediator	O
in	O
lidocaine	B-CHED
-	O
induced	O
convulsions	O
.	O

Erythropoietin	O
restores	O
the	O
anemia	O
-	O
induced	O
reduction	O
in	O
cyclophosphamide	B-CHED
cytotoxicity	O
in	O
rat	O
tumors	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
impact	O
of	O
anemia	O
prevention	O
by	O
recombinant	O
human	O
erythropoietin	O
(	O
rHuEPO	O
)	O
treatment	O
on	O
the	O
cytotoxicity	O
of	O
cyclophosphamide	B-CHED
in	O
solid	O
experimental	O
tumors	O
.	O

Anemia	O
was	O
induced	O
using	O
a	O
single	O
dose	O
of	O
carboplatin	B-CHED
(	O
50	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
resulting	O
in	O
a	O
long	O
-	O
lasting	O
reduction	O
(	O
30	O
%	O
)	O
of	O
the	O
hemoglobin	O
concentration	O
.	O

In	O
a	O
second	O
group	O
,	O
the	O
development	O
of	O
anemia	O
was	O
prevented	O
by	O
rHuEPO	O
(	O
1000	O
IU	O
/	O
kg	O
)	O
administered	O
s	O
.	O
c	O
.	O
three	O
times	O
/	O
week	O
starting	O
7	O
days	O
before	O
carboplatin	B-CHED
application	O
.	O

Four	O
days	O
after	O
carboplatin	B-CHED
treatment	O
,	O
tumors	O
(	O
DS	O
-	O
sarcoma	O
of	O
the	O
rat	O
)	O
were	O
implanted	O
s	O
.	O
c	O
.	O
onto	O
the	O
hind	O
food	O
dorsum	O
.	O

Neither	O
carboplatin	B-CHED
nor	O
rHuEPO	O
treatment	O
influenced	O
tumor	O
growth	O
rate	O
per	O
se	O
.	O

When	O
tumors	O
were	O
treated	O
with	O
a	O
single	O
dose	O
of	O
cyclophosphamide	B-CHED
(	O
60	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
5	O
days	O
after	O
implantation	O
,	O
a	O
growth	O
delay	O
with	O
a	O
subsequent	O
regrowth	O
of	O
the	O
tumors	O
was	O
observed	O
.	O

In	O
the	O
anemia	O
group	O
,	O
the	O
growth	O
delay	O
was	O
significantly	O
shorter	O
compared	O
with	O
nonanemic	O
controls	O
(	O
13	O
.	O
3	O
days	O
versus	O
8	O
.	O
6	O
days	O
)	O
.	O

In	O
the	O
group	O
where	O
anemia	O
was	O
prevented	O
by	O
rHuEPO	O
treatment	O
,	O
growth	O
delay	O
was	O
comparable	O
with	O
that	O
of	O
nonanemic	O
controls	O
(	O
13	O
.	O
3	O
days	O
)	O
.	O

These	O
results	O
suggest	O
that	O
chemotherapy	O
-	O
induced	O
anemia	O
reduces	O
cytotoxicity	O
of	O
cyclophosphamide	B-CHED
in	O
tumors	O
,	O
whereas	O
correction	O
of	O
anemia	O
by	O
rHuEPO	O
treatment	O
(	O
epoetin	O
alpha	O
)	O
increases	O
the	O
sensitivity	O
,	O
probably	O
as	O
a	O
result	O
of	O
an	O
improved	O
oxygen	B-CHED
supply	O
to	O
tumor	O
tissue	O
.	O

Fatal	O
haemorrhagic	O
myocarditis	O
secondary	O
to	O
cyclophosphamide	B-CHED
therapy	O
.	O

Haemorrhagic	O
myocarditis	O
is	O
a	O
rare	O
but	O
important	O
complication	O
of	O
cyclophosphamide	B-CHED
therapy	O
.	O

Echocardiographic	O
identification	O
of	O
the	O
disorder	O
can	O
be	O
made	O
.	O

We	O
believe	O
that	O
the	O
ultrasound	O
features	O
of	O
this	O
disorder	O
have	O
not	O
been	O
previously	O
reported	O
.	O

Effects	O
of	O
verapamil	B-CHED
on	O
atrial	O
fibrillation	O
and	O
its	O
electrophysiological	O
determinants	O
in	O
dogs	O
.	O

BACKGROUND	O
:	O
Atrial	O
tachycardia	O
-	O
induced	O
remodeling	O
promotes	O
the	O
occurrence	O
and	O
maintenance	O
of	O
atrial	O
fibrillation	O
(	O
AF	O
)	O
and	O
decreases	O
L	O
-	O
type	O
Ca	B-CHED
(	O
2	O
+	O
)	O
current	O
.	O

There	O
is	O
also	O
a	O
clinical	O
suggestion	O
that	O
acute	O
L	O
-	O
type	O
Ca	B-CHED
(	O
2	O
)	O
channel	O
blockade	O
can	O
promote	O
AF	O
,	O
consistent	O
with	O
an	O
AF	O
promoting	O
effect	O
of	O
Ca	B-CHED
(	O
2	O
+	O
)	O
channel	O
inhibition	O
.	O

METHODS	O
:	O
To	O
evaluate	O
the	O
potential	O
mechanisms	O
of	O
AF	O
promotion	O
by	O
Ca	B-CHED
(	O
2	O
+	O
)	O
channel	O
blockers	O
,	O
we	O
administered	O
verapamil	B-CHED
to	O
morphine	B-CHED
-	O
chloralose	B-CHED
anesthetized	O
dogs	O
.	O

Diltiazem	B-CHED
was	O
used	O
as	O
a	O
comparison	O
drug	O
and	O
autonomic	O
blockade	O
with	O
atropine	B-CHED
and	O
nadolol	B-CHED
was	O
applied	O
in	O
some	O
experiments	O
.	O

Epicardial	O
mapping	O
with	O
240	O
epicardial	O
electrodes	O
was	O
used	O
to	O
evaluate	O
activation	O
during	O
AF	O
.	O

RESULTS	O
:	O
Verapamil	B-CHED
caused	O
AF	O
promotion	O
in	O
six	O
dogs	O
,	O
increasing	O
mean	O
duration	O
of	O
AF	O
induced	O
by	O
burst	O
pacing	O
,	O
from	O
8	O
+	O
/	O
-	O
4	O
s	O
(	O
mean	O
+	O
/	O
-	O
S	O
.	O
E	O
.	O
)	O
to	O
95	O
+	O
/	O
-	O
39	O
s	O
(	O
P	O
<	O
0	O
.	O
01	O
vs	O
.	O
control	O
)	O
at	O
a	O
loading	O
dose	O
of	O
0	O
.	O
1	O
mg	O
/	O
kg	O
and	O
228	O
+	O
/	O
-	O
101	O
s	O
(	O
P	O
<	O
0	O
.	O
0005	O
vs	O
.	O
control	O
)	O
at	O
a	O
dose	O
of	O
0	O
.	O
2	O
mg	O
/	O
kg	O
.	O

Underlying	O
electrophysiological	O
mechanisms	O
were	O
studied	O
in	O
detail	O
in	O
five	O
additional	O
dogs	O
under	O
control	O
conditions	O
and	O
in	O
the	O
presence	O
of	O
the	O
higher	O
dose	O
of	O
verapamil	B-CHED
.	O

In	O
these	O
experiments	O
,	O
verapamil	B-CHED
shortened	O
mean	O
effective	O
refractory	O
period	O
(	O
ERP	O
)	O
from	O
122	O
+	O
/	O
-	O
5	O
to	O
114	O
+	O
/	O
-	O
4	O
ms	O
(	O
P	O
<	O
0	O
.	O
02	O
)	O
at	O
a	O
cycle	O
length	O
of	O
300	O
ms	O
,	O
decreased	O
ERP	O
heterogeneity	O
(	O
from	O
15	O
+	O
/	O
-	O
1	O
to	O
10	O
+	O
/	O
-	O
1	O
%	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
heterogeneously	O
accelerated	O
atrial	O
conduction	O
and	O
decreased	O
the	O
cycle	O
length	O
of	O
AF	O
(	O
94	O
+	O
/	O
-	O
4	O
to	O
84	O
+	O
/	O
-	O
3	O
ms	O
,	O
P	O
<	O
0	O
.	O
005	O
)	O
.	O

Diltiazem	B-CHED
did	O
not	O
affect	O
ERP	O
,	O
AF	O
cycle	O
length	O
or	O
AF	O
duration	O
,	O
but	O
produced	O
conduction	O
acceleration	O
similar	O
to	O
that	O
caused	O
by	O
verapamil	B-CHED
(	O
n	O
=	O
5	O
)	O
.	O

In	O
the	O
presence	O
of	O
autonomic	O
blockade	O
,	O
verapamil	B-CHED
failed	O
to	O
promote	O
AF	O
and	O
increased	O
,	O
rather	O
than	O
decreasing	O
,	O
refractoriness	O
.	O

Neither	O
verapamil	B-CHED
nor	O
diltiazem	B-CHED
affected	O
atrial	O
conduction	O
in	O
the	O
presence	O
of	O
autonomic	O
blockade	O
.	O

Epicardial	O
mapping	O
suggested	O
that	O
verapamil	B-CHED
promoted	O
AF	O
by	O
increasing	O
the	O
number	O
of	O
simultaneous	O
wavefronts	O
reflected	O
by	O
separate	O
zones	O
of	O
reactivation	O
in	O
each	O
cycle	O
.	O

CONCLUSIONS	O
:	O
Verapamil	B-CHED
promotes	O
AF	O
in	O
normal	O
dogs	O
by	O
promoting	O
multiple	O
circuit	O
reentry	O
,	O
an	O
effect	O
dependent	O
on	O
intact	O
autonomic	O
tone	O
and	O
not	O
shared	O
by	O
diltiazem	B-CHED
.	O

Calcitonin	O
gene	O
-	O
related	O
peptide	O
levels	O
during	O
nitric	B-CHED
oxide	I-CHED
-	O
induced	O
headache	O
in	O
patients	O
with	O
chronic	O
tension	O
-	O
type	O
headache	O
.	O

It	O
has	O
been	O
proposed	O
that	O
nitric	B-CHED
oxide	I-CHED
(	O
NO	B-CHED
)	O
induced	O
headache	O
in	O
primary	O
headaches	O
may	O
be	O
associated	O
with	O
release	O
of	O
calcitonin	O
gene	O
-	O
related	O
peptide	O
(	O
CGRP	O
)	O
.	O

In	O
the	O
present	O
study	O
we	O
aimed	O
to	O
investigate	O
plasma	O
levels	O
of	O
CGRP	O
during	O
headache	O
induced	O
by	O
the	O
NO	B-CHED
donor	O
glyceryl	B-CHED
trinitrate	I-CHED
(	O
GTN	B-CHED
)	O
in	O
16	O
patients	O
with	O
chronic	O
tension	O
-	O
type	O
headache	O
and	O
16	O
healthy	O
controls	O
.	O

The	O
subjects	O
were	O
randomly	O
allocated	O
to	O
receive	O
0	O
.	O
5	O
microg	O
/	O
kg	O
/	O
min	O
GTN	B-CHED
or	O
placebo	O
over	O
20	O
min	O
on	O
two	O
headache	O
-	O
free	O
days	O
.	O

Blood	O
samples	O
were	O
collected	O
at	O
baseline	O
,	O
10	O
,	O
20	O
and	O
60	O
min	O
after	O
start	O
of	O
infusion	O
.	O

Both	O
patients	O
and	O
controls	O
developed	O
significantly	O
stronger	O
immediate	O
headache	O
on	O
the	O
GTN	B-CHED
day	O
than	O
on	O
the	O
placebo	O
day	O
and	O
the	O
headache	O
was	O
significantly	O
more	O
pronounced	O
in	O
patients	O
than	O
in	O
controls	O
.	O

There	O
was	O
no	O
difference	O
between	O
the	O
area	O
under	O
the	O
CGRP	O
curve	O
(	O
AUCCGRP	O
)	O
on	O
GTN	B-CHED
vs	O
.	O
placebo	O
day	O
in	O
either	O
patients	O
(	O
P	O
=	O
0	O
.	O
65	O
)	O
or	O
controls	O
(	O
P	O
=	O
0	O
.	O
48	O
)	O
.	O

The	O
AUCCGRP	O
recorded	O
on	O
the	O
GTN	B-CHED
day	O
did	O
not	O
differ	O
between	O
patients	O
and	O
controls	O
(	O
P	O
=	O
0	O
.	O
36	O
)	O
.	O

Both	O
in	O
patients	O
and	O
controls	O
,	O
CGRP	O
levels	O
changed	O
significantly	O
over	O
time	O
,	O
on	O
both	O
the	O
GTN	B-CHED
and	O
placebo	O
days	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
present	O
study	O
indicates	O
that	O
NO	B-CHED
-	O
induced	O
immediate	O
headache	O
is	O
not	O
associated	O
with	O
release	O
of	O
CGRP	O
.	O

Fluconazole	B-CHED
-	O
induced	O
torsade	O
de	O
pointes	O
.	O

OBJECTIVE	O
:	O
To	O
present	O
a	O
case	O
of	O
fluconazole	B-CHED
-	O
associated	O
torsade	O
de	O
pointes	O
(	O
TDP	O
)	O
and	O
discuss	O
fluconazole	B-CHED
'	O
s	O
role	O
in	O
causing	O
TDP	O
.	O

CASE	O
SUMMARY	O
:	O
A	O
68	O
-	O
year	O
-	O
old	O
white	O
woman	O
with	O
Candida	O
glabrata	O
isolated	O
from	O
a	O
presacral	O
abscess	O
developed	O
TDP	O
eight	O
days	O
after	O
commencing	O
oral	O
fluconazole	B-CHED
The	O
patient	O
had	O
no	O
other	O
risk	O
factors	O
for	O
TDP	O
,	O
including	O
coronary	O
artery	O
disease	O
,	O
cardiomyopathy	O
,	O
congestive	O
heart	O
failure	O
,	O
and	O
electrolyte	O
abnormalities	O
There	O
was	O
a	O
temporal	O
association	O
between	O
the	O
initiation	O
of	O
fluconazole	B-CHED
and	O
TDP	O
.	O

The	O
TDP	O
resolved	O
when	O
fluconazole	B-CHED
was	O
discontinued	O
;	O
however	O
,	O
the	O
patient	O
continued	O
to	O
have	O
premature	O
ventricular	O
contractions	O
and	O
nonsustained	O
ventricular	O
tachycardia	O
(	O
NSVT	O
)	O
until	O
six	O
days	O
after	O
drug	O
cessation	O
DISCUSSION	O
:	O
Use	O
of	O
the	O
Naranjo	O
probability	O
scale	O
indicates	O
a	O
probable	O
relationship	O
between	O
the	O
use	O
of	O
fluconazole	B-CHED
and	O
the	O
development	O
of	O
TDP	O
.	O

The	O
possible	O
mechanism	O
is	O
depression	O
of	O
rapidly	O
activating	O
delayed	O
rectifier	O
potassium	B-CHED
currents	O
.	O

In	O
our	O
patient	O
,	O
there	O
was	O
no	O
other	O
etiology	O
identified	O
that	O
could	O
explain	O
QT	O
prolongation	O
or	O
TDP	O
The	O
complete	O
disappearance	O
of	O
NSVT	O
and	O
premature	O
ventricular	O
contractions	O
followed	O
by	O
normalization	O
of	O
QT	O
interval	O
after	O
the	O
drug	O
was	O
stopped	O
strongly	O
suggests	O
fluconazole	B-CHED
as	O
the	O
etiology	O
.	O

CONCLUSIONS	O
:	O
Clinicians	O
should	O
be	O
aware	O
that	O
fluconazole	B-CHED
,	O
even	O
at	O
low	O
doses	O
,	O
may	O
cause	O
prolongation	O
of	O
the	O
QT	O
interval	O
,	O
leading	O
to	O
TDP	O
.	O

Serial	O
electrocardiographic	O
monitoring	O
may	O
be	O
considered	O
when	O
fluconazole	B-CHED
is	O
administered	O
in	O
patients	O
who	O
are	O
at	O
risk	O
for	O
ventricular	O
arrhythmias	O
.	O

Cutaneous	O
leucocytoclastic	O
vasculitis	O
associated	O
with	O
oxacillin	B-CHED
.	O

A	O
67	O
-	O
year	O
-	O
old	O
man	O
who	O
was	O
treated	O
with	O
oxacillin	B-CHED
for	O
one	O
week	O
because	O
of	O
Staphylococcus	O
aureus	O
bacteremia	O
,	O
developed	O
renal	O
failure	O
and	O
diffuse	O
,	O
symmetric	O
,	O
palpable	O
purpuric	O
lesions	O
on	O
his	O
feet	O
.	O

Necrotic	O
blisters	O
were	O
noted	O
on	O
his	O
fingers	O
.	O

Skin	O
biopsies	O
showed	O
findings	O
diagnostic	O
of	O
leucocytoclastic	O
vasculitis	O
.	O

Oxacillin	B-CHED
was	O
discontinued	O
and	O
patient	O
was	O
treated	O
with	O
corticosteroids	B-CHED
.	O

The	O
rash	O
disappeared	O
after	O
three	O
weeks	O
and	O
renal	O
function	O
returned	O
to	O
normal	O
.	O

Leucocytoclastic	O
vasculitis	O
presents	O
as	O
palpable	O
purpura	O
of	O
the	O
lower	O
extremities	O
often	O
accompanied	O
by	O
abdominal	O
pain	O
,	O
arthralgia	O
,	O
and	O
renal	O
involvement	O
.	O

Etiologic	O
factors	O
or	O
associated	O
disorders	O
include	O
infections	O
,	O
medications	O
,	O
collagen	O
vascular	O
disease	O
and	O
neoplasia	O
.	O

However	O
,	O
in	O
half	O
of	O
the	O
cases	O
no	O
etiologic	O
factor	O
is	O
identified	O
.	O

Usually	O
it	O
is	O
a	O
self	O
-	O
limited	O
disorder	O
,	O
but	O
corticosteroid	B-CHED
therapy	O
may	O
be	O
needed	O
in	O
life	O
-	O
threatening	O
cases	O
since	O
early	O
treatment	O
with	O
corticosteroids	B-CHED
in	O
severe	O
cases	O
can	O
prevent	O
complications	O
.	O

Oxacillin	B-CHED
should	O
be	O
included	O
among	O
the	O
drugs	O
that	O
can	O
cause	O
leucocytoclastic	O
vasculitis	O
.	O

The	O
renal	O
pathology	O
in	O
a	O
case	O
of	O
lithium	B-CHED
-	O
induced	O
diabetes	O
insipidus	O
.	O

A	O
case	O
of	O
lithium	B-CHED
-	O
induced	O
diabetes	O
insipidus	O
is	O
reported	O
.	O

At	O
necropsy	O
microscopy	O
shoed	O
unique	O
and	O
extensive	O
damage	O
to	O
cells	O
lining	O
the	O
distal	O
nephron	O
.	O

It	O
is	O
suggested	O
that	O
these	O
changes	O
represent	O
a	O
specific	O
toxic	O
effect	O
of	O
lithium	B-CHED
,	O
reported	O
here	O
for	O
the	O
first	O
time	O
in	O
man	O
.	O

Cholestatic	O
jaundice	O
associated	O
with	O
the	O
use	O
of	O
metformin	B-CHED
.	O

We	O
report	O
a	O
patient	O
who	O
developed	O
cholestatic	O
jaundice	O
shortly	O
after	O
initiation	O
of	O
treatment	O
with	O
metformin	B-CHED
hydrochloride	I-CHED
.	O

Ultrasound	O
of	O
the	O
liver	O
and	O
abdominal	O
CT	O
were	O
normal	O
.	O

An	O
ERCP	O
showed	O
normal	O
biliary	O
anatomy	O
.	O

A	O
percutaneous	O
liver	O
biopsy	O
was	O
obtained	O
showing	O
marked	O
cholestasis	O
,	O
with	O
portal	O
edema	O
,	O
ductular	O
proliferation	O
,	O
and	O
acute	O
inflammation	O
.	O

Metformin	B-CHED
hydrochloride	I-CHED
was	O
discontinued	O
,	O
and	O
the	O
patient	O
'	O
s	O
jaundice	O
resolved	O
slowly	O
over	O
a	O
period	O
of	O
several	O
months	O
.	O

Given	O
the	O
onset	O
of	O
his	O
jaundice	O
2	O
wk	O
after	O
the	O
initiation	O
of	O
metformin	B-CHED
,	O
we	O
believe	O
that	O
this	O
case	O
represents	O
an	O
example	O
of	O
metformin	B-CHED
-	O
associated	O
hepatotoxicity	O
,	O
the	O
first	O
such	O
case	O
reported	O
.	O

Systemic	O
toxicity	O
and	O
resuscitation	O
in	O
bupivacaine	B-CHED
-	O
,	O
levobupivacaine	B-CHED
-	O
,	O
or	O
ropivacaine	B-CHED
-	O
infused	O
rats	O
.	O

We	O
compared	O
the	O
systemic	O
toxicity	O
of	O
bupivacaine	B-CHED
,	O
levobupivacaine	B-CHED
,	O
and	O
ropivacaine	B-CHED
in	O
anesthetized	O
rats	O
.	O

We	O
also	O
compared	O
the	O
ability	O
to	O
resuscitate	O
rats	O
after	O
lethal	O
doses	O
of	O
these	O
local	O
anesthetics	O
.	O

Bupivacaine	B-CHED
,	O
levobupivacaine	B-CHED
,	O
or	O
ropivacaine	B-CHED
was	O
infused	O
at	O
a	O
rate	O
of	O
2	O
mg	O
.	O

kg	O
(	O
-	O
1	O
)	O
.	O

min	O
(	O
-	O
1	O
)	O
while	O
electrocardiogram	O
,	O
electroencephalogram	O
,	O
and	O
arterial	O
pressure	O
were	O
continuously	O
monitored	O
.	O

When	O
asystole	O
was	O
recorded	O
,	O
drug	O
infusion	O
was	O
stopped	O
and	O
a	O
resuscitation	O
sequence	O
was	O
begun	O
.	O

Epinephrine	B-CHED
0	O
.	O
01	O
mg	O
/	O
kg	O
was	O
administered	O
at	O
1	O
-	O
min	O
intervals	O
while	O
external	O
cardiac	O
compressions	O
were	O
applied	O
.	O

Resuscitation	O
was	O
considered	O
successful	O
when	O
a	O
systolic	O
arterial	O
pressure	O
>	O
or	O
=	O
100	O
mm	O
Hg	O
was	O
achieved	O
within	O
5	O
min	O
.	O

The	O
cumulative	O
doses	O
of	O
levobupivacaine	B-CHED
and	O
ropivacaine	B-CHED
that	O
produced	O
seizures	O
were	O
similar	O
and	O
were	O
larger	O
than	O
those	O
of	O
bupivacaine	B-CHED
.	O

The	O
cumulative	O
doses	O
of	O
levobupivacaine	B-CHED
that	O
produced	O
dysrhythmias	O
and	O
asystole	O
were	O
smaller	O
than	O
the	O
corresponding	O
doses	O
of	O
ropivacaine	B-CHED
,	O
but	O
they	O
were	O
larger	O
than	O
those	O
of	O
bupivacaine	B-CHED
.	O

The	O
number	O
of	O
successful	O
resuscitations	O
did	O
not	O
differ	O
among	O
groups	O
.	O

However	O
,	O
a	O
smaller	O
dose	O
of	O
epinephrine	B-CHED
was	O
required	O
in	O
the	O
Ropivacaine	B-CHED
group	O
than	O
in	O
the	O
other	O
groups	O
.	O

We	O
conclude	O
that	O
the	O
systemic	O
toxicity	O
of	O
levobupivacaine	B-CHED
is	O
intermediate	O
between	O
that	O
of	O
ropivacaine	B-CHED
and	O
bupivacaine	B-CHED
when	O
administered	O
at	O
the	O
same	O
rate	O
and	O
that	O
ropivacaine	B-CHED
-	O
induced	O
cardiac	O
arrest	O
appears	O
to	O
be	O
more	O
susceptible	O
to	O
treatment	O
than	O
that	O
induced	O
by	O
bupivacaine	B-CHED
or	O
levobupivacaine	B-CHED
.	O

Amphotericin	B-CHED
B	I-CHED
-	O
induced	O
seizures	O
in	O
a	O
patient	O
with	O
AIDS	O
.	O

OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
multiple	O
episodes	O
of	O
seizure	O
activity	O
in	O
an	O
AIDS	O
patent	O
following	O
amphotericin	B-CHED
B	I-CHED
infusion	O
.	O

CASE	O
SUMMARY	O
:	O
A	O
46	O
-	O
year	O
-	O
old	O
African	O
-	O
American	O
man	O
experienced	O
recurrent	O
grand	O
mal	O
seizures	O
during	O
intravenous	O
infusion	O
of	O
amphotericin	B-CHED
B	I-CHED
,	O
then	O
petit	O
mal	O
seizures	O
as	O
the	O
infusion	O
was	O
stopped	O
and	O
the	O
drug	O
concentrations	O
decreased	O
with	O
time	O
.	O

The	O
patients	O
concurrent	O
medications	O
included	O
didanosine	B-CHED
,	O
hydroxyzine	B-CHED
,	O
promethazine	B-CHED
,	O
hydrocortisone	B-CHED
,	O
and	O
prochlorperazine	B-CHED
.	O

Despite	O
administration	O
of	O
phenytoin	B-CHED
and	O
lorazepam	B-CHED
,	O
the	O
seizures	O
persisted	O
and	O
occurred	O
only	O
during	O
amphotercin	B-CHED
B	I-CHED
administration	O
.	O

DISCUSSION	O
:	O
AIDS	O
and	O
cryptococcal	O
meningitis	O
,	O
both	O
of	O
which	O
the	O
patient	O
had	O
,	O
can	O
potentially	O
cause	O
seizures	O
.	O

The	O
patient	O
had	O
a	O
history	O
of	O
alcohol	O
abuse	O
;	O
alcohol	B-CHED
intake	O
as	O
well	O
as	O
withdrawal	O
can	O
also	O
cause	O
seizures	O
.	O

Didanosine	B-CHED
also	O
has	O
a	O
potential	O
for	O
inducing	O
seizures	O
.	O

However	O
,	O
these	O
other	O
potential	O
causes	O
of	O
seizure	O
were	O
ruled	O
out	O
.	O

The	O
time	O
course	O
of	O
events	O
suggested	O
that	O
amphotericin	B-CHED
B	I-CHED
was	O
the	O
cause	O
of	O
the	O
seizures	O
in	O
this	O
AIDS	O
patient	O
.	O

CONCLUSIONS	O
:	O
Amphotericin	B-CHED
B	I-CHED
seems	O
to	O
be	O
the	O
probable	O
cause	O
of	O
the	O
seizures	O
.	O

To	O
date	O
,	O
only	O
three	O
cases	O
of	O
seizures	O
associated	O
with	O
amphotericin	B-CHED
B	I-CHED
have	O
been	O
reported	O
in	O
the	O
literature	O
,	O
but	O
healthcare	O
providers	O
should	O
be	O
aware	O
of	O
the	O
potential	O
for	O
this	O
rare	O
adverse	O
effect	O
.	O

Sirolimus	B-CHED
and	O
mycophenolate	B-CHED
mofetil	I-CHED
for	O
calcineurin	O
-	O
free	O
immunosuppression	O
in	O
renal	O
transplant	O
recipients	O
.	O

Calcineurin	O
inhibitors	O
,	O
such	O
as	O
cyclosporine	B-CHED
and	O
tacrolimus	B-CHED
,	O
have	O
been	O
available	O
for	O
almost	O
20	O
years	O
.	O

Although	O
these	O
drugs	O
are	O
highly	O
effective	O
and	O
represent	O
the	O
mainstay	O
of	O
transplant	O
immunosuppression	O
,	O
they	O
are	O
associated	O
with	O
acute	O
and	O
chronic	O
nephrotoxicity	O
.	O

Acute	O
nephrotoxicity	O
,	O
which	O
occurs	O
in	O
the	O
early	O
period	O
after	O
transplantation	O
,	O
leads	O
to	O
a	O
higher	O
rate	O
of	O
dialysis	O
,	O
and	O
chronic	O
nephrotoxicity	O
may	O
eventually	O
result	O
in	O
graft	O
loss	O
.	O

Acute	O
and	O
chronic	O
nephrotoxicity	O
is	O
becoming	O
more	O
common	O
as	O
the	O
use	O
of	O
marginal	O
kidneys	O
for	O
transplantation	O
increases	O
.	O

Two	O
recently	O
available	O
immunosuppressive	O
agents	O
,	O
mycophenolate	B-CHED
mofetil	I-CHED
and	O
sirolimus	B-CHED
(	O
rapamycin	B-CHED
)	O
,	O
have	O
no	O
nephrotoxicity	O
.	O

The	O
use	O
of	O
these	O
drugs	O
in	O
combination	O
with	O
other	O
agents	O
has	O
led	O
to	O
the	O
development	O
of	O
new	O
paradigms	O
of	O
immunosuppressive	O
therapy	O
.	O

This	O
paper	O
reviews	O
the	O
results	O
of	O
clinical	O
trials	O
that	O
have	O
investigated	O
these	O
new	O
approaches	O
to	O
immunosuppression	O
in	O
renal	O
transplant	O
recipients	O
.	O

Tolerability	O
of	O
nimesulide	B-CHED
and	O
paracetamol	B-CHED
in	O
patients	O
with	O
NSAID	B-CHED
-	O
induced	O
urticaria	O
/	O
angioedema	O
.	O

Previous	O
studies	O
evaluated	O
the	O
tolerance	O
of	O
nimesulide	B-CHED
and	O
paracetamol	B-CHED
in	O
subjects	O
with	O
cutaneous	O
,	O
respiratory	O
and	O
anaphylactoid	O
reactions	O
induced	O
by	O
nonsteroidal	B-CHED
anti	I-CHED
-	I-CHED
inflammatory	I-CHED
drugs	I-CHED
(	O
NSAIDs	B-CHED
)	O
.	O

In	O
this	O
study	O
we	O
investigated	O
tolerability	O
and	O
reliability	O
of	O
nimesulide	B-CHED
and	O
paracetamol	B-CHED
in	O
a	O
very	O
large	O
number	O
of	O
patients	O
with	O
an	O
exclusive	O
well	O
-	O
documented	O
history	O
of	O
NSAID	B-CHED
-	O
induced	O
urticaria	O
/	O
angioedema	O
.	O

Furthermore	O
,	O
we	O
evaluated	O
whether	O
some	O
factors	O
have	O
the	O
potential	O
to	O
increase	O
the	O
risk	O
of	O
reaction	O
to	O
paracetamol	B-CHED
and	O
nimesulide	B-CHED
.	O

A	O
single	O
-	O
placebo	O
-	O
controlled	O
oral	O
challenge	O
procedure	O
with	O
nimesulide	B-CHED
or	O
paracetamol	B-CHED
was	O
applied	O
to	O
829	O
patients	O
with	O
a	O
history	O
of	O
NSAID	B-CHED
-	O
induced	O
urticaria	O
/	O
angioedema	O
.	O

A	O
total	O
of	O
75	O
/	O
829	O
(	O
9	O
.	O
4	O
%	O
)	O
patients	O
experienced	O
reactions	O
to	O
nimesulide	B-CHED
or	O
paracetamol	B-CHED
.	O

Of	O
the	O
715	O
patients	O
tested	O
with	O
nimesulide	B-CHED
62	O
(	O
8	O
.	O
6	O
%	O
)	O
showed	O
a	O
positive	O
test	O
,	O
while	O
of	O
114	O
subjects	O
submitted	O
to	O
the	O
challenge	O
with	O
paracetamol	B-CHED
,	O
13	O
(	O
9	O
.	O
6	O
%	O
)	O
did	O
not	O
tolerate	O
this	O
drug	O
.	O

Furthermore	O
,	O
18	O
.	O
28	O
%	O
of	O
patients	O
with	O
a	O
history	O
of	O
chronic	O
urticaria	O
and	O
11	O
.	O
8	O
%	O
of	O
subjects	O
with	O
an	O
history	O
of	O
NSAID	B-CHED
-	O
induced	O
urticaria	O
/	O
angioedema	O
or	O
angioedema	O
alone	O
(	O
with	O
or	O
without	O
chronic	O
urticaria	O
)	O
resulted	O
to	O
be	O
intolerant	O
to	O
alternative	O
drugs	O
.	O

Taken	O
together	O
,	O
our	O
results	O
confirm	O
the	O
good	O
tolerability	O
of	O
nimesulide	B-CHED
and	O
paracetamol	B-CHED
in	O
patients	O
who	O
experienced	O
urticaria	O
/	O
angioedema	O
caused	O
by	O
NSAIDs	B-CHED
.	O

However	O
,	O
the	O
risk	O
of	O
reaction	O
to	O
these	O
alternative	O
study	O
drugs	O
is	O
statistically	O
increased	O
by	O
a	O
history	O
of	O
chronic	O
urticaria	O
and	O
,	O
above	O
all	O
,	O
by	O
a	O
history	O
of	O
NSAID	B-CHED
-	O
induced	O
angioedema	O
.	O

Comparison	O
of	O
aqueous	O
and	O
gellan	O
ophthalmic	O
timolol	B-CHED
with	O
placebo	O
on	O
the	O
24	O
-	O
hour	O
heart	O
rate	O
response	O
in	O
patients	O
on	O
treatment	O
for	O
glaucoma	O
.	O

PURPOSE	O
:	O
Topical	O
beta	O
-	O
blocker	O
treatment	O
is	O
routine	O
therapy	O
in	O
the	O
management	O
of	O
patients	O
with	O
glaucoma	O
.	O

Therapy	O
results	O
in	O
systemic	O
absorption	O
,	O
however	O
,	O
the	O
degree	O
of	O
reduction	O
of	O
resting	O
and	O
peak	O
heart	O
rate	O
has	O
not	O
been	O
quantified	O
.	O

DESIGN	O
:	O
This	O
trial	O
evaluated	O
the	O
effect	O
of	O
placebo	O
,	O
0	O
.	O
5	O
%	O
aqueous	O
timolol	B-CHED
(	O
timolol	B-CHED
solution	O
)	O
and	O
a	O
0	O
.	O
5	O
%	O
timolol	B-CHED
suspension	O
that	O
forms	O
a	O
gel	O
on	O
application	O
to	O
the	O
conjunctiva	O
(	O
timolol	B-CHED
gellan	O
)	O
on	O
the	O
24	O
-	O
hour	O
heart	O
rate	O
in	O
patients	O
currently	O
being	O
treated	O
for	O
glaucoma	O
to	O
quantify	O
the	O
reduction	O
in	O
mean	O
heart	O
rate	O
.	O

METHODS	O
:	O
Forty	O
-	O
three	O
Caucasian	O
patients	O
with	O
primary	O
open	O
-	O
angle	O
glaucoma	O
or	O
ocular	O
hypertension	O
with	O
a	O
mean	O
(	O
+	O
/	O
-	O
SD	O
)	O
age	O
of	O
63	O
(	O
+	O
/	O
-	O
8	O
)	O
years	O
were	O
randomized	O
and	O
crossed	O
over	O
in	O
a	O
double	O
-	O
masked	O
manner	O
to	O
14	O
days	O
of	O
treatment	O
with	O
placebo	O
(	O
morning	O
and	O
evening	O
in	O
both	O
eyes	O
)	O
,	O
timolol	B-CHED
solution	O
(	O
morning	O
and	O
evening	O
in	O
both	O
eyes	O
)	O
,	O
or	O
timolol	B-CHED
gellan	O
(	O
morning	O
in	O
both	O
eyes	O
with	O
placebo	O
in	O
the	O
evening	O
)	O
.	O

On	O
the	O
13th	O
day	O
of	O
each	O
period	O
,	O
heart	O
rate	O
was	O
recorded	O
continuously	O
during	O
a	O
typical	O
,	O
ambulant	O
24	O
-	O
hour	O
period	O
.	O

RESULTS	O
:	O
Both	O
timolol	B-CHED
solution	O
and	O
timolol	B-CHED
gellan	O
reduced	O
the	O
mean	O
24	O
-	O
hour	O
heart	O
rate	O
compared	O
with	O
placebo	O
(	O
P	O
<	O
or	O
=	O
.	O
001	O
)	O
,	O
and	O
this	O
reduction	O
was	O
most	O
pronounced	O
during	O
the	O
daytime	O
(	O
-	O
7	O
.	O
5	O
%	O
change	O
in	O
mean	O
heart	O
rate	O
,	O
-	O
5	O
.	O
7	O
beats	O
/	O
min	O
)	O
.	O

Timolol	B-CHED
gellan	O
showed	O
a	O
numerically	O
but	O
not	O
significantly	O
smaller	O
reduction	O
in	O
24	O
-	O
hour	O
heart	O
rate	O
,	O
compared	O
with	O
timolol	B-CHED
solution	O
.	O

During	O
the	O
night	O
,	O
the	O
mean	O
12	O
-	O
hour	O
heart	O
rate	O
on	O
placebo	O
and	O
timolol	B-CHED
gellan	O
were	O
both	O
significantly	O
less	O
than	O
on	O
timolol	B-CHED
solution	O
;	O
the	O
difference	O
between	O
solution	O
and	O
gellan	O
treatments	O
was	O
statistically	O
significant	O
(	O
P	O
=	O
.	O
01	O
)	O
.	O

CONCLUSIONS	O
:	O
Both	O
timolol	B-CHED
solution	O
and	O
timolol	B-CHED
gellan	O
decrease	O
the	O
mean	O
24	O
-	O
hour	O
heart	O
rate	O
compared	O
with	O
placebo	O
.	O

This	O
response	O
was	O
most	O
pronounced	O
during	O
the	O
active	O
daytime	O
period	O
.	O

These	O
data	O
quantify	O
the	O
modest	O
bradycardia	O
associated	O
with	O
ophthalmic	O
beta	O
-	O
blocker	O
therapy	O
in	O
a	O
typical	O
patient	O
population	O
on	O
therapy	O
for	O
glaucoma	O
.	O

Although	O
exercise	O
performance	O
was	O
not	O
assessed	O
in	O
this	O
trial	O
,	O
reductions	O
of	O
this	O
magnitude	O
should	O
not	O
have	O
substantial	O
clinical	O
consequences	O
.	O

Management	O
strategies	O
for	O
ribavirin	B-CHED
-	O
induced	O
hemolytic	O
anemia	O
in	O
the	O
treatment	O
of	O
hepatitis	O
C	O
:	O
clinical	O
and	O
economic	O
implications	O
.	O

OBJECTIVES	O
:	O
Recently	O
published	O
studies	O
have	O
demonstrated	O
increased	O
efficacy	O
and	O
cost	O
-	O
effectiveness	O
of	O
combination	O
therapy	O
with	O
interferon	O
and	O
alpha	O
-	O
2b	O
/	O
ribavirin	B-CHED
compared	O
with	O
interferon	B-CHED
-	I-CHED
alpha	I-CHED
monotherapy	O
in	O
the	O
treatment	O
of	O
chronic	O
hepatitis	O
C	O
(	O
CHC	O
)	O
.	O

Combination	O
therapy	O
is	O
associated	O
with	O
a	O
clinically	O
important	O
adverse	O
effect	O
:	O
ribavirin	B-CHED
-	O
induced	O
hemolytic	O
anemia	O
(	O
RIHA	O
)	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
direct	O
health	O
-	O
care	O
costs	O
and	O
management	O
of	O
RIHA	O
during	O
treatment	O
of	O
CHC	O
in	O
a	O
clinical	O
trial	O
setting	O
.	O

METHODS	O
:	O
A	O
systematic	O
literature	O
review	O
was	O
conducted	O
to	O
synthesize	O
information	O
on	O
the	O
incidence	O
and	O
management	O
of	O
RIHA	O
.	O

Decision	O
-	O
analytic	O
techniques	O
were	O
used	O
to	O
estimate	O
the	O
cost	O
of	O
treating	O
RIHA	O
.	O

Uncertainty	O
was	O
evaluated	O
using	O
sensitivity	O
analyses	O
.	O

RESULTS	O
:	O
RIHA	O
,	O
defined	O
as	O
a	O
reduction	O
in	O
hemoglobin	O
to	O
less	O
than	O
100	O
g	O
/	O
L	O
,	O
occurs	O
in	O
approximately	O
7	O
%	O
to	O
9	O
%	O
of	O
patients	O
treated	O
with	O
combination	O
therapy	O
.	O

The	O
standard	O
of	O
care	O
for	O
management	O
of	O
RIHA	O
is	O
reduction	O
or	O
discontinuation	O
of	O
the	O
ribavirin	B-CHED
dosage	O
.	O

We	O
estimated	O
the	O
direct	O
cost	O
of	O
treating	O
clinically	O
significant	O
RIHA	O
to	O
be	O
170	O
per	O
patient	O
receiving	O
combination	O
therapy	O
per	O
48	O
-	O
week	O
treatment	O
course	O
(	O
range	O
68	O
-	O
692	O
)	O
.	O

The	O
results	O
of	O
the	O
one	O
-	O
way	O
sensitivity	O
analyses	O
ranged	O
from	O
57	O
to	O
317	O
.	O

In	O
comparison	O
,	O
the	O
cost	O
of	O
48	O
weeks	O
of	O
combination	O
therapy	O
is	O
16	O
,	O
459	O
.	O

CONCLUSIONS	O
:	O
The	O
direct	O
cost	O
of	O
treating	O
clinically	O
significant	O
RIHA	O
is	O
1	O
%	O
(	O
170	O
/	O
16	O
,	O
459	O
)	O
of	O
drug	O
treatment	O
costs	O
.	O

Questions	O
remain	O
about	O
the	O
optimal	O
dose	O
of	O
ribavirin	B-CHED
and	O
the	O
incidence	O
of	O
RIHA	O
in	O
a	O
real	O
-	O
world	O
population	O
.	O

Despite	O
these	O
uncertainties	O
,	O
this	O
initial	O
evaluation	O
of	O
the	O
direct	O
cost	O
of	O
treating	O
RIHA	O
provides	O
an	O
estimate	O
of	O
the	O
cost	O
and	O
management	O
implications	O
of	O
this	O
clinically	O
important	O
adverse	O
effect	O
.	O

Preliminary	O
efficacy	O
assessment	O
of	O
intrathecal	O
injection	O
of	O
an	O
American	O
formulation	O
of	O
adenosine	B-CHED
in	O
humans	O
.	O

BACKGROUND	O
:	O
Preclinical	O
studies	O
of	O
intrathecal	O
adenosine	B-CHED
suggest	O
it	O
may	O
be	O
effective	O
in	O
the	O
treatment	O
of	O
acute	O
and	O
chronic	O
pain	O
in	O
humans	O
,	O
and	O
preliminary	O
studies	O
in	O
volunteers	O
and	O
patients	O
with	O
a	O
Swedish	O
formulation	O
of	O
adenosine	B-CHED
suggests	O
it	O
may	O
be	O
effective	O
in	O
hypersensitivity	O
states	O
but	O
not	O
with	O
acute	O
noxious	O
stimulation	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
screen	O
for	O
efficacy	O
of	O
a	O
different	O
formulation	O
of	O
adenosine	B-CHED
marketed	O
in	O
the	O
US	O
,	O
using	O
both	O
acute	O
noxious	O
stimulation	O
and	O
capsaicin	B-CHED
-	O
evoked	O
mechanical	O
hypersensitivity	O
.	O

METHODS	O
:	O
Following	O
Food	O
and	O
Drug	O
Administration	O
and	O
institutional	O
review	O
board	O
approval	O
and	O
written	O
informed	O
consent	O
,	O
65	O
volunteers	O
were	O
studied	O
in	O
two	O
trials	O
:	O
an	O
open	O
-	O
label	O
,	O
dose	O
-	O
escalating	O
trial	O
with	O
intrathecal	O
adenosine	B-CHED
doses	O
of	O
0	O
.	O
25	O
-	O
2	O
.	O
0	O
mg	O
and	O
a	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
of	O
adenosine	B-CHED
,	O
2	O
mg	O
.	O

Cerebrospinal	O
fluid	O
was	O
obtained	O
for	O
pharmacokinetic	O
analysis	O
,	O
and	O
pain	O
ratings	O
in	O
response	O
to	O
acute	O
heat	O
stimuli	O
and	O
areas	O
of	O
mechanical	O
hyperalgesia	O
and	O
allodynia	O
after	O
intradermal	O
capsaicin	B-CHED
injection	O
were	O
determined	O
.	O

RESULTS	O
:	O
Adenosine	B-CHED
produced	O
no	O
effect	O
on	O
pain	O
report	O
to	O
acute	O
noxious	O
thermal	O
or	O
chemical	O
stimulation	O
but	O
reduced	O
mechanical	O
hyperalgesia	O
and	O
allodynia	O
from	O
intradermal	O
capsaicin	B-CHED
injection	O
for	O
at	O
least	O
24	O
h	O
.	O

In	O
contrast	O
,	O
residence	O
time	O
of	O
adenosine	B-CHED
in	O
cerebrospinal	O
fluid	O
was	O
short	O
(	O
<	O
4	O
h	O
)	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
show	O
selective	O
inhibition	O
by	O
intrathecal	O
adenosine	B-CHED
of	O
hypersensitivity	O
,	O
presumed	O
to	O
reflect	O
central	O
sensitization	O
in	O
humans	O
after	O
peripheral	O
capsaicin	B-CHED
injection	O
.	O

The	O
long	O
-	O
lasting	O
effect	O
is	O
consistent	O
with	O
that	O
observed	O
in	O
preliminary	O
reports	O
of	O
patients	O
with	O
chronic	O
neuropathic	O
pain	O
and	O
is	O
not	O
due	O
to	O
prolonged	O
residence	O
of	O
adenosine	B-CHED
in	O
cerebrospinal	O
fluid	O
.	O

Delayed	O
-	O
onset	O
heparin	B-CHED
-	O
induced	O
thrombocytopenia	O
.	O

BACKGROUND	O
:	O
Heparin	B-CHED
-	O
induced	O
thrombocytopenia	O
presents	O
5	O
to	O
12	O
days	O
after	O
heparin	B-CHED
exposure	O
,	O
with	O
or	O
without	O
arterial	O
or	O
venous	O
thromboemboli	O
.	O

Delayed	O
recognition	O
and	O
treatment	O
of	O
heparin	B-CHED
-	O
induced	O
thrombocytopenia	O
contribute	O
to	O
poor	O
patient	O
outcomes	O
.	O

OBJECTIVE	O
:	O
To	O
describe	O
and	O
increase	O
awareness	O
of	O
a	O
clinical	O
scenario	O
in	O
which	O
the	O
onset	O
or	O
manifestations	O
of	O
heparin	B-CHED
-	O
induced	O
thrombocytopenia	O
are	O
delayed	O
.	O

DESIGN	O
:	O
Retrospective	O
case	O
series	O
.	O

SETTING	O
:	O
Three	O
large	O
urban	O
hospitals	O
(	O
with	O
active	O
cardiovascular	O
surgery	O
programs	O
)	O
.	O

PATIENTS	O
:	O
14	O
patients	O
seen	O
over	O
a	O
3	O
-	O
year	O
period	O
in	O
whom	O
heparin	B-CHED
-	O
induced	O
thrombocytopenia	O
became	O
apparent	O
on	O
delayed	O
presentation	O
with	O
thromboembolic	O
complications	O
.	O

MEASUREMENTS	O
:	O
Platelet	O
counts	O
,	O
onset	O
of	O
objectively	O
determined	O
thromboembolism	O
,	O
results	O
of	O
heparin	B-CHED
-	O
induced	O
platelet	O
factor	O
4	O
antibody	O
tests	O
,	O
and	O
outcomes	O
.	O

RESULTS	O
:	O
Patients	O
went	O
home	O
after	O
hospitalizations	O
that	O
had	O
included	O
heparin	B-CHED
exposure	O
-	O
-	O
in	O
most	O
cases	O
,	O
with	O
no	O
thrombocytopenia	O
recognized	O
-	O
-	O
only	O
to	O
return	O
to	O
the	O
hospital	O
(	O
median	O
,	O
day	O
14	O
)	O
with	O
thromboembolic	O
complications	O
.	O

Thromboemboli	O
were	O
venous	O
(	O
12	O
patients	O
,	O
7	O
with	O
pulmonary	O
emboli	O
)	O
or	O
arterial	O
(	O
4	O
patients	O
)	O
or	O
both	O
.	O

Platelet	O
counts	O
were	O
mildly	O
decreased	O
in	O
all	O
but	O
2	O
patients	O
on	O
second	O
presentation	O
.	O

On	O
readmission	O
,	O
11	O
patients	O
received	O
therapeutic	O
heparin	B-CHED
,	O
which	O
worsened	O
the	O
patients	O
'	O
clinical	O
condition	O
and	O
,	O
in	O
all	O
11	O
cases	O
,	O
decreased	O
the	O
platelet	O
count	O
(	O
mean	O
at	O
readmission	O
,	O
143	O
x	O
10	O
(	O
9	O
)	O
cells	O
/	O
L	O
;	O
mean	O
nadir	O
after	O
heparin	B-CHED
re	O
-	O
exposure	O
,	O
39	O
x	O
10	O
(	O
9	O
)	O
cells	O
/	O
L	O
)	O
.	O

Results	O
of	O
serologic	O
tests	O
for	O
heparin	B-CHED
-	O
induced	O
antibodies	O
were	O
positive	O
in	O
all	O
patients	O
.	O

Subsequent	O
treatments	O
included	O
alternative	O
anticoagulants	O
(	O
11	O
patients	O
)	O
,	O
thrombolytic	O
drugs	O
(	O
3	O
patients	O
)	O
,	O
inferior	O
vena	O
cava	O
filters	O
(	O
3	O
patients	O
)	O
and	O
,	O
eventually	O
,	O
warfarin	B-CHED
(	O
11	O
patients	O
)	O
.	O

Three	O
patients	O
died	O
.	O

CONCLUSIONS	O
:	O
Delayed	O
-	O
onset	O
heparin	B-CHED
-	O
induced	O
thrombocytopenia	O
is	O
increasingly	O
being	O
recognized	O
.	O

To	O
avoid	O
disastrous	O
outcomes	O
,	O
physicians	O
must	O
consider	O
heparin	B-CHED
-	O
induced	O
thrombocytopenia	O
whenever	O
a	O
recently	O
hospitalized	O
patient	O
returns	O
with	O
thromboembolism	O
;	O
therapy	O
with	O
alternative	O
anticoagulants	O
,	O
not	O
heparin	B-CHED
,	O
should	O
be	O
initiated	O
.	O

Treatment	O
of	O
risperidone	B-CHED
-	O
induced	O
hyperprolactinemia	O
with	O
a	O
dopamine	B-CHED
agonist	O
in	O
children	O
.	O

BACKGROUND	O
:	O
Risperidone	B-CHED
,	O
a	O
potent	O
antagonist	O
of	O
both	O
serotonergic	O
(	O
5HT2A	O
)	O
and	O
dopaminergic	O
D2	O
receptors	O
is	O
associated	O
with	O
hyperprolactinemia	O
in	O
adults	O
and	O
children	O
.	O

Chronically	O
elevated	O
prolactin	O
levels	O
in	O
children	O
with	O
prolactinomas	O
may	O
be	O
associated	O
with	O
arrested	O
growth	O
and	O
development	O
resulting	O
in	O
either	O
delayed	O
puberty	O
or	O
short	O
stature	O
.	O

These	O
possibilities	O
stress	O
the	O
importance	O
of	O
developing	O
a	O
safe	O
and	O
effective	O
approach	O
to	O
drug	O
-	O
induced	O
hyperprolactinemia	O
in	O
youth	O
.	O

We	O
report	O
the	O
successful	O
treatment	O
of	O
risperidone	B-CHED
-	O
induced	O
hyperprolactinemia	O
with	O
cabergoline	B-CHED
in	O
youth	O
.	O

METHODS	O
:	O
We	O
undertook	O
a	O
retrospective	O
case	O
review	O
of	O
four	O
children	O
with	O
risperidone	B-CHED
-	O
induced	O
hyperprolactinemia	O
treated	O
with	O
cabergoline	B-CHED
.	O

RESULTS	O
:	O
Four	O
males	O
(	O
age	O
6	O
-	O
11	O
years	O
)	O
with	O
Diagnostic	O
and	O
Statistical	O
Manual	O
of	O
Mental	O
Disorders	O
(	O
fourth	O
edition	O
)	O
bipolar	O
disorder	O
or	O
psychoses	O
,	O
with	O
risperidone	B-CHED
-	O
induced	O
elevations	O
in	O
serum	O
prolactin	O
levels	O
(	O
57	O
.	O
5	O
-	O
129	O
ng	O
/	O
mL	O
,	O
normal	O
5	O
-	O
15	O
ng	O
/	O
mL	O
)	O
,	O
were	O
treated	O
with	O
cabergoline	B-CHED
(	O
mean	O
dose	O
2	O
.	O
13	O
+	O
/	O
-	O
0	O
.	O
09	O
mg	O
/	O
week	O
)	O
.	O

When	O
serum	O
prolactin	O
levels	O
normalized	O
in	O
all	O
four	O
subjects	O
(	O
mean	O
11	O
.	O
2	O
+	O
/	O
-	O
10	O
.	O
9	O
ng	O
/	O
mL	O
)	O
,	O
the	O
cabergoline	B-CHED
dose	O
was	O
reduced	O
to	O
1	O
mg	O
/	O
week	O
in	O
three	O
of	O
four	O
subjects	O
.	O

The	O
mean	O
duration	O
of	O
therapy	O
with	O
cabergoline	B-CHED
was	O
523	O
.	O
5	O
+	O
/	O
-	O
129	O
.	O
7	O
days	O
,	O
and	O
the	O
mean	O
duration	O
of	O
therapy	O
with	O
risperidone	B-CHED
was	O
788	O
.	O
5	O
+	O
/	O
-	O
162	O
.	O
5	O
days	O
.	O

Cabergoline	B-CHED
was	O
well	O
tolerated	O
without	O
adverse	O
effects	O
.	O

CONCLUSIONS	O
:	O
Cabergoline	B-CHED
may	O
be	O
useful	O
for	O
the	O
treatment	O
of	O
risperidone	B-CHED
-	O
induced	O
hyperprolactinemia	O
in	O
youth	O
;	O
however	O
,	O
further	O
research	O
is	O
needed	O
.	O

Acute	O
cholestatic	O
hepatitis	O
after	O
exposure	O
to	O
isoflurane	B-CHED
.	O

OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
acute	O
cholestatic	O
hepatitis	O
following	O
exposure	O
to	O
the	O
inhalational	O
anesthetic	O
isoflurane	B-CHED
.	O

CASE	O
SUMMARY	O
:	O
A	O
70	O
-	O
year	O
-	O
old	O
healthy	O
woman	O
from	O
Iraq	O
developed	O
acute	O
cholestatic	O
hepatitis	O
3	O
weeks	O
following	O
repair	O
of	O
the	O
right	O
rotator	O
cuff	O
under	O
general	O
anesthesia	O
.	O

There	O
was	O
no	O
evidence	O
for	O
viral	O
,	O
autoimmune	O
,	O
or	O
metabolic	O
causes	O
of	O
hepatitis	O
.	O

No	O
other	O
medications	O
were	O
involved	O
except	O
for	O
dipyrone	B-CHED
for	O
analgesia	O
.	O

The	O
alanine	B-CHED
aminotransferase	O
was	O
elevated	O
to	O
a	O
peak	O
concentration	O
of	O
1533	O
U	O
/	O
L	O
and	O
the	O
serum	O
bilirubin	B-CHED
reached	O
a	O
peak	O
of	O
17	O
.	O
0	O
mg	O
/	O
dL	O
.	O

There	O
was	O
slow	O
improvement	O
over	O
4	O
months	O
.	O

Accidental	O
reexposure	O
by	O
the	O
patient	O
to	O
dipyrone	B-CHED
was	O
uneventful	O
.	O

DISCUSSION	O
:	O
The	O
clinical	O
and	O
histologic	O
picture	O
of	O
this	O
case	O
resembles	O
halothane	O
hepatitis	O
,	O
which	O
has	O
a	O
significant	O
mortality	O
rate	O
.	O

CONCLUSIONS	O
:	O
Isoflurane	B-CHED
,	O
a	O
common	O
anesthetic	O
agent	O
,	O
can	O
cause	O
severe	O
cholestatic	O
hepatitis	O
.	O

Torsade	O
de	O
pointes	O
induced	O
by	O
metoclopramide	B-CHED
in	O
an	O
elderly	O
woman	O
with	O
preexisting	O
complete	O
left	O
bundle	O
branch	O
block	O
.	O

There	O
is	O
a	O
growing	O
list	O
of	O
drugs	O
implicated	O
in	O
acquired	O
long	O
QT	O
syndrome	O
and	O
torsade	O
de	O
pointes	O
.	O

However	O
,	O
the	O
torsadogenic	O
potential	O
of	O
metoclopramide	B-CHED
,	O
a	O
commonly	O
used	O
antiemetic	O
and	O
prokinetic	O
drug	O
,	O
has	O
not	O
been	O
reported	O
in	O
the	O
literature	O
,	O
despite	O
its	O
chemical	O
similarity	O
to	O
procainamide	B-CHED
.	O

We	O
report	O
on	O
a	O
92	O
-	O
year	O
-	O
old	O
woman	O
with	O
preexisting	O
complete	O
left	O
bundle	O
branch	O
block	O
who	O
developed	O
torsade	O
de	O
pointes	O
after	O
intravenous	O
and	O
oral	O
administration	O
of	O
metoclopramide	B-CHED
.	O

This	O
patient	O
also	O
developed	O
torsade	O
de	O
pointes	O
when	O
cisapride	B-CHED
and	O
erythromycin	B-CHED
were	O
given	O
simultaneously	O
.	O

These	O
two	O
episodes	O
were	O
suppressed	O
successfully	O
after	O
discontinuing	O
the	O
offending	O
drugs	O
and	O
administering	O
class	O
IB	O
drugs	O
.	O

This	O
is	O
the	O
first	O
documentation	O
that	O
metoclopramide	B-CHED
provokes	O
torsade	O
de	O
pointes	O
clinically	O
.	O

Metoclopramide	B-CHED
should	O
be	O
used	O
cautiously	O
in	O
patients	O
with	O
a	O
risk	O
of	O
torsade	O
de	O
pointes	O
.	O

Dopamine	B-CHED
D2	O
receptor	O
signaling	O
controls	O
neuronal	O
cell	O
death	O
induced	O
by	O
muscarinic	O
and	O
glutamatergic	O
drugs	O
.	O

Dopamine	B-CHED
(	O
DA	B-CHED
)	O
,	O
through	O
D1	O
/	O
D2	O
receptor	O
-	O
mediated	O
signaling	O
,	O
plays	O
a	O
major	O
role	O
in	O
the	O
control	O
of	O
epileptic	O
seizures	O
arising	O
in	O
the	O
limbic	O
system	O
.	O

Excitotoxicity	O
leading	O
to	O
neuronal	O
cell	O
death	O
in	O
the	O
affected	O
areas	O
is	O
a	O
major	O
consequence	O
of	O
seizures	O
at	O
the	O
cellular	O
level	O
.	O

In	O
this	O
respect	O
,	O
little	O
is	O
known	O
about	O
the	O
role	O
of	O
DA	B-CHED
receptors	O
in	O
the	O
occurrence	O
of	O
epilepsy	O
-	O
induced	O
neuronal	O
cell	O
death	O
.	O

Here	O
we	O
analyze	O
the	O
occurrence	O
of	O
seizures	O
and	O
neurotoxicity	O
in	O
D2R	O
-	O
/	O
-	O
mice	O
treated	O
with	O
the	O
cholinergic	O
agonist	O
pilocarpine	B-CHED
.	O

We	O
compared	O
these	O
results	O
with	O
those	O
previously	O
obtained	O
with	O
kainic	B-CHED
acid	I-CHED
(	O
KA	B-CHED
)	O
,	O
a	O
potent	O
glutamate	B-CHED
agonist	O
.	O

Importantly	O
,	O
D2R	O
-	O
/	O
-	O
mice	O
develop	O
seizures	O
at	O
doses	O
of	O
both	O
drugs	O
that	O
are	O
not	O
epileptogenic	O
for	O
WT	O
littermates	O
and	O
show	O
greater	O
neurotoxicity	O
.	O

However	O
,	O
pilocarpine	B-CHED
-	O
induced	O
seizures	O
result	O
in	O
a	O
more	O
widespread	O
neuronal	O
death	O
in	O
both	O
WT	O
and	O
D2R	O
-	O
/	O
-	O
brains	O
in	O
comparison	O
to	O
KA	B-CHED
.	O

Thus	O
,	O
the	O
absence	O
of	O
D2R	O
lowers	O
the	O
threshold	O
for	O
seizures	O
induced	O
by	O
both	O
glutamate	B-CHED
and	O
acetylcholine	B-CHED
.	O

Moreover	O
,	O
the	O
dopaminergic	O
control	O
of	O
epilepsy	O
-	O
induced	O
neurodegeneration	O
seems	O
to	O
be	O
mediated	O
by	O
distinct	O
interactions	O
of	O
D2R	O
signaling	O
with	O
these	O
two	O
neurotransmitters	O
.	O

Steroid	B-CHED
structure	O
and	O
pharmacological	O
properties	O
determine	O
the	O
anti	O
-	O
amnesic	O
effects	O
of	O
pregnenolone	B-CHED
sulphate	I-CHED
in	O
the	O
passive	O
avoidance	O
task	O
in	O
rats	O
.	O

Pregnenolone	B-CHED
sulphate	I-CHED
(	O
PREGS	B-CHED
)	O
has	O
generated	O
interest	O
as	O
one	O
of	O
the	O
most	O
potent	O
memory	O
-	O
enhancing	O
neurosteroids	O
to	O
be	O
examined	O
in	O
rodent	O
learning	O
studies	O
,	O
with	O
particular	O
importance	O
in	O
the	O
ageing	O
process	O
.	O

The	O
mechanism	O
by	O
which	O
this	O
endogenous	O
steroid	B-CHED
enhances	O
memory	O
formation	O
is	O
hypothesized	O
to	O
involve	O
actions	O
on	O
glutamatergic	O
and	O
GABAergic	O
systems	O
.	O

This	O
hypothesis	O
stems	O
from	O
findings	O
that	O
PREGS	B-CHED
is	O
a	O
potent	O
positive	O
modulator	O
of	O
N	B-CHED
-	I-CHED
methyl	I-CHED
-	I-CHED
d	I-CHED
-	I-CHED
aspartate	I-CHED
receptors	O
(	O
NMDARs	O
)	O
and	O
a	O
negative	O
modulator	O
of	O
gamma	B-CHED
-	I-CHED
aminobutyric	I-CHED
acid	I-CHED
(	O
A	O
)	O
receptors	O
(	O
GABA	B-CHED
(	O
A	O
)	O
Rs	O
)	O
.	O

Moreover	O
,	O
PREGS	B-CHED
is	O
able	O
to	O
reverse	O
the	O
amnesic	O
-	O
like	O
effects	O
of	O
NMDAR	O
and	O
GABA	B-CHED
(	O
A	O
)	O
R	O
ligands	O
.	O

To	O
investigate	O
this	O
hypothesis	O
,	O
the	O
present	O
study	O
in	O
rats	O
examined	O
the	O
memory	O
-	O
altering	O
abilities	O
of	O
structural	O
analogs	O
of	O
PREGS	B-CHED
,	O
which	O
differ	O
in	O
their	O
modulation	O
of	O
NMDAR	O
and	O
/	O
or	O
GABA	B-CHED
(	O
A	O
)	O
R	O
function	O
.	O

The	O
analogs	O
tested	O
were	O
:	O
11	B-CHED
-	I-CHED
ketopregnenolone	I-CHED
sulphate	I-CHED
(	O
an	O
agent	O
that	O
is	O
inactive	O
at	O
GABA	B-CHED
(	O
A	O
)	O
Rs	O
and	O
NMDARs	O
)	O
,	O
epipregnanolone	B-CHED
(	I-CHED
[	I-CHED
3beta	I-CHED
-	I-CHED
hydroxy	I-CHED
-	I-CHED
5beta	I-CHED
-	I-CHED
pregnan	I-CHED
-	I-CHED
20	I-CHED
-	I-CHED
one	I-CHED
]	I-CHED
sulphate	I-CHED
,	O
an	O
inhibitor	O
of	O
both	O
GABA	B-CHED
(	O
A	O
)	O
Rs	O
and	O
NMDARs	O
)	O
,	O
and	O
a	O
newly	O
synthesized	O
(	O
-	O
)	O
PREGS	B-CHED
enantiomer	O
(	O
which	O
is	O
identical	O
to	O
PREGS	B-CHED
in	O
effects	O
on	O
GABA	B-CHED
(	O
A	O
)	O
Rs	O
and	O
NMDARs	O
)	O
.	O

The	O
memory	O
-	O
enhancing	O
effects	O
of	O
PREGS	B-CHED
and	O
its	O
analogs	O
were	O
tested	O
in	O
the	O
passive	O
avoidance	O
task	O
using	O
the	O
model	O
of	O
scopolamine	B-CHED
-	O
induced	O
amnesia	O
.	O

Both	O
PREGS	B-CHED
and	O
its	O
(	O
-	O
)	O
enantiomer	O
blocked	O
the	O
effects	O
of	O
scopolamine	B-CHED
.	O

The	O
results	O
show	O
that	O
,	O
unlike	O
PREGS	B-CHED
,	O
11	B-CHED
-	I-CHED
ketopregnenolone	I-CHED
sulphate	I-CHED
and	O
epipregnanolone	B-CHED
sulphate	I-CHED
failed	O
to	O
block	O
the	O
effect	O
of	O
scopolamine	B-CHED
,	O
suggesting	O
that	O
altering	O
the	O
modulation	O
of	O
NMDA	B-CHED
receptors	O
diminishes	O
the	O
memory	O
-	O
enhancing	O
effects	O
of	O
PREGS	B-CHED
.	O

Moreover	O
,	O
enantioselectivity	O
was	O
demonstrated	O
by	O
the	O
ability	O
of	O
natural	O
PREGS	B-CHED
to	O
be	O
an	O
order	O
of	O
magnitude	O
more	O
effective	O
than	O
its	O
synthetic	O
enantiomer	O
in	O
reversing	O
scopolamine	B-CHED
-	O
induced	O
amnesia	O
.	O

These	O
results	O
identify	O
a	O
novel	O
neuropharmacological	O
site	O
for	O
the	O
modulation	O
of	O
memory	O
processes	O
by	O
neuroactive	O
steroids	B-CHED
.	O

Activation	O
of	O
poly	B-CHED
(	I-CHED
ADP	I-CHED
-	I-CHED
ribose	I-CHED
)	I-CHED
polymerase	O
contributes	O
to	O
development	O
of	O
doxorubicin	B-CHED
-	O
induced	O
heart	O
failure	O
.	O

Activation	O
of	O
the	O
nuclear	O
enzyme	O
poly	B-CHED
(	I-CHED
ADP	I-CHED
-	I-CHED
ribose	I-CHED
)	I-CHED
polymerase	O
(	O
PARP	O
)	O
by	O
oxidant	O
-	O
mediated	O
DNA	O
damage	O
is	O
an	O
important	O
pathway	O
of	O
cell	O
dysfunction	O
and	O
tissue	O
injury	O
in	O
conditions	O
associated	O
with	O
oxidative	O
stress	O
.	O

Increased	O
oxidative	O
stress	O
is	O
a	O
major	O
factor	O
implicated	O
in	O
the	O
cardiotoxicity	O
of	O
doxorubicin	B-CHED
(	O
DOX	B-CHED
)	O
,	O
a	O
widely	O
used	O
antitumor	O
anthracycline	B-CHED
antibiotic	O
.	O

Thus	O
,	O
we	O
hypothesized	O
that	O
the	O
activation	O
of	O
PARP	O
may	O
contribute	O
to	O
the	O
DOX	B-CHED
-	O
induced	O
cardiotoxicity	O
.	O

Using	O
a	O
dual	O
approach	O
of	O
PARP	O
-	O
1	O
suppression	O
,	O
by	O
genetic	O
deletion	O
or	O
pharmacological	O
inhibition	O
with	O
the	O
phenanthridinone	O
PARP	O
inhibitor	O
PJ34	B-CHED
,	O
we	O
now	O
demonstrate	O
the	O
role	O
of	O
PARP	O
in	O
the	O
development	O
of	O
cardiac	O
dysfunction	O
induced	O
by	O
DOX	B-CHED
.	O

PARP	O
-	O
1	O
+	O
/	O
+	O
and	O
PARP	O
-	O
1	O
-	O
/	O
-	O
mice	O
received	O
a	O
single	O
injection	O
of	O
DOX	B-CHED
(	O
25	O
mg	O
/	O
kg	O
i	O
.	O
p	O
)	O
.	O

Five	O
days	O
after	O
DOX	B-CHED
administration	O
,	O
left	O
ventricular	O
performance	O
was	O
significantly	O
depressed	O
in	O
PARP	O
-	O
1	O
+	O
/	O
+	O
mice	O
,	O
but	O
only	O
to	O
a	O
smaller	O
extent	O
in	O
PARP	O
-	O
1	O
-	O
/	O
-	O
ones	O
.	O

Similar	O
experiments	O
were	O
conducted	O
in	O
BALB	O
/	O
c	O
mice	O
treated	O
with	O
PJ34	B-CHED
or	O
vehicle	O
.	O

Treatment	O
with	O
a	O
PJ34	B-CHED
significantly	O
improved	O
cardiac	O
dysfunction	O
and	O
increased	O
the	O
survival	O
of	O
the	O
animals	O
.	O

In	O
addition	O
PJ34	B-CHED
significantly	O
reduced	O
the	O
DOX	B-CHED
-	O
induced	O
increase	O
in	O
the	O
serum	O
lactate	B-CHED
dehydrogenase	O
and	O
creatine	B-CHED
kinase	O
activities	O
but	O
not	O
metalloproteinase	O
activation	O
in	O
the	O
heart	O
.	O

Thus	O
,	O
PARP	O
activation	O
contributes	O
to	O
the	O
cardiotoxicity	O
of	O
DOX	B-CHED
.	O

PARP	O
inhibitors	O
may	O
exert	O
protective	O
effects	O
against	O
the	O
development	O
of	O
severe	O
cardiac	O
complications	O
associated	O
with	O
the	O
DOX	B-CHED
treatment	O
.	O

Spironolactone	B-CHED
:	O
is	O
it	O
a	O
novel	O
drug	O
for	O
the	O
prevention	O
of	O
amphotericin	B-CHED
B	I-CHED
-	O
related	O
hypokalemia	O
in	O
cancer	O
patients	O
?	O

OBJECTIVE	O
:	O
Nephrotoxicity	O
is	O
the	O
major	O
adverse	O
effect	O
of	O
amphotericin	B-CHED
B	I-CHED
(	O
AmB	B-CHED
)	O
,	O
often	O
limiting	O
administration	O
of	O
full	O
dosage	O
.	O

Selective	O
distal	O
tubular	O
epithelial	O
toxicity	O
seems	O
to	O
be	O
responsible	O
for	O
the	O
profound	O
potassium	B-CHED
wasting	O
that	O
is	O
a	O
major	O
clinical	O
side	O
effect	O
of	O
treatment	O
with	O
AmB	B-CHED
.	O

Potassium	B-CHED
depletion	O
also	O
potentiates	O
the	O
tubular	O
toxicity	O
of	O
AmB	B-CHED
.	O

This	O
study	O
was	O
designed	O
to	O
assess	O
the	O
ability	O
of	O
spironolactone	B-CHED
to	O
reduce	O
potassium	B-CHED
requirements	O
and	O
to	O
prevent	O
hypokalemia	O
in	O
neutropenic	O
patients	O
on	O
AmB	B-CHED
treatment	O
.	O

METHODS	O
:	O
In	O
this	O
study	O
26	O
patients	O
with	O
various	O
hematological	O
disorders	O
were	O
randomized	O
to	O
receive	O
either	O
intravenous	O
AmB	B-CHED
alone	O
or	O
AmB	B-CHED
and	O
oral	O
spironolactone	B-CHED
100	O
mg	O
twice	O
daily	O
when	O
developing	O
a	O
proven	O
or	O
suspected	O
fungal	O
infection	O
.	O

RESULTS	O
:	O
Patients	O
receiving	O
concomitant	O
AmB	B-CHED
and	O
spironolactone	B-CHED
had	O
significantly	O
higher	O
plasma	O
potassium	B-CHED
levels	O
than	O
those	O
receiving	O
AmB	B-CHED
alone	O
(	O
P	O
=	O
0	O
.	O
0027	O
)	O
.	O

Those	O
patients	O
receiving	O
AmB	B-CHED
and	O
spironolactone	B-CHED
required	O
significantly	O
less	O
potassium	B-CHED
supplementation	O
to	O
maintain	O
their	O
plasma	O
potassium	B-CHED
within	O
the	O
normal	O
range	O
(	O
P	O
=	O
0	O
.	O
022	O
)	O
.	O

Moreover	O
,	O
urinary	O
potassium	B-CHED
losses	O
were	O
significantly	O
less	O
in	O
patients	O
receiving	O
AmB	B-CHED
and	O
spironolactone	B-CHED
than	O
those	O
receiving	O
AmB	B-CHED
alone	O
(	O
P	O
=	O
0	O
.	O
040	O
)	O
.	O

CONCLUSION	O
:	O
This	O
study	O
showed	O
that	O
spironolactone	B-CHED
can	O
reduce	O
potassium	B-CHED
requirements	O
and	O
prevent	O
hypokalemia	O
by	O
reducing	O
urinary	O
potassium	B-CHED
loss	O
in	O
neutropenic	O
patients	O
on	O
AmB	B-CHED
treatment	O
.	O

Erectile	O
dysfunction	O
occurs	O
following	O
substantia	O
nigra	O
lesions	O
in	O
the	O
rat	O
.	O

Erectile	O
function	O
was	O
assessed	O
6	O
weeks	O
following	O
uni	O
-	O
and	O
bilateral	O
injections	O
of	O
6	B-CHED
-	I-CHED
hydroxydopamine	I-CHED
in	O
the	O
substantia	O
nigra	O
nucleus	O
of	O
the	O
brain	O
.	O

Behavioral	O
apomorphine	B-CHED
-	O
induced	O
penile	O
erections	O
were	O
reduced	O
(	O
5	O
/	O
8	O
)	O
and	O
increased	O
(	O
3	O
/	O
8	O
)	O
in	O
uni	O
-	O
and	O
bilateral	O
lesioned	O
animals	O
.	O

Intracavernous	O
pressures	O
,	O
following	O
electrical	O
stimulation	O
of	O
the	O
cavernous	O
nerve	O
,	O
decreased	O
in	O
lesioned	O
animals	O
.	O

Lesions	O
of	O
the	O
substantia	O
nigra	O
were	O
confirmed	O
by	O
histology	O
.	O

Concentration	O
of	O
dopamine	B-CHED
and	O
its	O
metabolites	O
were	O
decreased	O
in	O
the	O
striatum	O
of	O
substantia	O
nigra	O
lesioned	O
rats	O
.	O

Lesions	O
of	O
the	O
substantia	O
nigra	O
are	O
therefore	O
associated	O
with	O
erectile	O
dysfunction	O
in	O
rats	O
and	O
may	O
serve	O
as	O
a	O
model	O
to	O
study	O
erectile	O
dysfunction	O
in	O
Parkinson	O
'	O
s	O
disease	O
.	O

Nicotine	B-CHED
potentiation	O
of	O
morphine	B-CHED
-	O
induced	O
catalepsy	O
in	O
mice	O
.	O

In	O
the	O
present	O
study	O
,	O
effects	O
of	O
nicotine	B-CHED
on	O
catalepsy	O
induced	O
by	O
morphine	B-CHED
in	O
mice	O
have	O
been	O
investigated	O
.	O

Morphine	B-CHED
but	O
not	O
nicotine	B-CHED
induced	O
a	O
dose	O
-	O
dependent	O
catalepsy	O
.	O

The	O
response	O
of	O
morphine	B-CHED
was	O
potentiated	O
by	O
nicotine	B-CHED
.	O

Intraperitoneal	O
administration	O
of	O
atropine	B-CHED
,	O
naloxone	B-CHED
,	O
mecamylamine	B-CHED
,	O
and	O
hexamethonium	B-CHED
to	O
mice	O
reduced	O
catalepsy	O
induced	O
by	O
a	O
combination	O
of	O
morphine	B-CHED
with	O
nicotine	B-CHED
.	O

Intracerebroventricular	O
injection	O
of	O
atropine	B-CHED
,	O
hexamethonium	B-CHED
,	O
and	O
naloxone	B-CHED
also	O
decreased	O
catalepsy	O
induced	O
by	O
morphine	B-CHED
plus	O
nicotine	B-CHED
.	O

Intraperitoneal	O
administration	O
of	O
atropine	B-CHED
,	O
but	O
not	O
intraperitoneal	O
or	O
intracerebroventricular	O
injection	O
of	O
hexamethonium	B-CHED
,	O
decreased	O
the	O
effect	O
of	O
a	O
single	O
dose	O
of	O
morphine	B-CHED
.	O

It	O
was	O
concluded	O
that	O
morphine	B-CHED
catalepsy	O
can	O
be	O
elicited	O
by	O
opioid	O
and	O
cholinergic	O
receptors	O
,	O
and	O
the	O
potentiation	O
of	O
morphine	B-CHED
induced	O
by	O
nicotine	B-CHED
may	O
also	O
be	O
mediated	O
through	O
cholinergic	O
receptor	O
mechanisms	O
.	O

Force	O
overflow	O
and	O
levodopa	B-CHED
-	O
induced	O
dyskinesias	O
in	O
Parkinson	O
'	O
s	O
disease	O
.	O

We	O
assessed	O
force	O
coordination	O
of	O
the	O
hand	O
in	O
Parkinson	O
'	O
s	O
disease	O
and	O
its	O
relationship	O
to	O
motor	O
complications	O
of	O
levodopa	B-CHED
therapy	O
,	O
particularly	O
to	O
levodopa	B-CHED
-	O
induced	O
dyskinesias	O
(	O
LID	O
)	O
.	O

We	O
studied	O
two	O
groups	O
of	O
Parkinson	O
'	O
s	O
disease	O
patients	O
with	O
(	O
Parkinson	O
'	O
s	O
disease	O
+	O
LID	O
,	O
n	O
=	O
23	O
)	O
and	O
without	O
levodopa	B-CHED
-	O
induced	O
dyskinesias	O
(	O
Parkinson	O
'	O
s	O
disease	O
-	O
LID	O
,	O
n	O
=	O
10	O
)	O
,	O
and	O
age	O
-	O
matched	O
healthy	O
controls	O
.	O

The	O
motor	O
score	O
of	O
the	O
Unified	O
Parkinson	O
'	O
s	O
Disease	O
Rating	O
Scale	O
,	O
a	O
dyskinesia	O
score	O
and	O
force	O
in	O
a	O
grip	O
-	O
lift	O
paradigm	O
were	O
assessed	O
ON	O
and	O
OFF	O
levodopa	B-CHED
.	O

A	O
pathological	O
increase	O
of	O
forces	O
was	O
seen	O
in	O
ON	O
-	O
state	O
in	O
Parkinson	O
'	O
s	O
disease	O
+	O
LID	O
only	O
.	O

In	O
Parkinson	O
'	O
s	O
disease	O
+	O
LID	O
,	O
the	O
force	O
involved	O
in	O
pressing	O
down	O
the	O
object	O
before	O
lifting	O
was	O
significantly	O
increased	O
by	O
levodopa	B-CHED
(	O
by	O
61	O
%	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

An	O
overshooting	O
of	O
peak	O
grip	O
force	O
by	O
51	O
%	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
of	O
static	O
grip	O
force	O
by	O
45	O
%	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
was	O
observed	O
in	O
the	O
ON	O
-	O
compared	O
with	O
the	O
OFF	O
-	O
drug	O
condition	O
.	O

In	O
contrast	O
,	O
no	O
excessive	O
force	O
was	O
found	O
in	O
Parkinson	O
'	O
s	O
disease	O
-	O
LID	O
.	O

Peak	O
grip	O
force	O
in	O
ON	O
-	O
state	O
was	O
140	O
%	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
higher	O
in	O
Parkinson	O
'	O
s	O
disease	O
+	O
LID	O
than	O
in	O
Parkinson	O
'	O
s	O
disease	O
-	O
LID	O
,	O
while	O
static	O
grip	O
force	O
was	O
increased	O
by	O
138	O
%	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
between	O
groups	O
.	O

Severity	O
of	O
peak	O
-	O
dose	O
dyskinesias	O
was	O
strongly	O
correlated	O
with	O
grip	O
force	O
in	O
ON	O
-	O
state	O
(	O
r	O
=	O
0	O
.	O
79	O
with	O
peak	O
force	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

No	O
correlation	O
was	O
observed	O
between	O
forces	O
and	O
the	O
motor	O
score	O
as	O
well	O
as	O
with	O
the	O
daily	O
dose	O
of	O
dopaminergic	O
medication	O
.	O

Force	O
excess	O
was	O
only	O
observed	O
in	O
patients	O
with	O
LID	O
and	O
motor	O
fluctuations	O
.	O

A	O
close	O
relationship	O
was	O
seen	O
between	O
the	O
overshooting	O
of	O
forces	O
and	O
dyskinesias	O
in	O
the	O
ON	O
-	O
drug	O
condition	O
.	O

We	O
postulate	O
that	O
both	O
LID	O
and	O
grip	O
force	O
excess	O
share	O
common	O
pathophysiological	O
mechanisms	O
related	O
to	O
motor	O
fluctuations	O
.	O

Behavioral	O
effects	O
of	O
MK	B-CHED
-	I-CHED
801	I-CHED
on	O
reserpine	B-CHED
-	O
treated	O
mice	O
.	O

The	O
effects	O
of	O
dizocilpine	B-CHED
(	O
MK	B-CHED
-	I-CHED
801	I-CHED
)	O
,	O
a	O
noncompetitive	O
N	B-CHED
-	I-CHED
methyl	I-CHED
-	I-CHED
D	I-CHED
-	I-CHED
aspartate	I-CHED
(	O
NMDA	B-CHED
)	O
receptor	O
antagonist	O
,	O
were	O
studied	O
on	O
dopamine	B-CHED
-	O
related	O
behaviors	O
induced	O
by	O
reserpine	B-CHED
treatments	O
.	O

This	O
study	O
focuses	O
on	O
behavioral	O
syndromes	O
that	O
may	O
used	O
as	O
models	O
for	O
Parkinson	O
'	O
s	O
disease	O
,	O
or	O
tardive	O
dyskinesia	O
,	O
and	O
its	O
response	O
after	O
glutamatergic	O
blockage	O
.	O

Reserpine	B-CHED
(	O
1	O
mg	O
/	O
kg	O
)	O
,	O
administered	O
once	O
every	O
other	O
day	O
for	O
4	O
days	O
,	O
produced	O
increases	O
in	O
orofacial	O
dyskinesia	O
,	O
tongue	O
protrusion	O
and	O
vacuous	O
chewing	O
in	O
mice	O
,	O
which	O
are	O
signs	O
indicative	O
of	O
tardive	O
dyskinesia	O
.	O

Reserpine	B-CHED
also	O
produced	O
tremor	O
and	O
catalepsy	O
,	O
which	O
are	O
signs	O
suggestive	O
of	O
Parkinson	O
'	O
s	O
disease	O
.	O

MK	B-CHED
-	I-CHED
801	I-CHED
(	O
0	O
.	O
1	O
mg	O
/	O
kg	O
)	O
,	O
administered	O
30	O
min	O
before	O
the	O
observation	O
test	O
,	O
prevented	O
the	O
vacuous	O
chewing	O
movements	O
,	O
tongue	O
protrusions	O
and	O
catalepsy	O
induced	O
by	O
reserpine	B-CHED
.	O

However	O
,	O
MK	B-CHED
-	I-CHED
801	I-CHED
injection	O
produced	O
a	O
significant	O
increase	O
of	O
tremor	O
in	O
reserpine	B-CHED
-	O
treated	O
mice	O
.	O

Reserpine	B-CHED
(	O
1	O
mg	O
/	O
kg	O
)	O
,	O
administered	O
90	O
min	O
before	O
the	O
test	O
and	O
followed	O
by	O
apomophine	B-CHED
injection	O
(	O
0	O
.	O
1	O
mg	O
/	O
kg	O
)	O
5	O
min	O
before	O
the	O
test	O
,	O
did	O
not	O
produce	O
oral	O
dyskinesia	O
in	O
mice	O
.	O

On	O
the	O
other	O
hand	O
,	O
reserpine	B-CHED
induced	O
increases	O
in	O
tremor	O
and	O
catalepsy	O
compared	O
to	O
control	O
mice	O
.	O

MK	B-CHED
-	I-CHED
801	I-CHED
(	O
0	O
.	O
1	O
mg	O
/	O
kg	O
)	O
administration	O
attenuated	O
the	O
catalepsy	O
and	O
tremor	O
induced	O
by	O
reserpine	B-CHED
.	O

Pretreatment	O
with	O
reserpine	B-CHED
(	O
1	O
mg	O
/	O
kg	O
)	O
24	O
h	O
before	O
the	O
observation	O
test	O
produced	O
increases	O
in	O
vacuous	O
chewing	O
movements	O
and	O
tongue	O
protrusion	O
,	O
as	O
well	O
as	O
increases	O
in	O
tremor	O
and	O
catalepsy	O
,	O
whereas	O
MK	B-CHED
-	I-CHED
801	I-CHED
(	O
0	O
.	O
1	O
mg	O
/	O
kg	O
)	O
injection	O
90	O
min	O
before	O
the	O
test	O
reversed	O
the	O
effects	O
of	O
reserpine	B-CHED
.	O

These	O
results	O
show	O
that	O
reserpine	B-CHED
produces	O
different	O
and	O
abnormal	O
movements	O
,	O
which	O
are	O
related	O
to	O
dose	O
and	O
schedule	O
employed	O
and	O
can	O
be	O
considered	O
as	O
parkinsonian	O
-	O
like	O
and	O
tardive	O
dsykinesia	O
signs	O
.	O

The	O
glutamatergic	O
blockage	O
produced	O
by	O
NMDA	B-CHED
can	O
restore	O
these	O
signs	O
,	O
such	O
as	O
vacuous	O
chewing	O
movements	O
,	O
tongue	O
protrusions	O
,	O
catalepsy	O
and	O
tremor	O
according	O
to	O
the	O
employed	O
model	O
.	O

Risperidone	B-CHED
-	O
associated	O
,	O
benign	O
transient	O
visual	O
disturbances	O
in	O
schizophrenic	O
patients	O
with	O
a	O
past	O
history	O
of	O
LSD	B-CHED
abuse	O
.	O

Two	O
schizophrenic	O
patients	O
,	O
who	O
had	O
a	O
prior	O
history	O
of	O
LSD	B-CHED
abuse	O
and	O
who	O
had	O
previously	O
developed	O
EPS	O
with	O
classic	O
antipsychotics	O
,	O
were	O
successfully	O
treated	O
with	O
risperidone	B-CHED
.	O

They	O
both	O
reported	O
short	O
episodes	O
of	O
transient	O
visual	O
disturbances	O
,	O
which	O
appeared	O
immediately	O
after	O
starting	O
treatment	O
with	O
risperidone	B-CHED
.	O

This	O
imagery	O
resembled	O
visual	O
disturbances	O
previously	O
experienced	O
as	O
"	O
flashbacks	O
"	O
related	O
to	O
prior	O
LSD	B-CHED
consumption	O
.	O

Risperidone	B-CHED
administration	O
was	O
continued	O
and	O
the	O
visual	O
disturbances	O
gradually	O
wore	O
off	O
.	O

During	O
a	O
six	O
-	O
month	O
follow	O
-	O
up	O
period	O
,	O
there	O
was	O
no	O
recurrence	O
of	O
visual	O
disturbances	O
.	O

This	O
phenomenon	O
may	O
be	O
interpreted	O
as	O
a	O
benign	O
,	O
short	O
-	O
term	O
and	O
self	O
-	O
limiting	O
side	O
effect	O
which	O
does	O
not	O
contraindicate	O
the	O
use	O
of	O
risperidone	B-CHED
or	O
interfere	O
with	O
treatment	O
.	O

Conclusions	O
based	O
on	O
two	O
case	O
reports	O
should	O
be	O
taken	O
with	O
appropriate	O
caution	O
.	O

Topiramate	B-CHED
-	O
induced	O
nephrolithiasis	O
.	O

Topiramate	B-CHED
is	O
a	O
recently	O
developed	O
antiepileptic	O
medication	O
that	O
is	O
becoming	O
more	O
widely	O
prescribed	O
because	O
of	O
its	O
efficacy	O
in	O
treating	O
refractory	O
seizures	O
.	O

Urologists	O
should	O
be	O
aware	O
that	O
this	O
medication	O
can	O
cause	O
metabolic	O
acidosis	O
in	O
patients	O
secondary	O
to	O
inhibition	O
of	O
carbonic	O
anhydrase	O
.	O

In	O
addition	O
,	O
a	O
distal	O
tubular	O
acidification	O
defect	O
may	O
result	O
,	O
thus	O
impairing	O
the	O
normal	O
compensatory	O
drop	O
in	O
urine	O
pH	O
.	O

These	O
factors	O
can	O
lead	O
to	O
the	O
development	O
of	O
calcium	B-CHED
phosphate	I-CHED
nephrolithiasis	O
.	O

We	O
report	O
the	O
first	O
two	O
cases	O
of	O
topiramate	B-CHED
-	O
induced	O
nephrolithiasis	O
in	O
the	O
urologic	O
literature	O
.	O

Ketamine	B-CHED
in	O
war	O
/	O
tropical	O
surgery	O
(	O
a	O
final	O
tribute	O
to	O
the	O
racemic	O
mixture	O
)	O
.	O

A	O
technique	O
of	O
continuous	O
intravenous	O
anaesthesia	O
with	O
ketamine	B-CHED
was	O
used	O
successfully	O
during	O
the	O
Somalia	O
civil	O
war	O
in	O
1994	O
and	O
in	O
north	O
Uganda	O
in	O
1999	O
for	O
64	O
operations	O
in	O
62	O
patients	O
,	O
aged	O
from	O
6	O
weeks	O
to	O
70	O
years	O
,	O
undergoing	O
limb	O
and	O
abdominal	O
surgery	O
including	O
caesarian	O
sections	O
and	O
interventions	O
in	O
neonates	O
.	O

Operations	O
lasting	O
up	O
to	O
2h	O
could	O
be	O
performed	O
in	O
the	O
absence	O
of	O
sophisticated	O
equipment	O
such	O
as	O
pulse	O
oximeters	O
or	O
ventilators	O
in	O
patients	O
on	O
spontaneous	O
ventilation	O
breathing	O
air	O
/	O
oxygen	B-CHED
only	O
.	O

After	O
premedication	O
with	O
diazepam	B-CHED
,	O
glycopyrrolate	B-CHED
and	O
local	O
anaesthesia	O
,	O
and	O
induction	O
with	O
standard	O
doses	O
of	O
ketamine	B-CHED
,	O
a	O
maintenance	O
dose	O
of	O
10	O
-	O
20	O
microg	O
/	O
kg	O
/	O
min	O
of	O
ketamine	B-CHED
proved	O
safe	O
and	O
effective	O
.	O

Emphasis	O
was	O
placed	O
on	O
bedside	O
clinical	O
monitoring	O
,	O
relying	O
heavily	O
on	O
the	O
heart	O
rate	O
.	O

Diazepam	B-CHED
,	O
unless	O
contraindicated	O
or	O
risky	O
,	O
remains	O
the	O
only	O
necessary	O
complementary	O
drug	O
to	O
ketamine	B-CHED
as	O
it	O
buffers	O
its	O
cardiovascular	O
response	O
and	O
decreases	O
the	O
duration	O
and	O
intensity	O
of	O
operative	O
and	O
postoperative	O
hallucinations	O
.	O

Local	O
anaesthetic	O
blocks	O
were	O
useful	O
in	O
decreasing	O
the	O
requirement	O
for	O
postoperative	O
analgesia	O
.	O

An	O
antisialogue	O
was	O
usually	O
unnecessary	O
in	O
operations	O
lasting	O
up	O
to	O
2	O
h	O
,	O
glycopyrrolate	B-CHED
being	O
the	O
best	O
choice	O
for	O
its	O
lowest	O
psychotropic	O
and	O
chronotropic	O
effects	O
,	O
especially	O
in	O
a	O
hot	O
climate	O
.	O

Experience	O
in	O
war	O
/	O
tropical	O
settings	O
suggests	O
this	O
technique	O
could	O
be	O
useful	O
in	O
civilian	O
contexts	O
such	O
as	O
outdoor	O
life	O
-	O
saving	O
emergency	O
surgery	O
or	O
in	O
mass	O
casualties	O
where	O
,	O
e	O
.	O
g	O
.	O
amputation	O
and	O
rapid	O
extrication	O
were	O
required	O
.	O

Intravenous	O
ribavirin	B-CHED
treatment	O
for	O
severe	O
adenovirus	O
disease	O
in	O
immunocompromised	O
children	O
.	O

BACKGROUND	O
:	O
Adenovirus	O
is	O
an	O
important	O
cause	O
of	O
morbidity	O
and	O
mortality	O
in	O
the	O
immunocompromised	O
host	O
.	O

The	O
incidence	O
of	O
severe	O
adenovirus	O
disease	O
in	O
pediatrics	O
is	O
increasing	O
in	O
association	O
with	O
growing	O
numbers	O
of	O
immunocompromised	O
children	O
,	O
where	O
case	O
fatality	O
rates	O
as	O
high	O
as	O
50	O
%	O
to	O
80	O
%	O
have	O
been	O
reported	O
.	O

There	O
are	O
no	O
approved	O
antiviral	O
agents	O
with	O
proven	O
efficacy	O
for	O
the	O
treatment	O
of	O
severe	O
adenovirus	O
disease	O
,	O
nor	O
are	O
there	O
any	O
prospective	O
randomized	O
,	O
controlled	O
trials	O
of	O
potentially	O
useful	O
anti	O
-	O
adenovirus	O
therapies	O
.	O

Apparent	O
clinical	O
success	O
in	O
the	O
treatment	O
of	O
severe	O
adenovirus	O
disease	O
is	O
limited	O
to	O
a	O
few	O
case	O
reports	O
and	O
small	O
series	O
.	O

Experience	O
is	O
greatest	O
with	O
intravenous	O
ribavirin	B-CHED
and	O
cidofovir	B-CHED
.	O

Ribavirin	B-CHED
,	O
a	O
guanosine	B-CHED
analogue	O
,	O
has	O
broad	O
antiviral	O
activity	O
against	O
both	O
RNA	O
and	O
DNA	O
viruses	O
,	O
including	O
documented	O
activity	O
against	O
adenovirus	O
in	O
vitro	O
.	O

Ribavirin	B-CHED
is	O
licensed	O
in	O
aerosol	O
form	O
for	O
the	O
treatment	O
of	O
respiratory	O
syncytial	O
virus	O
infection	O
,	O
and	O
orally	O
in	O
combination	O
with	O
interferon	O
to	O
treat	O
hepatitis	O
C	O
.	O

Intravenous	O
ribavirin	B-CHED
is	O
the	O
treatment	O
of	O
choice	O
for	O
infection	O
with	O
hemorrhagic	O
fever	O
viruses	O
.	O

The	O
most	O
common	O
adverse	O
effect	O
of	O
intravenous	O
ribavirin	B-CHED
is	O
reversible	O
mild	O
anemia	O
.	O

The	O
use	O
of	O
cidofovir	B-CHED
in	O
severe	O
adenovirus	O
infection	O
has	O
been	O
limited	O
by	O
adverse	O
effects	O
,	O
the	O
most	O
significant	O
of	O
which	O
is	O
nephrotoxicity	O
.	O

OBJECTIVE	O
:	O
We	O
report	O
our	O
experience	O
with	O
intravenous	O
ribavirin	B-CHED
therapy	O
for	O
severe	O
adenovirus	O
disease	O
in	O
a	O
series	O
of	O
immunocompromised	O
children	O
and	O
review	O
the	O
literature	O
.	O

DESIGN	O
/	O
METHODS	O
:	O
We	O
retrospectively	O
reviewed	O
the	O
medical	O
records	O
of	O
5	O
children	O
treated	O
with	O
intravenous	O
ribavirin	B-CHED
for	O
documented	O
severe	O
adenovirus	O
disease	O
.	O

Two	O
patients	O
developed	O
adenovirus	O
hemorrhagic	O
cystitis	O
after	O
cardiac	O
and	O
bone	O
marrow	O
transplants	O
,	O
respectively	O
.	O

The	O
bone	O
marrow	O
transplant	O
patient	O
also	O
received	O
intravenous	O
cidofovir	B-CHED
for	O
progressive	O
disseminated	O
disease	O
.	O

An	O
additional	O
3	O
children	O
developed	O
adenovirus	O
pneumonia	O
;	O
2	O
were	O
neonates	O
,	O
1	O
of	O
whom	O
had	O
partial	O
DiGeorge	O
syndrome	O
.	O

The	O
remaining	O
infant	O
had	O
recently	O
undergone	O
a	O
cardiac	O
transplant	O
.	O

Intravenous	O
ribavirin	B-CHED
was	O
administered	O
on	O
a	O
compassionate	O
-	O
use	O
protocol	O
.	O

RESULTS	O
:	O
Complete	O
clinical	O
recovery	O
followed	O
later	O
by	O
viral	O
clearance	O
was	O
observed	O
in	O
2	O
children	O
:	O
the	O
cardiac	O
transplant	O
recipient	O
with	O
adenovirus	O
hemorrhagic	O
cystitis	O
and	O
the	O
immunocompetent	O
neonate	O
with	O
adenovirus	O
pneumonia	O
.	O

The	O
remaining	O
3	O
children	O
died	O
of	O
adenovirus	O
disease	O
.	O

Intravenous	O
ribavirin	B-CHED
therapy	O
was	O
well	O
tolerated	O
.	O

Use	O
of	O
cidofovir	B-CHED
in	O
1	O
child	O
was	O
associated	O
with	O
progressive	O
renal	O
failure	O
and	O
neutropenia	O
.	O

DISCUSSION	O
:	O
Our	O
series	O
of	O
patients	O
is	O
representative	O
of	O
the	O
spectrum	O
of	O
immunocompromised	O
children	O
at	O
greatest	O
risk	O
for	O
severe	O
adenovirus	O
disease	O
,	O
namely	O
solid	O
-	O
organ	O
and	O
bone	O
marrow	O
transplant	O
recipients	O
,	O
neonates	O
,	O
and	O
children	O
with	O
immunodeficiency	O
.	O

Although	O
intravenous	O
ribavirin	B-CHED
was	O
not	O
effective	O
for	O
all	O
children	O
with	O
severe	O
adenovirus	O
disease	O
in	O
this	O
series	O
or	O
in	O
the	O
literature	O
,	O
therapy	O
is	O
unlikely	O
to	O
be	O
of	O
benefit	O
if	O
begun	O
late	O
in	O
the	O
course	O
of	O
the	O
infection	O
.	O

Early	O
identification	O
,	O
eg	O
by	O
polymerase	O
chain	O
reaction	O
of	O
those	O
patients	O
at	O
risk	O
of	O
disseminated	O
adenovirus	O
disease	O
may	O
permit	O
earlier	O
antiviral	O
treatment	O
and	O
better	O
evaluation	O
of	O
therapeutic	O
response	O
.	O

CONCLUSIONS	O
:	O
Two	O
of	O
5	O
children	O
with	O
severe	O
adenovirus	O
disease	O
treated	O
with	O
intravenous	O
ribavirin	B-CHED
recovered	O
.	O

The	O
availability	O
of	O
newer	O
rapid	O
diagnostic	O
techniques	O
,	O
such	O
as	O
polymerase	O
chain	O
reaction	O
,	O
may	O
make	O
earlier	O
,	O
more	O
effective	O
treatment	O
of	O
adenovirus	O
infection	O
possible	O
.	O

Given	O
the	O
seriousness	O
and	O
increasing	O
prevalence	O
of	O
adenovirus	O
disease	O
in	O
certain	O
hosts	O
,	O
especially	O
children	O
,	O
a	O
large	O
,	O
multicenter	O
clinical	O
trial	O
of	O
potentially	O
useful	O
anti	O
-	O
adenoviral	O
therapies	O
,	O
such	O
as	O
intravenous	O
ribavirin	B-CHED
,	O
is	O
clearly	O
required	O
to	O
demonstrate	O
the	O
most	O
effective	O
and	O
least	O
toxic	O
therapy	O
.	O

Delayed	O
asystolic	O
cardiac	O
arrest	O
after	O
diltiazem	B-CHED
overdose	O
;	O
resuscitation	O
with	O
high	O
dose	O
intravenous	O
calcium	B-CHED
.	O

A	O
51	O
year	O
old	O
man	O
took	O
a	O
mixed	O
overdose	O
including	O
1	O
.	O
8	O
-	O
3	O
.	O
6	O
g	O
of	O
diltiazem	B-CHED
,	O
paracetamol	B-CHED
,	O
aspirin	B-CHED
,	O
isosorbide	B-CHED
nitrate	B-CHED
,	O
and	O
alcohol	B-CHED
.	O

He	O
initially	O
presented	O
to	O
hospital	O
after	O
six	O
hours	O
with	O
mild	O
hypotension	O
and	O
was	O
treated	O
with	O
activated	O
charcoal	O
and	O
intravenous	O
fluids	O
.	O

Eighteen	O
hours	O
after	O
the	O
overdose	O
he	O
had	O
two	O
generalised	O
tonic	O
-	O
clonic	O
seizures	O
.	O

The	O
patient	O
remained	O
unresponsive	O
with	O
junctional	O
bradycardia	O
,	O
unrecordable	O
blood	O
pressure	O
,	O
and	O
then	O
became	O
asystolic	O
.	O

He	O
was	O
resuscitated	O
with	O
high	O
dose	O
(	O
13	O
.	O
5	O
g	O
)	O
intravenous	O
calcium	B-CHED
and	O
adrenaline	B-CHED
(	O
epinephrine	B-CHED
)	O
.	O

He	O
required	O
inotropic	O
support	O
and	O
temporary	O
pacing	O
over	O
the	O
next	O
48	O
hours	O
.	O

This	O
case	O
suggests	O
there	O
is	O
a	O
role	O
for	O
aggressive	O
high	O
dose	O
intravenous	O
calcium	B-CHED
therapy	O
in	O
severe	O
diltiazem	B-CHED
overdose	O
,	O
particularly	O
with	O
the	O
onset	O
of	O
asystole	O
.	O

It	O
should	O
be	O
considered	O
early	O
in	O
cases	O
of	O
cardiac	O
arrest	O
after	O
diltiazem	B-CHED
overdose	O
.	O

The	O
case	O
also	O
highlights	O
the	O
problems	O
with	O
delayed	O
toxicity	O
when	O
whole	O
bowel	O
irrigation	O
is	O
not	O
administered	O
.	O

Low	B-CHED
-	I-CHED
molecular	I-CHED
-	I-CHED
weight	I-CHED
heparin	I-CHED
for	O
the	O
treatment	O
of	O
patients	O
with	O
mechanical	O
heart	O
valves	O
.	O

BACKGROUND	O
:	O
The	O
interruption	O
of	O
oral	O
anticoagulant	O
(	O
OAC	O
)	O
administration	O
is	O
sometimes	O
indicated	O
in	O
patients	O
with	O
mechanical	O
heart	O
valves	O
,	O
mainly	O
before	O
noncardiac	O
surgery	O
,	O
non	O
-	O
surgical	O
interventions	O
,	O
and	O
pregnancy	O
.	O

Unfractionated	B-CHED
heparin	I-CHED
(	O
UH	B-CHED
)	O
is	O
currently	O
the	O
substitute	O
for	O
selected	O
patients	O
.	O

Low	B-CHED
-	I-CHED
molecular	I-CHED
-	I-CHED
weight	I-CHED
heparin	I-CHED
(	O
LMWH	B-CHED
)	O
offers	O
theoretical	O
advantages	O
over	O
UH	B-CHED
,	O
but	O
is	O
not	O
currently	O
considered	O
in	O
clinical	O
guidelines	O
as	O
an	O
alternative	O
to	O
UH	B-CHED
in	O
patients	O
with	O
prosthetic	O
valves	O
.	O

HYPOTHESIS	O
:	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
review	O
the	O
data	O
accumulated	O
so	O
far	O
on	O
the	O
use	O
of	O
LMWH	B-CHED
in	O
this	O
patient	O
population	O
and	O
to	O
discuss	O
its	O
applicability	O
in	O
common	O
practice	O
.	O

METHODS	O
:	O
For	O
this	O
paper	O
,	O
the	O
current	O
medical	O
literature	O
on	O
LMWH	B-CHED
in	O
patients	O
with	O
mechanical	O
heart	O
valves	O
was	O
extensively	O
reviewed	O
.	O

RESULTS	O
:	O
There	O
were	O
eight	O
series	O
and	O
six	O
case	O
reports	O
.	O

None	O
of	O
the	O
studies	O
was	O
randomized	O
,	O
and	O
only	O
one	O
was	O
prospective	O
.	O

Data	O
to	O
establish	O
the	O
thromboembolic	O
risk	O
were	O
incomplete	O
.	O

After	O
excluding	O
case	O
reports	O
,	O
the	O
following	O
groups	O
were	O
constructed	O
:	O
(	O
a	O
)	O
short	O
-	O
term	O
administration	O
,	O
after	O
valve	O
insertion	O
(	O
n	O
=	O
212	O
)	O
;	O
(	O
b	O
)	O
short	O
-	O
term	O
,	O
perioperative	O
(	O
noncardiac	O
)	O
/	O
periprocedural	O
(	O
n	O
=	O
114	O
)	O
;	O
(	O
c	O
)	O
long	O
-	O
term	O
,	O
due	O
to	O
intolerance	O
to	O
OAC	O
(	O
n	O
=	O
16	O
)	O
;	O
(	O
d	O
)	O
long	O
-	O
term	O
,	O
in	O
pregnancy	O
(	O
n	O
=	O
10	O
)	O
.	O

The	O
incidence	O
rate	O
of	O
thromboembolism	O
was	O
0	O
.	O
9	O
%	O
for	O
all	O
the	O
studies	O
and	O
0	O
.	O
5	O
,	O
0	O
,	O
20	O
,	O
and	O
0	O
%	O
in	O
groups	O
a	O
,	O
b	O
,	O
c	O
,	O
and	O
d	O
,	O
respectively	O
;	O
for	O
hemorrhage	O
,	O
the	O
overall	O
rate	O
was	O
3	O
.	O
4	O
%	O
(	O
3	O
.	O
8	O
,	O
2	O
.	O
6	O
,	O
10	O
,	O
and	O
0	O
%	O
for	O
the	O
respective	O
groups	O
)	O
.	O

CONCLUSIONS	O
:	O
In	O
patients	O
with	O
mechanical	O
heart	O
valves	O
,	O
short	O
-	O
term	O
LMWH	B-CHED
therapy	O
compares	O
favorably	O
with	O
UH	B-CHED
.	O

Data	O
on	O
mid	O
-	O
and	O
long	O
-	O
term	O
LMWH	B-CHED
administration	O
in	O
these	O
patients	O
are	O
sparse	O
.	O

Further	O
randomized	O
studies	O
are	O
needed	O
to	O
confirm	O
the	O
safety	O
and	O
precise	O
indications	O
for	O
the	O
use	O
of	O
LMWH	B-CHED
in	O
patients	O
with	O
mechanical	O
heart	O
valves	O
.	O

Cardiac	O
arrest	O
after	O
intravenous	O
metoclopramide	B-CHED
-	O
a	O
case	O
of	O
five	O
repeated	O
injections	O
of	O
metoclopramide	B-CHED
causing	O
five	O
episodes	O
of	O
cardiac	O
arrest	O
.	O

We	O
describe	O
a	O
patient	O
where	O
intravenous	O
injection	O
of	O
metoclopramide	B-CHED
was	O
immediately	O
followed	O
by	O
asystole	O
repeatedly	O
.	O

The	O
patient	O
received	O
metoclopramide	B-CHED
10	O
mg	O
i	O
.	O
v	O
.	O
five	O
times	O
during	O
48	O
h	O
.	O

After	O
interviewing	O
the	O
attending	O
nurses	O
and	O
reviewing	O
the	O
written	O
documentation	O
,	O
it	O
is	O
clear	O
that	O
every	O
administration	O
of	O
metoclopramide	B-CHED
was	O
immediately	O
(	O
within	O
s	O
)	O
followed	O
by	O
asystole	O
.	O

The	O
asystole	O
lasted	O
15	O
-	O
30	O
s	O
on	O
four	O
occasions	O
,	O
on	O
one	O
occasion	O
it	O
lasted	O
2	O
min	O
.	O

The	O
patient	O
received	O
atropine	B-CHED
0	O
.	O
5	O
-	O
1	O
mg	O
and	O
chest	O
compressions	O
,	O
before	O
sinus	O
rhythm	O
again	O
took	O
over	O
.	O

We	O
interpret	O
this	O
as	O
episodes	O
of	O
cardiac	O
arrest	O
caused	O
by	O
metoclopramide	B-CHED
.	O

The	O
rapid	O
injection	O
via	O
the	O
central	O
venous	O
route	O
and	O
the	O
concomitant	O
tapering	O
of	O
dopamine	B-CHED
infusion	O
might	O
have	O
contributed	O
in	O
precipitating	O
the	O
adverse	O
drug	O
reaction	O
.	O

Immunohistochemical	O
study	O
on	O
inducible	O
type	O
of	O
nitric	B-CHED
oxide	I-CHED
(	O
iNOS	O
)	O
,	O
basic	O
fibroblast	O
growth	O
factor	O
(	O
bFGF	O
)	O
and	O
tumor	O
growth	O
factor	O
-	O
beta1	O
(	O
TGF	O
-	O
beta1	O
)	O
in	O
arteritis	O
induced	O
in	O
rats	O
by	O
fenoldopam	B-CHED
and	O
theophylline	B-CHED
,	O
vasodilators	O
.	O

Arteritis	O
induced	O
in	O
rats	O
by	O
vasodilators	O
,	O
fenoldopam	B-CHED
and	O
theophylline	B-CHED
,	O
was	O
examined	O
immunohistochemically	O
for	O
expressions	O
of	O
inducible	O
type	O
of	O
nitric	B-CHED
oxide	I-CHED
synthase	O
(	O
iNOS	O
)	O
,	O
basic	O
fibroblast	O
growth	O
factor	O
(	O
bFGF	O
)	O
and	O
tumor	O
growth	O
factor	O
-	O
beta1	O
(	O
TGF	O
-	O
beta1	O
)	O
.	O

Rats	O
were	O
administered	O
fenoldopam	B-CHED
for	O
24	O
hours	O
by	O
intravenous	O
infusion	O
with	O
or	O
without	O
following	O
repeated	O
daily	O
oral	O
administrations	O
of	O
theophylline	B-CHED
.	O

Irrespective	O
of	O
theophylline	B-CHED
administration	O
,	O
iNOS	O
antigens	O
were	O
remarkably	O
abundant	O
in	O
ED	O
-	O
1	O
-	O
positive	O
cells	O
on	O
day	O
5	O
and	O
8	O
post	O
-	O
fenoldopam	B-CHED
-	O
infusion	O
(	O
DPI	O
)	O
;	O
bFGF	O
antigens	O
were	O
remarkably	O
abundant	O
in	O
ED	O
-	O
1	O
-	O
positive	O
cells	O
on	O
1	O
and	O
3	O
DPI	O
;	O
TGF	O
-	O
beta1	O
antigens	O
were	O
observed	O
in	O
ED	O
-	O
1	O
-	O
positive	O
cells	O
on	O
and	O
after	O
5	O
DPI	O
.	O

These	O
results	O
suggest	O
that	O
the	O
peak	O
expression	O
of	O
iNOS	O
antigen	O
was	O
followed	O
by	O
that	O
of	O
bFGF	O
antigen	O
,	O
and	O
bFGF	O
may	O
have	O
a	O
suppressive	O
effect	O
on	O
iNOS	O
expression	O
in	O
these	O
rat	O
arteritis	O
models	O
.	O

On	O
the	O
other	O
hand	O
,	O
TGF	O
-	O
beta1	O
was	O
not	O
considered	O
to	O
have	O
a	O
suppressive	O
effect	O
on	O
iNOS	O
expression	O
in	O
these	O
models	O
.	O

The	O
striatum	O
as	O
a	O
target	O
for	O
anti	O
-	O
rigor	O
effects	O
of	O
an	O
antagonist	O
of	O
mGluR1	O
,	O
but	O
not	O
an	O
agonist	O
of	O
group	O
II	O
metabotropic	O
glutamate	B-CHED
receptors	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
find	O
out	O
whether	O
the	O
metabotropic	O
receptor	O
1	O
(	O
mGluR1	O
)	O
and	O
group	O
II	O
mGluRs	O
,	O
localized	O
in	O
the	O
striatum	O
,	O
are	O
involved	O
in	O
antiparkinsonian	O
-	O
like	O
effects	O
in	O
rats	O
.	O

Haloperidol	B-CHED
(	O
1	O
mg	O
/	O
kg	O
ip	O
)	O
induced	O
parkinsonian	O
-	O
like	O
muscle	O
rigidity	O
,	O
measured	O
as	O
an	O
increased	O
resistance	O
of	O
a	O
rat	O
'	O
s	O
hind	O
foot	O
to	O
passive	O
flexion	O
and	O
extension	O
at	O
the	O
ankle	O
joint	O
.	O

(	B-CHED
RS	I-CHED
)	I-CHED
-	I-CHED
1	I-CHED
-	I-CHED
aminoindan	I-CHED
-	I-CHED
1	I-CHED
,	I-CHED
5	I-CHED
-	I-CHED
dicarboxylic	I-CHED
acid	I-CHED
(	O
AIDA	B-CHED
;	O
0	O
.	O
5	O
-	O
15	O
microg	O
/	O
0	O
.	O
5	O
microl	O
)	O
,	O
a	O
potent	O
and	O
selective	O
mGluR1	O
antagonist	O
,	O
or	O
(	B-CHED
2R	I-CHED
,	I-CHED
4R	I-CHED
)	I-CHED
-	I-CHED
4	I-CHED
-	I-CHED
aminopyrrolidine	I-CHED
-	I-CHED
2	I-CHED
,	I-CHED
4	I-CHED
-	I-CHED
dicarboxylate	I-CHED
(	O
2R	B-CHED
,	I-CHED
4R	I-CHED
-	I-CHED
APDC	I-CHED
;	O
7	O
.	O
5	O
-	O
15	O
microg	O
/	O
0	O
.	O
5	O
microl	O
)	O
,	O
a	O
selective	O
group	O
II	O
agonist	O
,	O
was	O
injected	O
bilaterally	O
into	O
the	O
striatum	O
of	O
haloperidol	B-CHED
-	O
treated	O
animals	O
.	O

AIDA	B-CHED
in	O
doses	O
of	O
7	O
.	O
5	O
-	O
15	O
microg	O
/	O
0	O
.	O
5	O
microl	O
diminished	O
the	O
haloperidol	B-CHED
-	O
induced	O
muscle	O
rigidity	O
.	O

In	O
contrast	O
,	O
2R	B-CHED
,	I-CHED
4R	I-CHED
-	I-CHED
APDC	I-CHED
injections	O
were	O
ineffective	O
.	O

The	O
present	O
results	O
may	O
suggest	O
that	O
the	O
blockade	O
of	O
striatal	O
mGluR1	O
,	O
but	O
not	O
the	O
stimulation	O
of	O
group	O
II	O
mGluRs	O
,	O
may	O
ameliorate	O
parkinsonian	O
muscle	O
rigidity	O
.	O

A	O
phase	O
II	O
study	O
of	O
thalidomide	B-CHED
in	O
advanced	O
metastatic	O
renal	O
cell	O
carcinoma	O
.	O

OBJECTIVES	O
:	O
To	O
evaluate	O
the	O
toxicity	O
and	O
activity	O
of	O
thalidomide	B-CHED
in	O
patients	O
with	O
advanced	O
metastatic	O
renal	O
cell	O
cancer	O
and	O
to	O
measure	O
changes	O
of	O
one	O
angiogenic	O
factor	O
,	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
165	O
,	O
with	O
therapy	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
29	O
patients	O
were	O
enrolled	O
on	O
a	O
study	O
of	O
thalidomide	B-CHED
using	O
an	O
intra	O
-	O
patient	O
dose	O
escalation	O
schedule	O
.	O

Patients	O
began	O
thalidomide	B-CHED
at	O
400	O
mg	O
/	O
d	O
and	O
escalated	O
as	O
tolerated	O
to	O
1200	O
mg	O
/	O
d	O
by	O
day	O
54	O
.	O

Fifty	O
-	O
nine	O
per	O
cent	O
of	O
patients	O
had	O
had	O
previous	O
therapy	O
with	O
IL	O
-	O
2	O
and	O
52	O
%	O
were	O
performance	O
status	O
2	O
or	O
3	O
.	O

Systemic	O
plasma	O
VEGF165	O
levels	O
were	O
measured	O
by	O
dual	O
monoclonal	O
ELISA	O
in	O
8	O
patients	O
.	O

RESULTS	O
:	O
24	O
patients	O
were	O
evaluable	O
for	O
response	O
with	O
one	O
partial	O
response	O
of	O
11	O
months	O
duration	O
of	O
a	O
patient	O
with	O
hepatic	O
and	O
pulmonary	O
metastases	O
(	O
4	O
%	O
)	O
,	O
one	O
minor	O
response	O
,	O
and	O
2	O
patients	O
stable	O
for	O
over	O
6	O
months	O
.	O

Somnolence	O
and	O
constipation	O
were	O
prominent	O
toxicities	O
and	O
most	O
patients	O
could	O
not	O
tolerate	O
the	O
1200	O
mg	O
/	O
day	O
dose	O
level	O
.	O

Systemic	O
plasma	O
VEGF165	O
levels	O
did	O
not	O
change	O
with	O
therapy	O
.	O

CONCLUSION	O
:	O
These	O
results	O
are	O
consistent	O
with	O
a	O
low	O
level	O
of	O
activity	O
of	O
thalidomide	B-CHED
in	O
renal	O
cell	O
carcinoma	O
.	O

Administration	O
of	O
doses	O
over	O
800	O
mg	O
/	O
day	O
was	O
difficult	O
to	O
achieve	O
in	O
this	O
patient	O
population	O
,	O
however	O
lower	O
doses	O
were	O
practical	O
.	O

The	O
dose	O
-	O
response	O
relationship	O
,	O
if	O
any	O
,	O
of	O
thalidomide	B-CHED
for	O
renal	O
cell	O
carcinoma	O
is	O
unclear	O
.	O

Can	O
lidocaine	B-CHED
reduce	O
succinylcholine	B-CHED
induced	O
postoperative	O
myalgia	O
?	O

This	O
study	O
was	O
undertaken	O
to	O
determine	O
the	O
effect	O
of	O
lidocaine	B-CHED
pretreatment	O
on	O
reduction	O
of	O
succinylcholine	B-CHED
-	O
induced	O
myalgia	O
in	O
patients	O
undergoing	O
general	O
anesthesia	O
for	O
gynecological	O
surgery	O
.	O

One	O
hundred	O
and	O
thirty	O
-	O
five	O
patients	O
were	O
assigned	O
to	O
one	O
of	O
three	O
groups	O
in	O
a	O
prospective	O
,	O
double	O
blind	O
,	O
randomized	O
manner	O
.	O

Group	O
PS	O
,	O
the	O
control	O
group	O
,	O
received	O
normal	O
saline	O
and	O
succinylcholine	B-CHED
1	O
.	O
5	O
mg	O
x	O
kg	O
(	O
-	O
1	O
)	O
;	O
Group	O
LS	O
,	O
lidocaine	B-CHED
1	O
.	O
5	O
mg	O
x	O
kg	O
(	O
-	O
1	O
)	O
and	O
succinylcholine	B-CHED
1	O
.	O
5	O
mg	O
x	O
kg	O
(	O
-	O
1	O
)	O
;	O
Group	O
PR	O
,	O
normal	O
saline	O
and	O
rocuronium	B-CHED
0	O
.	O
6	O
mg	O
x	O
kg	O
(	O
-	O
1	O
)	O
.	O

Morphine	B-CHED
0	O
.	O
1	O
mg	O
x	O
kg	O
(	O
-	O
1	O
)	O
iv	O
was	O
given	O
for	O
premedication	O
and	O
all	O
patients	O
were	O
monitored	O
with	O
a	O
noninvasive	O
blood	O
pressure	O
monitor	O
,	O
ECG	O
and	O
pulse	O
oximetry	O
.	O

Anesthesia	O
was	O
induced	O
with	O
5	O
mg	O
.	O
kg	O
(	O
-	O
1	O
)	O
thiopental	B-CHED
iv	O
.	O
followed	O
by	O
succinylcholine	B-CHED
(	O
Group	O
PS	O
,	O
LS	O
)	O
or	O
rocuronium	B-CHED
(	O
Group	O
PR	O
)	O
for	O
tracheal	O
intubation	O
.	O

Following	O
administration	O
of	O
these	O
agents	O
,	O
the	O
presence	O
,	O
and	O
degree	O
of	O
fasciculation	O
were	O
assessed	O
visually	O
on	O
a	O
four	O
point	O
scale	O
by	O
one	O
investigator	O
who	O
was	O
blinded	O
to	O
the	O
drug	O
administered	O
.	O

The	O
blood	O
pressure	O
and	O
heart	O
rate	O
of	O
each	O
patient	O
were	O
monitored	O
on	O
nine	O
occasions	O
.	O

Twenty	O
-	O
four	O
hours	O
later	O
,	O
any	O
myalgia	O
experienced	O
was	O
assessed	O
according	O
to	O
a	O
structured	O
questionaire	O
and	O
graded	O
by	O
a	O
four	O
point	O
scale	O
by	O
one	O
investigator	O
blinded	O
to	O
the	O
intraoperative	O
management	O
.	O

The	O
results	O
indicate	O
that	O
muscle	O
fasciculation	O
was	O
not	O
found	O
in	O
Group	O
PR	O
while	O
the	O
patients	O
in	O
Group	O
LS	O
had	O
a	O
lower	O
incidence	O
of	O
muscle	O
fasciculation	O
than	O
those	O
in	O
Group	O
PS	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

At	O
24	O
h	O
,	O
the	O
incidence	O
of	O
myalgia	O
was	O
higher	O
in	O
Group	O
PS	O
than	O
in	O
Group	O
LS	O
and	O
PR	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

A	O
correlation	O
was	O
not	O
found	O
between	O
the	O
incidence	O
of	O
myalgia	O
and	O
the	O
occurrence	O
of	O
muscle	O
fasciculation	O
.	O

The	O
changes	O
in	O
systolic	O
and	O
diastolic	O
blood	O
pressure	O
and	O
heart	O
rate	O
were	O
not	O
significant	O
among	O
the	O
three	O
groups	O
.	O

In	O
conclusion	O
,	O
where	O
succinylcholine	B-CHED
is	O
used	O
,	O
lidocaine	B-CHED
is	O
proven	O
to	O
be	O
the	O
useful	O
pretreatment	O
agent	O
for	O
the	O
reduction	O
of	O
postoperative	O
myalgia	O
.	O

Reduced	O
sodium	B-CHED
channel	O
density	O
,	O
altered	O
voltage	O
dependence	O
of	O
inactivation	O
,	O
and	O
increased	O
susceptibility	O
to	O
seizures	O
in	O
mice	O
lacking	O
sodium	B-CHED
channel	O
beta	O
2	O
-	O
subunits	O
.	O

Sodium	B-CHED
channel	O
beta	O
-	O
subunits	O
modulate	O
channel	O
gating	O
,	O
assembly	O
,	O
and	O
cell	O
surface	O
expression	O
in	O
heterologous	O
cell	O
systems	O
.	O

We	O
generated	O
beta2	O
(	O
-	O
/	O
-	O
)	O
mice	O
to	O
investigate	O
the	O
role	O
of	O
beta2	O
in	O
control	O
of	O
sodium	B-CHED
channel	O
density	O
,	O
localization	O
,	O
and	O
function	O
in	O
neurons	O
in	O
vivo	O
.	O

Measurements	O
of	O
[	O
(	O
3	O
)	O
H	O
]	O
saxitoxin	B-CHED
(	O
STX	B-CHED
)	O
binding	O
showed	O
a	O
significant	O
reduction	O
in	O
the	O
level	O
of	O
plasma	O
membrane	O
sodium	B-CHED
channels	O
in	O
beta2	O
(	O
-	O
/	O
-	O
)	O
neurons	O
.	O

The	O
loss	O
of	O
beta2	O
resulted	O
in	O
negative	O
shifts	O
in	O
the	O
voltage	O
dependence	O
of	O
inactivation	O
as	O
well	O
as	O
significant	O
decreases	O
in	O
sodium	B-CHED
current	O
density	O
in	O
acutely	O
dissociated	O
hippocampal	O
neurons	O
.	O

The	O
integral	O
of	O
the	O
compound	O
action	O
potential	O
in	O
optic	O
nerve	O
was	O
significantly	O
reduced	O
,	O
and	O
the	O
threshold	O
for	O
action	O
potential	O
generation	O
was	O
increased	O
,	O
indicating	O
a	O
reduction	O
in	O
the	O
level	O
of	O
functional	O
plasma	O
membrane	O
sodium	B-CHED
channels	O
.	O

In	O
contrast	O
,	O
the	O
conduction	O
velocity	O
,	O
the	O
number	O
and	O
size	O
of	O
axons	O
in	O
the	O
optic	O
nerve	O
,	O
and	O
the	O
specific	O
localization	O
of	O
Na	B-CHED
(	O
v	O
)	O
1	O
.	O
6	O
channels	O
in	O
the	O
nodes	O
of	O
Ranvier	O
were	O
unchanged	O
.	O

beta2	O
(	O
-	O
/	O
-	O
)	O
mice	O
displayed	O
increased	O
susceptibility	O
to	O
seizures	O
,	O
as	O
indicated	O
by	O
reduced	O
latency	O
and	O
threshold	O
for	O
pilocarpine	B-CHED
-	O
induced	O
seizures	O
,	O
but	O
seemed	O
normal	O
in	O
other	O
neurological	O
tests	O
.	O

Our	O
observations	O
show	O
that	O
beta2	O
-	O
subunits	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
sodium	B-CHED
channel	O
density	O
and	O
function	O
in	O
neurons	O
in	O
vivo	O
and	O
are	O
required	O
for	O
normal	O
action	O
potential	O
generation	O
and	O
control	O
of	O
excitability	O
.	O

Acute	O
liver	O
failure	O
with	O
concurrent	O
bupropion	B-CHED
and	O
carbimazole	B-CHED
therapy	O
.	O

OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
fatal	O
liver	O
failure	O
possibly	O
associated	O
with	O
concurrent	O
use	O
of	O
bupropion	B-CHED
and	O
carbimazole	B-CHED
.	O

CASE	O
SUMMARY	O
:	O
A	O
41	O
-	O
year	O
-	O
old	O
Chinese	O
man	O
with	O
a	O
history	O
of	O
hyperthyroidism	O
had	O
been	O
treated	O
with	O
carbimazole	B-CHED
and	O
propranolol	B-CHED
for	O
the	O
past	O
5	O
years	O
.	O

He	O
received	O
a	O
10	O
-	O
day	O
course	O
of	O
bupropion	B-CHED
as	O
an	O
aid	O
for	O
smoking	O
cessation	O
10	O
weeks	O
prior	O
to	O
presentation	O
.	O

He	O
developed	O
acute	O
liver	O
failure	O
with	O
rapid	O
deterioration	O
of	O
renal	O
function	O
.	O

Liver	O
biopsy	O
showed	O
evidence	O
of	O
nonspecific	O
drug	O
-	O
induced	O
acute	O
liver	O
injury	O
.	O

His	O
condition	O
was	O
further	O
complicated	O
by	O
sepsis	O
and	O
coagulopathy	O
.	O

Death	O
resulted	O
19	O
days	O
after	O
the	O
onset	O
of	O
symptoms	O
.	O

The	O
likelihood	O
that	O
bupropion	B-CHED
induced	O
hepatotoxicity	O
in	O
our	O
patient	O
was	O
possible	O
,	O
based	O
on	O
the	O
Naranjo	O
probability	O
scale	O
.	O

DISCUSSION	O
:	O
Although	O
there	O
is	O
increasing	O
evidence	O
of	O
hepatotoxicity	O
induced	O
by	O
bupropion	B-CHED
,	O
this	O
is	O
the	O
first	O
case	O
of	O
fatality	O
that	O
could	O
have	O
resulted	O
from	O
acute	O
liver	O
failure	O
in	O
a	O
patient	O
receiving	O
bupropion	B-CHED
while	O
on	O
concomitant	O
treatment	O
with	O
carbimazole	B-CHED
.	O

CONCLUSIONS	O
:	O
Clinicians	O
should	O
be	O
aware	O
of	O
the	O
possibility	O
of	O
acute	O
liver	O
insult	O
induced	O
by	O
bupropion	B-CHED
given	O
concurrently	O
with	O
other	O
hepatotoxic	O
drugs	O
.	O

Pyeloureteral	O
filling	O
defects	O
associated	O
with	O
systemic	O
anticoagulation	O
:	O
a	O
case	O
report	O
.	O

The	O
etiology	O
of	O
pyeloureteritis	O
cystica	O
has	O
long	O
been	O
attributed	O
to	O
chronic	O
infection	O
and	O
inflammation	O
.	O

A	O
case	O
is	O
presented	O
that	O
is	O
unique	O
in	O
that	O
the	O
acute	O
onset	O
and	O
the	O
rapid	O
resolution	O
of	O
pyeloureteral	O
filling	O
defects	O
in	O
this	O
patient	O
were	O
documented	O
by	O
radiography	O
.	O

There	O
is	O
no	O
evidence	O
of	O
antecedent	O
or	O
concurrent	O
infection	O
in	O
this	O
patient	O
.	O

The	O
disease	O
occurred	O
subsequent	O
to	O
the	O
initiation	O
of	O
heparin	B-CHED
therapy	O
for	O
suspected	O
pelvic	O
thrombophlebitis	O
and	O
cleared	O
rapidly	O
subsequent	O
to	O
its	O
discontinuation	O
.	O

The	O
rate	O
of	O
resolution	O
of	O
the	O
radiographic	O
findings	O
may	O
be	O
helpful	O
in	O
distinguishing	O
between	O
true	O
pyeloureteritis	O
cystica	O
and	O
submucosal	O
hemorrhage	O
.	O

Nephrotoxic	O
effects	O
in	O
high	O
-	O
risk	O
patients	O
undergoing	O
angiography	O
.	O

BACKGROUND	O
:	O
The	O
use	O
of	O
iodinated	O
contrast	O
medium	O
can	O
result	O
in	O
nephropathy	O
.	O

Whether	O
iso	O
-	O
osmolar	O
contrast	O
medium	O
is	O
less	O
nephrotoxic	O
than	O
low	O
-	O
osmolar	O
contrast	O
medium	O
in	O
high	O
-	O
risk	O
patients	O
is	O
uncertain	O
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
prospective	O
,	O
multicenter	O
study	O
comparing	O
the	O
nephrotoxic	O
effects	O
of	O
an	O
iso	O
-	O
osmolar	O
,	O
dimeric	O
,	O
nonionic	O
contrast	O
medium	O
,	O
iodixanol	B-CHED
,	O
with	O
those	O
of	O
a	O
low	O
-	O
osmolar	O
,	O
nonionic	O
,	O
monomeric	O
contrast	O
medium	O
,	O
iohexol	B-CHED
.	O

The	O
study	O
involved	O
129	O
patients	O
with	O
diabetes	O
with	O
serum	O
creatinine	B-CHED
concentrations	O
of	O
1	O
.	O
5	O
to	O
3	O
.	O
5	O
mg	O
per	O
deciliter	O
who	O
underwent	O
coronary	O
or	O
aortofemoral	O
angiography	O
.	O

The	O
primary	O
end	O
point	O
was	O
the	O
peak	O
increase	O
from	O
base	O
line	O
in	O
the	O
creatinine	B-CHED
concentration	O
during	O
the	O
three	O
days	O
after	O
angiography	O
.	O

Other	O
end	O
points	O
were	O
an	O
increase	O
in	O
the	O
creatinine	B-CHED
concentration	O
of	O
0	O
.	O
5	O
mg	O
per	O
deciliter	O
or	O
more	O
,	O
an	O
increase	O
of	O
1	O
.	O
0	O
mg	O
per	O
deciliter	O
or	O
more	O
,	O
and	O
a	O
change	O
in	O
the	O
creatinine	B-CHED
concentration	O
from	O
day	O
0	O
to	O
day	O
7	O
.	O

RESULTS	O
:	O
The	O
creatinine	B-CHED
concentration	O
increased	O
significantly	O
less	O
in	O
patients	O
who	O
received	O
iodixanol	B-CHED
.	O

From	O
day	O
0	O
to	O
day	O
3	O
,	O
the	O
mean	O
peak	O
increase	O
in	O
creatinine	B-CHED
was	O
0	O
.	O
13	O
mg	O
per	O
deciliter	O
in	O
the	O
iodixanol	B-CHED
group	O
and	O
0	O
.	O
55	O
mg	O
per	O
deciliter	O
in	O
the	O
iohexol	B-CHED
group	O
(	O
P	O
=	O
0	O
.	O
001	O
;	O
the	O
increase	O
with	O
iodixanol	B-CHED
minus	O
the	O
increase	O
with	O
iohexol	B-CHED
,	O
-	O
0	O
.	O
42	O
mg	O
per	O
deciliter	O
[	O
95	O
percent	O
confidence	O
interval	O
,	O
-	O
0	O
.	O
73	O
to	O
-	O
0	O
.	O
22	O
]	O
)	O
.	O

Two	O
of	O
the	O
64	O
patients	O
in	O
the	O
iodixanol	B-CHED
group	O
(	O
3	O
percent	O
)	O
had	O
an	O
increase	O
in	O
the	O
creatinine	B-CHED
concentration	O
of	O
0	O
.	O
5	O
mg	O
per	O
deciliter	O
or	O
more	O
,	O
as	O
compared	O
with	O
17	O
of	O
the	O
65	O
patients	O
in	O
the	O
iohexol	B-CHED
group	O
(	O
26	O
percent	O
)	O
(	O
P	O
=	O
0	O
.	O
002	O
;	O
odds	O
ratio	O
for	O
such	O
an	O
increase	O
in	O
the	O
iodixanol	B-CHED
group	O
,	O
0	O
.	O
09	O
[	O
95	O
percent	O
confidence	O
interval	O
,	O
0	O
.	O
02	O
to	O
0	O
.	O
41	O
]	O
)	O
.	O

No	O
patient	O
receiving	O
iodixanol	B-CHED
had	O
an	O
increase	O
of	O
1	O
.	O
0	O
mg	O
per	O
deciliter	O
or	O
more	O
,	O
but	O
10	O
patients	O
in	O
the	O
iohexol	B-CHED
group	O
(	O
15	O
percent	O
)	O
did	O
.	O

The	O
mean	O
change	O
in	O
the	O
creatinine	B-CHED
concentration	O
from	O
day	O
0	O
to	O
day	O
7	O
was	O
0	O
.	O
07	O
mg	O
per	O
deciliter	O
in	O
the	O
iodixanol	B-CHED
group	O
and	O
0	O
.	O
24	O
mg	O
per	O
deciliter	O
in	O
the	O
iohexol	B-CHED
group	O
(	O
P	O
=	O
0	O
.	O
003	O
;	O
value	O
in	O
the	O
iodixanol	B-CHED
group	O
minus	O
the	O
value	O
in	O
the	O
iohexol	B-CHED
group	O
,	O
-	O
0	O
.	O
17	O
mg	O
per	O
deciliter	O
[	O
95	O
percent	O
confidence	O
interval	O
,	O
-	O
0	O
.	O
34	O
to	O
-	O
0	O
.	O
07	O
]	O
)	O
.	O

CONCLUSIONS	O
:	O
Nephropathy	O
induced	O
by	O
contrast	O
medium	O
may	O
be	O
less	O
likely	O
to	O
develop	O
in	O
high	O
-	O
risk	O
patients	O
when	O
iodixanol	B-CHED
is	O
used	O
rather	O
than	O
a	O
low	O
-	O
osmolar	O
,	O
nonionic	O
contrast	O
medium	O
.	O

Protective	O
effect	O
of	O
edaravone	B-CHED
against	O
streptomycin	B-CHED
-	O
induced	O
vestibulotoxicity	O
in	O
the	O
guinea	O
pig	O
.	O

This	O
study	O
investigated	O
alleviation	O
of	O
streptomycin	B-CHED
-	O
induced	O
vestibulotoxicity	O
by	O
edaravone	B-CHED
in	O
guinea	O
pigs	O
.	O

Edaravone	B-CHED
,	O
a	O
free	O
radical	O
scavenger	O
,	O
has	O
potent	O
free	O
radical	O
quenching	O
action	O
and	O
is	O
used	O
in	O
clinical	O
practice	O
to	O
treat	O
cerebral	O
infarction	O
.	O

Streptomycin	B-CHED
was	O
administered	O
to	O
the	O
inner	O
ear	O
by	O
osmotic	O
pump	O
for	O
24	O
h	O
,	O
and	O
edaravone	B-CHED
(	O
n	O
=	O
8	O
)	O
or	O
saline	O
(	O
n	O
=	O
6	O
)	O
was	O
intraperitoneally	O
injected	O
once	O
a	O
day	O
for	O
7	O
days	O
.	O

We	O
observed	O
horizontal	O
vestibulo	O
-	O
ocular	O
reflex	O
as	O
a	O
marker	O
of	O
postoperative	O
vestibular	O
function	O
.	O

Animals	O
injected	O
with	O
saline	O
showed	O
statistically	O
smaller	O
gains	O
than	O
those	O
injected	O
with	O
edaravone	B-CHED
.	O

These	O
results	O
suggest	O
that	O
edaravone	B-CHED
suppresses	O
streptomycin	B-CHED
-	O
induced	O
vestibulotoxicity	O
.	O

Levodopa	B-CHED
-	O
induced	O
oromandibular	O
dystonia	O
in	O
progressive	O
supranuclear	O
palsy	O
.	O

Levodopa	B-CHED
-	O
induced	O
dyskinesias	O
have	O
been	O
reported	O
in	O
Parkinson	O
'	O
s	O
disease	O
and	O
multiple	O
system	O
atrophy	O
.	O

Cranial	O
dystonias	O
are	O
rare	O
in	O
patients	O
with	O
progressive	O
supranuclear	O
palsy	O
(	O
PSP	O
)	O
.	O

In	O
this	O
report	O
we	O
describe	O
an	O
unusual	O
case	O
of	O
reversible	O
levodopa	B-CHED
-	O
induced	O
Oromandibular	O
dystonia	O
(	O
OMD	O
)	O
in	O
a	O
PSP	O
patient	O
to	O
highlight	O
the	O
importance	O
of	O
recognizing	O
this	O
drug	O
related	O
complication	O
in	O
the	O
management	O
of	O
PSP	O
,	O
and	O
discuss	O
the	O
possible	O
underlying	O
pathophysiology	O
.	O

Case	O
report	O
:	O
Dexatrim	B-CHED
(	O
Phenylpropanolamine	B-CHED
)	O
as	O
a	O
cause	O
of	O
myocardial	O
infarction	O
.	O

Phenylpropanolamine	B-CHED
(	O
PPA	B-CHED
)	O
is	O
a	O
sympathetic	O
amine	B-CHED
used	O
in	O
over	O
-	O
the	O
-	O
counter	O
cold	O
remedies	O
and	O
weight	O
-	O
control	O
preparations	O
worldwide	O
.	O

Its	O
use	O
has	O
been	O
associated	O
with	O
hypertensive	O
episodes	O
and	O
hemorrhagic	O
strokes	O
in	O
younger	O
women	O
.	O

Several	O
reports	O
have	O
linked	O
the	O
abuse	O
of	O
PPA	B-CHED
with	O
myocardial	O
injury	O
,	O
especially	O
when	O
overdose	O
is	O
involved	O
.	O

We	O
report	O
here	O
the	O
first	O
case	O
of	O
Dexatrim	B-CHED
(	O
PPA	B-CHED
)	O
-	O
induced	O
myocardial	O
injury	O
in	O
a	O
young	O
woman	O
who	O
was	O
using	O
it	O
at	O
recommended	O
doses	O
for	O
weight	O
control	O
.	O

In	O
addition	O
,	O
we	O
review	O
the	O
7	O
other	O
cases	O
of	O
PPA	B-CHED
related	O
myocardial	O
injury	O
that	O
have	O
been	O
reported	O
so	O
far	O
.	O

Physicians	O
and	O
patients	O
should	O
be	O
alert	O
to	O
the	O
potential	O
cardiac	O
risk	O
associated	O
with	O
the	O
use	O
of	O
PPA	B-CHED
,	O
even	O
at	O
doses	O
generally	O
considered	O
to	O
be	O
safe	O
.	O

Differential	O
diagnosis	O
of	O
high	O
serum	O
creatine	B-CHED
kinase	O
levels	O
in	O
systemic	O
lupus	O
erythematosus	O
.	O

We	O
report	O
the	O
clinical	O
and	O
bioptic	O
findings	O
for	O
a	O
57	O
-	O
year	O
-	O
old	O
woman	O
with	O
severe	O
chloroquine	B-CHED
-	O
induced	O
myopathy	O
.	O

Since	O
1989	O
,	O
she	O
had	O
been	O
suffering	O
from	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
with	O
renal	O
involvement	O
and	O
undergone	O
periods	O
of	O
treatment	O
with	O
azathioprine	B-CHED
and	O
cyclophosphamide	B-CHED
.	O

Additional	O
therapy	O
with	O
chloroquine	B-CHED
(	O
CQ	B-CHED
)	O
was	O
started	O
because	O
of	O
arthralgia	O
.	O

At	O
the	O
same	O
time	O
,	O
slightly	O
increased	O
creatine	B-CHED
kinase	O
(	O
CK	O
)	O
levels	O
were	O
noted	O
.	O

Myositis	O
was	O
suspected	O
,	O
and	O
the	O
patient	O
was	O
treated	O
with	O
steroids	B-CHED
.	O

The	O
CK	O
increase	O
persisted	O
,	O
however	O
,	O
and	O
she	O
developed	O
progressive	O
muscular	O
weakness	O
and	O
muscular	O
atrophy	O
.	O

Routine	O
controls	O
revealed	O
markedly	O
elevated	O
CK	O
levels	O
of	O
1	O
,	O
700	O
U	O
/	O
l	O
.	O

The	O
neurological	O
and	O
electrophysiological	O
findings	O
were	O
not	O
typical	O
of	O
myositis	O
.	O

Thus	O
,	O
muscle	O
biopsy	O
of	O
the	O
deltoid	O
muscle	O
was	O
performed	O
in	O
order	O
to	O
exclude	O
polymyositis	O
or	O
toxic	O
myopathy	O
.	O

As	O
it	O
revealed	O
chloroquine	B-CHED
-	O
induced	O
myopathy	O
,	O
medication	O
was	O
stopped	O
.	O

Discriminating	O
between	O
primary	O
SLE	O
-	O
induced	O
affection	O
of	O
the	O
musculoskeletal	O
system	O
and	O
drug	O
-	O
induced	O
side	O
effects	O
is	O
important	O
for	O
appropriate	O
treatment	O
of	O
SLE	O
patients	O
.	O

Seizure	O
associated	O
with	O
sleep	O
deprivation	O
and	O
sustained	O
-	O
release	O
bupropion	B-CHED
.	O

This	O
case	O
report	O
describes	O
a	O
generalized	O
seizure	O
associated	O
with	O
sustained	O
-	O
release	O
bupropion	B-CHED
use	O
and	O
sleep	O
deprivation	O
.	O

The	O
subject	O
,	O
a	O
31	O
-	O
year	O
-	O
old	O
female	O
smoker	O
,	O
was	O
participating	O
in	O
a	O
clinical	O
trial	O
evaluating	O
an	O
investigational	O
medication	O
for	O
smoking	O
cessation	O
that	O
used	O
sustained	O
-	O
release	O
bupropion	B-CHED
as	O
an	O
active	O
control	O
.	O

After	O
5	O
weeks	O
of	O
bupropion	B-CHED
use	O
,	O
the	O
subject	O
experienced	O
a	O
generalized	O
tonic	O
clonic	O
seizure	O
after	O
staying	O
up	O
nearly	O
all	O
night	O
packing	O
and	O
moving	O
to	O
a	O
new	O
residence	O
.	O

The	O
patient	O
had	O
no	O
other	O
risk	O
factors	O
for	O
seizures	O
.	O

We	O
suggest	O
that	O
sleep	O
deprivation	O
may	O
add	O
to	O
the	O
risk	O
of	O
bupropion	B-CHED
-	O
associated	O
seizures	O
.	O

Postoperative	O
myalgia	O
after	O
succinylcholine	B-CHED
:	O
no	O
evidence	O
for	O
an	O
inflammatory	O
origin	O
.	O

A	O
common	O
side	O
effect	O
associated	O
with	O
succinylcholine	B-CHED
is	O
postoperative	O
myalgia	O
.	O

The	O
pathogenesis	O
of	O
this	O
myalgia	O
is	O
still	O
unclear	O
;	O
inflammation	O
has	O
been	O
suggested	O
but	O
without	O
convincing	O
evidence	O
.	O

We	O
designed	O
the	O
present	O
study	O
to	O
investigate	O
whether	O
an	O
inflammatory	O
reaction	O
contributes	O
to	O
this	O
myalgia	O
.	O

The	O
incidence	O
and	O
severity	O
of	O
succinylcholine	B-CHED
-	O
associated	O
myalgia	O
was	O
determined	O
in	O
64	O
patients	O
pretreated	O
with	O
saline	O
or	O
dexamethasone	B-CHED
before	O
succinylcholine	B-CHED
(	O
n	O
=	O
32	O
for	O
each	O
)	O
.	O

Incidence	O
and	O
severity	O
of	O
myalgia	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
two	O
groups	O
:	O
15	O
patients	O
in	O
the	O
dexamethasone	B-CHED
group	O
complained	O
of	O
myalgia	O
compared	O
with	O
18	O
patients	O
in	O
the	O
saline	O
group	O
,	O
and	O
severe	O
myalgia	O
was	O
reported	O
by	O
five	O
patients	O
and	O
three	O
patients	O
,	O
respectively	O
(	O
not	O
significant	O
)	O
.	O

At	O
48	O
h	O
after	O
surgery	O
,	O
12	O
patients	O
in	O
both	O
groups	O
still	O
suffered	O
from	O
myalgia	O
(	O
not	O
significant	O
)	O
.	O

In	O
addition	O
,	O
interleukin	O
-	O
6	O
(	O
IL	O
-	O
6	O
)	O
as	O
an	O
early	O
marker	O
of	O
inflammation	O
was	O
assessed	O
in	O
a	O
subgroup	O
of	O
10	O
patients	O
pretreated	O
with	O
saline	O
.	O

We	O
found	O
an	O
increase	O
of	O
IL	O
-	O
6	O
for	O
only	O
three	O
patients	O
,	O
but	O
only	O
one	O
patient	O
reported	O
myalgia	O
;	O
no	O
relationship	O
between	O
myalgia	O
and	O
the	O
increase	O
of	O
IL	O
-	O
6	O
was	O
found	O
.	O

In	O
conclusion	O
,	O
there	O
is	O
no	O
evidence	O
for	O
an	O
inflammatory	O
origin	O
of	O
succinylcholine	B-CHED
-	O
associated	O
myalgia	O
.	O

IMPLICATIONS	O
:	O
Administration	O
of	O
dexamethasone	B-CHED
before	O
succinylcholine	B-CHED
was	O
not	O
effective	O
in	O
decreasing	O
the	O
incidence	O
or	O
the	O
severity	O
of	O
succinylcholine	B-CHED
-	O
induced	O
postoperative	O
myalgia	O
.	O

Furthermore	O
,	O
there	O
was	O
no	O
significant	O
relationship	O
between	O
postoperative	O
myalgia	O
and	O
time	O
course	O
of	O
interleukin	O
-	O
6	O
concentrations	O
,	O
a	O
marker	O
of	O
inflammation	O
.	O

Pretreatment	O
with	O
dexamethasone	B-CHED
is	O
not	O
justified	O
to	O
prevent	O
postoperative	O
myalgia	O
after	O
succinylcholine	B-CHED
.	O

Effect	O
of	O
lindane	B-CHED
on	O
hepatic	O
and	O
brain	O
cytochrome	O
P450s	O
and	O
influence	O
of	O
P450	O
modulation	O
in	O
lindane	B-CHED
induced	O
neurotoxicity	O
.	O

Oral	O
administration	O
of	O
lindane	B-CHED
(	O
2	O
.	O
5	O
,	O
5	O
,	O
10	O
and	O
15	O
mg	O
/	O
kg	O
,	O
body	O
weight	O
)	O
for	O
5	O
days	O
was	O
found	O
to	O
produce	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
the	O
activity	O
of	O
P450	O
dependent	O
7	O
-	O
ethoxyresorufin	O
-	O
O	O
-	O
deethylase	O
(	O
EROD	O
)	O
,	O
7	O
-	O
pentoxyresorufin	O
-	O
O	O
-	O
dealkylase	O
(	O
PROD	O
)	O
and	O
N	B-CHED
-	I-CHED
nitrosodimethylamine	I-CHED
demethylase	O
(	O
NDMA	B-CHED
-	O
d	O
)	O
in	O
rat	O
brain	O
and	O
liver	O
.	O

A	O
significant	O
increase	O
in	O
the	O
hepatic	O
and	O
brain	O
P450	O
monooxygenases	O
was	O
also	O
observed	O
when	O
the	O
duration	O
of	O
exposure	O
of	O
low	O
dose	O
(	O
2	O
.	O
5	O
mg	O
/	O
kg	O
)	O
of	O
lindane	B-CHED
was	O
increased	O
from	O
5	O
days	O
to	O
15	O
or	O
21	O
days	O
.	O

As	O
observed	O
with	O
different	O
doses	O
,	O
the	O
magnitude	O
of	O
induction	O
in	O
the	O
activity	O
of	O
P450	O
monooxygenases	O
was	O
several	O
fold	O
higher	O
in	O
liver	O
microsomes	O
when	O
compared	O
with	O
the	O
brain	O
.	O

Western	O
blotting	O
studies	O
have	O
indicated	O
that	O
the	O
increase	O
in	O
the	O
P450	O
enzymes	O
could	O
be	O
due	O
to	O
the	O
increase	O
in	O
the	O
expression	O
of	O
P450	O
1A1	O
/	O
1A2	O
,	O
2B1	O
/	O
2B2	O
and	O
2E1	O
isoenzymes	O
.	O

In	O
vitro	O
studies	O
using	O
organic	O
inhibitors	O
specific	O
for	O
individual	O
P450	O
isoenzymes	O
and	O
antibody	O
inhibition	O
experiments	O
have	O
further	O
demonstrated	O
that	O
the	O
increase	O
in	O
the	O
activity	O
of	O
PROD	O
,	O
EROD	O
and	O
NDMA	B-CHED
-	O
d	O
are	O
due	O
to	O
the	O
increase	O
in	O
the	O
levels	O
of	O
P450	O
2B1	O
/	O
2B2	O
,	O
1A1	O
/	O
1A2	O
and	O
2E1	O
isoenzymes	O
,	O
respectively	O
.	O

Induction	O
studies	O
have	O
further	O
shown	O
that	O
while	O
pretreatment	O
of	O
3	B-CHED
-	I-CHED
methylcholanthrene	I-CHED
(	O
MC	B-CHED
)	O
,	O
an	O
inducer	O
of	O
P4501A1	O
/	O
1A2	O
,	O
did	O
not	O
produce	O
any	O
significant	O
effect	O
in	O
the	O
incidence	O
of	O
lindane	B-CHED
induced	O
convulsions	O
,	O
pretreatment	O
with	O
phenobarbital	B-CHED
(	O
PB	O
)	O
,	O
an	O
inducer	O
of	O
P450	O
2B1	O
/	O
2B2	O
or	O
ethanol	B-CHED
,	O
an	O
inducer	O
of	O
P450	O
2E1	O
catalysed	O
reactions	O
,	O
significantly	O
increased	O
the	O
incidence	O
of	O
lindane	B-CHED
induced	O
convulsions	O
.	O

Similarly	O
,	O
when	O
the	O
P450	O
-	O
mediated	O
metabolism	O
of	O
lindane	B-CHED
was	O
blocked	O
by	O
cobalt	B-CHED
chloride	I-CHED
incidence	O
of	O
convulsions	O
was	O
increased	O
in	O
animals	O
treated	O
with	O
lindane	B-CHED
indicating	O
that	O
lindane	B-CHED
per	O
se	O
or	O
its	O
metabolites	O
formed	O
by	O
PB	O
or	O
ethanol	B-CHED
inducible	O
P450	O
isoenzymes	O
are	O
involved	O
in	O
its	O
neurobehavioral	O
toxicity	O
.	O

Absolute	O
and	O
attributable	O
risk	O
of	O
venous	O
thromboembolism	O
in	O
women	O
on	O
combined	O
cyproterone	B-CHED
acetate	I-CHED
and	O
ethinylestradiol	B-CHED
.	O

OBJECTIVE	O
:	O
To	O
achieve	O
absolute	O
risk	O
estimates	O
of	O
venous	O
thromboembolism	O
(	O
VTE	O
)	O
among	O
women	O
on	O
cyproterone	B-CHED
acetate	I-CHED
plus	O
ethinylestradiol	B-CHED
(	O
CPA	B-CHED
/	O
EE	B-CHED
)	O
,	O
and	O
among	O
women	O
on	O
combined	B-CHED
oral	I-CHED
contraceptives	I-CHED
(	O
COCs	B-CHED
)	O
.	O

METHODS	O
:	O
From	O
the	O
Danish	O
National	O
Register	O
of	O
Patients	O
(	O
NRP	O
)	O
,	O
1996	O
to	O
1998	O
,	O
the	O
records	O
of	O
1	O
.	O
1	O
million	O
Danish	O
women	O
,	O
ages	O
15	O
to	O
44	O
years	O
,	O
were	O
searched	O
for	O
evidence	O
of	O
VTE	O
.	O

COC	B-CHED
use	O
was	O
ascertained	O
through	O
mailed	O
questionnaires	O
.	O

Sales	O
statistics	O
of	O
COCs	B-CHED
and	O
CPA	B-CHED
/	O
EE	B-CHED
were	O
provided	O
through	O
Danish	O
Drug	O
Statistics	O
.	O

RESULTS	O
:	O
During	O
the	O
time	O
frame	O
of	O
the	O
study	O
,	O
330	O
women	O
were	O
found	O
to	O
have	O
had	O
VTE	O
while	O
on	O
COCs	B-CHED
.	O

Of	O
these	O
women	O
,	O
67	O
were	O
on	O
levonorgestrel	B-CHED
-	O
containing	O
COCs	B-CHED
.	O

Eleven	O
were	O
on	O
CPA	B-CHED
/	O
EE	B-CHED
.	O

The	O
corresponding	O
absolute	O
risk	O
of	O
VTE	O
was	O
3	O
.	O
4	O
(	O
range	O
,	O
3	O
.	O
1	O
-	O
3	O
.	O
8	O
)	O
per	O
10	O
000	O
women	O
years	O
among	O
the	O
women	O
on	O
COCs	B-CHED
,	O
4	O
.	O
2	O
(	O
range	O
,	O
3	O
.	O
2	O
-	O
5	O
.	O
2	O
)	O
per	O
10	O
000	O
women	O
years	O
among	O
women	O
on	O
levonorgestrel	B-CHED
-	O
containing	O
COCs	B-CHED
,	O
and	O
3	O
.	O
1	O
(	O
range	O
,	O
1	O
.	O
3	O
-	O
4	O
.	O
9	O
)	O
per	O
10	O
000	O
women	O
years	O
among	O
the	O
women	O
on	O
CPA	B-CHED
/	O
EE	B-CHED
.	O

CONCLUSION	O
:	O
Our	O
results	O
suggest	O
the	O
absolute	O
risk	O
of	O
VTE	O
among	O
Danish	O
women	O
on	O
COCs	B-CHED
is	O
similar	O
to	O
that	O
among	O
women	O
taking	O
CPA	B-CHED
/	O
EE	B-CHED
.	O

Comparison	O
of	O
developmental	O
toxicology	O
of	O
aspirin	B-CHED
(	O
acetylsalicylic	B-CHED
acid	I-CHED
)	O
in	O
rats	O
using	O
selected	O
dosing	O
paradigms	O
.	O

BACKGROUND	O
:	O
Analysis	O
of	O
the	O
literature	O
for	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
suggests	O
that	O
a	O
low	O
incidence	O
of	O
developmental	O
anomalies	O
occurs	O
in	O
rats	O
given	O
NSAIDs	O
on	O
specific	O
days	O
during	O
organogenesis	O
.	O

Aspirin	B-CHED
(	O
acetylsalicylic	B-CHED
acid	I-CHED
[	O
ASA	B-CHED
]	O
)	O
,	O
an	O
irreversible	O
cyclooxygenase	O
1	O
and	O
2	O
inhibitor	O
,	O
induces	O
developmental	O
anomalies	O
when	O
administered	O
to	O
Wistar	O
rats	O
on	O
gestational	O
day	O
(	O
GD	O
)	O
9	O
,	O
10	O
,	O
or	O
11	O
(	O
Kimmel	O
CA	O
,	O
Wilson	O
JG	O
,	O
Schumacher	O
HJ	O
.	O
Teratology	O
4	O
:	O
15	O
-	O
24	O
,	O
1971	O
)	O
.	O

There	O
are	O
no	O
published	O
ASA	B-CHED
studies	O
using	O
the	O
multiple	O
dosing	O
paradigm	O
of	O
GDs	O
6	O
to	O
17	O
.	O

Objectives	O
of	O
the	O
current	O
study	O
were	O
to	O
compare	O
results	O
between	O
Sprague	O
-	O
Dawley	O
(	O
SD	O
)	O
and	O
Wistar	O
strains	O
when	O
ASA	B-CHED
is	O
administered	O
on	O
GD	O
9	O
,	O
10	O
,	O
or	O
11	O
;	O
to	O
compare	O
the	O
malformation	O
patterns	O
following	O
single	O
and	O
multiple	O
dosings	O
during	O
organogenesis	O
in	O
SD	O
rats	O
;	O
and	O
to	O
test	O
the	O
hypothesis	O
that	O
maternal	O
gastrointestinal	O
toxicity	O
confounds	O
the	O
detection	O
of	O
low	O
incidence	O
malformations	O
with	O
ASA	B-CHED
when	O
a	O
multiple	O
dosing	O
paradigm	O
is	O
used	O
.	O

METHODS	O
:	O
ASA	B-CHED
was	O
administered	O
as	O
a	O
single	O
dose	O
on	O
GD	O
9	O
(	O
0	O
,	O
250	O
,	O
500	O
,	O
or	O
625	O
mg	O
/	O
kg	O
)	O
,	O
10	O
(	O
0	O
,	O
500	O
,	O
625	O
,	O
or	O
750	O
mg	O
/	O
kg	O
)	O
,	O
or	O
11	O
(	O
0	O
,	O
500	O
,	O
750	O
,	O
or	O
1000	O
mg	O
/	O
kg	O
)	O
and	O
from	O
GD	O
6	O
to	O
GD	O
17	O
(	O
0	O
,	O
50	O
,	O
125	O
,	O
or	O
250	O
mg	O
/	O
kg	O
a	O
day	O
)	O
in	O
the	O
multiple	O
dose	O
study	O
to	O
SD	O
rats	O
.	O

Animals	O
were	O
killed	O
on	O
GD	O
21	O
,	O
and	O
fetuses	O
were	O
examined	O
viscerally	O
.	O

RESULTS	O
:	O
The	O
literature	O
evaluation	O
suggested	O
that	O
NSAIDs	O
induce	O
ventricular	O
septal	O
defects	O
(	O
VSDs	O
)	O
and	O
midline	O
defects	O
(	O
MDs	O
)	O
in	O
rats	O
and	O
diaphragmatic	O
hernia	O
(	O
DH	O
)	O
,	O
MDs	O
,	O
and	O
VSDs	O
in	O
rabbits	O
(	O
Cook	O
JC	O
et	O
al	O
.	O
,	O
2003	O
)	O
;	O
hence	O
,	O
the	O
present	O
study	O
focused	O
on	O
these	O
malformations	O
,	O
even	O
though	O
ASA	B-CHED
induces	O
several	O
other	O
low	O
-	O
incidence	O
malformations	O
.	O

In	O
single	O
dose	O
studies	O
,	O
DH	O
,	O
MD	O
,	O
and	O
VSD	O
were	O
induced	O
on	O
GDs	O
9	O
and	O
10	O
.	O

VSD	O
also	O
was	O
noted	O
following	O
treatment	O
on	O
GD	O
11	O
.	O

In	O
contrast	O
,	O
DH	O
and	O
MD	O
were	O
noted	O
in	O
the	O
multiple	O
dose	O
study	O
design	O
only	O
in	O
the	O
high	O
-	O
dose	O
group	O
,	O
and	O
VSD	O
was	O
noted	O
across	O
all	O
dose	O
groups	O
.	O

CONCLUSIONS	O
:	O
High	O
concordance	O
in	O
major	O
developmental	O
anomalies	O
between	O
Wistar	O
and	O
SD	O
rats	O
were	O
noted	O
with	O
the	O
exception	O
of	O
VSD	O
in	O
the	O
SD	O
rats	O
and	O
hydrocephalus	O
in	O
the	O
Wistar	O
rats	O
.	O

Variations	O
and	O
malformations	O
were	O
similar	O
when	O
ASA	B-CHED
was	O
administered	O
as	O
a	O
single	O
dose	O
or	O
during	O
the	O
period	O
of	O
organogenesis	O
(	O
GDs	O
6	O
to	O
17	O
)	O
.	O

It	O
was	O
also	O
evident	O
that	O
,	O
by	O
titrating	O
the	O
dose	O
to	O
achieve	O
a	O
maximum	O
tolerated	O
dose	O
,	O
malformations	O
that	O
normally	O
occur	O
at	O
low	O
incidence	O
,	O
as	O
reported	O
from	O
previous	O
single	O
dose	O
studies	O
,	O
could	O
also	O
be	O
induced	O
with	O
ASA	B-CHED
given	O
at	O
multiple	O
doses	O
.	O

Reversal	O
of	O
central	O
benzodiazepine	B-CHED
effects	O
by	O
flumazenil	B-CHED
after	O
intravenous	O
conscious	O
sedation	O
with	O
diazepam	B-CHED
and	O
opioids	O
:	O
report	O
of	O
a	O
double	O
-	O
blind	O
multicenter	O
study	O
.	O

The	O
Flumazenil	B-CHED
in	O
Intravenous	O
Conscious	O
Sedation	O
with	O
Diazepam	B-CHED
Multicenter	O
Study	O
Group	O
II	O
.	O

The	O
efficacy	O
and	O
safety	O
of	O
a	O
new	O
benzodiazepine	B-CHED
antagonist	O
,	O
flumazenil	B-CHED
,	O
were	O
assessed	O
in	O
a	O
double	O
-	O
blind	O
multicenter	O
study	O
.	O

Flumazenil	B-CHED
(	O
mean	O
dose	O
,	O
0	O
.	O
76	O
mg	O
)	O
or	O
placebo	O
(	O
mean	O
dose	O
,	O
8	O
.	O
9	O
ml	O
)	O
was	O
administered	O
intravenously	O
to	O
130	O
and	O
67	O
patients	O
,	O
respectively	O
,	O
who	O
had	O
been	O
given	O
diazepam	B-CHED
in	O
conjunction	O
with	O
an	O
opioid	O
(	O
fentanyl	B-CHED
,	O
meperidine	B-CHED
,	O
or	O
morphine	B-CHED
)	O
for	O
the	O
induction	O
and	O
maintenance	O
of	O
intravenous	O
conscious	O
sedation	O
for	O
diagnostic	O
or	O
therapeutic	O
surgical	O
procedures	O
.	O

The	O
group	O
assessable	O
for	O
efficacy	O
comprised	O
122	O
patients	O
treated	O
with	O
flumazenil	B-CHED
and	O
64	O
patients	O
given	O
placebo	O
.	O

After	O
5	O
minutes	O
,	O
80	O
/	O
115	O
(	O
70	O
%	O
)	O
flumazenil	B-CHED
-	O
treated	O
patients	O
,	O
compared	O
with	O
21	O
/	O
63	O
(	O
33	O
%	O
)	O
placebo	O
-	O
treated	O
patients	O
,	O
were	O
completely	O
awake	O
and	O
alert	O
,	O
as	O
indicated	O
by	O
a	O
score	O
of	O
5	O
on	O
the	O
Observer	O
'	O
s	O
Assessment	O
of	O
Alertness	O
/	O
Sedation	O
Scale	O
.	O

Ninety	O
-	O
five	O
percent	O
of	O
patients	O
in	O
each	O
group	O
who	O
attained	O
a	O
score	O
of	O
5	O
at	O
the	O
5	O
-	O
minute	O
assessment	O
showed	O
no	O
loss	O
of	O
alertness	O
throughout	O
the	O
180	O
-	O
minute	O
assessment	O
period	O
.	O

Flumazenil	B-CHED
-	O
treated	O
patients	O
also	O
performed	O
significantly	O
better	O
on	O
the	O
Finger	O
-	O
to	O
-	O
Nose	O
Test	O
and	O
the	O
recall	O
of	O
pictures	O
shown	O
at	O
the	O
5	O
-	O
minute	O
assessment	O
.	O

Flumazenil	B-CHED
was	O
well	O
tolerated	O
,	O
with	O
no	O
serious	O
adverse	O
effects	O
reported	O
.	O

Thirty	O
-	O
nine	O
(	O
30	O
%	O
)	O
of	O
flumazenil	B-CHED
-	O
treated	O
patients	O
,	O
compared	O
with	O
17	O
(	O
25	O
%	O
)	O
of	O
placebo	O
-	O
treated	O
patients	O
had	O
one	O
or	O
more	O
drug	O
-	O
related	O
adverse	O
experiences	O
.	O

The	O
most	O
common	O
adverse	O
effects	O
were	O
nausea	O
and	O
vomiting	O
in	O
the	O
flumazenil	B-CHED
group	O
and	O
nausea	O
and	O
injection	O
-	O
site	O
pain	O
in	O
the	O
placebo	O
group	O
.	O

Flumazenil	B-CHED
was	O
found	O
to	O
promptly	O
reverse	O
sedation	O
induced	O
by	O
diazepam	B-CHED
in	O
the	O
presence	O
of	O
opioids	O
.	O

Methylphenidate	B-CHED
-	O
induced	O
obsessive	O
-	O
compulsive	O
symptoms	O
in	O
an	O
elderly	O
man	O
.	O

An	O
82	O
-	O
year	O
-	O
old	O
man	O
with	O
treatment	O
-	O
resistant	O
depression	O
and	O
early	O
Alzheimer	O
'	O
s	O
disease	O
was	O
started	O
on	O
methylphenidate	B-CHED
.	O

Significant	O
obsessive	O
-	O
compulsive	O
behavior	O
ensued	O
but	O
diminished	O
over	O
several	O
weeks	O
when	O
methylphenidate	B-CHED
was	O
replaced	O
by	O
fluvoxamine	B-CHED
.	O

The	O
patient	O
had	O
no	O
prior	O
psychiatric	O
history	O
,	O
but	O
he	O
had	O
a	O
sister	O
with	O
obsessive	O
-	O
compulsive	O
disorder	O
.	O

It	O
appears	O
that	O
methylphenidate	B-CHED
precipitated	O
the	O
patient	O
'	O
s	O
pathological	O
behavior	O
.	O

Ciprofloxacin	B-CHED
-	O
induced	O
acute	O
interstitial	O
nephritis	O
and	O
autoimmune	O
hemolytic	O
anemia	O
.	O

Ciprofloxacin	B-CHED
has	O
been	O
associated	O
with	O
several	O
side	O
effects	O
including	O
interstitial	O
nephritis	O
and	O
hemolytic	O
anemia	O
.	O

The	O
combination	O
of	O
both	O
side	O
effects	O
is	O
extremely	O
rare	O
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
a	O
case	O
of	O
ciprofloxacin	B-CHED
-	O
induced	O
interstitial	O
nephritis	O
and	O
autoimmune	O
hemolytic	O
anemia	O
.	O

Hemolytic	O
anemia	O
improved	O
after	O
stopping	O
the	O
drug	O
and	O
initiation	O
of	O
steroid	B-CHED
therapy	O
.	O

Unfortunately	O
,	O
acute	O
interstitial	O
nephritis	O
was	O
irreversible	O
and	O
the	O
patient	O
developed	O
end	O
-	O
stage	O
renal	O
disease	O
.	O

Potential	O
deleterious	O
effect	O
of	O
furosemide	B-CHED
in	O
radiocontrast	O
nephropathy	O
.	O

The	O
purpose	O
of	O
the	O
study	O
was	O
to	O
determine	O
the	O
efficacy	O
of	O
furosemide	B-CHED
in	O
addition	O
to	O
intravenous	O
fluids	O
in	O
the	O
prevention	O
of	O
radiocontrast	O
nephropathy	O
.	O

18	O
patients	O
,	O
referred	O
to	O
a	O
radiocontrast	O
study	O
,	O
considered	O
at	O
risk	O
because	O
of	O
preexisting	O
renal	O
insufficiency	O
,	O
were	O
enrolled	O
in	O
a	O
prospective	O
,	O
randomized	O
,	O
controlled	O
trial	O
,	O
performed	O
at	O
the	O
secondary	O
care	O
center	O
of	O
a	O
1	O
,	O
100	O
-	O
bed	O
private	O
university	O
hospital	O
.	O

In	O
addition	O
to	O
fluids	O
,	O
the	O
treatment	O
group	O
received	O
furosemide	B-CHED
(	O
mean	O
dose	O
110	O
mg	O
)	O
intravenously	O
30	O
min	O
prior	O
to	O
the	O
injection	O
of	O
contrast	O
material	O
.	O

The	O
control	O
group	O
received	O
fluids	O
(	O
mean	O
3	O
liters	O
)	O
.	O

Radiological	O
studies	O
were	O
mostly	O
angiographies	O
performed	O
with	O
both	O
ionic	O
and	O
non	O
-	O
ionic	O
contrast	O
material	O
,	O
at	O
an	O
average	O
dose	O
of	O
245	O
ml	O
.	O

Renal	O
function	O
significantly	O
deteriorated	O
in	O
the	O
group	O
pretreated	O
with	O
furosemide	B-CHED
(	O
p	O
<	O
0	O
.	O
005	O
by	O
ANOVA	O
)	O
,	O
with	O
a	O
rise	O
in	O
serum	O
creatinine	B-CHED
from	O
145	O
+	O
/	O
-	O
13	O
to	O
182	O
+	O
/	O
-	O
16	O
mumol	O
/	O
l	O
at	O
24	O
h	O
,	O
while	O
no	O
change	O
occurred	O
in	O
the	O
control	O
group	O
(	O
from	O
141	O
+	O
/	O
-	O
6	O
to	O
142	O
+	O
/	O
-	O
7	O
mumol	O
/	O
l	O
)	O
.	O

Renal	O
failure	O
was	O
associated	O
with	O
weight	O
loss	O
in	O
the	O
furosemide	B-CHED
-	O
treated	O
group	O
.	O

Furosemide	B-CHED
may	O
be	O
deleterious	O
in	O
the	O
prevention	O
of	O
radiocontrast	O
nephropathy	O
.	O

Progestational	O
agents	O
and	O
blood	O
coagulation	O
.	O

VII	O
.	O

Thromboembolic	O
and	O
other	O
complications	O
of	O
oral	B-CHED
contraceptive	I-CHED
therapy	O
in	O
relationship	O
to	O
pretreatment	O
levels	O
of	O
blood	O
coagulation	O
factors	O
:	O
summary	O
report	O
of	O
a	O
ten	O
-	O
year	O
study	O
.	O

During	O
a	O
ten	O
-	O
year	O
period	O
,	O
348	O
women	O
were	O
studied	O
for	O
a	O
total	O
of	O
5	O
,	O
877	O
patient	O
months	O
in	O
four	O
separate	O
studies	O
relating	O
oral	B-CHED
contraceptives	I-CHED
to	O
changes	O
in	O
hematologic	O
parameters	O
.	O

Significant	O
increases	O
in	O
certain	O
factors	O
of	O
the	O
blood	O
coagulation	O
and	O
fibrinolysin	O
systems	O
(	O
factors	O
I	O
,	O
II	O
,	O
VII	O
,	O
VIII	O
,	O
IX	O
,	O
and	O
X	O
and	O
plasminogen	O
)	O
were	O
observed	O
in	O
the	O
treated	O
groups	O
.	O

Severe	O
complications	O
developed	O
in	O
four	O
patients	O
.	O

All	O
four	O
had	O
an	O
abnormal	O
blood	O
coagulation	O
profile	O
,	O
suggesting	O
"	O
hypercoagulability	O
"	O
before	O
initiation	O
of	O
therapy	O
.	O

Some	O
of	O
these	O
findings	O
represented	O
the	O
most	O
extreme	O
abnormalities	O
seen	O
in	O
the	O
entire	O
group	O
of	O
patients	O
;	O
some	O
increased	O
further	O
during	O
therapy	O
.	O

One	O
of	O
these	O
patients	O
developed	O
a	O
myocardial	O
infarction	O
before	O
receiving	O
any	O
medication	O
,	O
shortly	O
after	O
the	O
base	O
-	O
line	O
values	O
were	O
obtained	O
.	O

One	O
patient	O
developed	O
retinopathy	O
19	O
months	O
after	O
she	O
began	O
therapy	O
,	O
and	O
another	O
developed	O
thrombophlebitis	O
after	O
27	O
months	O
of	O
therapy	O
.	O

The	O
fourth	O
patient	O
developed	O
thrombophlebitis	O
14	O
days	O
after	O
initiation	O
of	O
contraceptive	O
therapy	O
.	O

All	O
four	O
patients	O
were	O
of	O
the	O
A	O
or	O
AB	O
blood	O
group	O
.	O

Previous	O
studies	O
suggested	O
the	O
possiblility	O
of	O
increased	O
propensity	O
for	O
thromboembolic	O
episodes	O
in	O
patients	O
possessing	O
the	O
A	O
antigen	O
.	O

It	O
appears	O
from	O
these	O
data	O
that	O
hematologic	O
work	O
-	O
ups	O
may	O
be	O
useful	O
in	O
women	O
who	O
are	O
about	O
to	O
start	O
long	O
-	O
term	O
oral	B-CHED
contraceptive	I-CHED
therapy	O
.	O

Orthostatic	O
hypotension	O
occurs	O
following	O
alpha	O
2	O
-	O
adrenoceptor	O
blockade	O
in	O
chronic	O
prazosin	B-CHED
-	O
pretreated	O
conscious	O
spontaneously	O
hypertensive	O
rats	O
.	O

1	O
.	O

Studies	O
were	O
performed	O
to	O
evaluate	O
whether	O
chronic	O
prazosin	B-CHED
treatment	O
alters	O
the	O
alpha	O
2	O
-	O
adrenoceptor	O
function	O
for	O
orthostatic	O
control	O
of	O
arterial	O
blood	O
pressure	O
in	O
conscious	O
spontaneously	O
hypertensive	O
rats	O
(	O
SHR	O
)	O
.	O

2	O
.	O

Conscious	O
SHR	O
(	O
male	O
300	O
-	O
350	O
g	O
)	O
were	O
subjected	O
to	O
90	O
degrees	O
head	O
-	O
up	O
tilts	O
for	O
60	O
s	O
following	O
acute	O
administration	O
of	O
prazosin	B-CHED
(	O
0	O
.	O
1	O
mg	O
kg	O
-	O
1	O
i	O
.	O
p	O
.	O
)	O
or	O
rauwolscine	B-CHED
(	O
3	O
mg	O
kg	O
-	O
1	O
i	O
.	O
v	O
.	O
)	O
.	O

Orthostatic	O
hypotension	O
was	O
determined	O
by	O
the	O
average	O
decrease	O
(	O
%	O
)	O
in	O
mean	O
arterial	O
pressure	O
(	O
MAP	O
femoral	O
)	O
over	O
the	O
60	O
-	O
s	O
tilt	O
period	O
.	O

The	O
basal	O
MAP	O
of	O
conscious	O
SHR	O
was	O
reduced	O
to	O
a	O
similar	O
extent	O
by	O
prazosin	B-CHED
(	O
-	O
23	O
%	O
(	O
-	O
)	O
-	O
26	O
%	O
MAP	O
)	O
and	O
rauwolscine	B-CHED
(	O
-	O
16	O
%	O
(	O
-	O
)	O
-	O
33	O
%	O
MAP	O
)	O
.	O

However	O
,	O
the	O
head	O
-	O
up	O
tilt	O
induced	O
orthostatic	O
hypotension	O
in	O
the	O
SHR	O
treated	O
with	O
prazosin	B-CHED
(	O
-	O
16	O
%	O
MAP	O
,	O
n	O
=	O
6	O
)	O
,	O
but	O
not	O
in	O
the	O
SHR	O
treated	O
with	O
rauwolscine	B-CHED
(	O
less	O
than	O
+	O
2	O
%	O
MAP	O
,	O
n	O
=	O
6	O
)	O
.	O

3	O
.	O

Conscious	O
SHR	O
were	O
treated	O
for	O
4	O
days	O
with	O
prazosin	B-CHED
at	O
2	O
mg	O
kg	O
-	O
1	O
day	O
-	O
1	O
i	O
.	O
p	O
.	O
for	O
chronic	O
alpha	O
1	O
-	O
adrenoceptor	O
blockade	O
.	O

MAP	O
in	O
conscious	O
SHR	O
after	O
chronic	O
prazosin	B-CHED
treatment	O
was	O
14	O
%	O
lower	O
than	O
in	O
the	O
untreated	O
SHR	O
(	O
n	O
=	O
8	O
)	O
.	O

Head	O
-	O
up	O
tilts	O
in	O
these	O
rats	O
did	O
not	O
produce	O
orthostatic	O
hypotension	O
when	O
performed	O
either	O
prior	O
to	O
or	O
after	O
acute	O
dosing	O
of	O
prazosin	B-CHED
(	O
0	O
.	O
1	O
mg	O
kg	O
-	O
1	O
i	O
.	O
p	O
.	O
)	O
.	O

Conversely	O
,	O
administration	O
of	O
rauwolscine	B-CHED
(	O
3	O
mg	O
kg	O
-	O
1	O
i	O
.	O
v	O
.	O
)	O
in	O
chronic	O
prazosin	B-CHED
treated	O
SHR	O
decreased	O
the	O
basal	O
MAP	O
by	O
12	O
-	O
31	O
%	O
(	O
n	O
=	O
4	O
)	O
,	O
and	O
subsequent	O
tilts	O
induced	O
further	O
drops	O
of	O
MAP	O
by	O
19	O
-	O
23	O
%	O
in	O
these	O
rats	O
.	O

4	O
.	O

The	O
pressor	O
responses	O
and	O
bradycardia	O
to	O
the	O
alpha	O
1	O
-	O
agonist	O
cirazoline	B-CHED
(	O
0	O
.	O
6	O
and	O
2	O
micrograms	O
kg	O
-	O
1	O
i	O
.	O
v	O
.	O
)	O
,	O
the	O
alpha	O
2	O
-	O
agonist	O
Abbott	B-CHED
-	I-CHED
53693	I-CHED
(	O
1	O
and	O
3	O
micrograms	O
kg	O
-	O
1	O
i	O
.	O
v	O
.	O
)	O
,	O
and	O
noradrenaline	B-CHED
(	O
0	O
.	O
1	O
and	O
1	O
.	O
0	O
micrograms	O
kg	O
-	O
1	O
i	O
.	O
v	O
.	O
)	O
were	O
determined	O
in	O
conscious	O
SHR	O
with	O
and	O
without	O
chronic	O
prazosin	B-CHED
pretreatment	O
.	O

Both	O
the	O
pressor	O
and	O
bradycardia	O
effects	O
of	O
cirazoline	B-CHED
were	O
abolished	O
in	O
chronic	O
prazosin	B-CHED
treated	O
SHR	O
(	O
n	O
=	O
4	O
)	O
as	O
compared	O
to	O
the	O
untreated	O
SHR	O
(	O
n	O
=	O
4	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
pressor	O
effects	O
of	O
Abbott	B-CHED
-	I-CHED
53693	I-CHED
were	O
similar	O
in	O
both	O
groups	O
of	O
SHR	O
,	O
but	O
the	O
accompanying	O
bradycardia	O
was	O
greater	O
in	O
SHR	O
with	O
chronic	O
prazosin	B-CHED
treatment	O
than	O
without	O
such	O
treatment	O
.	O

Furthermore	O
,	O
the	O
bradycardia	O
that	O
accompanied	O
the	O
noradrenaline	B-CHED
-	O
induced	O
pressor	O
effect	O
in	O
SHR	O
was	O
similar	O
with	O
and	O
without	O
chronic	O
prazosin	B-CHED
treatment	O
despite	O
a	O
47	O
-	O
71	O
%	O
reduction	O
of	O
the	O
pressor	O
effect	O
in	O
chronic	O
alpha	O
1	O
-	O
receptor	O
blocked	O
SHR	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

Hemolytic	O
-	O
uremic	O
syndrome	O
associated	O
with	O
ingestion	O
of	O
quinine	B-CHED
.	O

Hemolytic	O
-	O
uremic	O
syndrome	O
following	O
quinine	B-CHED
ingestion	O
is	O
a	O
newly	O
described	O
phenomenon	O
,	O
with	O
just	O
two	O
previous	O
descriptions	O
of	O
4	O
cases	O
in	O
the	O
literature	O
.	O

We	O
describe	O
a	O
5th	O
case	O
.	O

The	O
reaction	O
may	O
be	O
mediated	O
by	O
the	O
presence	O
of	O
antibodies	O
reactive	O
against	O
platelets	O
in	O
the	O
presence	O
of	O
quinine	B-CHED
.	O

Treatment	O
has	O
included	O
use	O
of	O
plasma	O
exchange	O
,	O
prednisone	B-CHED
,	O
aspirin	B-CHED
,	O
and	O
dipyridamole	B-CHED
.	O

The	O
patients	O
have	O
all	O
regained	O
some	O
degree	O
of	O
renal	O
function	O
.	O

However	O
,	O
it	O
is	O
unclear	O
whether	O
pharmacological	O
treatment	O
or	O
spontaneous	O
resolution	O
is	O
responsible	O
for	O
the	O
improvement	O
.	O

Quinine	B-CHED
-	O
associated	O
hemolytic	O
-	O
uremic	O
syndrome	O
probably	O
occurs	O
more	O
often	O
than	O
is	O
recognized	O
.	O

It	O
is	O
important	O
to	O
recognize	O
this	O
reaction	O
when	O
it	O
occurs	O
and	O
to	O
avoid	O
further	O
quinine	B-CHED
exposure	O
,	O
since	O
the	O
reaction	O
seems	O
to	O
be	O
recurrent	O
.	O

Amnestic	O
syndrome	O
associated	O
with	O
propranolol	B-CHED
toxicity	O
:	O
a	O
case	O
report	O
.	O

An	O
elderly	O
woman	O
developed	O
an	O
Alzheimer	O
-	O
like	O
subacute	O
dementia	O
as	O
a	O
result	O
of	O
propranolol	B-CHED
toxicity	O
.	O

Analysis	O
of	O
the	O
manifestations	O
showed	O
that	O
severe	O
impairment	O
of	O
memory	O
accounted	O
for	O
virtually	O
all	O
of	O
the	O
abnormalities	O
.	O

There	O
is	O
evidence	O
that	O
cerebral	O
reactions	O
to	O
drug	O
toxicity	O
can	O
exhibit	O
patterns	O
that	O
suggest	O
highly	O
selective	O
involvement	O
of	O
functional	O
subdivisions	O
of	O
the	O
brain	O
.	O

Cefotetan	B-CHED
-	O
induced	O
immune	O
hemolytic	O
anemia	O
.	O

Immune	O
hemolytic	O
anemia	O
due	O
to	O
a	O
drug	O
-	O
adsorption	O
mechanism	O
has	O
been	O
described	O
primarily	O
in	O
patients	O
receiving	O
penicillins	B-CHED
and	O
first	O
-	O
generation	O
cephalosporins	B-CHED
.	O

We	O
describe	O
a	O
patient	O
who	O
developed	O
anemia	O
while	O
receiving	O
intravenous	O
cefotetan	B-CHED
.	O

Cefotetan	B-CHED
-	O
dependent	O
antibodies	O
were	O
detected	O
in	O
the	O
patient	O
'	O
s	O
serum	O
and	O
in	O
an	O
eluate	O
prepared	O
from	O
his	O
red	O
blood	O
cells	O
.	O

The	O
eluate	O
also	O
reacted	O
weakly	O
with	O
red	O
blood	O
cells	O
in	O
the	O
absence	O
of	O
cefotetan	B-CHED
,	O
suggesting	O
the	O
concomitant	O
formation	O
of	O
warm	O
-	O
reactive	O
autoantibodies	O
.	O

These	O
observations	O
,	O
in	O
conjunction	O
with	O
clinical	O
and	O
laboratory	O
evidence	O
of	O
extravascular	O
hemolysis	O
,	O
are	O
consistent	O
with	O
drug	O
-	O
induced	O
hemolytic	O
anemia	O
,	O
possibly	O
involving	O
both	O
drug	O
-	O
adsorption	O
and	O
autoantibody	O
formation	O
mechanisms	O
.	O

This	O
case	O
emphasizes	O
the	O
need	O
for	O
increased	O
awareness	O
of	O
hemolytic	O
reactions	O
to	O
all	O
cephalosporins	B-CHED
.	O

Use	O
of	O
dexamethasone	B-CHED
with	O
mesna	B-CHED
for	O
the	O
prevention	O
of	O
ifosfamide	B-CHED
-	O
induced	O
hemorrhagic	O
cystitis	O
.	O

AIM	O
:	O
Hemorrhagic	O
cystitis	O
(	O
HC	O
)	O
is	O
a	O
limiting	O
side	O
-	O
effect	O
of	O
chemotherapy	O
with	O
ifosfamide	B-CHED
(	O
IFS	B-CHED
)	O
.	O

In	O
the	O
study	O
presented	O
here	O
,	O
we	O
investigated	O
the	O
use	O
of	O
dexamethasone	B-CHED
in	O
combination	O
with	O
mesna	B-CHED
for	O
the	O
prevention	O
of	O
IFS	B-CHED
-	O
induced	O
HC	O
.	O

METHODS	O
:	O
Male	O
Wistar	O
rats	O
(	O
150	O
-	O
200	O
g	O
;	O
6	O
rats	O
per	O
group	O
)	O
were	O
treated	O
with	O
saline	O
or	O
mesna	B-CHED
5	O
min	O
(	O
i	O
.	O
p	O
.	O
)	O
before	O
and	O
2	O
and	O
6	O
h	O
after	O
(	O
v	O
.	O
o	O
.	O
)	O
administration	O
of	O
IFS	B-CHED
.	O

One	O
,	O
two	O
or	O
three	O
doses	O
of	O
mesna	B-CHED
were	O
replaced	O
with	O
dexamethasone	B-CHED
alone	O
or	O
with	O
dexamethasone	B-CHED
plus	O
mesna	B-CHED
.	O

Cystitis	O
was	O
evaluated	O
24	O
h	O
after	O
its	O
induction	O
by	O
the	O
changes	O
in	O
bladder	O
wet	O
weight	O
and	O
by	O
macroscopic	O
and	O
microscopic	O
analysis	O
.	O

RESULTS	O
:	O
The	O
replacement	O
of	O
the	O
last	O
dose	O
or	O
the	O
last	O
two	O
doses	O
of	O
mesna	B-CHED
with	O
dexamethasone	B-CHED
reduced	O
the	O
increase	O
in	O
bladder	O
wet	O
weight	O
induced	O
by	O
IFS	B-CHED
by	O
84	O
.	O
79	O
%	O
and	O
89	O
.	O
13	O
%	O
,	O
respectively	O
.	O

In	O
addition	O
,	O
it	O
almost	O
abolished	O
the	O
macroscopic	O
and	O
microscopic	O
alterations	O
induced	O
by	O
IFS	B-CHED
.	O

Moreover	O
,	O
the	O
addition	O
of	O
dexamethasone	B-CHED
to	O
the	O
last	O
two	O
doses	O
of	O
mesna	B-CHED
was	O
more	O
efficient	O
than	O
three	O
doses	O
of	O
mesna	B-CHED
alone	O
when	O
evaluated	O
microscopically	O
.	O

CONCLUSION	O
:	O
Dexamethasone	B-CHED
in	O
combination	O
with	O
mesna	B-CHED
was	O
efficient	O
in	O
blocking	O
IFS	B-CHED
-	O
induced	O
HC	O
.	O

However	O
,	O
the	O
replacement	O
of	O
last	O
two	O
doses	O
of	O
mesna	B-CHED
with	O
saline	O
or	O
all	O
of	O
the	O
mesna	B-CHED
doses	O
with	O
dexamethasone	B-CHED
did	O
not	O
prevent	O
HC	O
.	O

All	B-CHED
-	I-CHED
trans	I-CHED
-	I-CHED
retinoic	I-CHED
acid	I-CHED
-	O
induced	O
erythema	O
nodosum	O
in	O
patients	O
with	O
acute	O
promyelocytic	O
leukemia	O
.	O

Erythema	O
nodosum	O
associated	O
with	O
all	B-CHED
-	I-CHED
trans	I-CHED
-	I-CHED
retinoic	I-CHED
acid	I-CHED
(	O
ATRA	B-CHED
)	O
for	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
is	O
very	O
rare	O
.	O

We	O
describe	O
four	O
patients	O
with	O
classic	O
APL	O
who	O
developed	O
erythema	O
nodosum	O
during	O
ATRA	B-CHED
therapy	O
.	O

Fever	O
and	O
subsequent	O
multiple	O
painful	O
erythematous	O
nodules	O
over	O
extremities	O
developed	O
on	O
D11	O
,	O
D16	O
,	O
D17	O
,	O
and	O
D19	O
,	O
respectively	O
,	O
after	O
ATRA	B-CHED
therapy	O
.	O

The	O
skin	O
biopsy	O
taken	O
from	O
each	O
patient	O
was	O
consistent	O
with	O
erythema	O
nodosum	O
.	O

All	O
patients	O
received	O
short	O
course	O
of	O
steroids	B-CHED
.	O

Fever	O
subsided	O
rapidly	O
and	O
the	O
skin	O
lesions	O
regressed	O
completely	O
.	O

All	O
patients	O
achieved	O
complete	O
remission	O
without	O
withdrawal	O
of	O
ATRA	B-CHED
.	O

ATRA	B-CHED
seemed	O
to	O
be	O
the	O
most	O
possible	O
etiology	O
of	O
erythema	O
nodosum	O
in	O
our	O
patients	O
.	O

Short	O
-	O
term	O
use	O
of	O
steroid	B-CHED
is	O
very	O
effective	O
in	O
ATRA	B-CHED
-	O
induced	O
erythema	O
nodosum	O
.	O

Effect	O
of	O
some	O
convulsants	O
on	O
the	O
protective	O
activity	O
of	O
loreclezole	B-CHED
and	O
its	O
combinations	O
with	O
valproate	B-CHED
or	O
clonazepam	B-CHED
in	O
amygdala	O
-	O
kindled	O
rats	O
.	O

Loreclezole	B-CHED
(	O
5	O
mg	O
/	O
kg	O
)	O
exerted	O
a	O
significant	O
protective	O
action	O
in	O
amygdala	O
-	O
kindled	O
rats	O
,	O
reducing	O
both	O
seizure	O
and	O
afterdischarge	O
durations	O
.	O

The	O
combinations	O
of	O
loreclezole	B-CHED
(	O
2	O
.	O
5	O
mg	O
/	O
kg	O
)	O
with	O
valproate	B-CHED
,	O
clonazepam	B-CHED
,	O
or	O
carbamazepine	B-CHED
(	O
applied	O
at	O
their	O
subprotective	O
doses	O
)	O
also	O
exhibited	O
antiseizure	O
effect	O
in	O
this	O
test	O
.	O

However	O
,	O
only	O
two	O
first	O
combinations	O
occurred	O
to	O
be	O
of	O
pharmacodynamic	O
nature	O
.	O

Among	O
several	O
chemoconvulsants	O
,	O
bicuculline	B-CHED
,	O
N	B-CHED
-	I-CHED
methyl	I-CHED
-	I-CHED
D	I-CHED
-	I-CHED
aspartic	I-CHED
acid	I-CHED
and	O
BAY	B-CHED
k	I-CHED
-	I-CHED
8644	I-CHED
(	O
the	O
opener	O
of	O
L	O
-	O
type	O
calcium	B-CHED
channels	O
)	O
reversed	O
the	O
protective	O
activity	O
of	O
loreclezole	B-CHED
alone	O
and	O
its	O
combination	O
with	O
valproate	B-CHED
.	O

On	O
the	O
other	O
hand	O
,	O
bicuculline	B-CHED
,	O
aminophylline	B-CHED
and	O
BAY	B-CHED
k	I-CHED
-	I-CHED
8644	I-CHED
inhibited	O
the	O
anticonvulsive	O
action	O
of	O
loreclezole	B-CHED
combined	O
with	O
clonazepam	B-CHED
.	O

The	O
results	O
support	O
the	O
hypothesis	O
that	O
the	O
protective	O
activity	O
of	O
loreclezole	B-CHED
and	O
its	O
combinations	O
with	O
other	O
antiepileptics	O
may	O
involve	O
potentiation	O
of	O
GABAergic	O
neurotransmission	O
and	O
blockade	O
of	O
L	O
-	O
type	O
of	O
calcium	B-CHED
channels	O
.	O

Mitochondrial	O
DNA	O
and	O
its	O
respiratory	O
chain	O
products	O
are	O
defective	O
in	O
doxorubicin	B-CHED
nephrosis	O
.	O

BACKGROUND	O
:	O
Doxorubicin	B-CHED
induces	O
a	O
self	O
-	O
perpetuating	O
nephropathy	O
characterized	O
by	O
early	O
glomerular	O
and	O
late	O
-	O
onset	O
tubular	O
lesions	O
in	O
rats	O
.	O

We	O
investigated	O
the	O
potential	O
role	O
of	O
mitochondrial	O
injury	O
in	O
the	O
onset	O
of	O
these	O
lesions	O
.	O

METHODS	O
:	O
Rats	O
were	O
treated	O
with	O
intravenous	O
doxorubicin	B-CHED
(	O
1	O
mg	O
kg	O
(	O
-	O
1	O
)	O
week	O
(	O
-	O
1	O
)	O
)	O
for	O
7	O
weeks	O
and	O
were	O
sacrificed	O
either	O
1	O
week	O
(	O
'	O
short	O
-	O
term	O
'	O
)	O
or	O
30	O
weeks	O
(	O
'	O
long	O
-	O
term	O
'	O
)	O
following	O
the	O
last	O
dose	O
.	O

Additional	O
rats	O
received	O
a	O
single	O
dose	O
either	O
6	O
days	O
or	O
2	O
h	O
prior	O
to	O
euthanasia	O
.	O

All	O
rats	O
were	O
killed	O
at	O
48	O
weeks	O
of	O
age	O
.	O

Glomerular	O
and	O
tubular	O
injury	O
was	O
monitored	O
and	O
correlated	O
to	O
the	O
activity	O
or	O
expression	O
of	O
respiratory	O
chain	O
components	O
.	O

Finally	O
,	O
we	O
quantified	O
both	O
nuclear	O
and	O
mitochondrial	O
DNA	O
(	O
mtDNA	O
)	O
as	O
well	O
as	O
superoxide	B-CHED
production	O
and	O
the	O
4834	O
base	O
pair	O
'	O
common	O
'	O
mtDNA	O
deletion	O
.	O

RESULTS	O
:	O
The	O
'	O
long	O
-	O
term	O
'	O
group	O
had	O
significant	O
glomerular	O
and	O
tubular	O
lesions	O
,	O
depressed	O
activities	O
of	O
mtDNA	O
-	O
encoded	O
NADH	O
dehydrogenase	O
and	O
cytochrome	O
-	O
c	O
oxidase	O
(	O
COX	O
)	O
and	O
increased	O
citrate	B-CHED
synthase	O
activity	O
.	O

In	O
addition	O
,	O
expression	O
of	O
the	O
mtDNA	O
-	O
encoded	O
COX	O
subunit	O
I	O
was	O
reduced	O
and	O
mtDNA	O
levels	O
were	O
decreased	O
.	O

In	O
'	O
short	O
-	O
term	O
'	O
rats	O
,	O
there	O
were	O
fewer	O
tubular	O
lesions	O
,	O
but	O
similar	O
numbers	O
of	O
glomerular	O
lesions	O
activity	O
.	O

Among	O
all	O
animals	O
,	O
glomerular	O
and	O
tubular	O
injury	O
were	O
inversely	O
correlated	O
with	O
mtDNA	O
levels	O
,	O
mtDNA	O
-	O
encoded	O
respiratory	O
chain	O
activities	O
and	O
with	O
the	O
expression	O
of	O
the	O
mtDNA	O
-	O
encoded	O
respiratory	O
chain	O
subunit	O
COX	O
-	O
I	O
.	O

Injury	O
was	O
positively	O
correlated	O
with	O
superoxide	B-CHED
production	O
and	O
the	O
activities	O
of	O
nucleus	O
-	O
encoded	O
mitochondrial	O
or	O
cytoplasmic	O
enzymes	O
.	O

Kidneys	O
from	O
the	O
'	O
long	O
-	O
term	O
'	O
group	O
showed	O
more	O
mtDNA	O
deletions	O
than	O
in	O
'	O
short	O
-	O
term	O
'	O
animals	O
and	O
these	O
were	O
not	O
observed	O
in	O
the	O
other	O
groups	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
an	O
important	O
role	O
for	O
quantitative	O
and	O
qualitative	O
mtDNA	O
alterations	O
through	O
the	O
reduction	O
of	O
mtDNA	O
-	O
encoded	O
respiratory	O
chain	O
function	O
and	O
induction	O
of	O
superoxide	B-CHED
in	O
doxorubicin	B-CHED
-	O
induced	O
renal	O
lesions	O
.	O

A	O
randomized	O
,	O
placebo	O
-	O
controlled	O
,	O
crossover	O
study	O
of	O
ephedrine	B-CHED
for	O
SSRI	O
-	O
induced	O
female	O
sexual	O
dysfunction	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
ephedrine	B-CHED
,	O
an	O
alpha	O
-	O
and	O
beta	O
-	O
adrenergic	O
agonist	O
previously	O
shown	O
to	O
enhance	O
genital	O
blood	O
flow	O
in	O
women	O
,	O
has	O
beneficial	O
effects	O
in	O
reversing	O
antidepressant	O
-	O
induced	O
sexual	O
dysfunction	O
.	O

Nineteen	O
sexually	O
dysfunctional	O
women	O
receiving	O
either	O
fluoxetine	B-CHED
,	O
sertraline	B-CHED
,	O
or	O
paroxetine	B-CHED
participated	O
in	O
an	O
eight	O
-	O
week	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
cross	O
-	O
over	O
study	O
of	O
the	O
effects	O
of	O
ephedrine	B-CHED
(	O
50	O
mg	O
)	O
on	O
self	O
-	O
report	O
measures	O
of	O
sexual	O
desire	O
,	O
arousal	O
,	O
orgasm	O
,	O
and	O
sexual	O
satisfaction	O
.	O

Although	O
there	O
were	O
significant	O
improvements	O
relative	O
to	O
baseline	O
in	O
sexual	O
desire	O
and	O
orgasm	O
intensity	O
/	O
pleasure	O
on	O
50	O
mg	O
ephedrine	B-CHED
1	O
-	O
hr	O
prior	O
to	O
sexual	O
activity	O
,	O
significant	O
improvements	O
in	O
these	O
measures	O
,	O
as	O
well	O
as	O
in	O
sexual	O
arousal	O
and	O
orgasmic	O
ability	O
also	O
were	O
noted	O
with	O
placebo	O
.	O

These	O
findings	O
highlight	O
the	O
importance	O
of	O
conducting	O
placebo	O
-	O
controlled	O
trials	O
for	O
this	O
condition	O
.	O

Does	O
hormone	O
therapy	O
for	O
the	O
treatment	O
of	O
breast	O
cancer	O
have	O
a	O
detrimental	O
effect	O
on	O
memory	O
and	O
cognition	O
?	O

A	O
pilot	O
study	O
.	O

This	O
pilot	O
study	O
examines	O
whether	O
hormone	O
therapy	O
for	O
breast	O
cancer	O
affects	O
cognition	O
.	O

Patients	O
participating	O
in	O
a	O
randomised	O
trial	O
of	O
anastrozole	B-CHED
,	O
tamoxifen	B-CHED
alone	O
or	O
combined	O
(	O
ATAC	O
)	O
(	O
n	O
=	O
94	O
)	O
and	O
a	O
group	O
of	O
women	O
without	O
breast	O
cancer	O
(	O
n	O
=	O
35	O
)	O
completed	O
a	O
battery	O
of	O
neuropsychological	O
measures	O
.	O

Compared	O
with	O
the	O
control	O
group	O
,	O
the	O
patients	O
were	O
impaired	O
on	O
a	O
processing	O
speed	O
task	O
(	O
p	O
=	O
0	O
.	O
032	O
)	O
and	O
on	O
a	O
measure	O
of	O
immediate	O
verbal	O
memory	O
(	O
p	O
=	O
0	O
.	O
026	O
)	O
after	O
controlling	O
for	O
the	O
use	O
of	O
hormone	O
replacement	O
therapy	O
in	O
both	O
groups	O
.	O

Patient	O
group	O
performance	O
was	O
not	O
significantly	O
related	O
to	O
length	O
of	O
treatment	O
or	O
measures	O
of	O
psychological	O
morbidity	O
.	O

The	O
results	O
showed	O
specific	O
impairments	O
in	O
processing	O
speed	O
and	O
verbal	O
memory	O
in	O
women	O
receiving	O
hormonal	O
therapy	O
for	O
the	O
treatment	O
of	O
breast	O
cancer	O
.	O

Verbal	O
memory	O
may	O
be	O
especially	O
sensitive	O
to	O
changes	O
in	O
oestrogen	B-CHED
levels	O
,	O
a	O
finding	O
commonly	O
reported	O
in	O
studies	O
of	O
hormone	O
replacement	O
therapy	O
in	O
healthy	O
women	O
.	O

In	O
view	O
of	O
the	O
increased	O
use	O
of	O
hormone	O
therapies	O
in	O
an	O
adjuvant	O
and	O
preventative	O
setting	O
their	O
impact	O
on	O
cognitive	O
functioning	O
should	O
be	O
investigated	O
more	O
thoroughly	O
.	O

Expression	O
of	O
p300	O
protects	O
cardiac	O
myocytes	O
from	O
apoptosis	O
in	O
vivo	O
.	O

Doxorubicin	B-CHED
is	O
an	O
anti	O
-	O
tumor	O
agent	O
that	O
represses	O
cardiac	O
-	O
specific	O
gene	O
expression	O
and	O
induces	O
myocardial	O
cell	O
apoptosis	O
.	O

Doxorubicin	B-CHED
depletes	O
cardiac	O
p300	O
,	O
a	O
transcriptional	O
coactivator	O
that	O
is	O
required	O
for	O
the	O
maintenance	O
of	O
the	O
differentiated	O
phenotype	O
of	O
cardiac	O
myocytes	O
.	O

However	O
,	O
the	O
role	O
of	O
p300	O
in	O
protection	O
against	O
doxorubicin	B-CHED
-	O
induced	O
apoptosis	O
is	O
unknown	O
.	O

Transgenic	O
mice	O
overexpressing	O
p300	O
in	O
the	O
heart	O
and	O
wild	O
-	O
type	O
mice	O
were	O
subjected	O
to	O
doxorubicin	B-CHED
treatment	O
.	O

Compared	O
with	O
wild	O
-	O
type	O
mice	O
,	O
transgenic	O
mice	O
exhibited	O
higher	O
survival	O
rate	O
as	O
well	O
as	O
more	O
preserved	O
left	O
ventricular	O
function	O
and	O
cardiac	O
expression	O
of	O
alpha	O
-	O
sarcomeric	O
actin	O
.	O

Doxorubicin	B-CHED
induced	O
myocardial	O
cell	O
apoptosis	O
in	O
wild	O
-	O
type	O
mice	O
but	O
not	O
in	O
transgenic	O
mice	O
.	O

Expression	O
of	O
p300	O
increased	O
the	O
cardiac	O
level	O
of	O
bcl	O
-	O
2	O
and	O
mdm	O
-	O
2	O
,	O
but	O
not	O
that	O
of	O
p53	O
or	O
other	O
members	O
of	O
the	O
bcl	O
-	O
2	O
family	O
.	O

These	O
findings	O
demonstrate	O
that	O
overexpression	O
of	O
p300	O
protects	O
cardiac	O
myocytes	O
from	O
doxorubicin	B-CHED
-	O
induced	O
apoptosis	O
and	O
reduces	O
the	O
extent	O
of	O
acute	O
heart	O
failure	O
in	O
adult	O
mice	O
in	O
vivo	O
.	O

Methimazole	B-CHED
-	O
induced	O
cholestatic	O
jaundice	O
.	O

Methimazole	B-CHED
is	O
a	O
widely	O
used	O
and	O
generally	O
well	O
-	O
tolerated	O
antithyroid	O
agent	O
.	O

A	O
43	O
-	O
year	O
-	O
old	O
woman	O
had	O
severe	O
jaundice	O
and	O
itching	O
1	O
month	O
after	O
receiving	O
methimazole	B-CHED
(	O
10	O
mg	O
tid	O
)	O
and	O
propranolol	B-CHED
(	O
20	O
mg	O
tid	O
)	O
for	O
treatment	O
of	O
hyperthyroidism	O
.	O

The	O
patient	O
continued	O
treatment	O
for	O
another	O
4	O
days	O
after	O
the	O
appearance	O
of	O
jaundice	O
until	O
she	O
finished	O
both	O
medications	O
.	O

When	O
seen	O
at	O
the	O
emergency	O
department	O
2	O
weeks	O
later	O
,	O
she	O
still	O
had	O
severe	O
icterus	O
,	O
pruritus	O
,	O
and	O
hyperbilirubinemia	O
,	O
formed	O
mainly	O
of	O
the	O
conjugated	O
fraction	O
.	O

Methimazole	B-CHED
-	O
induced	O
cholestasis	O
was	O
diagnosed	O
,	O
and	O
propranolol	B-CHED
therapy	O
was	O
resumed	O
.	O

Over	O
the	O
following	O
9	O
days	O
,	O
the	O
symptoms	O
improved	O
and	O
plasma	O
bilirubin	B-CHED
levels	O
were	O
normal	O
after	O
12	O
weeks	O
without	O
methimazole	B-CHED
.	O

In	O
rare	O
cases	O
within	O
the	O
first	O
few	O
weeks	O
of	O
therapy	O
,	O
this	O
drug	O
can	O
cause	O
severe	O
and	O
reversible	O
cholestatic	O
jaundice	O
.	O

Physicians	O
and	O
patients	O
should	O
be	O
aware	O
of	O
this	O
adverse	O
effect	O
so	O
that	O
,	O
upon	O
occurrence	O
,	O
they	O
can	O
discontinue	O
methimazole	B-CHED
therapy	O
and	O
avoid	O
unnecessary	O
invasive	O
procedures	O
.	O

Atrial	O
fibrillation	O
following	O
chemotherapy	O
for	O
stage	O
IIIE	O
diffuse	O
large	O
B	O
-	O
cell	O
gastric	O
lymphoma	O
in	O
a	O
patient	O
with	O
myotonic	O
dystrophy	O
(	O
Steinert	O
'	O
s	O
disease	O
)	O
.	O

The	O
authors	O
describe	O
the	O
unusual	O
association	O
between	O
diffuse	O
B	O
-	O
cell	O
gastric	O
lymphoma	O
and	O
myotonic	O
dystrophy	O
,	O
the	O
most	O
common	O
form	O
of	O
adult	O
muscular	O
dystrophy	O
,	O
and	O
sudden	O
atrial	O
fibrillation	O
following	O
one	O
cycle	O
of	O
doxorubicin	B-CHED
-	O
based	O
chemotherapy	O
in	O
the	O
same	O
patient	O
.	O

Atrial	O
fibrillation	O
or	O
other	O
cardiac	O
arrhythmias	O
are	O
unusual	O
complications	O
in	O
patients	O
treated	O
with	O
chemotherapy	O
.	O

The	O
cardiac	O
toxicity	O
intrinsically	O
associated	O
with	O
the	O
aggressive	O
chemotherapy	O
employed	O
could	O
function	O
as	O
a	O
triggering	O
factor	O
for	O
the	O
arrhythmia	O
in	O
the	O
predisposed	O
myocardium	O
of	O
this	O
patient	O
.	O

Hypersensitivity	O
immune	O
reaction	O
as	O
a	O
mechanism	O
for	O
dilevalol	B-CHED
-	O
associated	O
hepatitis	O
.	O

OBJECTIVE	O
:	O
To	O
assess	O
lymphocyte	O
reactivity	O
to	O
dilevalol	B-CHED
and	O
to	O
serum	O
containing	O
putative	O
ex	O
vivo	O
dilevalol	B-CHED
antigens	O
or	O
metabolites	O
in	O
a	O
case	O
of	O
dilevalol	B-CHED
-	O
induced	O
liver	O
injury	O
.	O

PATIENT	O
:	O
A	O
58	O
-	O
year	O
-	O
old	O
woman	O
with	O
a	O
clinical	O
diagnosis	O
of	O
dilevalol	B-CHED
-	O
induced	O
liver	O
injury	O
.	O

METHODS	O
:	O
Peripheral	O
blood	O
mononuclear	O
cells	O
collected	O
from	O
the	O
patient	O
were	O
cultured	O
in	O
the	O
presence	O
of	O
a	O
solution	O
of	O
dilevalol	B-CHED
and	O
also	O
with	O
sera	O
collected	O
from	O
a	O
volunteer	O
before	O
and	O
after	O
dilevalol	B-CHED
intake	O
.	O

A	O
similar	O
protocol	O
was	O
performed	O
with	O
lymphocytes	O
from	O
a	O
healthy	O
subject	O
.	O

RESULTS	O
:	O
No	O
lymphocyte	O
proliferation	O
was	O
observed	O
either	O
in	O
the	O
patient	O
or	O
in	O
the	O
healthy	O
volunteer	O
in	O
the	O
presence	O
of	O
dilevalol	B-CHED
solutions	O
.	O

A	O
significant	O
proliferative	O
response	O
to	O
serum	O
collected	O
after	O
dilevalol	B-CHED
intake	O
was	O
observed	O
in	O
the	O
case	O
of	O
the	O
patient	O
compared	O
with	O
the	O
proliferative	O
response	O
to	O
the	O
serum	O
collected	O
before	O
the	O
drug	O
intake	O
.	O

No	O
reactivity	O
was	O
found	O
when	O
lymphocytes	O
from	O
the	O
healthy	O
subject	O
were	O
tested	O
under	O
similar	O
conditions	O
.	O

CONCLUSIONS	O
:	O
The	O
methodology	O
used	O
allowed	O
the	O
detection	O
of	O
lymphocyte	O
sensitization	O
to	O
sera	O
containing	O
ex	O
vivo	O
-	O
prepared	O
dilevalol	B-CHED
antigens	O
,	O
suggesting	O
the	O
involvement	O
of	O
an	O
immunologic	O
mechanism	O
in	O
dilevalol	B-CHED
-	O
induced	O
liver	O
injury	O
.	O

Increased	O
expression	O
and	O
apical	O
targeting	O
of	O
renal	O
ENaC	O
subunits	O
in	O
puromycin	B-CHED
aminonucleoside	I-CHED
-	O
induced	O
nephrotic	O
syndrome	O
in	O
rats	O
.	O

Nephrotic	O
syndrome	O
is	O
often	O
accompanied	O
by	O
sodium	B-CHED
retention	O
and	O
generalized	O
edema	O
.	O

However	O
,	O
the	O
molecular	O
basis	O
for	O
the	O
decreased	O
renal	O
sodium	B-CHED
excretion	O
remains	O
undefined	O
.	O

We	O
hypothesized	O
that	O
epithelial	O
Na	B-CHED
channel	O
(	O
ENaC	O
)	O
subunit	O
dysregulation	O
may	O
be	O
responsible	O
for	O
the	O
increased	O
sodium	B-CHED
retention	O
.	O

An	O
experimental	O
group	O
of	O
rats	O
was	O
treated	O
with	O
puromycin	B-CHED
aminonucleoside	I-CHED
(	O
PAN	B-CHED
;	O
180	O
mg	O
/	O
kg	O
iv	O
)	O
,	O
whereas	O
the	O
control	O
group	O
received	O
only	O
vehicle	O
.	O

After	O
7	O
days	O
,	O
PAN	B-CHED
treatment	O
induced	O
significant	O
proteinuria	O
,	O
hypoalbuminemia	O
,	O
decreased	O
urinary	O
sodium	B-CHED
excretion	O
,	O
and	O
extensive	O
ascites	O
.	O

The	O
protein	O
abundance	O
of	O
alpha	O
-	O
ENaC	O
and	O
beta	O
-	O
ENaC	O
was	O
increased	O
in	O
the	O
inner	O
stripe	O
of	O
the	O
outer	O
medulla	O
(	O
ISOM	O
)	O
and	O
in	O
the	O
inner	O
medulla	O
(	O
IM	O
)	O
but	O
was	O
not	O
altered	O
in	O
the	O
cortex	O
.	O

gamma	O
-	O
ENaC	O
abundance	O
was	O
increased	O
in	O
the	O
cortex	O
,	O
ISOM	O
,	O
and	O
IM	O
.	O

Immunoperoxidase	O
brightfield	O
-	O
and	O
laser	O
-	O
scanning	O
confocal	O
fluorescence	O
microscopy	O
demonstrated	O
increased	O
targeting	O
of	O
alpha	O
-	O
ENaC	O
,	O
beta	O
-	O
ENaC	O
,	O
and	O
gamma	O
-	O
ENaC	O
subunits	O
to	O
the	O
apical	O
plasma	O
membrane	O
in	O
the	O
distal	O
convoluted	O
tubule	O
(	O
DCT2	O
)	O
,	O
connecting	O
tubule	O
,	O
and	O
cortical	O
and	O
medullary	O
collecting	O
duct	O
segments	O
.	O

Immunoelectron	O
microscopy	O
further	O
revealed	O
an	O
increased	O
labeling	O
of	O
alpha	O
-	O
ENaC	O
in	O
the	O
apical	O
plasma	O
membrane	O
of	O
cortical	O
collecting	O
duct	O
principal	O
cells	O
of	O
PAN	B-CHED
-	O
treated	O
rats	O
,	O
indicating	O
enhanced	O
apical	O
targeting	O
of	O
alpha	O
-	O
ENaC	O
subunits	O
.	O

In	O
contrast	O
,	O
the	O
protein	O
abundances	O
of	O
Na	B-CHED
(	O
+	O
)	O
/	O
H	B-CHED
(	O
+	O
)	O
exchanger	O
type	O
3	O
(	O
NHE3	O
)	O
,	O
Na	B-CHED
(	O
+	O
)	O
-	O
K	B-CHED
(	O
+	O
)	O
-	O
2Cl	B-CHED
(	O
-	O
)	O
cotransporter	O
(	O
BSC	O
-	O
1	O
)	O
,	O
and	O
thiazide	B-CHED
-	O
sensitive	O
Na	B-CHED
(	O
+	O
)	O
-	O
Cl	B-CHED
(	O
-	O
)	O
cotransporter	O
(	O
TSC	O
)	O
were	O
decreased	O
.	O

Moreover	O
,	O
the	O
abundance	O
of	O
the	O
alpha	O
(	O
1	O
)	O
-	O
subunit	O
of	O
the	O
Na	B-CHED
-	O
K	B-CHED
-	O
ATPase	O
was	O
decreased	O
in	O
the	O
cortex	O
and	O
ISOM	O
,	O
but	O
it	O
remained	O
unchanged	O
in	O
the	O
IM	O
.	O

In	O
conclusion	O
,	O
the	O
increased	O
or	O
sustained	O
expression	O
of	O
ENaC	O
subunits	O
combined	O
with	O
increased	O
apical	O
targeting	O
in	O
the	O
DCT2	O
,	O
connecting	O
tubule	O
,	O
and	O
collecting	O
duct	O
are	O
likely	O
to	O
play	O
a	O
role	O
in	O
the	O
sodium	B-CHED
retention	O
associated	O
with	O
PAN	B-CHED
-	O
induced	O
nephrotic	O
syndrome	O
.	O

The	O
decreased	O
abundance	O
of	O
NHE3	O
,	O
BSC	O
-	O
1	O
,	O
TSC	O
,	O
and	O
Na	B-CHED
-	O
K	B-CHED
-	O
ATPase	O
may	O
play	O
a	O
compensatory	O
role	O
to	O
promote	O
sodium	B-CHED
excretion	O
.	O

Pallidal	O
stimulation	O
:	O
an	O
alternative	O
to	O
pallidotomy	O
?	O

A	O
resurgence	O
of	O
interest	O
in	O
the	O
surgical	O
treatment	O
of	O
Parkinson	O
'	O
s	O
disease	O
(	O
PD	O
)	O
came	O
with	O
the	O
rediscovery	O
of	O
posteroventral	O
pallidotomy	O
by	O
Laitinen	O
in	O
1985	O
.	O

Laitinen	O
'	O
s	O
procedure	O
improved	O
most	O
symptoms	O
in	O
drug	O
-	O
resistant	O
PD	O
,	O
which	O
engendered	O
wide	O
interest	O
in	O
the	O
neurosurgical	O
community	O
.	O

Another	O
lesioning	O
procedure	O
,	O
ventrolateral	O
thalamotomy	O
,	O
has	O
become	O
a	O
powerful	O
alternative	O
to	O
stimulate	O
the	O
nucleus	O
ventralis	O
intermedius	O
,	O
producing	O
high	O
long	O
-	O
term	O
success	O
rates	O
and	O
low	O
morbidity	O
rates	O
.	O

Pallidal	O
stimulation	O
has	O
not	O
met	O
with	O
the	O
same	O
success	O
.	O

According	O
to	O
the	O
literature	O
pallidotomy	O
improves	O
the	O
"	O
on	O
"	O
symptoms	O
of	O
PD	O
,	O
such	O
as	O
dyskinesias	O
,	O
as	O
well	O
as	O
the	O
"	O
off	O
"	O
symptoms	O
,	O
such	O
as	O
rigidity	O
,	O
bradykinesia	O
,	O
and	O
on	O
-	O
off	O
fluctuations	O
.	O

Pallidal	O
stimulation	O
improves	O
bradykinesia	O
and	O
rigidity	O
to	O
a	O
minor	O
extent	O
;	O
however	O
,	O
its	O
strength	O
seems	O
to	O
be	O
in	O
improving	O
levodopa	B-CHED
-	O
induced	O
dyskinesias	O
.	O

Stimulation	O
often	O
produces	O
an	O
improvement	O
in	O
the	O
hyper	O
-	O
or	O
dyskinetic	O
upper	O
limbs	O
,	O
but	O
increases	O
the	O
"	O
freezing	O
"	O
phenomenon	O
in	O
the	O
lower	O
limbs	O
at	O
the	O
same	O
time	O
.	O

Considering	O
the	O
small	O
increase	O
in	O
the	O
patient	O
'	O
s	O
independence	O
,	O
the	O
high	O
costs	O
of	O
bilateral	O
implants	O
,	O
and	O
the	O
difficulty	O
most	O
patients	O
experience	O
in	O
handling	O
the	O
devices	O
,	O
the	O
question	O
arises	O
as	O
to	O
whether	O
bilateral	O
pallidal	O
stimulation	O
is	O
a	O
real	O
alternative	O
to	O
pallidotomy	O
.	O

Effects	O
of	O
the	O
cyclooxygenase	O
-	O
2	O
specific	O
inhibitor	O
valdecoxib	B-CHED
versus	O
nonsteroidal	O
antiinflammatory	O
agents	O
and	O
placebo	O
on	O
cardiovascular	O
thrombotic	O
events	O
in	O
patients	O
with	O
arthritis	O
.	O

There	O
have	O
been	O
concerns	O
that	O
the	O
risk	O
of	O
cardiovascular	O
thrombotic	O
events	O
may	O
be	O
higher	O
with	O
cyclooxygenase	O
(	O
COX	O
)	O
-	O
2	O
-	O
specific	O
inhibitors	O
than	O
nonselective	O
nonsteroidal	O
antiinflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
.	O

We	O
evaluated	O
cardiovascular	O
event	O
data	O
for	O
valdecoxib	B-CHED
,	O
a	O
new	O
COX	O
-	O
2	O
-	O
specific	O
inhibitor	O
in	O
approximately	O
8000	O
patients	O
with	O
osteoarthritis	O
and	O
rheumatoid	O
arthritis	O
treated	O
with	O
this	O
agent	O
in	O
randomized	O
clinical	O
trials	O
.	O

The	O
incidence	O
of	O
cardiovascular	O
thrombotic	O
events	O
(	O
cardiac	O
,	O
cerebrovascular	O
and	O
peripheral	O
vascular	O
,	O
or	O
arterial	O
thrombotic	O
)	O
was	O
determined	O
by	O
analyzing	O
pooled	O
valdecoxib	B-CHED
(	O
10	O
-	O
80	O
mg	O
daily	O
)	O
,	O
nonselective	O
NSAID	O
(	O
diclofenac	B-CHED
75	O
mg	O
bid	O
,	O
ibuprofen	B-CHED
800	O
mg	O
tid	O
,	O
or	O
naproxen	B-CHED
500	O
mg	O
bid	O
)	O
and	O
placebo	O
data	O
from	O
10	O
randomized	O
osteoarthritis	O
and	O
rheumatoid	O
arthritis	O
trials	O
that	O
were	O
6	O
-	O
52	O
weeks	O
in	O
duration	O
.	O

The	O
incidence	O
rates	O
of	O
events	O
were	O
determined	O
in	O
all	O
patients	O
(	O
n	O
=	O
7934	O
)	O
and	O
in	O
users	O
of	O
low	O
-	O
dose	O
(	O
<	O
or	O
=	O
325	O
mg	O
daily	O
)	O
aspirin	B-CHED
(	O
n	O
=	O
1051	O
)	O
and	O
nonusers	O
of	O
aspirin	B-CHED
(	O
n	O
=	O
6883	O
)	O
.	O

Crude	O
and	O
exposure	O
-	O
adjusted	O
incidences	O
of	O
thrombotic	O
events	O
were	O
similar	O
for	O
valdecoxib	B-CHED
,	O
NSAIDs	O
,	O
and	O
placebo	O
.	O

The	O
risk	O
of	O
serious	O
thrombotic	O
events	O
was	O
also	O
similar	O
for	O
each	O
valdecoxib	B-CHED
dose	O
.	O

Thrombotic	O
risk	O
was	O
consistently	O
higher	O
for	O
users	O
of	O
aspirin	B-CHED
users	O
than	O
nonusers	O
of	O
aspirin	B-CHED
(	O
placebo	O
,	O
1	O
.	O
4	O
%	O
vs	O
.	O
0	O
%	O
;	O
valdecoxib	B-CHED
,	O
1	O
.	O
7	O
%	O
vs	O
.	O
0	O
.	O
2	O
%	O
;	O
NSAIDs	O
,	O
1	O
.	O
9	O
%	O
vs	O
.	O
0	O
.	O
5	O
%	O
)	O
.	O

The	O
rates	O
of	O
events	O
in	O
users	O
of	O
aspirin	B-CHED
were	O
similar	O
for	O
all	O
3	O
treatment	O
groups	O
and	O
across	O
valdecoxib	B-CHED
doses	O
.	O

Short	O
-	O
and	O
intermediate	O
-	O
term	O
treatment	O
with	O
therapeutic	O
(	O
10	O
or	O
20	O
mg	O
daily	O
)	O
and	O
supratherapeutic	O
(	O
40	O
or	O
80	O
mg	O
daily	O
)	O
valdecoxib	B-CHED
doses	O
was	O
not	O
associated	O
with	O
an	O
increased	O
incidence	O
of	O
thrombotic	O
events	O
relative	O
to	O
nonselective	O
NSAIDs	O
or	O
placebo	O
in	O
osteoarthritis	O
and	O
rheumatoid	O
arthritis	O
patients	O
in	O
controlled	O
clinical	O
trials	O
.	O

Hypersensitivity	O
myocarditis	O
complicating	O
hypertrophic	O
cardiomyopathy	O
heart	O
.	O

The	O
present	O
report	O
describes	O
a	O
case	O
of	O
eosinophilic	O
myocarditis	O
complicating	O
hypertrophic	O
cardiomyopathy	O
.	O

The	O
47	O
-	O
year	O
-	O
old	O
female	O
patient	O
,	O
known	O
to	O
have	O
hypertrophic	O
cardiomyopathy	O
,	O
was	O
admitted	O
with	O
biventricular	O
failure	O
and	O
managed	O
aggressively	O
with	O
dobutamine	B-CHED
infusion	O
and	O
other	O
drugs	O
while	O
being	O
assessed	O
for	O
heart	O
transplantation	O
.	O

On	O
transthoracic	O
echocardiogram	O
,	O
she	O
had	O
moderate	O
left	O
ventricular	O
dysfunction	O
with	O
regional	O
variability	O
and	O
moderate	O
mitral	O
regurgitation	O
.	O

The	O
recipient	O
'	O
s	O
heart	O
showed	O
the	O
features	O
of	O
apical	O
hypertrophic	O
cardiomyopathy	O
and	O
myocarditis	O
with	O
abundant	O
eosinophils	O
.	O

Myocarditis	O
is	O
rare	O
and	O
eosinophilic	O
myocarditis	O
is	O
rarer	O
.	O

It	O
is	O
likely	O
that	O
the	O
hypersensitivity	O
(	O
eosinophilic	O
)	O
myocarditis	O
was	O
related	O
to	O
dobutamine	B-CHED
infusion	O
therapy	O
.	O

Eosinophilic	O
myocarditis	O
has	O
been	O
reported	O
with	O
an	O
incidence	O
of	O
2	O
.	O
4	O
%	O
to	O
7	O
.	O
2	O
%	O
in	O
explanted	O
hearts	O
and	O
may	O
be	O
related	O
to	O
multidrug	O
therapy	O
.	O

Time	O
trends	O
in	O
warfarin	B-CHED
-	O
associated	O
hemorrhage	O
.	O

The	O
annual	O
incidence	O
of	O
warfarin	B-CHED
-	O
related	O
bleeding	O
at	O
Brigham	O
and	O
Women	O
'	O
s	O
Hospital	O
increased	O
from	O
0	O
.	O
97	O
/	O
1	O
,	O
000	O
patient	O
admissions	O
in	O
the	O
first	O
time	O
period	O
(	O
January	O
1995	O
to	O
October	O
1998	O
)	O
to	O
1	O
.	O
19	O
/	O
1	O
,	O
000	O
patient	O
admissions	O
in	O
the	O
second	O
time	O
period	O
(	O
November	O
1998	O
to	O
August	O
2002	O
)	O
of	O
this	O
study	O
.	O

The	O
proportion	O
of	O
patients	O
with	O
major	O
and	O
intracranial	O
bleeding	O
increased	O
from	O
20	O
.	O
2	O
%	O
and	O
1	O
.	O
9	O
%	O
,	O
respectively	O
,	O
in	O
the	O
first	O
time	O
period	O
,	O
to	O
33	O
.	O
3	O
%	O
and	O
7	O
.	O
8	O
%	O
,	O
respectively	O
,	O
in	O
the	O
second	O
.	O

Yohimbine	B-CHED
treatment	O
of	O
sexual	O
side	O
effects	O
induced	O
by	O
serotonin	B-CHED
reuptake	O
blockers	O
.	O

BACKGROUND	O
:	O
Preclinical	O
and	O
clinical	O
studies	O
suggest	O
that	O
yohimbine	B-CHED
facilitates	O
sexual	O
behavior	O
and	O
may	O
be	O
helpful	O
in	O
the	O
treatment	O
of	O
male	O
impotence	O
.	O

A	O
single	O
case	O
report	O
suggests	O
that	O
yohimbine	B-CHED
may	O
be	O
used	O
to	O
treat	O
the	O
sexual	O
side	O
effects	O
of	O
clomipramine	B-CHED
.	O

This	O
study	O
evaluated	O
yohimbine	B-CHED
as	O
a	O
treatment	O
for	O
the	O
sexual	O
side	O
effects	O
caused	O
by	O
serotonin	B-CHED
reuptake	O
blockers	O
.	O

METHOD	O
:	O
Six	O
patients	O
with	O
either	O
obsessive	O
compulsive	O
disorder	O
,	O
trichotillomania	O
,	O
anxiety	O
,	O
or	O
affective	O
disorders	O
who	O
suffered	O
sexual	O
side	O
effects	O
after	O
treatment	O
with	O
serotonin	B-CHED
reuptake	O
blockers	O
were	O
given	O
yohimbine	B-CHED
on	O
a	O
p	O
.	O
r	O
.	O
n	O
.	O
basis	O
in	O
an	O
open	O
clinical	O
trial	O
.	O

Various	O
doses	O
of	O
yohimbine	B-CHED
were	O
used	O
to	O
determine	O
the	O
ideal	O
dose	O
for	O
each	O
patient	O
.	O

RESULTS	O
:	O
Five	O
of	O
the	O
six	O
patients	O
experienced	O
improved	O
sexual	O
functioning	O
after	O
taking	O
yohimbine	B-CHED
.	O

One	O
patient	O
who	O
failed	O
to	O
comply	O
with	O
yohimbine	B-CHED
treatment	O
had	O
no	O
therapeutic	O
effects	O
.	O

Side	O
effects	O
of	O
yohimbine	B-CHED
included	O
excessive	O
sweating	O
,	O
increased	O
anxiety	O
,	O
and	O
a	O
wound	O
-	O
up	O
feeling	O
in	O
some	O
patients	O
.	O

CONCLUSION	O
:	O
The	O
results	O
of	O
this	O
study	O
indicate	O
that	O
yohimbine	B-CHED
may	O
be	O
an	O
effective	O
treatment	O
for	O
the	O
sexual	O
side	O
effects	O
caused	O
by	O
serotonin	B-CHED
reuptake	O
blockers	O
.	O

Future	O
controlled	O
studies	O
are	O
needed	O
to	O
further	O
investigate	O
the	O
effectiveness	O
and	O
safety	O
of	O
yohimbine	B-CHED
for	O
this	O
indication	O
.	O

Hemorrhagic	O
cystitis	O
complicating	O
bone	O
marrow	O
transplantation	O
.	O

Hemorrhagic	O
cystitis	O
is	O
a	O
potentially	O
serious	O
complication	O
of	O
high	O
-	O
dose	O
cyclophosphamide	B-CHED
therapy	O
administered	O
before	O
bone	O
marrow	O
transplantation	O
.	O

As	O
standard	O
practice	O
at	O
our	O
institution	O
,	O
patients	O
who	O
are	O
scheduled	O
to	O
receive	O
a	O
bone	O
marrow	O
transplant	O
are	O
treated	O
prophylactically	O
with	O
forced	O
hydration	O
and	O
bladder	O
irrigation	O
.	O

In	O
an	O
attempt	O
to	O
obviate	O
the	O
inconvenience	O
of	O
bladder	O
irrigation	O
,	O
we	O
conducted	O
a	O
feasibility	O
trial	O
of	O
uroprophylaxis	O
with	O
mesna	B-CHED
,	O
which	O
neutralizes	O
the	O
hepatic	O
metabolite	O
of	O
cyclophosphamide	B-CHED
that	O
causes	O
hemorrhagic	O
cystitis	O
.	O

Of	O
97	O
patients	O
who	O
received	O
standard	O
prophylaxis	O
,	O
4	O
had	O
symptomatic	O
hemorrhagic	O
cystitis	O
.	O

In	O
contrast	O
,	O
two	O
of	O
four	O
consecutive	O
patients	O
who	O
received	O
mesna	B-CHED
uroprophylaxis	O
before	O
allogeneic	O
bone	O
marrow	O
transplantation	O
had	O
severe	O
hemorrhagic	O
cystitis	O
for	O
at	O
least	O
2	O
weeks	O
.	O

Because	O
of	O
this	O
suboptimal	O
result	O
,	O
we	O
resumed	O
the	O
use	O
of	O
bladder	O
irrigation	O
and	O
forced	O
hydration	O
to	O
minimize	O
the	O
risk	O
of	O
hemorrhagic	O
cystitis	O
.	O

Consensus	O
statement	O
concerning	O
cardiotoxicity	O
occurring	O
during	O
haematopoietic	O
stem	O
cell	O
transplantation	O
in	O
the	O
treatment	O
of	O
autoimmune	O
diseases	O
,	O
with	O
special	O
reference	O
to	O
systemic	O
sclerosis	O
and	O
multiple	O
sclerosis	O
.	O

Autologous	O
haematopoietic	O
stem	O
cell	O
transplantation	O
is	O
now	O
a	O
feasible	O
and	O
effective	O
treatment	O
for	O
selected	O
patients	O
with	O
severe	O
autoimmune	O
diseases	O
.	O

Worldwide	O
,	O
over	O
650	O
patients	O
have	O
been	O
transplanted	O
in	O
the	O
context	O
of	O
phase	O
I	O
and	O
II	O
clinical	O
trials	O
.	O

The	O
results	O
are	O
encouraging	O
enough	O
to	O
begin	O
randomised	O
phase	O
III	O
trials	O
.	O

However	O
,	O
as	O
predicted	O
,	O
significant	O
transplant	O
-	O
related	O
morbidity	O
and	O
mortality	O
have	O
been	O
observed	O
.	O

This	O
is	O
primarily	O
due	O
to	O
complications	O
related	O
to	O
either	O
the	O
stage	O
of	O
the	O
disease	O
at	O
transplant	O
or	O
due	O
to	O
infections	O
.	O

The	O
number	O
of	O
deaths	O
related	O
to	O
cardiac	O
toxicity	O
is	O
low	O
.	O

However	O
,	O
caution	O
is	O
required	O
when	O
cyclophosphamide	B-CHED
or	O
anthracyclines	B-CHED
such	O
as	O
mitoxantrone	B-CHED
are	O
used	O
in	O
patients	O
with	O
a	O
possible	O
underlying	O
heart	O
damage	O
,	O
for	O
example	O
,	O
systemic	O
sclerosis	O
patients	O
.	O

In	O
November	O
2002	O
,	O
a	O
meeting	O
was	O
held	O
in	O
Florence	O
,	O
bringing	O
together	O
a	O
number	O
of	O
experts	O
in	O
various	O
fields	O
,	O
including	O
rheumatology	O
,	O
cardiology	O
,	O
neurology	O
,	O
pharmacology	O
and	O
transplantation	O
medicine	O
.	O

The	O
object	O
of	O
the	O
meeting	O
was	O
to	O
analyse	O
existing	O
data	O
,	O
both	O
published	O
or	O
available	O
,	O
in	O
the	O
European	O
Group	O
for	O
Blood	O
and	O
Marrow	O
Transplantation	O
autoimmune	O
disease	O
database	O
,	O
and	O
to	O
propose	O
a	O
safe	O
approach	O
to	O
such	O
patients	O
.	O

A	O
full	O
cardiological	O
assessment	O
before	O
and	O
during	O
the	O
transplant	O
emerged	O
as	O
the	O
major	O
recommendation	O
.	O

Does	O
supplemental	O
vitamin	B-CHED
C	I-CHED
increase	O
cardiovascular	O
disease	O
risk	O
in	O
women	O
with	O
diabetes	O
?	O

BACKGROUND	O
:	O
Vitamin	B-CHED
C	I-CHED
acts	O
as	O
a	O
potent	O
antioxidant	O
;	O
however	O
,	O
it	O
can	O
also	O
be	O
a	O
prooxidant	O
and	O
glycate	O
protein	O
under	O
certain	O
circumstances	O
in	O
vitro	O
.	O

These	O
observations	O
led	O
us	O
to	O
hypothesize	O
that	O
a	O
high	O
intake	O
of	O
vitamin	B-CHED
C	I-CHED
in	O
diabetic	O
persons	O
might	O
promote	O
atherosclerosis	O
.	O

OBJECTIVE	O
:	O
The	O
objective	O
was	O
to	O
examine	O
the	O
relation	O
between	O
vitamin	B-CHED
C	I-CHED
intake	O
and	O
mortality	O
from	O
cardiovascular	O
disease	O
.	O

DESIGN	O
:	O
We	O
studied	O
the	O
relation	O
between	O
vitamin	B-CHED
C	I-CHED
intake	O
and	O
mortality	O
from	O
total	O
cardiovascular	O
disease	O
(	O
n	O
=	O
281	O
)	O
,	O
coronary	O
artery	O
disease	O
(	O
n	O
=	O
175	O
)	O
,	O
and	O
stroke	O
(	O
n	O
=	O
57	O
)	O
in	O
1923	O
postmenopausal	O
women	O
who	O
reported	O
being	O
diabetic	O
at	O
baseline	O
.	O

Diet	O
was	O
assessed	O
with	O
a	O
food	O
-	O
frequency	O
questionnaire	O
at	O
baseline	O
,	O
and	O
subjects	O
initially	O
free	O
of	O
coronary	O
artery	O
disease	O
were	O
prospectively	O
followed	O
for	O
15	O
y	O
.	O

RESULTS	O
:	O
After	O
adjustment	O
for	O
cardiovascular	O
disease	O
risk	O
factors	O
,	O
type	O
of	O
diabetes	O
medication	O
used	O
,	O
duration	O
of	O
diabetes	O
,	O
and	O
intakes	O
of	O
folate	B-CHED
,	O
vitamin	B-CHED
E	I-CHED
,	O
and	O
beta	B-CHED
-	I-CHED
carotene	I-CHED
,	O
the	O
adjusted	O
relative	O
risks	O
of	O
total	O
cardiovascular	O
disease	O
mortality	O
were	O
1	O
.	O
0	O
,	O
0	O
.	O
97	O
,	O
1	O
.	O
11	O
,	O
1	O
.	O
47	O
,	O
and	O
1	O
.	O
84	O
(	O
P	O
for	O
trend	O
<	O
0	O
.	O
01	O
)	O
across	O
quintiles	O
of	O
total	O
vitamin	B-CHED
C	I-CHED
intake	O
from	O
food	O
and	O
supplements	O
.	O

Adjusted	O
relative	O
risks	O
of	O
coronary	O
artery	O
disease	O
were	O
1	O
.	O
0	O
,	O
0	O
.	O
81	O
,	O
0	O
.	O
99	O
,	O
1	O
.	O
26	O
,	O
and	O
1	O
.	O
91	O
(	O
P	O
for	O
trend	O
=	O
0	O
.	O
01	O
)	O
and	O
of	O
stroke	O
were	O
1	O
.	O
0	O
,	O
0	O
.	O
52	O
,	O
1	O
.	O
23	O
,	O
2	O
.	O
22	O
,	O
and	O
2	O
.	O
57	O
(	O
P	O
for	O
trend	O
<	O
0	O
.	O
01	O
)	O
.	O

When	O
dietary	O
and	O
supplemental	O
vitamin	B-CHED
C	I-CHED
were	O
analyzed	O
separately	O
,	O
only	O
supplemental	O
vitamin	B-CHED
C	I-CHED
showed	O
a	O
positive	O
association	O
with	O
mortality	O
endpoints	O
.	O

Vitamin	B-CHED
C	I-CHED
intake	O
was	O
unrelated	O
to	O
mortality	O
from	O
cardiovascular	O
disease	O
in	O
the	O
nondiabetic	O
subjects	O
at	O
baseline	O
.	O

CONCLUSION	O
:	O
A	O
high	O
vitamin	B-CHED
C	I-CHED
intake	O
from	O
supplements	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
cardiovascular	O
disease	O
mortality	O
in	O
postmenopausal	O
women	O
with	O
diabetes	O
.	O

Optical	O
coherence	O
tomography	O
can	O
measure	O
axonal	O
loss	O
in	O
patients	O
with	O
ethambutol	B-CHED
-	O
induced	O
optic	O
neuropathy	O
.	O

PURPOSE	O
:	O
To	O
map	O
and	O
identify	O
the	O
pattern	O
,	O
in	O
vivo	O
,	O
of	O
axonal	O
degeneration	O
in	O
ethambutol	B-CHED
-	O
induced	O
optic	O
neuropathy	O
using	O
optical	O
coherence	O
tomography	O
(	O
OCT	O
)	O
.	O

Ethambutol	B-CHED
is	O
an	O
antimycobacterial	O
agent	O
often	O
used	O
to	O
treat	O
tuberculosis	O
.	O

A	O
serious	O
complication	O
of	O
ethambutol	B-CHED
is	O
an	O
optic	O
neuropathy	O
that	O
impairs	O
visual	O
acuity	O
,	O
contrast	O
sensitivity	O
,	O
and	O
color	O
vision	O
.	O

However	O
,	O
early	O
on	O
,	O
when	O
the	O
toxic	O
optic	O
neuropathy	O
is	O
mild	O
and	O
partly	O
reversible	O
,	O
the	O
funduscopic	O
findings	O
are	O
often	O
subtle	O
and	O
easy	O
to	O
miss	O
.	O

METHODS	O
:	O
Three	O
subjects	O
with	O
a	O
history	O
of	O
ethambutol	B-CHED
(	O
EMB	B-CHED
)	O
-	O
induced	O
optic	O
neuropathy	O
of	O
short	O
-	O
,	O
intermediate	O
-	O
,	O
and	O
long	O
-	O
term	O
visual	O
deficits	O
were	O
administered	O
a	O
full	O
neuro	O
-	O
ophthalmologic	O
examination	O
including	O
visual	O
acuity	O
,	O
color	O
vision	O
,	O
contrast	O
sensitivity	O
,	O
and	O
fundus	O
examination	O
.	O

In	O
addition	O
,	O
OCT	O
(	O
OCT	O
3000	O
,	O
Humphrey	O
-	O
Zeiss	O
,	O
Dublin	O
,	O
CA	O
)	O
was	O
performed	O
on	O
both	O
eyes	O
of	O
each	O
subject	O
using	O
the	O
retinal	O
nerve	O
fiber	O
layer	O
(	O
RNFL	O
)	O
analysis	O
protocol	O
.	O

OCT	O
interpolates	O
data	O
from	O
100	O
points	O
around	O
the	O
optic	O
nerve	O
to	O
effectively	O
map	O
out	O
the	O
RNFL	O
.	O

RESULTS	O
:	O
The	O
results	O
were	O
compared	O
to	O
the	O
calculated	O
average	O
RNFL	O
of	O
normal	O
eyes	O
accumulated	O
from	O
four	O
prior	O
studies	O
using	O
OCT	O
,	O
n	O
=	O
661	O
.	O

In	O
all	O
subjects	O
with	O
history	O
of	O
EMB	B-CHED
-	O
induced	O
optic	O
neuropathy	O
,	O
there	O
was	O
a	O
mean	O
loss	O
of	O
72	O
%	O
nerve	O
fiber	O
layer	O
thickness	O
in	O
the	O
temporal	O
quadrant	O
(	O
patient	O
A	O
,	O
with	O
eventual	O
recovery	O
of	O
visual	O
acuity	O
and	O
fields	O
,	O
58	O
%	O
loss	O
;	O
patient	O
B	O
,	O
with	O
intermediate	O
visual	O
deficits	O
,	O
68	O
%	O
loss	O
;	O
patient	O
C	O
,	O
with	O
chronic	O
visual	O
deficits	O
,	O
90	O
%	O
loss	O
)	O
,	O
with	O
an	O
average	O
mean	O
optic	O
nerve	O
thickness	O
of	O
26	O
+	O
/	O
-	O
16	O
microm	O
.	O

There	O
was	O
a	O
combined	O
mean	O
loss	O
of	O
46	O
%	O
of	O
fibers	O
from	O
the	O
superior	O
,	O
inferior	O
,	O
and	O
nasal	O
quadrants	O
in	O
the	O
(	O
six	O
)	O
eyes	O
of	O
all	O
three	O
subjects	O
(	O
mean	O
average	O
thickness	O
of	O
55	O
+	O
/	O
-	O
29	O
microm	O
)	O
.	O

In	O
both	O
sets	O
(	O
four	O
)	O
of	O
eyes	O
of	O
the	O
subjects	O
with	O
persistent	O
visual	O
deficits	O
(	O
patients	O
B	O
and	O
C	O
)	O
,	O
there	O
was	O
an	O
average	O
loss	O
of	O
79	O
%	O
of	O
nerve	O
fiber	O
thickness	O
in	O
the	O
temporal	O
quadrant	O
.	O

CONCLUSIONS	O
:	O
The	O
OCT	O
results	O
in	O
these	O
patients	O
with	O
EMB	B-CHED
-	O
induced	O
optic	O
neuropathy	O
show	O
considerable	O
loss	O
especially	O
of	O
the	O
temporal	O
fibers	O
.	O

This	O
is	O
consistent	O
with	O
prior	O
histopathological	O
studies	O
that	O
show	O
predominant	O
loss	O
of	O
parvo	O
-	O
cellular	O
axons	O
(	O
or	O
small	O
-	O
caliber	O
axons	O
)	O
within	O
the	O
papillo	O
-	O
macular	O
bundle	O
in	O
toxic	O
or	O
hereditary	O
optic	O
neuropathies	O
.	O

OCT	O
can	O
be	O
a	O
valuable	O
tool	O
in	O
the	O
quantitative	O
analysis	O
of	O
optic	O
neuropathies	O
.	O

Additionally	O
,	O
in	O
terms	O
of	O
management	O
of	O
EMB	B-CHED
-	O
induced	O
optic	O
neuropathy	O
,	O
it	O
is	O
important	O
to	O
properly	O
manage	O
ethambutol	B-CHED
dosing	O
in	O
patients	O
with	O
renal	O
impairment	O
and	O
to	O
achieve	O
proper	O
transition	O
to	O
a	O
maintenance	O
dose	O
once	O
an	O
appropriate	O
loading	O
dose	O
has	O
been	O
reached	O
.	O

Hypoxia	O
in	O
renal	O
disease	O
with	O
proteinuria	O
and	O
/	O
or	O
glomerular	O
hypertension	O
.	O

Despite	O
the	O
increasing	O
need	O
to	O
identify	O
and	O
quantify	O
tissue	O
oxygenation	O
at	O
the	O
cellular	O
level	O
,	O
relatively	O
few	O
methods	O
have	O
been	O
available	O
.	O

In	O
this	O
study	O
,	O
we	O
developed	O
a	O
new	O
hypoxia	O
-	O
responsive	O
reporter	O
vector	O
using	O
a	O
hypoxia	O
-	O
responsive	O
element	O
of	O
the	O
5	O
'	O
vascular	O
endothelial	O
growth	O
factor	O
untranslated	O
region	O
and	O
generated	O
a	O
novel	O
hypoxia	O
-	O
sensing	O
transgenic	O
rat	O
.	O

We	O
then	O
applied	O
this	O
animal	O
model	O
to	O
the	O
detection	O
of	O
tubulointerstitial	O
hypoxia	O
in	O
the	O
diseased	O
kidney	O
.	O

With	O
this	O
model	O
,	O
we	O
were	O
able	O
to	O
identify	O
diffuse	O
cortical	O
hypoxia	O
in	O
the	O
puromycin	B-CHED
aminonucleoside	I-CHED
-	O
induced	O
nephrotic	O
syndrome	O
and	O
focal	O
and	O
segmental	O
hypoxia	O
in	O
the	O
remnant	O
kidney	O
model	O
.	O

Expression	O
of	O
the	O
hypoxia	O
-	O
responsive	O
transgene	O
increased	O
throughout	O
the	O
observation	O
period	O
,	O
reaching	O
2	O
.	O
2	O
-	O
fold	O
at	O
2	O
weeks	O
in	O
the	O
puromycin	B-CHED
aminonucleoside	I-CHED
model	O
and	O
2	O
.	O
6	O
-	O
fold	O
at	O
4	O
weeks	O
in	O
the	O
remnant	O
kidney	O
model	O
,	O
whereas	O
that	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
showed	O
a	O
mild	O
decrease	O
,	O
reflecting	O
distinct	O
behaviors	O
of	O
the	O
two	O
genes	O
.	O

The	O
degree	O
of	O
hypoxia	O
showed	O
a	O
positive	O
correlation	O
with	O
microscopic	O
tubulointerstitial	O
injury	O
in	O
both	O
models	O
.	O

Finally	O
,	O
we	O
identified	O
the	O
localization	O
of	O
proliferating	O
cell	O
nuclear	O
antigen	O
-	O
positive	O
,	O
ED	O
-	O
1	O
-	O
positive	O
,	O
and	O
terminal	O
dUTP	O
nick	O
-	O
end	O
labeled	O
-	O
positive	O
cells	O
in	O
the	O
hypoxic	O
cortical	O
area	O
in	O
the	O
remnant	O
kidney	O
model	O
.	O

We	O
propose	O
here	O
a	O
possible	O
pathological	O
tie	O
between	O
chronic	O
tubulointerstitial	O
hypoxia	O
and	O
progressive	O
glomerular	O
diseases	O
.	O

Adequate	O
timing	O
of	O
ribavirin	B-CHED
reduction	O
in	O
patients	O
with	O
hemolysis	O
during	O
combination	O
therapy	O
of	O
interferon	B-CHED
and	O
ribavirin	B-CHED
for	O
chronic	O
hepatitis	O
C	O
.	O

BACKGROUND	O
:	O
Hemolytic	O
anemia	O
is	O
one	O
of	O
the	O
major	O
adverse	O
events	O
of	O
the	O
combination	O
therapy	O
of	O
interferon	B-CHED
and	O
ribavirin	B-CHED
.	O

Because	O
of	O
ribavirin	B-CHED
-	O
related	O
hemolytic	O
anemia	O
,	O
dose	O
reduction	O
is	O
a	O
common	O
event	O
in	O
this	O
therapy	O
.	O

In	O
this	O
clinical	O
retrospective	O
cohort	O
study	O
we	O
have	O
examined	O
the	O
suitable	O
timing	O
of	O
ribavirin	B-CHED
reduction	O
in	O
patients	O
with	O
hemolysis	O
during	O
combination	O
therapy	O
.	O

METHODS	O
:	O
Thirty	O
-	O
seven	O
of	O
160	O
patients	O
who	O
had	O
HCV	O
-	O
genotype	O
1b	O
,	O
had	O
high	O
virus	O
load	O
,	O
and	O
received	O
24	O
-	O
week	O
combination	O
therapy	O
developed	O
anemia	O
with	O
hemoglobin	O
level	O
<	O
10	O
g	O
/	O
dl	O
or	O
anemia	O
-	O
related	O
signs	O
during	O
therapy	O
.	O

After	O
that	O
,	O
these	O
37	O
patients	O
were	O
reduced	O
one	O
tablet	O
of	O
ribavirin	B-CHED
(	O
200	O
mg	O
)	O
per	O
day	O
.	O

After	O
reduction	O
of	O
ribavirin	B-CHED
,	O
27	O
of	O
37	O
patients	O
could	O
continue	O
combination	O
therapy	O
for	O
a	O
total	O
of	O
24	O
weeks	O
(	O
group	O
A	O
)	O
.	O

However	O
,	O
10	O
of	O
37	O
patients	O
with	O
reduction	O
of	O
ribavirin	B-CHED
could	O
not	O
continue	O
combination	O
therapy	O
because	O
their	O
<	O
8	O
.	O
5	O
g	O
/	O
dl	O
hemoglobin	O
values	O
decreased	O
to	O
or	O
anemia	O
-	O
related	O
severe	O
side	O
effects	O
occurred	O
(	O
group	O
B	O
)	O
.	O

We	O
assessed	O
the	O
final	O
efficacy	O
and	O
safety	O
after	O
reduction	O
of	O
ribavirin	B-CHED
in	O
groups	O
A	O
and	O
B	O
.	O

RESULTS	O
:	O
A	O
sustained	O
virological	O
response	O
(	O
SVR	O
)	O
was	O
29	O
.	O
6	O
%	O
(	O
8	O
/	O
27	O
)	O
in	O
group	O
A	O
and	O
10	O
%	O
(	O
1	O
/	O
10	O
)	O
in	O
group	O
B	O
,	O
respectively	O
.	O

A	O
34	O
.	O
4	O
%	O
(	O
12	O
/	O
27	O
)	O
of	O
SVR	O
+	O
biological	O
response	O
in	O
group	O
A	O
was	O
higher	O
than	O
10	O
%	O
(	O
1	O
/	O
10	O
)	O
in	O
group	O
B	O
(	O
P	O
=	O
0	O
.	O
051	O
)	O
,	O
with	O
slight	O
significance	O
.	O

With	O
respect	O
to	O
hemoglobin	O
level	O
at	O
the	O
time	O
of	O
ribavirin	B-CHED
reduction	O
,	O
a	O
rate	O
of	O
continuation	O
of	O
therapy	O
in	O
patients	O
with	O
>	O
or	O
=	O
10	O
g	O
/	O
dl	O
hemoglobin	O
was	O
higher	O
than	O
that	O
in	O
patients	O
with	O
<	O
10	O
g	O
/	O
dl	O
(	O
P	O
=	O
0	O
.	O
036	O
)	O
.	O

CONCLUSIONS	O
:	O
Reduction	O
of	O
ribavirin	B-CHED
at	O
hemoglobin	O
level	O
>	O
or	O
=	O
10	O
g	O
/	O
dl	O
is	O
suitable	O
in	O
terms	O
of	O
efficacy	O
and	O
side	O
effects	O
.	O

Aging	O
process	O
of	O
epithelial	O
cells	O
of	O
the	O
rat	O
prostate	O
lateral	O
lobe	O
in	O
experimental	O
hyperprolactinemia	O
induced	O
by	O
haloperidol	B-CHED
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
examine	O
the	O
influence	O
of	O
hyperprolactinemia	O
,	O
induced	O
by	O
haloperidol	B-CHED
(	O
HAL	B-CHED
)	O
on	O
age	O
related	O
morphology	O
and	O
function	O
changes	O
of	O
epithelial	O
cells	O
in	O
rat	O
prostate	O
lateral	O
lobe	O
.	O

The	O
study	O
was	O
performed	O
on	O
sexually	O
mature	O
male	O
rats	O
.	O

Serum	O
concentrations	O
of	O
prolactin	O
(	O
PRL	B-CHED
)	O
and	O
testosterone	B-CHED
(	O
T	B-CHED
)	O
were	O
measured	O
.	O

Tissue	O
sections	O
were	O
evaluated	O
with	O
light	O
and	O
electron	O
microscopy	O
.	O

Immunohistochemical	O
reactions	O
for	O
Anti	O
-	O
Proliferating	O
Cell	O
Nuclear	O
Antigen	O
(	O
PCNA	O
)	O
were	O
performed	O
.	O

In	O
rats	O
of	O
the	O
experimental	O
group	O
,	O
the	O
mean	O
concentration	O
of	O
:	O
PRL	B-CHED
was	O
more	O
than	O
twice	O
higher	O
,	O
whereas	O
T	B-CHED
concentration	O
was	O
almost	O
twice	O
lower	O
than	O
that	O
in	O
the	O
control	O
group	O
.	O

Light	O
microscopy	O
visualized	O
the	O
following	O
:	O
hypertrophy	O
and	O
epithelium	O
hyperplasia	O
of	O
the	O
glandular	O
ducts	O
,	O
associated	O
with	O
increased	O
PCNA	O
expression	O
.	O

Electron	O
microscopy	O
revealed	O
changes	O
in	O
columnar	O
epithelial	O
cells	O
,	O
concerning	O
organelles	O
,	O
engaged	O
in	O
protein	O
synthesis	O
and	O
secretion	O
.	O

Relation	O
of	O
perfusion	O
defects	O
observed	O
with	O
myocardial	O
contrast	O
echocardiography	O
to	O
the	O
severity	O
of	O
coronary	O
stenosis	O
:	O
correlation	O
with	O
thallium	B-CHED
-	O
201	O
single	O
-	O
photon	O
emission	O
tomography	O
.	O

It	O
has	O
been	O
previously	O
shown	O
that	O
myocardial	O
contrast	O
echocardiography	O
is	O
a	O
valuable	O
technique	O
for	O
delineating	O
regions	O
of	O
myocardial	O
underperfusion	O
secondary	O
to	O
coronary	O
occlusion	O
and	O
to	O
critical	O
coronary	O
stenoses	O
in	O
the	O
presence	O
of	O
hyperemic	O
stimulation	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
myocardial	O
contrast	O
echocardiography	O
performed	O
with	O
a	O
stable	O
solution	O
of	O
sonicated	O
albumin	O
could	O
detect	O
regions	O
of	O
myocardial	O
underperfusion	O
resulting	O
from	O
various	O
degrees	O
of	O
coronary	O
stenosis	O
.	O

The	O
perfusion	O
defect	O
produced	O
in	O
16	O
open	O
chest	O
dogs	O
was	O
compared	O
with	O
the	O
anatomic	O
area	O
at	O
risk	O
measured	O
by	O
the	O
postmortem	O
dual	O
-	O
perfusion	O
technique	O
and	O
with	O
thallium	B-CHED
-	O
201	O
single	O
-	O
photon	O
emission	O
tomography	O
(	O
SPECT	O
)	O
.	O

During	O
a	O
transient	O
(	O
20	O
-	O
s	O
)	O
coronary	O
occlusion	O
,	O
a	O
perfusion	O
defect	O
was	O
observed	O
with	O
contrast	O
echocardiography	O
in	O
14	O
of	O
the	O
15	O
dogs	O
in	O
which	O
the	O
occlusion	O
was	O
produced	O
.	O

The	O
perfusion	O
defect	O
correlated	O
significantly	O
with	O
the	O
anatomic	O
area	O
at	O
risk	O
(	O
r	O
=	O
0	O
.	O
74	O
;	O
p	O
less	O
than	O
0	O
.	O
002	O
)	O
.	O

During	O
dipyridamole	B-CHED
-	O
induced	O
hyperemia	O
,	O
12	O
of	O
the	O
16	O
dogs	O
with	O
a	O
partial	O
coronary	O
stenosis	O
had	O
a	O
visible	O
area	O
of	O
hypoperfusion	O
by	O
contrast	O
echocardiography	O
.	O

The	O
four	O
dogs	O
without	O
a	O
perfusion	O
defect	O
had	O
a	O
stenosis	O
that	O
resulted	O
in	O
a	O
mild	O
(	O
0	O
%	O
to	O
50	O
%	O
)	O
reduction	O
in	O
dipyridamole	B-CHED
-	O
induced	O
hyperemia	O
.	O

The	O
size	O
of	O
the	O
perfusion	O
defect	O
during	O
stenosis	O
correlated	O
significantly	O
with	O
the	O
anatomic	O
area	O
at	O
risk	O
(	O
r	O
=	O
0	O
.	O
61	O
;	O
p	O
=	O
0	O
.	O
02	O
)	O
.	O

Thallium	B-CHED
-	O
201	O
SPECT	O
demonstrated	O
a	O
perfusion	O
defect	O
in	O
all	O
14	O
dogs	O
analyzed	O
during	O
dipyridamole	B-CHED
-	O
induced	O
hyperemia	O
;	O
the	O
size	O
of	O
the	O
perfusion	O
defect	O
correlated	O
with	O
the	O
anatomic	O
area	O
at	O
risk	O
(	O
r	O
=	O
0	O
.	O
58	O
;	O
p	O
less	O
than	O
0	O
.	O
03	O
)	O
and	O
with	O
the	O
perfusion	O
defect	O
by	O
contrast	O
echocardiography	O
(	O
r	O
=	O
0	O
.	O
58	O
;	O
p	O
less	O
than	O
0	O
.	O
03	O
)	O
.	O

Thus	O
,	O
myocardial	O
contrast	O
echocardiography	O
can	O
be	O
used	O
to	O
visualize	O
and	O
quantitate	O
the	O
amount	O
of	O
jeopardized	O
myocardium	O
during	O
moderate	O
to	O
severe	O
degrees	O
of	O
coronary	O
stenosis	O
.	O

The	O
results	O
obtained	O
show	O
a	O
correlation	O
with	O
the	O
anatomic	O
area	O
at	O
risk	O
similar	O
to	O
that	O
obtained	O
with	O
thallium	B-CHED
-	O
201	O
SPECT	O
.	O

The	O
activation	O
of	O
spinal	O
N	B-CHED
-	I-CHED
methyl	I-CHED
-	I-CHED
D	I-CHED
-	I-CHED
aspartate	I-CHED
receptors	O
may	O
contribute	O
to	O
degeneration	O
of	O
spinal	O
motor	O
neurons	O
induced	O
by	O
neuraxial	O
morphine	B-CHED
after	O
a	O
noninjurious	O
interval	O
of	O
spinal	O
cord	O
ischemia	O
.	O

We	O
investigated	O
the	O
relationship	O
between	O
the	O
degeneration	O
of	O
spinal	O
motor	O
neurons	O
and	O
activation	O
of	O
N	B-CHED
-	I-CHED
methyl	I-CHED
-	I-CHED
d	I-CHED
-	I-CHED
aspartate	I-CHED
(	O
NMDA	B-CHED
)	O
receptors	O
after	O
neuraxial	O
morphine	B-CHED
following	O
a	O
noninjurious	O
interval	O
of	O
aortic	O
occlusion	O
in	O
rats	O
.	O

Spinal	O
cord	O
ischemia	O
was	O
induced	O
by	O
aortic	O
occlusion	O
for	O
6	O
min	O
with	O
a	O
balloon	O
catheter	O
.	O

In	O
a	O
microdialysis	O
study	O
,	O
10	O
muL	O
of	O
saline	O
(	O
group	O
C	O
;	O
n	O
=	O
8	O
)	O
or	O
30	O
mug	O
of	O
morphine	B-CHED
(	O
group	O
M	O
;	O
n	O
=	O
8	O
)	O
was	O
injected	O
intrathecally	O
(	O
IT	O
)	O
0	O
.	O
5	O
h	O
after	O
reflow	O
,	O
and	O
30	O
mug	O
of	O
morphine	B-CHED
(	O
group	O
SM	O
;	O
n	O
=	O
8	O
)	O
or	O
10	O
muL	O
of	O
saline	O
(	O
group	O
SC	O
;	O
n	O
=	O
8	O
)	O
was	O
injected	O
IT	O
0	O
.	O
5	O
h	O
after	O
sham	O
operation	O
.	O

Microdialysis	O
samples	O
were	O
collected	O
preischemia	O
,	O
before	O
IT	O
injection	O
,	O
and	O
at	O
2	O
,	O
4	O
,	O
8	O
,	O
24	O
,	O
and	O
48	O
h	O
of	O
reperfusion	O
(	O
after	O
IT	O
injection	O
)	O
.	O

Second	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
IT	O
MK	B-CHED
-	I-CHED
801	I-CHED
(	O
30	O
mug	O
)	O
on	O
the	O
histopathologic	O
changes	O
in	O
the	O
spinal	O
cord	O
after	O
morphine	B-CHED
-	O
induced	O
spastic	O
paraparesis	O
.	O

After	O
IT	O
morphine	B-CHED
,	O
the	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
glutamate	B-CHED
concentration	O
was	O
increased	O
in	O
group	O
M	O
relative	O
to	O
both	O
baseline	O
and	O
group	O
C	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

This	O
increase	O
persisted	O
for	O
8	O
hrs	O
.	O

IT	O
MK	B-CHED
-	I-CHED
801	I-CHED
significantly	O
reduced	O
the	O
number	O
of	O
dark	O
-	O
stained	O
alpha	O
-	O
motoneurons	O
after	O
morphine	B-CHED
-	O
induced	O
spastic	O
paraparesis	O
compared	O
with	O
the	O
saline	O
group	O
.	O

These	O
data	O
indicate	O
that	O
IT	O
morphine	B-CHED
induces	O
spastic	O
paraparesis	O
with	O
a	O
concomitant	O
increase	O
in	O
CSF	O
glutamate	B-CHED
,	O
which	O
is	O
involved	O
in	O
NMDA	B-CHED
receptor	O
activation	O
.	O

We	O
suggest	O
that	O
opioids	O
may	O
be	O
neurotoxic	O
in	O
the	O
setting	O
of	O
spinal	O
cord	O
ischemia	O
via	O
NMDA	B-CHED
receptor	O
activation	O
.	O

Acute	O
low	O
back	O
pain	O
during	O
intravenous	O
administration	O
of	O
amiodarone	B-CHED
:	O
a	O
report	O
of	O
two	O
cases	O
.	O

Amiodarone	B-CHED
represents	O
an	O
effective	O
antiarrhythmic	O
drug	O
for	O
cardioversion	O
of	O
recent	O
-	O
onset	O
atrial	O
fibrillation	O
(	O
AF	O
)	O
and	O
maintenance	O
of	O
sinus	O
rhythm	O
.	O

We	O
briefly	O
describe	O
two	O
patients	O
suffering	O
from	O
recent	O
-	O
onset	O
atrial	O
fibrillation	O
,	O
who	O
experienced	O
an	O
acute	O
devastating	O
low	O
back	O
pain	O
a	O
few	O
minutes	O
after	O
initiation	O
of	O
intravenous	O
amiodarone	B-CHED
loading	O
.	O

Notably	O
,	O
this	O
side	O
effect	O
has	O
not	O
been	O
ever	O
reported	O
in	O
the	O
medical	O
literature	O
.	O

Clinicians	O
should	O
be	O
aware	O
of	O
this	O
reaction	O
since	O
prompt	O
termination	O
of	O
parenteral	O
administration	O
leads	O
to	O
complete	O
resolution	O
.	O

Quantitative	O
drug	O
levels	O
in	O
stimulant	O
psychosis	O
:	O
relationship	O
to	O
symptom	O
severity	O
,	O
catecholamines	B-CHED
and	O
hyperkinesia	O
.	O

To	O
examine	O
the	O
relationship	O
between	O
quantitative	O
stimulant	O
drug	O
levels	O
,	O
catecholamines	B-CHED
,	O
and	O
psychotic	O
symptoms	O
,	O
nineteen	O
patients	O
in	O
a	O
psychiatric	O
emergency	O
service	O
with	O
a	O
diagnosis	O
of	O
amphetamine	B-CHED
-	O
or	O
cocaine	B-CHED
-	O
induced	O
psychosis	O
were	O
interviewed	O
,	O
and	O
plasma	O
and	O
urine	O
were	O
collected	O
for	O
quantitative	O
assays	O
of	O
stimulant	O
drug	O
and	O
catecholamine	B-CHED
metabolite	O
levels	O
.	O

Methamphetamine	B-CHED
or	O
amphetamine	B-CHED
levels	O
were	O
related	O
to	O
several	O
psychopathology	O
scores	O
and	O
the	O
global	O
hyperkinesia	O
rating	O
.	O

HVA	O
levels	O
were	O
related	O
to	O
global	O
hyperkinesia	O
but	O
not	O
to	O
psychopathology	O
ratings	O
.	O

Although	O
many	O
other	O
factors	O
such	O
as	O
sensitization	O
may	O
play	O
a	O
role	O
,	O
intensity	O
of	O
stimulant	O
-	O
induced	O
psychotic	O
symptoms	O
and	O
stereotypies	O
appears	O
to	O
be	O
at	O
least	O
in	O
part	O
dose	O
-	O
related	O
.	O

Pheochromocytoma	O
unmasked	O
by	O
amisulpride	B-CHED
and	O
tiapride	B-CHED
.	O

OBJECTIVE	O
:	O
To	O
describe	O
the	O
unmasking	O
of	O
pheochromocytoma	O
in	O
a	O
patient	O
treated	O
with	O
amisulpride	B-CHED
and	O
tiapride	B-CHED
.	O

CASE	O
SUMMARY	O
:	O
A	O
42	O
-	O
year	O
-	O
old	O
white	O
man	O
developed	O
acute	O
hypertension	O
with	O
severe	O
headache	O
and	O
vomiting	O
2	O
hours	O
after	O
the	O
first	O
doses	O
of	O
amisulpride	B-CHED
100	O
mg	O
and	O
tiapride	B-CHED
100	O
mg	O
.	O

Both	O
drugs	O
were	O
immediately	O
discontinued	O
,	O
and	O
the	O
patient	O
recovered	O
after	O
subsequent	O
nicardipine	B-CHED
and	O
verapamil	B-CHED
treatment	O
.	O

Abdominal	O
ultrasound	O
showed	O
an	O
adrenal	O
mass	O
,	O
and	O
postoperative	O
histologic	O
examination	O
confirmed	O
the	O
diagnosis	O
of	O
pheochromocytoma	O
.	O

DISCUSSION	O
:	O
Drug	O
-	O
induced	O
symptoms	O
of	O
pheochromocytoma	O
are	O
often	O
associated	O
with	O
the	O
use	O
of	O
substituted	O
benzamide	B-CHED
drugs	O
,	O
but	O
the	O
underlying	O
mechanism	O
is	O
unknown	O
.	O

In	O
our	O
case	O
,	O
use	O
of	O
the	O
Naranjo	O
probability	O
scale	O
indicated	O
a	O
possible	O
relationship	O
between	O
the	O
hypertensive	O
crisis	O
and	O
amisulpride	B-CHED
and	O
tiapride	B-CHED
therapy	O
.	O

CONCLUSIONS	O
:	O
As	O
of	O
March	O
24	O
,	O
2005	O
,	O
this	O
is	O
the	O
first	O
reported	O
case	O
of	O
amisulpride	B-CHED
-	O
and	O
tiapride	B-CHED
-	O
induced	O
hypertensive	O
crisis	O
in	O
a	O
patient	O
with	O
pheochromocytoma	O
.	O

Physicians	O
and	O
other	O
healthcare	O
professionals	O
should	O
be	O
aware	O
of	O
this	O
potential	O
adverse	O
effect	O
of	O
tiapride	B-CHED
and	O
amisulpride	B-CHED
.	O

Minor	O
neurological	O
dysfunction	O
,	O
cognitive	O
development	O
,	O
and	O
somatic	O
development	O
at	O
the	O
age	O
of	O
3	O
to	O
7	O
years	O
after	O
dexamethasone	B-CHED
treatment	O
in	O
very	O
-	O
low	O
birth	O
-	O
weight	O
infants	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
assess	O
minor	O
neurological	O
dysfunction	O
,	O
cognitive	O
development	O
,	O
and	O
somatic	O
development	O
after	O
dexamethasone	B-CHED
therapy	O
in	O
very	O
-	O
low	O
-	O
birthweight	O
infants	O
.	O

Thirty	O
-	O
three	O
children	O
after	O
dexamethasone	B-CHED
treatment	O
were	O
matched	O
to	O
33	O
children	O
without	O
dexamethasone	B-CHED
treatment	O
.	O

Data	O
were	O
assessed	O
at	O
the	O
age	O
of	O
3	O
-	O
7	O
years	O
.	O

Dexamethasone	B-CHED
was	O
started	O
between	O
the	O
7th	O
and	O
the	O
28th	O
day	O
of	O
life	O
over	O
7	O
days	O
with	O
a	O
total	O
dose	O
of	O
2	O
.	O
35	O
mg	O
/	O
kg	O
/	O
day	O
.	O

Exclusion	O
criteria	O
were	O
asphyxia	O
,	O
malformations	O
,	O
major	O
surgical	O
interventions	O
,	O
small	O
for	O
gestational	O
age	O
,	O
intraventricular	O
haemorrhage	O
grades	O
III	O
and	O
IV	O
,	O
periventricular	O
leukomalacia	O
,	O
and	O
severe	O
psychomotor	O
retardation	O
.	O

Each	O
child	O
was	O
examined	O
by	O
a	O
neuropediatrician	O
for	O
minor	O
neurological	O
dysfunctions	O
and	O
tested	O
by	O
a	O
psychologist	O
for	O
cognitive	O
development	O
with	O
a	O
Kaufman	O
Assessment	O
Battery	O
for	O
Children	O
and	O
a	O
Draw	O
-	O
a	O
-	O
Man	O
Test	O
.	O

There	O
were	O
no	O
differences	O
in	O
demographic	O
data	O
,	O
growth	O
,	O
and	O
socio	O
-	O
economic	O
status	O
between	O
the	O
two	O
groups	O
.	O

Fine	O
motor	O
skills	O
and	O
gross	O
motor	O
function	O
were	O
significantly	O
better	O
in	O
the	O
control	O
group	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

In	O
the	O
Draw	O
-	O
a	O
-	O
Man	O
Test	O
,	O
the	O
control	O
group	O
showed	O
better	O
results	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

There	O
were	O
no	O
differences	O
in	O
development	O
of	O
speech	O
,	O
social	O
development	O
,	O
and	O
the	O
Kaufman	O
Assessment	O
Battery	O
for	O
Children	O
.	O

After	O
dexamethasone	B-CHED
treatment	O
,	O
children	O
showed	O
a	O
higher	O
rate	O
of	O
minor	O
neurological	O
dysfunctions	O
.	O

Neurological	O
development	O
was	O
affected	O
even	O
without	O
neurological	O
diagnosis	O
.	O

Further	O
long	O
-	O
term	O
follow	O
-	O
up	O
studies	O
will	O
be	O
necessary	O
to	O
fully	O
evaluate	O
the	O
impact	O
of	O
dexamethasone	B-CHED
on	O
neurological	O
and	O
cognitive	O
development	O
.	O

Valproic	B-CHED
acid	I-CHED
I	O
:	O
time	O
course	O
of	O
lipid	O
peroxidation	O
biomarkers	O
,	O
liver	O
toxicity	O
,	O
and	O
valproic	B-CHED
acid	I-CHED
metabolite	O
levels	O
in	O
rats	O
.	O

A	O
single	O
dose	O
of	O
valproic	B-CHED
acid	I-CHED
(	O
VPA	B-CHED
)	O
,	O
which	O
is	O
a	O
widely	O
used	O
antiepileptic	O
drug	O
,	O
is	O
associated	O
with	O
oxidative	O
stress	O
in	O
rats	O
,	O
as	O
recently	O
demonstrated	O
by	O
elevated	O
levels	O
of	O
15	B-CHED
-	I-CHED
F	I-CHED
(	I-CHED
2t	I-CHED
)	I-CHED
-	I-CHED
isoprostane	I-CHED
(	O
15	B-CHED
-	I-CHED
F	I-CHED
(	I-CHED
2t	I-CHED
)	I-CHED
-	I-CHED
IsoP	I-CHED
)	O
.	O

To	O
determine	O
whether	O
there	O
was	O
a	O
temporal	O
relationship	O
between	O
VPA	B-CHED
-	O
associated	O
oxidative	O
stress	O
and	O
hepatotoxicity	O
,	O
adult	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
were	O
treated	O
ip	O
with	O
VPA	B-CHED
(	O
500	O
mg	O
/	O
kg	O
)	O
or	O
0	O
.	O
9	O
%	O
saline	O
(	O
vehicle	O
)	O
once	O
daily	O
for	O
2	O
,	O
4	O
,	O
7	O
,	O
10	O
,	O
or	O
14	O
days	O
.	O

Oxidative	O
stress	O
was	O
assessed	O
by	O
determining	O
plasma	O
and	O
liver	O
levels	O
of	O
15	B-CHED
-	I-CHED
F	I-CHED
(	I-CHED
2t	I-CHED
)	I-CHED
-	I-CHED
IsoP	I-CHED
,	O
lipid	B-CHED
hydroperoxides	I-CHED
(	O
LPO	B-CHED
)	O
,	O
and	O
thiobarbituric	B-CHED
acid	I-CHED
reactive	I-CHED
substances	I-CHED
(	O
TBARs	B-CHED
)	O
.	O

Plasma	O
and	O
liver	O
15	B-CHED
-	I-CHED
F	I-CHED
(	I-CHED
2t	I-CHED
)	I-CHED
-	I-CHED
IsoP	I-CHED
were	O
elevated	O
and	O
reached	O
a	O
plateau	O
after	O
day	O
2	O
of	O
VPA	B-CHED
treatment	O
compared	O
to	O
control	O
.	O

Liver	O
LPO	B-CHED
levels	O
were	O
not	O
elevated	O
until	O
day	O
7	O
of	O
treatment	O
(	O
1	O
.	O
8	O
-	O
fold	O
versus	O
control	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Liver	O
and	O
plasma	O
TBARs	B-CHED
were	O
not	O
increased	O
until	O
14	O
days	O
(	O
2	O
-	O
fold	O
vs	O
.	O
control	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Liver	O
toxicity	O
was	O
evaluated	O
based	O
on	O
serum	O
levels	O
of	O
alpha	O
-	O
glutathione	B-CHED
S	O
-	O
transferase	O
(	O
alpha	O
-	O
GST	O
)	O
and	O
by	O
histology	O
.	O

Serum	O
alpha	O
-	O
GST	O
levels	O
were	O
significantly	O
elevated	O
by	O
day	O
4	O
,	O
which	O
corresponded	O
to	O
hepatotoxicity	O
as	O
shown	O
by	O
the	O
increasing	O
incidence	O
of	O
inflammation	O
of	O
the	O
liver	O
capsule	O
,	O
necrosis	O
,	O
and	O
steatosis	O
throughout	O
the	O
study	O
.	O

The	O
liver	O
levels	O
of	O
beta	O
-	O
oxidation	O
metabolites	O
of	O
VPA	B-CHED
were	O
decreased	O
by	O
day	O
14	O
,	O
while	O
the	O
levels	O
of	O
4	B-CHED
-	I-CHED
ene	I-CHED
-	I-CHED
VPA	I-CHED
and	O
(	O
E	O
)	O
-	O
2	B-CHED
,	I-CHED
4	I-CHED
-	I-CHED
diene	I-CHED
-	I-CHED
VPA	I-CHED
were	O
not	O
elevated	O
throughout	O
the	O
study	O
.	O

Overall	O
,	O
these	O
findings	O
indicate	O
that	O
VPA	B-CHED
treatment	O
results	O
in	O
oxidative	O
stress	O
,	O
as	O
measured	O
by	O
levels	O
of	O
15	B-CHED
-	I-CHED
F	I-CHED
(	I-CHED
2t	I-CHED
)	I-CHED
-	I-CHED
IsoP	I-CHED
,	O
which	O
precedes	O
the	O
onset	O
of	O
necrosis	O
,	O
steatosis	O
,	O
and	O
elevated	O
levels	O
of	O
serum	O
alpha	O
-	O
GST	O
.	O

Assessment	O
of	O
perinatal	O
hepatitis	O
B	O
and	O
rubella	O
prevention	O
in	O
New	O
Hampshire	O
delivery	O
hospitals	O
.	O

OBJECTIVE	O
:	O
To	O
evaluate	O
current	O
performance	O
on	O
recommended	O
perinatal	O
hepatitis	O
B	O
and	O
rubella	O
prevention	O
practices	O
in	O
New	O
Hampshire	O
.	O

METHODS	O
:	O
Data	O
were	O
extracted	O
from	O
2021	O
paired	O
mother	O
-	O
infant	O
records	O
for	O
the	O
year	O
2000	O
birth	O
cohort	O
in	O
New	O
Hampshire	O
'	O
s	O
25	O
delivery	O
hospitals	O
.	O

Assessment	O
was	O
done	O
on	O
the	O
following	O
:	O
prenatal	O
screening	O
for	O
hepatitis	O
B	O
and	O
rubella	O
,	O
administration	O
of	O
the	O
hepatitis	O
B	O
vaccine	O
birth	O
dose	O
to	O
all	O
infants	O
,	O
administration	O
of	O
hepatitis	O
B	O
immune	O
globulin	O
to	O
infants	O
who	O
were	O
born	O
to	O
hepatitis	B-CHED
B	I-CHED
surface	I-CHED
antigen	I-CHED
-	O
positive	O
mothers	O
,	O
rubella	O
immunity	O
,	O
and	O
administration	O
of	O
in	O
-	O
hospital	O
postpartum	O
rubella	O
vaccine	O
to	O
rubella	O
nonimmune	O
women	O
.	O

RESULTS	O
:	O
Prenatal	O
screening	O
rates	O
for	O
hepatitis	O
B	O
(	O
98	O
.	O
8	O
%	O
)	O
and	O
rubella	O
(	O
99	O
.	O
4	O
%	O
)	O
were	O
high	O
.	O

Hepatitis	O
B	O
vaccine	O
birth	O
dose	O
was	O
administered	O
to	O
76	O
.	O
2	O
%	O
of	O
all	O
infants	O
.	O

All	O
infants	O
who	O
were	O
born	O
to	O
hepatitis	B-CHED
B	I-CHED
surface	I-CHED
antigen	I-CHED
-	O
positive	O
mothers	O
also	O
received	O
hepatitis	O
B	O
immune	O
globulin	O
.	O

Multivariate	O
logistic	O
regression	O
showed	O
that	O
the	O
month	O
of	O
delivery	O
and	O
infant	O
birth	O
weight	O
were	O
independent	O
predictors	O
of	O
hepatitis	O
B	O
vaccination	O
.	O

The	O
proportion	O
of	O
infants	O
who	O
were	O
vaccinated	O
in	O
January	O
and	O
February	O
2000	O
(	O
48	O
.	O
5	O
%	O
and	O
67	O
.	O
5	O
%	O
,	O
respectively	O
)	O
was	O
less	O
than	O
any	O
other	O
months	O
,	O
whereas	O
the	O
proportion	O
who	O
were	O
vaccinated	O
in	O
December	O
2000	O
(	O
88	O
.	O
2	O
%	O
)	O
was	O
the	O
highest	O
.	O

Women	O
who	O
were	O
born	O
between	O
1971	O
and	O
1975	O
had	O
the	O
highest	O
rate	O
of	O
rubella	O
nonimmunity	O
(	O
9	O
.	O
5	O
%	O
)	O
.	O

In	O
-	O
hospital	O
postpartum	O
rubella	O
vaccine	O
administration	O
was	O
documented	O
for	O
75	O
.	O
6	O
%	O
of	O
nonimmune	O
women	O
.	O

CONCLUSION	O
:	O
This	O
study	O
documents	O
good	O
compliance	O
in	O
New	O
Hampshire	O
'	O
s	O
birthing	O
hospitals	O
with	O
national	O
guidelines	O
for	O
perinatal	O
hepatitis	O
B	O
and	O
rubella	O
prevention	O
and	O
highlights	O
potential	O
areas	O
for	O
improvement	O
.	O

Succinylcholine	B-CHED
-	O
induced	O
masseter	O
muscle	O
rigidity	O
during	O
bronchoscopic	O
removal	O
of	O
a	O
tracheal	O
foreign	O
body	O
.	O

Masseter	O
muscle	O
rigidity	O
during	O
general	O
anesthesia	O
is	O
considered	O
an	O
early	O
warning	O
sign	O
of	O
a	O
possible	O
episode	O
of	O
malignant	O
hyperthermia	O
.	O

The	O
decision	O
whether	O
to	O
continue	O
or	O
discontinue	O
the	O
procedure	O
depends	O
on	O
the	O
urgency	O
of	O
the	O
surgery	O
and	O
severity	O
of	O
masseter	O
muscle	O
rigidity	O
.	O

Here	O
,	O
we	O
describe	O
a	O
case	O
of	O
severe	O
masseter	O
muscle	O
rigidity	O
(	O
jaw	O
of	O
steel	O
)	O
after	O
succinylcholine	B-CHED
(	O
Sch	B-CHED
)	O
administration	O
during	O
general	O
anesthetic	O
management	O
for	O
rigid	O
bronchoscopic	O
removal	O
of	O
a	O
tracheal	O
foreign	O
body	O
.	O

Anesthesia	O
was	O
continued	O
uneventfully	O
with	O
propofol	B-CHED
infusion	O
while	O
all	O
facilities	O
were	O
available	O
to	O
detect	O
and	O
treat	O
malignant	O
hyperthermia	O
.	O

Dexrazoxane	B-CHED
protects	O
against	O
myelosuppression	O
from	O
the	O
DNA	O
cleavage	O
-	O
enhancing	O
drugs	O
etoposide	B-CHED
and	O
daunorubicin	B-CHED
but	O
not	O
doxorubicin	B-CHED
.	O

PURPOSE	O
:	O
The	O
anthracyclines	B-CHED
daunorubicin	B-CHED
and	O
doxorubicin	B-CHED
and	O
the	O
epipodophyllotoxin	B-CHED
etoposide	B-CHED
are	O
potent	O
DNA	O
cleavage	O
-	O
enhancing	O
drugs	O
that	O
are	O
widely	O
used	O
in	O
clinical	O
oncology	O
;	O
however	O
,	O
myelosuppression	O
and	O
cardiac	O
toxicity	O
limit	O
their	O
use	O
.	O

Dexrazoxane	B-CHED
(	O
ICRF	B-CHED
-	I-CHED
187	I-CHED
)	O
is	O
recommended	O
for	O
protection	O
against	O
anthracycline	B-CHED
-	O
induced	O
cardiotoxicity	O
.	O

EXPERIMENTAL	O
DESIGN	O
:	O
Because	O
of	O
their	O
widespread	O
use	O
,	O
the	O
hematologic	O
toxicity	O
following	O
coadministration	O
of	O
dexrazoxane	B-CHED
and	O
these	O
three	O
structurally	O
different	O
DNA	O
cleavage	O
enhancers	O
was	O
investigated	O
:	O
Sensitivity	O
of	O
human	O
and	O
murine	O
blood	O
progenitor	O
cells	O
to	O
etoposide	B-CHED
,	O
daunorubicin	B-CHED
,	O
and	O
doxorubicin	B-CHED
+	O
/	O
-	O
dexrazoxane	B-CHED
was	O
determined	O
in	O
granulocyte	O
-	O
macrophage	O
colony	O
forming	O
assays	O
.	O

Likewise	O
,	O
in	O
vivo	O
,	O
B6D2F1	O
mice	O
were	O
treated	O
with	O
etoposide	B-CHED
,	O
daunorubicin	B-CHED
,	O
and	O
doxorubicin	B-CHED
,	O
with	O
or	O
without	O
dexrazoxane	B-CHED
over	O
a	O
wide	O
range	O
of	O
doses	O
:	O
posttreatment	O
,	O
a	O
full	O
hematologic	O
evaluation	O
was	O
done	O
.	O

RESULTS	O
:	O
Nontoxic	O
doses	O
of	O
dexrazoxane	B-CHED
reduced	O
myelosuppression	O
and	O
weight	O
loss	O
from	O
daunorubicin	B-CHED
and	O
etoposide	B-CHED
in	O
mice	O
and	O
antagonized	O
their	O
antiproliferative	O
effects	O
in	O
the	O
colony	O
assay	O
;	O
however	O
,	O
dexrazoxane	B-CHED
neither	O
reduced	O
myelosuppression	O
,	O
weight	O
loss	O
,	O
nor	O
the	O
in	O
vitro	O
cytotoxicity	O
from	O
doxorubicin	B-CHED
.	O

CONCLUSION	O
:	O
Although	O
our	O
findings	O
support	O
the	O
observation	O
that	O
dexrazoxane	B-CHED
reduces	O
neither	O
hematologic	O
activity	O
nor	O
antitumor	O
activity	O
from	O
doxorubicin	B-CHED
clinically	O
,	O
the	O
potent	O
antagonism	O
of	O
daunorubicin	B-CHED
activity	O
raises	O
concern	O
;	O
a	O
possible	O
interference	O
with	O
anticancer	O
efficacy	O
certainly	O
would	O
call	O
for	O
renewed	O
attention	O
.	O

Our	O
data	O
also	O
suggest	O
that	O
significant	O
etoposide	B-CHED
dose	O
escalation	O
is	O
perhaps	O
possible	O
by	O
the	O
use	O
of	O
dexrazoxane	B-CHED
.	O

Clinical	O
trials	O
in	O
patients	O
with	O
brain	O
metastases	O
combining	O
dexrazoxane	B-CHED
and	O
high	O
doses	O
of	O
etoposide	B-CHED
is	O
ongoing	O
with	O
the	O
aim	O
of	O
improving	O
efficacy	O
without	O
aggravating	O
hematologic	O
toxicity	O
.	O

If	O
successful	O
,	O
this	O
represents	O
an	O
exciting	O
mechanism	O
for	O
pharmacologic	O
regulation	O
of	O
side	O
effects	O
from	O
cytotoxic	O
chemotherapy	O
.	O

Assessment	O
of	O
the	O
onset	O
and	O
persistence	O
of	O
amnesia	O
during	O
procedural	O
sedation	O
with	O
propofol	B-CHED
.	O

OBJECTIVES	O
:	O
To	O
assess	O
patients	O
'	O
ability	O
to	O
repeat	O
and	O
recall	O
words	O
presented	O
to	O
them	O
while	O
undergoing	O
procedural	O
sedation	O
with	O
propofol	B-CHED
,	O
and	O
correlate	O
their	O
recall	O
with	O
their	O
level	O
of	O
awareness	O
as	O
measured	O
by	O
bispectral	O
index	O
(	O
BIS	O
)	O
monitoring	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
prospective	O
,	O
single	O
-	O
intervention	O
study	O
of	O
consenting	O
adult	O
patients	O
undergoing	O
procedural	O
sedation	O
with	O
propofol	B-CHED
between	O
December	O
28	O
,	O
2002	O
,	O
and	O
October	O
31	O
,	O
2003	O
.	O

BIS	O
monitoring	O
was	O
initiated	O
starting	O
3	O
minutes	O
before	O
the	O
procedure	O
and	O
continuing	O
until	O
the	O
patient	O
had	O
regained	O
baseline	O
mental	O
status	O
.	O

At	O
1	O
-	O
minute	O
intervals	O
during	O
the	O
procedural	O
sedation	O
,	O
until	O
the	O
patient	O
regained	O
baseline	O
mental	O
status	O
at	O
the	O
end	O
of	O
the	O
procedure	O
,	O
a	O
word	O
from	O
a	O
standardized	O
list	O
was	O
read	O
aloud	O
,	O
and	O
the	O
patient	O
was	O
asked	O
to	O
immediately	O
repeat	O
the	O
word	O
to	O
the	O
investigator	O
.	O

The	O
BIS	O
score	O
at	O
the	O
time	O
the	O
word	O
was	O
read	O
and	O
the	O
patient	O
'	O
s	O
ability	O
to	O
repeat	O
the	O
word	O
were	O
recorded	O
.	O

After	O
the	O
procedure	O
,	O
the	O
patient	O
was	O
asked	O
to	O
state	O
all	O
of	O
the	O
words	O
from	O
the	O
list	O
that	O
he	O
or	O
she	O
could	O
recall	O
,	O
and	O
to	O
identify	O
the	O
last	O
word	O
recalled	O
from	O
prior	O
to	O
the	O
start	O
of	O
the	O
procedure	O
and	O
the	O
first	O
word	O
recalled	O
from	O
after	O
the	O
procedure	O
was	O
completed	O
.	O

RESULTS	O
:	O
Seventy	O
-	O
five	O
consenting	O
patients	O
were	O
enrolled	O
;	O
one	O
patient	O
was	O
excluded	O
from	O
data	O
analysis	O
for	O
a	O
protocol	O
violation	O
.	O

No	O
serious	O
adverse	O
events	O
were	O
noted	O
during	O
the	O
procedural	O
sedations	O
.	O

The	O
mean	O
(	O
+	O
/	O
-	O
standard	O
deviation	O
)	O
time	O
of	O
data	O
collection	O
was	O
16	O
.	O
4	O
minutes	O
(	O
+	O
/	O
-	O
7	O
.	O
1	O
;	O
range	O
5	O
to	O
34	O
minutes	O
)	O
.	O

The	O
mean	O
initial	O
(	O
preprocedure	O
)	O
BIS	O
score	O
was	O
97	O
.	O
1	O
(	O
+	O
/	O
-	O
2	O
.	O
3	O
;	O
range	O
92	O
to	O
99	O
)	O
.	O

The	O
mean	O
lowest	O
BIS	O
score	O
occurring	O
during	O
these	O
procedural	O
sedations	O
was	O
66	O
.	O
9	O
(	O
+	O
/	O
-	O
14	O
.	O
4	O
;	O
range	O
33	O
to	O
91	O
)	O
.	O

The	O
mean	O
lowest	O
BIS	O
score	O
corresponding	O
to	O
the	O
ability	O
of	O
the	O
patient	O
to	O
immediately	O
repeat	O
words	O
read	O
from	O
the	O
list	O
was	O
77	O
.	O
1	O
(	O
95	O
%	O
CI	O
=	O
74	O
.	O
3	O
to	O
80	O
.	O
0	O
)	O
.	O

The	O
mean	O
highest	O
BIS	O
score	O
corresponding	O
to	O
the	O
inability	O
to	O
repeat	O
words	O
was	O
81	O
.	O
5	O
(	O
95	O
%	O
CI	O
=	O
78	O
.	O
1	O
to	O
84	O
.	O
8	O
)	O
.	O

The	O
mean	O
BIS	O
score	O
corresponding	O
to	O
the	O
last	O
word	O
recalled	O
from	O
prior	O
to	O
the	O
initiation	O
of	O
the	O
sedation	O
was	O
96	O
.	O
7	O
(	O
+	O
/	O
-	O
2	O
.	O
4	O
;	O
range	O
84	O
to	O
98	O
)	O
.	O

The	O
mean	O
BIS	O
score	O
corresponding	O
to	O
the	O
first	O
word	O
recalled	O
after	O
the	O
procedure	O
was	O
completed	O
was	O
91	O
.	O
2	O
(	O
95	O
%	O
CI	O
=	O
88	O
.	O
1	O
to	O
94	O
.	O
3	O
)	O
.	O

All	O
patients	O
recalled	O
at	O
least	O
one	O
word	O
that	O
had	O
been	O
read	O
to	O
them	O
during	O
the	O
protocol	O
.	O

The	O
mean	O
lowest	O
BIS	O
score	O
for	O
any	O
recalled	O
word	O
was	O
91	O
.	O
5	O
(	O
+	O
/	O
-	O
11	O
.	O
1	O
;	O
range	O
79	O
to	O
98	O
)	O
,	O
and	O
no	O
words	O
were	O
recalled	O
when	O
the	O
corresponding	O
BIS	O
score	O
was	O
less	O
than	O
90	O
.	O

CONCLUSIONS	O
:	O
There	O
is	O
a	O
range	O
of	O
BIS	O
scores	O
during	O
which	O
sedated	O
patients	O
are	O
able	O
to	O
repeat	O
words	O
read	O
to	O
them	O
but	O
are	O
not	O
able	O
to	O
subsequently	O
recall	O
these	O
words	O
.	O

Furthermore	O
,	O
patients	O
had	O
no	O
recall	O
of	O
words	O
repeated	O
prior	O
to	O
procedural	O
sedation	O
in	O
BIS	O
ranges	O
associated	O
with	O
recall	O
after	O
procedural	O
sedation	O
,	O
suggestive	O
of	O
retrograde	O
amnesia	O
.	O

Amiodarone	B-CHED
pulmonary	O
toxicity	O
.	O

Amiodarone	B-CHED
is	O
an	O
effective	O
antiarrhythmic	O
agent	O
whose	O
utility	O
is	O
limited	O
by	O
many	O
side	O
-	O
effects	O
,	O
the	O
most	O
problematic	O
being	O
pneumonitis	O
.	O

The	O
pulmonary	O
toxicity	O
of	O
amiodarone	B-CHED
is	O
thought	O
to	O
result	O
from	O
direct	O
injury	O
related	O
to	O
the	O
intracellular	O
accumulation	O
of	O
phospholipid	O
and	O
T	O
cell	O
-	O
mediated	O
hypersensitivity	O
pneumonitis	O
.	O

The	O
clinical	O
and	O
radiographic	O
features	O
of	O
amiodarone	B-CHED
-	O
induced	O
pulmonary	O
toxicity	O
are	O
characteristic	O
but	O
nonspecific	O
.	O

The	O
diagnosis	O
depends	O
on	O
exclusion	O
of	O
other	O
entities	O
,	O
such	O
as	O
heart	O
failure	O
,	O
infection	O
,	O
and	O
malignancy	O
.	O

While	O
withdrawal	O
of	O
amiodarone	B-CHED
leads	O
to	O
clinical	O
improvement	O
in	O
majority	O
of	O
cases	O
,	O
this	O
is	O
not	O
always	O
possible	O
or	O
advisable	O
.	O

Dose	O
reduction	O
or	O
concomitant	O
steroid	B-CHED
therapy	O
may	O
have	O
a	O
role	O
in	O
selected	O
patients	O
.	O

Two	O
prodrugs	O
of	O
potent	O
and	O
selective	O
GluR5	O
kainate	B-CHED
receptor	O
antagonists	O
actives	O
in	O
three	O
animal	O
models	O
of	O
pain	O
.	O

Amino	O
acids	O
5	O
and	O
7	O
,	O
two	O
potent	O
and	O
selective	O
competitive	O
GluR5	O
KA	B-CHED
receptor	O
antagonists	O
,	O
exhibited	O
high	O
GluR5	O
receptor	O
affinity	O
over	O
other	O
glutamate	B-CHED
receptors	O
.	O

Their	O
ester	O
prodrugs	O
6	O
and	O
8	O
were	O
orally	O
active	O
in	O
three	O
models	O
of	O
pain	O
:	O
reversal	O
of	O
formalin	B-CHED
-	O
induced	O
paw	O
licking	O
,	O
carrageenan	B-CHED
-	O
induced	O
thermal	O
hyperalgesia	O
,	O
and	O
capsaicin	B-CHED
-	O
induced	O
mechanical	O
hyperalgesia	O
.	O

Possible	O
azithromycin	B-CHED
-	O
associated	O
hiccups	O
.	O

OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
persistent	O
hiccups	O
associated	O
by	O
azithromycin	B-CHED
therapy	O
.	O

CASE	O
SUMMARY	O
:	O
A	O
76	O
-	O
year	O
-	O
old	O
man	O
presented	O
with	O
persistent	O
hiccups	O
after	O
beginning	O
azithromycin	B-CHED
for	O
the	O
treatment	O
of	O
pharyngitis	O
.	O

Hiccups	O
were	O
persistent	O
and	O
exhausting	O
.	O

Discontinuation	O
of	O
azithromycin	B-CHED
and	O
therapy	O
with	O
baclofen	B-CHED
finally	O
resolved	O
hiccups	O
.	O

No	O
organic	O
cause	O
of	O
hiccups	O
was	O
identified	O
despite	O
extensive	O
investigation	O
.	O

DISCUSSION	O
:	O
Pharmacotherapeutic	O
agents	O
have	O
been	O
uncommonly	O
associated	O
with	O
hiccups	O
.	O

Corticosteroids	O
(	O
dexamethasone	B-CHED
and	O
methylprednisolone	B-CHED
)	O
,	O
benzodiazepines	B-CHED
(	O
midazolam	B-CHED
)	O
and	O
general	O
anaesthesia	O
have	O
been	O
the	O
specific	O
agents	O
mentioned	O
most	O
frequently	O
in	O
the	O
literature	O
as	O
being	O
associated	O
with	O
the	O
development	O
of	O
hiccups	O
.	O

Few	O
cases	O
of	O
drug	O
-	O
induced	O
hiccups	O
have	O
been	O
reported	O
related	O
to	O
macrolide	B-CHED
antimicrobials	O
.	O

Using	O
the	O
Naranjo	O
adverse	O
effect	O
reaction	O
probability	O
scale	O
this	O
event	O
could	O
be	O
classified	O
as	O
possible	O
(	O
score	O
5	O
points	O
)	O
,	O
mostly	O
because	O
of	O
the	O
close	O
temporal	O
sequence	O
,	O
previous	O
reports	O
on	O
this	O
reaction	O
with	O
other	O
macrolides	B-CHED
and	O
the	O
absence	O
of	O
any	O
alternative	O
explanation	O
for	O
hiccups	O
.	O

Our	O
hypothesis	O
is	O
that	O
a	O
vagal	O
mechanism	O
mediated	O
by	O
azithromycin	B-CHED
could	O
be	O
the	O
pathogenesis	O
of	O
hiccups	O
in	O
our	O
patient	O
.	O

CONCLUSIONS	O
:	O
Diagnosis	O
of	O
drug	O
-	O
induced	O
hiccups	O
is	O
difficult	O
and	O
often	O
achieved	O
only	O
by	O
a	O
process	O
of	O
elimination	O
.	O

However	O
,	O
macrolide	B-CHED
antimicrobials	O
have	O
been	O
reported	O
to	O
be	O
associated	O
with	O
hiccups	O
and	O
vagal	O
mechanism	O
could	O
explain	O
the	O
development	O
of	O
this	O
side	O
-	O
effect	O
.	O

Calcium	B-CHED
carbonate	I-CHED
toxicity	O
:	O
the	O
updated	O
milk	O
-	O
alkali	O
syndrome	O
;	O
report	O
of	O
3	O
cases	O
and	O
review	O
of	O
the	O
literature	O
.	O

OBJECTIVE	O
:	O
To	O
describe	O
3	O
patients	O
with	O
calcium	B-CHED
carbonate	I-CHED
-	O
induced	O
hypercalcemia	O
and	O
gain	O
insights	O
into	O
the	O
cause	O
and	O
management	O
of	O
the	O
milk	O
-	O
alkali	O
syndrome	O
.	O

METHODS	O
:	O
We	O
report	O
the	O
clinical	O
and	O
laboratory	O
data	O
in	O
3	O
patients	O
who	O
presented	O
with	O
severe	O
hypercalcemia	O
(	O
corrected	O
serum	O
calcium	B-CHED
>	O
or	O
=	O
14	O
mg	O
/	O
dL	O
)	O
and	O
review	O
the	O
pertinent	O
literature	O
on	O
milk	O
-	O
alkali	O
syndrome	O
.	O

RESULTS	O
:	O
The	O
3	O
patients	O
had	O
acute	O
renal	O
insufficiency	O
,	O
relative	O
metabolic	O
alkalosis	O
,	O
and	O
low	O
parathyroid	O
hormone	O
(	O
PTH	O
)	O
,	O
PTH	O
-	O
related	O
peptide	O
,	O
and	O
1	B-CHED
,	I-CHED
25	I-CHED
-	I-CHED
dihydroxyvitamin	I-CHED
D	I-CHED
concentrations	O
.	O

No	O
malignant	O
lesion	O
was	O
found	O
.	O

Treatment	O
included	O
aggressive	O
hydration	O
and	O
varied	O
amounts	O
of	O
furosemide	B-CHED
.	O

The	O
2	O
patients	O
with	O
the	O
higher	O
serum	O
calcium	B-CHED
concentrations	O
received	O
pamidronate	B-CHED
intravenously	O
(	O
60	O
and	O
30	O
mg	O
,	O
respectively	O
)	O
,	O
which	O
caused	O
severe	O
hypocalcemia	O
.	O

Of	O
the	O
3	O
patients	O
,	O
2	O
were	O
ingesting	O
acceptable	O
doses	O
of	O
elemental	O
calcium	B-CHED
(	O
1	O
g	O
and	O
2	O
g	O
daily	O
,	O
respectively	O
)	O
in	O
the	O
form	O
of	O
calcium	B-CHED
carbonate	I-CHED
.	O

In	O
addition	O
to	O
our	O
highlighted	O
cases	O
,	O
we	O
review	O
the	O
history	O
,	O
classification	O
,	O
pathophysiologic	O
features	O
,	O
and	O
treatment	O
of	O
milk	O
-	O
alkali	O
syndrome	O
and	O
summarize	O
the	O
cases	O
reported	O
from	O
early	O
1995	O
to	O
November	O
2003	O
.	O

CONCLUSION	O
:	O
Milk	O
-	O
alkali	O
syndrome	O
may	O
be	O
a	O
common	O
cause	O
of	O
unexplained	O
hypercalcemia	O
and	O
can	O
be	O
precipitated	O
by	O
small	O
amounts	O
of	O
orally	O
ingested	O
calcium	B-CHED
carbonate	I-CHED
in	O
susceptible	O
persons	O
.	O

Treatment	O
with	O
hydration	O
,	O
furosemide	B-CHED
,	O
and	O
discontinuation	O
of	O
the	O
calcium	B-CHED
and	O
vitamin	B-CHED
D	I-CHED
source	O
is	O
adequate	O
.	O

Pamidronate	B-CHED
treatment	O
is	O
associated	O
with	O
considerable	O
risk	O
for	O
hypocalcemia	O
,	O
even	O
in	O
cases	O
of	O
initially	O
severe	O
hypercalcemia	O
.	O

Warfarin	B-CHED
-	O
induced	O
leukocytoclastic	O
vasculitis	O
.	O

Skin	O
reactions	O
associated	O
with	O
oral	O
coumarin	B-CHED
-	O
derived	O
anticoagulants	O
are	O
an	O
uncommon	O
occurrence	O
.	O

Leukocytoclastic	O
vasculitis	O
(	O
LV	O
)	O
is	O
primarily	O
a	O
cutaneous	O
small	O
vessel	O
vasculitis	O
,	O
though	O
systemic	O
involvement	O
may	O
be	O
encountered	O
.	O

We	O
report	O
4	O
patients	O
with	O
late	O
-	O
onset	O
LV	O
probably	O
due	O
to	O
warfarin	B-CHED
.	O

All	O
4	O
patients	O
presented	O
with	O
skin	O
eruptions	O
that	O
developed	O
after	O
receiving	O
warfarin	B-CHED
for	O
several	O
years	O
.	O

The	O
results	O
of	O
skin	O
lesion	O
biopsies	O
were	O
available	O
in	O
3	O
patients	O
,	O
confirming	O
LV	O
Cutaneous	O
lesions	O
resolved	O
in	O
all	O
patients	O
after	O
warfarin	B-CHED
was	O
discontinued	O
.	O

In	O
2	O
of	O
the	O
4	O
patients	O
,	O
rechallenge	O
with	O
warfarin	B-CHED
led	O
to	O
recurrence	O
of	O
the	O
lesions	O
.	O

LV	O
may	O
be	O
a	O
late	O
-	O
onset	O
adverse	O
reaction	O
associated	O
with	O
warfarin	B-CHED
therapy	O
.	O

Cocaine	B-CHED
-	O
induced	O
brainstem	O
seizures	O
and	O
behavior	O
.	O

A	O
variety	O
of	O
abnormal	O
sensory	O
/	O
motor	O
behaviors	O
associated	O
with	O
electrical	O
discharges	O
recorded	O
from	O
the	O
bilateral	O
brainstem	O
were	O
induced	O
in	O
adult	O
WKY	O
rats	O
by	O
mechanical	O
(	O
electrode	O
implants	O
)	O
and	O
DC	O
electrical	O
current	O
stimulations	O
and	O
by	O
acute	O
and	O
chronic	O
administration	O
of	O
cocaine	B-CHED
.	O

The	O
electrode	O
implant	O
implicated	O
one	O
side	O
or	O
the	O
other	O
of	O
the	O
reticular	O
system	O
of	O
the	O
brainstem	O
but	O
subjects	O
were	O
not	O
incapacitated	O
by	O
the	O
stimulations	O
.	O

Cocaine	B-CHED
(	O
40	O
mg	O
/	O
kg	O
)	O
was	O
injected	O
subcutaneously	O
for	O
an	O
acute	O
experiment	O
and	O
subsequent	O
20	O
mg	O
/	O
kg	O
doses	O
twice	O
daily	O
for	O
3	O
days	O
in	O
a	O
chronic	O
study	O
.	O

Cocaine	B-CHED
generated	O
more	O
abnormal	O
behaviors	O
in	O
the	O
brainstem	O
perturbation	O
group	O
,	O
especially	O
the	O
electrically	O
perturbated	O
subjects	O
.	O

The	O
abnormal	O
behaviors	O
were	O
yawning	O
,	O
retrocollis	O
,	O
hyperactivity	O
,	O
hypersensitivity	O
,	O
"	O
beating	O
drum	O
"	O
behavior	O
,	O
squealing	O
,	O
head	O
bobbing	O
,	O
circling	O
,	O
sniffing	O
,	O
abnormal	O
posturing	O
,	O
and	O
facial	O
twitching	O
.	O

Shifts	O
in	O
the	O
power	O
frequency	O
spectra	O
of	O
the	O
discharge	O
patterns	O
were	O
noted	O
between	O
quiet	O
and	O
pacing	O
behavioral	O
states	O
.	O

Hypersensitivity	O
to	O
various	O
auditory	O
,	O
tactile	O
,	O
and	O
visual	O
stimulation	O
was	O
present	O
and	O
shifts	O
in	O
the	O
brainstem	O
ambient	O
power	O
spectral	O
frequency	O
occurred	O
in	O
response	O
to	O
tactile	O
stimulation	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
brainstem	O
generates	O
and	O
propagates	O
pathological	O
discharges	O
that	O
can	O
be	O
elicited	O
by	O
mechanical	O
and	O
DC	O
electrical	O
perturbation	O
.	O

Cocaine	B-CHED
was	O
found	O
to	O
activate	O
the	O
discharge	O
system	O
and	O
thus	O
induce	O
abnormal	O
behaviors	O
that	O
are	O
generated	O
at	O
the	O
discharge	O
site	O
and	O
at	O
distant	O
sites	O
to	O
which	O
the	O
discharge	O
propagates	O
.	O

Cognitive	O
functions	O
may	O
also	O
be	O
involved	O
since	O
dopaminergic	O
and	O
serotonergic	O
cellular	O
elements	O
at	O
the	O
brainstem	O
level	O
are	O
also	O
implicated	O
.	O

rTMS	O
of	O
supplementary	O
motor	O
area	O
modulates	O
therapy	O
-	O
induced	O
dyskinesias	O
in	O
Parkinson	O
disease	O
.	O

The	O
neural	O
mechanisms	O
and	O
circuitry	O
involved	O
in	O
levodopa	B-CHED
-	O
induced	O
dyskinesia	O
are	O
unclear	O
.	O

Using	O
repetitive	O
transcranial	O
magnetic	O
stimulation	O
(	O
rTMS	O
)	O
over	O
the	O
supplementary	O
motor	O
area	O
(	O
SMA	O
)	O
in	O
a	O
group	O
of	O
patients	O
with	O
advanced	O
Parkinson	O
disease	O
,	O
the	O
authors	O
investigated	O
whether	O
modulation	O
of	O
SMA	O
excitability	O
may	O
result	O
in	O
a	O
modification	O
of	O
a	O
dyskinetic	O
state	O
induced	O
by	O
continuous	O
apomorphine	B-CHED
infusion	O
.	O

rTMS	O
at	O
1	O
Hz	O
was	O
observed	O
to	O
markedly	O
reduce	O
drug	O
-	O
induced	O
dyskinesias	O
,	O
whereas	O
5	O
-	O
Hz	O
rTMS	O
induced	O
a	O
slight	O
but	O
not	O
significant	O
increase	O
.	O

Intracavitary	O
chemotherapy	O
(	O
paclitaxel	B-CHED
/	O
carboplatin	B-CHED
liquid	O
crystalline	O
cubic	O
phases	O
)	O
for	O
recurrent	O
glioblastoma	O
-	O
-	O
clinical	O
observations	O
.	O

Human	O
malignant	O
brain	O
tumors	O
have	O
a	O
poor	O
prognosis	O
in	O
spite	O
of	O
surgery	O
and	O
radiation	O
therapy	O
.	O

Cubic	O
phases	O
consist	O
of	O
curved	O
biocontinuous	O
lipid	O
bilayers	O
,	O
separating	O
two	O
congruent	O
networks	O
of	O
water	O
channels	O
.	O

Used	O
as	O
a	O
host	O
for	O
cytotoxic	O
drugs	O
,	O
the	O
gel	O
-	O
like	O
matrix	O
can	O
easily	O
be	O
applied	O
to	O
the	O
walls	O
of	O
a	O
surgical	O
resection	O
cavity	O
.	O

For	O
human	O
glioblastoma	O
recurrences	O
,	O
the	O
feasibility	O
,	O
safety	O
,	O
and	O
short	O
-	O
term	O
effects	O
of	O
a	O
surgical	O
intracavitary	O
application	O
of	O
paclitaxel	B-CHED
and	O
carboplatin	B-CHED
encapsulated	O
by	O
liquid	O
crystalline	O
cubic	O
phases	O
are	O
examined	O
in	O
a	O
pilot	O
study	O
.	O

A	O
total	O
of	O
12	O
patients	O
with	O
a	O
recurrence	O
of	O
a	O
glioblastoma	O
multiforme	O
underwent	O
re	O
-	O
resection	O
and	O
received	O
an	O
intracavitary	O
application	O
of	O
paclitaxel	B-CHED
and	O
carboplatin	B-CHED
cubic	O
phases	O
in	O
different	O
dosages	O
.	O

Six	O
of	O
the	O
patients	O
received	O
more	O
than	O
15	O
mg	O
paclitaxel	B-CHED
and	O
suffered	O
from	O
moderate	O
to	O
severe	O
brain	O
edema	O
,	O
while	O
the	O
remaining	O
patients	O
received	O
only	O
a	O
total	O
of	O
15	O
mg	O
paclitaxel	B-CHED
.	O

In	O
the	O
latter	O
group	O
,	O
brain	O
edema	O
was	O
markedly	O
reduced	O
and	O
dealt	O
medically	O
.	O

Intracavitary	O
chemotherapy	O
in	O
recurrent	O
glioblastoma	O
using	O
cubic	O
phases	O
is	O
feasible	O
and	O
safe	O
,	O
yet	O
the	O
clinical	O
benefit	O
remains	O
to	O
be	O
examined	O
in	O
a	O
clinical	O
phase	O
II	O
study	O
.	O

Lamotrigine	B-CHED
associated	O
with	O
exacerbation	O
or	O
de	O
novo	O
myoclonus	O
in	O
idiopathic	O
generalized	O
epilepsies	O
.	O

Five	O
patients	O
with	O
idiopathic	O
generalized	O
epilepsies	O
(	O
IGE	O
)	O
treated	O
with	O
lamotrigine	B-CHED
(	O
LTG	B-CHED
)	O
experienced	O
exacerbation	O
or	O
de	O
novo	O
appearance	O
of	O
myoclonic	O
jerks	O
(	O
MJ	O
)	O
.	O

In	O
three	O
patients	O
,	O
LTG	B-CHED
exacerbated	O
MJ	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
with	O
early	O
aggravation	O
during	O
titration	O
.	O

MJ	O
disappeared	O
when	O
LTG	B-CHED
dose	O
was	O
decreased	O
by	O
25	O
to	O
50	O
%	O
.	O

In	O
two	O
patients	O
,	O
LTG	B-CHED
exacerbated	O
MJ	O
in	O
a	O
delayed	O
but	O
more	O
severe	O
manner	O
,	O
with	O
myoclonic	O
status	O
that	O
only	O
ceased	O
after	O
LTG	B-CHED
withdrawal	O
.	O

Absence	O
of	O
acute	O
cerebral	O
vasoconstriction	O
after	O
cocaine	B-CHED
-	O
associated	O
subarachnoid	O
hemorrhage	O
.	O

INTRODUCTION	O
:	O
Cocaine	B-CHED
use	O
has	O
been	O
associated	O
with	O
neurovascular	O
complications	O
,	O
including	O
arterial	O
vasoconstriction	O
and	O
vasculitis	O
.	O

However	O
,	O
there	O
are	O
few	O
studies	O
of	O
angiographic	O
effects	O
of	O
cocaine	B-CHED
on	O
human	O
cerebral	O
arteries	O
.	O

Information	O
on	O
these	O
effects	O
could	O
be	O
obtained	O
from	O
angiograms	O
of	O
patients	O
with	O
cocaine	B-CHED
-	O
associated	O
subarachnoid	O
hemorrhage	O
(	O
SAH	O
)	O
who	O
underwent	O
angiography	O
shortly	O
after	O
cocaine	B-CHED
use	O
.	O

METHODS	O
:	O
We	O
screened	O
patients	O
with	O
SAH	O
retrospectively	O
and	O
identified	O
those	O
with	O
positive	O
urine	O
toxicology	O
for	O
cocaine	B-CHED
or	O
its	O
metabolites	O
.	O

Quantitative	O
arterial	O
diameter	O
measurements	O
from	O
angiograms	O
of	O
these	O
patients	O
were	O
compared	O
to	O
measurements	O
from	O
control	O
patients	O
with	O
SAH	O
who	O
were	O
matched	O
for	O
factors	O
known	O
to	O
influence	O
arterial	O
diameter	O
.	O

Qualitative	O
comparisons	O
of	O
small	O
artery	O
changes	O
also	O
were	O
made	O
.	O

RESULTS	O
:	O
Thirteen	O
patients	O
with	O
positive	O
cocaine	B-CHED
toxicology	O
were	O
compared	O
to	O
26	O
controls	O
.	O

There	O
were	O
no	O
significant	O
differences	O
between	O
groups	O
in	O
the	O
mean	O
diameters	O
of	O
the	O
intradural	O
internal	O
carotid	O
,	O
sphenoidal	O
segment	O
of	O
the	O
middle	O
cerebral	O
,	O
precommunicating	O
segment	O
of	O
the	O
anterior	O
cerebral	O
,	O
or	O
basilar	O
arteries	O
(	O
p	O
greater	O
than	O
0	O
.	O
05	O
for	O
all	O
comparisons	O
,	O
unpaired	O
t	O
-	O
tests	O
)	O
.	O

There	O
also	O
were	O
no	O
significant	O
differences	O
between	O
groups	O
when	O
expressing	O
diameters	O
as	O
the	O
sum	O
of	O
the	O
precommunicating	O
segment	O
of	O
the	O
anterior	O
cerebral	O
+	O
sphenoidal	O
segment	O
of	O
the	O
middle	O
cerebral	O
+	O
supraclinoid	O
internal	O
carotid	O
artery	O
+	O
basilar	O
artery	O
divided	O
by	O
the	O
diameter	O
of	O
the	O
petrous	O
internal	O
carotid	O
artery	O
(	O
p	O
greater	O
than	O
0	O
.	O
05	O
,	O
unpaired	O
t	O
-	O
tests	O
)	O
.	O

Qualitative	O
assessments	O
showed	O
two	O
arterial	O
irregularities	O
in	O
the	O
distal	O
vasculature	O
in	O
each	O
group	O
.	O

CONCLUSION	O
:	O
No	O
quantitative	O
evidence	O
for	O
narrowing	O
of	O
large	O
cerebral	O
arteries	O
or	O
qualitative	O
angiographic	O
evidence	O
for	O
distal	O
narrowing	O
or	O
vasculitis	O
could	O
be	O
found	O
in	O
patients	O
who	O
underwent	O
angiography	O
after	O
aneurysmal	O
SAH	O
associated	O
with	O
cocaine	B-CHED
use	O
.	O

Methamphetamine	B-CHED
causes	O
alterations	O
in	O
the	O
MAP	O
kinase	O
-	O
related	O
pathways	O
in	O
the	O
brains	O
of	O
mice	O
that	O
display	O
increased	O
aggressiveness	O
.	O

Aggressive	O
behaviors	O
have	O
been	O
reported	O
in	O
patients	O
who	O
suffer	O
from	O
some	O
psychiatric	O
disorders	O
,	O
and	O
are	O
common	O
in	O
methamphetamine	B-CHED
(	O
METH	B-CHED
)	O
abusers	O
.	O

Herein	O
,	O
we	O
report	O
that	O
multiple	O
(	O
but	O
not	O
single	O
)	O
injections	O
of	O
METH	B-CHED
significantly	O
increased	O
aggressiveness	O
in	O
male	O
CD	O
-	O
1	O
mice	O
.	O

This	O
increase	O
in	O
aggressiveness	O
was	O
not	O
secondary	O
to	O
METH	B-CHED
-	O
induced	O
hyperactivity	O
.	O

Analysis	O
of	O
protein	O
expression	O
using	O
antibody	O
microarrays	O
and	O
Western	O
blotting	O
revealed	O
differential	O
changes	O
in	O
MAP	O
kinase	O
-	O
related	O
pathways	O
after	O
multiple	O
and	O
single	O
METH	B-CHED
injections	O
.	O

There	O
were	O
statistically	O
significant	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
decreases	O
in	O
MEK1	O
,	O
Erk2p	O
,	O
GSK3alpha	O
,	O
14	O
-	O
3	O
-	O
3e	O
,	O
and	O
MEK7	O
in	O
the	O
striata	O
of	O
mice	O
after	O
multiple	O
injections	O
of	O
METH	B-CHED
.	O

MEK1	O
was	O
significantly	O
decreased	O
also	O
after	O
a	O
single	O
injection	O
of	O
METH	B-CHED
,	O
but	O
to	O
a	O
much	O
lesser	O
degree	O
than	O
after	O
multiple	O
injections	O
of	O
METH	B-CHED
.	O

In	O
the	O
frontal	O
cortex	O
,	O
there	O
was	O
a	O
statistically	O
significant	O
decrease	O
in	O
GSK3alpha	O
after	O
multiple	O
(	O
but	O
not	O
single	O
)	O
injections	O
of	O
METH	B-CHED
.	O

These	O
findings	O
suggest	O
that	O
alterations	O
in	O
MAP	O
kinase	O
-	O
related	O
pathways	O
in	O
the	O
prefronto	O
-	O
striatal	O
circuitries	O
might	O
be	O
involved	O
in	O
the	O
manifestation	O
of	O
aggressive	O
behaviors	O
in	O
mice	O
.	O

Amisulpride	B-CHED
related	O
tic	O
-	O
like	O
symptoms	O
in	O
an	O
adolescent	O
schizophrenic	O
.	O

Tic	O
disorders	O
can	O
be	O
effectively	O
treated	O
by	O
atypical	O
antipsychotics	O
such	O
as	O
risperidone	B-CHED
,	O
olanzapine	B-CHED
and	O
ziprasidone	B-CHED
.	O

However	O
,	O
there	O
are	O
two	O
case	O
reports	O
that	O
show	O
tic	O
-	O
like	O
symptoms	O
,	O
including	O
motor	O
and	O
phonic	O
variants	O
,	O
occurring	O
during	O
treatment	O
with	O
quetiapine	B-CHED
or	O
clozapine	B-CHED
.	O

We	O
present	O
a	O
15	O
-	O
year	O
-	O
old	O
girl	O
schizophrenic	O
who	O
developed	O
frequent	O
involuntary	O
eye	O
-	O
blinking	O
movements	O
after	O
5	O
months	O
of	O
amisulpride	B-CHED
treatment	O
(	O
1000	O
mg	O
per	O
day	O
)	O
.	O

The	O
tic	O
-	O
like	O
symptoms	O
resolved	O
completely	O
after	O
we	O
reduced	O
the	O
dose	O
of	O
amisulpride	B-CHED
down	O
to	O
800	O
mg	O
per	O
day	O
.	O

However	O
,	O
her	O
psychosis	O
recurred	O
after	O
the	O
dose	O
reduction	O
.	O

We	O
then	O
placed	O
her	O
on	O
an	O
additional	O
100	O
mg	O
per	O
day	O
of	O
quetiapine	B-CHED
.	O

She	O
has	O
been	O
in	O
complete	O
remission	O
under	O
the	O
combined	O
medications	O
for	O
more	O
than	O
one	O
year	O
and	O
maintains	O
a	O
fair	O
role	O
function	O
.	O

No	O
more	O
tic	O
-	O
like	O
symptoms	O
or	O
other	O
side	O
effects	O
have	O
been	O
reported	O
.	O

Together	O
with	O
previously	O
reported	O
cases	O
,	O
our	O
patient	O
suggests	O
that	O
tic	O
-	O
like	O
symptoms	O
might	O
occur	O
in	O
certain	O
vulnerable	O
individuals	O
during	O
treatment	O
with	O
atypical	O
antipsychotics	O
such	O
as	O
quetiapine	B-CHED
,	O
clozapine	B-CHED
,	O
or	O
amisulpride	B-CHED
.	O

Chloroquine	B-CHED
related	O
complete	O
heart	O
block	O
with	O
blindness	O
:	O
case	O
report	O
.	O

A	O
27	O
-	O
year	O
old	O
African	O
woman	O
with	O
history	O
of	O
regular	O
chloroquine	B-CHED
ingestion	O
presented	O
with	O
progressive	O
deterioration	O
of	O
vision	O
,	O
easy	O
fatiguability	O
,	O
dyspnoea	O
,	O
dizziness	O
progressing	O
to	O
syncopal	O
attacks	O
.	O

Ophthalmological	O
assessment	O
revealed	O
features	O
of	O
chloroquine	B-CHED
retinopathy	O
,	O
cardiac	O
assessment	O
revealed	O
features	O
of	O
heart	O
failure	O
and	O
a	O
complete	O
heart	O
block	O
with	O
right	O
bundle	O
branch	O
block	O
pattern	O
.	O

The	O
heart	O
block	O
was	O
treated	O
by	O
pacemaker	O
insertion	O
and	O
the	O
heart	O
failure	O
resolved	O
spontaneously	O
following	O
chloroquine	B-CHED
discontinuation	O
.	O

She	O
however	O
remains	O
blind	O
.	O

Effects	O
of	O
suprofen	B-CHED
on	O
the	O
isolated	O
perfused	O
rat	O
kidney	O
.	O

Although	O
suprofen	B-CHED
has	O
been	O
associated	O
with	O
the	O
development	O
of	O
acute	O
renal	O
failure	O
in	O
greater	O
than	O
100	O
subjects	O
,	O
the	O
mechanism	O
of	O
damage	O
remains	O
unclear	O
.	O

The	O
direct	O
nephrotoxic	O
effects	O
of	O
a	O
single	O
dose	O
of	O
15	O
mg	O
of	O
suprofen	B-CHED
were	O
compared	O
in	O
the	O
recirculating	O
isolated	O
rat	O
kidney	O
perfused	O
with	O
cell	O
-	O
free	O
buffer	O
with	O
or	O
without	O
the	O
addition	O
of	O
5	O
mg	O
/	O
dL	O
of	O
uric	B-CHED
acid	I-CHED
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
renal	O
sodium	B-CHED
excretion	O
,	O
oxygen	B-CHED
consumption	O
,	O
or	O
urinary	O
flow	O
rates	O
in	O
kidneys	O
perfused	O
with	O
suprofen	B-CHED
compared	O
with	O
the	O
drug	O
-	O
free	O
control	O
groups	O
.	O

In	O
contrast	O
,	O
a	O
significant	O
decline	O
in	O
glomerular	O
filtration	O
rate	O
was	O
found	O
after	O
the	O
introduction	O
of	O
suprofen	B-CHED
to	O
the	O
kidney	O
perfused	O
with	O
uric	B-CHED
acid	I-CHED
;	O
no	O
changes	O
were	O
found	O
with	O
suprofen	B-CHED
in	O
the	O
absence	O
of	O
uric	B-CHED
acid	I-CHED
.	O

A	O
significant	O
decrease	O
in	O
the	O
baseline	O
excretion	O
rate	O
of	O
uric	B-CHED
acid	I-CHED
was	O
found	O
in	O
rats	O
given	O
suprofen	B-CHED
,	O
compared	O
with	O
drug	O
-	O
free	O
controls	O
.	O

However	O
,	O
the	O
fractional	O
excretion	O
of	O
uric	B-CHED
acid	I-CHED
was	O
unchanged	O
between	O
the	O
groups	O
over	O
the	O
experimental	O
period	O
.	O

In	O
summary	O
,	O
suprofen	B-CHED
causes	O
acute	O
declines	O
in	O
renal	O
function	O
,	O
most	O
likely	O
by	O
directly	O
altering	O
the	O
intrarenal	O
distribution	O
of	O
uric	B-CHED
acid	I-CHED
.	O

Microinjection	O
of	O
ritanserin	B-CHED
into	O
the	O
CA1	O
region	O
of	O
hippocampus	O
improves	O
scopolamine	B-CHED
-	O
induced	O
amnesia	O
in	O
adult	O
male	O
rats	O
.	O

The	O
effect	O
of	O
ritanserin	B-CHED
(	O
5	O
-	O
HT2	O
antagonist	O
)	O
on	O
scopolamine	B-CHED
(	O
muscarinic	O
cholinergic	O
antagonist	O
)	O
-	O
induced	O
amnesia	O
in	O
Morris	O
water	O
maze	O
(	O
MWM	O
)	O
was	O
investigated	O
.	O

Rats	O
were	O
divided	O
into	O
eight	O
groups	O
and	O
bilaterally	O
cannulated	O
into	O
CA1	O
region	O
of	O
the	O
hippocampus	O
.	O

One	O
week	O
later	O
,	O
they	O
received	O
repeatedly	O
vehicles	O
(	O
saline	O
,	O
DMSO	B-CHED
,	O
saline	O
+	O
DMSO	B-CHED
)	O
,	O
scopolamine	B-CHED
(	O
2	O
microg	O
/	O
0	O
.	O
5	O
microl	O
saline	O
/	O
side	O
;	O
30	O
min	O
before	O
training	O
)	O
,	O
ritanserin	B-CHED
(	O
2	O
,	O
4	O
and	O
8	O
microg	O
/	O
0	O
.	O
5	O
microl	O
DMSO	B-CHED
/	O
side	O
;	O
20	O
min	O
before	O
training	O
)	O
and	O
scopolamine	B-CHED
(	O
2	O
microg	O
/	O
0	O
.	O
5	O
microl	O
;	O
30	O
min	O
before	O
ritanserin	B-CHED
injection	O
)	O
+	O
ritanserin	B-CHED
(	O
4	O
microg	O
/	O
0	O
.	O
5	O
microl	O
DMSO	B-CHED
)	O
through	O
cannulae	O
each	O
day	O
.	O

Animals	O
were	O
tested	O
for	O
four	O
consecutive	O
days	O
(	O
4	O
trial	O
/	O
day	O
)	O
in	O
MWM	O
during	O
which	O
the	O
position	O
of	O
hidden	O
platform	O
was	O
unchanged	O
.	O

In	O
the	O
fifth	O
day	O
,	O
the	O
platform	O
was	O
elevated	O
above	O
the	O
water	O
surface	O
in	O
another	O
position	O
to	O
evaluate	O
the	O
function	O
of	O
motor	O
,	O
motivational	O
and	O
visual	O
systems	O
.	O

The	O
results	O
showed	O
a	O
significant	O
increase	O
in	O
escape	O
latencies	O
and	O
traveled	O
distances	O
to	O
find	O
platform	O
in	O
scopolamine	B-CHED
-	O
treated	O
group	O
as	O
compared	O
to	O
saline	O
group	O
.	O

Ritanserin	B-CHED
-	O
treated	O
rats	O
(	O
4	O
microg	O
/	O
0	O
.	O
5	O
microl	O
/	O
side	O
)	O
showed	O
a	O
significant	O
decrease	O
in	O
the	O
mentioned	O
parameters	O
as	O
compared	O
to	O
DMSO	B-CHED
-	O
treated	O
group	O
.	O

However	O
,	O
scopolamine	B-CHED
and	O
ritanserin	B-CHED
co	O
-	O
administration	O
resulted	O
in	O
a	O
significant	O
decrease	O
in	O
escape	O
latencies	O
and	O
traveled	O
distances	O
as	O
compared	O
to	O
the	O
scopolamine	B-CHED
-	O
treated	O
rats	O
.	O

Our	O
findings	O
show	O
that	O
microinjection	O
of	O
ritanserin	B-CHED
into	O
the	O
CA1	O
region	O
of	O
the	O
hippocampus	O
improves	O
the	O
scopolamine	B-CHED
-	O
induced	O
amnesia	O
.	O

PTU	B-CHED
-	O
associated	O
vasculitis	O
in	O
a	O
girl	O
with	O
Turner	O
Syndrome	O
and	O
Graves	O
'	O
disease	O
.	O

Palpable	O
purpura	O
is	O
a	O
concerning	O
clinical	O
finding	O
in	O
pediatric	O
patients	O
and	O
can	O
have	O
many	O
causes	O
,	O
including	O
infectious	O
and	O
autoimmune	O
processes	O
.	O

A	O
rare	O
cause	O
,	O
drug	O
-	O
induced	O
vasculitis	O
,	O
may	O
result	O
from	O
the	O
production	O
of	O
antineutrophil	O
cytoplasmic	O
antibodies	O
(	O
ANCAs	O
)	O
in	O
response	O
to	O
a	O
medication	O
.	O

We	O
report	O
a	O
girl	O
with	O
Turner	O
syndrome	O
and	O
Graves	O
'	O
disease	O
who	O
presented	O
with	O
palpable	O
purpuric	O
lesions	O
.	O

The	O
diagnosis	O
of	O
propylthiouracil	B-CHED
(	O
PTU	B-CHED
)	O
-	O
associated	O
vasculitis	O
was	O
made	O
by	O
observation	O
of	O
consistent	O
clinical	O
features	O
,	O
the	O
detection	O
of	O
elevated	O
ANA	O
and	O
ANCA	O
in	O
the	O
blood	O
,	O
and	O
the	O
observed	O
clinical	O
resolution	O
of	O
symptoms	O
following	O
withdrawal	O
of	O
PTU	B-CHED
.	O

Subsequent	O
treatment	O
of	O
persistent	O
hyperthyroidism	O
with	O
radioablation	O
did	O
not	O
result	O
in	O
an	O
exacerbation	O
of	O
the	O
vasculitis	O
,	O
a	O
complication	O
described	O
in	O
prior	O
case	O
reports	O
.	O

Daidzein	B-CHED
activates	O
choline	B-CHED
acetyltransferase	O
from	O
MC	O
-	O
IXC	O
cells	O
and	O
improves	O
drug	O
-	O
induced	O
amnesia	O
.	O

The	O
choline	B-CHED
acetyltransferase	O
(	O
ChAT	O
)	O
activator	O
,	O
which	O
enhances	O
cholinergic	O
transmission	O
via	O
an	O
augmentation	O
of	O
the	O
enzymatic	O
production	O
of	O
acetylcholine	B-CHED
(	O
ACh	B-CHED
)	O
,	O
is	O
an	O
important	O
factor	O
in	O
the	O
treatment	O
of	O
Alzheimer	O
'	O
s	O
disease	O
(	O
AD	O
)	O
.	O

Methanolic	O
extracts	O
from	O
Pueraria	O
thunbergiana	O
exhibited	O
an	O
activation	O
effect	O
(	O
46	O
%	O
)	O
on	O
ChAT	O
in	O
vitro	O
.	O

Via	O
the	O
sequential	O
isolation	O
of	O
Pueraria	O
thunbergiana	O
,	O
the	O
active	O
component	O
was	O
ultimately	O
identified	O
as	O
daidzein	B-CHED
(	O
4	B-CHED
'	I-CHED
,	I-CHED
7	I-CHED
-	I-CHED
dihydroxy	I-CHED
-	I-CHED
isoflavone	I-CHED
)	O
.	O

In	O
order	O
to	O
investigate	O
the	O
effects	O
of	O
daidzein	B-CHED
from	O
Pueraria	O
thunbergiana	O
on	O
scopolamine	B-CHED
-	O
induced	O
impairments	O
of	O
learning	O
and	O
memory	O
,	O
we	O
conducted	O
a	O
series	O
of	O
in	O
vivo	O
tests	O
.	O

Administration	O
of	O
daidzein	B-CHED
(	O
4	O
.	O
5	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
to	O
mice	O
was	O
shown	O
significantly	O
to	O
reverse	O
scopolamine	B-CHED
-	O
induced	O
amnesia	O
,	O
according	O
to	O
the	O
results	O
of	O
a	O
Y	O
-	O
maze	O
test	O
.	O

Injections	O
of	O
scopolamine	B-CHED
into	O
mice	O
resulted	O
in	O
impaired	O
performance	O
on	O
Y	O
-	O
maze	O
tests	O
(	O
a	O
37	O
%	O
decreases	O
in	O
alternation	O
behavior	O
)	O
.	O

By	O
way	O
of	O
contrast	O
,	O
mice	O
treated	O
with	O
daidzein	B-CHED
prior	O
to	O
the	O
scopolamine	B-CHED
injections	O
were	O
noticeably	O
protected	O
from	O
this	O
performance	O
impairment	O
(	O
an	O
approximately	O
12	O
%	O
-	O
21	O
%	O
decrease	O
in	O
alternation	O
behavior	O
)	O
.	O

These	O
results	O
indicate	O
that	O
daidzein	B-CHED
might	O
play	O
a	O
role	O
in	O
acetylcholine	B-CHED
biosynthesis	O
as	O
a	O
ChAT	O
activator	O
,	O
and	O
that	O
it	O
also	O
ameliorates	O
scopolamine	B-CHED
-	O
induced	O
amnesia	O
.	O

Urinary	O
symptoms	O
and	O
quality	O
of	O
life	O
changes	O
in	O
Thai	O
women	O
with	O
overactive	O
bladder	O
after	O
tolterodine	B-CHED
treatment	O
.	O

OBJECTIVES	O
:	O
To	O
study	O
the	O
urinary	O
symptoms	O
and	O
quality	O
of	O
life	O
changes	O
in	O
Thai	O
women	O
with	O
overactive	O
bladder	O
(	O
OAB	O
)	O
after	O
tolterodine	B-CHED
treatment	O
.	O

MATERIAL	O
AND	O
METHOD	O
:	O
Thirty	O
women	O
(	O
aged	O
30	O
-	O
77	O
years	O
)	O
diagnosed	O
as	O
having	O
OAB	O
at	O
the	O
Gynecology	O
Clinic	O
,	O
King	O
Chulalongkorn	O
Memorial	O
Hospital	O
from	O
January	O
to	O
April	O
2004	O
were	O
included	O
in	O
the	O
present	O
study	O
.	O

Tolterodine	B-CHED
2	O
mg	O
,	O
twice	O
daily	O
was	O
given	O
.	O

After	O
8	O
weeks	O
treatment	O
,	O
changes	O
in	O
micturition	O
diary	O
variables	O
and	O
tolerability	O
were	O
determined	O
.	O

Short	O
form	O
36	O
(	O
SF36	O
)	O
questionaires	O
(	O
Thai	O
version	O
)	O
were	O
given	O
before	O
and	O
after	O
8	O
weeks	O
of	O
treatment	O
.	O

RESULTS	O
:	O
At	O
8	O
weeks	O
,	O
all	O
micturition	O
per	O
day	O
decreased	O
from	O
16	O
.	O

7	O
+	O
/	O
-	O
5	O
.	O

3	O
to	O
6	O
.	O

7	O
+	O
/	O
-	O
2	O
.	O
4	O
times	O
per	O
day	O
.	O

The	O
number	O
of	O
nocturia	O
episodes	O
decreased	O
from	O
5	O
.	O
4	O
+	O
/	O
-	O
4	O
.	O
2	O
to	O
1	O
.	O
1	O
+	O
/	O
-	O
1	O
.	O
0	O
times	O
per	O
night	O
.	O

The	O
most	O
common	O
side	O
effect	O
was	O
dry	O
month	O
in	O
5	O
cases	O
(	O
16	O
.	O
7	O
%	O
)	O
with	O
2	O
cases	O
reporting	O
a	O
moderate	O
degree	O
and	O
1	O
case	O
with	O
severe	O
degree	O
.	O

Only	O
one	O
case	O
(	O
3	O
.	O
3	O
%	O
)	O
withdrew	O
from	O
the	O
present	O
study	O
due	O
to	O
a	O
severe	O
dry	O
mouth	O
.	O

The	O
SF	O
-	O
36	O
scores	O
changed	O
significantly	O
in	O
the	O
domains	O
of	O
physical	O
functioning	O
,	O
role	O
function	O
emotional	O
,	O
social	O
function	O
and	O
mental	O
heath	O
.	O

CONCLUSION	O
:	O
Tolterodine	B-CHED
was	O
well	O
tolerated	O
and	O
its	O
effects	O
improved	O
the	O
quality	O
of	O
life	O
in	O
Thai	O
women	O
with	O
OAB	O
.	O

Remifentanil	B-CHED
pretreatment	O
reduces	O
myoclonus	O
after	O
etomidate	B-CHED
.	O

STUDY	O
OBJECTIVE	O
:	O
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
compare	O
the	O
effect	O
of	O
pretreatment	O
with	O
remifentanil	B-CHED
1	O
microg	O
/	O
kg	O
and	O
the	O
effect	O
of	O
gender	O
on	O
the	O
incidence	O
of	O
myoclonus	O
after	O
anesthesia	O
induction	O
with	O
etomidate	B-CHED
.	O

DESIGN	O
:	O
This	O
was	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
study	O
.	O

SETTING	O
:	O
The	O
study	O
was	O
conducted	O
at	O
a	O
university	O
hospital	O
.	O

PATIENTS	O
:	O
Sixty	O
patients	O
were	O
pretreated	O
in	O
a	O
randomized	O
double	O
-	O
blinded	O
fashion	O
with	O
remifentanil	B-CHED
1	O
microg	O
/	O
kg	O
or	O
placebo	O
.	O

Two	O
minutes	O
after	O
remifentanil	B-CHED
or	O
placebo	O
injection	O
,	O
etomidate	B-CHED
0	O
.	O
3	O
mg	O
/	O
kg	O
was	O
given	O
.	O

MEASUREMENTS	O
:	O
Myoclonus	O
was	O
recorded	O
with	O
a	O
scale	O
of	O
0	O
to	O
3	O
.	O

The	O
grade	O
of	O
sedation	O
(	O
none	O
,	O
mild	O
,	O
moderate	O
,	O
severe	O
)	O
,	O
nausea	O
,	O
pruritus	O
,	O
and	O
apnea	O
were	O
recorded	O
after	O
injection	O
of	O
both	O
drugs	O
.	O

MAIN	O
RESULTS	O
:	O
The	O
incidence	O
of	O
myoclonus	O
was	O
significantly	O
lower	O
in	O
the	O
remifentanil	B-CHED
group	O
(	O
6	O
.	O
7	O
%	O
)	O
than	O
in	O
the	O
placebo	O
group	O
(	O
70	O
%	O
)	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

None	O
of	O
the	O
patients	O
experienced	O
sedation	O
,	O
apnea	O
,	O
nausea	O
,	O
or	O
pruritus	O
after	O
injection	O
of	O
both	O
drugs	O
.	O

In	O
the	O
placebo	O
group	O
,	O
male	O
patients	O
were	O
associated	O
with	O
significantly	O
increased	O
incidence	O
of	O
myoclonus	O
after	O
etomidate	B-CHED
administration	O
.	O

CONCLUSION	O
:	O
Pretreatment	O
with	O
remifentanil	B-CHED
1	O
microg	O
/	O
kg	O
reduced	O
myoclonus	O
after	O
etomidate	B-CHED
induction	O
without	O
side	O
effects	O
such	O
as	O
sedation	O
,	O
apnea	O
,	O
nausea	O
,	O
or	O
pruritus	O
.	O

Men	O
experience	O
increased	O
incidence	O
of	O
myoclonus	O
than	O
women	O
after	O
etomidate	B-CHED
administration	O
.	O

Memory	O
function	O
and	O
serotonin	B-CHED
transporter	O
promoter	O
gene	O
polymorphism	O
in	O
ecstasy	B-CHED
(	O
MDMA	B-CHED
)	O
users	O
.	O

Although	O
3	B-CHED
,	I-CHED
4	I-CHED
-	I-CHED
methylenedioxymethamphetamine	I-CHED
(	O
MDMA	B-CHED
or	O
ecstasy	B-CHED
)	O
has	O
been	O
shown	O
to	O
damage	O
brain	O
serotonin	B-CHED
(	O
5	B-CHED
-	I-CHED
HT	I-CHED
)	O
neurons	O
in	O
animals	O
and	O
possibly	O
humans	O
,	O
little	O
is	O
known	O
about	O
the	O
long	O
-	O
term	O
consequences	O
of	O
MDMA	B-CHED
-	O
induced	O
5	B-CHED
-	I-CHED
HT	I-CHED
neurotoxic	O
lesions	O
on	O
functions	O
in	O
which	O
5	B-CHED
-	I-CHED
HT	I-CHED
is	O
involved	O
,	O
such	O
as	O
cognitive	O
function	O
.	O

Because	O
5	B-CHED
-	I-CHED
HT	I-CHED
transporters	O
play	O
a	O
key	O
element	O
in	O
the	O
regulation	O
of	O
synaptic	O
5	B-CHED
-	I-CHED
HT	I-CHED
transmission	O
it	O
may	O
be	O
important	O
to	O
control	O
for	O
the	O
potential	O
covariance	O
effect	O
of	O
a	O
polymorphism	O
in	O
the	O
5	B-CHED
-	I-CHED
HT	I-CHED
transporter	O
promoter	O
gene	O
region	O
(	O
5	O
-	O
HTTLPR	O
)	O
when	O
studying	O
the	O
effects	O
of	O
MDMA	B-CHED
as	O
well	O
as	O
cognitive	O
functioning	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
moderate	O
and	O
heavy	O
MDMA	B-CHED
use	O
on	O
cognitive	O
function	O
,	O
as	O
well	O
as	O
the	O
effects	O
of	O
long	O
-	O
term	O
abstention	O
from	O
MDMA	B-CHED
,	O
in	O
subjects	O
genotyped	O
for	O
5	O
-	O
HTTLPR	O
.	O

A	O
second	O
aim	O
of	O
the	O
study	O
was	O
to	O
determine	O
whether	O
these	O
effects	O
differ	O
for	O
females	O
and	O
males	O
.	O

Fifteen	O
moderate	O
MDMA	B-CHED
users	O
(	O
<	O
55	O
lifetime	O
tablets	O
)	O
,	O
22	O
heavy	O
MDMA	B-CHED
+	O
users	O
(	O
>	O
55	O
lifetime	O
tablets	O
)	O
,	O
16	O
ex	O
-	O
MDMA	B-CHED
+	O
users	O
(	O
last	O
tablet	O
>	O
1	O
year	O
ago	O
)	O
and	O
13	O
controls	O
were	O
compared	O
on	O
a	O
battery	O
of	O
neuropsychological	O
tests	O
.	O

DNA	O
from	O
peripheral	O
nuclear	O
blood	O
cells	O
was	O
genotyped	O
for	O
5	O
-	O
HTTLPR	O
using	O
standard	O
polymerase	O
chain	O
reaction	O
methods	O
.	O
A	O
significant	O
group	O
effect	O
was	O
observed	O
only	O
on	O
memory	O
function	O
tasks	O
(	O
p	O
=	O
0	O
.	O
04	O
)	O
but	O
not	O
on	O
reaction	O
times	O
(	O
p	O
=	O
0	O
.	O
61	O
)	O
or	O
attention	O
/	O
executive	O
functioning	O
(	O
p	O
=	O
0	O
.	O
59	O
)	O
.	O

Heavy	O
and	O
ex	O
-	O
MDMA	B-CHED
+	O
users	O
performed	O
significantly	O
poorer	O
on	O
memory	O
tasks	O
than	O
controls	O
.	O

In	O
contrast	O
,	O
no	O
evidence	O
of	O
memory	O
impairment	O
was	O
observed	O
in	O
moderate	O
MDMA	B-CHED
users	O
.	O

No	O
significant	O
effect	O
of	O
5	O
-	O
HTTLPR	O
or	O
gender	O
was	O
observed	O
.	O

While	O
the	O
use	O
of	O
MDMA	B-CHED
in	O
quantities	O
that	O
may	O
be	O
considered	O
"	O
moderate	O
"	O
is	O
not	O
associated	O
with	O
impaired	O
memory	O
functioning	O
,	O
heavy	O
use	O
of	O
MDMA	B-CHED
use	O
may	O
lead	O
to	O
long	O
lasting	O
memory	O
impairments	O
.	O

No	O
effect	O
of	O
5	O
-	O
HTTLPR	O
or	O
gender	O
on	O
memory	O
function	O
or	O
MDMA	B-CHED
use	O
was	O
observed	O
.	O

Role	O
of	O
mangiferin	B-CHED
on	O
biochemical	O
alterations	O
and	O
antioxidant	O
status	O
in	O
isoproterenol	B-CHED
-	O
induced	O
myocardial	O
infarction	O
in	O
rats	O
.	O

The	O
current	O
study	O
dealt	O
with	O
the	O
protective	O
role	O
of	O
mangiferin	B-CHED
,	O
a	O
polyphenol	B-CHED
from	O
Mangifera	O
indica	O
Linn	O
.	O

(	O
Anacardiaceae	O
)	O
,	O
on	O
isoproterenol	B-CHED
(	O
ISPH	B-CHED
)	O
-	O
induced	O
myocardial	O
infarction	O
(	O
MI	O
)	O
in	O
rats	O
through	O
its	O
antioxidative	O
mechanism	O
.	O

Subcutaneous	O
injection	O
of	O
ISPH	B-CHED
(	O
200	O
mg	O
/	O
kg	O
body	O
weight	O
in	O
1	O
ml	O
saline	O
)	O
to	O
rats	O
for	O
2	O
consecutive	O
days	O
caused	O
myocardial	O
damage	O
in	O
rat	O
heart	O
,	O
which	O
was	O
determined	O
by	O
the	O
increased	O
activity	O
of	O
serum	O
lactate	B-CHED
dehydrogenase	O
(	O
LDH	O
)	O
and	O
creatine	B-CHED
phosphokinase	O
isoenzymes	O
(	O
CK	O
-	O
MB	O
)	O
,	O
increased	O
uric	B-CHED
acid	I-CHED
level	O
and	O
reduced	O
plasma	O
iron	B-CHED
binding	O
capacity	O
.	O

The	O
protective	O
role	O
of	O
mangiferin	B-CHED
was	O
analyzed	O
by	O
triphenyl	B-CHED
tetrazolium	I-CHED
chloride	I-CHED
(	O
TTC	B-CHED
)	O
test	O
used	O
for	O
macroscopic	O
enzyme	O
mapping	O
assay	O
of	O
the	O
ischemic	O
myocardium	O
.	O

The	O
heart	O
tissue	O
antioxidant	O
enzymes	O
such	O
as	O
superoxide	B-CHED
dismutase	O
,	O
catalase	O
,	O
glutathione	B-CHED
peroxidase	O
,	O
glutathione	B-CHED
transferase	O
and	O
glutathione	B-CHED
reductase	O
activities	O
,	O
non	O
-	O
enzymic	O
antioxidants	O
such	O
as	O
cerruloplasmin	O
,	O
Vitamin	B-CHED
C	I-CHED
,	O
Vitamin	B-CHED
E	I-CHED
and	O
glutathione	B-CHED
levels	O
were	O
altered	O
in	O
MI	O
rats	O
.	O

Upon	O
pretreatment	O
with	O
mangiferin	B-CHED
(	O
100	O
mg	O
/	O
kg	O
body	O
weight	O
suspended	O
in	O
2	O
ml	O
of	O
dimethyl	B-CHED
sulphoxide	I-CHED
)	O
given	O
intraperitoneally	O
for	O
28	O
days	O
to	O
MI	O
rats	O
protected	O
the	O
above	O
-	O
mentioned	O
parameters	O
to	O
fall	O
from	O
the	O
normal	O
levels	O
.	O

Activities	O
of	O
heart	O
tissue	O
enzymic	O
antioxidants	O
and	O
serum	O
non	O
-	O
enzymic	O
antioxidants	O
levels	O
rose	O
significantly	O
upon	O
mangiferin	B-CHED
administration	O
as	O
compared	O
to	O
ISPH	B-CHED
-	O
induced	O
MI	O
rats	O
.	O

From	O
the	O
present	O
study	O
it	O
is	O
concluded	O
that	O
mangiferin	B-CHED
exerts	O
a	O
beneficial	O
effect	O
against	O
ISPH	B-CHED
-	O
induced	O
MI	O
due	O
to	O
its	O
antioxidant	O
potential	O
,	O
which	O
regulated	O
the	O
tissues	O
defense	O
system	O
against	O
cardiac	O
damage	O
.	O

Cardiovascular	O
risk	O
with	O
cyclooxygenase	B-CHED
inhibitors	I-CHED
:	O
general	O
problem	O
with	O
substance	O
specific	O
differences	O
?	O

Randomised	O
clinical	O
trials	O
and	O
observational	O
studies	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
myocardial	O
infarction	O
,	O
stroke	O
,	O
hypertension	O
and	O
heart	O
failure	O
during	O
treatment	O
with	O
cyclooxygenase	B-CHED
inhibitors	I-CHED
.	O

Adverse	O
cardiovascular	O
effects	O
occurred	O
mainly	O
,	O
but	O
not	O
exclusively	O
,	O
in	O
patients	O
with	O
concomitant	O
risk	O
factors	O
.	O

Cyclooxygenase	B-CHED
inhibitors	I-CHED
cause	O
complex	O
changes	O
in	O
renal	O
,	O
vascular	O
and	O
cardiac	O
prostanoid	O
profiles	O
thereby	O
increasing	O
vascular	O
resistance	O
and	O
fluid	O
retention	O
.	O

The	O
incidence	O
of	O
cardiovascular	O
adverse	O
events	O
tends	O
to	O
increase	O
with	O
the	O
daily	O
dose	O
and	O
total	O
exposure	O
time	O
.	O

A	O
comparison	O
of	O
individual	O
selective	O
and	O
unselective	O
cyclooxygenase	B-CHED
inhibitors	I-CHED
suggests	O
substance	O
-	O
specific	O
differences	O
,	O
which	O
may	O
depend	O
on	O
differences	O
in	O
pharmacokinetic	O
parameters	O
or	O
inhibitory	O
potency	O
and	O
may	O
be	O
contributed	O
by	O
prostaglandin	B-CHED
-	O
independent	O
effects	O
.	O

Diagnostic	O
markers	O
such	O
as	O
N	B-CHED
-	I-CHED
terminal	I-CHED
pro	I-CHED
brain	I-CHED
natriuretic	I-CHED
peptide	I-CHED
(	O
NT	B-CHED
-	I-CHED
proBNP	I-CHED
)	O
or	O
high	O
-	O
sensitive	O
C	O
-	O
reactive	O
protein	O
might	O
help	O
in	O
the	O
early	O
identification	O
of	O
patients	O
at	O
risk	O
,	O
thus	O
avoiding	O
the	O
occurrence	O
of	O
serious	O
cardiovascular	O
toxicity	O
.	O

Pilocarpine	B-CHED
seizures	O
cause	O
age	O
-	O
dependent	O
impairment	O
in	O
auditory	O
location	O
discrimination	O
.	O

Children	O
who	O
have	O
status	O
epilepticus	O
have	O
continuous	O
or	O
rapidly	O
repeating	O
seizures	O
that	O
may	O
be	O
life	O
-	O
threatening	O
and	O
may	O
cause	O
life	O
-	O
long	O
changes	O
in	O
brain	O
and	O
behavior	O
.	O

The	O
extent	O
to	O
which	O
status	O
epilepticus	O
causes	O
deficits	O
in	O
auditory	O
discrimination	O
is	O
unknown	O
.	O

A	O
naturalistic	O
auditory	O
location	O
discrimination	O
method	O
was	O
used	O
to	O
evaluate	O
this	O
question	O
using	O
an	O
animal	O
model	O
of	O
status	O
epilepticus	O
.	O

Male	O
Sprague	O
-	O
Dawley	O
rats	O
were	O
injected	O
with	O
saline	O
on	O
postnatal	O
day	O
(	O
P	O
)	O
20	O
,	O
or	O
a	O
convulsant	O
dose	O
of	O
pilocarpine	B-CHED
on	O
P20	O
or	O
P45	O
.	O

Pilocarpine	B-CHED
on	O
either	O
day	O
induced	O
status	O
epilepticus	O
;	O
status	O
epilepticus	O
at	O
P45	O
resulted	O
in	O
CA3	O
cell	O
loss	O
and	O
spontaneous	O
seizures	O
,	O
whereas	O
P20	O
rats	O
had	O
no	O
cell	O
loss	O
or	O
spontaneous	O
seizures	O
.	O

Mature	O
rats	O
were	O
trained	O
with	O
sound	O
-	O
source	O
location	O
and	O
sound	O
-	O
silence	O
discriminations	O
.	O

Control	O
(	O
saline	O
P20	O
)	O
rats	O
acquired	O
both	O
discriminations	O
immediately	O
.	O

In	O
status	O
epilepticus	O
(	O
P20	O
)	O
rats	O
,	O
acquisition	O
of	O
the	O
sound	O
-	O
source	O
location	O
discrimination	O
was	O
moderately	O
impaired	O
.	O

Status	O
epilepticus	O
(	O
P45	O
)	O
rats	O
failed	O
to	O
acquire	O
either	O
sound	O
-	O
source	O
location	O
or	O
sound	O
-	O
silence	O
discriminations	O
.	O

Status	O
epilepticus	O
in	O
rat	O
causes	O
an	O
age	O
-	O
dependent	O
,	O
long	O
-	O
term	O
impairment	O
in	O
auditory	O
discrimination	O
.	O

This	O
impairment	O
may	O
explain	O
one	O
cause	O
of	O
impaired	O
auditory	O
location	O
discrimination	O
in	O
humans	O
.	O

Nerve	O
growth	O
factor	O
and	O
prostaglandins	B-CHED
in	O
the	O
urine	O
of	O
female	O
patients	O
with	O
overactive	O
bladder	O
.	O

PURPOSE	O
:	O
NGF	O
and	O
PGs	B-CHED
in	O
the	O
bladder	O
can	O
be	O
affected	O
by	O
pathological	O
changes	O
in	O
the	O
bladder	O
and	O
these	O
changes	O
can	O
be	O
detected	O
in	O
urine	O
.	O

We	O
investigated	O
changes	O
in	O
urinary	O
NGF	O
and	O
PGs	B-CHED
in	O
women	O
with	O
OAB	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
The	O
study	O
groups	O
included	O
65	O
women	O
with	O
OAB	O
and	O
20	O
without	O
bladder	O
symptoms	O
who	O
served	O
as	O
controls	O
.	O

Evaluation	O
included	O
patient	O
history	O
,	O
urinalysis	O
,	O
a	O
voiding	O
diary	O
and	O
urodynamic	O
studies	O
.	O

Urine	O
samples	O
were	O
collected	O
.	O

NGF	O
,	O
PGE2	B-CHED
,	O
PGF2alpha	B-CHED
and	O
PGI2	B-CHED
were	O
measured	O
using	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
and	O
compared	O
between	O
the	O
groups	O
.	O

In	O
addition	O
,	O
correlations	O
between	O
urinary	O
NGF	O
and	O
PG	B-CHED
,	O
and	O
urodynamic	O
parameters	O
in	O
patients	O
with	O
OAB	O
were	O
examined	O
.	O

RESULTS	O
:	O
Urinary	O
NGF	O
,	O
PGE2	B-CHED
and	O
PGF2alpha	B-CHED
were	O
significantly	O
increased	O
in	O
patients	O
with	O
OAB	O
compared	O
with	O
controls	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

However	O
,	O
urinary	O
PGI2	B-CHED
was	O
not	O
different	O
between	O
controls	O
and	O
patients	O
with	O
OAB	O
.	O

In	O
patients	O
with	O
OAB	O
urinary	O
PGE2	B-CHED
positively	O
correlated	O
with	O
volume	O
at	O
first	O
desire	O
to	O
void	O
and	O
maximum	O
cystometric	O
capacity	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Urinary	O
NGF	O
,	O
PGF2alpha	B-CHED
and	O
PGI2	B-CHED
did	O
not	O
correlate	O
with	O
urodynamic	O
parameters	O
in	O
patients	O
with	O
OAB	O
.	O

CONCLUSIONS	O
:	O
NGF	O
and	O
PGs	B-CHED
have	O
important	O
roles	O
in	O
the	O
development	O
of	O
OAB	O
symptoms	O
in	O
female	O
patients	O
.	O

Urinary	O
levels	O
of	O
these	O
factors	O
may	O
be	O
used	O
as	O
markers	O
to	O
evaluate	O
OAB	O
symptoms	O
.	O

Definition	O
and	O
management	O
of	O
anemia	O
in	O
patients	O
infected	O
with	O
hepatitis	O
C	O
virus	O
.	O

Chronic	O
infection	O
with	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
can	O
progress	O
to	O
cirrhosis	O
,	O
hepatocellular	O
carcinoma	O
,	O
and	O
end	O
-	O
stage	O
liver	O
disease	O
.	O

The	O
current	O
best	O
treatment	O
for	O
HCV	O
infection	O
is	O
combination	O
therapy	O
with	O
pegylated	O
interferon	B-CHED
and	O
ribavirin	B-CHED
.	O

Although	O
this	O
regimen	O
produces	O
sustained	O
virologic	O
responses	O
(	O
SVRs	O
)	O
in	O
approximately	O
50	O
%	O
of	O
patients	O
,	O
it	O
can	O
be	O
associated	O
with	O
a	O
potentially	O
dose	O
-	O
limiting	O
hemolytic	O
anemia	O
.	O

Hemoglobin	O
concentrations	O
decrease	O
mainly	O
as	O
a	O
result	O
of	O
ribavirin	B-CHED
-	O
induced	O
hemolysis	O
,	O
and	O
this	O
anemia	O
can	O
be	O
problematic	O
in	O
patients	O
with	O
HCV	O
infection	O
,	O
especially	O
those	O
who	O
have	O
comorbid	O
renal	O
or	O
cardiovascular	O
disorders	O
.	O

In	O
general	O
,	O
anemia	O
can	O
increase	O
the	O
risk	O
of	O
morbidity	O
and	O
mortality	O
,	O
and	O
may	O
have	O
negative	O
effects	O
on	O
cerebral	O
function	O
and	O
quality	O
of	O
life	O
.	O

Although	O
ribavirin	B-CHED
-	O
associated	O
anemia	O
can	O
be	O
reversed	O
by	O
dose	O
reduction	O
or	O
discontinuation	O
,	O
this	O
approach	O
compromises	O
outcomes	O
by	O
significantly	O
decreasing	O
SVR	O
rates	O
.	O

Recombinant	O
human	O
erythropoietin	O
has	O
been	O
used	O
to	O
manage	O
ribavirin	B-CHED
-	O
associated	O
anemia	O
but	O
has	O
other	O
potential	O
disadvantages	O
.	O

Viramidine	B-CHED
,	O
a	O
liver	O
-	O
targeting	O
prodrug	O
of	O
ribavirin	B-CHED
,	O
has	O
the	O
potential	O
to	O
maintain	O
the	O
virologic	O
efficacy	O
of	O
ribavirin	B-CHED
while	O
decreasing	O
the	O
risk	O
of	O
hemolytic	O
anemia	O
in	O
patients	O
with	O
chronic	O
hepatitis	O
C	O
.	O

Impact	O
of	O
alcohol	B-CHED
exposure	O
after	O
pregnancy	O
recognition	O
on	O
ultrasonographic	O
fetal	O
growth	O
measures	O
.	O

BACKGROUND	O
:	O
More	O
than	O
3	O
decades	O
after	O
Jones	O
and	O
Smith	O
(	O
1973	O
)	O
reported	O
on	O
the	O
devastation	O
caused	O
by	O
alcohol	B-CHED
exposure	O
on	O
fetal	O
development	O
,	O
the	O
rates	O
of	O
heavy	O
drinking	O
during	O
pregnancy	O
remain	O
relatively	O
unchanged	O
.	O

Early	O
identification	O
of	O
fetal	O
alcohol	B-CHED
exposure	O
and	O
maternal	O
abstinence	O
led	O
to	O
better	O
infant	O
outcomes	O
.	O

This	O
study	O
examined	O
the	O
utility	O
of	O
biometry	O
for	O
detecting	O
alcohol	B-CHED
-	O
related	O
fetal	O
growth	O
impairment	O
.	O

METHODS	O
:	O
We	O
obtained	O
fetal	O
ultrasound	O
measures	O
from	O
routine	O
ultrasound	O
examinations	O
for	O
167	O
pregnant	O
hazardous	O
drinkers	O
who	O
were	O
enrolled	O
in	O
a	O
brief	O
alcohol	B-CHED
intervention	O
study	O
.	O

The	O
fetal	O
measures	O
for	O
women	O
who	O
quit	O
after	O
learning	O
of	O
their	O
pregnancies	O
were	O
compared	O
with	O
measures	O
for	O
women	O
who	O
continued	O
some	O
drinking	O
throughout	O
the	O
course	O
of	O
their	O
pregnancies	O
.	O

Because	O
intensity	O
of	O
alcohol	B-CHED
consumption	O
is	O
associated	O
with	O
poorer	O
fetal	O
outcomes	O
,	O
separate	O
analyses	O
were	O
conducted	O
for	O
the	O
heavy	O
(	O
average	O
of	O
>	O
or	O
=	O
5	O
drinks	O
per	O
drinking	O
day	O
)	O
alcohol	B-CHED
consumers	O
.	O

Fetal	O
measures	O
from	O
the	O
heavy	O
-	O
exposed	O
fetuses	O
were	O
also	O
compared	O
with	O
measures	O
from	O
a	O
nondrinking	O
group	O
that	O
was	O
representative	O
of	O
normal	O
,	O
uncomplicated	O
pregnancies	O
from	O
our	O
clinics	O
.	O

Analyses	O
of	O
covariance	O
were	O
used	O
to	O
determine	O
whether	O
there	O
were	O
differences	O
between	O
groups	O
after	O
controlling	O
for	O
influences	O
of	O
gestational	O
age	O
and	O
drug	O
abuse	O
.	O

RESULTS	O
:	O
Nearly	O
half	O
of	O
the	O
pregnant	O
drinkers	O
abstained	O
after	O
learning	O
of	O
their	O
pregnancies	O
.	O

When	O
women	O
reportedly	O
quit	O
drinking	O
early	O
in	O
their	O
pregnancies	O
,	O
fetal	O
growth	O
measures	O
were	O
not	O
significantly	O
different	O
from	O
a	O
non	O
-	O
alcohol	B-CHED
-	O
exposed	O
group	O
,	O
regardless	O
of	O
prior	O
drinking	O
patterns	O
.	O

Any	O
alcohol	B-CHED
consumption	O
postpregnancy	O
recognition	O
among	O
the	O
heavy	O
drinkers	O
resulted	O
in	O
reduced	O
cerebellar	O
growth	O
as	O
well	O
as	O
decreased	O
cranial	O
to	O
body	O
growth	O
in	O
comparison	O
with	O
women	O
who	O
either	O
quit	O
drinking	O
or	O
who	O
were	O
nondrinkers	O
.	O

Amphetamine	B-CHED
abuse	O
was	O
predictive	O
of	O
larger	O
cranial	O
to	O
body	O
growth	O
ratios	O
.	O

CONCLUSIONS	O
:	O
Alterations	O
in	O
fetal	O
biometric	O
measurements	O
were	O
observed	O
among	O
the	O
heavy	O
drinkers	O
only	O
when	O
they	O
continued	O
drinking	O
after	O
becoming	O
aware	O
of	O
their	O
pregnancies	O
.	O

Although	O
the	O
reliance	O
on	O
self	O
-	O
reported	O
drinking	O
is	O
a	O
limitation	O
in	O
this	O
study	O
,	O
these	O
findings	O
support	O
the	O
benefits	O
of	O
early	O
abstinence	O
and	O
the	O
potential	O
for	O
ultrasound	O
examinations	O
in	O
the	O
detection	O
of	O
fetal	O
alcohol	B-CHED
effects	O
.	O

Ethambutol	B-CHED
-	O
associated	O
optic	O
neuropathy	O
.	O

INTRODUCTION	O
:	O
Ethambutol	B-CHED
is	O
used	O
in	O
the	O
treatment	O
of	O
tuberculosis	O
,	O
which	O
is	O
still	O
prevalent	O
in	O
Southeast	O
Asia	O
,	O
and	O
can	O
be	O
associated	O
with	O
permanent	O
visual	O
loss	O
.	O

We	O
report	O
3	O
cases	O
which	O
presented	O
with	O
bitemporal	O
hemianopia	O
.	O

CLINICAL	O
PICTURE	O
:	O
Three	O
patients	O
with	O
ethambutol	B-CHED
-	O
associated	O
toxic	O
optic	O
neuropathy	O
are	O
described	O
.	O

All	O
3	O
patients	O
had	O
loss	O
of	O
central	O
visual	O
acuity	O
,	O
colour	O
vision	O
(	O
Ishihara	O
)	O
and	O
visual	O
field	O
.	O

The	O
visual	O
field	O
loss	O
had	O
a	O
bitemporal	O
flavour	O
,	O
suggesting	O
involvement	O
of	O
the	O
optic	O
chiasm	O
.	O

TREATMENT	O
:	O
Despite	O
stopping	O
ethambutol	B-CHED
on	O
diagnosis	O
,	O
visual	O
function	O
continued	O
to	O
deteriorate	O
for	O
a	O
few	O
months	O
.	O

Subsequent	O
improvement	O
was	O
mild	O
in	O
2	O
cases	O
.	O

In	O
the	O
third	O
case	O
,	O
visual	O
acuity	O
and	O
colour	O
vision	O
normalised	O
but	O
the	O
optic	O
discs	O
were	O
pale	O
.	O

OUTCOME	O
:	O
All	O
3	O
patients	O
had	O
some	O
permanent	O
loss	O
of	O
visual	O
function	O
.	O

CONCLUSIONS	O
:	O
Ethambutol	B-CHED
usage	O
is	O
associated	O
with	O
permanent	O
visual	O
loss	O
and	O
should	O
be	O
avoided	O
if	O
possible	O
or	O
used	O
with	O
caution	O
and	O
proper	O
ophthalmological	O
follow	O
-	O
up	O
.	O

The	O
author	O
postulates	O
that	O
in	O
cases	O
of	O
ethambutol	B-CHED
associated	O
chiasmopathy	O
,	O
ethambutol	B-CHED
may	O
initially	O
affect	O
the	O
optic	O
nerves	O
and	O
subsequently	O
progress	O
to	O
involve	O
the	O
optic	O
chiasm	O
.	O

Possible	O
neuroleptic	O
malignant	O
syndrome	O
related	O
to	O
concomitant	O
treatment	O
with	O
paroxetine	B-CHED
and	O
alprazolam	B-CHED
.	O

A	O
74	O
-	O
year	O
-	O
old	O
man	O
with	O
depressive	O
symptoms	O
was	O
admitted	O
to	O
a	O
psychiatric	O
hospital	O
due	O
to	O
insomnia	O
,	O
loss	O
of	O
appetite	O
,	O
exhaustion	O
,	O
and	O
agitation	O
.	O

Medical	O
treatment	O
was	O
initiated	O
at	O
a	O
daily	O
dose	O
of	O
20	O
mg	O
paroxetine	B-CHED
and	O
1	O
.	O
2	O
mg	O
alprazolam	B-CHED
.	O

On	O
the	O
10th	O
day	O
of	O
paroxetine	B-CHED
and	O
alprazolam	B-CHED
treatment	O
,	O
the	O
patient	O
exhibited	O
marked	O
psychomotor	O
retardation	O
,	O
disorientation	O
,	O
and	O
severe	O
muscle	O
rigidity	O
with	O
tremors	O
.	O

The	O
patient	O
had	O
a	O
fever	O
(	O
38	O
.	O
2	O
degrees	O
C	O
)	O
,	O
fluctuating	O
blood	O
pressure	O
(	O
between	O
165	O
/	O
90	O
and	O
130	O
/	O
70	O
mg	O
mm	O
Hg	O
)	O
,	O
and	O
severe	O
extrapyramidal	O
symptoms	O
.	O

Laboratory	O
tests	O
showed	O
an	O
elevation	O
of	O
creatine	B-CHED
phosphokinase	O
(	O
2218	O
IU	O
/	O
L	O
)	O
,	O
aspartate	B-CHED
aminotransferase	O
(	O
134	O
IU	O
/	O
L	O
)	O
,	O
alanine	B-CHED
aminotransferase	O
(	O
78	O
IU	O
/	O
L	O
)	O
,	O
and	O
BUN	O
(	O
27	O
.	O
9	O
mg	O
/	O
ml	O
)	O
levels	O
.	O

The	O
patient	O
received	O
bromocriptine	B-CHED
and	O
diazepam	B-CHED
to	O
treat	O
his	O
symptoms	O
.	O

7	O
days	O
later	O
,	O
the	O
fever	O
disappeared	O
and	O
the	O
patient	O
'	O
s	O
serum	O
CPK	O
levels	O
were	O
normalized	O
(	O
175	O
IU	O
/	O
L	O
)	O
.	O

This	O
patient	O
presented	O
with	O
symptoms	O
of	O
neuroleptic	O
malignant	O
syndrome	O
(	O
NMS	O
)	O
,	O
thus	O
demonstrating	O
that	O
NMS	O
-	O
like	O
symptoms	O
can	O
occur	O
after	O
combined	O
paroxetine	B-CHED
and	O
alprazolam	B-CHED
treatment	O
.	O

The	O
adverse	O
drug	O
reaction	O
score	O
obtained	O
by	O
the	O
Naranjo	O
algorithm	O
was	O
6	O
in	O
our	O
case	O
,	O
indicating	O
a	O
probable	O
relationship	O
between	O
the	O
patient	O
'	O
s	O
NMS	O
-	O
like	O
adverse	O
symptoms	O
and	O
the	O
combined	O
treatment	O
used	O
in	O
this	O
case	O
.	O

The	O
involvement	O
of	O
physiologic	O
and	O
environmental	O
aspects	O
specific	O
to	O
this	O
patient	O
was	O
suspected	O
.	O

Several	O
risk	O
factors	O
for	O
NMS	O
should	O
be	O
noted	O
in	O
elderly	O
depressive	O
patients	O
whose	O
symptoms	O
often	O
include	O
dehydration	O
,	O
agitation	O
,	O
malnutrition	O
,	O
and	O
exhaustion	O
.	O

Careful	O
therapeutic	O
intervention	O
is	O
necessary	O
in	O
cases	O
involving	O
elderly	O
patients	O
who	O
suffer	O
from	O
depression	O
.	O

Down	O
-	O
regulation	O
of	O
norepinephrine	B-CHED
transporter	O
function	O
induced	O
by	O
chronic	O
administration	O
of	O
desipramine	B-CHED
linking	O
to	O
the	O
alteration	O
of	O
sensitivity	O
of	O
local	O
-	O
anesthetics	O
-	O
induced	O
convulsions	O
and	O
the	O
counteraction	O
by	O
co	O
-	O
administration	O
with	O
local	O
anesthetics	O
.	O

Alterations	O
of	O
norepinephrine	B-CHED
transporter	O
(	O
NET	O
)	O
function	O
by	O
chronic	O
inhibition	O
of	O
NET	O
in	O
relation	O
to	O
sensitization	O
to	O
seizures	O
induce	O
by	O
cocaine	B-CHED
and	O
local	O
anesthetics	O
were	O
studied	O
in	O
mice	O
.	O

Daily	O
administration	O
of	O
desipramine	B-CHED
,	O
an	O
inhibitor	O
of	O
the	O
NET	O
,	O
for	O
5	O
days	O
decreased	O
[	O
(	O
3	O
)	O
H	O
]	O
norepinephrine	B-CHED
uptake	O
in	O
the	O
P2	O
fractions	O
of	O
hippocampus	O
but	O
not	O
cortex	O
,	O
striatum	O
or	O
amygdalae	O
.	O

Co	O
-	O
administration	O
of	O
lidocaine	B-CHED
,	O
bupivacaine	B-CHED
or	O
tricaine	B-CHED
with	O
desipramine	B-CHED
reversed	O
this	O
effect	O
.	O

Daily	O
treatment	O
of	O
cocaine	B-CHED
increased	O
[	O
(	O
3	O
)	O
H	O
]	O
norepinephrine	B-CHED
uptake	O
into	O
the	O
hippocampus	O
.	O

Daily	O
administration	O
of	O
desipramine	B-CHED
increased	O
the	O
incidence	O
of	O
appearance	O
of	O
lidocaine	B-CHED
-	O
induced	O
convulsions	O
and	O
decreased	O
that	O
of	O
cocaine	B-CHED
-	O
induced	O
convulsions	O
.	O

Co	O
-	O
administration	O
of	O
lidocaine	B-CHED
with	O
desipramine	B-CHED
reversed	O
the	O
changes	O
of	O
convulsive	O
activity	O
of	O
lidocaine	B-CHED
and	O
cocaine	B-CHED
induced	O
by	O
repeated	O
administration	O
of	O
desipramine	B-CHED
.	O

These	O
results	O
suggest	O
that	O
down	O
-	O
regulation	O
of	O
hippocampal	O
NET	O
induced	O
by	O
chronic	O
administration	O
of	O
desipramine	B-CHED
may	O
be	O
relevant	O
to	O
desipramine	B-CHED
-	O
induced	O
sensitization	O
of	O
lidocaine	B-CHED
convulsions	O
.	O

Inhibition	O
of	O
Na	B-CHED
(	O
+	O
)	O
channels	O
by	O
local	O
anesthetics	O
may	O
regulate	O
desipramine	B-CHED
-	O
induced	O
down	O
-	O
regulation	O
of	O
NET	O
function	O
.	O

Repeated	O
administration	O
of	O
cocaine	B-CHED
induces	O
up	O
-	O
regulation	O
of	O
hippocampal	O
NET	O
function	O
.	O

Desipramine	B-CHED
-	O
induced	O
sensitization	O
of	O
lidocaine	B-CHED
seizures	O
may	O
have	O
a	O
mechanism	O
distinct	O
from	O
kindling	O
resulting	O
from	O
repeated	O
administration	O
of	O
cocaine	B-CHED
.	O

Atorvastatin	B-CHED
prevented	O
and	O
reversed	O
dexamethasone	B-CHED
-	O
induced	O
hypertension	O
in	O
the	O
rat	O
.	O

To	O
assess	O
the	O
antioxidant	O
effects	O
of	O
atorvastatin	B-CHED
(	O
atorva	B-CHED
)	O
on	O
dexamethasone	B-CHED
(	O
dex	B-CHED
)	O
-	O
induced	O
hypertension	O
,	O
60	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
were	O
treated	O
with	O
atorva	B-CHED
30	O
mg	O
/	O
kg	O
/	O
day	O
or	O
tap	O
water	O
for	O
15	O
days	O
.	O

Dex	B-CHED
increased	O
systolic	O
blood	O
pressure	O
(	O
SBP	O
)	O
from	O
109	O
+	O
/	O
-	O
1	O
.	O
8	O
to	O
135	O
+	O
/	O
-	O
0	O
.	O
6	O
mmHg	O
and	O
plasma	O
superoxide	B-CHED
(	O
5711	O
+	O
/	O
-	O
284	O
.	O
9	O
saline	O
,	O
7931	O
+	O
/	O
-	O
392	O
.	O
8	O
U	O
/	O
ml	O
dex	B-CHED
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

In	O
this	O
prevention	O
study	O
,	O
SBP	O
in	O
the	O
atorva	B-CHED
+	O
dex	B-CHED
group	O
was	O
increased	O
from	O
115	O
+	O
/	O
-	O
0	O
.	O
4	O
to	O
124	O
+	O
/	O
-	O
1	O
.	O
5	O
mmHg	O
,	O
but	O
this	O
was	O
significantly	O
lower	O
than	O
in	O
the	O
dex	B-CHED
-	O
only	O
group	O
(	O
P	O
'	O
<	O
0	O
.	O
05	O
)	O
.	O

Atorva	B-CHED
reversed	O
dex	B-CHED
-	O
induced	O
hypertension	O
(	O
129	O
+	O
/	O
-	O
0	O
.	O
6	O
mmHg	O
,	O
vs	O
.	O
135	O
+	O
/	O
-	O
0	O
.	O
6	O
mmHg	O
P	O
'	O
<	O
0	O
.	O
05	O
)	O
and	O
decreased	O
plasma	O
superoxide	B-CHED
(	O
7931	O
+	O
/	O
-	O
392	O
.	O
8	O
dex	B-CHED
,	O
1187	O
+	O
/	O
-	O
441	O
.	O
2	O
atorva	B-CHED
+	O
dex	B-CHED
,	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O

Plasma	O
nitrate	B-CHED
/	O
nitrite	B-CHED
(	O
NOx	O
)	O
was	O
decreased	O
in	O
dex	B-CHED
-	O
treated	O
rats	O
compared	O
to	O
saline	O
-	O
treated	O
rats	O
(	O
11	O
.	O
2	O
+	O
/	O
-	O
1	O
.	O
08	O
microm	O
,	O
15	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
17	O
microm	O
,	O
respectively	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Atorva	B-CHED
affected	O
neither	O
plasma	O
NOx	O
nor	O
thymus	O
weight	O
.	O

Thus	O
,	O
atorvastatin	B-CHED
prevented	O
and	O
reversed	O
dexamethasone	B-CHED
-	O
induced	O
hypertension	O
in	O
the	O
rat	O
.	O

Peripheral	O
neuropathy	O
caused	O
by	O
high	O
-	O
dose	O
cytosine	B-CHED
arabinoside	I-CHED
treatment	O
in	O
a	O
patient	O
with	O
acute	O
myeloid	O
leukemia	O
.	O

The	O
central	O
nervous	O
system	O
toxicity	O
of	O
high	O
-	O
dose	O
cytosine	B-CHED
arabinoside	I-CHED
is	O
well	O
recognized	O
,	O
but	O
the	O
toxicity	O
of	O
cytosine	B-CHED
arabinoside	I-CHED
in	O
the	O
peripheral	O
nervous	O
system	O
has	O
been	O
infrequently	O
reported	O
.	O

A	O
49	O
-	O
year	O
-	O
old	O
Japanese	O
man	O
was	O
diagnosed	O
with	O
acute	O
myeloid	O
leukemia	O
.	O

After	O
he	O
achieved	O
complete	O
remission	O
,	O
he	O
received	O
high	O
-	O
dose	O
cytosine	B-CHED
arabinoside	I-CHED
treatment	O
(	O
2	O
g	O
/	O
m2	O
twice	O
a	O
day	O
for	O
5	O
days	O
;	O
total	O
,	O
20	O
g	O
/	O
m2	O
)	O
as	O
consolidation	O
therapy	O
.	O

The	O
first	O
course	O
of	O
high	O
-	O
dose	O
cytosine	B-CHED
arabinoside	I-CHED
resulted	O
in	O
no	O
unusual	O
symptoms	O
,	O
but	O
on	O
day	O
21	O
of	O
the	O
second	O
course	O
of	O
treatment	O
,	O
the	O
patient	O
complained	O
of	O
numbness	O
in	O
his	O
right	O
foot	O
.	O

Electromyogram	O
and	O
nerve	O
-	O
conduction	O
studies	O
showed	O
peripheral	O
neuropathy	O
in	O
both	O
peroneal	O
nerves	O
.	O

This	O
neuropathy	O
was	O
gradually	O
resolving	O
;	O
however	O
,	O
after	O
the	O
patient	O
received	O
allogeneic	O
bone	O
marrow	O
transplantation	O
,	O
the	O
symptoms	O
worsened	O
,	O
with	O
the	O
development	O
of	O
graft	O
-	O
versus	O
-	O
host	O
disease	O
,	O
and	O
the	O
symptoms	O
subsequently	O
responded	O
to	O
methylprednisolone	B-CHED
.	O

Although	O
the	O
mechanisms	O
of	O
peripheral	O
neuropathy	O
are	O
still	O
unclear	O
,	O
high	O
-	O
dose	O
cytosine	B-CHED
arabinoside	I-CHED
is	O
a	O
therapy	O
that	O
is	O
potentially	O
toxic	O
to	O
the	O
peripheral	O
nervous	O
system	O
,	O
and	O
auto	O
/	O
alloimmunity	O
may	O
play	O
an	O
important	O
role	O
in	O
these	O
mechanisms	O
.	O

Effect	O
of	O
alpha	B-CHED
-	I-CHED
tocopherol	I-CHED
and	O
deferoxamine	B-CHED
on	O
methamphetamine	B-CHED
-	O
induced	O
neurotoxicity	O
.	O

Methamphetamine	B-CHED
(	O
MA	B-CHED
)	O
-	O
induced	O
dopaminergic	O
neurotoxicity	O
is	O
believed	O
to	O
be	O
associated	O
with	O
the	O
increased	O
formation	O
of	O
free	O
radicals	O
.	O

This	O
study	O
examined	O
the	O
effect	O
of	O
alpha	B-CHED
-	I-CHED
tocopherol	I-CHED
(	O
alpha	B-CHED
-	I-CHED
TC	I-CHED
)	O
,	O
a	O
scavenger	O
of	O
reactive	O
oxygen	B-CHED
species	O
,	O
and	O
deferoxamine	B-CHED
(	O
DFO	B-CHED
)	O
,	O
an	O
iron	B-CHED
chelator	O
,	O
on	O
the	O
MA	B-CHED
-	O
induced	O
neurotoxicity	O
.	O

Male	O
rats	O
were	O
treated	O
with	O
MA	B-CHED
(	O
10	O
mg	O
/	O
kg	O
,	O
every	O
2	O
h	O
for	O
four	O
injections	O
)	O
.	O

The	O
rat	O
received	O
either	O
alpha	B-CHED
-	I-CHED
TC	I-CHED
(	O
20	O
mg	O
/	O
kg	O
)	O
intraperitoneally	O
for	O
3	O
days	O
and	O
30	O
min	O
prior	O
to	O
MA	B-CHED
administration	O
or	O
DFO	B-CHED
(	O
50	O
mg	O
/	O
kg	O
)	O
subcutaneously	O
30	O
min	O
before	O
MA	B-CHED
administration	O
.	O

The	O
concentrations	O
of	O
dopamine	B-CHED
(	O
DA	B-CHED
)	O
,	O
serotonin	B-CHED
and	O
their	O
metabolites	O
decreased	O
significantly	O
after	O
MA	B-CHED
administration	O
,	O
which	O
was	O
inhibited	O
by	O
the	O
alpha	B-CHED
-	I-CHED
TC	I-CHED
and	O
DFO	B-CHED
pretreatment	O
.	O

alpha	B-CHED
-	I-CHED
TC	I-CHED
and	O
DFO	B-CHED
attenuated	O
the	O
MA	B-CHED
-	O
induced	O
hyperthermia	O
as	O
well	O
as	O
the	O
alterations	O
in	O
the	O
locomotor	O
activity	O
.	O

The	O
level	O
of	O
lipid	O
peroxidation	O
was	O
higher	O
and	O
the	O
reduced	O
glutathione	B-CHED
concentration	O
was	O
lower	O
in	O
the	O
MA	B-CHED
-	O
treated	O
rats	O
.	O

These	O
changes	O
were	O
significantly	O
attenuated	O
by	O
alpha	B-CHED
-	I-CHED
TC	I-CHED
and	O
DFO	B-CHED
.	O

This	O
suggests	O
that	O
alpha	B-CHED
-	I-CHED
TC	I-CHED
and	O
DFO	B-CHED
ameliorate	O
the	O
MA	B-CHED
-	O
induced	O
neuronal	O
damage	O
by	O
decreasing	O
the	O
level	O
of	O
oxidative	O
stress	O
.	O

Blockade	O
of	O
both	O
D	O
-	O
1	O
and	O
D	O
-	O
2	O
dopamine	B-CHED
receptors	O
may	O
induce	O
catalepsy	O
in	O
mice	O
.	O

1	O
.	O

The	O
catalepsy	O
induced	O
by	O
dopamine	B-CHED
antagonists	O
has	O
been	O
tested	O
and	O
the	O
possible	O
dopamine	B-CHED
subtypes	O
involved	O
in	O
catalepsy	O
was	O
determined	O
.	O

2	O
.	O

Dopamine	B-CHED
antagonist	O
fluphenazine	B-CHED
,	O
D	O
-	O
1	O
antagonist	O
SCH	B-CHED
23390	I-CHED
or	O
D	O
-	O
2	O
antagonist	O
sulpiride	B-CHED
induced	O
catalepsy	O
.	O

The	O
effect	O
of	O
fluphenazine	B-CHED
and	O
sulpiride	B-CHED
was	O
dose	O
-	O
dependent	O
.	O

Combination	O
of	O
SCH	B-CHED
23390	I-CHED
with	O
sulpiride	B-CHED
did	O
not	O
induce	O
catalepsy	O
potentiation	O
.	O

3	O
.	O

D	O
-	O
1	O
agonist	O
SKF	B-CHED
38393	I-CHED
or	O
D	O
-	O
2	O
agonist	O
quinpirole	B-CHED
decreased	O
the	O
catalepsy	O
induced	O
by	O
fluphenazine	B-CHED
,	O
SCH	B-CHED
23390	I-CHED
or	O
sulpiride	B-CHED
.	O

4	O
.	O

Combination	O
of	O
SKF	B-CHED
38393	I-CHED
with	O
quinpirole	B-CHED
did	O
not	O
cause	O
potentiated	O
inhibitory	O
effect	O
on	O
catalepsy	O
induced	O
by	O
dopamine	B-CHED
antagonists	O
.	O

5	O
.	O

The	O
data	O
may	O
indicate	O
that	O
although	O
D	O
-	O
2	O
receptor	O
blockade	O
is	O
involved	O
in	O
catalepsy	O
,	O
the	O
D	O
-	O
1	O
receptor	O
may	O
plan	O
a	O
role	O
.	O

Sustained	O
clinical	O
improvement	O
of	O
a	O
patient	O
with	O
decompensated	O
hepatitis	O
B	O
virus	O
-	O
related	O
cirrhosis	O
after	O
treatment	O
with	O
lamivudine	B-CHED
monotherapy	O
.	O

Hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
infection	O
,	O
which	O
causes	O
liver	O
cirrhosis	O
and	O
hepatocellular	O
carcinoma	O
,	O
remains	O
a	O
major	O
health	O
problem	O
in	O
Asian	O
countries	O
.	O

Recent	O
development	O
of	O
vaccine	O
for	O
prevention	O
is	O
reported	O
to	O
be	O
successful	O
in	O
reducing	O
the	O
size	O
of	O
chronically	O
infected	O
carriers	O
,	O
although	O
the	O
standard	O
medical	O
therapies	O
have	O
not	O
been	O
established	O
up	O
to	O
now	O
.	O

In	O
this	O
report	O
,	O
we	O
encountered	O
a	O
patient	O
with	O
decompensated	O
HBV	O
-	O
related	O
cirrhosis	O
who	O
exhibited	O
the	O
dramatic	O
improvements	O
after	O
antiviral	O
therapy	O
.	O

The	O
patient	O
was	O
a	O
50	O
-	O
year	O
-	O
old	O
woman	O
.	O

Previous	O
conventional	O
medical	O
treatments	O
were	O
not	O
effective	O
for	O
this	O
patient	O
,	O
thus	O
this	O
patient	O
had	O
been	O
referred	O
to	O
our	O
hospital	O
.	O

However	O
,	O
the	O
administration	O
of	O
lamivudine	B-CHED
,	O
a	O
reverse	O
transcriptase	O
inhibitor	O
,	O
for	O
23	O
months	O
dramatically	O
improved	O
her	O
liver	O
severity	O
.	O

During	O
this	O
period	O
,	O
no	O
drug	O
resistant	O
mutant	O
HBV	O
emerged	O
,	O
and	O
the	O
serum	O
HBV	O
-	O
DNA	O
level	O
was	O
continuously	O
suppressed	O
.	O

These	O
virological	O
responses	O
were	O
also	O
maintained	O
even	O
after	O
the	O
antiviral	O
therapy	O
was	O
discontinued	O
.	O

Moreover	O
,	O
both	O
hepatitis	B-CHED
B	I-CHED
surface	I-CHED
antigen	I-CHED
and	I-CHED
e	I-CHED
antigen	I-CHED
were	O
observed	O
to	O
have	O
disappeared	O
in	O
this	O
patient	O
.	O

The	O
administration	O
of	O
lamivudine	B-CHED
to	O
patients	O
with	O
HBV	O
-	O
related	O
cirrhosis	O
,	O
like	O
our	O
present	O
case	O
,	O
should	O
be	O
considered	O
as	O
an	O
initial	O
medical	O
therapeutic	O
option	O
,	O
especially	O
in	O
countries	O
where	O
liver	O
transplantation	O
is	O
not	O
reliably	O
available	O
.	O

Antiarrhythmic	O
effects	O
of	O
optical	O
isomers	O
of	O
cibenzoline	B-CHED
on	O
canine	O
ventricular	O
arrhythmias	O
.	O

Antiarrhythmic	O
effects	O
of	O
(	O
+	O
)	O
-	O
cibenzoline	B-CHED
and	O
(	O
-	O
)	O
-	O
cibenzoline	B-CHED
were	O
examined	O
using	O
two	O
canine	O
ventricular	O
arrhythmia	O
models	O
.	O

Digitalis	B-CHED
arrhythmia	O
,	O
which	O
is	O
suppressed	O
by	O
Na	B-CHED
channel	O
blockers	O
,	O
was	O
induced	O
by	O
intermittent	O
intravenous	O
(	O
i	O
.	O
v	O
.	O
)	O
injection	O
of	O
ouabain	B-CHED
in	O
pentobarbital	B-CHED
-	O
anesthetized	O
dogs	O
.	O

Adrenaline	O
arrhythmia	O
,	O
which	O
is	O
suppressed	O
by	O
Ca	B-CHED
channel	O
blockers	O
,	O
was	O
induced	O
by	O
adrenaline	B-CHED
infusion	O
in	O
halothane	B-CHED
-	O
anesthetized	O
dogs	O
.	O

Ten	O
and	O
5	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
(	O
+	O
)	O
-	O
cibenzoline	B-CHED
suppressed	O
digitalis	B-CHED
-	O
and	O
adrenaline	B-CHED
-	O
induced	O
arrhythmias	O
,	O
respectively	O
.	O

The	O
minimum	O
effective	O
plasma	O
concentrations	O
of	O
(	O
+	O
)	O
-	O
cibenzoline	B-CHED
for	O
digitalis	B-CHED
-	O
and	O
adrenaline	B-CHED
-	O
induced	O
arrhythmias	O
were	O
1	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
4	O
and	O
2	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
6	O
micrograms	O
/	O
ml	O
,	O
respectively	O
(	O
mean	O
+	O
/	O
-	O
SD	O
,	O
n	O
=	O
6	O
)	O
.	O

A	O
lower	O
dose	O
of	O
1	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
of	O
(	O
-	O
)	O
-	O
cibenzoline	B-CHED
suppressed	O
the	O
digitalis	B-CHED
-	O
induced	O
arrhythmia	O
,	O
whereas	O
5	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
was	O
needed	O
to	O
suppress	O
adrenaline	B-CHED
-	O
induced	O
arrhythmias	O
.	O

The	O
minimum	O
effective	O
plasma	O
concentrations	O
of	O
(	O
-	O
)	O
-	O
cibenzoline	B-CHED
for	O
digitalis	B-CHED
-	O
and	O
adrenaline	B-CHED
-	O
induced	O
arrhythmia	O
were	O
0	O
.	O
06	O
+	O
/	O
-	O
0	O
.	O
04	O
and	O
0	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
1	O
micrograms	O
/	O
ml	O
,	O
respectively	O
(	O
mean	O
+	O
/	O
-	O
SD	O
,	O
n	O
=	O
6	O
)	O
.	O

The	O
stronger	O
antiarrhythmic	O
effect	O
of	O
(	O
-	O
)	O
-	O
cibenzoline	B-CHED
indicates	O
that	O
(	O
-	O
)	O
-	O
isomer	O
may	O
have	O
an	O
effect	O
nearly	O
5	O
-	O
20	O
times	O
stronger	O
in	O
suppressing	O
Na	B-CHED
channels	O
,	O
but	O
effects	O
of	O
both	O
drugs	O
on	O
Ca	B-CHED
channels	O
may	O
be	O
almost	O
equipotent	O
.	O

Passage	O
of	O
mannitol	B-CHED
into	O
the	O
brain	O
around	O
gliomas	O
:	O
a	O
potential	O
cause	O
of	O
rebound	O
phenomenon	O
.	O

A	O
study	O
on	O
21	O
patients	O
.	O

AIM	O
:	O
Widespread	O
use	O
of	O
mannitol	B-CHED
to	O
reduce	O
brain	O
edema	O
and	O
lower	O
elevated	O
ICP	O
in	O
brain	O
tumor	O
patients	O
continues	O
to	O
be	O
afflicted	O
by	O
the	O
so	O
-	O
called	O
rebound	O
phenomenon	O
.	O

Leakage	O
of	O
mannitol	B-CHED
into	O
the	O
brain	O
parenchyma	O
through	O
an	O
altered	O
BBB	O
and	O
secondary	O
reversal	O
of	O
osmotic	O
gradient	O
is	O
considered	O
the	O
major	O
cause	O
of	O
rebound	O
.	O

This	O
has	O
only	O
been	O
demonstrated	O
experimentally	O
in	O
animals	O
.	O

As	O
a	O
contribution	O
to	O
this	O
issue	O
we	O
decided	O
to	O
research	O
the	O
possible	O
passage	O
of	O
mannitol	B-CHED
into	O
the	O
brain	O
after	O
administration	O
to	O
21	O
brain	O
tumor	O
patients	O
.	O

METHODS	O
:	O
Mannitol	B-CHED
(	O
18	O
%	O
solution	O
;	O
1	O
g	O
/	O
kg	O
)	O
was	O
administered	O
as	O
a	O
bolus	O
to	O
patients	O
(	O
ten	O
had	O
malignant	O
glioma	O
,	O
seven	O
brain	O
metastases	O
and	O
four	O
meningioma	O
)	O
about	O
30	O
minutes	O
before	O
craniotomy	O
.	O

During	O
resection	O
,	O
a	O
sample	O
of	O
the	O
surrounding	O
edematous	O
white	O
matter	O
was	O
taken	O
at	O
the	O
same	O
time	O
as	O
a	O
10	O
ml	O
venous	O
blood	O
sample	O
.	O

Mannitol	B-CHED
concentrations	O
were	O
measured	O
in	O
plasma	O
and	O
white	O
matter	O
by	O
a	O
modified	O
version	O
of	O
the	O
enzyme	O
assay	O
of	O
Blonquist	O
et	O
al	O
.	O

RESULTS	O
:	O
In	O
most	O
glioma	O
patients	O
,	O
mannitol	B-CHED
concentrations	O
in	O
white	O
matter	O
were	O
2	O
to	O
6	O
times	O
higher	O
than	O
in	O
plasma	O
(	O
mean	O
3	O
.	O
5	O
times	O
)	O
.	O

In	O
meningioma	O
and	O
metastases	O
patients	O
plasma	O
concentrations	O
of	O
mannitol	B-CHED
were	O
higher	O
than	O
white	O
matter	O
concentrations	O
except	O
in	O
three	O
cases	O
with	O
infiltration	O
by	O
neoplastic	O
cells	O
.	O

CONCLUSIONS	O
:	O
The	O
results	O
of	O
our	O
study	O
show	O
that	O
even	O
after	O
a	O
single	O
bolus	O
,	O
mannitol	B-CHED
may	O
leak	O
through	O
the	O
altered	O
BBB	O
near	O
gliomas	O
,	O
reversing	O
the	O
initial	O
plasma	O
-	O
to	O
-	O
blood	O
osmotic	O
gradient	O
,	O
aggravating	O
peritumoral	O
edema	O
and	O
promoting	O
rebound	O
of	O
ICP	O
.	O

Placebo	O
-	O
level	O
incidence	O
of	O
extrapyramidal	O
symptoms	O
(	O
EPS	O
)	O
with	O
quetiapine	B-CHED
in	O
controlled	O
studies	O
of	O
patients	O
with	O
bipolar	O
mania	O
.	O

OBJECTIVES	O
:	O
To	O
evaluate	O
extrapyramidal	O
symptoms	O
(	O
EPS	O
)	O
,	O
including	O
akathisia	O
,	O
with	O
quetiapine	B-CHED
in	O
patients	O
with	O
bipolar	O
mania	O
.	O

METHODS	O
:	O
Data	O
were	O
analyzed	O
from	O
four	O
similarly	O
designed	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
3	O
-	O
to	O
12	O
-	O
week	O
studies	O
.	O

Two	O
studies	O
evaluated	O
quetiapine	B-CHED
monotherapy	O
(	O
up	O
to	O
800	O
mg	O
/	O
day	O
)	O
(	O
n	O
=	O
209	O
)	O
versus	O
placebo	O
(	O
n	O
=	O
198	O
)	O
,	O
with	O
lithium	B-CHED
or	O
haloperidol	B-CHED
monotherapy	O
as	O
respective	O
active	O
controls	O
.	O

Two	O
studies	O
evaluated	O
quetiapine	B-CHED
(	O
up	O
to	O
800	O
mg	O
/	O
day	O
)	O
in	O
combination	O
with	O
a	O
mood	O
stabilizer	O
(	O
lithium	B-CHED
or	O
divalproex	B-CHED
,	O
QTP	B-CHED
+	O
Li	B-CHED
/	O
DVP	B-CHED
)	O
(	O
n	O
=	O
196	O
)	O
compared	O
to	O
placebo	O
and	O
mood	O
stabilizer	O
(	O
PBO	O
+	O
Li	B-CHED
/	O
DVP	B-CHED
)	O
(	O
n	O
=	O
203	O
)	O
.	O

Extrapyramidal	O
symptoms	O
were	O
evaluated	O
using	O
the	O
Simpson	O
-	O
Angus	O
Scale	O
(	O
SAS	O
)	O
,	O
the	O
Barnes	O
Akathisia	O
Rating	O
Scale	O
(	O
BARS	O
)	O
,	O
adverse	O
event	O
reports	O
and	O
anticholinergic	O
drug	O
usage	O
.	O

RESULTS	O
:	O
The	O
incidence	O
of	O
EPS	O
-	O
related	O
adverse	O
events	O
,	O
including	O
akathisia	O
,	O
was	O
no	O
different	O
with	O
quetiapine	B-CHED
monotherapy	O
(	O
12	O
.	O
9	O
%	O
)	O
than	O
with	O
placebo	O
(	O
13	O
.	O
1	O
%	O
)	O
.	O

Similarly	O
,	O
EPS	O
-	O
related	O
adverse	O
events	O
with	O
QTP	B-CHED
+	O
Li	B-CHED
/	O
DVP	B-CHED
(	O
21	O
.	O
4	O
%	O
)	O
were	O
no	O
different	O
than	O
with	O
PBO	O
+	O
Li	B-CHED
/	O
DVP	B-CHED
(	O
19	O
.	O
2	O
%	O
)	O
.	O

Adverse	O
events	O
related	O
to	O
EPS	O
occurred	O
in	O
59	O
.	O
6	O
%	O
of	O
patients	O
treated	O
with	O
haloperidol	B-CHED
(	O
n	O
=	O
99	O
)	O
monotherapy	O
,	O
whereas	O
26	O
.	O
5	O
%	O
of	O
patients	O
treated	O
with	O
lithium	B-CHED
(	O
n	O
=	O
98	O
)	O
monotherapy	O
experienced	O
adverse	O
events	O
related	O
to	O
EPS	O
.	O

The	O
incidence	O
of	O
akathisia	O
was	O
low	O
and	O
similar	O
with	O
quetiapine	B-CHED
monotherapy	O
(	O
3	O
.	O
3	O
%	O
)	O
and	O
placebo	O
(	O
6	O
.	O
1	O
%	O
)	O
,	O
and	O
with	O
QTP	B-CHED
+	O
Li	B-CHED
/	O
DVP	B-CHED
(	O
3	O
.	O
6	O
%	O
)	O
and	O
PBO	O
+	O
Li	B-CHED
/	O
DVP	B-CHED
(	O
4	O
.	O
9	O
%	O
)	O
.	O

Lithium	B-CHED
was	O
associated	O
with	O
a	O
significantly	O
higher	O
incidence	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
of	O
tremor	O
(	O
18	O
.	O
4	O
%	O
)	O
than	O
quetiapine	B-CHED
(	O
5	O
.	O
6	O
%	O
)	O
;	O
cerebellar	O
tremor	O
,	O
which	O
is	O
a	O
known	O
adverse	O
effect	O
of	O
lithium	B-CHED
,	O
may	O
have	O
contributed	O
to	O
the	O
elevated	O
rate	O
of	O
tremor	O
in	O
patients	O
receiving	O
lithium	B-CHED
therapy	O
.	O

Haloperidol	B-CHED
induced	O
a	O
significantly	O
higher	O
incidence	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
of	O
akathisia	O
(	O
33	O
.	O
3	O
%	O
versus	O
5	O
.	O
9	O
%	O
)	O
,	O
tremor	O
(	O
30	O
.	O
3	O
%	O
versus	O
7	O
.	O
8	O
%	O
)	O
,	O
and	O
extrapyramidal	O
syndrome	O
(	O
35	O
.	O
4	O
%	O
versus	O
5	O
.	O
9	O
%	O
)	O
than	O
quetiapine	B-CHED
.	O

No	O
significant	O
differences	O
were	O
observed	O
between	O
quetiapine	B-CHED
and	O
placebo	O
on	O
SAS	O
and	O
BARS	O
scores	O
.	O

Anticholinergic	O
use	O
was	O
low	O
and	O
similar	O
with	O
quetiapine	B-CHED
or	O
placebo	O
.	O

CONCLUSIONS	O
:	O
In	O
bipolar	O
mania	O
,	O
the	O
incidence	O
of	O
EPS	O
,	O
including	O
akathisia	O
,	O
with	O
quetiapine	B-CHED
therapy	O
is	O
similar	O
to	O
that	O
with	O
placebo	O
.	O

Is	O
phenytoin	B-CHED
administration	O
safe	O
in	O
a	O
hypothermic	O
child	O
?	O

A	O
male	O
neonate	O
with	O
a	O
Chiari	O
malformation	O
and	O
a	O
leaking	O
myelomeningocoele	O
underwent	O
ventriculoperitoneal	O
shunt	O
insertion	O
followed	O
by	O
repair	O
of	O
myelomeningocoele	O
.	O

During	O
anaesthesia	O
and	O
surgery	O
,	O
he	O
inadvertently	O
became	O
moderately	O
hypothermic	O
.	O

Intravenous	O
phenytoin	B-CHED
was	O
administered	O
during	O
the	O
later	O
part	O
of	O
the	O
surgery	O
for	O
seizure	O
prophylaxis	O
.	O

Following	O
phenytoin	B-CHED
administration	O
,	O
the	O
patient	O
developed	O
acute	O
severe	O
bradycardia	O
,	O
refractory	O
to	O
atropine	B-CHED
and	O
adrenaline	B-CHED
.	O

The	O
cardiac	O
depressant	O
actions	O
of	O
phenytoin	B-CHED
and	O
hypothermia	O
can	O
be	O
additive	O
.	O

Administration	O
of	O
phenytoin	B-CHED
in	O
the	O
presence	O
of	O
hypothermia	O
may	O
lead	O
to	O
an	O
adverse	O
cardiac	O
event	O
in	O
children	O
.	O

As	O
phenytoin	B-CHED
is	O
a	O
commonly	O
used	O
drug	O
,	O
clinicians	O
need	O
to	O
be	O
aware	O
of	O
this	O
interaction	O
.	O

Valproate	B-CHED
-	O
induced	O
chorea	O
and	O
encephalopathy	O
in	O
atypical	O
nonketotic	O
hyperglycinemia	O
.	O

Nonketotic	O
hyperglycinemia	O
is	O
a	O
disorder	O
of	O
amino	O
acid	O
metabolism	O
in	O
which	O
a	O
defect	O
in	O
the	O
glycine	B-CHED
cleavage	O
system	O
leads	O
to	O
an	O
accumulation	O
of	O
glycine	B-CHED
in	O
the	O
brain	O
and	O
other	O
body	O
compartments	O
.	O

In	O
the	O
classical	O
form	O
it	O
presents	O
as	O
neonatal	O
apnea	O
,	O
intractable	O
seizures	O
,	O
and	O
hypotonia	O
,	O
followed	O
by	O
significant	O
psychomotor	O
retardation	O
.	O

An	O
important	O
subset	O
of	O
children	O
with	O
nonketotic	O
hyperglycinemia	O
are	O
atypical	O
variants	O
who	O
present	O
in	O
a	O
heterogeneous	O
manner	O
.	O

This	O
report	O
describes	O
a	O
patient	O
with	O
mild	O
language	O
delay	O
and	O
mental	O
retardation	O
,	O
who	O
was	O
found	O
to	O
have	O
nonketotic	O
hyperglycinemia	O
following	O
her	O
presentation	O
with	O
acute	O
encephalopathy	O
and	O
chorea	O
shortly	O
after	O
initiation	O
of	O
valproate	B-CHED
therapy	O
.	O

Delayed	O
institution	O
of	O
hypertension	O
during	O
focal	O
cerebral	O
ischemia	O
:	O
effect	O
on	O
brain	O
edema	O
.	O

The	O
effect	O
of	O
induced	O
hypertension	O
instituted	O
after	O
a	O
2	O
-	O
h	O
delay	O
following	O
middle	O
cerebral	O
artery	O
occlusion	O
(	O
MCAO	O
)	O
on	O
brain	O
edema	O
formation	O
and	O
histochemical	O
injury	O
was	O
studied	O
.	O

Under	O
isoflurane	B-CHED
anesthesia	O
,	O
the	O
MCA	O
of	O
14	O
spontaneously	O
hypertensive	O
rats	O
was	O
occluded	O
.	O

In	O
the	O
control	O
group	O
(	O
n	O
=	O
7	O
)	O
,	O
the	O
mean	O
arterial	O
pressure	O
(	O
MAP	O
)	O
was	O
not	O
manipulated	O
.	O

In	O
the	O
hypertensive	O
group	O
(	O
n	O
=	O
7	O
)	O
,	O
the	O
MAP	O
was	O
elevated	O
by	O
25	O
-	O
30	O
mm	O
Hg	O
beginning	O
2	O
h	O
after	O
MCAO	O
.	O

Four	O
hours	O
after	O
MCAO	O
,	O
the	O
rats	O
were	O
killed	O
and	O
the	O
brains	O
harvested	O
.	O

The	O
brains	O
were	O
sectioned	O
along	O
coronal	O
planes	O
spanning	O
the	O
distribution	O
of	O
ischemia	O
produced	O
by	O
MCAO	O
.	O

Specific	O
gravity	O
(	O
SG	O
)	O
was	O
determined	O
in	O
the	O
subcortex	O
and	O
in	O
two	O
sites	O
in	O
the	O
cortex	O
(	O
core	O
and	O
periphery	O
of	O
the	O
ischemic	O
territory	O
)	O
.	O

The	O
extent	O
of	O
neuronal	O
injury	O
was	O
determined	O
by	O
2	B-CHED
,	I-CHED
3	I-CHED
,	I-CHED
5	I-CHED
-	I-CHED
triphenyltetrazolium	I-CHED
staining	O
.	O

In	O
the	O
ischemic	O
core	O
,	O
there	O
was	O
no	O
difference	O
in	O
SG	O
in	O
the	O
subcortex	O
and	O
cortex	O
in	O
the	O
two	O
groups	O
.	O

In	O
the	O
periphery	O
of	O
the	O
ischemic	O
territory	O
,	O
SG	O
in	O
the	O
cortex	O
was	O
greater	O
(	O
less	O
edema	O
accumulation	O
)	O
in	O
the	O
hypertensive	O
group	O
(	O
1	O
.	O
041	O
+	O
/	O
-	O
0	O
.	O
001	O
vs	O
1	O
.	O
039	O
+	O
/	O
-	O
0	O
.	O
001	O
,	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

The	O
area	O
of	O
histochemical	O
injury	O
(	O
as	O
a	O
percent	O
of	O
the	O
cross	O
-	O
sectional	O
area	O
of	O
the	O
hemisphere	O
)	O
was	O
less	O
in	O
the	O
hypertensive	O
group	O
(	O
33	O
+	O
/	O
-	O
3	O
%	O
vs	O
21	O
+	O
/	O
-	O
2	O
%	O
,	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

The	O
data	O
indicate	O
that	O
phenylephrine	B-CHED
-	O
induced	O
hypertension	O
instituted	O
2	O
h	O
after	O
MCAO	O
does	O
not	O
aggravate	O
edema	O
in	O
the	O
ischemic	O
core	O
,	O
that	O
it	O
improves	O
edema	O
in	O
the	O
periphery	O
of	O
the	O
ischemic	O
territory	O
,	O
and	O
that	O
it	O
reduces	O
the	O
area	O
of	O
histochemical	O
neuronal	O
dysfunction	O
.	O

Behavioral	O
effects	O
of	O
pubertal	O
anabolic	O
androgenic	O
steroid	B-CHED
exposure	O
in	O
male	O
rats	O
with	O
low	O
serotonin	B-CHED
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
interactive	O
effects	O
of	O
chronic	O
anabolic	O
androgenic	O
steroid	B-CHED
(	O
AAS	O
)	O
exposure	O
and	O
brain	O
serotonin	B-CHED
(	O
5	B-CHED
-	I-CHED
hydroxytryptamine	I-CHED
,	O
5	B-CHED
-	I-CHED
HT	I-CHED
)	O
depletion	O
on	O
behavior	O
of	O
pubertal	O
male	O
rats	O
.	O

Serotonin	B-CHED
was	O
depleted	O
beginning	O
on	O
postnatal	O
day	O
26	O
with	O
parachlorophenylalanine	B-CHED
(	O
PCPA	B-CHED
100	O
mg	O
/	O
kg	O
,	O
every	O
other	O
day	O
)	O
;	O
controls	O
received	O
saline	O
.	O

At	O
puberty	O
(	O
P40	O
)	O
,	O
half	O
the	O
PCPA	B-CHED
-	O
treated	O
rats	O
and	O
half	O
the	O
saline	O
-	O
treated	O
rats	O
began	O
treatment	O
with	O
testosterone	B-CHED
(	O
T	B-CHED
,	O
5	O
mg	O
/	O
kg	O
,	O
5	O
days	O
/	O
week	O
)	O
.	O

Behavioral	O
measures	O
included	O
locomotion	O
,	O
irritability	O
,	O
copulation	O
,	O
partner	O
preference	O
,	O
and	O
aggression	O
.	O

Animals	O
were	O
tested	O
for	O
aggression	O
in	O
their	O
home	O
cage	O
,	O
both	O
with	O
and	O
without	O
physical	O
provocation	O
(	O
mild	O
tail	O
pinch	O
)	O
.	O

Brain	O
levels	O
of	O
5	B-CHED
-	I-CHED
HT	I-CHED
and	O
its	O
metabolite	O
,	O
5	B-CHED
-	I-CHED
hydroxyindoleacetic	I-CHED
acid	I-CHED
(	O
5	B-CHED
-	I-CHED
HIAA	I-CHED
)	O
,	O
were	O
determined	O
using	O
HPLC	O
.	O

PCPA	B-CHED
significantly	O
and	O
substantially	O
depleted	O
5	B-CHED
-	I-CHED
HT	I-CHED
and	O
5	B-CHED
-	I-CHED
HIAA	I-CHED
in	O
all	O
brain	O
regions	O
examined	O
.	O

Chronic	O
T	B-CHED
treatment	O
significantly	O
decreased	O
5	B-CHED
-	I-CHED
HT	I-CHED
and	O
5	B-CHED
-	I-CHED
HIAA	I-CHED
in	O
certain	O
brain	O
areas	O
,	O
but	O
to	O
a	O
much	O
lesser	O
extent	O
than	O
PCPA	B-CHED
.	O

Chronic	O
exposure	O
to	O
PCPA	B-CHED
alone	O
significantly	O
decreased	O
locomotor	O
activity	O
and	O
increased	O
irritability	O
but	O
had	O
no	O
effect	O
on	O
sexual	O
behavior	O
,	O
partner	O
preference	O
,	O
or	O
aggression	O
.	O

T	B-CHED
alone	O
had	O
no	O
effect	O
on	O
locomotion	O
,	O
irritability	O
,	O
or	O
sexual	O
behavior	O
but	O
increased	O
partner	O
preference	O
and	O
aggression	O
.	O

The	O
most	O
striking	O
effect	O
of	O
combining	O
T	B-CHED
+	O
PCPA	B-CHED
was	O
a	O
significant	O
increase	O
in	O
attack	O
frequency	O
as	O
well	O
as	O
a	O
significant	O
decrease	O
in	O
the	O
latency	O
to	O
attack	O
,	O
particularly	O
following	O
physical	O
provocation	O
.	O

Based	O
on	O
these	O
data	O
,	O
it	O
can	O
be	O
speculated	O
that	O
pubertal	O
AAS	O
users	O
with	O
low	O
central	O
5	B-CHED
-	I-CHED
HT	I-CHED
may	O
be	O
especially	O
prone	O
to	O
exhibit	O
aggressive	O
behavior	O
.	O

Effects	O
of	O
UMB24	B-CHED
and	O
(	O
+	O
/	O
-	O
)	O
-	O
SM	B-CHED
21	I-CHED
,	O
putative	O
sigma2	O
-	O
preferring	O
antagonists	O
,	O
on	O
behavioral	O
toxic	O
and	O
stimulant	O
effects	O
of	O
cocaine	B-CHED
in	O
mice	O
.	O

Earlier	O
studies	O
have	O
demonstrated	O
that	O
antagonism	O
of	O
sigma1	O
receptors	O
attenuates	O
the	O
convulsive	O
,	O
lethal	O
,	O
locomotor	O
stimulatory	O
and	O
rewarding	O
actions	O
of	O
cocaine	B-CHED
in	O
mice	O
.	O

In	O
contrast	O
,	O
the	O
contribution	O
of	O
sigma2	O
receptors	O
is	O
unclear	O
because	O
experimental	O
tools	O
to	O
selectively	O
target	O
this	O
subtype	O
are	O
unavailable	O
.	O

To	O
begin	O
addressing	O
this	O
need	O
,	O
we	O
characterized	O
UMB24	B-CHED
(	O
1	B-CHED
-	I-CHED
(	I-CHED
2	I-CHED
-	I-CHED
phenethyl	I-CHED
)	I-CHED
-	I-CHED
4	I-CHED
-	I-CHED
(	I-CHED
2	I-CHED
-	I-CHED
pyridyl	I-CHED
)	I-CHED
-	I-CHED
piperazine	I-CHED
)	O
and	O
(	O
+	O
/	O
-	O
)	O
-	O
SM	B-CHED
21	I-CHED
(	O
3alpha	B-CHED
-	I-CHED
tropanyl	I-CHED
-	I-CHED
2	I-CHED
-	I-CHED
(	I-CHED
4	I-CHED
-	I-CHED
chorophenoxy	I-CHED
)	I-CHED
butyrate	I-CHED
)	O
in	O
receptor	O
binding	O
and	O
behavioral	O
studies	O
.	O

Receptor	O
binding	O
studies	O
confirmed	O
that	O
UMB24	B-CHED
and	O
(	O
+	O
/	O
-	O
)	O
-	O
SM	B-CHED
21	I-CHED
display	O
preferential	O
affinity	O
for	O
sigma2	O
over	O
sigma1	O
receptors	O
.	O

In	O
behavioral	O
studies	O
,	O
pretreatment	O
of	O
Swiss	O
Webster	O
mice	O
with	O
UMB24	B-CHED
or	O
(	O
+	O
/	O
-	O
)	O
-	O
SM	B-CHED
21	I-CHED
significantly	O
attenuated	O
cocaine	B-CHED
-	O
induced	O
convulsions	O
and	O
locomotor	O
activity	O
,	O
but	O
not	O
lethality	O
.	O

When	O
administered	O
alone	O
,	O
(	O
+	O
/	O
-	O
)	O
-	O
SM	B-CHED
21	I-CHED
produced	O
no	O
significant	O
effects	O
compared	O
to	O
control	O
injections	O
of	O
saline	O
,	O
but	O
UMB24	B-CHED
had	O
locomotor	O
depressant	O
actions	O
.	O

Together	O
,	O
the	O
data	O
suggest	O
that	O
sigma2	O
receptor	O
antagonists	O
have	O
the	O
potential	O
to	O
attenuate	O
some	O
of	O
the	O
behavioral	O
effects	O
of	O
cocaine	B-CHED
,	O
and	O
further	O
development	O
of	O
more	O
selective	O
,	O
high	O
affinity	O
ligands	O
are	O
warranted	O
.	O

Cardiac	O
arrest	O
in	O
a	O
child	O
with	O
cerebral	O
palsy	O
undergoing	O
sevoflurane	B-CHED
induction	O
of	O
anesthesia	O
after	O
preoperative	O
clonidine	B-CHED
.	O

Clonidine	B-CHED
is	O
a	O
frequently	O
administered	O
alpha2	O
-	O
adrenergic	O
agonist	O
which	O
can	O
decrease	O
heart	O
rate	O
and	O
blood	O
pressure	O
.	O

We	O
present	O
a	O
case	O
of	O
a	O
5	O
-	O
year	O
-	O
old	O
child	O
with	O
cerebral	O
palsy	O
and	O
seizure	O
disorder	O
,	O
receiving	O
clonidine	B-CHED
for	O
restlessness	O
,	O
who	O
presented	O
for	O
placement	O
of	O
a	O
baclofen	B-CHED
pump	O
.	O

Without	O
the	O
knowledge	O
of	O
the	O
medical	O
personnel	O
,	O
the	O
patient	O
'	O
s	O
mother	O
administered	O
three	O
doses	O
of	O
clonidine	B-CHED
during	O
the	O
evening	O
before	O
and	O
morning	O
of	O
surgery	O
to	O
reduce	O
anxiety	O
.	O

During	O
induction	O
of	O
anesthesia	O
,	O
the	O
patient	O
developed	O
bradycardia	O
and	O
hypotension	O
requiring	O
cardiac	O
resuscitation	O
.	O

There	O
are	O
no	O
previous	O
reports	O
of	O
clonidine	B-CHED
-	O
associated	O
cardiac	O
arrest	O
in	O
a	O
child	O
undergoing	O
induction	O
of	O
anesthesia	O
.	O

Angiotensin	O
-	O
converting	O
enzyme	O
(	O
ACE	O
)	O
inhibitor	O
-	O
associated	O
angioedema	O
of	O
the	O
stomach	O
and	O
small	O
intestine	O
:	O
a	O
case	O
report	O
.	O

This	O
is	O
a	O
case	O
report	O
on	O
a	O
45	O
-	O
year	O
old	O
African	O
-	O
American	O
female	O
with	O
newly	O
diagnosed	O
hypertension	O
,	O
who	O
was	O
started	O
on	O
a	O
combination	O
pill	O
of	O
amlodipine	B-CHED
/	O
benazapril	B-CHED
10	O
/	O
5	O
mg	O
.	O

The	O
very	O
next	O
day	O
,	O
she	O
presented	O
at	O
the	O
emergency	O
room	O
(	O
ER	O
)	O
with	O
abdominal	O
pain	O
,	O
nausea	O
and	O
vomiting	O
.	O

Physical	O
exam	O
,	O
complete	O
metabolic	O
panel	O
,	O
and	O
hemogram	O
were	O
in	O
the	O
normal	O
range	O
.	O

She	O
was	O
discharged	O
from	O
the	O
ER	O
after	O
a	O
few	O
hours	O
of	O
treatment	O
with	O
fluid	O
and	O
analgesics	O
.	O

However	O
,	O
she	O
returned	O
to	O
the	O
ER	O
the	O
next	O
day	O
with	O
the	O
same	O
complaints	O
.	O

This	O
time	O
the	O
physical	O
exam	O
was	O
significant	O
for	O
a	O
distended	O
abdomen	O
with	O
dullness	O
to	O
percussion	O
.	O

CT	O
scan	O
of	O
the	O
abdomen	O
revealed	O
markedly	O
thickened	O
antrum	O
of	O
the	O
stomach	O
,	O
duodenum	O
and	O
jejunum	O
,	O
along	O
with	O
fluid	O
in	O
the	O
abdominal	O
and	O
pelvic	O
cavity	O
.	O

Angiotensin	O
-	O
converting	O
enzyme	O
inhibitor	O
(	O
ACEI	O
)	O
-	O
induced	O
angioedema	O
was	O
suspected	O
,	O
and	O
anti	O
-	O
hypertensive	O
medications	O
were	O
discontinued	O
.	O

Her	O
symptoms	O
improved	O
within	O
the	O
next	O
24	O
hours	O
,	O
and	O
repeat	O
CT	O
after	O
72	O
hours	O
revealed	O
marked	O
improvement	O
in	O
stomach	O
and	O
small	O
bowel	O
thickening	O
and	O
resolution	O
of	O
ascites	O
.	O

The	O
recognition	O
of	O
angiotensin	B-CHED
-	O
converting	O
enzyme	O
(	O
ACE	O
)	O
and	O
angiotensin	B-CHED
receptor	O
blocker	O
(	O
ARB	O
)	O
intestinal	O
angioedema	O
constitutes	O
a	O
challenge	O
to	O
primary	O
care	O
physicians	O
,	O
internists	O
,	O
emergency	O
room	O
personal	O
and	O
surgeons	O
.	O

Carbamazepine	B-CHED
-	O
induced	O
cardiac	O
dysfunction	O
.	O

Characterization	O
of	O
two	O
distinct	O
clinical	O
syndromes	O
.	O

A	O
patient	O
with	O
sinus	O
bradycardia	O
and	O
atrioventricular	O
block	O
,	O
induced	O
by	O
carbamazepine	B-CHED
,	O
prompted	O
an	O
extensive	O
literature	O
review	O
of	O
all	O
previously	O
reported	O
cases	O
.	O

From	O
the	O
analysis	O
of	O
these	O
cases	O
,	O
two	O
distinct	O
forms	O
of	O
carbamazepine	B-CHED
-	O
associated	O
cardiac	O
dysfunction	O
emerged	O
.	O

One	O
patient	O
group	O
developed	O
sinus	O
tachycardias	O
in	O
the	O
setting	O
of	O
a	O
massive	O
carbamazepine	B-CHED
overdose	O
.	O

The	O
second	O
group	O
consisted	O
almost	O
exclusively	O
of	O
elderly	O
women	O
who	O
developed	O
potentially	O
life	O
-	O
threatening	O
bradyarrhythmias	O
or	O
atrioventricular	O
conduction	O
delay	O
,	O
associated	O
with	O
either	O
therapeutic	O
or	O
modestly	O
elevated	O
carbamazepine	B-CHED
serum	O
levels	O
.	O

Because	O
carbamazepine	B-CHED
is	O
widely	O
used	O
in	O
the	O
treatment	O
of	O
many	O
neurologic	O
and	O
psychiatric	O
conditions	O
,	O
the	O
recognition	O
of	O
the	O
latter	O
syndrome	O
has	O
important	O
implications	O
for	O
the	O
use	O
of	O
this	O
drug	O
in	O
elderly	O
patients	O
.	O

Detection	O
of	O
abnormal	O
cardiac	O
adrenergic	O
neuron	O
activity	O
in	O
adriamycin	B-CHED
-	O
induced	O
cardiomyopathy	O
with	O
iodine	B-CHED
-	I-CHED
125	I-CHED
-	I-CHED
metaiodobenzylguanidine	I-CHED
.	O

Radiolabeled	B-CHED
metaiodobenzylguanidine	I-CHED
(	O
MIBG	B-CHED
)	O
,	O
an	O
analog	O
of	O
norepinephrine	B-CHED
(	O
NE	B-CHED
)	O
,	O
serves	O
as	O
an	O
index	O
of	O
adrenergic	O
neuron	O
integrity	O
and	O
function	O
.	O

Using	O
a	O
rat	O
model	O
of	O
adriamycin	B-CHED
-	O
induced	O
cardiomyopathy	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
abnormal	O
cardiac	O
adrenergic	O
neuron	O
activity	O
may	O
appear	O
and	O
be	O
exacerbated	O
dose	O
-	O
dependently	O
in	O
adriamycin	B-CHED
cardiomyopathy	O
.	O

The	O
degree	O
of	O
vacuolar	O
degeneration	O
of	O
myocardial	O
cells	O
was	O
analyzed	O
in	O
relation	O
to	O
the	O
duration	O
of	O
adriamycin	B-CHED
treatment	O
(	O
2	O
mg	O
/	O
kg	O
,	O
once	O
a	O
week	O
)	O
.	O

There	O
were	O
no	O
abnormalities	O
or	O
only	O
isolated	O
degeneration	O
in	O
the	O
1	O
-	O
or	O
2	O
-	O
wk	O
treatment	O
groups	O
,	O
isolated	O
or	O
scattered	O
degeneration	O
in	O
half	O
of	O
the	O
3	O
-	O
wk	O
group	O
,	O
frequent	O
scattered	O
degeneration	O
in	O
the	O
4	O
-	O
wk	O
group	O
,	O
scattered	O
or	O
focal	O
degeneration	O
in	O
the	O
5	O
-	O
wk	O
group	O
,	O
and	O
extensive	O
degeneration	O
in	O
the	O
8	O
-	O
wk	O
group	O
.	O

Myocardial	O
accumulation	O
of	O
[	O
125I	O
]	O
MIBG	B-CHED
4	O
hr	O
after	O
intravenous	O
injection	O
did	O
not	O
differ	O
between	O
the	O
controls	O
and	O
the	O
groups	O
treated	O
3	O
wk	O
or	O
less	O
.	O

However	O
,	O
the	O
4	O
-	O
wk	O
group	O
had	O
a	O
slightly	O
lower	O
accumulation	O
in	O
the	O
right	O
ventricular	O
wall	O
(	O
82	O
%	O
of	O
the	O
control	O
)	O
and	O
significantly	O
lower	O
accumulation	O
in	O
the	O
left	O
ventricular	O
wall	O
(	O
about	O
66	O
%	O
of	O
the	O
control	O
:	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

In	O
the	O
5	O
-	O
wk	O
group	O
,	O
MIBG	B-CHED
accumulation	O
in	O
the	O
right	O
and	O
left	O
ventricular	O
wall	O
was	O
35	O
%	O
and	O
27	O
%	O
of	O
that	O
in	O
controls	O
,	O
respectively	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

In	O
the	O
8	O
-	O
wk	O
group	O
,	O
MIBG	B-CHED
accumulation	O
in	O
the	O
right	O
and	O
left	O
ventricular	O
wall	O
was	O
18	O
%	O
and	O
14	O
%	O
of	O
that	O
in	O
controls	O
,	O
respectively	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

Thus	O
,	O
MIBG	B-CHED
accumulation	O
in	O
the	O
myocardium	O
decreased	O
in	O
an	O
adriamycin	B-CHED
dose	O
-	O
dependent	O
manner	O
.	O

The	O
appearance	O
of	O
impaired	O
cardiac	O
adrenergic	O
neuron	O
activity	O
in	O
the	O
presence	O
of	O
slight	O
myocardial	O
impairment	O
(	O
scattered	O
or	O
focal	O
vacuolar	O
degeneration	O
)	O
indicates	O
that	O
MIBG	B-CHED
scintigraphy	O
may	O
be	O
a	O
useful	O
method	O
for	O
detection	O
of	O
adriamycin	B-CHED
-	O
induced	O
cardiomyopathy	O
.	O

Syncope	O
and	O
QT	O
prolongation	O
among	O
patients	O
treated	O
with	O
methadone	B-CHED
for	O
heroin	B-CHED
dependence	O
in	O
the	O
city	O
of	O
Copenhagen	O
.	O

BACKGROUND	O
:	O
Methadone	B-CHED
is	O
prescribed	O
to	O
heroin	B-CHED
addicts	O
to	O
decrease	O
illicit	O
opioid	O
use	O
.	O

Prolongation	O
of	O
the	O
QT	O
interval	O
in	O
the	O
ECG	O
of	O
patients	O
with	O
torsade	O
de	O
pointes	O
(	O
TdP	O
)	O
has	O
been	O
reported	O
in	O
methadone	B-CHED
users	O
.	O

As	O
heroin	B-CHED
addicts	O
sometimes	O
faint	O
while	O
using	O
illicit	O
drugs	O
,	O
doctors	O
might	O
attribute	O
too	O
many	O
episodes	O
of	O
syncope	O
to	O
illicit	O
drug	O
use	O
and	O
thereby	O
underestimate	O
the	O
incidence	O
of	O
TdP	O
in	O
this	O
special	O
population	O
,	O
and	O
the	O
high	O
mortality	O
in	O
this	O
population	O
may	O
,	O
in	O
part	O
,	O
be	O
caused	O
by	O
the	O
proarrhythmic	O
effect	O
of	O
methadone	B-CHED
.	O

METHODS	O
:	O
In	O
this	O
cross	O
-	O
sectional	O
study	O
interview	O
,	O
ECGs	O
and	O
blood	O
samples	O
were	O
collected	O
in	O
a	O
population	O
of	O
adult	O
heroin	B-CHED
addicts	O
treated	O
with	O
methadone	B-CHED
or	O
buprenorphine	B-CHED
on	O
a	O
daily	O
basis	O
.	O

Of	O
the	O
patients	O
at	O
the	O
Drug	O
Addiction	O
Service	O
in	O
the	O
municipal	O
of	O
Copenhagen	O
,	O
450	O
(	O
approximately	O
52	O
%	O
)	O
were	O
included	O
.	O

The	O
QT	O
interval	O
was	O
estimated	O
from	O
12	O
lead	O
ECGs	O
.	O

All	O
participants	O
were	O
interviewed	O
about	O
any	O
experience	O
of	O
syncope	O
.	O

The	O
association	O
between	O
opioid	O
dose	O
and	O
QT	O
,	O
and	O
methadone	B-CHED
dose	O
and	O
reporting	O
of	O
syncope	O
was	O
assessed	O
using	O
multivariate	O
linear	O
regression	O
and	O
logistic	O
regression	O
,	O
respectively	O
.	O

RESULTS	O
:	O
Methadone	B-CHED
dose	O
was	O
associated	O
with	O
longer	O
QT	O
interval	O
of	O
0	O
.	O
140	O
ms	O
/	O
mg	O
(	O
p	O
=	O
0	O
.	O
002	O
)	O
.	O

No	O
association	O
between	O
buprenorphine	B-CHED
and	O
QTc	O
was	O
found	O
.	O

Among	O
the	O
subjects	O
treated	O
with	O
methadone	B-CHED
,	O
28	O
%	O
men	O
and	O
32	O
%	O
women	O
had	O
prolonged	O
QTc	O
interval	O
.	O

None	O
of	O
the	O
subjects	O
treated	O
with	O
buprenorphine	B-CHED
had	O
QTc	O
interval	O
>	O
0	O
.	O
440	O
s	O
(	O
(	O
1	O
/	O
2	O
)	O
)	O
.	O

A	O
50	O
mg	O
higher	O
methadone	B-CHED
dose	O
was	O
associated	O
with	O
a	O
1	O
.	O
2	O
(	O
95	O
%	O
CI	O
1	O
.	O
1	O
to	O
1	O
.	O
4	O
)	O
times	O
higher	O
odds	O
for	O
syncope	O
.	O

CONCLUSIONS	O
:	O
Methadone	B-CHED
is	O
associated	O
with	O
QT	O
prolongation	O
and	O
higher	O
reporting	O
of	O
syncope	O
in	O
a	O
population	O
of	O
heroin	B-CHED
addicts	O
.	O

Neuroleptic	O
malignant	O
syndrome	O
induced	O
by	O
ziprasidone	B-CHED
on	O
the	O
second	O
day	O
of	O
treatment	O
.	O

Neuroleptic	O
malignant	O
syndrome	O
(	O
NMS	O
)	O
is	O
the	O
rarest	O
and	O
most	O
serious	O
of	O
the	O
neuroleptic	O
-	O
induced	O
movement	O
disorders	O
.	O

We	O
describe	O
a	O
case	O
of	O
neuroleptic	O
malignant	O
syndrome	O
(	O
NMS	O
)	O
associated	O
with	O
the	O
use	O
of	O
ziprasidone	B-CHED
.	O

Although	O
conventional	O
neuroleptics	O
are	O
more	O
frequently	O
associated	O
with	O
NMS	O
,	O
atypical	O
antipsychotic	O
drugs	O
like	O
ziprasidone	B-CHED
may	O
also	O
be	O
a	O
cause	O
.	O

The	O
patient	O
is	O
a	O
24	O
-	O
year	O
-	O
old	O
male	O
with	O
a	O
history	O
of	O
schizophrenia	O
who	O
developed	O
signs	O
and	O
symptoms	O
of	O
NMS	O
after	O
2	O
days	O
of	O
treatment	O
with	O
an	O
80	O
-	O
mg	O
/	O
day	O
dose	O
of	O
orally	O
administrated	O
ziprasidone	B-CHED
.	O

This	O
case	O
is	O
the	O
earliest	O
(	O
second	O
day	O
of	O
treatment	O
)	O
NMS	O
due	O
to	O
ziprasidone	B-CHED
reported	O
in	O
the	O
literature	O
.	O

Peripheral	O
iron	B-CHED
dextran	I-CHED
induced	O
degeneration	O
of	O
dopaminergic	O
neurons	O
in	O
rat	O
substantia	O
nigra	O
.	O

Iron	B-CHED
accumulation	O
is	O
considered	O
to	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
Parkinson	O
'	O
s	O
disease	O
.	O

To	O
demonstrate	O
the	O
relationship	O
between	O
peripheral	O
iron	B-CHED
overload	O
and	O
dopaminergic	O
neuron	O
loss	O
in	O
rat	O
substantia	O
nigra	O
(	O
SN	O
)	O
,	O
in	O
the	O
present	O
study	O
we	O
used	O
fast	O
cyclic	O
voltammetry	O
,	O
tyrosine	B-CHED
hydroxylase	O
(	O
TH	O
)	O
immunohistochemistry	O
,	O
Perls	O
'	O
iron	B-CHED
staining	O
,	O
and	O
high	O
performance	O
liquid	O
chromatography	O
-	O
electrochemical	O
detection	O
to	O
study	O
the	O
degeneration	O
of	O
dopaminergic	O
neurons	O
and	O
increased	O
iron	B-CHED
content	O
in	O
the	O
SN	O
of	O
iron	B-CHED
dextran	I-CHED
overloaded	O
animals	O
.	O

The	O
findings	O
showed	O
that	O
peripheral	O
iron	B-CHED
dextran	I-CHED
overload	O
increased	O
the	O
iron	B-CHED
staining	O
positive	O
cells	O
and	O
reduced	O
the	O
number	O
of	O
TH	O
-	O
immunoreactive	O
neurons	O
in	O
the	O
SN	O
.	O

As	O
a	O
result	O
,	O
dopamine	B-CHED
release	O
and	O
content	O
,	O
as	O
well	O
as	O
its	O
metabolites	O
contents	O
were	O
decreased	O
in	O
caudate	O
putamen	O
.	O

Even	O
more	O
dramatic	O
changes	O
were	O
found	O
in	O
chronic	O
overload	O
group	O
.	O

These	O
results	O
suggest	O
that	O
peripheral	O
iron	B-CHED
dextran	I-CHED
can	O
increase	O
the	O
iron	B-CHED
level	O
in	O
the	O
SN	O
,	O
where	O
excessive	O
iron	B-CHED
causes	O
the	O
degeneration	O
of	O
dopaminergic	O
neurons	O
.	O

The	O
chronic	O
iron	B-CHED
overload	O
may	O
be	O
more	O
destructive	O
to	O
dopaminergic	O
neurons	O
than	O
the	O
acute	O
iron	B-CHED
overload	O
.	O

Attenuated	O
disruption	O
of	O
prepulse	O
inhibition	O
by	O
dopaminergic	O
stimulation	O
after	O
maternal	O
deprivation	O
and	O
adolescent	O
corticosterone	B-CHED
treatment	O
in	O
rats	O
.	O

The	O
development	O
of	O
schizophrenia	O
may	O
include	O
an	O
early	O
neurodevelopmental	O
stress	O
component	O
which	O
increases	O
vulnerability	O
to	O
later	O
stressful	O
life	O
events	O
,	O
in	O
combination	O
leading	O
to	O
overt	O
disease	O
.	O

We	O
investigated	O
the	O
effect	O
of	O
an	O
early	O
stress	O
,	O
in	O
the	O
form	O
of	O
maternal	O
deprivation	O
,	O
combined	O
with	O
a	O
later	O
stress	O
,	O
simulated	O
by	O
chronic	O
periadolescent	O
corticosterone	B-CHED
treatment	O
,	O
on	O
behaviour	O
in	O
rats	O
.	O

Acute	O
treatment	O
with	O
apomorphine	B-CHED
caused	O
disruption	O
of	O
prepulse	O
inhibition	O
(	O
PPI	O
)	O
in	O
controls	O
and	O
in	O
rats	O
that	O
had	O
undergone	O
either	O
maternal	O
deprivation	O
or	O
corticosterone	B-CHED
treatment	O
,	O
but	O
was	O
surprisingly	O
absent	O
in	O
rats	O
that	O
had	O
undergone	O
the	O
combined	O
early	O
and	O
late	O
stress	O
.	O

Amphetamine	B-CHED
treatment	O
significantly	O
disrupted	O
PPI	O
in	O
both	O
non	O
-	O
deprived	O
groups	O
,	O
but	O
was	O
absent	O
in	O
both	O
maternally	O
deprived	O
groups	O
.	O

The	O
serotonin	B-CHED
-	O
1A	O
receptor	O
agonist	O
,	O
8	B-CHED
-	I-CHED
OH	I-CHED
-	I-CHED
DPAT	I-CHED
,	O
induced	O
a	O
significant	O
disruption	O
of	O
PPI	O
in	O
all	O
groups	O
.	O

Amphetamine	B-CHED
-	O
induced	O
locomotor	O
hyperactivity	O
was	O
similar	O
in	O
all	O
groups	O
.	O

These	O
results	O
show	O
an	O
inhibitory	O
interaction	O
of	O
early	O
stress	O
,	O
caused	O
by	O
maternal	O
deprivation	O
,	O
combined	O
with	O
'	O
adolescent	O
'	O
stress	O
,	O
simulated	O
by	O
corticosterone	B-CHED
treatment	O
,	O
on	O
dopaminergic	O
regulation	O
of	O
PPI	O
.	O

The	O
altered	O
effects	O
of	O
apomorphine	B-CHED
and	O
amphetamine	B-CHED
could	O
indicate	O
differential	O
changes	O
in	O
dopamine	B-CHED
receptor	O
signalling	O
leading	O
to	O
functional	O
desensitisation	O
,	O
or	O
altered	O
modulation	O
of	O
sensory	O
gating	O
in	O
the	O
nucleus	O
accumbens	O
by	O
limbic	O
structures	O
such	O
as	O
the	O
hippocampus	O
.	O

An	O
extremely	O
rare	O
case	O
of	O
delusional	O
parasitosis	O
in	O
a	O
chronic	O
hepatitis	O
C	O
patient	O
during	O
pegylated	B-CHED
interferon	I-CHED
alpha	I-CHED
-	I-CHED
2b	I-CHED
and	O
ribavirin	B-CHED
treatment	O
.	O

During	O
treatment	O
of	O
chronic	O
hepatitis	O
C	O
patients	O
with	O
interferon	O
and	O
ribavirin	B-CHED
,	O
a	O
lot	O
of	O
side	O
effects	O
are	O
described	O
.	O

Twenty	O
-	O
three	O
percent	O
to	O
44	O
%	O
of	O
patients	O
develop	O
depression	O
.	O

A	O
minority	O
of	O
patients	O
evolve	O
to	O
psychosis	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
no	O
cases	O
of	O
psychogenic	O
parasitosis	O
occurring	O
during	O
interferon	O
therapy	O
have	O
been	O
described	O
in	O
the	O
literature	O
.	O

We	O
present	O
a	O
49	O
-	O
year	O
-	O
old	O
woman	O
who	O
developed	O
a	O
delusional	O
parasitosis	O
during	O
treatment	O
with	O
pegylated	B-CHED
interferon	I-CHED
alpha	I-CHED
-	I-CHED
2b	I-CHED
weekly	O
and	O
ribavirin	B-CHED
.	O

She	O
complained	O
of	O
seeing	O
parasites	O
and	O
the	O
larvae	O
of	O
fleas	O
in	O
her	O
stools	O
.	O

This	O
could	O
not	O
be	O
confirmed	O
by	O
any	O
technical	O
examination	O
.	O

All	O
the	O
complaints	O
disappeared	O
after	O
stopping	O
pegylated	B-CHED
interferon	I-CHED
alpha	I-CHED
-	I-CHED
2b	I-CHED
and	O
reappeared	O
after	O
restarting	O
it	O
.	O

She	O
had	O
a	O
complete	O
sustained	O
viral	O
response	O
.	O

Hepatonecrosis	O
and	O
cholangitis	O
related	O
to	O
long	O
-	O
term	O
phenobarbital	B-CHED
therapy	O
:	O
an	O
autopsy	O
report	O
of	O
two	O
patients	O
.	O

Phenobarbital	B-CHED
(	O
PB	B-CHED
)	O
has	O
a	O
reputation	O
for	O
safety	O
,	O
and	O
it	O
is	O
commonly	O
believed	O
that	O
PB	B-CHED
-	O
related	O
increases	O
in	O
serum	O
aminotransferase	O
levels	O
do	O
not	O
indicate	O
or	O
predict	O
the	O
development	O
of	O
significant	O
chronic	O
liver	O
disease	O
.	O

Here	O
we	O
report	O
of	O
two	O
adult	O
patients	O
with	O
a	O
long	O
history	O
of	O
epilepsy	O
treated	O
with	O
PB	B-CHED
who	O
died	O
suddenly	O
:	O
one	O
as	O
consequence	O
of	O
cardiac	O
arrest	O
,	O
the	O
other	O
of	O
acute	O
bronchopneumonia	O
.	O

At	O
autopsy	O
,	O
analysis	O
of	O
liver	O
parenchyma	O
revealed	O
rich	O
portal	O
inflammatory	O
infiltrate	O
,	O
which	O
consisted	O
of	O
mixed	O
eosinophil	O
and	O
monocyte	O
cells	O
,	O
associated	O
with	O
several	O
foci	O
of	O
necrosis	O
surrounded	O
by	O
a	O
hard	O
ring	O
of	O
non	O
-	O
specific	O
granulomatous	O
tissue	O
.	O

Inflammatory	O
reactions	O
of	O
internal	O
and	O
external	O
hepatic	O
biliary	O
ducts	O
were	O
also	O
seen	O
.	O

Our	O
findings	O
illustrate	O
that	O
PB	B-CHED
may	O
be	O
associated	O
with	O
chronic	O
liver	O
damage	O
,	O
which	O
may	O
lead	O
to	O
more	O
serious	O
and	O
deleterious	O
consequences	O
.	O

For	O
this	O
reason	O
,	O
each	O
clinician	O
should	O
recognize	O
this	O
entity	O
in	O
the	O
differential	O
diagnosis	O
of	O
PB	B-CHED
-	O
related	O
asymptomatic	O
chronic	O
hepatic	O
enzyme	O
dysfunction	O
.	O

Delayed	O
leukoencephalopathy	O
with	O
stroke	O
-	O
like	O
presentation	O
in	O
chemotherapy	O
recipients	O
.	O

BACKGROUND	O
:	O
A	O
transient	O
leukoencephalopathy	O
mimicking	O
cerebrovascular	O
accident	O
has	O
been	O
described	O
as	O
a	O
complication	O
of	O
chemotherapy	O
,	O
most	O
commonly	O
in	O
recipients	O
of	O
intrathecal	O
methotrexate	B-CHED
for	O
childhood	O
leukaemia	O
.	O

Recently	O
published	O
neuroimaging	O
data	O
suggest	O
a	O
common	O
pathophysiology	O
associated	O
with	O
a	O
variety	O
of	O
chemotherapy	O
agents	O
and	O
modes	O
of	O
administration	O
.	O

METHODS	O
:	O
We	O
reviewed	O
the	O
medical	O
literature	O
for	O
single	O
reports	O
and	O
case	O
series	O
of	O
patients	O
presenting	O
with	O
stroke	O
-	O
like	O
episodes	O
while	O
receiving	O
systemic	O
or	O
intrathecal	O
chemotherapy	O
.	O

We	O
only	O
included	O
studies	O
providing	O
detailed	O
neuroimaging	O
data	O
.	O

Patients	O
with	O
cerebrovascular	O
accidents	O
were	O
excluded	O
.	O

RESULTS	O
:	O
We	O
identified	O
27	O
reports	O
of	O
toxic	O
leukoencephalopathy	O
in	O
patients	O
treated	O
with	O
methotrexate	B-CHED
(	O
intrathecal	O
,	O
systemic	O
)	O
,	O
5	B-CHED
-	I-CHED
fluorouracil	I-CHED
and	O
its	O
derivative	O
carmofur	B-CHED
,	O
and	O
capecitabine	B-CHED
.	O

Diffusion	O
weighted	O
imaging	O
(	O
DWI	O
)	O
of	O
all	O
patients	O
revealed	O
well	O
demarcated	O
hyperintense	O
lesions	O
within	O
the	O
subcortical	O
white	O
matter	O
of	O
the	O
cerebral	O
hemispheres	O
and	O
the	O
corpus	O
callosum	O
,	O
corresponding	O
to	O
areas	O
of	O
decreased	O
proton	O
diffusion	O
on	O
apparent	O
diffusion	O
coefficient	O
(	O
ADC	O
)	O
maps	O
(	O
available	O
in	O
21	O
/	O
27	O
patients	O
)	O
.	O

Lesions	O
exceeded	O
the	O
confines	O
of	O
adjacent	O
vascular	O
territories	O
.	O

Complete	O
resolution	O
of	O
symptoms	O
within	O
1	O
-	O
4	O
days	O
was	O
accompanied	O
by	O
normalisation	O
of	O
ADC	O
abnormalities	O
.	O

However	O
,	O
fluid	O
attenuated	O
inversion	O
recovery	O
(	O
FLAIR	O
)	O
sequences	O
frequently	O
revealed	O
persistent	O
white	O
matter	O
abnormalities	O
.	O

CONCLUSIONS	O
:	O
Several	O
pathophysiological	O
models	O
of	O
delayed	O
leukoencephalopathy	O
after	O
exposure	O
to	O
intrathecal	O
or	O
systemic	O
chemotherapy	O
have	O
been	O
proposed	O
.	O

DWI	O
findings	O
in	O
this	O
cohort	O
are	O
indicative	O
of	O
cytotoxic	O
oedema	O
within	O
cerebral	O
white	O
matter	O
and	O
lend	O
support	O
to	O
an	O
at	O
least	O
partially	O
reversible	O
metabolic	O
derangement	O
as	O
the	O
basis	O
for	O
this	O
syndrome	O
.	O

Prenatal	O
exposure	O
to	O
fluoxetine	B-CHED
induces	O
fetal	O
pulmonary	O
hypertension	O
in	O
the	O
rat	O
.	O

RATIONALE	O
:	O
Fluoxetine	B-CHED
is	O
a	O
selective	O
serotonin	B-CHED
reuptake	O
inhibitor	O
antidepressant	O
widely	O
used	O
by	O
pregnant	O
women	O
.	O

Epidemiological	O
data	O
suggest	O
that	O
fluoxetine	B-CHED
exposure	O
prenatally	O
increases	O
the	O
prevalence	O
of	O
persistent	O
pulmonary	O
hypertension	O
syndrome	O
of	O
the	O
newborn	O
.	O

The	O
mechanism	O
responsible	O
for	O
this	O
effect	O
is	O
unclear	O
and	O
paradoxical	O
,	O
considering	O
the	O
current	O
evidence	O
of	O
a	O
pulmonary	O
hypertension	O
protective	O
fluoxetine	B-CHED
effect	O
in	O
adult	O
rodents	O
.	O

OBJECTIVES	O
:	O
To	O
evaluate	O
the	O
fluoxetine	B-CHED
effect	O
on	O
fetal	O
rat	O
pulmonary	O
vascular	O
smooth	O
muscle	O
mechanical	O
properties	O
and	O
cell	O
proliferation	O
rate	O
.	O

METHODS	O
:	O
Pregnant	O
rats	O
were	O
treated	O
with	O
fluoxetine	B-CHED
(	O
10	O
mg	O
/	O
kg	O
)	O
from	O
Day	O
11	O
through	O
Day	O
21	O
of	O
gestation	O
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
:	O
Fetuses	O
were	O
delivered	O
by	O
cesarean	O
section	O
.	O

As	O
compared	O
with	O
controls	O
,	O
fluoxetine	B-CHED
exposure	O
resulted	O
in	O
fetal	O
pulmonary	O
hypertension	O
as	O
evidenced	O
by	O
an	O
increase	O
in	O
the	O
weight	O
ratio	O
of	O
the	O
right	O
ventricle	O
to	O
the	O
left	O
ventricle	O
plus	O
septum	O
(	O
P	O
=	O
0	O
.	O
02	O
)	O
and	O
by	O
an	O
increase	O
in	O
pulmonary	O
arterial	O
medial	O
thickness	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

Postnatal	O
mortality	O
was	O
increased	O
among	O
experimental	O
animals	O
,	O
and	O
arterial	O
oxygen	B-CHED
saturation	O
was	O
96	O
+	O
/	O
-	O
1	O
%	O
in	O
1	O
-	O
day	O
-	O
old	O
control	O
animals	O
and	O
significantly	O
lower	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
in	O
fluoxetine	B-CHED
-	O
exposed	O
pups	O
(	O
79	O
+	O
/	O
-	O
2	O
%	O
)	O
.	O

In	O
vitro	O
,	O
fluoxetine	B-CHED
induced	O
pulmonary	O
arterial	O
muscle	O
contraction	O
in	O
fetal	O
,	O
but	O
not	O
adult	O
,	O
animals	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
reduced	O
serotonin	B-CHED
-	O
induced	O
contraction	O
at	O
both	O
ages	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

After	O
in	O
utero	O
exposure	O
to	O
a	O
low	O
fluoxetine	B-CHED
concentration	O
the	O
pulmonary	O
arterial	O
smooth	O
muscle	O
cell	O
proliferation	O
rate	O
was	O
significantly	O
increased	O
in	O
fetal	O
,	O
but	O
not	O
adult	O
,	O
cells	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

CONCLUSIONS	O
:	O
In	O
contrast	O
to	O
the	O
adult	O
,	O
fluoxetine	B-CHED
exposure	O
in	O
utero	O
induces	O
pulmonary	O
hypertension	O
in	O
the	O
fetal	O
rat	O
as	O
a	O
result	O
of	O
a	O
developmentally	O
regulated	O
increase	O
in	O
pulmonary	O
vascular	O
smooth	O
muscle	O
proliferation	O
.	O

Disulfiram	B-CHED
-	O
induced	O
transient	O
optic	O
and	O
peripheral	O
neuropathy	O
:	O
a	O
case	O
report	O
.	O

AIM	O
:	O
To	O
report	O
a	O
case	O
of	O
optic	O
and	O
peripheral	O
neuropathy	O
after	O
chronic	O
use	O
of	O
disulfiram	B-CHED
for	O
alcohol	O
dependence	O
management	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
A	O
case	O
report	O
.	O

RESULTS	O
:	O
A	O
57	O
-	O
year	O
-	O
old	O
male	O
presented	O
with	O
gradual	O
loss	O
of	O
vision	O
in	O
both	O
eyes	O
with	O
intermittent	O
headaches	O
for	O
2	O
months	O
.	O

He	O
also	O
complained	O
of	O
paraesthesia	O
with	O
numbness	O
in	O
both	O
feet	O
.	O

His	O
vision	O
was	O
6	O
/	O
15	O
and	O
2	O
/	O
60	O
in	O
the	O
right	O
and	O
left	O
eyes	O
,	O
respectively	O
.	O

Fundoscopy	O
revealed	O
bilaterally	O
swollen	O
optic	O
nerve	O
heads	O
.	O

Visual	O
field	O
testing	O
confirmed	O
bilateral	O
central	O
-	O
caecal	O
scotomata	O
.	O

He	O
had	O
been	O
taking	O
disulfiram	B-CHED
for	O
alcohol	O
dependence	O
for	O
the	O
preceding	O
3	O
years	O
.	O

Disulfiram	B-CHED
discontinuation	O
lead	O
to	O
an	O
immediate	O
symptomatic	O
improvement	O
.	O

CONCLUSION	O
:	O
Physicians	O
initiating	O
long	O
-	O
term	O
disulfiram	B-CHED
therapy	O
should	O
be	O
aware	O
of	O
these	O
adverse	O
effects	O
.	O

They	O
should	O
recommend	O
annual	O
ophthalmic	O
reviews	O
with	O
visual	O
field	O
testing	O
.	O

Patients	O
should	O
be	O
reassured	O
with	O
respect	O
to	O
the	O
reversibility	O
of	O
these	O
adverse	O
effects	O
.	O

Intraocular	O
pressure	O
in	O
patients	O
with	O
uveitis	O
treated	O
with	O
fluocinolone	B-CHED
acetonide	I-CHED
implants	O
.	O

OBJECTIVE	O
:	O
To	O
report	O
the	O
incidence	O
and	O
management	O
of	O
elevated	O
intraocular	O
pressure	O
(	O
IOP	O
)	O
in	O
patients	O
with	O
uveitis	O
treated	O
with	O
the	O
fluocinolone	B-CHED
acetonide	I-CHED
(	O
FA	B-CHED
)	O
intravitreal	O
implant	O
.	O

DESIGN	O
:	O
Pooled	O
data	O
from	O
3	O
multicenter	O
,	O
double	O
-	O
masked	O
,	O
randomized	O
,	O
controlled	O
,	O
phase	O
2b	O
/	O
3	O
clinical	O
trials	O
evaluating	O
the	O
safety	O
and	O
efficacy	O
of	O
the	O
0	O
.	O
59	O
-	O
mg	O
or	O
2	O
.	O
1	O
-	O
mg	O
FA	B-CHED
intravitreal	O
implant	O
or	O
standard	O
therapy	O
were	O
analyzed	O
.	O

RESULTS	O
:	O
During	O
the	O
3	O
-	O
year	O
follow	O
-	O
up	O
,	O
71	O
.	O
0	O
%	O
of	O
implanted	O
eyes	O
had	O
an	O
IOP	O
increase	O
of	O
10	O
mm	O
Hg	O
or	O
more	O
than	O
baseline	O
and	O
55	O
.	O
1	O
%	O
,	O
24	O
.	O
7	O
%	O
,	O
and	O
6	O
.	O
2	O
%	O
of	O
eyes	O
reached	O
an	O
IOP	O
of	O
30	O
mm	O
Hg	O
or	O
more	O
,	O
40	O
mm	O
Hg	O
or	O
more	O
,	O
and	O
50	O
mm	O
Hg	O
or	O
more	O
,	O
respectively	O
.	O

Topical	O
IOP	O
-	O
lowering	O
medication	O
was	O
administered	O
in	O
74	O
.	O
8	O
%	O
of	O
implanted	O
eyes	O
,	O
and	O
IOP	O
-	O
lowering	O
surgeries	O
,	O
most	O
of	O
which	O
were	O
trabeculectomies	O
(	O
76	O
.	O
2	O
%	O
)	O
,	O
were	O
performed	O
on	O
36	O
.	O
6	O
%	O
of	O
implanted	O
eyes	O
.	O

Intraocular	O
pressure	O
-	O
lowering	O
surgeries	O
were	O
considered	O
a	O
success	O
(	O
postoperative	O
IOP	O
of	O
6	O
-	O
21	O
mm	O
Hg	O
with	O
or	O
without	O
additional	O
IOP	O
-	O
lowering	O
medication	O
)	O
in	O
85	O
.	O
1	O
%	O
of	O
eyes	O
at	O
1	O
year	O
.	O

The	O
rate	O
of	O
hypotony	O
(	O
IOP	O
<	O
/	O
=	O
5	O
mm	O
Hg	O
)	O
following	O
IOP	O
-	O
lowering	O
surgery	O
(	O
42	O
.	O
5	O
%	O
)	O
was	O
not	O
different	O
from	O
that	O
of	O
implanted	O
eyes	O
not	O
subjected	O
to	O
surgery	O
(	O
35	O
.	O
4	O
%	O
)	O
(	O
P	O
=	O
.	O
09	O
)	O
.	O

CONCLUSION	O
:	O
Elevated	O
IOP	O
is	O
a	O
significant	O
complication	O
with	O
the	O
FA	O
intravitreal	O
implant	O
but	O
may	O
be	O
controlled	O
with	O
medication	O
and	O
surgery	O
.	O

Myocardial	O
Fas	O
ligand	O
expression	O
increases	O
susceptibility	O
to	O
AZT	B-CHED
-	O
induced	O
cardiomyopathy	O
.	O

BACKGROUND	O
:	O
Dilated	O
cardiomyopathy	O
(	O
DCM	O
)	O
and	O
myocarditis	O
occur	O
in	O
many	O
HIV	O
-	O
infected	O
individuals	O
,	O
resulting	O
in	O
symptomatic	O
heart	O
failure	O
in	O
up	O
to	O
5	O
%	O
of	O
patients	O
.	O

Highly	O
active	O
antiretroviral	O
therapy	O
(	O
HAART	O
)	O
has	O
significantly	O
reduced	O
morbidity	O
and	O
mortality	O
of	O
acquired	O
immunodeficiency	O
syndrome	O
(	O
AIDS	O
)	O
,	O
but	O
has	O
resulted	O
in	O
an	O
increase	O
in	O
cardiac	O
and	O
skeletal	O
myopathies	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
In	O
order	O
to	O
investigate	O
whether	O
the	O
HAART	O
component	O
zidovudine	B-CHED
(	O
3	B-CHED
'	I-CHED
-	I-CHED
azido	I-CHED
-	I-CHED
2	I-CHED
'	I-CHED
,	I-CHED
3	I-CHED
'	I-CHED
-	I-CHED
deoxythymidine	I-CHED
;	O
AZT	B-CHED
)	O
triggers	O
the	O
Fas	O
-	O
dependent	O
cell	O
-	O
death	O
pathway	O
and	O
cause	O
cytoskeletal	O
disruption	O
in	O
a	O
murine	O
model	O
of	O
DCM	O
,	O
8	O
-	O
week	O
-	O
old	O
transgenic	O
(	O
expressing	O
Fas	O
ligand	O
in	O
the	O
myocardium	O
:	O
FasL	O
Tg	O
)	O
and	O
non	O
-	O
transgenic	O
(	O
NTg	O
)	O
mice	O
received	O
water	O
ad	O
libitum	O
containing	O
different	O
concentrations	O
of	O
AZT	B-CHED
(	O
0	O
,	O
0	O
.	O
07	O
,	O
0	O
.	O
2	O
,	O
and	O
0	O
.	O
7	O
mg	O
/	O
ml	O
)	O
.	O

After	O
6	O
weeks	O
,	O
cardiac	O
function	O
was	O
assessed	O
by	O
echocardiography	O
and	O
morphology	O
was	O
assessed	O
by	O
histopathologic	O
and	O
immunohistochemical	O
methods	O
.	O

NTg	O
and	O
untreated	O
FasL	O
Tg	O
mice	O
showed	O
little	O
or	O
no	O
change	O
in	O
cardiac	O
structure	O
or	O
function	O
.	O

In	O
contrast	O
,	O
AZT	B-CHED
-	O
treated	O
FasL	O
Tg	O
mice	O
developed	O
cardiac	O
dilation	O
and	O
depressed	O
cardiac	O
function	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
with	O
concomitant	O
inflammatory	O
infiltration	O
of	O
both	O
ventricles	O
.	O

These	O
changes	O
were	O
associated	O
with	O
an	O
increased	O
sarcolemmal	O
expression	O
of	O
Fas	O
and	O
FasL	O
,	O
as	O
well	O
as	O
increased	O
activation	O
of	O
caspase	O
3	O
,	O
translocation	O
of	O
calpain	O
1	O
to	O
the	O
sarcolemma	O
and	O
sarcomere	O
,	O
and	O
increased	O
numbers	O
of	O
cells	O
undergoing	O
apoptosis	O
.	O

These	O
were	O
associated	O
with	O
changes	O
in	O
dystrophin	O
and	O
cardiac	O
troponin	O
I	O
localization	O
,	O
as	O
well	O
as	O
loss	O
of	O
sarcolemmal	O
integrity	O
.	O

CONCLUSIONS	O
:	O
The	O
expression	O
of	O
Fas	O
ligand	O
in	O
the	O
myocardium	O
,	O
as	O
identified	O
in	O
HIV	O
-	O
positive	O
patients	O
,	O
might	O
increase	O
the	O
susceptibility	O
to	O
HAART	O
-	O
induced	O
cardiomyopathy	O
due	O
to	O
activation	O
of	O
apoptotic	O
pathways	O
,	O
resulting	O
in	O
cardiac	O
dilation	O
and	O
dysfunction	O
.	O

Gastrointestinal	O
tolerability	O
of	O
etoricoxib	B-CHED
in	O
rheumatoid	O
arthritis	O
patients	O
:	O
results	O
of	O
the	O
etoricoxib	B-CHED
vs	O
diclofenac	B-CHED
sodium	I-CHED
gastrointestinal	O
tolerability	O
and	O
effectiveness	O
trial	O
(	O
EDGE	O
-	O
II	O
)	O
.	O

OBJECTIVE	O
:	O
A	O
randomised	O
,	O
double	O
-	O
blind	O
study	O
to	O
compare	O
the	O
gastrointestinal	O
(	O
GI	O
)	O
tolerability	O
,	O
safety	O
and	O
efficacy	O
of	O
etoricoxib	B-CHED
and	O
diclofenac	B-CHED
in	O
patients	O
with	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
A	O
total	O
of	O
4086	O
patients	O
(	O
mean	O
age	O
60	O
.	O
8	O
years	O
)	O
diagnosed	O
with	O
RA	O
were	O
enrolled	O
and	O
received	O
etoricoxib	B-CHED
90	O
mg	O
daily	O
(	O
n	O
=	O
2032	O
)	O
or	O
diclofenac	B-CHED
75	O
mg	O
twice	O
daily	O
(	O
n	O
=	O
2054	O
)	O
.	O

Use	O
of	O
gastroprotective	O
agents	O
and	O
low	O
-	O
dose	O
aspirin	B-CHED
was	O
allowed	O
.	O

The	O
prespecified	O
primary	O
end	O
point	O
consisted	O
of	O
the	O
cumulative	O
rate	O
of	O
patient	O
discontinuations	O
due	O
to	O
clinical	O
and	O
laboratory	O
GI	O
adverse	O
experiences	O
(	O
AEs	O
)	O
.	O

General	O
safety	O
was	O
also	O
assessed	O
,	O
including	O
adjudicated	O
thrombotic	O
cardiovascular	O
event	O
data	O
.	O

Efficacy	O
was	O
evaluated	O
using	O
the	O
Patient	O
Global	O
Assessment	O
of	O
Disease	O
Status	O
(	O
PGADS	O
;	O
0	O
-	O
4	O
point	O
scale	O
)	O
.	O

RESULTS	O
:	O
Mean	O
(	O
SD	O
;	O
maximum	O
)	O
duration	O
of	O
treatment	O
was	O
19	O
.	O
3	O
(	O
10	O
.	O
3	O
;	O
32	O
.	O
9	O
)	O
and	O
19	O
.	O
1	O
(	O
10	O
.	O
4	O
;	O
33	O
.	O
1	O
)	O
months	O
in	O
the	O
etoricoxib	B-CHED
and	O
diclofenac	B-CHED
groups	O
,	O
respectively	O
.	O

The	O
cumulative	O
discontinuation	O
rate	O
due	O
to	O
GI	O
AEs	O
was	O
significantly	O
lower	O
with	O
etoricoxib	B-CHED
than	O
diclofenac	B-CHED
(	O
5	O
.	O
2	O
vs	O
8	O
.	O
5	O
events	O
per	O
100	O
patient	O
-	O
years	O
,	O
respectively	O
;	O
hazard	O
ratio	O
0	O
.	O
62	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
47	O
,	O
0	O
.	O
81	O
;	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
)	O
.	O

The	O
incidence	O
of	O
discontinuations	O
for	O
hypertension	O
-	O
related	O
and	O
oedema	O
-	O
related	O
AEs	O
were	O
significantly	O
higher	O
with	O
etoricoxib	B-CHED
(	O
2	O
.	O
5	O
%	O
and	O
1	O
.	O
1	O
%	O
respectively	O
)	O
compared	O
with	O
diclofenac	B-CHED
(	O
1	O
.	O
5	O
%	O
and	O
0	O
.	O
4	O
%	O
respectively	O
;	O
p	O
<	O
0	O
.	O
001	O
for	O
hypertension	O
and	O
p	O
<	O
0	O
.	O
01	O
for	O
oedema	O
)	O
.	O

Etoricoxib	B-CHED
and	O
diclofenac	B-CHED
treatment	O
resulted	O
in	O
similar	O
efficacy	O
(	O
PGADS	O
mean	O
changes	O
from	O
baseline	O
-	O
0	O
.	O
62	O
vs	O
-	O
0	O
.	O
58	O
,	O
respectively	O
)	O
.	O

CONCLUSIONS	O
:	O
Etoricoxib	B-CHED
90	O
mg	O
demonstrated	O
a	O
significantly	O
lower	O
risk	O
for	O
discontinuing	O
treatment	O
due	O
to	O
GI	O
AEs	O
compared	O
with	O
diclofenac	B-CHED
150	O
mg	O
.	O

Discontinuations	O
from	O
renovascular	O
AEs	O
,	O
although	O
less	O
common	O
than	O
discontinuations	O
from	O
GI	O
AEs	O
,	O
were	O
significantly	O
higher	O
with	O
etoricoxib	B-CHED
.	O

Anxiogenic	O
potential	O
of	O
ciprofloxacin	B-CHED
and	O
norfloxacin	B-CHED
in	O
rats	O
.	O

INTRODUCTION	O
:	O
The	O
possible	O
anxiogenic	O
effects	O
of	O
fluoroquinolones	B-CHED
,	O
namely	O
ciprofloxacin	B-CHED
and	O
norfloxacin	B-CHED
,	O
were	O
investigated	O
in	O
adult	O
Charles	O
Foster	O
albino	O
rats	O
of	O
either	O
sex	O
,	O
weighing	O
150	O
-	O
200	O
g	O
.	O

METHODS	O
:	O
The	O
drugs	O
were	O
given	O
orally	O
,	O
in	O
doses	O
of	O
50	O
mg	O
/	O
kg	O
for	O
five	O
consecutive	O
days	O
and	O
the	O
experiments	O
were	O
performed	O
on	O
the	O
fifth	O
day	O
.	O

The	O
tests	O
included	O
open	O
-	O
field	O
exploratory	O
behaviour	O
,	O
elevated	O
plus	O
maze	O
and	O
elevated	O
zero	O
maze	O
,	O
social	O
interaction	O
and	O
novelty	O
-	O
suppressed	O
feeding	O
latency	O
behaviour	O
.	O

RESULTS	O
:	O
The	O
results	O
indicate	O
that	O
ciprofloxacin	B-CHED
-	O
and	O
norfloxacin	B-CHED
-	O
treated	O
rats	O
showed	O
anxious	O
behaviour	O
in	O
comparison	O
to	O
control	O
rats	O
in	O
all	O
the	O
parameters	O
studied	O
.	O

However	O
,	O
ciprofloxacin	B-CHED
-	O
and	O
norfloxacin	B-CHED
-	O
treated	O
rats	O
did	O
not	O
differ	O
significantly	O
from	O
each	O
other	O
in	O
various	O
behavioural	O
parameters	O
.	O

CONCLUSION	O
:	O
The	O
present	O
experimental	O
findings	O
substantiate	O
the	O
clinically	O
observed	O
anxiogenic	O
potential	O
of	O
ciprofloxacin	B-CHED
and	O
norfloxacin	B-CHED
.	O

Reduction	O
of	O
pain	O
during	O
induction	O
with	O
target	O
-	O
controlled	O
propofol	B-CHED
and	O
remifentanil	B-CHED
.	O

BACKGROUND	O
:	O
Pain	O
on	O
injection	O
of	O
propofol	B-CHED
is	O
unpleasant	O
.	O

We	O
hypothesized	O
that	O
propofol	B-CHED
infusion	O
pain	O
might	O
be	O
prevented	O
by	O
infusing	O
remifentanil	B-CHED
before	O
starting	O
the	O
propofol	B-CHED
infusion	O
in	O
a	O
clinical	O
setting	O
where	O
target	O
-	O
controlled	O
infusions	O
(	O
TCI	O
)	O
of	O
both	O
drugs	O
were	O
used	O
.	O

A	O
prospective	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
was	O
performed	O
to	O
determine	O
the	O
effect	O
-	O
site	O
concentration	O
(	O
Ce	O
)	O
of	O
remifentanil	B-CHED
to	O
prevent	O
the	O
pain	O
without	O
producing	O
complications	O
.	O

METHODS	O
:	O
A	O
total	O
of	O
128	O
patients	O
undergoing	O
general	O
surgery	O
were	O
randomly	O
allocated	O
to	O
receive	O
normal	O
saline	O
(	O
control	O
)	O
or	O
remifentanil	B-CHED
to	O
a	O
target	O
Ce	O
of	O
2	O
ng	O
ml	O
(	O
-	O
1	O
)	O
(	O
R2	O
)	O
,	O
4	O
ng	O
ml	O
(	O
-	O
1	O
)	O
(	O
R4	O
)	O
,	O
or	O
6	O
ng	O
ml	O
(	O
-	O
1	O
)	O
(	O
R6	O
)	O
administered	O
via	O
TCI	O
.	O

After	O
the	O
target	O
Ce	O
was	O
achieved	O
,	O
the	O
infusion	O
of	O
propofol	B-CHED
was	O
started	O
.	O

Remifentanil	B-CHED
-	O
related	O
complications	O
were	O
assessed	O
during	O
the	O
remifentanil	B-CHED
infusion	O
,	O
and	O
pain	O
caused	O
by	O
propofol	B-CHED
was	O
evaluated	O
using	O
a	O
four	O
-	O
point	O
scale	O
during	O
the	O
propofol	B-CHED
infusion	O
.	O

RESULTS	O
:	O
The	O
incidence	O
of	O
pain	O
was	O
significantly	O
lower	O
in	O
Groups	O
R4	O
and	O
R6	O
than	O
in	O
the	O
control	O
and	O
R2	O
groups	O
(	O
12	O
/	O
32	O
and	O
6	O
/	O
31	O
vs	O
26	O
/	O
31	O
and	O
25	O
/	O
32	O
,	O
respectively	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Pain	O
was	O
less	O
severe	O
in	O
Groups	O
R4	O
and	O
R6	O
than	O
in	O
the	O
control	O
and	O
R2	O
groups	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

However	O
,	O
both	O
incidence	O
and	O
severity	O
of	O
pain	O
were	O
not	O
different	O
between	O
Groups	O
R4	O
and	O
R6	O
.	O

No	O
significant	O
complications	O
were	O
observed	O
during	O
the	O
study	O
.	O

CONCLUSIONS	O
:	O
During	O
induction	O
of	O
anaesthesia	O
with	O
TCI	O
of	O
propofol	B-CHED
and	O
remifentanil	B-CHED
,	O
a	O
significant	O
reduction	O
in	O
propofol	B-CHED
infusion	O
pain	O
was	O
achieved	O
without	O
significant	O
complications	O
by	O
prior	O
administration	O
of	O
remifentanil	B-CHED
at	O
a	O
target	O
Ce	O
of	O
4	O
ng	O
ml	O
(	O
-	O
1	O
)	O
.	O

Dexmedetomidine	B-CHED
and	O
cardiac	O
protection	O
for	O
non	O
-	O
cardiac	O
surgery	O
:	O
a	O
meta	O
-	O
analysis	O
of	O
randomised	O
controlled	O
trials	O
.	O

We	O
conducted	O
a	O
systematic	O
review	O
of	O
the	O
effects	O
of	O
dexmedetomidine	B-CHED
on	O
cardiac	O
outcomes	O
following	O
non	O
-	O
cardiac	O
surgery	O
.	O

We	O
included	O
prospective	O
,	O
randomised	O
peri	O
-	O
operative	O
studies	O
of	O
dexmedetomidine	B-CHED
that	O
reported	O
mortality	O
,	O
cardiac	O
morbidity	O
or	O
adverse	O
drug	O
events	O
.	O

A	O
PubMed	O
Central	O
and	O
EMBASE	O
search	O
was	O
conducted	O
up	O
to	O
July	O
2007	O
.	O

The	O
reference	O
lists	O
of	O
identified	O
papers	O
were	O
examined	O
for	O
further	O
trials	O
.	O

Of	O
425	O
studies	O
identified	O
,	O
20	O
were	O
included	O
in	O
the	O
meta	O
-	O
analysis	O
(	O
840	O
patients	O
)	O
.	O

Dexmedetomidine	B-CHED
was	O
associated	O
with	O
a	O
trend	O
towards	O
improved	O
cardiac	O
outcomes	O
;	O
all	O
-	O
cause	O
mortality	O
(	O
OR	O
0	O
.	O
27	O
,	O
95	O
%	O
CI	O
0	O
.	O
01	O
-	O
7	O
.	O
13	O
,	O
p	O
=	O
0	O
.	O
44	O
)	O
,	O
non	O
-	O
fatal	O
myocardial	O
infarction	O
(	O
OR	O
0	O
.	O
26	O
,	O
95	O
%	O
CI	O
0	O
.	O
04	O
-	O
1	O
.	O
60	O
,	O
p	O
=	O
0	O
.	O
14	O
)	O
,	O
and	O
myocardial	O
ischaemia	O
(	O
OR	O
0	O
.	O
65	O
,	O
95	O
%	O
CI	O
0	O
.	O
26	O
-	O
1	O
.	O
63	O
,	O
p	O
=	O
0	O
.	O
36	O
)	O
.	O

Peri	O
-	O
operative	O
hypotension	O
(	O
26	O
%	O
,	O
OR	O
3	O
.	O
80	O
,	O
95	O
%	O
CI	O
1	O
.	O
91	O
-	O
7	O
.	O
54	O
,	O
p	O
=	O
0	O
.	O
0001	O
)	O
and	O
bradycardia	O
(	O
17	O
%	O
,	O
OR	O
5	O
.	O
45	O
,	O
95	O
%	O
CI	O
2	O
.	O
98	O
-	O
9	O
.	O
95	O
,	O
p	O
<	O
0	O
.	O
00001	O
)	O
were	O
significantly	O
increased	O
.	O

An	O
anticholinergic	O
did	O
not	O
reduce	O
the	O
incidence	O
of	O
bradycardia	O
(	O
p	O
=	O
0	O
.	O
43	O
)	O
.	O

A	O
randomised	O
placebo	O
-	O
controlled	O
trial	O
of	O
dexmedetomidine	B-CHED
is	O
warranted	O
.	O

Myocardial	O
infarction	O
in	O
pregnancy	O
associated	O
with	O
clomiphene	B-CHED
citrate	I-CHED
for	O
ovulation	O
induction	O
:	O
a	O
case	O
report	O
.	O

BACKGROUND	O
:	O
Clomiphene	B-CHED
citrate	I-CHED
(	O
CC	B-CHED
)	O
is	O
commonly	O
prescribed	O
for	O
ovulation	O
induction	O
.	O

It	O
is	O
considered	O
safe	O
,	O
with	O
minimal	O
side	O
effects	O
.	O

Thromboembolism	O
is	O
a	O
rare	O
but	O
life	O
-	O
threatening	O
complication	O
that	O
has	O
been	O
reported	O
after	O
ovulation	O
induction	O
with	O
CC	B-CHED
.	O

Spontaneous	O
coronary	O
thrombosis	O
or	O
thromboembolism	O
with	O
subsequent	O
clot	O
lysis	O
has	O
been	O
suggested	O
as	O
one	O
of	O
the	O
most	O
common	O
causes	O
of	O
myocardial	O
infarction	O
(	O
MI	O
)	O
during	O
pregnancy	O
,	O
with	O
a	O
subsequently	O
normal	O
coronary	O
angiogram	O
.	O

CASE	O
:	O
A	O
33	O
-	O
year	O
-	O
old	O
woman	O
with	O
a	O
5	O
-	O
week	O
gestation	O
had	O
recently	O
received	O
CC	B-CHED
for	O
ovulation	O
induction	O
and	O
presented	O
with	O
chest	O
pain	O
.	O

An	O
electrocardiogram	O
showed	O
a	O
lateral	O
and	O
anterior	O
wall	O
myocardial	O
infarction	O
.	O

Cardiac	O
enzymes	O
showed	O
a	O
peak	O
rise	O
in	O
troponin	O
I	O
to	O
9	O
.	O
10	O
ng	O
/	O
mL	O
.	O

An	O
initial	O
exercise	O
stress	O
test	O
was	O
normal	O
.	O

At	O
the	O
time	O
of	O
admission	O
,	O
the	O
patient	O
was	O
at	O
high	O
risk	O
of	O
radiation	O
injury	O
to	O
the	O
fetus	O
,	O
so	O
a	O
coronary	O
angiogram	O
was	O
postponed	O
until	O
the	O
second	O
trimester	O
.	O

It	O
showed	O
normal	O
coronary	O
vessels	O
.	O

CONCLUSION	O
:	O
This	O
appears	O
to	O
be	O
the	O
first	O
reported	O
case	O
documenting	O
a	O
possible	O
association	O
between	O
CC	B-CHED
and	O
myocardial	O
infarction	O
.	O

Thrombosis	O
might	O
be	O
a	O
rare	O
but	O
hazardous	O
complication	O
of	O
CC	B-CHED
.	O

Given	O
this	O
life	O
-	O
threatening	O
complication	O
,	O
appropriate	O
prophylactic	O
measures	O
should	O
be	O
used	O
in	O
high	O
-	O
risk	O
woman	O
undergoing	O
ovarian	O
stimulation	O
.	O

Reverse	O
or	O
inverted	O
left	O
ventricular	O
apical	O
ballooning	O
syndrome	O
(	O
reverse	O
Takotsubo	O
cardiomyopathy	O
)	O
in	O
a	O
young	O
woman	O
in	O
the	O
setting	O
of	O
amphetamine	B-CHED
use	O
.	O

Transient	O
left	O
ventricular	O
apical	O
ballooning	O
syndrome	O
was	O
first	O
described	O
in	O
Japan	O
as	O
"	O
Takotsubo	O
cardiomyopathy	O
.	O
"	O
This	O
syndrome	O
has	O
been	O
identified	O
in	O
many	O
other	O
countries	O
.	O

Many	O
variations	O
of	O
this	O
syndrome	O
have	O
been	O
recently	O
described	O
in	O
the	O
literature	O
.	O

One	O
of	O
the	O
rarest	O
is	O
the	O
reverse	O
type	O
of	O
this	O
syndrome	O
,	O
with	O
hyperdynamic	O
apex	O
and	O
complete	O
akinesia	O
of	O
the	O
base	O
(	O
as	O
opposed	O
to	O
the	O
classic	O
apical	O
ballooning	O
)	O
.	O

In	O
this	O
article	O
,	O
we	O
report	O
an	O
interesting	O
case	O
of	O
a	O
young	O
woman	O
who	O
presented	O
with	O
this	O
rare	O
type	O
of	O
reverse	O
apical	O
ballooning	O
syndrome	O
occurring	O
after	O
amphetamine	B-CHED
use	O
.	O

This	O
report	O
is	O
followed	O
by	O
review	O
of	O
the	O
literature	O
.	O

Results	O
of	O
a	O
comparative	O
,	O
phase	O
III	O
,	O
12	O
-	O
week	O
,	O
multicenter	O
,	O
prospective	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
assessment	O
of	O
the	O
efficacy	O
and	O
tolerability	O
of	O
a	O
fixed	O
-	O
dose	O
combination	O
of	O
telmisartan	B-CHED
and	O
amlodipine	B-CHED
versus	O
amlodipine	B-CHED
monotherapy	O
in	O
Indian	O
adults	O
with	O
stage	O
II	O
hypertension	O
.	O

OBJECTIVE	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
efficacy	O
and	O
tolerability	O
of	O
a	O
new	O
fixed	O
-	O
dose	O
combination	O
(	O
FDC	O
)	O
of	O
telmisartan	B-CHED
40	O
mg	O
+	O
amlodipine	B-CHED
5	O
mg	O
(	O
T	O
+	O
A	O
)	O
compared	O
with	O
amlodipine	B-CHED
5	O
-	O
mg	O
monotherapy	O
(	O
A	O
)	O
in	O
adult	O
Indian	O
patients	O
with	O
stage	O
II	O
hypertension	O
.	O

METHODS	O
:	O
This	O
comparative	O
,	O
Phase	O
III	O
,	O
12	O
-	O
week	O
,	O
multicenter	O
,	O
prospective	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
study	O
was	O
conducted	O
in	O
Indian	O
patients	O
aged	O
18	O
to	O
65	O
years	O
with	O
established	O
stage	O
II	O
hypertension	O
.	O

Patients	O
were	O
treated	O
with	O
oral	O
FDC	O
of	O
T	O
+	O
A	O
or	O
A	O
QD	O
before	O
breakfast	O
for	O
12	O
weeks	O
;	O
blood	O
pressure	O
(	O
BP	O
)	O
and	O
heart	O
rate	O
were	O
measured	O
in	O
the	O
sitting	O
position	O
.	O

Primary	O
efficacy	O
end	O
points	O
were	O
reduction	O
in	O
clinical	O
systolic	O
BP	O
(	O
SBP	O
)	O
/	O
diastolic	O
BP	O
(	O
DBP	O
)	O
from	O
baseline	O
to	O
study	O
end	O
and	O
number	O
of	O
responders	O
(	O
ie	O
,	O
patients	O
who	O
achieved	O
target	O
SBP	O
/	O
DBP	O
<	O
130	O
/	O
<	O
80	O
mm	O
Hg	O
)	O
at	O
end	O
of	O
study	O
.	O

Tolerability	O
was	O
assessed	O
by	O
treatment	O
-	O
emergent	O
adverse	O
events	O
,	O
identified	O
using	O
physical	O
examination	O
,	O
laboratory	O
analysis	O
,	O
and	O
electrocardiography	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
210	O
patients	O
were	O
enrolled	O
in	O
the	O
study	O
;	O
203	O
patients	O
(	O
143	O
men	O
,	O
60	O
women	O
)	O
completed	O
the	O
study	O
while	O
7	O
were	O
lost	O
to	O
follow	O
-	O
up	O
(	O
4	O
patients	O
in	O
the	O
T	O
+	O
A	O
group	O
and	O
3	O
in	O
the	O
A	O
group	O
)	O
and	O
considered	O
with	O
-	O
drawn	O
.	O

At	O
study	O
end	O
,	O
statistically	O
significant	O
percentage	O
reductions	O
from	O
baseline	O
within	O
groups	O
and	O
between	O
groups	O
were	O
observed	O
in	O
SBP	O
(	O
T	O
+	O
A	O
[	O
-	O
27	O
.	O
4	O
%	O
]	O
;	O
A	O
[	O
-	O
16	O
.	O
6	O
%	O
]	O
)	O
and	O
DBP	O
(	O
T	O
+	O
A	O
[	O
-	O
20	O
.	O
1	O
%	O
]	O
;	O
A	O
[	O
-	O
13	O
.	O
3	O
%	O
]	O
)	O
(	O
all	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Response	O
rates	O
were	O
87	O
.	O
3	O
%	O
(	O
89	O
/	O
102	O
)	O
in	O
the	O
T	O
+	O
A	O
group	O
and	O
69	O
.	O
3	O
%	O
(	O
70	O
/	O
101	O
)	O
in	O
the	O
A	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
prevalences	O
of	O
adverse	O
events	O
were	O
not	O
significantly	O
different	O
between	O
the	O
2	O
treatment	O
groups	O
(	O
T	O
+	O
A	O
,	O
16	O
.	O
0	O
%	O
[	O
17	O
/	O
106	O
]	O
;	O
A	O
,	O
15	O
.	O
4	O
%	O
[	O
16	O
/	O
104	O
]	O
)	O
.	O

Peripheral	O
edema	O
was	O
reported	O
in	O
8	O
.	O
5	O
%	O
patients	O
(	O
9	O
/	O
106	O
)	O
in	O
the	O
T	O
+	O
A	O
group	O
compared	O
with	O
13	O
.	O
5	O
%	O
(	O
14	O
/	O
104	O
)	O
in	O
the	O
A	O
group	O
,	O
and	O
cough	O
was	O
reported	O
in	O
3	O
.	O
8	O
%	O
patients	O
(	O
4	O
/	O
106	O
)	O
in	O
the	O
T	O
+	O
A	O
group	O
and	O
1	O
.	O
0	O
%	O
(	O
1	O
/	O
104	O
)	O
patients	O
in	O
the	O
A	O
group	O
;	O
these	O
differences	O
did	O
not	O
reach	O
statistical	O
significance	O
.	O

The	O
incidences	O
of	O
headache	O
,	O
dizziness	O
,	O
and	O
diarrhea	O
were	O
similar	O
between	O
the	O
2	O
groups	O
.	O

CONCLUSIONS	O
:	O
Among	O
these	O
Indian	O
patients	O
with	O
stage	O
II	O
hypertension	O
,	O
the	O
FDC	O
of	O
T	O
+	O
A	O
was	O
found	O
to	O
be	O
significantly	O
more	O
effective	O
,	O
with	O
regard	O
to	O
BP	O
reductions	O
,	O
than	O
A	O
,	O
and	O
both	O
treatments	O
were	O
well	O
tolerated	O
.	O

Increased	O
mental	O
slowing	O
associated	O
with	O
the	O
APOE	O
epsilon4	O
allele	O
after	O
trihexyphenidyl	B-CHED
oral	O
anticholinergic	O
challenge	O
in	O
healthy	O
elderly	O
.	O

OBJECTIVES	O
:	O
The	O
objectives	O
of	O
this	O
study	O
were	O
to	O
examine	O
the	O
relationship	O
between	O
APOE	O
epsilon4	O
and	O
subjective	O
effects	O
of	O
trihexyphenidyl	B-CHED
on	O
measures	O
reflecting	O
sedation	O
and	O
confusion	O
and	O
to	O
investigate	O
the	O
relationship	O
between	O
trihexyphenidyl	B-CHED
-	O
induced	O
subjective	O
effects	O
and	O
objective	O
memory	O
performance	O
.	O

METHODS	O
:	O
This	O
study	O
comprised	O
24	O
cognitively	O
intact	O
,	O
health	O
elderly	O
adults	O
(	O
12	O
APOE	O
epsilon4	O
carriers	O
)	O
at	O
an	O
outpatient	O
geriatric	O
psychiatry	O
research	O
clinic	O
.	O

This	O
was	O
a	O
randomized	O
,	O
double	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
three	O
-	O
way	O
,	O
crossover	O
experimental	O
design	O
.	O

All	O
participants	O
received	O
1	O
.	O
0	O
mg	O
or	O
2	O
.	O
0	O
mg	O
trihexyphenidyl	B-CHED
or	O
placebo	O
administered	O
in	O
counterbalanced	O
sequences	O
over	O
a	O
period	O
of	O
three	O
consecutive	O
weeks	O
.	O

Bond	O
and	O
Lader	O
'	O
s	O
visual	O
analog	O
scales	O
and	O
alternate	O
versions	O
of	O
the	O
Buschke	O
Selective	O
Reminding	O
Test	O
were	O
administered	O
in	O
a	O
repeated	O
measures	O
design	O
at	O
baseline	O
,	O
1	O
,	O
2	O
.	O
5	O
,	O
and	O
5	O
hours	O
postdrug	O
administration	O
.	O

RESULTS	O
:	O
A	O
2	O
.	O
0	O
-	O
mg	O
oral	O
dose	O
of	O
trihexyphenidyl	B-CHED
resulted	O
in	O
increased	O
subjective	O
ratings	O
of	O
mental	O
slowness	O
in	O
carriers	O
of	O
the	O
APOE	O
epsilon4	O
allele	O
only	O
.	O

Drug	O
effects	O
as	O
determined	O
by	O
difference	O
scores	O
between	O
2	O
.	O
0	O
mg	O
trihexyphenidyl	B-CHED
and	O
placebo	O
on	O
ratings	O
of	O
mental	O
slowness	O
significantly	O
correlated	O
with	O
total	O
and	O
delayed	O
recall	O
on	O
the	O
Buschke	O
Selective	O
Reminding	O
Test	O
in	O
carriers	O
of	O
the	O
APOE	O
epsilon4	O
allele	O
only	O
.	O

However	O
,	O
no	O
significant	O
effects	O
were	O
found	O
with	O
other	O
visual	O
analog	O
scales	O
reflecting	O
subjective	O
sedation	O
and	O
clear	O
-	O
headedness	O
.	O

CONCLUSION	O
:	O
The	O
epsilon4	O
allele	O
in	O
healthy	O
elderly	O
was	O
associated	O
with	O
increased	O
subjective	O
mental	O
slowing	O
after	O
trihexyphenidyl	B-CHED
anticholinergic	O
challenge	O
.	O

An	O
evaluation	O
of	O
amikacin	B-CHED
nephrotoxicity	O
in	O
the	O
hematology	O
/	O
oncology	O
population	O
.	O

Amikacin	B-CHED
is	O
an	O
aminoglycoside	B-CHED
commonly	O
used	O
to	O
provide	O
empirical	O
double	O
gram	O
-	O
negative	O
treatment	O
for	O
febrile	O
neutropenia	O
and	O
other	O
suspected	O
infections	O
.	O

Strategies	O
of	O
extended	O
-	O
interval	O
and	O
conventional	O
dosing	O
have	O
been	O
utilized	O
extensively	O
in	O
the	O
general	O
medical	O
population	O
;	O
however	O
,	O
data	O
are	O
lacking	O
to	O
support	O
a	O
dosing	O
strategy	O
in	O
the	O
hematology	O
/	O
oncology	O
population	O
.	O

To	O
evaluate	O
amikacin	B-CHED
-	O
associated	O
nephrotoxicity	O
in	O
an	O
adult	O
hematology	O
/	O
oncology	O
population	O
,	O
a	O
prospective	O
,	O
randomized	O
,	O
open	O
-	O
label	O
trial	O
was	O
conducted	O
at	O
a	O
university	O
-	O
affiliated	O
medical	O
center	O
.	O

Forty	O
patients	O
with	O
a	O
diagnosis	O
consistent	O
with	O
a	O
hematologic	O
/	O
oncologic	O
disorder	O
that	O
required	O
treatment	O
with	O
an	O
aminoglycoside	B-CHED
were	O
randomized	O
to	O
either	O
conventional	O
or	O
extended	O
-	O
interval	O
amikacin	B-CHED
.	O

The	O
occurrence	O
of	O
nephrotoxicity	O
by	O
means	O
of	O
an	O
increase	O
in	O
serum	O
creatinine	B-CHED
and	O
evaluation	O
of	O
efficacy	O
via	O
amikacin	B-CHED
serum	O
concentrations	O
with	O
respective	O
pathogens	O
were	O
assessed	O
.	O

The	O
occurrence	O
of	O
nephrotoxicity	O
was	O
similar	O
between	O
the	O
conventional	O
and	O
extended	O
-	O
interval	O
groups	O
,	O
at	O
10	O
%	O
and	O
5	O
%	O
,	O
respectively	O
(	O
P	O
=	O
1	O
.	O
00	O
)	O
.	O

Six	O
patients	O
in	O
the	O
conventional	O
group	O
had	O
a	O
positive	O
culture	O
,	O
compared	O
with	O
none	O
in	O
the	O
extended	O
-	O
interval	O
group	O
(	O
P	O
=	O
0	O
.	O
002	O
)	O
.	O

The	O
occurrence	O
of	O
nephrotoxicity	O
was	O
similar	O
between	O
the	O
two	O
dosing	O
regimens	O
,	O
but	O
the	O
distribution	O
of	O
risk	O
factors	O
was	O
variable	O
between	O
the	O
two	O
groups	O
.	O

Efficacy	O
could	O
not	O
be	O
assessed	O
.	O

High	O
dose	O
dexmedetomidine	B-CHED
as	O
the	O
sole	O
sedative	O
for	O
pediatric	O
MRI	O
.	O

OBJECTIVE	O
:	O
This	O
large	O
-	O
scale	O
retrospective	O
review	O
evaluates	O
the	O
sedation	O
profile	O
of	O
dexmedetomidine	B-CHED
.	O

AIM	O
:	O
To	O
determine	O
the	O
hemodynamic	O
responses	O
,	O
efficacy	O
and	O
adverse	O
events	O
associated	O
with	O
the	O
use	O
of	O
high	O
dose	O
dexmedetomidine	B-CHED
as	O
the	O
sole	O
sedative	O
for	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
studies	O
.	O

BACKGROUND	O
:	O
Dexmedetomidine	B-CHED
has	O
been	O
used	O
at	O
our	O
institution	O
since	O
2005	O
to	O
provide	O
sedation	O
for	O
pediatric	O
radiological	O
imaging	O
studies	O
.	O

Over	O
time	O
,	O
an	O
effective	O
protocol	O
utilizing	O
high	O
dose	O
dexmedetomidine	B-CHED
as	O
the	O
sole	O
sedative	O
agent	O
has	O
evolved	O
.	O

METHODS	O
/	O
MATERIALS	O
:	O
As	O
part	O
of	O
the	O
ongoing	O
Quality	O
Assurance	O
process	O
,	O
data	O
on	O
all	O
sedations	O
are	O
reviewed	O
monthly	O
and	O
protocols	O
modified	O
as	O
needed	O
.	O

Data	O
were	O
analyzed	O
from	O
all	O
747	O
consecutive	O
patients	O
who	O
received	O
dexmedetomidine	B-CHED
for	O
MRI	O
sedation	O
from	O
April	O
2005	O
to	O
April	O
2007	O
.	O

RESULTS	O
:	O
Since	O
2005	O
,	O
the	O
10	O
-	O
min	O
loading	O
dose	O
of	O
our	O
dexmedetomidine	B-CHED
protocol	O
increased	O
from	O
2	O
to	O
3	O
microg	O
.	O
kg	O
(	O
-	O
1	O
)	O
,	O
and	O
the	O
infusion	O
rate	O
increased	O
from	O
1	O
to	O
1	O
.	O
5	O
to	O
2	O
microg	O
.	O
kg	O
(	O
-	O
1	O
)	O
.	O
h	O
(	O
-	O
1	O
)	O
.	O

The	O
current	O
sedation	O
protocol	O
progressively	O
increased	O
the	O
rate	O
of	O
successful	O
sedation	O
(	O
able	O
to	O
complete	O
the	O
imaging	O
study	O
)	O
when	O
using	O
dexmedetomidine	B-CHED
alone	O
from	O
91	O
.	O
8	O
%	O
to	O
97	O
.	O
6	O
%	O
(	O
P	O
=	O
0	O
.	O
009	O
)	O
,	O
reducing	O
the	O
requirement	O
for	O
adjuvant	O
pentobarbital	B-CHED
in	O
the	O
event	O
of	O
sedation	O
failure	O
with	O
dexmedetomidine	B-CHED
alone	O
and	O
decreased	O
the	O
mean	O
recovery	O
time	O
by	O
10	O
min	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Although	O
dexmedetomidine	B-CHED
sedation	O
was	O
associated	O
with	O
a	O
16	O
%	O
incidence	O
of	O
bradycardia	O
,	O
all	O
concomitant	O
mean	O
arterial	O
blood	O
pressures	O
were	O
within	O
20	O
%	O
of	O
age	O
-	O
adjusted	O
normal	O
range	O
and	O
oxygen	B-CHED
saturations	O
were	O
95	O
%	O
or	O
higher	O
.	O

CONCLUSION	O
:	O
Dexmedetomidine	B-CHED
in	O
high	O
doses	O
provides	O
adequate	O
sedation	O
for	O
pediatric	O
MRI	O
studies	O
.	O

While	O
use	O
of	O
high	O
dose	O
dexmedetomidine	B-CHED
is	O
associated	O
with	O
decreases	O
in	O
heart	O
rate	O
and	O
blood	O
pressure	O
outside	O
the	O
established	O
'	O
awake	O
'	O
norms	O
,	O
this	O
deviation	O
is	O
generally	O
within	O
20	O
%	O
of	O
norms	O
,	O
and	O
is	O
not	O
associated	O
with	O
adverse	O
sequelae	O
.	O

Dexmedetomidine	B-CHED
is	O
useful	O
as	O
the	O
sole	O
sedative	O
for	O
pediatric	O
MRI	O
.	O

Hepatotoxicity	O
associated	O
with	O
sulfasalazine	B-CHED
in	O
inflammatory	O
arthritis	O
:	O
A	O
case	O
series	O
from	O
a	O
local	O
surveillance	O
of	O
serious	O
adverse	O
events	O
.	O

BACKGROUND	O
:	O
Spontaneous	O
reporting	O
systems	O
for	O
adverse	O
drug	O
reactions	O
(	O
ADRs	O
)	O
are	O
handicapped	O
by	O
under	O
-	O
reporting	O
and	O
limited	O
detail	O
on	O
individual	O
cases	O
.	O

We	O
report	O
an	O
investigation	O
from	O
a	O
local	O
surveillance	O
for	O
serious	O
adverse	O
drug	O
reactions	O
associated	O
with	O
disease	O
modifying	O
anti	O
-	O
rheumatic	O
drugs	O
that	O
was	O
triggered	O
by	O
the	O
occurrence	O
of	O
liver	O
failure	O
in	O
two	O
of	O
our	O
patients	O
.	O

METHODS	O
:	O
Serious	O
ADR	O
reports	O
have	O
been	O
solicited	O
from	O
local	O
clinicians	O
by	O
regular	O
postcards	O
over	O
the	O
past	O
seven	O
years	O
.	O

Patients	O
'	O
,	O
who	O
had	O
hepatotoxicity	O
on	O
sulfasalazine	B-CHED
and	O
met	O
a	O
definition	O
of	O
a	O
serious	O
ADR	O
,	O
were	O
identified	O
.	O

Two	O
clinicians	O
reviewed	O
structured	O
case	O
reports	O
and	O
assessed	O
causality	O
by	O
consensus	O
and	O
by	O
using	O
a	O
causality	O
assessment	O
instrument	O
.	O

The	O
likely	O
frequency	O
of	O
hepatotoxicity	O
with	O
sulfasalazine	B-CHED
was	O
estimated	O
by	O
making	O
a	O
series	O
of	O
conservative	O
assumptions	O
.	O

RESULTS	O
:	O
Ten	O
cases	O
were	O
identified	O
:	O
eight	O
occurred	O
during	O
surveillance	O
.	O

Eight	O
patients	O
were	O
hospitalised	O
,	O
two	O
in	O
hepatic	O
failure	O
-	O
one	O
died	O
after	O
a	O
liver	O
transplant	O
.	O

All	O
but	O
one	O
event	O
occurred	O
within	O
6	O
weeks	O
of	O
treatment	O
.	O

Seven	O
patients	O
had	O
a	O
skin	O
rash	O
,	O
three	O
eosinophilia	O
and	O
one	O
interstitial	O
nephritis	O
.	O

Five	O
patients	O
were	O
of	O
Black	O
British	O
of	O
African	O
or	O
Caribbean	O
descent	O
.	O

Liver	O
enzymes	O
showed	O
a	O
hepatocellular	O
pattern	O
in	O
four	O
cases	O
and	O
a	O
mixed	O
pattern	O
in	O
six	O
.	O

Drug	O
-	O
related	O
hepatotoxicity	O
was	O
judged	O
probable	O
or	O
highly	O
probable	O
in	O
8	O
patients	O
.	O

The	O
likely	O
frequency	O
of	O
serious	O
hepatotoxicity	O
with	O
sulfasalazine	B-CHED
was	O
estimated	O
at	O
0	O
.	O
4	O
%	O
of	O
treated	O
patients	O
.	O

CONCLUSION	O
:	O
Serious	O
hepatotoxicity	O
associated	O
with	O
sulfasalazine	B-CHED
appears	O
to	O
be	O
under	O
-	O
appreciated	O
and	O
intensive	O
monitoring	O
and	O
vigilance	O
in	O
the	O
first	O
6	O
weeks	O
of	O
treatment	O
is	O
especially	O
important	O
.	O

Complete	O
atrioventricular	O
block	O
secondary	O
to	O
lithium	B-CHED
therapy	O
.	O

Sinus	O
node	O
dysfunction	O
has	O
been	O
reported	O
most	O
frequently	O
among	O
the	O
adverse	O
cardiovascular	O
effects	O
of	O
lithium	B-CHED
.	O

In	O
the	O
present	O
case	O
,	O
complete	O
atrioventricular	O
(	O
AV	O
)	O
block	O
with	O
syncopal	O
attacks	O
developed	O
secondary	O
to	O
lithium	B-CHED
therapy	O
,	O
necessitating	O
permanent	O
pacemaker	O
implantation	O
.	O

Serum	O
lithium	B-CHED
levels	O
remained	O
under	O
or	O
within	O
the	O
therapeutic	O
range	O
during	O
the	O
syncopal	O
attacks	O
.	O

Lithium	B-CHED
should	O
be	O
used	O
with	O
extreme	O
caution	O
,	O
especially	O
in	O
patients	O
with	O
mild	O
disturbance	O
of	O
AV	O
conduction	O
.	O

Exaggerated	O
expression	O
of	O
inflammatory	O
mediators	O
in	O
vasoactive	O
intestinal	O
polypeptide	O
knockout	O
(	O
VIP	O
-	O
/	O
-	O
)	O
mice	O
with	O
cyclophosphamide	B-CHED
(	O
CYP	B-CHED
)	O
-	O
induced	O
cystitis	O
.	O

Vasoactive	O
intestinal	O
polypeptide	O
(	O
VIP	O
)	O
is	O
an	O
immunomodulatory	O
neuropeptide	O
distributed	O
in	O
micturition	O
pathways	O
.	O

VIP	O
(	O
-	O
/	O
-	O
)	O
mice	O
exhibit	O
altered	O
bladder	O
function	O
and	O
neurochemical	O
properties	O
in	O
micturition	O
pathways	O
after	O
cyclophosphamide	B-CHED
(	O
CYP	B-CHED
)	O
-	O
induced	O
cystitis	O
.	O

Given	O
VIP	O
'	O
s	O
role	O
as	O
an	O
anti	O
-	O
inflammatory	O
mediator	O
,	O
we	O
hypothesized	O
that	O
VIP	O
(	O
-	O
/	O
-	O
)	O
mice	O
would	O
exhibit	O
enhanced	O
inflammatory	O
mediator	O
expression	O
after	O
cystitis	O
.	O

A	O
mouse	O
inflammatory	O
cytokine	O
and	O
receptor	O
RT2	O
profiler	O
array	O
was	O
used	O
to	O
determine	O
regulated	O
transcripts	O
in	O
the	O
urinary	O
bladder	O
of	O
wild	O
type	O
(	O
WT	O
)	O
and	O
VIP	O
(	O
-	O
/	O
-	O
)	O
mice	O
with	O
or	O
without	O
CYP	B-CHED
-	O
induced	O
cystitis	O
(	O
150	O
mg	O
/	O
kg	O
;	O
i	O
.	O
p	O
.	O
;	O
48	O
h	O
)	O
.	O

Four	O
binary	O
comparisons	O
were	O
made	O
:	O
WT	O
control	O
versus	O
CYP	B-CHED
treatment	O
(	O
48	O
h	O
)	O
,	O
VIP	O
(	O
-	O
/	O
-	O
)	O
control	O
versus	O
CYP	B-CHED
treatment	O
(	O
48	O
h	O
)	O
,	O
WT	O
control	O
versus	O
VIP	O
(	O
-	O
/	O
-	O
)	O
control	O
,	O
and	O
WT	O
with	O
CYP	B-CHED
treatment	O
(	O
48	O
h	O
)	O
versus	O
VIP	O
(	O
-	O
/	O
-	O
)	O
with	O
CYP	B-CHED
treatment	O
(	O
48	O
h	O
)	O
.	O

The	O
genes	O
presented	O
represent	O
(	O
1	O
)	O
greater	O
than	O
1	O
.	O
5	O
-	O
fold	O
change	O
in	O
either	O
direction	O
and	O
(	O
2	O
)	O
the	O
p	O
value	O
is	O
less	O
than	O
0	O
.	O
05	O
for	O
the	O
comparison	O
being	O
made	O
.	O

Several	O
regulated	O
genes	O
were	O
validated	O
using	O
enzyme	O
-	O
linked	O
immunoassays	O
including	O
IL	O
-	O
1beta	O
and	O
CXCL1	O
.	O

CYP	B-CHED
treatment	O
significantly	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
increased	O
expression	O
of	O
CXCL1	O
and	O
IL	O
-	O
1beta	O
in	O
the	O
urinary	O
bladder	O
of	O
WT	O
and	O
VIP	O
(	O
-	O
/	O
-	O
)	O
mice	O
,	O
but	O
expression	O
in	O
VIP	O
(	O
-	O
/	O
-	O
)	O
mice	O
with	O
CYP	B-CHED
treatment	O
was	O
significantly	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
greater	O
(	O
4	O
.	O
2	O
-	O
to	O
13	O
-	O
fold	O
increase	O
)	O
than	O
that	O
observed	O
in	O
WT	O
urinary	O
bladder	O
(	O
3	O
.	O
6	O
-	O
to	O
5	O
-	O
fold	O
increase	O
)	O
.	O

The	O
data	O
suggest	O
that	O
in	O
VIP	O
(	O
-	O
/	O
-	O
)	O
mice	O
with	O
bladder	O
inflammation	O
,	O
inflammatory	O
mediators	O
are	O
increased	O
above	O
that	O
observed	O
in	O
WT	O
with	O
CYP	B-CHED
.	O

This	O
shift	O
in	O
balance	O
may	O
contribute	O
to	O
increased	O
bladder	O
dysfunction	O
in	O
VIP	O
(	O
-	O
/	O
-	O
)	O
mice	O
with	O
bladder	O
inflammation	O
and	O
altered	O
neurochemical	O
expression	O
in	O
micturition	O
pathways	O
.	O

Debrisoquine	B-CHED
phenotype	O
and	O
the	O
pharmacokinetics	O
and	O
beta	O
-	O
2	O
receptor	O
pharmacodynamics	O
of	O
metoprolol	B-CHED
and	O
its	O
enantiomers	O
.	O

The	O
metabolism	O
of	O
the	O
cardioselective	O
beta	O
-	O
blocker	O
metoprolol	B-CHED
is	O
under	O
genetic	O
control	O
of	O
the	O
debrisoquine	B-CHED
/	O
sparteine	B-CHED
type	O
.	O

The	O
two	O
metabolic	O
phenotypes	O
,	O
extensive	O
(	O
EM	O
)	O
and	O
poor	O
metabolizers	O
(	O
PM	O
)	O
,	O
show	O
different	O
stereoselective	O
metabolism	O
,	O
resulting	O
in	O
apparently	O
higher	O
beta	O
-	O
1	O
adrenoceptor	O
antagonistic	O
potency	O
of	O
racemic	O
metoprolol	B-CHED
in	O
EMs	O
.	O

We	O
investigated	O
if	O
the	O
latter	O
also	O
applies	O
to	O
the	O
beta	O
-	O
2	O
adrenoceptor	O
antagonism	O
by	O
metoprolol	B-CHED
.	O

The	O
drug	O
effect	O
studied	O
was	O
the	O
antagonism	O
by	O
metoprolol	B-CHED
of	O
terbutaline	B-CHED
-	O
induced	O
hypokalemia	O
.	O

By	O
using	O
pharmacokinetic	O
pharmacodynamic	O
modeling	O
the	O
pharmacodynamics	O
of	O
racemic	O
metoprolol	B-CHED
and	O
the	O
active	O
S	O
-	O
isomer	O
,	O
were	O
quantitated	O
in	O
EMs	O
and	O
PMs	O
in	O
terms	O
of	O
IC50	O
values	O
,	O
representing	O
metoprolol	B-CHED
plasma	O
concentrations	O
resulting	O
in	O
half	O
-	O
maximum	O
receptor	O
occupancy	O
.	O

Six	O
EMs	O
received	O
0	O
.	O
5	O
mg	O
of	O
terbutaline	B-CHED
s	O
.	O
c	O
.	O
on	O
two	O
different	O
occasions	O
:	O
1	O
)	O
1	O
hr	O
after	O
administration	O
of	O
a	O
placebo	O
and	O
2	O
)	O
1	O
hr	O
after	O
150	O
mg	O
of	O
metoprolol	B-CHED
p	O
.	O
o	O
.	O

Five	O
PMs	O
were	O
studied	O
according	O
to	O
the	O
same	O
protocol	O
,	O
except	O
for	O
a	O
higher	O
terbutaline	B-CHED
dose	O
(	O
0	O
.	O
75	O
mg	O
)	O
on	O
day	O
2	O
.	O

Blood	O
samples	O
for	O
the	O
analysis	O
of	O
plasma	O
potassium	B-CHED
,	O
terbutaline	B-CHED
,	O
metoprolol	B-CHED
(	O
racemic	O
,	O
R	O
-	O
and	O
S	O
-	O
isomer	O
)	O
,	O
and	O
alpha	B-CHED
-	I-CHED
hydroxymetoprolol	I-CHED
concentrations	O
were	O
taken	O
at	O
regular	O
time	O
intervals	O
,	O
during	O
8	O
hr	O
after	O
metoprolol	B-CHED
.	O

In	O
PMs	O
,	O
metoprolol	B-CHED
increased	O
the	O
terbutaline	B-CHED
area	O
under	O
the	O
plasma	O
concentration	O
vs	O
.	O
time	O
curve	O
(	O
+	O
67	O
%	O
)	O
.	O

Higher	O
metoprolol	B-CHED
/	O
alpha	B-CHED
-	I-CHED
hydroxymetoprolol	I-CHED
ratios	O
in	O
PMs	O
were	O
predictive	O
for	O
higher	O
R	O
-	O
/	O
S	O
-	O
isomer	O
ratios	O
of	O
unchanged	O
drug	O
.	O

There	O
was	O
a	O
difference	O
in	O
metoprolol	B-CHED
potency	O
with	O
higher	O
racemic	O
metoprolol	B-CHED
IC50	O
values	O
in	O
PMs	O
(	O
72	O
+	O
/	O
-	O
7	O
ng	O
.	O
ml	O
-	O
1	O
)	O
than	O
EMs	O
(	O
42	O
+	O
/	O
-	O
8	O
ng	O
.	O
ml	O
-	O
1	O
,	O
P	O
less	O
than	O
.	O
001	O
)	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

The	O
hemodynamics	O
of	O
oxytocin	B-CHED
and	O
other	O
vasoactive	O
agents	O
during	O
neuraxial	O
anesthesia	O
for	O
cesarean	O
delivery	O
:	O
findings	O
in	O
six	O
cases	O
.	O

Oxytocin	B-CHED
is	O
a	O
commonly	O
used	O
uterotonic	O
that	O
can	O
cause	O
significant	O
and	O
even	O
fatal	O
hypotension	O
,	O
particularly	O
when	O
given	O
as	O
a	O
bolus	O
.	O

The	O
resulting	O
hypotension	O
can	O
be	O
produced	O
by	O
a	O
decrease	O
in	O
systemic	O
vascular	O
resistance	O
or	O
cardiac	O
output	O
through	O
a	O
decrease	O
in	O
venous	O
return	O
.	O

Parturients	O
with	O
normal	O
volume	O
status	O
,	O
heart	O
valves	O
and	O
pulmonary	O
vasculature	O
most	O
often	O
respond	O
to	O
this	O
hypotension	O
with	O
a	O
compensatory	O
increase	O
in	O
heart	O
rate	O
and	O
stroke	O
volume	O
.	O

Oxytocin	B-CHED
-	O
induced	O
hypotension	O
at	O
cesarean	O
delivery	O
may	O
be	O
incorrectly	O
attributed	O
to	O
blood	O
loss	O
.	O

Pulse	O
power	O
analysis	O
(	O
also	O
called	O
"	O
pulse	O
contour	O
analysis	O
"	O
)	O
of	O
an	O
arterial	O
pressure	O
wave	O
form	O
allows	O
continuous	O
evaluation	O
of	O
systemic	O
vascular	O
resistance	O
and	O
cardiac	O
output	O
in	O
real	O
time	O
,	O
thereby	O
elucidating	O
the	O
causative	O
factors	O
behind	O
changes	O
in	O
blood	O
pressure	O
.	O

Pulse	O
power	O
analysis	O
was	O
conducted	O
in	O
six	O
cases	O
of	O
cesarean	O
delivery	O
performed	O
under	O
neuraxial	O
anesthesia	O
.	O

Hypotension	O
in	O
response	O
to	O
oxytocin	B-CHED
was	O
associated	O
with	O
a	O
decrease	O
in	O
systemic	O
vascular	O
resistance	O
and	O
a	O
compensatory	O
increase	O
in	O
stroke	O
volume	O
,	O
heart	O
rate	O
and	O
cardiac	O
output	O
.	O

Pulse	O
power	O
analysis	O
may	O
be	O
helpful	O
in	O
determining	O
the	O
etiology	O
of	O
and	O
treating	O
hypotension	O
during	O
cesarean	O
delivery	O
under	O
neuraxial	O
anesthesia	O
.	O

Protective	O
effects	O
of	O
antithrombin	O
on	O
puromycin	B-CHED
aminonucleoside	I-CHED
nephrosis	O
in	O
rats	O
.	O

We	O
investigated	O
the	O
effects	O
of	O
antithrombin	O
,	O
a	O
plasma	O
inhibitor	O
of	O
coagulation	O
factors	O
,	O
in	O
rats	O
with	O
puromycin	B-CHED
aminonucleoside	I-CHED
-	O
induced	O
nephrosis	O
,	O
which	O
is	O
an	O
experimental	O
model	O
of	O
human	O
nephrotic	O
syndrome	O
.	O

Antithrombin	O
(	O
50	O
or	O
500	O
IU	O
/	O
kg	O
/	O
i	O
.	O
v	O
.	O
)	O
was	O
administered	O
to	O
rats	O
once	O
a	O
day	O
for	O
10	O
days	O
immediately	O
after	O
the	O
injection	O
of	O
puromycin	B-CHED
aminonucleoside	I-CHED
(	O
50	O
mg	O
/	O
kg	O
/	O
i	O
.	O
v	O
.	O
)	O
.	O

Treatment	O
with	O
antithrombin	O
attenuated	O
the	O
puromycin	B-CHED
aminonucleoside	I-CHED
-	O
induced	O
hematological	O
abnormalities	O
.	O

Puromycin	B-CHED
aminonucleoside	I-CHED
-	O
induced	O
renal	O
dysfunction	O
and	O
hyperlipidemia	O
were	O
also	O
suppressed	O
.	O

Histopathological	O
examination	O
revealed	O
severe	O
renal	O
damage	O
such	O
as	O
proteinaceous	O
casts	O
in	O
tubuli	O
and	O
tubular	O
expansion	O
in	O
the	O
kidney	O
of	O
control	O
rats	O
,	O
while	O
an	O
improvement	O
of	O
the	O
damage	O
was	O
seen	O
in	O
antithrombin	O
-	O
treated	O
rats	O
.	O

In	O
addition	O
,	O
antithrombin	O
treatment	O
markedly	O
suppressed	O
puromycin	B-CHED
aminonucleoside	I-CHED
-	O
induced	O
apoptosis	O
of	O
renal	O
tubular	O
epithelial	O
cells	O
.	O

Furthermore	O
,	O
puromycin	B-CHED
aminonucleoside	I-CHED
-	O
induced	O
increases	O
in	O
renal	O
cytokine	O
content	O
were	O
also	O
decreased	O
.	O

These	O
findings	O
suggest	O
that	O
thrombin	O
plays	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
puromycin	B-CHED
aminonucleoside	I-CHED
-	O
induced	O
nephrotic	O
syndrome	O
.	O

Treatment	O
with	O
antithrombin	O
may	O
be	O
clinically	O
effective	O
in	O
patients	O
with	O
nephrotic	O
syndrome	O
.	O

Heparin	B-CHED
-	O
induced	O
thrombocytopenia	O
after	O
liver	O
transplantation	O
.	O

BACKGROUND	O
:	O
Unfractionated	B-CHED
heparin	I-CHED
sodium	I-CHED
(	O
UFH	B-CHED
)	O
or	O
low	B-CHED
-	I-CHED
molecular	I-CHED
weight	I-CHED
heparin	I-CHED
(	O
LMWH	O
)	O
is	O
used	O
in	O
anticoagulant	O
protocols	O
at	O
several	O
institutions	O
to	O
prevent	O
thrombosis	O
after	O
liver	O
transplantation	O
.	O

Heparin	B-CHED
-	O
induced	O
thrombocytopenia	O
(	O
HIT	O
)	O
is	O
an	O
adverse	O
immune	O
-	O
mediated	O
reaction	O
to	O
heparin	B-CHED
,	O
resulting	O
in	O
platelet	O
count	O
decreases	O
of	O
more	O
than	O
50	O
%	O
.	O

The	O
frequencies	O
of	O
HIT	O
after	O
liver	O
transplantation	O
and	O
platelet	O
factor	O
4	O
/	O
heparin	B-CHED
-	O
reactive	O
antibody	O
(	O
HIT	O
antibody	O
)	O
positivity	O
in	O
liver	O
transplantation	O
patients	O
,	O
however	O
,	O
are	O
unknown	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
The	O
32	O
men	O
and	O
20	O
women	O
underwent	O
living	O
donor	O
liver	O
transplantation	O
.	O

We	O
started	O
LMWH	O
(	O
25	O
IU	O
/	O
kg	O
/	O
h	O
)	O
on	O
postoperative	O
day	O
(	O
POD	O
)	O
1	O
,	O
switching	O
to	O
UFH	B-CHED
(	O
5000	O
U	O
/	O
d	O
)	O
on	O
POD	O
2	O
or	O
3	O
.	O

The	O
dose	O
of	O
UFH	B-CHED
was	O
changed	O
according	O
to	O
the	O
activated	O
clotting	O
time	O
level	O
.	O

HIT	O
antibody	O
levels	O
were	O
measured	O
the	O
day	O
before	O
surgery	O
and	O
on	O
POD	O
7	O
and	O
14	O
.	O

Platelet	O
count	O
was	O
measured	O
daily	O
for	O
3	O
weeks	O
.	O

RESULTS	O
:	O
The	O
average	O
platelet	O
counts	O
preoperatively	O
,	O
and	O
on	O
POD	O
7	O
,	O
14	O
,	O
and	O
21	O
were	O
65	O
,	O
88	O
,	O
149	O
,	O
and	O
169	O
x	O
10	O
(	O
9	O
)	O
/	O
L	O
,	O
respectively	O
.	O

Two	O
patients	O
developed	O
hepatic	O
artery	O
thrombosis	O
on	O
POD	O
11	O
and	O
19	O
,	O
respectively	O
,	O
although	O
they	O
were	O
HIT	O
antibody	O
-	O
negative	O
and	O
their	O
platelet	O
counts	O
were	O
stable	O
.	O

In	O
2	O
other	O
patients	O
,	O
the	O
platelet	O
count	O
decreased	O
suddenly	O
from	O
107	O
x	O
10	O
(	O
9	O
)	O
/	O
L	O
on	O
POD	O
4	O
to	O
65	O
x	O
10	O
(	O
9	O
)	O
/	O
L	O
on	O
POD	O
6	O
and	O
from	O
76	O
x	O
10	O
(	O
9	O
)	O
/	O
L	O
on	O
POD	O
7	O
to	O
33	O
x	O
10	O
(	O
9	O
)	O
/	O
L	O
on	O
POD	O
9	O
,	O
respectively	O
.	O

The	O
heparin	B-CHED
-	O
induced	O
platelet	O
aggregation	O
test	O
was	O
negative	O
in	O
these	O
patients	O
.	O

The	O
percentage	O
of	O
HIT	O
antibody	O
-	O
positive	O
patients	O
was	O
0	O
.	O
5	O
%	O
preoperatively	O
,	O
5	O
.	O
6	O
%	O
on	O
POD	O
7	O
,	O
and	O
5	O
.	O
6	O
%	O
on	O
POD	O
14	O
.	O

None	O
of	O
the	O
subjects	O
/	O
patients	O
developed	O
UFH	B-CHED
-	O
related	O
HIT	O
.	O

CONCLUSIONS	O
:	O
In	O
our	O
series	O
,	O
the	O
occurrence	O
of	O
HIT	O
after	O
liver	O
transplantation	O
was	O
uncommon	O
.	O

Doxorubicin	B-CHED
cardiomyopathy	O
-	O
induced	O
inflammation	O
and	O
apoptosis	O
are	O
attenuated	O
by	O
gene	O
deletion	O
of	O
the	O
kinin	O
B1	O
receptor	O
.	O

Clinical	O
use	O
of	O
the	O
anthracycline	B-CHED
doxorubicin	B-CHED
(	O
DOX	B-CHED
)	O
is	O
limited	O
by	O
its	O
cardiotoxic	O
effects	O
,	O
which	O
are	O
attributed	O
to	O
the	O
induction	O
of	O
apoptosis	O
.	O

To	O
elucidate	O
the	O
possible	O
role	O
of	O
the	O
kinin	O
B1	O
receptor	O
(	O
B1R	O
)	O
during	O
the	O
development	O
of	O
DOX	B-CHED
cardiomyopathy	O
,	O
we	O
studied	O
B1R	O
knockout	O
mice	O
(	O
B1R	O
(	O
-	O
/	O
-	O
)	O
)	O
by	O
investigating	O
cardiac	O
inflammation	O
and	O
apoptosis	O
after	O
induction	O
of	O
DOX	B-CHED
-	O
induced	O
cardiomyopathy	O
.	O

DOX	B-CHED
control	O
mice	O
showed	O
cardiac	O
dysfunction	O
measured	O
by	O
pressure	O
-	O
volume	O
loops	O
in	O
vivo	O
.	O

This	O
was	O
associated	O
with	O
a	O
reduced	O
activation	O
state	O
of	O
AKT	O
,	O
as	O
well	O
as	O
an	O
increased	O
bax	O
/	O
bcl2	O
ratio	O
in	O
Western	O
blots	O
,	O
indicating	O
cardiac	O
apoptosis	O
.	O

Furthermore	O
,	O
mRNA	O
levels	O
of	O
the	O
proinflammatory	O
cytokine	O
interleukin	O
6	O
were	O
increased	O
in	O
the	O
cardiac	O
tissue	O
.	O

In	O
DOX	B-CHED
B1R	O
(	O
-	O
/	O
-	O
)	O
mice	O
,	O
cardiac	O
dysfunction	O
was	O
improved	O
compared	O
to	O
DOX	B-CHED
control	O
mice	O
,	O
which	O
was	O
associated	O
with	O
normalization	O
of	O
the	O
bax	O
/	O
bcl	O
-	O
2	O
ratio	O
and	O
interleukin	O
6	O
,	O
as	O
well	O
as	O
AKT	O
activation	O
state	O
.	O

These	O
findings	O
suggest	O
that	O
B1R	O
is	O
detrimental	O
in	O
DOX	B-CHED
cardiomyopathy	O
in	O
that	O
it	O
mediates	O
the	O
inflammatory	O
response	O
and	O
apoptosis	O
.	O

These	O
insights	O
might	O
have	O
useful	O
implications	O
for	O
future	O
studies	O
utilizing	O
B1R	O
antagonists	O
for	O
treatment	O
of	O
human	O
DOX	B-CHED
cardiomyopathy	O
.	O

Detailed	O
spectral	O
profile	O
analysis	O
of	O
penicillin	B-CHED
-	O
induced	O
epileptiform	O
activity	O
in	O
anesthetized	O
rats	O
.	O

Penicillin	B-CHED
model	O
is	O
a	O
widely	O
used	O
experimental	O
model	O
for	O
epilepsy	O
research	O
.	O

In	O
the	O
present	O
study	O
we	O
aimed	O
to	O
portray	O
a	O
detailed	O
spectral	O
analysis	O
of	O
penicillin	B-CHED
-	O
induced	O
epileptiform	O
activity	O
in	O
comparison	O
with	O
basal	O
brain	O
activity	O
in	O
anesthetized	O
Wistar	O
rats	O
.	O

Male	O
Wistar	O
rats	O
were	O
anesthetized	O
with	O
i	O
.	O
p	O
.	O
urethane	B-CHED
and	O
connected	O
to	O
an	O
electrocorticogram	O
setup	O
.	O

After	O
a	O
short	O
period	O
of	O
basal	O
activity	O
recording	O
,	O
epileptic	O
focus	O
was	O
induced	O
by	O
injecting	O
400IU	O
/	O
2	O
microl	O
penicillin	B-CHED
-	I-CHED
G	I-CHED
potassium	I-CHED
into	O
the	O
left	O
lateral	O
ventricle	O
while	O
the	O
cortical	O
activity	O
was	O
continuously	O
recorded	O
.	O

Basal	O
activity	O
,	O
latent	O
period	O
and	O
the	O
penicillin	B-CHED
-	O
induced	O
epileptiform	O
activity	O
periods	O
were	O
then	O
analyzed	O
using	O
both	O
conventional	O
methods	O
and	O
spectral	O
analysis	O
.	O

Spectral	O
analyses	O
were	O
conducted	O
by	O
dividing	O
the	O
whole	O
spectrum	O
into	O
different	O
frequency	O
bands	O
including	O
delta	O
,	O
theta	O
(	O
slow	O
and	O
fast	O
)	O
,	O
alpha	O
-	O
sigma	O
,	O
beta	O
(	O
1	O
and	O
2	O
)	O
and	O
gamma	O
(	O
1	O
and	O
2	O
)	O
bands	O
.	O

Our	O
results	O
show	O
that	O
the	O
most	O
affected	O
frequency	O
bands	O
were	O
delta	O
,	O
theta	O
,	O
beta	O
-	O
2	O
and	O
gamma	O
-	O
2	O
bands	O
during	O
the	O
epileptiform	O
activity	O
and	O
there	O
were	O
marked	O
differences	O
in	O
terms	O
of	O
spectral	O
densities	O
between	O
three	O
investigated	O
episodes	O
(	O
basal	O
activity	O
,	O
latent	O
period	O
and	O
epileptiform	O
activity	O
)	O
.	O

Our	O
results	O
may	O
help	O
to	O
analyze	O
novel	O
data	O
obtained	O
using	O
similar	O
experimental	O
models	O
and	O
the	O
simple	O
analysis	O
method	O
described	O
here	O
can	O
be	O
used	O
in	O
similar	O
studies	O
to	O
investigate	O
the	O
basic	O
neuronal	O
mechanism	O
of	O
this	O
or	O
other	O
types	O
of	O
experimental	O
epilepsies	O
.	O

High	O
fat	B-CHED
diet	O
-	O
fed	O
obese	O
rats	O
are	O
highly	O
sensitive	O
to	O
doxorubicin	B-CHED
-	O
induced	O
cardiotoxicity	O
.	O

Often	O
,	O
chemotherapy	O
by	O
doxorubicin	B-CHED
(	O
Adriamycin	B-CHED
)	O
is	O
limited	O
due	O
to	O
life	O
threatening	O
cardiotoxicity	O
in	O
patients	O
during	O
and	O
posttherapy	O
.	O

Recently	O
,	O
we	O
have	O
shown	O
that	O
moderate	O
diet	O
restriction	O
remarkably	O
protects	O
against	O
doxorubicin	B-CHED
-	O
induced	O
cardiotoxicity	O
.	O

This	O
cardioprotection	O
is	O
accompanied	O
by	O
decreased	O
cardiac	O
oxidative	O
stress	O
and	O
triglycerides	B-CHED
and	O
increased	O
cardiac	O
fatty	O
-	O
acid	O
oxidation	O
,	O
ATP	B-CHED
synthesis	O
,	O
and	O
upregulated	O
JAK	O
/	O
STAT3	O
pathway	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
investigated	O
whether	O
a	O
physiological	O
intervention	O
by	O
feeding	O
40	O
%	O
high	O
fat	B-CHED
diet	O
(	O
HFD	O
)	O
,	O
which	O
induces	O
obesity	O
in	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
(	O
250	O
-	O
275	O
g	O
)	O
,	O
sensitizes	O
to	O
doxorubicin	B-CHED
-	O
induced	O
cardiotoxicity	O
.	O

A	O
LD	O
(	O
10	O
)	O
dose	O
(	O
8	O
mg	O
doxorubicin	B-CHED
/	O
kg	O
,	O
ip	O
)	O
administered	O
on	O
day	O
43	O
of	O
the	O
HFD	O
feeding	O
regimen	O
led	O
to	O
higher	O
cardiotoxicity	O
,	O
cardiac	O
dysfunction	O
,	O
lipid	O
peroxidation	O
,	O
and	O
80	O
%	O
mortality	O
in	O
the	O
obese	O
(	O
OB	O
)	O
rats	O
in	O
the	O
absence	O
of	O
any	O
significant	O
renal	O
or	O
hepatic	O
toxicity	O
.	O

Doxorubicin	B-CHED
toxicokinetics	O
studies	O
revealed	O
no	O
change	O
in	O
accumulation	O
of	O
doxorubicin	B-CHED
and	O
doxorubicinol	B-CHED
(	O
toxic	O
metabolite	O
)	O
in	O
the	O
normal	O
diet	O
-	O
fed	O
(	O
ND	O
)	O
and	O
OB	O
hearts	O
.	O

Mechanistic	O
studies	O
revealed	O
that	O
OB	O
rats	O
are	O
sensitized	O
due	O
to	O
:	O
(	O
1	O
)	O
higher	O
oxyradical	O
stress	O
leading	O
to	O
upregulation	O
of	O
uncoupling	O
proteins	O
2	O
and	O
3	O
,	O
(	O
2	O
)	O
downregulation	O
of	O
cardiac	O
peroxisome	O
proliferators	O
activated	O
receptor	O
-	O
alpha	O
,	O
(	O
3	O
)	O
decreased	O
plasma	O
adiponectin	O
levels	O
,	O
(	O
4	O
)	O
decreased	O
cardiac	O
fatty	O
-	O
acid	O
oxidation	O
(	O
666	O
.	O
9	O
+	O
/	O
-	O
14	O
.	O
0	O
nmol	O
/	O
min	O
/	O
g	O
heart	O
in	O
ND	O
versus	O
400	O
.	O
2	O
+	O
/	O
-	O
11	O
.	O
8	O
nmol	O
/	O
min	O
/	O
g	O
heart	O
in	O
OB	O
)	O
,	O
(	O
5	O
)	O
decreased	O
mitochondrial	O
AMP	B-CHED
-	O
alpha2	O
protein	O
kinase	O
,	O
and	O
(	O
6	O
)	O
86	O
%	O
drop	O
in	O
cardiac	O
ATP	B-CHED
levels	O
accompanied	O
by	O
decreased	O
ATP	B-CHED
/	O
ADP	B-CHED
ratio	O
after	O
doxorubicin	B-CHED
administration	O
.	O

Decreased	O
cardiac	O
erythropoietin	O
and	O
increased	O
SOCS3	O
further	O
downregulated	O
the	O
cardioprotective	O
JAK	O
/	O
STAT3	O
pathway	O
.	O

In	O
conclusion	O
,	O
HFD	O
-	O
induced	O
obese	O
rats	O
are	O
highly	O
sensitized	O
to	O
doxorubicin	B-CHED
-	O
induced	O
cardiotoxicity	O
by	O
substantially	O
downregulating	O
cardiac	O
mitochondrial	O
ATP	B-CHED
generation	O
,	O
increasing	O
oxidative	O
stress	O
and	O
downregulating	O
the	O
JAK	O
/	O
STAT3	O
pathway	O
.	O

Isoproterenol	B-CHED
induces	O
primary	O
loss	O
of	O
dystrophin	O
in	O
rat	O
hearts	O
:	O
correlation	O
with	O
myocardial	O
injury	O
.	O

The	O
mechanism	O
of	O
isoproterenol	B-CHED
-	O
induced	O
myocardial	O
damage	O
is	O
unknown	O
,	O
but	O
a	O
mismatch	O
of	O
oxygen	B-CHED
supply	O
vs	O
.	O
demand	O
following	O
coronary	O
hypotension	O
and	O
myocardial	O
hyperactivity	O
is	O
the	O
best	O
explanation	O
for	O
the	O
complex	O
morphological	O
alterations	O
observed	O
.	O

Severe	O
alterations	O
in	O
the	O
structural	O
integrity	O
of	O
the	O
sarcolemma	O
of	O
cardiomyocytes	O
have	O
been	O
demonstrated	O
to	O
be	O
caused	O
by	O
isoproterenol	B-CHED
.	O

Taking	O
into	O
account	O
that	O
the	O
sarcolemmal	O
integrity	O
is	O
stabilized	O
by	O
the	O
dystrophin	O
-	O
glycoprotein	O
complex	O
(	O
DGC	O
)	O
that	O
connects	O
actin	O
and	O
laminin	O
in	O
contractile	O
machinery	O
and	O
extracellular	O
matrix	O
and	O
by	O
integrins	O
,	O
this	O
study	O
tests	O
the	O
hypothesis	O
that	O
isoproterenol	B-CHED
affects	O
sarcolemmal	O
stability	O
through	O
changes	O
in	O
the	O
DGC	O
and	O
integrins	O
.	O

We	O
found	O
different	O
sensitivity	O
of	O
the	O
DGC	O
and	O
integrin	O
to	O
isoproterenol	B-CHED
subcutaneous	O
administration	O
.	O

Immunofluorescent	O
staining	O
revealed	O
that	O
dystrophin	O
is	O
the	O
most	O
sensitive	O
among	O
the	O
structures	O
connecting	O
the	O
actin	O
in	O
the	O
cardiomyocyte	O
cytoskeleton	O
and	O
the	O
extracellular	O
matrix	O
.	O

The	O
sarcomeric	O
actin	O
dissolution	O
occurred	O
after	O
the	O
reduction	O
or	O
loss	O
of	O
dystrophin	O
.	O

Subsequently	O
,	O
after	O
lysis	O
of	O
myofilaments	O
,	O
gamma	O
-	O
sarcoglycan	O
,	O
beta	O
-	O
dystroglycan	O
,	O
beta1	O
-	O
integrin	O
,	O
and	O
laminin	O
alpha	O
-	O
2	O
expressions	O
were	O
reduced	O
followed	O
by	O
their	O
breakdown	O
,	O
as	O
epiphenomena	O
of	O
the	O
myocytolytic	O
process	O
.	O

In	O
conclusion	O
,	O
administration	O
of	O
isoproterenol	B-CHED
to	O
rats	O
results	O
in	O
primary	O
loss	O
of	O
dystrophin	O
,	O
the	O
most	O
sensitive	O
among	O
the	O
structural	O
proteins	O
that	O
form	O
the	O
DGC	O
that	O
connects	O
the	O
extracellular	O
matrix	O
and	O
the	O
cytoskeleton	O
in	O
cardiomyocyte	O
.	O

These	O
changes	O
,	O
related	O
to	O
ischaemic	O
injury	O
,	O
explain	O
the	O
severe	O
alterations	O
in	O
the	O
structural	O
integrity	O
of	O
the	O
sarcolemma	O
of	O
cardiomyocytes	O
and	O
hence	O
severe	O
and	O
irreversible	O
injury	O
induced	O
by	O
isoproterenol	B-CHED
.	O

Etiologic	O
factors	O
in	O
the	O
pathogenesis	O
of	O
liver	O
tumors	O
associated	O
with	O
oral	B-CHED
contraceptives	I-CHED
.	O

Within	O
the	O
last	O
several	O
years	O
,	O
previously	O
rare	O
liver	O
tumors	O
have	O
been	O
seen	O
in	O
young	O
women	O
using	O
oral	B-CHED
contraceptive	I-CHED
steroids	B-CHED
.	O

The	O
Registry	O
for	O
Liver	O
Tumors	O
Associated	O
with	O
Oral	B-CHED
Contraceptives	I-CHED
at	O
the	O
University	O
of	O
California	O
,	O
Irvine	O
,	O
has	O
clearly	O
identified	O
27	O
cases	O
.	O

The	O
recent	O
literature	O
contains	O
44	O
case	O
reports	O
.	O

Common	O
to	O
these	O
71	O
cases	O
has	O
been	O
a	O
histopathologic	O
diagnosis	O
of	O
focal	O
nodular	O
hyperplasia	O
,	O
adenoma	O
,	O
hamartoma	O
,	O
and	O
hepatoma	O
.	O

Significant	O
statistical	O
etiologic	O
factors	O
include	O
prolonged	O
uninterrupted	O
usage	O
of	O
oral	B-CHED
contraceptive	I-CHED
steroids	B-CHED
.	O

Eight	O
deaths	O
and	O
liver	O
rupture	O
in	O
18	O
patients	O
attest	O
to	O
the	O
seriousness	O
of	O
this	O
new	O
potentially	O
lethal	O
adverse	O
phenomenon	O
.	O

Ifosfamide	B-CHED
continuous	O
infusion	O
without	O
mesna	B-CHED
.	O

A	O
phase	O
I	O
trial	O
of	O
a	O
14	O
-	O
day	O
cycle	O
.	O

Twenty	O
patients	O
received	O
27	O
courses	O
of	O
ifosfamide	B-CHED
administered	O
as	O
a	O
24	O
-	O
hour	O
continuous	O
infusion	O
for	O
14	O
days	O
without	O
Mesna	B-CHED
.	O

The	O
goal	O
of	O
the	O
study	O
was	O
to	O
deliver	O
a	O
dose	O
rate	O
and	O
total	O
cumulative	O
dose	O
of	O
ifosfamide	B-CHED
that	O
would	O
be	O
comparable	O
to	O
standard	O
bolus	O
or	O
short	O
-	O
term	O
infusions	O
administered	O
with	O
Mesna	B-CHED
.	O

Dose	O
escalations	O
proceeded	O
from	O
200	O
to	O
300	O
,	O
400	O
,	O
450	O
,	O
500	O
,	O
and	O
550	O
mg	O
/	O
m2	O
/	O
d	O
.	O

Four	O
patients	O
developed	O
transient	O
microscopic	O
hematuria	O
at	O
400	O
,	O
450	O
,	O
and	O
500	O
mg	O
/	O
m2	O
/	O
d	O
.	O

There	O
were	O
no	O
instances	O
of	O
macroscopic	O
hematuria	O
.	O

At	O
550	O
mg	O
/	O
m2	O
/	O
d	O
,	O
three	O
patients	O
experienced	O
nonurologic	O
toxicity	O
;	O
confusion	O
(	O
1	O
)	O
,	O
nausea	O
(	O
1	O
)	O
,	O
and	O
Grade	O
2	O
leukopenia	O
(	O
1	O
)	O
.	O

The	O
recommended	O
dose	O
of	O
500	O
mg	O
/	O
m2	O
/	O
d	O
delivers	O
a	O
total	O
dose	O
of	O
7	O
g	O
/	O
m2	O
per	O
cycle	O
,	O
which	O
is	O
comparable	O
to	O
that	O
delivered	O
in	O
clinical	O
practice	O
for	O
bolus	O
or	O
short	O
-	O
term	O
infusion	O
.	O

Because	O
few	O
patients	O
received	O
multiple	O
courses	O
over	O
time	O
,	O
the	O
cumulative	O
effects	O
are	O
indeterminate	O
in	O
the	O
present	O
trial	O
.	O

The	O
frequency	O
and	O
predictability	O
of	O
hematuria	O
are	O
not	O
precise	O
,	O
and	O
at	O
least	O
daily	O
monitoring	O
by	O
urine	O
Hematest	O
is	O
essential	O
,	O
adding	O
Mesna	B-CHED
to	O
the	O
infusate	O
in	O
patients	O
with	O
persistent	O
hematuria	O
.	O

The	O
protracted	O
infusion	O
schedule	O
for	O
ifosfamide	B-CHED
permits	O
convenient	O
outpatient	O
administration	O
without	O
Mesna	B-CHED
and	O
reduces	O
the	O
drug	O
cost	O
of	O
clinical	O
usage	O
of	O
this	O
agent	O
by	O
up	O
to	O
890	O
per	O
cycle	O
.	O

Clinical	O
activity	O
was	O
demonstrated	O
in	O
a	O
single	O
patient	O
,	O
but	O
a	O
comparative	O
trial	O
of	O
standard	O
bolus	O
schedules	O
with	O
the	O
protracted	O
infusion	O
schedule	O
will	O
be	O
necessary	O
to	O
determine	O
if	O
the	O
clinical	O
effectiveness	O
of	O
the	O
drug	O
is	O
maintained	O
.	O

A	O
case	O
of	O
ventricular	O
tachycardia	O
related	O
to	O
caffeine	B-CHED
pretreatment	O
.	O

Suboptimal	O
seizure	O
duration	O
is	O
commonly	O
encountered	O
in	O
electroconvulsive	O
therapy	O
practice	O
,	O
especially	O
in	O
older	O
patients	O
with	O
higher	O
seizure	O
thresholds	O
.	O

Intravenous	O
caffeine	B-CHED
is	O
commonly	O
used	O
to	O
improve	O
seizure	O
duration	O
and	O
quality	O
in	O
such	O
patients	O
and	O
is	O
generally	O
well	O
tolerated	O
aside	O
from	O
occasional	O
reports	O
of	O
relatively	O
benign	O
ventricular	O
ectopy	O
.	O

We	O
describe	O
a	O
patient	O
with	O
no	O
previous	O
history	O
of	O
cardiac	O
disease	O
or	O
arrhythmia	O
who	O
developed	O
sustained	O
bigeminy	O
and	O
2	O
brief	O
runs	O
of	O
ventricular	O
tachycardia	O
after	O
caffeine	B-CHED
administration	O
.	O

Although	O
intravenous	O
caffeine	B-CHED
is	O
generally	O
well	O
tolerated	O
,	O
the	O
clinician	O
should	O
be	O
aware	O
of	O
the	O
potential	O
for	O
unpredictable	O
and	O
serious	O
ventricular	O
arrhythmias	O
.	O

Fatal	O
haemopericardium	O
and	O
gastrointestinal	O
haemorrhage	O
due	O
to	O
possible	O
interaction	O
of	O
cranberry	O
juice	O
with	O
warfarin	B-CHED
.	O

We	O
report	O
a	O
case	O
of	O
fatal	O
internal	O
haemorrhage	O
in	O
an	O
elderly	O
man	O
who	O
consumed	O
only	O
cranberry	O
juice	O
for	O
two	O
weeks	O
while	O
maintaining	O
his	O
usual	O
dosage	O
of	O
warfarin	B-CHED
.	O

We	O
propose	O
that	O
naturally	O
occurring	O
compounds	O
such	O
as	O
flavonoids	B-CHED
,	O
which	O
are	O
present	O
in	O
fruit	O
juices	O
,	O
may	O
increase	O
the	O
potency	O
of	O
warfarin	B-CHED
by	O
competing	O
for	O
the	O
enzymes	O
that	O
normally	O
inactivate	O
warfarin	B-CHED
.	O

While	O
traditionally	O
regarded	O
as	O
foodstuffs	O
,	O
consumption	O
of	O
fruit	O
juices	O
should	O
be	O
considered	O
when	O
patients	O
develop	O
adverse	O
drug	O
reactions	O
.	O

Effect	O
of	O
increasing	O
intraperitoneal	O
infusion	O
rates	O
on	O
bupropion	B-CHED
hydrochloride	I-CHED
-	O
induced	O
seizures	O
in	O
mice	O
.	O

BACKGROUND	O
:	O
It	O
is	O
not	O
known	O
if	O
there	O
is	O
a	O
relationship	O
between	O
input	O
rate	O
and	O
incidence	O
of	O
bupropion	B-CHED
-	O
induced	O
seizures	O
.	O

This	O
is	O
important	O
,	O
since	O
different	O
controlled	O
release	O
formulations	O
of	O
bupropion	B-CHED
release	O
the	O
active	O
drug	O
at	O
different	O
rates	O
.	O

METHODS	O
:	O
We	O
investigated	O
the	O
effect	O
of	O
varying	O
the	O
intraperitoneal	O
infusion	O
rates	O
of	O
bupropion	B-CHED
HCl	I-CHED
120	O
mg	O
/	O
kg	O
,	O
a	O
known	O
convulsive	O
dose	O
50	O
(	O
CD50	O
)	O
,	O
on	O
the	O
incidence	O
and	O
severity	O
of	O
bupropion	B-CHED
-	O
induced	O
convulsions	O
in	O
the	O
Swiss	O
albino	O
mice	O
.	O

A	O
total	O
of	O
69	O
mice	O
,	O
approximately	O
7	O
weeks	O
of	O
age	O
,	O
and	O
weighing	O
21	O
.	O
0	O
to	O
29	O
.	O
1	O
g	O
were	O
randomly	O
assigned	O
to	O
bupropion	B-CHED
HCl	I-CHED
120	O
mg	O
/	O
kg	O
treatment	O
by	O
intraperitoneal	O
(	O
IP	O
)	O
administration	O
in	O
7	O
groups	O
(	O
9	O
to	O
10	O
animals	O
per	O
group	O
)	O
.	O

Bupropion	B-CHED
HCl	I-CHED
was	O
infused	O
through	O
a	O
surgically	O
implanted	O
IP	O
dosing	O
catheter	O
with	O
infusions	O
in	O
each	O
group	O
of	O
0	O
min	O
,	O
15	O
min	O
,	O
30	O
min	O
,	O
60	O
min	O
,	O
90	O
min	O
,	O
120	O
min	O
,	O
and	O
240	O
min	O
.	O

The	O
number	O
,	O
time	O
of	O
onset	O
,	O
duration	O
and	O
the	O
intensity	O
of	O
the	O
convulsions	O
or	O
absence	O
of	O
convulsions	O
were	O
recorded	O
.	O

RESULTS	O
:	O
The	O
results	O
showed	O
that	O
IP	O
administration	O
of	O
bupropion	B-CHED
HCl	I-CHED
120	O
mg	O
/	O
kg	O
by	O
bolus	O
injection	O
induced	O
convulsions	O
in	O
6	O
out	O
of	O
10	O
mice	O
(	O
60	O
%	O
of	O
convulsing	O
mice	O
)	O
in	O
group	O
1	O
.	O

Logistic	O
regression	O
analysis	O
revealed	O
that	O
infusion	O
time	O
was	O
significant	O
(	O
p	O
=	O
0	O
.	O
0004	O
;	O
odds	O
ratio	O
=	O
0	O
.	O
974	O
)	O
and	O
increasing	O
the	O
IP	O
infusion	O
time	O
of	O
bupropion	B-CHED
HCl	I-CHED
120	O
mg	O
/	O
kg	O
was	O
associated	O
with	O
a	O
91	O
%	O
reduced	O
odds	O
of	O
convulsions	O
at	O
infusion	O
times	O
of	O
15	O
to	O
90	O
min	O
compared	O
to	O
bolus	O
injection	O
.	O

Further	O
increase	O
in	O
infusion	O
time	O
resulted	O
in	O
further	O
reduction	O
in	O
the	O
odds	O
of	O
convulsions	O
to	O
99	O
.	O
8	O
%	O
reduction	O
at	O
240	O
min	O
.	O

CONCLUSION	O
:	O
In	O
conclusion	O
,	O
the	O
demonstration	O
of	O
an	O
inverse	O
relationship	O
between	O
infusion	O
time	O
of	O
a	O
fixed	O
and	O
convulsive	O
dose	O
of	O
bupropion	B-CHED
and	O
the	O
risk	O
of	O
convulsions	O
in	O
a	O
prospective	O
study	O
is	O
novel	O
.	O

Graft	O
-	O
versus	O
-	O
host	O
disease	O
prophylaxis	O
with	O
everolimus	B-CHED
and	O
tacrolimus	B-CHED
is	O
associated	O
with	O
a	O
high	O
incidence	O
of	O
sinusoidal	O
obstruction	O
syndrome	O
and	O
microangiopathy	O
:	O
results	O
of	O
the	O
EVTAC	O
trial	O
.	O

A	O
calcineurin	O
inhibitor	O
combined	O
with	O
methotrexate	B-CHED
is	O
the	O
standard	O
prophylaxis	O
for	O
graft	O
-	O
versus	O
-	O
host	O
disease	O
(	O
GVHD	O
)	O
after	O
allogeneic	O
hematopoietic	O
stem	O
cell	O
transplantation	O
(	O
HSCT	O
)	O
.	O

Everolimus	B-CHED
,	O
a	O
derivative	O
of	O
sirolimus	B-CHED
,	O
seems	O
to	O
mediate	O
antileukemia	O
effects	O
.	O

We	O
report	O
on	O
a	O
combination	O
of	O
everolimus	B-CHED
and	O
tacrolimus	B-CHED
in	O
24	O
patients	O
(	O
median	O
age	O
,	O
62	O
years	O
)	O
with	O
either	O
myelodysplastic	O
syndrome	O
(	O
MDS	O
;	O
n	O
=	O
17	O
)	O
or	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
;	O
n	O
=	O
7	O
)	O
undergoing	O
intensive	O
conditioning	O
followed	O
by	O
HSCT	O
from	O
related	O
(	O
n	O
=	O
4	O
)	O
or	O
unrelated	O
(	O
n	O
=	O
20	O
)	O
donors	O
.	O

All	O
patients	O
engrafted	O
,	O
and	O
only	O
1	O
patient	O
experienced	O
grade	O
IV	O
mucositis	O
.	O

Nine	O
patients	O
(	O
37	O
%	O
)	O
developed	O
acute	O
grade	O
II	O
-	O
IV	O
GVHD	O
,	O
and	O
11	O
of	O
17	O
evaluable	O
patients	O
(	O
64	O
%	O
)	O
developed	O
chronic	O
extensive	O
GVHD	O
.	O

Transplantation	O
-	O
associated	O
microangiopathy	O
(	O
TMA	O
)	O
occurred	O
in	O
7	O
patients	O
(	O
29	O
%	O
)	O
,	O
with	O
2	O
cases	O
of	O
acute	O
renal	O
failure	O
.	O

The	O
study	O
was	O
terminated	O
prematurely	O
because	O
an	O
additional	O
6	O
patients	O
(	O
25	O
%	O
)	O
developed	O
sinusoidal	O
obstruction	O
syndrome	O
(	O
SOS	O
)	O
,	O
which	O
was	O
fatal	O
in	O
2	O
cases	O
.	O

With	O
a	O
median	O
follow	O
-	O
up	O
of	O
26	O
months	O
,	O
the	O
2	O
-	O
year	O
overall	O
survival	O
rate	O
was	O
47	O
%	O
.	O

Although	O
this	O
new	O
combination	O
appears	O
to	O
be	O
effective	O
as	O
a	O
prophylactic	O
regimen	O
for	O
acute	O
GVHD	O
,	O
the	O
incidence	O
of	O
TMA	O
and	O
SOS	O
is	O
considerably	O
higher	O
than	O
seen	O
with	O
other	O
regimens	O
.	O

Longitudinal	O
assessment	O
of	O
air	O
conduction	O
audiograms	O
in	O
a	O
phase	O
III	O
clinical	O
trial	O
of	O
difluoromethylornithine	B-CHED
and	O
sulindac	B-CHED
for	O
prevention	O
of	O
sporadic	O
colorectal	O
adenomas	O
.	O

A	O
phase	O
III	O
clinical	O
trial	O
assessed	O
the	O
recurrence	O
of	O
adenomatous	O
polyps	O
after	O
treatment	O
for	O
36	O
months	O
with	O
difluoromethylornithine	B-CHED
(	O
DFMO	B-CHED
)	O
plus	O
sulindac	B-CHED
or	O
matched	O
placebos	O
.	O

Temporary	O
hearing	O
loss	O
is	O
a	O
known	O
toxicity	O
of	O
treatment	O
with	O
DFMO	B-CHED
,	O
thus	O
a	O
comprehensive	O
approach	O
was	O
developed	O
to	O
analyze	O
serial	O
air	O
conduction	O
audiograms	O
.	O

The	O
generalized	O
estimating	O
equation	O
method	O
estimated	O
the	O
mean	O
difference	O
between	O
treatment	O
arms	O
with	O
regard	O
to	O
change	O
in	O
air	O
conduction	O
pure	O
tone	O
thresholds	O
while	O
accounting	O
for	O
within	O
-	O
subject	O
correlation	O
due	O
to	O
repeated	O
measurements	O
at	O
frequencies	O
.	O

Based	O
on	O
290	O
subjects	O
,	O
there	O
was	O
an	O
average	O
difference	O
of	O
0	O
.	O
50	O
dB	O
between	O
subjects	O
treated	O
with	O
DFMO	B-CHED
plus	O
sulindac	B-CHED
compared	O
with	O
those	O
treated	O
with	O
placebo	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
-	O
0	O
.	O
64	O
to	O
1	O
.	O
63	O
dB	O
;	O
P	O
=	O
0	O
.	O
39	O
)	O
,	O
adjusted	O
for	O
baseline	O
values	O
,	O
age	O
,	O
and	O
frequencies	O
.	O

In	O
the	O
normal	O
speech	O
range	O
of	O
500	O
to	O
3	O
,	O
000	O
Hz	O
,	O
an	O
estimated	O
difference	O
of	O
0	O
.	O
99	O
dB	O
(	O
-	O
0	O
.	O
17	O
to	O
2	O
.	O
14	O
dB	O
;	O
P	O
=	O
0	O
.	O
09	O
)	O
was	O
detected	O
.	O

Dose	O
intensity	O
did	O
not	O
add	O
information	O
to	O
models	O
.	O

There	O
were	O
14	O
of	O
151	O
(	O
9	O
.	O
3	O
%	O
)	O
in	O
the	O
DFMO	B-CHED
plus	O
sulindac	B-CHED
group	O
and	O
4	O
of	O
139	O
(	O
2	O
.	O
9	O
%	O
)	O
in	O
the	O
placebo	O
group	O
who	O
experienced	O
at	O
least	O
15	O
dB	O
hearing	O
reduction	O
from	O
baseline	O
in	O
2	O
or	O
more	O
consecutive	O
frequencies	O
across	O
the	O
entire	O
range	O
tested	O
(	O
P	O
=	O
0	O
.	O
02	O
)	O
.	O

Follow	O
-	O
up	O
air	O
conduction	O
done	O
at	O
least	O
6	O
months	O
after	O
end	O
of	O
treatment	O
showed	O
an	O
adjusted	O
mean	O
difference	O
in	O
hearing	O
thresholds	O
of	O
1	O
.	O
08	O
dB	O
(	O
-	O
0	O
.	O
81	O
to	O
2	O
.	O
96	O
dB	O
;	O
P	O
=	O
0	O
.	O
26	O
)	O
between	O
treatment	O
arms	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
proportion	O
of	O
subjects	O
in	O
the	O
DFMO	B-CHED
plus	O
sulindac	B-CHED
group	O
who	O
experienced	O
clinically	O
significant	O
hearing	O
loss	O
compared	O
with	O
the	O
placebo	O
group	O
.	O

The	O
estimated	O
attributable	O
risk	O
of	O
ototoxicity	O
from	O
exposure	O
to	O
the	O
drug	O
is	O
8	O
.	O
4	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
-	O
2	O
.	O
0	O
%	O
to	O
18	O
.	O
8	O
%	O
;	O
P	O
=	O
0	O
.	O
12	O
)	O
.	O

There	O
is	O
a	O
<	O
2	O
dB	O
difference	O
in	O
mean	O
threshold	O
for	O
patients	O
treated	O
with	O
DFMO	B-CHED
plus	O
sulindac	B-CHED
compared	O
with	O
those	O
treated	O
with	O
placebo	O
.	O

Proteinase	O
3	O
-	O
antineutrophil	O
cytoplasmic	O
antibody	O
-	O
(	O
PR3	O
-	O
ANCA	O
)	O
positive	O
necrotizing	O
glomerulonephritis	O
after	O
restarting	O
sulphasalazine	B-CHED
treatment	O
.	O

A	O
59	O
-	O
year	O
-	O
old	O
woman	O
with	O
ulcerative	O
colitis	O
developed	O
red	O
eyes	O
,	O
pleural	O
effusion	O
,	O
eosinophilia	O
and	O
urinary	O
abnormalities	O
after	O
restarting	O
of	O
sulphasalazine	B-CHED
treatment	O
.	O

Light	O
microscopy	O
of	O
a	O
kidney	O
biopsy	O
revealed	O
segmental	O
necrotizing	O
glomerulonephritis	O
without	O
deposition	O
of	O
immunoglobulin	O
or	O
complement	O
.	O

Proteinase	O
3	O
-	O
antineutrophil	O
cytoplasmic	O
antibody	O
(	O
PR3	O
-	O
ANCA	O
)	O
titer	O
was	O
elevated	O
at	O
183	O
ELISA	O
units	O
(	O
EU	O
)	O
in	O
sera	O
(	O
normal	O
range	O
less	O
than	O
10	O
EU	O
)	O
,	O
myeloperoxidase	O
-	O
ANCA	O
was	O
negative	O
.	O

PR3	O
-	O
ANCA	O
titer	O
was	O
250	O
and	O
1	O
,	O
070	O
EU	O
in	O
pleural	O
effusions	O
on	O
right	O
and	O
left	O
side	O
,	O
respectively	O
.	O

Although	O
cessation	O
of	O
sulphasalazine	B-CHED
treatment	O
resulted	O
in	O
improvements	O
in	O
fever	O
,	O
red	O
eyes	O
,	O
chest	O
pain	O
,	O
titer	O
of	O
C	O
-	O
reactive	O
protein	O
and	O
volume	O
of	O
the	O
pleural	O
effusions	O
,	O
we	O
initiated	O
steroid	B-CHED
therapy	O
,	O
because	O
PR3	O
-	O
ANCA	O
titer	O
rose	O
to	O
320	O
EU	O
,	O
eosinophil	O
count	O
increased	O
to	O
1	O
,	O
100	O
cells	O
/	O
microl	O
,	O
and	O
the	O
pleural	O
effusion	O
remained	O
.	O

One	O
month	O
after	O
steroid	B-CHED
therapy	O
,	O
the	O
pleural	O
effusion	O
disappeared	O
,	O
and	O
PR3	O
-	O
ANCA	O
titer	O
normalized	O
3	O
months	O
later	O
.	O

This	O
case	O
suggests	O
that	O
sulphasalazine	B-CHED
can	O
induce	O
PR3	O
-	O
ANCA	O
-	O
positive	O
necrotizing	O
glomerulonephritis	O
.	O

Comparison	O
of	O
unilateral	O
pallidotomy	O
and	O
subthalamotomy	O
findings	O
in	O
advanced	O
idiopathic	O
Parkinson	O
'	O
s	O
disease	O
.	O

A	O
prospective	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
pilot	O
study	O
to	O
compare	O
the	O
results	O
of	O
stereotactic	O
unilateral	O
pallidotomy	O
and	O
subthalamotomy	O
in	O
advanced	O
idiopathic	O
Parkinson	O
'	O
s	O
disease	O
(	O
PD	O
)	O
refractory	O
to	O
medical	O
treatment	O
was	O
designed	O
.	O

Ten	O
consecutive	O
patients	O
(	O
mean	O
age	O
,	O
58	O
.	O
4	O
+	O
/	O
-	O
6	O
.	O
8	O
years	O
;	O
7	O
men	O
,	O
3	O
women	O
)	O
with	O
similar	O
characteristics	O
at	O
the	O
duration	O
of	O
disease	O
(	O
mean	O
disease	O
time	O
,	O
8	O
.	O
4	O
+	O
/	O
-	O
3	O
.	O
5	O
years	O
)	O
,	O
disabling	O
motor	O
fluctuations	O
(	O
Hoehn	O
_	O
Yahr	O
stage	O
3	O
-	O
5	O
in	O
off	O
-	O
drug	O
phases	O
)	O
and	O
levodopa	B-CHED
-	O
induced	O
dyskinesias	O
were	O
selected	O
.	O

All	O
patients	O
had	O
bilateral	O
symptoms	O
and	O
their	O
levodopa	B-CHED
equivalent	O
dosing	O
were	O
analysed	O
.	O

Six	O
patients	O
were	O
operated	O
on	O
in	O
the	O
globus	O
pallidus	O
interna	O
(	O
GPi	O
)	O
and	O
four	O
in	O
the	O
subthalamic	O
nucleus	O
(	O
STN	O
)	O
.	O

Clinical	O
evaluation	O
included	O
the	O
use	O
of	O
the	O
Unified	O
Parkinson	O
'	O
s	O
Disease	O
Rating	O
Scale	O
(	O
UPDRS	O
)	O
,	O
Hoehn	O
_	O
Yahr	O
score	O
and	O
Schwab	O
England	O
activities	O
of	O
daily	O
living	O
(	O
ADL	O
)	O
score	O
in	O
'	O
on	O
'	O
-	O
and	O
'	O
off	O
'	O
-	O
drug	O
conditions	O
before	O
surgery	O
and	O
6	O
months	O
after	O
surgery	O
.	O

There	O
was	O
statistically	O
significant	O
improvement	O
in	O
all	O
contralateral	O
major	O
parkinsonian	O
motor	O
signs	O
in	O
all	O
patients	O
followed	O
for	O
6	O
months	O
.	O

Levodopa	B-CHED
equivalent	O
daily	O
intake	O
was	O
significantly	O
reduced	O
in	O
the	O
STN	O
group	O
.	O

Changes	O
in	O
UPDRS	O
,	O
Hoehn	O
_	O
Yahr	O
and	O
Schwab	O
England	O
ADL	O
scores	O
were	O
similar	O
in	O
both	O
groups	O
.	O

Cognitive	O
functions	O
were	O
unchanged	O
in	O
both	O
groups	O
.	O

Complications	O
were	O
observed	O
in	O
two	O
patients	O
:	O
one	O
had	O
a	O
left	O
homonymous	O
hemianopsia	O
after	O
pallidotomy	O
and	O
another	O
one	O
developed	O
left	O
hemiballistic	O
movements	O
3	O
days	O
after	O
subthalamotomy	O
which	O
partly	O
improved	O
within	O
1	O
month	O
with	O
Valproate	B-CHED
1000	O
mg	O
/	O
day	O
.	O

The	O
findings	O
of	O
this	O
study	O
suggest	O
that	O
lesions	O
of	O
the	O
unilateral	O
STN	O
and	O
GPi	O
are	O
equally	O
effective	O
treatment	O
for	O
patients	O
with	O
advanced	O
PD	O
refractory	O
to	O
medical	O
treatment	O
.	O

DSMM	O
XI	O
study	O
:	O
dose	O
definition	O
for	O
intravenous	O
cyclophosphamide	B-CHED
in	O
combination	O
with	O
bortezomib	B-CHED
/	O
dexamethasone	B-CHED
for	O
remission	O
induction	O
in	O
patients	O
with	O
newly	O
diagnosed	O
myeloma	O
.	O

A	O
clinical	O
trial	O
was	O
initiated	O
to	O
evaluate	O
the	O
recommended	O
dose	O
of	O
cyclophosphamide	B-CHED
in	O
combination	O
with	O
bortezomib	B-CHED
and	O
dexamethasone	B-CHED
as	O
induction	O
treatment	O
before	O
stem	O
cell	O
transplantation	O
for	O
younger	O
patients	O
with	O
newly	O
diagnosed	O
multiple	O
myeloma	O
(	O
MM	O
)	O
.	O

Thirty	O
patients	O
were	O
treated	O
with	O
three	O
21	O
-	O
day	O
cycles	O
of	O
bortezomib	B-CHED
1	O
.	O
3	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
,	O
4	O
,	O
8	O
,	O
and	O
11	O
plus	O
dexamethasone	B-CHED
40	O
mg	O
on	O
the	O
day	O
of	O
bortezomib	B-CHED
injection	O
and	O
the	O
day	O
after	O
plus	O
cyclophosphamide	B-CHED
at	O
900	O
,	O
1	O
,	O
200	O
,	O
or	O
1	O
,	O
500	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
day	O
1	O
.	O

The	O
maximum	O
tolerated	O
dose	O
of	O
cyclophosphamide	B-CHED
was	O
defined	O
as	O
900	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O

At	O
this	O
dose	O
level	O
,	O
92	O
%	O
of	O
patients	O
achieved	O
at	O
least	O
a	O
partial	O
response	O
.	O

The	O
overall	O
response	O
rate	O
[	O
complete	O
response	O
(	O
CR	O
)	O
plus	O
partial	O
response	O
(	O
PR	O
)	O
]	O
across	O
all	O
dose	O
levels	O
was	O
77	O
%	O
,	O
with	O
a	O
10	O
%	O
CR	O
rate	O
.	O

No	O
patient	O
experienced	O
progressive	O
disease	O
.	O

The	O
most	O
frequent	O
adverse	O
events	O
were	O
hematological	O
and	O
gastrointestinal	O
toxicities	O
as	O
well	O
as	O
neuropathy	O
.	O

The	O
results	O
suggest	O
that	O
bortezomib	B-CHED
in	O
combination	O
with	O
cyclophosphamide	B-CHED
at	O
900	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
dexamethasone	B-CHED
is	O
an	O
effective	O
induction	O
treatment	O
for	O
patients	O
with	O
newly	O
diagnosed	O
MM	O
that	O
warrants	O
further	O
investigation	O
.	O

Naloxone	B-CHED
reversal	O
of	O
hypotension	O
due	O
to	O
captopril	B-CHED
overdose	O
.	O

The	O
hemodynamic	O
effects	O
of	O
captopril	B-CHED
and	O
other	O
angiotensin	B-CHED
-	I-CHED
converting	I-CHED
enzyme	I-CHED
inhibitors	I-CHED
may	O
be	O
mediated	O
by	O
the	O
endogenous	O
opioid	O
system	O
.	O

The	O
opioid	O
antagonist	O
naloxone	B-CHED
has	O
been	O
shown	O
to	O
block	O
or	O
reverse	O
the	O
hypotensive	O
actions	O
of	O
captopril	B-CHED
.	O

We	O
report	O
a	O
case	O
of	O
an	O
intentional	O
captopril	B-CHED
overdose	O
,	O
manifested	O
by	O
marked	O
hypotension	O
,	O
that	O
resolved	O
promptly	O
with	O
the	O
administration	O
of	O
naloxone	B-CHED
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
reported	O
case	O
of	O
captopril	B-CHED
-	O
induced	O
hypotension	O
treated	O
with	O
naloxone	B-CHED
.	O

Our	O
experience	O
demonstrates	O
a	O
possible	O
role	O
of	O
naloxone	B-CHED
in	O
the	O
reversal	O
of	O
hypotension	O
resulting	O
from	O
captopril	B-CHED
.	O

Identification	O
of	O
a	O
simple	O
and	O
sensitive	O
microplate	O
method	O
for	O
the	O
detection	O
of	O
oversulfated	O
chondroitin	B-CHED
sulfate	I-CHED
in	O
heparin	B-CHED
products	O
.	O

Heparin	B-CHED
is	O
a	O
commonly	O
implemented	O
anticoagulant	O
used	O
to	O
treat	O
critically	O
ill	O
patients	O
.	O

Recently	O
,	O
a	O
number	O
of	O
commercial	O
lots	O
of	O
heparin	B-CHED
products	O
were	O
found	O
to	O
be	O
contaminated	O
with	O
an	O
oversulfated	O
chondroitin	B-CHED
sulfate	I-CHED
(	O
OSCS	O
)	O
derivative	O
that	O
could	O
elicit	O
a	O
hypotensive	O
response	O
in	O
pigs	O
following	O
a	O
single	O
high	O
-	O
dose	O
infusion	O
.	O

Using	O
both	O
contaminated	O
heparin	B-CHED
products	O
and	O
the	O
synthetically	O
produced	O
derivative	O
,	O
we	O
showed	O
that	O
the	O
OSCS	O
produces	O
dose	O
-	O
dependent	O
hypotension	O
in	O
pigs	O
.	O

The	O
no	O
observed	O
effect	O
level	O
(	O
NOEL	O
)	O
for	O
this	O
contaminant	O
appears	O
to	O
be	O
approximately	O
1mg	O
/	O
kg	O
,	O
corresponding	O
to	O
a	O
contamination	O
level	O
of	O
approximately	O
3	O
%	O
.	O

We	O
also	O
demonstrated	O
that	O
OSCS	O
can	O
be	O
identified	O
in	O
heparin	B-CHED
products	O
using	O
a	O
simple	O
,	O
inexpensive	O
,	O
commercially	O
available	O
heparin	B-CHED
enzyme	O
immunoassay	O
(	O
EIA	O
)	O
kit	O
that	O
has	O
a	O
limit	O
of	O
detection	O
of	O
approximately	O
0	O
.	O
1	O
%	O
,	O
well	O
below	O
the	O
NOEL	O
.	O

This	O
kit	O
may	O
provide	O
a	O
useful	O
method	O
to	O
test	O
heparin	B-CHED
products	O
for	O
contamination	O
with	O
oversulfated	O
GAG	O
derivatives	O
.	O

5	B-CHED
flourouracil	I-CHED
-	O
induced	O
apical	O
ballooning	O
syndrome	O
:	O
a	O
case	O
report	O
.	O

The	O
apical	O
ballooning	O
syndrome	O
(	O
ABS	O
)	O
is	O
a	O
recently	O
described	O
stress	O
-	O
mediated	O
acute	O
cardiac	O
syndrome	O
characterized	O
by	O
transient	O
wall	O
-	O
motion	O
abnormalities	O
involving	O
the	O
apex	O
and	O
midventricle	O
with	O
hyperkinesis	O
of	O
the	O
basal	O
left	O
ventricular	O
(	O
LV	O
)	O
segments	O
without	O
obstructive	O
epicardial	O
coronary	O
disease	O
.	O

Cardiotoxicity	O
is	O
not	O
an	O
uncommon	O
adverse	O
effect	O
of	O
chemotherapeutic	O
agents	O
.	O

However	O
,	O
there	O
are	O
no	O
reports	O
of	O
ABS	O
secondary	O
to	O
chemotherapeutic	O
agents	O
.	O

We	O
describe	O
the	O
case	O
of	O
a	O
woman	O
who	O
developed	O
the	O
syndrome	O
after	O
chemotherapy	O
for	O
metastatic	O
cancer	O
.	O

A	O
79	O
-	O
year	O
-	O
old	O
woman	O
presented	O
with	O
typical	O
ischemic	O
chest	O
pain	O
,	O
elevated	O
cardiac	O
enzymes	O
with	O
significant	O
ST	O
-	O
segment	O
abnormalities	O
on	O
her	O
electrocardiogram	O
.	O

She	O
underwent	O
recent	O
chemotherapy	O
with	O
fluorouracil	B-CHED
for	O
metastatic	O
colorectal	O
cancer	O
.	O

Echocardiography	O
revealed	O
a	O
wall	O
-	O
motion	O
abnormality	O
involving	O
the	O
apical	O
and	O
periapical	O
segments	O
which	O
appeared	O
akinetic	O
.	O

Coronary	O
angiography	O
revealed	O
no	O
obstructive	O
coronary	O
lesions	O
.	O

The	O
patient	O
was	O
stabilized	O
with	O
medical	O
therapy	O
.	O

Four	O
weeks	O
later	O
she	O
remained	O
completely	O
asymptomatic	O
.	O

Echocardiogram	O
revealed	O
a	O
normal	O
ejection	O
fraction	O
and	O
a	O
resolution	O
of	O
the	O
apical	O
akinesis	O
.	O

Pathogenetic	O
mechanisms	O
of	O
cardiac	O
complications	O
in	O
cancer	O
patients	O
undergoing	O
chemotherapy	O
include	O
coronary	O
vasospasm	O
,	O
endothelial	O
damage	O
and	O
consequent	O
thrombus	O
formation	O
.	O

In	O
our	O
patient	O
,	O
both	O
supraphysiologic	O
levels	O
of	O
plasma	O
catecholamines	B-CHED
and	O
stress	O
related	O
neuropeptides	O
caused	O
by	O
cancer	O
diagnosis	O
as	O
well	O
as	O
chemotherapy	O
may	O
have	O
contributed	O
the	O
development	O
of	O
ABS	O
.	O

Rapid	O
reversal	O
of	O
anticoagulation	O
reduces	O
hemorrhage	O
volume	O
in	O
a	O
mouse	O
model	O
of	O
warfarin	B-CHED
-	O
associated	O
intracerebral	O
hemorrhage	O
.	O

Warfarin	B-CHED
-	O
associated	O
intracerebral	O
hemorrhage	O
(	O
W	O
-	O
ICH	O
)	O
is	O
a	O
severe	O
type	O
of	O
stroke	O
.	O

There	O
is	O
no	O
consensus	O
on	O
the	O
optimal	O
treatment	O
for	O
W	O
-	O
ICH	O
.	O

Using	O
a	O
mouse	O
model	O
,	O
we	O
tested	O
whether	O
the	O
rapid	O
reversal	O
of	O
anticoagulation	O
using	O
human	O
prothrombin	B-CHED
complex	I-CHED
concentrate	I-CHED
(	O
PCC	B-CHED
)	O
can	O
reduce	O
hemorrhagic	O
blood	O
volume	O
.	O

Male	O
CD	O
-	O
1	O
mice	O
were	O
treated	O
with	O
warfarin	B-CHED
(	O
2	O
mg	O
/	O
kg	O
over	O
24	O
h	O
)	O
,	O
resulting	O
in	O
a	O
mean	O
(	O
+	O
/	O
-	O
s	O
.	O
d	O
.	O
)	O
International	O
Normalized	O
Ratio	O
of	O
3	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
9	O
.	O

First	O
,	O
we	O
showed	O
that	O
an	O
intravenous	O
administration	O
of	O
human	O
PCC	B-CHED
rapidly	O
reversed	O
anticoagulation	O
in	O
mice	O
.	O

Second	O
,	O
a	O
stereotactic	O
injection	O
of	O
collagenase	O
was	O
administered	O
to	O
induce	O
hemorrhage	O
in	O
the	O
right	O
striatum	O
.	O

Forty	O
-	O
five	O
minutes	O
later	O
,	O
the	O
animals	O
were	O
randomly	O
treated	O
with	O
PCC	B-CHED
(	O
100	O
U	O
/	O
kg	O
)	O
or	O
saline	O
i	O
.	O
v	O
.	O
(	O
n	O
=	O
12	O
per	O
group	O
)	O
.	O

Twenty	O
-	O
four	O
hours	O
after	O
hemorrhage	O
induction	O
,	O
hemorrhagic	O
blood	O
volume	O
was	O
quantified	O
using	O
a	O
photometric	O
hemoglobin	O
assay	O
.	O

The	O
mean	O
hemorrhagic	O
blood	O
volume	O
was	O
reduced	O
in	O
PCC	B-CHED
-	O
treated	O
animals	O
(	O
6	O
.	O
5	O
+	O
/	O
-	O
3	O
.	O
1	O
microL	O
)	O
compared	O
with	O
saline	O
controls	O
(	O
15	O
.	O
3	O
+	O
/	O
-	O
11	O
.	O
2	O
microL	O
,	O
P	O
=	O
0	O
.	O
015	O
)	O
.	O

In	O
the	O
saline	O
group	O
,	O
45	O
%	O
of	O
the	O
mice	O
developed	O
large	O
hematomas	O
(	O
i	O
.	O
e	O
.	O
,	O
>	O
15	O
microL	O
)	O
.	O

In	O
contrast	O
,	O
such	O
extensive	O
lesions	O
were	O
never	O
found	O
in	O
the	O
PCC	B-CHED
group	O
.	O

We	O
provide	O
experimental	O
data	O
suggesting	O
PCC	B-CHED
to	O
be	O
an	O
effective	O
acute	O
treatment	O
for	O
W	O
-	O
ICH	O
in	O
terms	O
of	O
reducing	O
hemorrhagic	O
blood	O
volume	O
.	O

Future	O
studies	O
are	O
needed	O
to	O
assess	O
the	O
therapeutic	O
potential	O
emerging	O
from	O
our	O
finding	O
for	O
human	O
W	O
-	O
ICH	O
.	O

Long	O
term	O
hormone	O
therapy	O
for	O
perimenopausal	O
and	O
postmenopausal	O
women	O
.	O

BACKGROUND	O
:	O
Hormone	O
therapy	O
(	O
HT	O
)	O
is	O
widely	O
used	O
for	O
controlling	O
menopausal	O
symptoms	O
and	O
has	O
also	O
been	O
used	O
for	O
the	O
management	O
and	O
prevention	O
of	O
cardiovascular	O
disease	O
,	O
osteoporosis	O
and	O
dementia	O
in	O
older	O
women	O
.	O

This	O
is	O
an	O
updated	O
version	O
of	O
the	O
original	O
Cochrane	O
review	O
first	O
published	O
in	O
2005	O
.	O

OBJECTIVES	O
:	O
To	O
assess	O
the	O
effect	O
of	O
long	O
-	O
term	O
HT	O
on	O
mortality	O
,	O
cardiovascular	O
outcomes	O
,	O
cancer	O
,	O
gallbladder	O
disease	O
,	O
cognition	O
,	O
fractures	O
and	O
quality	O
of	O
life	O
.	O

SEARCH	O
STRATEGY	O
:	O
We	O
searched	O
the	O
following	O
databases	O
to	O
November	O
2007	O
:	O
Trials	O
Register	O
of	O
the	O
Cochrane	O
Menstrual	O
Disorders	O
and	O
Subfertility	O
Group	O
,	O
Cochrane	O
Central	O
Register	O
of	O
Controlled	O
Trials	O
,	O
MEDLINE	O
,	O
EMBASE	O
,	O
Biological	O
Abstracts	O
.	O

Also	O
relevant	O
non	O
-	O
indexed	O
journals	O
and	O
conference	O
abstracts	O
.	O

SELECTION	O
CRITERIA	O
:	O
Randomised	O
double	O
-	O
blind	O
trials	O
of	O
HT	O
versus	O
placebo	O
,	O
taken	O
for	O
at	O
least	O
one	O
year	O
by	O
perimenopausal	O
or	O
postmenopausal	O
women	O
.	O

HT	O
included	O
oestrogens	B-CHED
,	O
with	O
or	O
without	O
progestogens	B-CHED
,	O
via	O
oral	O
,	O
transdermal	O
,	O
subcutaneous	O
or	O
transnasal	O
routes	O
.	O

DATA	O
COLLECTION	O
AND	O
ANALYSIS	O
:	O
Two	O
authors	O
independently	O
assessed	O
trial	O
quality	O
and	O
extracted	O
data	O
.	O

MAIN	O
RESULTS	O
:	O
Nineteen	O
trials	O
involving	O
41	O
,	O
904	O
women	O
were	O
included	O
.	O

In	O
relatively	O
healthy	O
women	O
,	O
combined	O
continuous	O
HT	O
significantly	O
increased	O
the	O
risk	O
of	O
venous	O
thrombo	O
-	O
embolism	O
or	O
coronary	O
event	O
(	O
after	O
one	O
year	O
'	O
s	O
use	O
)	O
,	O
stroke	O
(	O
after	O
three	O
years	O
)	O
,	O
breast	O
cancer	O
and	O
gallbladder	O
disease	O
.	O

Long	O
-	O
term	O
oestrogen	B-CHED
-	O
only	O
HT	O
significantly	O
increased	O
the	O
risk	O
of	O
venous	O
thrombo	O
-	O
embolism	O
,	O
stroke	O
and	O
gallbladder	O
disease	O
(	O
after	O
one	O
to	O
two	O
years	O
,	O
three	O
years	O
and	O
seven	O
years	O
'	O
use	O
respectively	O
)	O
,	O
but	O
did	O
not	O
significantly	O
increase	O
the	O
risk	O
of	O
breast	O
cancer	O
.	O

The	O
only	O
statistically	O
significant	O
benefits	O
of	O
HT	O
were	O
a	O
decreased	O
incidence	O
of	O
fractures	O
and	O
(	O
for	O
combined	O
HT	O
)	O
colon	O
cancer	O
,	O
with	O
long	O
-	O
term	O
use	O
.	O

Among	O
women	O
aged	O
over	O
65	O
who	O
were	O
relatively	O
healthy	O
(	O
i	O
.	O
e	O
.	O
generally	O
fit	O
,	O
without	O
overt	O
disease	O
)	O
and	O
taking	O
continuous	O
combined	O
HT	O
,	O
there	O
was	O
a	O
statistically	O
significant	O
increase	O
in	O
the	O
incidence	O
of	O
dementia	O
.	O

Among	O
women	O
with	O
cardiovascular	O
disease	O
,	O
long	O
-	O
term	O
use	O
of	O
combined	O
continuous	O
HT	O
significantly	O
increased	O
the	O
risk	O
of	O
venous	O
thrombo	O
-	O
embolism	O
.	O
One	O
trial	O
analysed	O
subgroups	O
of	O
2839	O
relatively	O
healthy	O
50	O
to	O
59	O
year	O
old	O
women	O
taking	O
combined	O
continuous	O
HT	O
and	O
1637	O
taking	O
oestrogen	B-CHED
-	O
only	O
HT	O
,	O
versus	O
similar	O
-	O
sized	O
placebo	O
groups	O
.	O

The	O
only	O
significantly	O
increased	O
risk	O
reported	O
was	O
for	O
venous	O
thrombo	O
-	O
embolism	O
in	O
women	O
taking	O
combined	O
continuous	O
HT	O
:	O
their	O
absolute	O
risk	O
remained	O
low	O
,	O
at	O
less	O
than	O
1	O
/	O
500	O
.	O

However	O
,	O
this	O
study	O
was	O
not	O
powered	O
to	O
detect	O
differences	O
between	O
groups	O
of	O
younger	O
women	O
.	O

AUTHORS	O
'	O
CONCLUSIONS	O
:	O
HT	O
is	O
not	O
indicated	O
for	O
the	O
routine	O
management	O
of	O
chronic	O
disease	O
.	O

We	O
need	O
more	O
evidence	O
on	O
the	O
safety	O
of	O
HT	O
for	O
menopausal	O
symptom	O
control	O
,	O
though	O
short	O
-	O
term	O
use	O
appears	O
to	O
be	O
relatively	O
safe	O
for	O
healthy	O
younger	O
women	O
.	O

Acute	O
renal	O
failure	O
in	O
patients	O
with	O
AIDS	O
on	O
tenofovir	B-CHED
while	O
receiving	O
prolonged	O
vancomycin	B-CHED
course	O
for	O
osteomyelitis	O
.	O

Renal	O
failure	O
developed	O
after	O
a	O
prolonged	O
course	O
of	O
vancomycin	B-CHED
therapy	O
in	O
2	O
patients	O
who	O
were	O
receiving	O
tenofovir	B-CHED
disoproxil	I-CHED
fumarate	I-CHED
as	O
part	O
of	O
an	O
antiretroviral	O
regimen	O
.	O

Tenofovir	B-CHED
has	O
been	O
implicated	O
in	O
the	O
development	O
of	O
Fanconi	O
syndrome	O
and	O
renal	O
insufficiency	O
because	O
of	O
its	O
effects	O
on	O
the	O
proximal	O
renal	O
tubule	O
.	O

Vancomycin	B-CHED
nephrotoxicity	O
is	O
infrequent	O
but	O
may	O
result	O
from	O
coadministration	O
with	O
a	O
nephrotoxic	O
agent	O
.	O

Clinicians	O
should	O
be	O
aware	O
that	O
tenofovir	B-CHED
may	O
raise	O
the	O
risk	O
of	O
renal	O
failure	O
during	O
prolonged	O
administration	O
of	O
vancomycin	B-CHED
.	O

Recurrent	O
dysosmia	O
induced	O
by	O
pyrazinamide	B-CHED
.	O

Pyrazinamide	B-CHED
can	O
have	O
adverse	O
effects	O
such	O
as	O
hepatic	O
toxicity	O
,	O
hyperuricemia	O
or	O
digestive	O
disorders	O
.	O

In	O
rare	O
cases	O
,	O
alterations	O
in	O
taste	O
and	O
smell	O
function	O
have	O
been	O
reported	O
for	O
pyrazinamide	B-CHED
when	O
combined	O
with	O
other	O
drugs	O
.	O

We	O
report	O
a	O
case	O
of	O
reversible	O
olfactory	O
disorder	O
related	O
to	O
pyrazinamide	B-CHED
in	O
a	O
woman	O
,	O
with	O
a	O
positive	O
rechallenge	O
.	O

The	O
patient	O
presented	O
every	O
day	O
a	O
sensation	O
of	O
smelling	O
something	O
burning	O
15	O
min	O
after	O
drug	O
intake	O
.	O

Dysosmia	O
disappeared	O
completely	O
after	O
pyrazinamide	B-CHED
withdrawal	O
and	O
recurred	O
after	O
its	O
rechallenge	O
.	O

The	O
case	O
was	O
reported	O
to	O
the	O
Tunisian	O
Centre	O
of	O
Pharmacovigilance	O
.	O

Mice	O
lacking	O
mPGES	O
-	O
1	O
are	O
resistant	O
to	O
lithium	B-CHED
-	O
induced	O
polyuria	O
.	O

Cyclooxygenase	O
-	O
2	O
activity	O
is	O
required	O
for	O
the	O
development	O
of	O
lithium	B-CHED
-	O
induced	O
polyuria	O
.	O

However	O
,	O
the	O
involvement	O
of	O
a	O
specific	O
,	O
terminal	O
prostaglandin	B-CHED
(	O
PG	B-CHED
)	O
isomerase	O
has	O
not	O
been	O
evaluated	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
assess	O
lithium	B-CHED
-	O
induced	O
polyuria	O
in	O
mice	O
deficient	O
in	O
microsomal	O
prostaglandin	B-CHED
E	I-CHED
synthase	O
-	O
1	O
(	O
mPGES	O
-	O
1	O
)	O
.	O

A	O
2	O
-	O
wk	O
administration	O
of	O
LiCl	B-CHED
(	O
4	O
mmol	O
.	O
kg	O
(	O
-	O
1	O
)	O
.	O
day	O
(	O
-	O
1	O
)	O
ip	O
)	O
in	O
mPGES	O
-	O
1	O
+	O
/	O
+	O
mice	O
led	O
to	O
a	O
marked	O
polyuria	O
with	O
hyposmotic	O
urine	O
.	O

This	O
was	O
associated	O
with	O
elevated	O
renal	O
mPGES	O
-	O
1	O
protein	O
expression	O
and	O
increased	O
urine	O
PGE	B-CHED
(	I-CHED
2	I-CHED
)	I-CHED
excretion	O
.	O

In	O
contrast	O
,	O
mPGES	O
-	O
1	O
-	O
/	O
-	O
mice	O
were	O
largely	O
resistant	O
to	O
lithium	B-CHED
-	O
induced	O
polyuria	O
and	O
a	O
urine	O
concentrating	O
defect	O
,	O
accompanied	O
by	O
nearly	O
complete	O
blockade	O
of	O
high	O
urine	O
PGE	B-CHED
(	I-CHED
2	I-CHED
)	I-CHED
and	O
cAMP	O
output	O
.	O

Immunoblotting	O
,	O
immunohistochemistry	O
,	O
and	O
quantitative	O
(	O
q	O
)	O
RT	O
-	O
PCR	O
consistently	O
detected	O
a	O
significant	O
decrease	O
in	O
aquaporin	O
-	O
2	O
(	O
AQP2	O
)	O
protein	O
expression	O
in	O
both	O
the	O
renal	O
cortex	O
and	O
medulla	O
of	O
lithium	B-CHED
-	O
treated	O
+	O
/	O
+	O
mice	O
.	O

This	O
decrease	O
was	O
significantly	O
attenuated	O
in	O
the	O
-	O
/	O
-	O
mice	O
.	O

qRT	O
-	O
PCR	O
detected	O
similar	O
patterns	O
of	O
changes	O
in	O
AQP2	O
mRNA	O
in	O
the	O
medulla	O
but	O
not	O
in	O
the	O
cortex	O
.	O

Similarly	O
,	O
the	O
total	O
protein	O
abundance	O
of	O
the	O
Na	B-CHED
-	O
K	B-CHED
-	O
2Cl	B-CHED
cotransporter	O
(	O
NKCC2	O
)	O
in	O
the	O
medulla	O
but	O
not	O
in	O
the	O
cortex	O
of	O
the	O
+	O
/	O
+	O
mice	O
was	O
significantly	O
reduced	O
by	O
lithium	B-CHED
treatment	O
.	O

In	O
contrast	O
,	O
the	O
dowregulation	O
of	O
renal	O
medullary	O
NKCC2	O
expression	O
was	O
significantly	O
attenuated	O
in	O
the	O
-	O
/	O
-	O
mice	O
.	O

We	O
conclude	O
that	O
mPGES	O
-	O
1	O
-	O
derived	O
PGE	B-CHED
(	I-CHED
2	I-CHED
)	I-CHED
mediates	O
lithium	B-CHED
-	O
induced	O
polyuria	O
likely	O
via	O
inhibition	O
of	O
AQP2	O
and	O
NKCC2	O
expression	O
.	O

Preservation	O
of	O
renal	O
blood	O
flow	O
during	O
hypotension	O
induced	O
with	O
fenoldopam	B-CHED
in	O
dogs	O
.	O

The	O
introduction	O
of	O
drugs	O
that	O
could	O
induce	O
hypotension	O
with	O
different	O
pharmacological	O
actions	O
would	O
be	O
advantageous	O
because	O
side	O
effects	O
unique	O
to	O
a	O
specific	O
drug	O
could	O
be	O
minimized	O
by	O
selecting	O
appropriate	O
therapy	O
.	O

Specific	O
dopamine	B-CHED
-	O
1	O
,	O
(	O
DA1	B-CHED
)	O
and	O
dopamine	B-CHED
-	O
2	O
(	O
DA2	B-CHED
)	O
receptor	O
agonists	O
are	O
now	O
under	O
clinical	O
investigation	O
.	O

Fenoldopam	B-CHED
mesylate	I-CHED
is	O
a	O
specific	O
DA1	O
receptor	O
agonist	O
that	O
lowers	O
blood	O
pressure	O
by	O
vasodilatation	O
.	O

The	O
hypothesis	O
that	O
fenoldopam	B-CHED
could	O
be	O
used	O
to	O
induce	O
hypotension	O
and	O
preserve	O
blood	O
flow	O
to	O
the	O
kidney	O
was	O
tested	O
.	O

Systemic	O
aortic	O
blood	O
pressure	O
and	O
renal	O
blood	O
flow	O
were	O
measured	O
continuously	O
with	O
a	O
carotid	O
arterial	O
catheter	O
and	O
an	O
electromagnetic	O
flow	O
probe	O
respectively	O
,	O
in	O
order	O
to	O
compare	O
the	O
cardiovascular	O
and	O
renal	O
vascular	O
effects	O
of	O
fenoldopam	B-CHED
and	O
sodium	B-CHED
nitroprusside	B-CHED
in	O
ten	O
dogs	O
under	O
halothane	B-CHED
general	O
anaesthesia	O
.	O

Mean	O
arterial	O
pressure	O
was	O
decreased	O
30	O
+	O
/	O
-	O
8	O
per	O
cent	O
from	O
control	O
with	O
infusion	O
of	O
fenoldopam	B-CHED
(	O
3	O
.	O
4	O
+	O
/	O
-	O
2	O
.	O
0	O
micrograms	O
.	O
kg	O
-	O
1	O
.	O
min	O
-	O
1	O
)	O
and	O
34	O
+	O
/	O
-	O
4	O
per	O
cent	O
with	O
infusion	O
of	O
sodium	B-CHED
nitroprusside	B-CHED
(	O
5	O
.	O
9	O
micrograms	O
.	O
kg	O
-	O
1	O
.	O
min	O
-	O
1	O
)	O
(	O
NS	O
)	O
.	O

Renal	O
blood	O
flow	O
(	O
RBF	O
)	O
increased	O
during	O
fenoldopam	B-CHED
-	O
induced	O
hypotension	O
11	O
+	O
/	O
-	O
7	O
per	O
cent	O
and	O
decreased	O
21	O
+	O
/	O
-	O
8	O
per	O
cent	O
during	O
sodium	B-CHED
nitroprusside	B-CHED
-	O
induced	O
hypotension	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

Sodium	O
nitroprusside	B-CHED
is	O
a	O
non	O
-	O
selective	O
arteriolar	O
and	O
venous	O
vasodilator	O
that	O
can	O
produce	O
redistribution	O
of	O
blood	O
flow	O
away	O
from	O
the	O
kidney	O
during	O
induced	O
hypotension	O
.	O

Fenoldopam	O
is	O
a	O
selective	O
dopamine	B-CHED
-	O
1	O
(	O
DA1	O
)	O
receptor	O
agonist	O
that	O
causes	O
vasodilatation	O
to	O
the	O
kidney	O
and	O
other	O
organs	O
with	O
DA1	O
receptors	O
and	O
preserves	O
blood	O
flow	O
to	O
the	O
kidney	O
during	O
induced	O
hypotension	O
.	O

Seizures	O
associated	O
with	O
levofloxacin	B-CHED
:	O
case	O
presentation	O
and	O
literature	O
review	O
.	O

PURPOSE	O
:	O
We	O
present	O
a	O
case	O
of	O
a	O
patient	O
who	O
developed	O
seizures	O
shortly	O
after	O
initiating	O
treatment	O
with	O
levofloxacin	B-CHED
and	O
to	O
discuss	O
the	O
potential	O
drug	O
-	O
drug	O
interactions	O
related	O
to	O
the	O
inhibition	O
of	O
cytochrome	O
P450	O
(	O
CYP	O
)	O
1A2	O
in	O
this	O
case	O
,	O
as	O
well	O
as	O
in	O
other	O
cases	O
,	O
of	O
levofloxacin	B-CHED
-	O
induced	O
seizures	O
.	O

METHODS	O
:	O
Several	O
biomedical	O
databases	O
were	O
searched	O
including	O
MEDLINE	O
,	O
Cochrane	O
and	O
Ovid	O
.	O

The	O
main	O
search	O
terms	O
utilized	O
were	O
case	O
report	O
and	O
levofloxacin	B-CHED
.	O

The	O
search	O
was	O
limited	O
to	O
studies	O
published	O
in	O
English	O
.	O

RESULTS	O
:	O
Six	O
cases	O
of	O
levofloxacin	B-CHED
-	O
induced	O
seizures	O
have	O
been	O
reported	O
in	O
the	O
literature	O
.	O

Drug	O
-	O
drug	O
interactions	O
related	O
to	O
the	O
inhibition	O
of	O
CYP1A2	O
by	O
levofloxacin	B-CHED
are	O
likely	O
involved	O
in	O
the	O
clinical	O
outcome	O
of	O
these	O
cases	O
.	O

CONCLUSIONS	O
:	O
Clinicians	O
are	O
exhorted	O
to	O
pay	O
close	O
attention	O
when	O
initiating	O
levofloxacin	B-CHED
therapy	O
in	O
patients	O
taking	O
medications	O
with	O
epileptogenic	O
properties	O
that	O
are	O
CYP1A2	O
substrates	O
.	O

Dextran	B-CHED
-	O
etodolac	B-CHED
conjugates	O
:	O
synthesis	O
,	O
in	O
vitro	O
and	O
in	O
vivo	O
evaluation	O
.	O

Etodolac	B-CHED
(	O
E	B-CHED
)	O
,	O
is	O
a	O
non	O
-	O
narcotic	O
analgesic	O
and	O
antiinflammatory	O
drug	O
.	O

A	O
biodegradable	O
polymer	O
dextran	B-CHED
has	O
been	O
utilized	O
as	O
a	O
carrier	O
for	O
synthesis	O
of	O
etodolac	B-CHED
-	O
dextran	B-CHED
conjugates	O
(	O
ED	O
)	O
to	O
improve	O
its	O
aqueous	O
solubility	O
and	O
reduce	O
gastrointestinal	O
side	O
effects	O
.	O

An	O
activated	O
moiety	O
,	O
i	O
.	O
e	O
.	O
N	B-CHED
-	I-CHED
acylimidazole	I-CHED
derivative	O
of	O
etodolac	B-CHED
(	O
EAI	B-CHED
)	O
,	O
was	O
condensed	O
with	O
the	O
polysaccharide	O
polymer	O
dextran	B-CHED
of	O
different	O
molecular	O
weights	O
(	O
40000	O
,	O
60000	O
,	O
110000	O
and	O
200000	O
)	O
.	O

IR	O
spectral	O
data	O
confirmed	O
formation	O
of	O
ester	O
bonding	O
in	O
the	O
conjugates	O
.	O

Etodolac	B-CHED
contents	O
were	O
evaluated	O
by	O
UV	O
-	O
spectrophotometric	O
analysis	O
.	O

The	O
molecular	O
weights	O
were	O
determined	O
by	O
measuring	O
viscosity	O
using	O
the	O
Mark	O
-	O
Howink	O
-	O
Sakurada	O
equation	O
.	O

In	O
vitro	O
hydrolysis	O
of	O
ED	O
was	O
done	O
in	O
aqueous	O
buffers	O
(	O
pH	O
1	O
.	O
2	O
,	O
7	O
.	O
4	O
,	O
9	O
)	O
and	O
in	O
80	O
%	O
(	O
v	O
/	O
v	O
)	O
human	O
plasma	O
(	O
pH	O
7	O
.	O
4	O
)	O
.	O

At	O
pH	O
9	O
,	O
a	O
higher	O
rate	O
of	O
etodolac	B-CHED
release	O
from	O
ED	O
was	O
observed	O
as	O
compared	O
to	O
aqueous	O
buffer	O
of	O
pH	O
7	O
.	O
4	O
and	O
80	O
%	O
human	O
plasma	O
(	O
pH	O
7	O
.	O
4	O
)	O
,	O
following	O
first	O
-	O
order	O
kinetics	O
.	O

In	O
vivo	O
investigations	O
were	O
performed	O
in	O
animals	O
.	O

Acute	O
analgesic	O
and	O
antiinflammatory	O
activities	O
were	O
ascertained	O
using	O
acetic	B-CHED
acid	I-CHED
induced	O
writhing	O
model	O
(	O
mice	O
)	O
and	O
carrageenan	B-CHED
-	O
induced	O
rat	O
paw	O
edema	O
model	O
,	O
respectively	O
.	O

In	O
comparison	O
to	O
control	O
,	O
E	B-CHED
and	O
ED1	O
-	O
ED4	O
showed	O
highly	O
significant	O
analgesic	O
and	O
antiinflammatory	O
activities	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Biological	O
evaluation	O
suggested	O
that	O
conjugates	O
(	O
ED1	O
-	O
ED4	O
)	O
retained	O
comparable	O
analgesic	O
and	O
antiinflammatory	O
activities	O
with	O
remarkably	O
reduced	O
ulcerogenicity	O
as	O
compared	O
to	O
their	O
parent	O
drug	O
-	O
-	O
etodolac	B-CHED
.	O

The	O
antiarrhythmic	O
effect	O
and	O
possible	O
ionic	O
mechanisms	O
of	O
pilocarpine	B-CHED
on	O
animal	O
models	O
.	O

This	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
effects	O
of	O
pilocarpine	B-CHED
and	O
explore	O
the	O
underlying	O
ionic	O
mechanism	O
,	O
using	O
both	O
aconitine	B-CHED
-	O
induced	O
rat	O
and	O
ouabain	B-CHED
-	O
induced	O
guinea	O
pig	O
arrhythmia	O
models	O
.	O

Confocal	O
microscopy	O
was	O
used	O
to	O
measure	O
intracellular	O
free	O
-	O
calcium	B-CHED
concentrations	O
(	O
[	O
Ca	B-CHED
(	O
2	O
+	O
)	O
]	O
(	O
i	O
)	O
)	O
in	O
isolated	O
myocytes	O
.	O

The	O
current	O
data	O
showed	O
that	O
pilocarpine	B-CHED
significantly	O
delayed	O
onset	O
of	O
arrhythmias	O
,	O
decreased	O
the	O
time	O
course	O
of	O
ventricular	O
tachycardia	O
and	O
fibrillation	O
,	O
reduced	O
arrhythmia	O
score	O
,	O
and	O
increased	O
the	O
survival	O
time	O
of	O
arrhythmic	O
rats	O
and	O
guinea	O
pigs	O
.	O

[	O
Ca	B-CHED
(	O
2	O
+	O
)	O
]	O
(	O
i	O
)	O
overload	O
induced	O
by	O
aconitine	B-CHED
or	O
ouabain	B-CHED
was	O
reduced	O
in	O
isolated	O
myocytes	O
pretreated	O
with	O
pilocarpine	B-CHED
.	O

Moreover	O
,	O
M	O
(	O
3	O
)	O
-	O
muscarinic	O
acetylcholine	B-CHED
receptor	O
(	O
mAChR	O
)	O
antagonist	O
4	B-CHED
-	I-CHED
DAMP	I-CHED
(	O
4	B-CHED
-	I-CHED
diphenylacetoxy	I-CHED
-	I-CHED
N	I-CHED
-	I-CHED
methylpiperidine	I-CHED
-	I-CHED
methiodide	I-CHED
)	O
partially	O
abolished	O
the	O
beneficial	O
effects	O
of	O
pilocarpine	B-CHED
.	O

These	O
data	O
suggest	O
that	O
pilocarpine	B-CHED
produced	O
antiarrhythmic	O
actions	O
on	O
arrhythmic	O
rat	O
and	O
guinea	O
pig	O
models	O
induced	O
by	O
aconitine	B-CHED
or	O
ouabain	B-CHED
via	O
stimulating	O
the	O
cardiac	O
M	O
(	O
3	O
)	O
-	O
mAChR	O
.	O

The	O
mechanism	O
may	O
be	O
related	O
to	O
the	O
improvement	O
of	O
Ca	B-CHED
(	O
2	O
+	O
)	O
handling	O
.	O

Effect	O
of	O
Hibiscus	B-CHED
rosa	I-CHED
sinensis	I-CHED
on	O
reserpine	B-CHED
-	O
induced	O
neurobehavioral	O
and	O
biochemical	O
alterations	O
in	O
rats	O
.	O

Effect	O
of	O
methanolic	O
extract	O
of	O
Hibiscus	B-CHED
rosa	I-CHED
sinensis	I-CHED
(	O
100	O
-	O
300	O
mg	O
/	O
kg	O
)	O
was	O
studied	O
on	O
reserpine	B-CHED
-	O
induced	O
orofacial	O
dyskinesia	O
and	O
neurochemical	O
alterations	O
.	O

The	O
rats	O
were	O
treated	O
with	O
intraperitoneal	O
reserpine	B-CHED
(	O
1	O
mg	O
/	O
kg	O
,	O
ip	O
)	O
for	O
3	O
days	O
every	O
other	O
day	O
.	O

On	O
day	O
5	O
,	O
vacuous	O
chewing	O
movements	O
and	O
tongue	O
protrusions	O
were	O
counted	O
for	O
5	O
min	O
.	O

Reserpine	B-CHED
treated	O
rats	O
significantly	O
developed	O
vacuous	O
chewing	O
movements	O
and	O
tongue	O
protrusions	O
however	O
,	O
coadministration	O
of	O
Hibiscus	B-CHED
rosa	I-CHED
sinensis	I-CHED
roots	O
extract	O
(	O
100	O
,	O
200	O
and	O
300	O
mg	O
/	O
kg	O
,	O
per	O
orally	O
)	O
attenuated	O
the	O
effects	O
.	O

Biochemical	O
analysis	O
of	O
brain	O
revealed	O
that	O
the	O
reserpine	B-CHED
treatment	O
significantly	O
increased	O
lipid	O
peroxidation	O
and	O
decreased	O
levels	O
of	O
superoxide	B-CHED
dismutase	O
(	O
SOD	O
)	O
,	O
catalase	O
(	O
CAT	O
)	O
and	O
glutathione	B-CHED
reductase	O
(	O
GSH	O
)	O
,	O
an	O
index	O
of	O
oxidative	O
stress	O
process	O
.	O

Coadministration	O
of	O
extract	O
significantly	O
reduced	O
the	O
lipid	O
peroxidation	O
and	O
reversed	O
the	O
decrease	O
in	O
brain	O
SOD	O
,	O
CAT	O
and	O
GSH	O
levels	O
.	O

The	O
results	O
of	O
the	O
present	O
study	O
suggested	O
that	O
Hibiscus	B-CHED
rosa	I-CHED
sinensis	I-CHED
had	O
a	O
protective	O
role	O
against	O
reserpine	B-CHED
-	O
induced	O
orofacial	O
dyskinesia	O
and	O
oxidative	O
stress	O
.	O

Dynamic	O
response	O
of	O
blood	O
vessel	O
in	O
acute	O
renal	O
failure	O
.	O

In	O
this	O
study	O
we	O
postulated	O
that	O
during	O
acute	O
renal	O
failure	O
induced	O
by	O
gentamicin	B-CHED
the	O
transient	O
or	O
dynamic	O
response	O
of	O
blood	O
vessels	O
could	O
be	O
affected	O
,	O
and	O
that	O
antioxidants	O
can	O
prevent	O
the	O
changes	O
in	O
dynamic	O
responses	O
of	O
blood	O
vessels	O
.	O

The	O
new	O
approach	O
to	O
ex	O
vivo	O
blood	O
vessel	O
experiments	O
in	O
which	O
not	O
only	O
the	O
end	O
points	O
of	O
vessels	O
response	O
within	O
the	O
time	O
interval	O
is	O
considered	O
,	O
but	O
also	O
dynamics	O
of	O
this	O
response	O
,	O
was	O
used	O
in	O
this	O
paper	O
.	O

Our	O
results	O
confirm	O
the	O
alteration	O
in	O
dynamic	O
response	O
of	O
blood	O
vessels	O
during	O
the	O
change	O
of	O
pressure	O
in	O
gentamicin	B-CHED
-	O
treated	O
animals	O
.	O

The	O
beneficial	O
effects	O
of	O
vitamin	B-CHED
C	I-CHED
administration	O
to	O
gentamicin	B-CHED
-	O
treated	O
animals	O
are	O
also	O
confirmed	O
through	O
:	O
lower	O
level	O
of	O
blood	O
urea	B-CHED
and	O
creatinine	B-CHED
and	O
higher	O
level	O
of	O
potassium	B-CHED
.	O

The	O
pressure	O
dynamic	O
responses	O
of	O
isolated	O
blood	O
vessels	O
show	O
a	O
faster	O
pressure	O
change	O
in	O
gentamicin	B-CHED
-	O
treated	O
animals	O
(	O
8	O
.	O
07	O
+	O
/	O
-	O
1	O
.	O
7	O
s	O
vs	O
.	O
5	O
.	O
64	O
+	O
/	O
-	O
0	O
.	O
18	O
s	O
)	O
.	O

Vitamin	B-CHED
C	I-CHED
administration	O
induced	O
slowdown	O
of	O
pressure	O
change	O
back	O
to	O
the	O
control	O
values	O
.	O

The	O
pressure	O
dynamic	O
properties	O
,	O
quantitatively	O
defined	O
by	O
comparative	O
pressure	O
dynamic	O
and	O
total	O
pressure	O
dynamic	O
,	O
confirm	O
the	O
alteration	O
in	O
dynamic	O
response	O
of	O
blood	O
vessels	O
during	O
the	O
change	O
of	O
pressure	O
in	O
gentamicin	B-CHED
-	O
treated	O
animals	O
and	O
beneficial	O
effects	O
of	O
vitamin	B-CHED
C	I-CHED
administration	O
.	O

Reversible	O
myocardial	O
hypertrophy	O
induced	O
by	O
tacrolimus	B-CHED
in	O
a	O
pediatric	O
heart	O
transplant	O
recipient	O
:	O
case	O
report	O
.	O

Tacrolimus	B-CHED
is	O
a	O
potent	O
immunosuppressant	O
that	O
is	O
frequently	O
used	O
in	O
organ	O
transplantation	O
.	O

However	O
,	O
adverse	O
effects	O
include	O
cardiac	O
toxicity	O
.	O

Herein	O
we	O
describe	O
transient	O
myocardial	O
hypertrophy	O
induced	O
by	O
tacrolimus	B-CHED
after	O
heart	O
transplantation	O
.	O

The	O
hypertrophy	O
caused	O
no	O
clinical	O
symptoms	O
but	O
was	O
noted	O
because	O
of	O
elevation	O
of	O
plasma	O
brain	O
natriuretic	O
peptide	O
concentration	O
and	O
confirmed	O
at	O
echocardiography	O
.	O

Initially	O
,	O
allograft	O
rejection	O
was	O
feared	O
;	O
however	O
,	O
myocardial	O
biopsy	O
samples	O
revealed	O
only	O
interstitial	O
edema	O
and	O
mild	O
myocardial	O
hypertrophy	O
;	O
neither	O
cellular	O
nor	O
humoral	O
rejection	O
was	O
detected	O
.	O

The	O
blood	O
tacrolimus	B-CHED
concentration	O
was	O
higher	O
than	O
usual	O
at	O
that	O
time	O
;	O
thus	O
,	O
tacrolimus	B-CHED
dosage	O
was	O
reduced	O
.	O

Myocardial	O
hypertrophy	O
completely	O
resolved	O
upon	O
reducing	O
the	O
target	O
concentration	O
of	O
tacrolimus	B-CHED
and	O
did	O
not	O
recur	O
,	O
as	O
confirmed	O
at	O
echocardiography	O
and	O
myocardial	O
biopsy	O
.	O

Thus	O
,	O
we	O
conclude	O
that	O
tacrolimus	B-CHED
induces	O
reversible	O
myocardial	O
hypertrophy	O
.	O

In	O
patients	O
receiving	O
tacrolimus	B-CHED
therapy	O
,	O
blood	O
concentration	O
should	O
be	O
carefully	O
controlled	O
and	O
extreme	O
attention	O
paid	O
to	O
cardiac	O
involvement	O
.	O

Nimodipine	B-CHED
prevents	O
memory	O
impairment	O
caused	O
by	O
nitroglycerin	B-CHED
-	O
induced	O
hypotension	O
in	O
adult	O
mice	O
.	O

BACKGROUND	O
:	O
Hypotension	O
and	O
a	O
resultant	O
decrease	O
in	O
cerebral	O
blood	O
flow	O
have	O
been	O
implicated	O
in	O
the	O
development	O
of	O
cognitive	O
dysfunction	O
.	O

We	O
tested	O
the	O
hypothesis	O
that	O
nimodipine	B-CHED
(	O
NIMO	B-CHED
)	O
administered	O
at	O
the	O
onset	O
of	O
nitroglycerin	B-CHED
(	O
NTG	B-CHED
)	O
-	O
induced	O
hypotension	O
would	O
preserve	O
long	O
-	O
term	O
associative	O
memory	O
.	O

METHODS	O
:	O
The	O
passive	O
avoidance	O
(	O
PA	O
)	O
paradigm	O
was	O
used	O
to	O
assess	O
memory	O
retention	O
.	O

For	O
PA	O
training	O
,	O
latencies	O
(	O
seconds	O
)	O
were	O
recorded	O
for	O
entry	O
from	O
a	O
suspended	O
platform	O
into	O
a	O
Plexiglas	O
tube	O
where	O
a	O
shock	O
was	O
automatically	O
delivered	O
.	O

Latencies	O
were	O
recorded	O
48	O
h	O
later	O
for	O
a	O
testing	O
trial	O
.	O

Ninety	O
-	O
six	O
Swiss	O
-	O
Webster	O
mice	O
(	O
30	O
-	O
35	O
g	O
,	O
6	O
-	O
8	O
wk	O
)	O
,	O
were	O
randomized	O
into	O
6	O
groups	O
1	O
)	O
saline	O
(	O
control	O
)	O
,	O
2	O
)	O
NTG	B-CHED
immediately	O
after	O
learning	O
,	O
3	O
)	O
NTG	B-CHED
3	O
h	O
after	O
learning	O
,	O
4	O
)	O
NTG	B-CHED
and	O
NIMO	B-CHED
,	O
5	O
)	O
vehicle	O
,	O
and	O
6	O
)	O
NIMO	B-CHED
alone	O
.	O

The	O
extent	O
of	O
hypotension	O
and	O
changes	O
in	O
brain	O
tissue	O
oxygenation	O
(	O
PbtO	O
(	O
2	O
)	O
)	O
and	O
in	O
cerebral	O
blood	O
flow	O
were	O
studied	O
in	O
a	O
separate	O
group	O
of	O
animals	O
.	O

RESULTS	O
:	O
All	O
groups	O
exhibited	O
similar	O
training	O
latencies	O
(	O
17	O
.	O
0	O
+	O
/	O
-	O
4	O
.	O
6	O
s	O
)	O
.	O

Mice	O
subjected	O
to	O
hypotensive	O
episodes	O
showed	O
a	O
significant	O
decrease	O
in	O
latency	O
time	O
(	O
178	O
+	O
/	O
-	O
156	O
s	O
)	O
compared	O
with	O
those	O
injected	O
with	O
saline	O
,	O
NTG	B-CHED
+	O
NIMO	B-CHED
,	O
or	O
delayed	O
NTG	B-CHED
(	O
580	O
+	O
/	O
-	O
81	O
s	O
,	O
557	O
+	O
/	O
-	O
67	O
s	O
,	O
and	O
493	O
+	O
/	O
-	O
146	O
s	O
,	O
respectively	O
)	O
.	O

A	O
Kruskal	O
-	O
Wallis	O
1	O
-	O
way	O
analysis	O
of	O
variance	O
indicated	O
a	O
significant	O
difference	O
among	O
the	O
4	O
treatment	O
groups	O
(	O
H	O
=	O
15	O
.	O
34	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

In	O
a	O
separate	O
group	O
of	O
mice	O
not	O
subjected	O
to	O
behavioral	O
studies	O
,	O
the	O
same	O
dose	O
of	O
NTG	B-CHED
(	O
n	O
=	O
3	O
)	O
and	O
NTG	B-CHED
+	O
NIMO	B-CHED
(	O
n	O
=	O
3	O
)	O
caused	O
mean	O
arterial	O
blood	O
pressure	O
to	O
decrease	O
from	O
85	O
.	O
9	O
+	O
/	O
-	O
3	O
.	O
8	O
mm	O
Hg	O
sem	O
to	O
31	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
8	O
mm	O
Hg	O
sem	O
and	O
from	O
86	O
.	O
2	O
+	O
/	O
-	O
3	O
.	O
7	O
mm	O
Hg	O
sem	O
to	O
32	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
2	O
mm	O
Hg	O
sem	O
,	O
respectively	O
.	O

Mean	O
arterial	O
blood	O
pressure	O
in	O
mice	O
treated	O
with	O
NIMO	B-CHED
alone	O
decreased	O
from	O
88	O
.	O
1	O
+	O
/	O
-	O
3	O
.	O
8	O
mm	O
Hg	O
to	O
80	O
.	O
0	O
+	O
/	O
-	O
2	O
.	O
9	O
mm	O
Hg	O
.	O

The	O
intergroup	O
difference	O
was	O
statistically	O
significant	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

PbtO	O
(	O
2	O
)	O
decreased	O
from	O
51	O
.	O
7	O
+	O
/	O
-	O
4	O
.	O
5	O
mm	O
Hg	O
sem	O
to	O
33	O
.	O
8	O
+	O
/	O
-	O
5	O
.	O
2	O
mm	O
Hg	O
sem	O
in	O
the	O
NTG	B-CHED
group	O
and	O
from	O
38	O
.	O
6	O
+	O
/	O
-	O
6	O
.	O
1	O
mm	O
Hg	O
sem	O
to	O
25	O
.	O
4	O
+	O
/	O
-	O
2	O
.	O
0	O
mm	O
Hg	O
sem	O
in	O
the	O
NTG	B-CHED
+	O
NIMO	B-CHED
groups	O
,	O
respectively	O
.	O

There	O
were	O
no	O
significant	O
differences	O
among	O
groups	O
.	O

CONCLUSION	O
:	O
In	O
a	O
PA	O
retention	O
paradigm	O
,	O
the	O
injection	O
of	O
NTG	B-CHED
immediately	O
after	O
learning	O
produced	O
a	O
significant	O
impairment	O
of	O
long	O
-	O
term	O
associative	O
memory	O
in	O
mice	O
,	O
whereas	O
delayed	O
induced	O
hypotension	O
had	O
no	O
effect	O
.	O

NIMO	B-CHED
attenuated	O
the	O
disruption	O
in	O
consolidation	O
of	O
long	O
-	O
term	O
memory	O
caused	O
by	O
NTG	B-CHED
but	O
did	O
not	O
improve	O
latency	O
in	O
the	O
absence	O
of	O
hypotension	O
.	O

The	O
observed	O
effect	O
of	O
NIMO	B-CHED
may	O
have	O
been	O
attributable	O
to	O
the	O
preservation	O
of	O
calcium	B-CHED
homeostasis	O
during	O
hypotension	O
,	O
because	O
there	O
were	O
no	O
differences	O
in	O
the	O
PbtO	O
(	O
2	O
)	O
indices	O
among	O
groups	O
.	O

Metabotropic	O
glutamate	B-CHED
7	O
receptor	O
subtype	O
modulates	O
motor	O
symptoms	O
in	O
rodent	O
models	O
of	O
Parkinson	O
'	O
s	O
disease	O
.	O

Metabotropic	O
glutamate	B-CHED
(	O
mGlu	O
)	O
receptors	O
modulate	O
synaptic	O
transmission	O
in	O
the	O
central	O
nervous	O
system	O
and	O
represent	O
promising	O
therapeutic	O
targets	O
for	O
symptomatic	O
treatment	O
of	O
Parkinson	O
'	O
s	O
disease	O
(	O
PD	O
)	O
.	O

Among	O
the	O
eight	O
mGlu	O
receptor	O
subtypes	O
,	O
mGlu7	O
receptor	O
is	O
prominently	O
expressed	O
in	O
the	O
basal	O
ganglia	O
,	O
but	O
its	O
role	O
in	O
restoring	O
motor	O
function	O
in	O
animal	O
models	O
of	O
PD	O
is	O
not	O
known	O
.	O

The	O
effects	O
of	O
N	B-CHED
,	I-CHED
N	I-CHED
'	I-CHED
-	I-CHED
dibenzhydrylethane	I-CHED
-	I-CHED
1	I-CHED
,	I-CHED
2	I-CHED
-	I-CHED
diamine	I-CHED
dihydrochloride	I-CHED
(	O
AMN082	B-CHED
)	O
,	O
the	O
first	O
selective	O
allosteric	O
activator	O
of	O
mGlu7	O
receptors	O
,	O
were	O
thus	O
tested	O
in	O
different	O
rodent	O
models	O
of	O
PD	O
.	O

Here	O
,	O
we	O
show	O
that	O
oral	O
(	O
5	O
mg	O
/	O
kg	O
)	O
or	O
intrastriatal	O
administration	O
(	O
0	O
.	O
1	O
and	O
0	O
.	O
5	O
nmol	O
)	O
of	O
AMN082	B-CHED
reverses	O
haloperidol	B-CHED
-	O
induced	O
catalepsy	O
in	O
rats	O
.	O

AMN082	B-CHED
(	O
2	O
.	O
5	O
and	O
5	O
mg	O
/	O
kg	O
)	O
reduces	O
apomorphine	B-CHED
-	O
induced	O
rotations	O
in	O
unilateral	O
6	B-CHED
-	I-CHED
hydroxydopamine	I-CHED
(	O
6	B-CHED
-	I-CHED
OHDA	I-CHED
)	O
-	O
lesioned	O
rats	O
.	O

In	O
a	O
more	O
complex	O
task	O
commonly	O
used	O
to	O
evaluate	O
major	O
akinetic	O
symptoms	O
of	O
PD	O
patients	O
,	O
5	O
mg	O
/	O
kg	O
AMN082	B-CHED
reverses	O
the	O
increased	O
reaction	O
time	O
to	O
respond	O
to	O
a	O
cue	O
of	O
bilateral	O
6	B-CHED
-	I-CHED
OHDA	I-CHED
-	O
lesioned	O
rats	O
.	O

In	O
addition	O
,	O
AMN082	B-CHED
reduces	O
the	O
duration	O
of	O
haloperidol	B-CHED
-	O
induced	O
catalepsy	O
in	O
a	O
mGlu7	O
receptor	O
-	O
dependent	O
manner	O
in	O
wild	O
-	O
type	O
but	O
not	O
mGlu7	O
receptor	O
knockout	O
mice	O
.	O

Higher	O
doses	O
of	O
AMN082	B-CHED
(	O
10	O
and	O
20	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O
)	O
have	O
no	O
effect	O
on	O
the	O
same	O
models	O
of	O
PD	O
.	O

Overall	O
these	O
findings	O
suggest	O
that	O
mGlu7	O
receptor	O
activation	O
can	O
reverse	O
motor	O
dysfunction	O
associated	O
with	O
reduced	O
dopamine	B-CHED
activity	O
.	O

Selective	O
ligands	O
of	O
mGlu7	O
receptor	O
subtypes	O
may	O
thus	O
be	O
considered	O
as	O
promising	O
compounds	O
for	O
the	O
development	O
of	O
antiparkinsonian	O
therapeutic	O
strategies	O
.	O

Sorafenib	B-CHED
-	O
induced	O
acute	O
myocardial	O
infarction	O
due	O
to	O
coronary	O
artery	O
spasm	O
.	O

A	O
65	O
-	O
year	O
-	O
old	O
man	O
with	O
advanced	O
renal	O
cell	O
carcinoma	O
was	O
admitted	O
due	O
to	O
continuing	O
chest	O
pain	O
at	O
rest	O
.	O

Two	O
weeks	O
before	O
his	O
admission	O
,	O
sorafenib	B-CHED
had	O
been	O
started	O
.	O

He	O
was	O
diagnosed	O
with	O
non	O
-	O
ST	O
-	O
elevation	O
myocardial	O
infarction	O
by	O
laboratory	O
data	O
and	O
electrocardiogram	O
.	O

Enhanced	O
heart	O
magnetic	O
resonance	O
imaging	O
also	O
showed	O
subendocardial	O
infarction	O
.	O

However	O
,	O
there	O
was	O
no	O
stenosis	O
in	O
coronary	O
arteries	O
on	O
angiography	O
.	O

Coronary	O
artery	O
spasm	O
was	O
induced	O
by	O
a	O
provocative	O
test	O
.	O

Cessation	O
of	O
sorafenib	B-CHED
and	O
administration	O
of	O
Ca	B-CHED
-	O
channel	O
blocker	O
and	O
nitrates	B-CHED
ameliorated	O
his	O
symptoms	O
,	O
but	O
relapse	O
occurred	O
after	O
resumption	O
of	O
sorafenib	B-CHED
.	O

Addition	O
of	O
oral	O
nicorandil	B-CHED
reduced	O
his	O
symptoms	O
and	O
maintained	O
stable	O
angina	O
status	O
.	O

We	O
report	O
the	O
first	O
case	O
of	O
sorafenib	B-CHED
-	O
induced	O
coronary	O
artery	O
spasm	O
.	O

Sorafenib	B-CHED
is	O
a	O
multikinase	O
inhibitor	O
that	O
targets	O
signaling	O
pathways	O
necessary	O
for	O
cellular	O
proliferation	O
and	O
survival	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
Rho	O
/	O
ROCK	O
pathway	O
has	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
coronary	O
artery	O
spasm	O
.	O

Our	O
report	O
may	O
show	O
an	O
adverse	O
effect	O
on	O
the	O
Rho	O
/	O
ROCK	O
pathway	O
by	O
sorafenib	B-CHED
use	O
.	O

A	O
novel	O
animal	O
model	O
to	O
evaluate	O
the	O
ability	O
of	O
a	O
drug	O
delivery	O
system	O
to	O
promote	O
the	O
passage	O
through	O
the	O
BBB	O
.	O

The	O
purpose	O
of	O
this	O
investigation	O
was	O
to	O
explore	O
the	O
potentiality	O
of	O
a	O
novel	O
animal	O
model	O
to	O
be	O
used	O
for	O
the	O
in	O
vivo	O
evaluation	O
of	O
the	O
ability	O
of	O
a	O
drug	O
delivery	O
system	O
to	O
promote	O
the	O
passage	O
through	O
the	O
blood	O
-	O
brain	O
barrier	O
(	O
BBB	O
)	O
and	O
/	O
or	O
to	O
improve	O
the	O
brain	O
localization	O
of	O
a	O
bioactive	O
compound	O
.	O

A	O
Tween	O
80	O
-	O
coated	O
poly	B-CHED
-	I-CHED
L	I-CHED
-	I-CHED
lactid	I-CHED
acid	I-CHED
nanoparticles	O
was	O
used	O
as	O
a	O
model	O
of	O
colloidal	O
drug	O
delivery	O
system	O
,	O
able	O
to	O
trespass	O
the	O
BBB	O
.	O

Tacrine	B-CHED
,	O
administered	O
in	O
LiCl	B-CHED
pre	O
-	O
treated	O
rats	O
,	O
induces	O
electrocorticographic	O
seizures	O
and	O
delayed	O
hippocampal	O
damage	O
.	O

The	O
toxic	O
effects	O
of	O
tacrine	B-CHED
-	O
loaded	O
poly	B-CHED
-	I-CHED
L	I-CHED
-	I-CHED
lactid	I-CHED
acid	I-CHED
nanoparticles	O
(	O
5mg	O
/	O
kg	O
)	O
,	O
a	O
saline	O
solution	O
of	O
tacrine	B-CHED
(	O
5mg	O
/	O
kg	O
)	O
and	O
an	O
empty	O
colloidal	O
nanoparticle	O
suspension	O
were	O
compared	O
following	O
i	O
.	O
p	O
.	O
administration	O
in	O
LiCl	B-CHED
-	O
pre	O
-	O
treated	O
Wistar	O
rats	O
.	O

All	O
the	O
animals	O
treated	O
with	O
tacrine	B-CHED
-	O
loaded	O
nanoparticles	O
showed	O
an	O
earlier	O
outcome	O
of	O
CNS	O
adverse	O
symptoms	O
,	O
i	O
.	O
e	O
.	O
epileptic	O
onset	O
,	O
with	O
respect	O
to	O
those	O
animals	O
treated	O
with	O
the	O
free	O
compound	O
(	O
10	O
min	O
vs	O
.	O
22	O
min	O
respectively	O
)	O
.	O

In	O
addition	O
,	O
tacrine	B-CHED
-	O
loaded	O
nanoparticles	O
administration	O
induced	O
damage	O
of	O
neuronal	O
cells	O
in	O
CA1	O
field	O
of	O
the	O
hippocampus	O
in	O
all	O
treated	O
animals	O
,	O
while	O
the	O
saline	O
solution	O
of	O
tacrine	B-CHED
only	O
in	O
60	O
%	O
of	O
animals	O
.	O

Empty	O
nanoparticles	O
provided	O
similar	O
results	O
to	O
control	O
(	O
saline	O
-	O
treated	O
)	O
group	O
of	O
animals	O
.	O

In	O
conclusion	O
,	O
the	O
evaluation	O
of	O
time	O
-	O
to	O
-	O
onset	O
of	O
symptoms	O
and	O
the	O
severity	O
of	O
neurodegenerative	O
processes	O
induced	O
by	O
the	O
tacrine	B-CHED
-	O
lithium	B-CHED
model	O
of	O
epilepsy	O
in	O
the	O
rat	O
,	O
could	O
be	O
used	O
to	O
evaluate	O
preliminarily	O
the	O
capability	O
of	O
a	O
drug	O
delivery	O
system	O
to	O
trespass	O
(	O
or	O
not	O
)	O
the	O
BBB	O
in	O
vivo	O
.	O

High	O
-	O
dose	O
tranexamic	B-CHED
Acid	I-CHED
is	O
associated	O
with	O
nonischemic	O
clinical	O
seizures	O
in	O
cardiac	O
surgical	O
patients	O
.	O

BACKGROUND	O
:	O
In	O
2	O
separate	O
centers	O
,	O
we	O
observed	O
a	O
notable	O
increase	O
in	O
the	O
incidence	O
of	O
postoperative	O
convulsive	O
seizures	O
from	O
1	O
.	O
3	O
%	O
to	O
3	O
.	O
8	O
%	O
in	O
patients	O
having	O
undergone	O
major	O
cardiac	O
surgical	O
procedures	O
.	O

These	O
events	O
were	O
temporally	O
coincident	O
with	O
the	O
initial	O
use	O
of	O
high	O
-	O
dose	O
tranexamic	B-CHED
acid	I-CHED
(	O
TXA	B-CHED
)	O
therapy	O
after	O
withdrawal	O
of	O
aprotinin	O
from	O
general	O
clinical	O
usage	O
.	O

The	O
purpose	O
of	O
this	O
review	O
was	O
to	O
perform	O
a	O
retrospective	O
analysis	O
to	O
examine	O
whether	O
there	O
was	O
a	O
relation	O
between	O
TXA	B-CHED
usage	O
and	O
seizures	O
after	O
cardiac	O
surgery	O
.	O

METHODS	O
:	O
An	O
in	O
-	O
depth	O
chart	O
review	O
was	O
undertaken	O
in	O
all	O
24	O
patients	O
who	O
developed	O
perioperative	O
seizures	O
.	O

Electroencephalographic	O
activity	O
was	O
recorded	O
in	O
11	O
of	O
these	O
patients	O
,	O
and	O
all	O
patients	O
had	O
a	O
formal	O
neurological	O
evaluation	O
and	O
brain	O
imaging	O
studies	O
.	O

RESULTS	O
:	O
Twenty	O
-	O
one	O
of	O
the	O
24	O
patients	O
did	O
not	O
have	O
evidence	O
of	O
new	O
cerebral	O
ischemic	O
injury	O
,	O
but	O
seizures	O
were	O
likely	O
due	O
to	O
ischemic	O
brain	O
injury	O
in	O
3	O
patients	O
.	O

All	O
patients	O
with	O
seizures	O
did	O
not	O
have	O
permanent	O
neurological	O
abnormalities	O
.	O

All	O
24	O
patients	O
with	O
seizures	O
received	O
high	O
doses	O
of	O
TXA	B-CHED
intraoperatively	O
ranging	O
from	O
61	O
to	O
259	O
mg	O
/	O
kg	O
,	O
had	O
a	O
mean	O
age	O
of	O
69	O
.	O
9	O
years	O
,	O
and	O
21	O
of	O
24	O
had	O
undergone	O
open	O
chamber	O
rather	O
than	O
coronary	O
bypass	O
procedures	O
.	O

All	O
but	O
one	O
patient	O
were	O
managed	O
using	O
cardiopulmonary	O
bypass	O
.	O

No	O
evidence	O
of	O
brain	O
ischemic	O
,	O
metabolic	O
,	O
or	O
hyperthermia	O
-	O
induced	O
causes	O
for	O
their	O
seizures	O
was	O
apparent	O
.	O

CONCLUSION	O
:	O
Our	O
results	O
suggest	O
that	O
use	O
of	O
high	O
-	O
dose	O
TXA	B-CHED
in	O
older	O
patients	O
in	O
conjunction	O
with	O
cardiopulmonary	O
bypass	O
and	O
open	O
-	O
chamber	O
cardiac	O
surgery	O
is	O
associated	O
with	O
clinical	O
seizures	O
in	O
susceptible	O
patients	O
.	O

Electrocardiographic	O
changes	O
and	O
cardiac	O
arrhythmias	O
in	O
patients	O
receiving	O
psychotropic	O
drugs	O
.	O

Eight	O
patients	O
had	O
cardiac	O
manifestations	O
that	O
were	O
life	O
-	O
threatening	O
in	O
five	O
while	O
taking	O
psychotropic	O
drugs	O
,	O
either	O
phenothiazines	B-CHED
or	O
tricyclic	O
antidepressants	O
.	O

Although	O
most	O
patients	O
were	O
receiving	O
several	O
drugs	O
,	O
Mellaril	B-CHED
(	O
thioridazine	B-CHED
)	O
appeared	O
to	O
be	O
responsible	O
for	O
five	O
cases	O
of	O
ventricular	O
tachycardia	O
,	O
one	O
of	O
which	O
was	O
fatal	O
in	O
a	O
35	O
year	O
old	O
woman	O
.	O

Supraventricular	O
tachycardia	O
developed	O
in	O
one	O
patient	O
receiving	O
Thorazine	B-CHED
(	O
chlorpromazine	B-CHED
)	O
.	O

Aventyl	B-CHED
(	O
nortriptyline	B-CHED
)	O
and	O
Elavil	B-CHED
(	O
amitriptyline	B-CHED
)	O
each	O
produced	O
left	O
bundle	O
branch	O
block	O
in	O
a	O
73	O
year	O
old	O
woman	O
.	O

Electrocardiographic	O
T	O
and	O
U	O
wave	O
abnormalities	O
were	O
present	O
in	O
most	O
patients	O
.	O

The	O
ventricular	O
arrhythmias	O
responded	O
to	O
intravenous	O
administration	O
of	O
lidocaine	B-CHED
and	O
to	O
direct	O
current	O
electric	O
shock	O
;	O
ventricular	O
pacing	O
was	O
required	O
in	O
some	O
instances	O
and	O
intravenous	O
administration	O
of	O
propranolol	B-CHED
combined	O
with	O
ventricular	O
pacing	O
in	O
one	O
.	O

The	O
tachyarrhythmias	O
generally	O
subsided	O
within	O
48	O
hours	O
after	O
administration	O
of	O
the	O
drugs	O
was	O
stopped	O
.	O

Five	O
of	O
the	O
eight	O
patients	O
were	O
50	O
years	O
of	O
age	O
or	O
younger	O
;	O
only	O
one	O
clearly	O
had	O
antecedent	O
heart	O
disease	O
.	O

Major	O
cardiac	O
arrhythmias	O
are	O
a	O
potential	O
hazard	O
in	O
patients	O
without	O
heart	O
disease	O
who	O
are	O
receiving	O
customary	O
therapeutic	O
doses	O
of	O
psychotropic	O
drugs	O
.	O

A	O
prospective	O
clinical	O
trial	O
is	O
suggested	O
to	O
quantify	O
the	O
risk	O
of	O
cardiac	O
complications	O
to	O
patients	O
receiving	O
phenothiazines	B-CHED
or	O
tricyclic	O
antidepressant	O
drugs	O
.	O

Sensitivity	O
of	O
erythroid	O
progenitor	O
colonies	O
to	O
erythropoietin	O
in	O
azidothymidine	B-CHED
treated	O
immunodeficient	O
mice	O
.	O

The	O
anaemia	O
induced	O
by	O
3	B-CHED
'	I-CHED
-	I-CHED
azido	I-CHED
-	I-CHED
3	I-CHED
'	I-CHED
dideoxythymidine	I-CHED
(	O
AZT	B-CHED
)	O
is	O
poorly	O
understood	O
.	O

We	O
have	O
used	O
a	O
murine	O
model	O
of	O
AIDS	O
,	O
infection	O
of	O
female	O
C57BL	O
/	O
6	O
mice	O
with	O
LP	O
-	O
BM5	O
murine	O
leukaemia	O
(	O
MuLV	O
)	O
virus	O
,	O
to	O
determine	O
if	O
AZT	B-CHED
-	O
induced	O
anaemia	O
is	O
due	O
,	O
in	O
part	O
,	O
to	O
decreased	O
responsiveness	O
of	O
erythropoietic	O
precursors	O
(	O
BFU	O
-	O
e	O
)	O
to	O
erythropoietin	O
(	O
EPO	O
)	O
.	O

Mice	O
in	O
the	O
early	O
stage	O
of	O
LP	O
-	O
BM5	O
MuLV	O
disease	O
were	O
given	O
AZT	B-CHED
in	O
their	O
drinking	O
water	O
at	O
1	O
.	O
0	O
and	O
2	O
.	O
5	O
mg	O
/	O
ml	O
.	O

AZT	B-CHED
produced	O
anaemia	O
in	O
both	O
groups	O
,	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
.	O

Despite	O
the	O
anaemia	O
,	O
the	O
number	O
of	O
splenic	O
and	O
bone	O
marrow	O
BFU	O
-	O
e	O
in	O
AZT	B-CHED
treated	O
mice	O
increased	O
up	O
to	O
five	O
-	O
fold	O
over	O
levels	O
observed	O
in	O
infected	O
untreated	O
animals	O
after	O
15	O
d	O
of	O
treatment	O
.	O

Colony	O
formation	O
by	O
splenic	O
and	O
bone	O
marrow	O
BFUe	O
was	O
stimulated	O
at	O
lower	O
concentrations	O
of	O
EPO	O
in	O
mice	O
receiving	O
AZT	B-CHED
for	O
15	O
d	O
than	O
for	O
infected	O
,	O
untreated	O
mice	O
.	O

By	O
day	O
30	O
,	O
sensitivity	O
of	O
both	O
splenic	O
and	O
bone	O
marrow	O
BFU	O
-	O
e	O
of	O
treated	O
animals	O
returned	O
to	O
that	O
observed	O
from	O
cells	O
of	O
infected	O
untreated	O
animals	O
.	O

The	O
mean	O
plasma	O
levels	O
of	O
EPO	O
observed	O
in	O
AZT	B-CHED
treated	O
mice	O
were	O
appropriate	O
for	O
the	O
degree	O
of	O
anaemia	O
observed	O
when	O
compared	O
with	O
phenylhydrazine	B-CHED
(	O
PHZ	B-CHED
)	O
treated	O
mice	O
.	O

The	O
numbers	O
of	O
BFU	O
-	O
e	O
and	O
the	O
percentage	O
of	O
bone	O
marrow	O
erythroblasts	O
observed	O
were	O
comparable	O
in	O
AZT	B-CHED
and	O
PHZ	B-CHED
treated	O
mice	O
with	O
similar	O
degrees	O
of	O
anaemia	O
.	O

However	O
,	O
reticulocytosis	O
was	O
inappropriate	O
for	O
the	O
degree	O
of	O
anaemia	O
observed	O
in	O
AZT	B-CHED
treated	O
infected	O
mice	O
.	O

AZT	B-CHED
-	O
induced	O
peripheral	O
anaemia	O
in	O
the	O
face	O
of	O
increased	O
numbers	O
of	O
BFU	O
-	O
e	O
and	O
increased	O
levels	O
of	O
plasma	O
EPO	O
suggest	O
a	O
lesion	O
in	O
terminal	O
differentiation	O
.	O

Sedation	O
depth	O
during	O
spinal	O
anesthesia	O
and	O
the	O
development	O
of	O
postoperative	O
delirium	O
in	O
elderly	O
patients	O
undergoing	O
hip	O
fracture	O
repair	O
.	O

OBJECTIVE	O
:	O
To	O
determine	O
whether	O
limiting	O
intraoperative	O
sedation	O
depth	O
during	O
spinal	O
anesthesia	O
for	O
hip	O
fracture	O
repair	O
in	O
elderly	O
patients	O
can	O
decrease	O
the	O
prevalence	O
of	O
postoperative	O
delirium	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
We	O
performed	O
a	O
double	O
-	O
blind	O
,	O
randomized	O
controlled	O
trial	O
at	O
an	O
academic	O
medical	O
center	O
of	O
elderly	O
patients	O
(	O
>	O
or	O
=	O
65	O
years	O
)	O
without	O
preoperative	O
delirium	O
or	O
severe	O
dementia	O
who	O
underwent	O
hip	O
fracture	O
repair	O
under	O
spinal	O
anesthesia	O
with	O
propofol	B-CHED
sedation	O
.	O

Sedation	O
depth	O
was	O
titrated	O
using	O
processed	O
electroencephalography	O
with	O
the	O
bispectral	O
index	O
(	O
BIS	O
)	O
,	O
and	O
patients	O
were	O
randomized	O
to	O
receive	O
either	O
deep	O
(	O
BIS	O
,	O
approximately	O
50	O
)	O
or	O
light	O
(	O
BIS	O
,	O
>	O
or	O
=	O
80	O
)	O
sedation	O
.	O

Postoperative	O
delirium	O
was	O
assessed	O
as	O
defined	O
by	O
Diagnostic	O
and	O
Statistical	O
Manual	O
of	O
Mental	O
Disorders	O
(	O
Third	O
Edition	O
Revised	O
)	O
criteria	O
using	O
the	O
Confusion	O
Assessment	O
Method	O
beginning	O
at	O
any	O
time	O
from	O
the	O
second	O
day	O
after	O
surgery	O
.	O

RESULTS	O
:	O
From	O
April	O
2	O
,	O
2005	O
,	O
through	O
October	O
30	O
,	O
2008	O
,	O
a	O
total	O
of	O
114	O
patients	O
were	O
randomized	O
.	O

The	O
prevalence	O
of	O
postoperative	O
delirium	O
was	O
significantly	O
lower	O
in	O
the	O
light	O
sedation	O
group	O
(	O
11	O
/	O
57	O
[	O
19	O
%	O
]	O
vs	O
23	O
/	O
57	O
[	O
40	O
%	O
]	O
in	O
the	O
deep	O
sedation	O
group	O
;	O
P	O
=	O
.	O
02	O
)	O
,	O
indicating	O
that	O
1	O
incident	O
of	O
delirium	O
will	O
be	O
prevented	O
for	O
every	O
4	O
.	O
7	O
patients	O
treated	O
with	O
light	O
sedation	O
.	O

The	O
mean	O
+	O
/	O
-	O
SD	O
number	O
of	O
days	O
of	O
delirium	O
during	O
hospitalization	O
was	O
lower	O
in	O
the	O
light	O
sedation	O
group	O
than	O
in	O
the	O
deep	O
sedation	O
group	O
(	O
0	O
.	O
5	O
+	O
/	O
-	O
1	O
.	O
5	O
days	O
vs	O
1	O
.	O
4	O
+	O
/	O
-	O
4	O
.	O
0	O
days	O
;	O
P	O
=	O
.	O
01	O
)	O
.	O

CONCLUSION	O
:	O
The	O
use	O
of	O
light	O
propofol	B-CHED
sedation	O
decreased	O
the	O
prevalence	O
of	O
postoperative	O
delirium	O
by	O
50	O
%	O
compared	O
with	O
deep	O
sedation	O
.	O

Limiting	O
depth	O
of	O
sedation	O
during	O
spinal	O
anesthesia	O
is	O
a	O
simple	O
,	O
safe	O
,	O
and	O
cost	O
-	O
effective	O
intervention	O
for	O
preventing	O
postoperative	O
delirium	O
in	O
elderly	O
patients	O
that	O
could	O
be	O
widely	O
and	O
readily	O
adopted	O
.	O

The	O
protective	O
role	O
of	O
Nrf2	O
in	O
streptozotocin	B-CHED
-	O
induced	O
diabetic	O
nephropathy	O
.	O

OBJECTIVE	O
:	O
Diabetic	O
nephropathy	O
is	O
one	O
of	O
the	O
major	O
causes	O
of	O
renal	O
failure	O
,	O
which	O
is	O
accompanied	O
by	O
the	O
production	O
of	O
reactive	O
oxygen	B-CHED
species	O
(	O
ROS	O
)	O
.	O

Nrf2	O
is	O
the	O
primary	O
transcription	O
factor	O
that	O
controls	O
the	O
antioxidant	O
response	O
essential	O
for	O
maintaining	O
cellular	O
redox	O
homeostasis	O
.	O

Here	O
,	O
we	O
report	O
our	O
findings	O
demonstrating	O
a	O
protective	O
role	O
of	O
Nrf2	O
against	O
diabetic	O
nephropathy	O
.	O

RESEARCH	O
DESIGN	O
AND	O
METHODS	O
:	O
We	O
explore	O
the	O
protective	O
role	O
of	O
Nrf2	O
against	O
diabetic	O
nephropathy	O
using	O
human	O
kidney	O
biopsy	O
tissues	O
from	O
diabetic	O
nephropathy	O
patients	O
,	O
a	O
streptozotocin	B-CHED
-	O
induced	O
diabetic	O
nephropathy	O
model	O
in	O
Nrf2	O
(	O
-	O
/	O
-	O
)	O
mice	O
,	O
and	O
cultured	O
human	O
mesangial	O
cells	O
.	O

RESULTS	O
:	O
The	O
glomeruli	O
of	O
human	O
diabetic	O
nephropathy	O
patients	O
were	O
under	O
oxidative	O
stress	O
and	O
had	O
elevated	O
Nrf2	O
levels	O
.	O

In	O
the	O
animal	O
study	O
,	O
Nrf2	O
was	O
demonstrated	O
to	O
be	O
crucial	O
in	O
ameliorating	O
streptozotocin	B-CHED
-	O
induced	O
renal	O
damage	O
.	O

This	O
is	O
evident	O
by	O
Nrf2	O
(	O
-	O
/	O
-	O
)	O
mice	O
having	O
higher	O
ROS	O
production	O
and	O
suffering	O
from	O
greater	O
oxidative	O
DNA	O
damage	O
and	O
renal	O
injury	O
compared	O
with	O
Nrf2	O
(	O
+	O
/	O
+	O
)	O
mice	O
.	O

Mechanistic	O
studies	O
in	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
systems	O
showed	O
that	O
the	O
Nrf2	O
-	O
mediated	O
protection	O
against	O
diabetic	O
nephropathy	O
is	O
,	O
at	O
least	O
,	O
partially	O
through	O
inhibition	O
of	O
transforming	O
growth	O
factor	O
-	O
beta1	O
(	O
TGF	O
-	O
beta1	O
)	O
and	O
reduction	O
of	O
extracellular	O
matrix	O
production	O
.	O

In	O
human	O
renal	O
mesangial	O
cells	O
,	O
high	O
glucose	B-CHED
induced	O
ROS	O
production	O
and	O
activated	O
expression	O
of	O
Nrf2	O
and	O
its	O
downstream	O
genes	O
.	O

Furthermore	O
,	O
activation	O
or	O
overexpression	O
of	O
Nrf2	O
inhibited	O
the	O
promoter	O
activity	O
of	O
TGF	O
-	O
beta1	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
whereas	O
knockdown	O
of	O
Nrf2	O
by	O
siRNA	O
enhanced	O
TGF	O
-	O
beta1	O
transcription	O
and	O
fibronectin	O
production	O
.	O

CONCLUSIONS	O
:	O
This	O
work	O
clearly	O
indicates	O
a	O
protective	O
role	O
of	O
Nrf2	O
in	O
diabetic	O
nephropathy	O
,	O
suggesting	O
that	O
dietary	O
or	O
therapeutic	O
activation	O
of	O
Nrf2	O
could	O
be	O
used	O
as	O
a	O
strategy	O
to	O
prevent	O
or	O
slow	O
down	O
the	O
progression	O
of	O
diabetic	O
nephropathy	O
.	O

Metformin	B-CHED
prevents	O
experimental	O
gentamicin	B-CHED
-	O
induced	O
nephropathy	O
by	O
a	O
mitochondria	O
-	O
dependent	O
pathway	O
.	O

The	O
antidiabetic	O
drug	O
metformin	B-CHED
can	O
diminish	O
apoptosis	O
induced	O
by	O
oxidative	O
stress	O
in	O
endothelial	O
cells	O
and	O
prevent	O
vascular	O
dysfunction	O
even	O
in	O
nondiabetic	O
patients	O
.	O

Here	O
we	O
tested	O
whether	O
it	O
has	O
a	O
beneficial	O
effect	O
in	O
a	O
rat	O
model	O
of	O
gentamicin	B-CHED
toxicity	O
.	O

Mitochondrial	O
analysis	O
,	O
respiration	O
intensity	O
,	O
levels	O
of	O
reactive	O
oxygen	B-CHED
species	O
,	O
permeability	O
transition	O
,	O
and	O
cytochrome	O
c	O
release	O
were	O
assessed	O
3	O
and	O
6	O
days	O
after	O
gentamicin	B-CHED
administration	O
.	O

Metformin	B-CHED
treatment	O
fully	O
blocked	O
gentamicin	B-CHED
-	O
mediated	O
acute	O
renal	O
failure	O
.	O

This	O
was	O
accompanied	O
by	O
a	O
lower	O
activity	O
of	O
N	O
-	O
acetyl	O
-	O
beta	O
-	O
D	O
-	O
glucosaminidase	O
,	O
together	O
with	O
a	O
decrease	O
of	O
lipid	O
peroxidation	O
and	O
increase	O
of	O
antioxidant	O
systems	O
.	O

Metformin	B-CHED
also	O
protected	O
the	O
kidney	O
from	O
histological	O
damage	O
6	O
days	O
after	O
gentamicin	B-CHED
administration	O
.	O

These	O
in	O
vivo	O
markers	O
of	O
kidney	O
dysfunction	O
and	O
their	O
correction	O
by	O
metformin	B-CHED
were	O
complemented	O
by	O
in	O
vitro	O
studies	O
of	O
mitochondrial	O
function	O
.	O

We	O
found	O
that	O
gentamicin	B-CHED
treatment	O
depleted	O
respiratory	O
components	O
(	O
cytochrome	O
c	O
,	O
NADH	O
)	O
,	O
probably	O
due	O
to	O
the	O
opening	O
of	O
mitochondrial	O
transition	O
pores	O
.	O

These	O
injuries	O
,	O
partly	O
mediated	O
by	O
a	O
rise	O
in	O
reactive	O
oxygen	B-CHED
species	O
from	O
the	O
electron	O
transfer	O
chain	O
,	O
were	O
significantly	O
decreased	O
by	O
metformin	B-CHED
.	O

Thus	O
,	O
our	O
study	O
suggests	O
that	O
pleiotropic	O
effects	O
of	O
metformin	B-CHED
can	O
lessen	O
gentamicin	B-CHED
nephrotoxicity	O
and	O
improve	O
mitochondrial	O
homeostasis	O
.	O

Risk	O
of	O
nephropathy	O
after	O
consumption	O
of	O
nonionic	O
contrast	B-CHED
media	I-CHED
by	O
children	O
undergoing	O
cardiac	O
angiography	O
:	O
a	O
prospective	O
study	O
.	O

Despite	O
increasing	O
reports	O
on	O
nonionic	O
contrast	B-CHED
media	I-CHED
-	O
induced	O
nephropathy	O
(	O
CIN	O
)	O
in	O
hospitalized	O
adult	O
patients	O
during	O
cardiac	O
procedures	O
,	O
the	O
studies	O
in	O
pediatrics	O
are	O
limited	O
,	O
with	O
even	O
less	O
focus	O
on	O
possible	O
predisposing	O
factors	O
and	O
preventive	O
measures	O
for	O
patients	O
undergoing	O
cardiac	O
angiography	O
.	O

This	O
prospective	O
study	O
determined	O
the	O
incidence	O
of	O
CIN	O
for	O
two	O
nonionic	O
contrast	B-CHED
media	I-CHED
(	O
CM	B-CHED
)	O
,	O
iopromide	B-CHED
and	O
iohexol	B-CHED
,	O
among	O
80	O
patients	O
younger	O
than	O
18	O
years	O
and	O
compared	O
the	O
rates	O
for	O
this	O
complication	O
in	O
relation	O
to	O
the	O
type	O
and	O
dosage	O
of	O
CM	B-CHED
and	O
the	O
presence	O
of	O
cyanosis	O
.	O

The	O
80	O
patients	O
in	O
the	O
study	O
consecutively	O
received	O
either	O
iopromide	B-CHED
(	O
group	O
A	O
,	O
n	O
=	O
40	O
)	O
or	O
iohexol	B-CHED
(	O
group	O
B	O
,	O
n	O
=	O
40	O
)	O
.	O

Serum	O
sodium	B-CHED
(	O
Na	B-CHED
)	O
,	O
potassium	B-CHED
(	O
K	B-CHED
)	O
,	O
and	O
creatinine	B-CHED
(	O
Cr	B-CHED
)	O
were	O
measured	O
24	O
h	O
before	O
angiography	O
as	O
baseline	O
values	O
,	O
then	O
measured	O
again	O
at	O
12	O
-	O
,	O
24	O
-	O
,	O
and	O
48	O
-	O
h	O
intervals	O
after	O
CM	B-CHED
use	O
.	O

Urine	O
samples	O
for	O
Na	B-CHED
and	O
Cr	B-CHED
also	O
were	O
checked	O
at	O
the	O
same	O
intervals	O
.	O

Risk	O
of	O
renal	O
failure	O
,	O
Injury	O
to	O
the	O
kidney	O
,	O
Failure	O
of	O
kidney	O
function	O
,	O
Loss	O
of	O
kidney	O
function	O
,	O
and	O
End	O
-	O
stage	O
renal	O
damage	O
(	O
RIFLE	O
criteria	O
)	O
were	O
used	O
to	O
define	O
CIN	O
and	O
its	O
incidence	O
in	O
the	O
study	O
population	O
.	O

Accordingly	O
,	O
among	O
the	O
15	O
CIN	O
patients	O
(	O
18	O
.	O
75	O
%	O
)	O
,	O
7	O
.	O
5	O
%	O
of	O
the	O
patients	O
in	O
group	O
A	O
had	O
increased	O
risk	O
and	O
3	O
.	O
75	O
%	O
had	O
renal	O
injury	O
,	O
whereas	O
5	O
%	O
of	O
group	O
B	O
had	O
increased	O
risk	O
and	O
2	O
.	O
5	O
%	O
had	O
renal	O
injury	O
.	O

Whereas	O
33	O
.	O
3	O
%	O
of	O
the	O
patients	O
with	O
CIN	O
were	O
among	O
those	O
who	O
received	O
the	O
proper	O
dosage	O
of	O
CM	B-CHED
,	O
the	O
percentage	O
increased	O
to	O
66	O
.	O
6	O
%	O
among	O
those	O
who	O
received	O
larger	O
doses	O
,	O
with	O
a	O
significant	O
difference	O
in	O
the	O
incidence	O
of	O
CIN	O
related	O
to	O
the	O
different	O
dosages	O
of	O
CM	B-CHED
(	O
p	O
=	O
0	O
.	O
014	O
)	O
.	O

Among	O
the	O
15	O
patients	O
with	O
CIN	O
,	O
6	O
had	O
cyanotic	O
congenital	O
heart	O
diseases	O
,	O
but	O
the	O
incidence	O
did	O
not	O
differ	O
significantly	O
from	O
that	O
for	O
the	O
noncyanotic	O
patients	O
(	O
p	O
=	O
0	O
.	O
243	O
)	O
.	O

Although	O
clinically	O
silent	O
,	O
CIN	O
is	O
not	O
rare	O
in	O
pediatrics	O
.	O

The	O
incidence	O
depends	O
on	O
dosage	O
but	O
not	O
on	O
the	O
type	O
of	O
consumed	O
nonionic	O
CM	B-CHED
,	O
nor	O
on	O
the	O
presence	O
of	O
cyanosis	O
,	O
and	O
although	O
CIN	O
usually	O
is	O
reversible	O
,	O
more	O
concern	O
is	O
needed	O
for	O
the	O
prevention	O
of	O
such	O
a	O
complication	O
in	O
children	O
.	O

Renal	O
function	O
and	O
hemodynamics	O
during	O
prolonged	O
isoflurane	B-CHED
-	O
induced	O
hypotension	O
in	O
humans	O
.	O

The	O
effect	O
of	O
isoflurane	B-CHED
-	O
induced	O
hypotension	O
on	O
glomerular	O
function	O
and	O
renal	O
blood	O
flow	O
was	O
investigated	O
in	O
20	O
human	O
subjects	O
.	O

Glomerular	O
filtration	O
rate	O
(	O
GFR	O
)	O
and	O
effective	O
renal	O
plasma	O
flow	O
(	O
ERPF	O
)	O
were	O
measured	O
by	O
inulin	O
and	O
para	B-CHED
-	I-CHED
aminohippurate	I-CHED
(	O
PAH	B-CHED
)	O
clearance	O
,	O
respectively	O
.	O

Anesthesia	O
was	O
maintained	O
with	O
fentanyl	B-CHED
,	O
nitrous	B-CHED
oxide	I-CHED
,	O
oxygen	B-CHED
,	O
and	O
isoflurane	B-CHED
.	O

Hypotension	O
was	O
induced	O
for	O
236	O
.	O
9	O
+	O
/	O
-	O
15	O
.	O
1	O
min	O
by	O
increasing	O
the	O
isoflurane	B-CHED
inspired	O
concentration	O
to	O
maintain	O
a	O
mean	O
arterial	O
pressure	O
of	O
59	O
.	O
8	O
+	O
/	O
-	O
0	O
.	O
4	O
mmHg	O
.	O

GFR	O
and	O
ERPF	O
decreased	O
with	O
the	O
induction	O
of	O
anesthesia	O
but	O
not	O
significantly	O
more	O
during	O
hypotension	O
.	O

Postoperatively	O
,	O
ERPF	O
returned	O
to	O
preoperative	O
values	O
,	O
whereas	O
GFR	O
was	O
higher	O
than	O
preoperative	O
values	O
.	O

Renal	O
vascular	O
resistance	O
increased	O
during	O
anesthesia	O
but	O
decreased	O
when	O
hypotension	O
was	O
induced	O
,	O
allowing	O
the	O
maintenance	O
of	O
renal	O
blood	O
flow	O
.	O

We	O
conclude	O
that	O
renal	O
compensatory	O
mechanisms	O
are	O
preserved	O
during	O
isoflurane	B-CHED
-	O
induced	O
hypotension	O
and	O
that	O
renal	O
function	O
and	O
hemodynamics	O
quickly	O
return	O
to	O
normal	O
when	O
normotension	O
is	O
resumed	O
.	O

Brainstem	O
dysgenesis	O
in	O
an	O
infant	O
prenatally	O
exposed	O
to	O
cocaine	B-CHED
.	O

Many	O
authors	O
described	O
the	O
effects	O
on	O
the	O
fetus	O
of	O
maternal	O
cocaine	O
abuse	O
during	O
pregnancy	O
.	O

Vasoconstriction	O
appears	O
to	O
be	O
the	O
common	O
mechanism	O
of	O
action	O
leading	O
to	O
a	O
wide	O
range	O
of	O
fetal	O
anomalies	O
.	O

We	O
report	O
on	O
an	O
infant	O
with	O
multiple	O
cranial	O
-	O
nerve	O
involvement	O
attributable	O
to	O
brainstem	O
dysgenesis	O
,	O
born	O
to	O
a	O
cocaine	O
-	O
addicted	O
mother	O
.	O

A	O
cross	O
-	O
sectional	O
evaluation	O
of	O
the	O
effect	O
of	O
risperidone	B-CHED
and	O
selective	O
serotonin	B-CHED
reuptake	O
inhibitors	O
on	O
bone	O
mineral	O
density	O
in	O
boys	O
.	O

OBJECTIVE	O
:	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
risperidone	B-CHED
-	O
induced	O
hyperprolactinemia	O
on	O
trabecular	O
bone	O
mineral	O
density	O
(	O
BMD	O
)	O
in	O
children	O
and	O
adolescents	O
.	O

METHOD	O
:	O
Medically	O
healthy	O
7	O
-	O
to	O
17	O
-	O
year	O
-	O
old	O
males	O
chronically	O
treated	O
,	O
in	O
a	O
naturalistic	O
setting	O
,	O
with	O
risperidone	B-CHED
were	O
recruited	O
for	O
this	O
cross	O
-	O
sectional	O
study	O
through	O
child	O
psychiatry	O
outpatient	O
clinics	O
between	O
November	O
2005	O
and	O
June	O
2007	O
.	O

Anthropometric	O
measurements	O
and	O
laboratory	O
testing	O
were	O
conducted	O
.	O

The	O
clinical	O
diagnoses	O
were	O
based	O
on	O
chart	O
review	O
,	O
and	O
developmental	O
and	O
treatment	O
history	O
was	O
obtained	O
from	O
the	O
medical	O
record	O
.	O

Volumetric	O
BMD	O
of	O
the	O
ultradistal	O
radius	O
was	O
measured	O
using	O
peripheral	O
quantitative	O
computed	O
tomography	O
,	O
and	O
areal	O
BMD	O
of	O
the	O
lumbar	O
spine	O
was	O
estimated	O
using	O
dual	O
-	O
energy	O
x	O
-	O
ray	O
absorptiometry	O
.	O

RESULTS	O
:	O
Hyperprolactinemia	O
was	O
present	O
in	O
49	O
%	O
of	O
83	O
boys	O
(	O
n	O
=	O
41	O
)	O
treated	O
with	O
risperidone	B-CHED
for	O
a	O
mean	O
of	O
2	O
.	O
9	O
years	O
.	O

Serum	O
testosterone	B-CHED
concentration	O
increased	O
with	O
pubertal	O
status	O
but	O
was	O
not	O
affected	O
by	O
hyperprolactinemia	O
.	O

As	O
expected	O
,	O
bone	O
mineral	O
content	O
and	O
BMD	O
increased	O
with	O
sexual	O
maturity	O
.	O

After	O
adjusting	O
for	O
the	O
stage	O
of	O
sexual	O
development	O
and	O
height	O
and	O
BMI	O
z	O
scores	O
,	O
serum	O
prolactin	O
was	O
negatively	O
associated	O
with	O
trabecular	O
volumetric	O
BMD	O
at	O
the	O
ultradistal	O
radius	O
(	O
P	O
<	O
.	O
03	O
)	O
.	O

Controlling	O
for	O
relevant	O
covariates	O
,	O
we	O
also	O
found	O
treatment	O
with	O
selective	O
serotonin	B-CHED
reuptake	O
inhibitors	O
(	O
SSRIs	O
)	O
to	O
be	O
associated	O
with	O
lower	O
trabecular	O
BMD	O
at	O
the	O
radius	O
(	O
P	O
=	O
.	O
03	O
)	O
and	O
BMD	O
z	O
score	O
at	O
the	O
lumbar	O
spine	O
(	O
P	O
<	O
.	O
05	O
)	O
.	O

These	O
findings	O
became	O
more	O
marked	O
when	O
the	O
analysis	O
was	O
restricted	O
to	O
non	O
-	O
Hispanic	O
white	O
patients	O
.	O

Of	O
13	O
documented	O
fractures	O
,	O
3	O
occurred	O
after	O
risperidone	B-CHED
and	O
SSRIs	O
were	O
started	O
,	O
and	O
none	O
occurred	O
in	O
patients	O
with	O
hyperprolactinemia	O
.	O

CONCLUSIONS	O
:	O
This	O
is	O
the	O
first	O
study	O
to	O
link	O
risperidone	B-CHED
-	O
induced	O
hyperprolactinemia	O
and	O
SSRI	O
treatment	O
to	O
lower	O
BMD	O
in	O
children	O
and	O
adolescents	O
.	O

Future	O
research	O
should	O
evaluate	O
the	O
longitudinal	O
course	O
of	O
this	O
adverse	O
event	O
to	O
determine	O
its	O
temporal	O
stability	O
and	O
whether	O
a	O
higher	O
fracture	O
rate	O
ensues	O
.	O

Fear	O
-	O
potentiated	O
startle	O
,	O
but	O
not	O
light	O
-	O
enhanced	O
startle	O
,	O
is	O
enhanced	O
by	O
anxiogenic	O
drugs	O
.	O

RATIONALE	O
AND	O
OBJECTIVES	O
:	O
The	O
light	O
-	O
enhanced	O
startle	O
paradigm	O
(	O
LES	O
)	O
is	O
suggested	O
to	O
model	O
anxiety	O
,	O
because	O
of	O
the	O
non	O
-	O
specific	O
cue	O
and	O
the	O
long	O
-	O
term	O
effect	O
.	O

In	O
contrast	O
,	O
the	O
fear	O
-	O
potentiated	O
startle	O
(	O
FPS	O
)	O
is	O
suggested	O
to	O
model	O
conditioned	O
fear	O
.	O

However	O
,	O
the	O
pharmacological	O
profiles	O
of	O
these	O
two	O
paradigms	O
are	O
very	O
similar	O
.	O

The	O
present	O
study	O
investigated	O
the	O
effects	O
of	O
putative	O
anxiogenic	O
drugs	O
on	O
LES	O
and	O
FPS	O
and	O
aimed	O
at	O
determining	O
the	O
sensitivity	O
of	O
LES	O
for	O
anxiogenic	O
drugs	O
and	O
to	O
potentially	O
showing	O
a	O
pharmacological	O
differentiation	O
between	O
these	O
two	O
paradigms	O
.	O

METHODS	O
:	O
Male	O
Wistar	O
rats	O
received	O
each	O
dose	O
of	O
the	O
alpha	O
(	O
2	O
)	O
-	O
adrenoceptor	O
antagonist	O
yohimbine	B-CHED
(	O
0	O
.	O
25	O
-	O
1	O
.	O
0mg	O
/	O
kg	O
)	O
,	O
the	O
5	B-CHED
-	I-CHED
HT	I-CHED
(	O
2C	O
)	O
receptor	O
agonist	O
m	B-CHED
-	I-CHED
chlorophenylpiperazine	I-CHED
(	O
mCPP	B-CHED
,	O
0	O
.	O
5	O
-	O
2	O
.	O
0mg	O
/	O
kg	O
)	O
or	O
the	O
GABA	B-CHED
(	O
A	O
)	O
inverse	O
receptor	O
agonist	O
pentylenetetrazole	B-CHED
(	O
PTZ	B-CHED
,	O
3	O
-	O
30mg	O
/	O
kg	O
)	O
and	O
were	O
subsequently	O
tested	O
in	O
either	O
LES	O
or	O
FPS	O
.	O

RESULTS	O
:	O
None	O
of	O
the	O
drugs	O
enhanced	O
LES	O
,	O
whereas	O
mCPP	B-CHED
increased	O
percentage	O
FPS	O
and	O
yohimbine	B-CHED
increased	O
absolute	O
FPS	O
values	O
.	O

Furthermore	O
,	O
yohimbine	B-CHED
increased	O
baseline	O
startle	O
amplitude	O
in	O
the	O
LES	O
,	O
while	O
mCPP	B-CHED
suppressed	O
baseline	O
startle	O
in	O
both	O
the	O
LES	O
and	O
FPS	O
and	O
PTZ	B-CHED
suppressed	O
baseline	O
startle	O
in	O
the	O
FPS	O
.	O

CONCLUSIONS	O
:	O
In	O
contrast	O
to	O
findings	O
in	O
the	O
FPS	O
paradigm	O
,	O
none	O
of	O
the	O
drugs	O
were	O
able	O
to	O
exacerbate	O
the	O
LES	O
response	O
.	O

Thus	O
,	O
a	O
clear	O
pharmacological	O
differentiation	O
was	O
found	O
between	O
LES	O
and	O
FPS	O
.	O

Rosaceiform	O
dermatitis	O
associated	O
with	O
topical	O
tacrolimus	B-CHED
treatment	O
.	O

We	O
describe	O
herein	O
3	O
patients	O
who	O
developed	O
rosacea	O
-	O
like	O
dermatitis	O
eruptions	O
while	O
using	O
0	O
.	O
03	O
%	O
or	O
0	O
.	O
1	O
%	O
tacrolimus	B-CHED
ointment	O
for	O
facial	O
dermatitis	O
.	O

Skin	O
biopsy	O
specimens	O
showed	O
telangiectasia	O
and	O
noncaseating	O
epithelioid	O
granulomatous	O
tissue	O
formation	O
in	O
the	O
papillary	O
to	O
mid	O
dermis	O
.	O

Continuous	O
topical	O
use	O
of	O
immunomodulators	O
such	O
as	O
tacrolimus	B-CHED
or	O
pimecrolimus	B-CHED
should	O
be	O
regarded	O
as	O
a	O
potential	O
cause	O
of	O
rosaceiform	O
dermatitis	O
,	O
although	O
many	O
cases	O
have	O
not	O
been	O
reported	O
.	O

Coenzyme	B-CHED
Q10	I-CHED
treatment	O
ameliorates	O
acute	O
cisplatin	B-CHED
nephrotoxicity	O
in	O
mice	O
.	O

The	O
nephroprotective	O
effect	O
of	O
coenzyme	B-CHED
Q10	I-CHED
was	O
investigated	O
in	O
mice	O
with	O
acute	O
renal	O
injury	O
induced	O
by	O
a	O
single	O
i	O
.	O
p	O
.	O
injection	O
of	O
cisplatin	B-CHED
(	O
5	O
mg	O
/	O
kg	O
)	O
.	O

Coenzyme	B-CHED
Q10	I-CHED
treatment	O
(	O
10	O
mg	O
/	O
kg	O
/	O
day	O
,	O
i	O
.	O
p	O
.	O
)	O
was	O
applied	O
for	O
6	O
consecutive	O
days	O
,	O
starting	O
1	O
day	O
before	O
cisplatin	B-CHED
administration	O
.	O

Coenzyme	B-CHED
Q10	I-CHED
significantly	O
reduced	O
blood	B-CHED
urea	I-CHED
nitrogen	I-CHED
and	O
serum	O
creatinine	B-CHED
levels	O
which	O
were	O
increased	O
by	O
cisplatin	B-CHED
.	O

Coenzyme	B-CHED
Q10	I-CHED
significantly	O
compensated	O
deficits	O
in	O
the	O
antioxidant	O
defense	O
mechanisms	O
(	O
reduced	B-CHED
glutathione	I-CHED
level	O
and	O
superoxide	B-CHED
dismutase	O
activity	O
)	O
,	O
suppressed	O
lipid	O
peroxidation	O
,	O
decreased	O
the	O
elevations	O
of	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
,	O
nitric	B-CHED
oxide	I-CHED
and	O
platinum	B-CHED
ion	O
concentration	O
,	O
and	O
attenuated	O
the	O
reductions	O
of	O
selenium	B-CHED
and	O
zinc	B-CHED
ions	O
in	O
renal	O
tissue	O
resulted	O
from	O
cisplatin	B-CHED
administration	O
.	O

Also	O
,	O
histopathological	O
renal	O
tissue	O
damage	O
mediated	O
by	O
cisplatin	B-CHED
was	O
ameliorated	O
by	O
coenzyme	B-CHED
Q10	I-CHED
treatment	O
.	O

Immunohistochemical	O
analysis	O
revealed	O
that	O
coenzyme	B-CHED
Q10	I-CHED
significantly	O
decreased	O
the	O
cisplatin	B-CHED
-	O
induced	O
overexpression	O
of	O
inducible	O
nitric	B-CHED
oxide	I-CHED
synthase	O
,	O
nuclear	O
factor	O
-	O
kappaB	O
,	O
caspase	O
-	O
3	O
and	O
p53	O
in	O
renal	O
tissue	O
.	O

It	O
was	O
concluded	O
that	O
coenzyme	B-CHED
Q10	I-CHED
represents	O
a	O
potential	O
therapeutic	O
option	O
to	O
protect	O
against	O
acute	O
cisplatin	B-CHED
nephrotoxicity	O
commonly	O
encountered	O
in	O
clinical	O
practice	O
.	O

Reversible	O
cholestasis	O
with	O
bile	O
duct	O
injury	O
following	O
azathioprine	B-CHED
therapy	O
.	O

A	O
case	O
report	O
.	O

A	O
67	O
-	O
year	O
-	O
old	O
patient	O
,	O
with	O
primary	O
polymyositis	O
and	O
without	O
previous	O
evidence	O
of	O
liver	O
disease	O
,	O
developed	O
clinical	O
and	O
biochemical	O
features	O
of	O
severe	O
cholestasis	O
3	O
months	O
after	O
initiation	O
of	O
azathioprine	B-CHED
therapy	O
.	O

Liver	O
biopsy	O
showed	O
cholestasis	O
with	O
both	O
cytological	O
and	O
architectural	O
alterations	O
of	O
interlobular	O
bile	O
ducts	O
.	O

Azathioprine	B-CHED
withdrawal	O
resulted	O
after	O
7	O
weeks	O
in	O
the	O
resolution	O
of	O
clinical	O
and	O
biochemical	O
abnormalities	O
.	O

It	O
is	O
believed	O
that	O
this	O
is	O
the	O
first	O
reported	O
case	O
of	O
reversible	O
azathioprine	B-CHED
-	O
induced	O
cholestasis	O
associated	O
with	O
histological	O
evidence	O
of	O
bile	O
duct	O
injury	O
.	O

Dopamine	B-CHED
is	O
not	O
essential	O
for	O
the	O
development	O
of	O
methamphetamine	B-CHED
-	O
induced	O
neurotoxicity	O
.	O

It	O
is	O
widely	O
believed	O
that	O
dopamine	B-CHED
(	O
DA	B-CHED
)	O
mediates	O
methamphetamine	B-CHED
(	O
METH	B-CHED
)	O
-	O
induced	O
toxicity	O
to	O
brain	O
dopaminergic	O
neurons	O
,	O
because	O
drugs	O
that	O
interfere	O
with	O
DA	B-CHED
neurotransmission	O
decrease	O
toxicity	O
,	O
whereas	O
drugs	O
that	O
increase	O
DA	B-CHED
neurotransmission	O
enhance	O
toxicity	O
.	O

However	O
,	O
temperature	O
effects	O
of	O
drugs	O
that	O
have	O
been	O
used	O
to	O
manipulate	O
brain	O
DA	B-CHED
neurotransmission	O
confound	O
interpretation	O
of	O
the	O
data	O
.	O

Here	O
we	O
show	O
that	O
the	O
recently	O
reported	O
ability	O
of	O
L	B-CHED
-	I-CHED
dihydroxyphenylalanine	I-CHED
to	O
reverse	O
the	O
protective	O
effect	O
of	O
alpha	B-CHED
-	I-CHED
methyl	I-CHED
-	I-CHED
para	I-CHED
-	I-CHED
tyrosine	I-CHED
on	O
METH	B-CHED
-	O
induced	O
DA	B-CHED
neurotoxicity	O
is	O
also	O
confounded	O
by	O
drug	O
effects	O
on	O
body	O
temperature	O
.	O

Further	O
,	O
we	O
show	O
that	O
mice	O
genetically	O
engineered	O
to	O
be	O
deficient	O
in	O
brain	O
DA	B-CHED
develop	O
METH	B-CHED
neurotoxicity	O
,	O
as	O
long	O
as	O
the	O
thermic	O
effects	O
of	O
METH	B-CHED
are	O
preserved	O
.	O

In	O
addition	O
,	O
we	O
demonstrate	O
that	O
mice	O
genetically	O
engineered	O
to	O
have	O
unilateral	O
brain	O
DA	B-CHED
deficits	O
develop	O
METH	B-CHED
-	O
induced	O
dopaminergic	O
deficits	O
that	O
are	O
of	O
comparable	O
magnitude	O
on	O
both	O
sides	O
of	O
the	O
brain	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
demonstrate	O
that	O
DA	B-CHED
is	O
not	O
essential	O
for	O
the	O
development	O
of	O
METH	B-CHED
-	O
induced	O
dopaminergic	O
neurotoxicity	O
and	O
suggest	O
that	O
mechanisms	O
independent	O
of	O
DA	B-CHED
warrant	O
more	O
intense	O
investigation	O
.	O

Swallowing	O
-	O
induced	O
atrial	O
tachyarrhythmia	O
triggered	O
by	O
salbutamol	B-CHED
:	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

CASE	O
:	O
A	O
49	O
-	O
year	O
-	O
old	O
patient	O
experienced	O
chest	O
discomfort	O
while	O
swallowing	O
.	O

On	O
electrocardiogram	O
,	O
episodes	O
of	O
atrial	O
tachyarrhythmia	O
were	O
recorded	O
immediately	O
after	O
swallowing	O
;	O
24	O
-	O
hour	O
Holter	O
monitoring	O
recorded	O
several	O
events	O
.	O

The	O
arrhythmia	O
resolved	O
after	O
therapy	O
with	O
atenolol	B-CHED
,	O
but	O
recurred	O
a	O
year	O
later	O
.	O

The	O
patient	O
noticed	O
that	O
before	O
these	O
episodes	O
he	O
had	O
been	O
using	O
an	O
inhalator	O
of	O
salbutamol	B-CHED
.	O

After	O
stopping	O
the	O
beta	O
-	O
agonist	O
,	O
and	O
after	O
a	O
week	O
with	O
the	O
atenolol	B-CHED
,	O
the	O
arrhythmia	O
disappeared	O
.	O

DISCUSSION	O
:	O
Swallowing	O
-	O
induced	O
atrial	O
tachyarrhythmia	O
(	O
SIAT	O
)	O
is	O
a	O
rare	O
phenomenon	O
.	O

Fewer	O
than	O
50	O
cases	O
of	O
SIAT	O
have	O
been	O
described	O
in	O
the	O
literature	O
.	O

This	O
article	O
summarizes	O
all	O
the	O
cases	O
published	O
,	O
creating	O
a	O
comprehensive	O
review	O
of	O
the	O
current	O
knowledge	O
and	O
approach	O
to	O
SIAT	O
.	O

It	O
discusses	O
demographics	O
,	O
clinical	O
characteristics	O
and	O
types	O
of	O
arrhythmia	O
,	O
postulated	O
mechanisms	O
of	O
SIAT	O
,	O
and	O
different	O
treatment	O
possibilities	O
such	O
as	O
medications	O
,	O
surgery	O
,	O
and	O
radiofrequency	O
catheter	O
ablation	O
(	O
RFCA	O
)	O
.	O

CONCLUSION	O
:	O
Salbutamol	B-CHED
is	O
presented	O
here	O
as	O
a	O
possible	O
trigger	O
for	O
SIAT	O
.	O

Although	O
it	O
is	O
difficult	O
to	O
define	O
causality	O
in	O
a	O
case	O
report	O
,	O
it	O
is	O
logical	O
to	O
think	O
that	O
a	O
beta	O
-	O
agonist	O
like	O
salbutamol	B-CHED
(	O
known	O
to	O
induce	O
tachycardia	O
)	O
may	O
be	O
the	O
trigger	O
of	O
adrenergic	O
reflexes	O
originating	O
in	O
the	O
esophagus	O
while	O
swallowing	O
and	O
that	O
a	O
beta	O
-	O
blocker	O
such	O
as	O
atenolol	B-CHED
(	O
that	O
blocks	O
the	O
adrenergic	O
activity	O
)	O
may	O
relieve	O
it	O
.	O

The	O
ability	O
of	O
insulin	O
treatment	O
to	O
reverse	O
or	O
prevent	O
the	O
changes	O
in	O
urinary	O
bladder	O
function	O
caused	O
by	O
streptozotocin	B-CHED
-	O
induced	O
diabetes	O
mellitus	O
.	O

1	O
.	O

The	O
effects	O
of	O
insulin	O
treatment	O
on	O
in	O
vivo	O
and	O
in	O
vitro	O
urinary	O
bladder	O
function	O
in	O
streptozotocin	B-CHED
-	O
diabetic	O
rats	O
were	O
investigated	O
.	O

2	O
.	O

Diabetes	O
of	O
2	O
months	O
duration	O
resulted	O
in	O
decreases	O
in	O
body	O
weight	O
and	O
increases	O
in	O
fluid	O
consumption	O
,	O
urine	O
volume	O
,	O
frequency	O
of	O
micturition	O
,	O
and	O
average	O
volume	O
per	O
micturition	O
;	O
effects	O
which	O
were	O
prevented	O
by	O
insulin	O
treatment	O
.	O

3	O
.	O

Insulin	O
treatment	O
also	O
prevented	O
the	O
increases	O
in	O
contractile	O
responses	O
of	O
bladder	O
body	O
strips	O
from	O
diabetic	O
rats	O
to	O
nerve	O
stimulation	O
,	O
ATP	B-CHED
,	O
and	O
bethanechol	B-CHED
.	O

4	O
.	O

Diabetes	O
of	O
4	O
months	O
duration	O
also	O
resulted	O
in	O
decreases	O
in	O
body	O
weight	O
,	O
and	O
increases	O
in	O
fluid	O
consumption	O
,	O
urine	O
volume	O
,	O
frequency	O
of	O
micturition	O
,	O
and	O
average	O
volume	O
per	O
micturition	O
,	O
effects	O
which	O
were	O
reversed	O
by	O
insulin	O
treatment	O
for	O
the	O
final	O
2	O
months	O
of	O
the	O
study	O
.	O

5	O
.	O

Insulin	O
treatment	O
reversed	O
the	O
increases	O
in	O
contractile	O
responses	O
of	O
bladder	O
body	O
strips	O
from	O
diabetic	O
rats	O
to	O
nerve	O
stimulation	O
,	O
ATP	B-CHED
,	O
and	O
bethanechol	B-CHED
.	O

6	O
.	O

The	O
data	O
indicate	O
that	O
the	O
effects	O
of	O
streptozotocin	B-CHED
-	O
induced	O
diabetes	O
on	O
urinary	O
bladder	O
function	O
are	O
both	O
prevented	O
and	O
reversed	O
by	O
insulin	O
treatment	O
.	O

Glutamatergic	O
neurotransmission	O
mediated	O
by	O
NMDA	B-CHED
receptors	O
in	O
the	O
inferior	O
colliculus	O
can	O
modulate	O
haloperidol	B-CHED
-	O
induced	O
catalepsy	O
.	O

The	O
inferior	O
colliculus	O
(	O
IC	O
)	O
is	O
primarily	O
involved	O
in	O
the	O
processing	O
of	O
auditory	O
information	O
,	O
but	O
it	O
is	O
distinguished	O
from	O
other	O
auditory	O
nuclei	O
in	O
the	O
brainstem	O
by	O
its	O
connections	O
with	O
structures	O
of	O
the	O
motor	O
system	O
.	O

Functional	O
evidence	O
relating	O
the	O
IC	O
to	O
motor	O
behavior	O
derives	O
from	O
experiments	O
showing	O
that	O
activation	O
of	O
the	O
IC	O
by	O
electrical	O
stimulation	O
or	O
excitatory	O
amino	B-CHED
acid	I-CHED
microinjection	O
causes	O
freezing	O
,	O
escape	O
-	O
like	O
behavior	O
,	O
and	O
immobility	O
.	O

However	O
,	O
the	O
nature	O
of	O
this	O
immobility	O
is	O
still	O
unclear	O
.	O

The	O
present	O
study	O
examined	O
the	O
influence	O
of	O
excitatory	O
amino	B-CHED
acid	I-CHED
-	O
mediated	O
mechanisms	O
in	O
the	O
IC	O
on	O
the	O
catalepsy	O
induced	O
by	O
the	O
dopamine	B-CHED
receptor	O
blocker	O
haloperidol	B-CHED
administered	O
systemically	O
(	O
1	O
or	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
in	O
rats	O
.	O

Haloperidol	B-CHED
-	O
induced	O
catalepsy	O
was	O
challenged	O
with	O
prior	O
intracollicular	O
microinjections	O
of	O
glutamate	B-CHED
NMDA	B-CHED
receptor	O
antagonists	O
,	O
MK	B-CHED
-	I-CHED
801	I-CHED
(	O
15	O
or	O
30	O
mmol	O
/	O
0	O
.	O
5	O
microl	O
)	O
and	O
AP7	B-CHED
(	O
10	O
or	O
20	O
nmol	O
/	O
0	O
.	O
5	O
microl	O
)	O
,	O
or	O
of	O
the	O
NMDA	B-CHED
receptor	O
agonist	O
N	B-CHED
-	I-CHED
methyl	I-CHED
-	I-CHED
d	I-CHED
-	I-CHED
aspartate	I-CHED
(	O
NMDA	B-CHED
,	O
20	O
or	O
30	O
nmol	O
/	O
0	O
.	O
5	O
microl	O
)	O
.	O

The	O
results	O
showed	O
that	O
intracollicular	O
microinjection	O
of	O
MK	B-CHED
-	I-CHED
801	I-CHED
and	O
AP7	B-CHED
previous	O
to	O
systemic	O
injections	O
of	O
haloperidol	B-CHED
significantly	O
attenuated	O
the	O
catalepsy	O
,	O
as	O
indicated	O
by	O
a	O
reduced	O
latency	O
to	O
step	O
down	O
from	O
a	O
horizontal	O
bar	O
.	O

Accordingly	O
,	O
intracollicular	O
microinjection	O
of	O
NMDA	B-CHED
increased	O
the	O
latency	O
to	O
step	O
down	O
the	O
bar	O
.	O

These	O
findings	O
suggest	O
that	O
glutamate	B-CHED
-	O
mediated	O
mechanisms	O
in	O
the	O
neural	O
circuits	O
at	O
the	O
IC	O
level	O
influence	O
haloperidol	B-CHED
-	O
induced	O
catalepsy	O
and	O
participate	O
in	O
the	O
regulation	O
of	O
motor	O
activity	O
.	O

Severe	O
congestive	O
heart	O
failure	O
patient	O
on	O
amiodarone	B-CHED
presenting	O
with	O
myxedemic	O
coma	O
:	O
a	O
case	O
report	O
.	O

This	O
is	O
a	O
case	O
report	O
of	O
myxedema	O
coma	O
secondary	O
to	O
amiodarone	B-CHED
-	O
induced	O
hypothyroidism	O
in	O
a	O
patient	O
with	O
severe	O
congestive	O
heart	O
failure	O
(	O
CHF	O
)	O
.	O

To	O
our	O
knowledge	O
and	O
after	O
reviewing	O
the	O
literature	O
there	O
is	O
one	O
case	O
report	O
of	O
myxedema	O
coma	O
during	O
long	O
term	O
amiodarone	B-CHED
therapy	O
.	O

Myxedema	O
coma	O
is	O
a	O
life	O
threatening	O
condition	O
that	O
carries	O
a	O
mortality	O
reaching	O
as	O
high	O
as	O
20	O
%	O
with	O
treatment	O
.	O

The	O
condition	O
is	O
treated	O
with	O
intravenous	O
thyroxine	B-CHED
(	O
T4	B-CHED
)	O
or	O
intravenous	O
tri	B-CHED
-	I-CHED
iodo	I-CHED
-	I-CHED
thyronine	I-CHED
(	O
T3	B-CHED
)	O
.	O

Patients	O
with	O
CHF	O
on	O
amiodarone	B-CHED
may	O
suffer	O
serious	O
morbidity	O
and	O
mortality	O
from	O
hypothyroidism	O
,	O
and	O
thus	O
may	O
deserve	O
closer	O
follow	O
up	O
for	O
thyroid	O
stimulating	O
hormone	O
(	O
TSH	O
)	O
levels	O
.	O

This	O
case	O
report	O
carries	O
an	O
important	O
clinical	O
application	O
given	O
the	O
frequent	O
usage	O
of	O
amiodarone	B-CHED
among	O
CHF	O
patients	O
.	O

The	O
myriad	O
clinical	O
presentation	O
of	O
myxedema	O
coma	O
and	O
its	O
serious	O
morbidity	O
and	O
mortality	O
stresses	O
the	O
need	O
to	O
suspect	O
this	O
clinical	O
syndrome	O
among	O
CHF	O
patients	O
presenting	O
with	O
hypotension	O
,	O
weakness	O
or	O
other	O
unexplained	O
symptoms	O
.	O

Effects	O
of	O
active	O
constituents	O
of	O
Crocus	O
sativus	O
L	O
.	O
,	O
crocin	B-CHED
on	O
streptozocin	B-CHED
-	O
induced	O
model	O
of	O
sporadic	O
Alzheimer	O
'	O
s	O
disease	O
in	O
male	O
rats	O
.	O

BACKGROUND	O
:	O
The	O
involvement	O
of	O
water	O
-	O
soluble	O
carotenoids	B-CHED
,	O
crocins	B-CHED
,	O
as	O
the	O
main	O
and	O
active	O
components	O
of	O
Crocus	O
sativus	O
L	O
.	O
extract	O
in	O
learning	O
and	O
memory	O
processes	O
has	O
been	O
proposed	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
effect	O
of	O
crocins	B-CHED
on	O
sporadic	O
Alzheimer	O
'	O
s	O
disease	O
induced	O
by	O
intracerebroventricular	O
(	O
icv	O
)	O
streptozocin	B-CHED
(	O
STZ	B-CHED
)	O
in	O
male	O
rats	O
was	O
investigated	O
.	O

METHODS	O
:	O
Male	O
adult	O
Wistar	O
rats	O
(	O
n	O
=	O
90	O
and	O
260	O
-	O
290	O
g	O
)	O
were	O
divided	O
into	O
1	O
,	O
control	O
;	O
2	O
and	O
3	O
,	O
crocins	B-CHED
(	O
15	O
and	O
30	O
mg	O
/	O
kg	O
)	O
;	O
4	O
,	O
STZ	B-CHED
;	O
5	O
and	O
6	O
,	O
STZ	B-CHED
+	O
crocins	B-CHED
(	O
15	O
and	O
30	O
mg	O
/	O
kg	O
)	O
groups	O
.	O

In	O
Alzheimer	O
'	O
s	O
disease	O
groups	O
,	O
rats	O
were	O
injected	O
with	O
STZ	B-CHED
-	O
icv	O
bilaterally	O
(	O
3	O
mg	O
/	O
kg	O
)	O
in	O
first	O
day	O
and	O
3	O
days	O
later	O
,	O
a	O
similar	O
STZ	B-CHED
-	O
icv	O
application	O
was	O
repeated	O
.	O

In	O
STZ	B-CHED
+	O
crocin	B-CHED
animal	O
groups	O
,	O
crocin	B-CHED
was	O
applied	O
in	O
doses	O
of	O
15	O
and	O
30	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
,	O
one	O
day	O
pre	O
-	O
surgery	O
and	O
continued	O
for	O
three	O
weeks	O
.	O

Prescription	O
of	O
crocin	B-CHED
in	O
each	O
dose	O
was	O
repeated	O
once	O
for	O
two	O
days	O
.	O

However	O
,	O
the	O
learning	O
and	O
memory	O
performance	O
was	O
assessed	O
using	O
passive	O
avoidance	O
paradigm	O
,	O
and	O
for	O
spatial	O
cognition	O
evaluation	O
,	O
Y	O
-	O
maze	O
task	O
was	O
used	O
.	O

RESULTS	O
:	O
It	O
was	O
found	O
out	O
that	O
crocin	B-CHED
(	O
30	O
mg	O
/	O
kg	O
)	O
-	O
treated	O
STZ	B-CHED
-	O
injected	O
rats	O
show	O
higher	O
correct	O
choices	O
and	O
lower	O
errors	O
in	O
Y	O
-	O
maze	O
than	O
vehicle	O
-	O
treated	O
STZ	B-CHED
-	O
injected	O
rats	O
.	O

In	O
addition	O
,	O
crocin	B-CHED
in	O
the	O
mentioned	O
dose	O
could	O
significantly	O
attenuated	O
learning	O
and	O
memory	O
impairment	O
in	O
treated	O
STZ	B-CHED
-	O
injected	O
group	O
in	O
passive	O
avoidance	O
test	O
.	O

CONCLUSION	O
:	O
Therefore	O
,	O
these	O
results	O
demonstrate	O
the	O
effectiveness	O
of	O
crocin	B-CHED
(	O
30	O
mg	O
/	O
kg	O
)	O
in	O
antagonizing	O
the	O
cognitive	O
deficits	O
caused	O
by	O
STZ	B-CHED
-	O
icv	O
in	O
rats	O
and	O
its	O
potential	O
in	O
the	O
treatment	O
of	O
neurodegenerative	O
diseases	O
such	O
as	O
Alzheimer	O
'	O
s	O
disease	O
.	O

Serotonin	B-CHED
6	O
receptor	O
gene	O
is	O
associated	O
with	O
methamphetamine	B-CHED
-	O
induced	O
psychosis	O
in	O
a	O
Japanese	O
population	O
.	O

BACKGROUND	O
:	O
Altered	O
serotonergic	O
neural	O
transmission	O
is	O
hypothesized	O
to	O
be	O
a	O
susceptibility	O
factor	O
for	O
psychotic	O
disorders	O
such	O
as	O
schizophrenia	O
.	O

The	O
serotonin	B-CHED
6	O
(	O
5	B-CHED
-	I-CHED
HT6	I-CHED
)	O
receptor	O
is	O
therapeutically	O
targeted	O
by	O
several	O
second	O
generation	O
antipsychotics	O
,	O
such	O
as	O
clozapine	B-CHED
and	O
olanzapine	B-CHED
,	O
and	O
d	B-CHED
-	I-CHED
amphetamine	I-CHED
-	O
induced	O
hyperactivity	O
in	O
rats	O
is	O
corrected	O
with	O
the	O
use	O
of	O
a	O
selective	O
5	B-CHED
-	I-CHED
HT6	I-CHED
receptor	O
antagonist	O
.	O

In	O
addition	O
,	O
the	O
disrupted	O
prepulse	O
inhibition	O
induced	O
by	O
d	B-CHED
-	I-CHED
amphetamine	I-CHED
or	O
phencyclidine	B-CHED
was	O
restored	O
by	O
5	B-CHED
-	I-CHED
HT6	I-CHED
receptor	O
antagonist	O
in	O
an	O
animal	O
study	O
using	O
rats	O
.	O

These	O
animal	O
models	O
were	O
considered	O
to	O
reflect	O
the	O
positive	O
symptoms	O
of	O
schizophrenia	O
,	O
and	O
the	O
above	O
evidence	O
suggests	O
that	O
altered	O
5	B-CHED
-	I-CHED
HT6	I-CHED
receptors	O
are	O
involved	O
in	O
the	O
pathophysiology	O
of	O
psychotic	O
disorders	O
.	O

The	O
symptoms	O
of	O
methamphetamine	B-CHED
(	O
METH	B-CHED
)	O
-	O
induced	O
psychosis	O
are	O
similar	O
to	O
those	O
of	O
paranoid	O
type	O
schizophrenia	O
.	O

Therefore	O
,	O
we	O
conducted	O
an	O
analysis	O
of	O
the	O
association	O
of	O
the	O
5	B-CHED
-	I-CHED
HT6	I-CHED
gene	O
(	O
HTR6	O
)	O
with	O
METH	B-CHED
-	O
induced	O
psychosis	O
.	O

METHOD	O
:	O
Using	O
five	O
tagging	O
SNPs	O
(	O
rs6693503	O
,	O
rs1805054	O
,	O
rs4912138	O
,	O
rs3790757	O
and	O
rs9659997	O
)	O
,	O
we	O
conducted	O
a	O
genetic	O
association	O
analysis	O
of	O
case	O
-	O
control	O
samples	O
(	O
197	O
METH	B-CHED
-	O
induced	O
psychosis	O
patients	O
and	O
337	O
controls	O
)	O
in	O
the	O
Japanese	O
population	O
.	O

The	O
age	O
and	O
sex	O
of	O
the	O
control	O
subjects	O
did	O
not	O
differ	O
from	O
those	O
of	O
the	O
methamphetamine	B-CHED
dependence	O
patients	O
.	O

RESULTS	O
:	O
rs6693503	O
was	O
associated	O
with	O
METH	B-CHED
-	O
induced	O
psychosis	O
patients	O
in	O
the	O
allele	O
/	O
genotype	O
-	O
wise	O
analysis	O
.	O

Moreover	O
,	O
this	O
association	O
remained	O
significant	O
after	O
Bonferroni	O
correction	O
.	O

In	O
the	O
haplotype	O
-	O
wise	O
analysis	O
,	O
we	O
detected	O
an	O
association	O
between	O
two	O
markers	O
(	O
rs6693503	O
and	O
rs1805054	O
)	O
and	O
three	O
markers	O
(	O
rs6693503	O
,	O
rs1805054	O
and	O
rs4912138	O
)	O
in	O
HTR6	O
and	O
METH	B-CHED
-	O
induced	O
psychosis	O
patients	O
,	O
respectively	O
.	O

CONCLUSION	O
:	O
HTR6	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathophysiology	O
of	O
METH	B-CHED
-	O
induced	O
psychosis	O
in	O
the	O
Japanese	O
population	O
.	O

Neural	O
correlates	O
of	O
S	B-CHED
-	I-CHED
ketamine	I-CHED
induced	O
psychosis	O
during	O
overt	O
continuous	O
verbal	O
fluency	O
.	O

The	O
glutamatergic	O
N	B-CHED
-	I-CHED
methyl	I-CHED
-	I-CHED
D	I-CHED
-	I-CHED
aspartate	I-CHED
(	O
NMDA	B-CHED
)	O
receptor	O
has	O
been	O
implicated	O
in	O
the	O
pathophysiology	O
of	O
schizophrenia	O
.	O

Administered	O
to	O
healthy	O
volunteers	O
,	O
a	O
subanesthetic	O
dose	O
of	O
the	O
non	O
-	O
competitive	O
NMDA	B-CHED
receptor	O
antagonist	O
ketamine	B-CHED
leads	O
to	O
psychopathological	O
symptoms	O
similar	O
to	O
those	O
observed	O
in	O
schizophrenia	O
.	O

In	O
patients	O
with	O
schizophrenia	O
,	O
ketamine	B-CHED
exacerbates	O
the	O
core	O
symptoms	O
of	O
illness	O
,	O
supporting	O
the	O
hypothesis	O
of	O
a	O
glutamatergic	O
dysfunction	O
.	O

In	O
a	O
counterbalanced	O
,	O
placebo	O
-	O
controlled	O
,	O
double	O
-	O
blind	O
study	O
design	O
,	O
healthy	O
subjects	O
were	O
administered	O
a	O
continuous	O
subanesthetic	O
S	B-CHED
-	I-CHED
ketamine	I-CHED
infusion	O
while	O
differences	O
in	O
BOLD	O
responses	O
measured	O
with	O
fMRI	O
were	O
detected	O
.	O

During	O
the	O
scanning	O
period	O
,	O
subjects	O
performed	O
continuous	O
overt	O
verbal	O
fluency	O
tasks	O
(	O
phonological	O
,	O
lexical	O
and	O
semantic	O
)	O
.	O

Ketamine	B-CHED
-	O
induced	O
psychopathological	O
symptoms	O
were	O
assessed	O
with	O
the	O
Positive	O
and	O
Negative	O
Syndrome	O
Scale	O
(	O
PANSS	O
)	O
.	O

Ketamine	B-CHED
elicited	O
psychosis	O
like	O
psychopathology	O
.	O

Post	O
-	O
hoc	O
t	O
-	O
tests	O
revealed	O
significant	O
differences	O
between	O
placebo	O
and	O
ketamine	B-CHED
for	O
the	O
amounts	O
of	O
words	O
generated	O
during	O
lexical	O
and	O
semantic	O
verbal	O
fluency	O
,	O
while	O
the	O
phonological	O
domain	O
remained	O
unaffected	O
.	O

Ketamine	B-CHED
led	O
to	O
enhanced	O
cortical	O
activations	O
in	O
supramarginal	O
and	O
frontal	O
brain	O
regions	O
for	O
phonological	O
and	O
lexical	O
verbal	O
fluency	O
,	O
but	O
not	O
for	O
semantic	O
verbal	O
fluency	O
.	O

Ketamine	B-CHED
induces	O
activation	O
changes	O
in	O
healthy	O
subjects	O
similar	O
to	O
those	O
observed	O
in	O
patients	O
with	O
schizophrenia	O
,	O
particularly	O
in	O
frontal	O
and	O
temporal	O
brain	O
regions	O
.	O

Our	O
results	O
provide	O
further	O
support	O
for	O
the	O
hypothesis	O
of	O
an	O
NMDA	B-CHED
receptor	O
dysfunction	O
in	O
the	O
pathophysiology	O
of	O
schizophrenia	O
.	O

Long	O
-	O
term	O
prognosis	O
for	O
transplant	O
-	O
free	O
survivors	O
of	O
paracetamol	B-CHED
-	O
induced	O
acute	O
liver	O
failure	O
.	O

BACKGROUND	O
:	O
The	O
prognosis	O
for	O
transplant	O
-	O
free	O
survivors	O
of	O
paracetamol	B-CHED
-	O
induced	O
acute	O
liver	O
failure	O
remains	O
unknown	O
.	O

AIM	O
:	O
To	O
examine	O
whether	O
paracetamol	B-CHED
-	O
induced	O
acute	O
liver	O
failure	O
increases	O
long	O
-	O
term	O
mortality	O
.	O

METHODS	O
:	O
We	O
followed	O
up	O
all	O
transplant	O
-	O
free	O
survivors	O
of	O
paracetamol	B-CHED
-	O
induced	O
acute	O
liver	O
injury	O
,	O
hospitalized	O
in	O
a	O
Danish	O
national	O
referral	O
centre	O
during	O
1984	O
-	O
2004	O
.	O

We	O
compared	O
age	O
-	O
specific	O
mortality	O
rates	O
from	O
1	O
year	O
post	O
-	O
discharge	O
through	O
2008	O
between	O
those	O
in	O
whom	O
the	O
liver	O
injury	O
led	O
to	O
an	O
acute	O
liver	O
failure	O
and	O
those	O
in	O
whom	O
it	O
did	O
not	O
.	O

RESULTS	O
:	O
We	O
included	O
641	O
patients	O
.	O

On	O
average	O
,	O
age	O
-	O
specific	O
mortality	O
rates	O
were	O
slightly	O
higher	O
for	O
the	O
101	O
patients	O
whose	O
paracetamol	B-CHED
-	O
induced	O
liver	O
injury	O
had	O
caused	O
an	O
acute	O
liver	O
failure	O
(	O
adjusted	O
mortality	O
rate	O
ratio	O
=	O
1	O
.	O
70	O
,	O
95	O
%	O
CI	O
1	O
.	O
02	O
-	O
2	O
.	O
85	O
)	O
,	O
but	O
the	O
association	O
was	O
age	O
-	O
dependent	O
,	O
and	O
no	O
survivors	O
of	O
acute	O
liver	O
failure	O
died	O
of	O
liver	O
disease	O
,	O
whereas	O
suicides	O
were	O
frequent	O
in	O
both	O
groups	O
.	O

These	O
observations	O
speak	O
against	O
long	O
-	O
term	O
effects	O
of	O
acute	O
liver	O
failure	O
.	O

More	O
likely	O
,	O
the	O
elevated	O
mortality	O
rate	O
ratio	O
resulted	O
from	O
incomplete	O
adjustment	O
for	O
the	O
greater	O
prevalence	O
of	O
substance	O
abuse	O
among	O
survivors	O
of	O
acute	O
liver	O
failure	O
.	O

CONCLUSIONS	O
:	O
Paracetamol	B-CHED
-	O
induced	O
acute	O
liver	O
failure	O
did	O
not	O
affect	O
long	O
-	O
term	O
mortality	O
.	O

Clinical	O
follow	O
-	O
up	O
may	O
be	O
justified	O
by	O
the	O
cause	O
of	O
the	O
liver	O
failure	O
,	O
but	O
not	O
by	O
the	O
liver	O
failure	O
itself	O
.	O

In	O
vivo	O
characterization	O
of	O
a	O
dual	O
adenosine	B-CHED
A2A	I-CHED
/	I-CHED
A1	I-CHED
receptor	I-CHED
antagonist	I-CHED
in	O
animal	O
models	O
of	O
Parkinson	O
'	O
s	O
disease	O
.	O

The	O
in	O
vivo	O
characterization	O
of	O
a	O
dual	O
adenosine	B-CHED
A	I-CHED
(	I-CHED
2A	I-CHED
)	I-CHED
/	I-CHED
A	I-CHED
(	I-CHED
1	I-CHED
)	I-CHED
receptor	I-CHED
antagonist	I-CHED
in	O
several	O
animal	O
models	O
of	O
Parkinson	O
'	O
s	O
disease	O
is	O
described	O
.	O

Discovery	O
and	O
scale	O
-	O
up	O
syntheses	O
of	O
compound	O
1	O
are	O
described	O
in	O
detail	O
,	O
highlighting	O
optimization	O
steps	O
that	O
increased	O
the	O
overall	O
yield	O
of	O
1	O
from	O
10	O
.	O
0	O
%	O
to	O
30	O
.	O
5	O
%	O
.	O

Compound	O
1	O
is	O
a	O
potent	O
A	O
(	O
2A	O
)	O
/	O
A	O
(	O
1	O
)	O
receptor	O
antagonist	O
in	O
vitro	O
(	O
A	O
(	O
2A	O
)	O
K	O
(	O
i	O
)	O
=	O
4	O
.	O
1	O
nM	O
;	O
A	O
(	O
1	O
)	O
K	O
(	O
i	O
)	O
=	O
17	O
.	O
0	O
nM	O
)	O
that	O
has	O
excellent	O
activity	O
,	O
after	O
oral	O
administration	O
,	O
across	O
a	O
number	O
of	O
animal	O
models	O
of	O
Parkinson	O
'	O
s	O
disease	O
including	O
mouse	O
and	O
rat	O
models	O
of	O
haloperidol	B-CHED
-	O
induced	O
catalepsy	O
,	O
mouse	O
model	O
of	O
reserpine	B-CHED
-	O
induced	O
akinesia	O
,	O
rat	O
6	B-CHED
-	I-CHED
hydroxydopamine	I-CHED
(	O
6	B-CHED
-	I-CHED
OHDA	I-CHED
)	O
lesion	O
model	O
of	O
drug	O
-	O
induced	O
rotation	O
,	O
and	O
MPTP	B-CHED
-	O
treated	O
non	O
-	O
human	O
primate	O
model	O
.	O

Effects	O
of	O
the	O
hippocampal	O
deep	O
brain	O
stimulation	O
on	O
cortical	O
epileptic	O
discharges	O
in	O
penicillin	B-CHED
-	O
induced	O
epilepsy	O
model	O
in	O
rats	O
.	O

AIM	O
:	O
Experimental	O
and	O
clinical	O
studies	O
have	O
revealed	O
that	O
hippocampal	O
DBS	O
can	O
control	O
epileptic	O
activity	O
,	O
but	O
the	O
mechanism	O
of	O
action	O
is	O
obscure	O
and	O
optimal	O
stimulation	O
parameters	O
are	O
not	O
clearly	O
defined	O
.	O

The	O
aim	O
was	O
to	O
evaluate	O
the	O
effects	O
of	O
high	O
frequency	O
hippocampal	O
stimulation	O
on	O
cortical	O
epileptic	O
activity	O
in	O
penicillin	B-CHED
-	O
induced	O
epilepsy	O
model	O
.	O

MATERIAL	O
AND	O
METHODS	O
:	O
Twenty	O
-	O
five	O
Sprague	O
-	O
Dawley	O
rats	O
were	O
implanted	O
DBS	O
electrodes	O
.	O

In	O
group	O
-	O
1	O
(	O
n	O
=	O
10	O
)	O
hippocampal	O
DBS	O
was	O
off	O
and	O
in	O
the	O
group	O
-	O
2	O
(	O
n	O
=	O
10	O
)	O
hippocampal	O
DBS	O
was	O
on	O
(	O
185	O
Hz	O
,	O
0	O
.	O
5V	O
,	O
1V	O
,	O
2V	O
,	O
and	O
5V	O
for	O
60	O
sec	O
)	O
following	O
penicillin	B-CHED
G	I-CHED
injection	O
intracortically	O
.	O

In	O
the	O
control	O
group	O
hippocampal	O
DBS	O
was	O
on	O
following	O
8	O
l	O
saline	O
injection	O
intracortically	O
.	O

EEG	O
recordings	O
were	O
obtained	O
before	O
and	O
15	O
minutes	O
following	O
penicillin	B-CHED
-	I-CHED
G	I-CHED
injection	O
,	O
and	O
at	O
10th	O
minutes	O
following	O
each	O
stimulus	O
for	O
analysis	O
in	O
terms	O
of	O
frequency	O
,	O
amplitude	O
,	O
and	O
power	O
spectrum	O
.	O

RESULTS	O
:	O
High	O
frequency	O
hippocampal	O
DBS	O
suppressed	O
the	O
acute	O
penicillin	B-CHED
-	O
induced	O
cortical	O
epileptic	O
activity	O
independent	O
from	O
stimulus	O
intensity	O
.	O

In	O
the	O
control	O
group	O
,	O
hippocampal	O
stimulation	O
alone	O
lead	O
only	O
to	O
diffuse	O
slowing	O
of	O
cerebral	O
bioelectrical	O
activity	O
at	O
5V	O
stimulation	O
.	O

CONCLUSION	O
:	O
Our	O
results	O
revealed	O
that	O
continuous	O
high	O
frequency	O
stimulation	O
of	O
the	O
hippocampus	O
suppressed	O
acute	O
cortical	O
epileptic	O
activity	O
effectively	O
without	O
causing	O
secondary	O
epileptic	O
discharges	O
.	O

These	O
results	O
are	O
important	O
in	O
terms	O
of	O
defining	O
the	O
optimal	O
parameters	O
of	O
hippocampal	O
DBS	O
in	O
patients	O
with	O
epilepsy	O
.	O

CCNU	B-CHED
(	O
lomustine	B-CHED
)	O
toxicity	O
in	O
dogs	O
:	O
a	O
retrospective	O
study	O
(	O
2002	O
-	O
07	O
)	O
.	O

OBJECTIVE	O
:	O
To	O
describe	O
the	O
incidence	O
of	O
haematological	O
,	O
renal	O
,	O
hepatic	O
and	O
gastrointestinal	O
toxicities	O
in	O
tumour	O
-	O
bearing	O
dogs	O
receiving	O
1	B-CHED
-	I-CHED
(	I-CHED
2	I-CHED
-	I-CHED
chloroethyl	I-CHED
)	I-CHED
-	I-CHED
3	I-CHED
-	I-CHED
cyclohexyl	I-CHED
-	I-CHED
1	I-CHED
-	I-CHED
nitrosourea	I-CHED
(	O
CCNU	B-CHED
)	O
.	O

DESIGN	O
:	O
The	O
medical	O
records	O
of	O
206	O
dogs	O
that	O
were	O
treated	O
with	O
CCNU	B-CHED
at	O
the	O
Melbourne	O
Veterinary	O
Specialist	O
Centre	O
between	O
February	O
2002	O
and	O
December	O
2007	O
were	O
retrospectively	O
evaluated	O
.	O

RESULTS	O
:	O
Of	O
the	O
206	O
dogs	O
treated	O
with	O
CCNU	B-CHED
,	O
185	O
met	O
the	O
inclusion	O
criteria	O
for	O
at	O
least	O
one	O
class	O
of	O
toxicity	O
.	O

CCNU	B-CHED
was	O
used	O
most	O
commonly	O
in	O
the	O
treatment	O
of	O
lymphoma	O
,	O
mast	O
cell	O
tumour	O
,	O
brain	O
tumour	O
,	O
histiocytic	O
tumours	O
and	O
epitheliotropic	O
lymphoma	O
.	O

Throughout	O
treatment	O
,	O
56	O
.	O
9	O
%	O
of	O
dogs	O
experienced	O
neutropenia	O
,	O
34	O
.	O
2	O
%	O
experienced	O
anaemia	O
and	O
14	O
.	O
2	O
%	O
experienced	O
thrombocytopenia	O
.	O

Gastrointestinal	O
toxicosis	O
was	O
detected	O
in	O
37	O
.	O
8	O
%	O
of	O
dogs	O
,	O
the	O
most	O
common	O
sign	O
of	O
which	O
was	O
vomiting	O
(	O
24	O
.	O
3	O
%	O
)	O
.	O

Potential	O
renal	O
toxicity	O
and	O
elevated	O
alanine	B-CHED
transaminase	O
(	O
ALT	O
)	O
concentration	O
were	O
reported	O
in	O
12	O
.	O
2	O
%	O
and	O
48	O
.	O
8	O
%	O
of	O
dogs	O
,	O
respectively	O
.	O

The	O
incidence	O
of	O
hepatic	O
failure	O
was	O
1	O
.	O
2	O
%	O
.	O

CONCLUSIONS	O
:	O
CCNU	B-CHED
-	O
associated	O
toxicity	O
in	O
dogs	O
is	O
common	O
,	O
but	O
is	O
usually	O
not	O
life	O
threatening	O
.	O

Central	O
vein	O
thrombosis	O
and	O
topical	O
dipivalyl	B-CHED
epinephrine	I-CHED
.	O

A	O
report	O
is	O
given	O
on	O
an	O
83	O
-	O
year	O
-	O
old	O
female	O
who	O
acquired	O
central	O
vein	O
thrombosis	O
in	O
her	O
seeing	O
eye	O
one	O
day	O
after	O
having	O
started	O
topical	O
medication	O
with	O
dipivalyl	B-CHED
epinephrine	I-CHED
for	O
advanced	O
glaucoma	O
discovered	O
in	O
the	O
other	O
eye	O
.	O

From	O
present	O
knowledge	O
about	O
the	O
effects	O
of	O
adrenergic	O
eye	O
drops	O
on	O
ocular	O
blood	O
circulation	O
,	O
it	O
is	O
difficult	O
to	O
suggest	O
an	O
association	O
between	O
the	O
two	O
events	O
,	O
which	O
may	O
be	O
coincidental	O
only	O
.	O

Benzylacyclouridine	B-CHED
reverses	O
azidothymidine	B-CHED
-	O
induced	O
marrow	O
suppression	O
without	O
impairment	O
of	O
anti	O
-	O
human	O
immunodeficiency	O
virus	O
activity	O
.	O

Increased	O
extracellular	O
concentrations	O
of	O
uridine	B-CHED
(	O
Urd	B-CHED
)	O
have	O
been	O
reported	O
to	O
reduce	O
,	O
in	O
vitro	O
,	O
azidothymidine	B-CHED
(	O
AZT	B-CHED
)	O
-	O
induced	O
inhibition	O
of	O
human	O
granulocyte	O
-	O
macrophage	O
progenitor	O
cells	O
without	O
impairment	O
of	O
its	O
antihuman	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
activity	O
.	O

Because	O
of	O
the	O
clinical	O
toxicities	O
associated	O
with	O
chronic	O
Urd	B-CHED
administration	O
,	O
the	O
ability	O
of	O
benzylacyclouridine	B-CHED
(	O
BAU	B-CHED
)	O
to	O
effect	O
,	O
in	O
vivo	O
,	O
AZT	B-CHED
-	O
induced	O
anemia	O
and	O
leukopenia	O
was	O
assessed	O
.	O

This	O
agent	O
inhibits	O
Urd	B-CHED
catabolism	O
and	O
,	O
in	O
vivo	O
,	O
increases	O
the	O
plasma	O
concentration	O
of	O
Urd	B-CHED
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
without	O
Urd	B-CHED
-	O
related	O
toxicity	O
.	O

In	O
mice	O
rendered	O
anemic	O
and	O
leukopenic	O
by	O
the	O
administration	O
of	O
AZT	B-CHED
for	O
28	O
days	O
in	O
drinking	O
water	O
(	O
1	O
.	O
5	O
mg	O
/	O
mL	O
)	O
,	O
the	O
continued	O
administration	O
of	O
AZT	B-CHED
plus	O
daily	O
BAU	B-CHED
(	O
300	O
mg	O
/	O
kg	O
,	O
orally	O
)	O
partially	O
reversed	O
AZT	B-CHED
-	O
induced	O
anemia	O
and	O
leukopenia	O
(	O
P	O
less	O
than	O
.	O
05	O
)	O
,	O
increased	O
peripheral	O
reticulocytes	O
(	O
to	O
4	O
.	O
9	O
%	O
,	O
P	O
less	O
than	O
.	O
01	O
)	O
,	O
increased	O
cellularity	O
in	O
the	O
marrow	O
,	O
and	O
improved	O
megaloblastosis	O
.	O

When	O
coadministered	O
with	O
AZT	B-CHED
from	O
the	O
onset	O
of	O
drug	O
administration	O
,	O
BAU	B-CHED
reduced	O
AZT	B-CHED
-	O
induced	O
marrow	O
toxicity	O
.	O

In	O
vitro	O
,	O
at	O
a	O
concentration	O
of	O
100	O
mumol	O
/	O
L	O
,	O
BAU	B-CHED
possesses	O
minimal	O
anti	O
-	O
HIV	O
activity	O
and	O
has	O
no	O
effect	O
on	O
the	O
ability	O
of	O
AZT	B-CHED
to	O
reverse	O
the	O
HIV	O
-	O
induced	O
cytopathic	O
effect	O
in	O
MT4	O
cells	O
.	O

The	O
clinical	O
and	O
biochemical	O
implications	O
of	O
these	O
findings	O
are	O
discussed	O
.	O

Lethal	O
anuria	O
complicating	O
high	O
dose	O
ifosfamide	B-CHED
chemotherapy	O
in	O
a	O
breast	O
cancer	O
patient	O
with	O
an	O
impaired	O
renal	O
function	O
.	O

A	O
sixty	O
-	O
year	O
-	O
old	O
woman	O
with	O
advanced	O
breast	O
cancer	O
,	O
previously	O
treated	O
with	O
cisplatin	B-CHED
,	O
developed	O
an	O
irreversible	O
lethal	O
renal	O
failure	O
with	O
anuria	O
,	O
the	O
day	O
after	O
5	O
g	O
/	O
m2	O
bolus	O
ifosfamide	B-CHED
.	O

Postrenal	O
failure	O
was	O
excluded	O
by	O
echography	O
.	O

A	O
prerenal	O
component	O
could	O
have	O
contributed	O
to	O
renal	O
failure	O
because	O
of	O
a	O
transient	O
hypotension	O
,	O
due	O
to	O
an	O
increasing	O
ascitis	O
,	O
occurring	O
just	O
before	O
anuria	O
.	O

However	O
,	O
correction	O
of	O
the	O
hemodynamic	O
parameters	O
did	O
not	O
improve	O
renal	O
function	O
.	O

Ifosfamide	B-CHED
is	O
a	O
known	O
nephrotoxic	O
drug	O
with	O
demonstrated	O
tubulopathies	O
.	O

We	O
strongly	O
suspect	O
that	O
this	O
lethal	O
anuria	O
was	O
mainly	O
due	O
to	O
ifosfamide	B-CHED
,	O
occurring	O
in	O
a	O
patient	O
having	O
received	O
previous	O
cisplatin	B-CHED
chemotherapy	O
and	O
with	O
poor	O
kidney	O
perfusion	O
due	O
to	O
transient	O
hypotension	O
.	O

We	O
recommend	O
careful	O
use	O
of	O
ifosfamide	B-CHED
in	O
patients	O
pretreated	O
with	O
nephrotoxic	O
chemotherapy	O
and	O
inadequate	O
renal	O
perfusion	O
.	O

Nociceptive	O
effects	O
induced	O
by	O
intrathecal	O
administration	O
of	O
prostaglandin	B-CHED
D2	I-CHED
,	I-CHED
E2	I-CHED
,	I-CHED
or	I-CHED
F2	I-CHED
alpha	I-CHED
to	O
conscious	O
mice	O
.	O

The	O
effects	O
of	O
intrathecal	O
administration	O
of	O
prostaglandins	B-CHED
on	O
pain	O
responses	O
in	O
conscious	O
mice	O
were	O
evaluated	O
by	O
using	O
hot	O
plate	O
and	O
acetic	B-CHED
acid	I-CHED
writhing	O
tests	O
.	O

Prostaglandin	B-CHED
D2	I-CHED
(	O
0	O
.	O
5	O
-	O
3	O
ng	O
/	O
mouse	O
)	O
had	O
a	O
hyperalgesic	O
action	O
on	O
the	O
response	O
to	O
a	O
hot	O
plate	O
during	O
a	O
3	O
-	O
60	O
min	O
period	O
after	O
injection	O
.	O

Prostaglandin	B-CHED
E2	I-CHED
showed	O
a	O
hyperalgesic	O
effect	O
at	O
doses	O
of	O
1	O
pg	B-CHED
to	O
10	O
ng	O
/	O
mouse	O
,	O
but	O
the	O
effect	O
lasted	O
shorter	O
(	O
3	O
-	O
30	O
min	O
)	O
than	O
that	O
of	O
prostaglandin	B-CHED
D2	I-CHED
.	O

Similar	O
results	O
were	O
obtained	O
by	O
acetic	B-CHED
acid	I-CHED
writhing	O
tests	O
.	O

The	O
hyperalgesic	O
effect	O
of	O
prostaglandin	B-CHED
D2	I-CHED
was	O
blocked	O
by	O
simultaneous	O
injection	O
of	O
a	O
substance	O
P	O
antagonist	O
(	O
greater	O
than	O
or	O
equal	O
to	O
100	O
ng	O
)	O
but	O
not	O
by	O
AH6809	B-CHED
,	O
a	O
prostanoid	O
EP1	O
-	O
receptor	O
antagonist	O
.	O

Conversely	O
,	O
prostaglandin	B-CHED
E2	I-CHED
-	O
induced	O
hyperalgesia	O
was	O
blocked	O
by	O
AH6809	B-CHED
(	O
greater	O
than	O
or	O
equal	O
to	O
500	O
ng	O
)	O
but	O
not	O
by	O
the	O
substance	O
P	O
antagonist	O
.	O

Prostaglandin	B-CHED
F2	I-CHED
alpha	I-CHED
had	O
little	O
effect	O
on	O
pain	O
responses	O
.	O

These	O
results	O
demonstrate	O
that	O
both	O
prostaglandin	B-CHED
D2	I-CHED
and	O
prostaglandin	B-CHED
E2	I-CHED
exert	O
hyperalgesia	O
in	O
the	O
spinal	O
cord	O
,	O
but	O
in	O
different	O
ways	O
.	O

D	B-CHED
-	I-CHED
penicillamine	I-CHED
in	O
the	O
treatment	O
of	O
localized	O
scleroderma	O
.	O

Localized	O
scleroderma	O
has	O
no	O
recognized	O
internal	O
organ	O
involvement	O
but	O
may	O
be	O
disfiguring	O
and	O
disabling	O
when	O
the	O
cutaneous	O
lesions	O
are	O
extensive	O
or	O
affect	O
children	O
.	O

There	O
is	O
no	O
accepted	O
or	O
proven	O
treatment	O
for	O
localized	O
scleroderma	O
.	O

Case	O
reports	O
of	O
11	O
patients	O
with	O
severe	O
,	O
extensive	O
localized	O
scleroderma	O
who	O
were	O
treated	O
with	O
D	B-CHED
-	I-CHED
penicillamine	I-CHED
are	O
summarized	O
in	O
this	O
article	O
.	O

This	O
drug	O
was	O
judged	O
to	O
have	O
a	O
favorable	O
effect	O
on	O
the	O
disease	O
course	O
in	O
7	O
(	O
64	O
%	O
)	O
of	O
11	O
patients	O
.	O

Improvement	O
began	O
within	O
3	O
to	O
6	O
months	O
and	O
consisted	O
of	O
cessation	O
of	O
active	O
cutaneous	O
lesions	O
in	O
all	O
7	O
patients	O
,	O
skin	O
softening	O
in	O
5	O
,	O
and	O
more	O
normal	O
growth	O
of	O
the	O
affected	O
limb	O
in	O
2	O
of	O
3	O
children	O
.	O

Joint	O
stiffness	O
and	O
contractures	O
also	O
improved	O
.	O

The	O
dose	O
of	O
D	B-CHED
-	I-CHED
penicillamine	I-CHED
associated	O
with	O
a	O
favorable	O
response	O
was	O
as	O
low	O
as	O
2	O
to	O
5	O
mg	O
/	O
kg	O
per	O
day	O
given	O
over	O
a	O
period	O
ranging	O
from	O
15	O
to	O
53	O
months	O
.	O

D	B-CHED
-	I-CHED
Penicillamine	I-CHED
caused	O
nephrotic	O
syndrome	O
in	O
1	O
patient	O
and	O
milder	O
reversible	O
proteinuria	O
in	O
3	O
other	O
patients	O
;	O
none	O
developed	O
renal	O
insufficiency	O
.	O

These	O
data	O
suggest	O
that	O
D	B-CHED
-	I-CHED
penicillamine	I-CHED
may	O
be	O
effective	O
in	O
severe	O
cases	O
of	O
localized	O
scleroderma	O
.	O

Cerebral	O
sinus	O
thrombosis	O
as	O
a	O
potential	O
hazard	O
of	O
antifibrinolytic	O
treatment	O
in	O
menorrhagia	O
.	O

We	O
describe	O
a	O
42	O
-	O
year	O
-	O
old	O
woman	O
who	O
developed	O
superior	O
sagittal	O
and	O
left	O
transverse	O
sinus	O
thrombosis	O
associated	O
with	O
prolonged	O
epsilon	B-CHED
-	I-CHED
aminocaproic	I-CHED
acid	I-CHED
therapy	O
for	O
menorrhagia	O
.	O

This	O
antifibrinolytic	O
agent	O
has	O
been	O
used	O
in	O
women	O
with	O
menorrhagia	O
to	O
promote	O
clotting	O
and	O
reduce	O
blood	O
loss	O
.	O

Although	O
increased	O
risk	O
of	O
thromboembolic	O
disease	O
has	O
been	O
reported	O
during	O
treatment	O
with	O
epsilon	B-CHED
-	I-CHED
aminocaproic	I-CHED
acid	I-CHED
,	O
cerebral	O
sinus	O
thrombosis	O
has	O
not	O
been	O
previously	O
described	O
.	O

Careful	O
use	O
of	O
epsilon	B-CHED
-	I-CHED
aminocaproic	I-CHED
acid	I-CHED
therapy	O
is	O
recommended	O
.	O

Seizure	O
activity	O
with	O
imipenem	B-CHED
therapy	O
:	O
incidence	O
and	O
risk	O
factors	O
.	O

Two	O
elderly	O
patients	O
with	O
a	O
history	O
of	O
either	O
cerebral	O
vascular	O
accident	O
(	O
CVA	O
)	O
or	O
head	O
trauma	O
and	O
no	O
evidence	O
of	O
renal	O
disease	O
developed	O
seizures	O
while	O
receiving	O
maximum	O
doses	O
of	O
imipenem	B-CHED
/	I-CHED
cilastatin	I-CHED
.	O

Neither	O
patient	O
had	O
reported	O
previous	O
seizures	O
or	O
seizure	O
-	O
like	O
activity	O
nor	O
was	O
receiving	O
anticonvulsant	O
agents	O
.	O

All	O
seizures	O
were	O
controlled	O
with	O
therapeutic	O
doses	O
of	O
phenytoin	B-CHED
.	O

Both	O
patients	O
had	O
received	O
maximum	O
doses	O
of	O
other	O
beta	B-CHED
-	I-CHED
lactam	I-CHED
antibiotics	O
without	O
evidence	O
of	O
seizure	O
activity	O
.	O

Midline	O
B3	O
serotonin	B-CHED
nerves	O
in	O
rat	O
medulla	O
are	O
involved	O
in	O
hypotensive	O
effect	O
of	O
methyldopa	B-CHED
.	O

Previous	O
experiments	O
in	O
this	O
laboratory	O
have	O
shown	O
that	O
microinjection	O
of	O
methyldopa	B-CHED
onto	O
the	O
ventrolateral	O
cells	O
of	O
the	O
B3	O
serotonin	B-CHED
neurons	O
in	O
the	O
medulla	O
elicits	O
a	O
hypotensive	O
response	O
mediated	O
by	O
a	O
projection	O
descending	O
into	O
the	O
spinal	O
cord	O
.	O

The	O
present	O
experiments	O
were	O
designed	O
to	O
investigate	O
the	O
role	O
of	O
the	O
midline	O
cells	O
of	O
the	O
B3	O
serotonin	B-CHED
neurons	O
in	O
the	O
medulla	O
,	O
coinciding	O
with	O
the	O
raphe	O
magnus	O
.	O

In	O
spontaneously	O
hypertensive	O
,	O
stroke	O
-	O
prone	O
rats	O
,	O
microinjection	O
of	O
methyldopa	B-CHED
into	O
the	O
area	O
of	O
the	O
midline	O
B3	O
serotonin	B-CHED
cell	O
group	O
in	O
the	O
ventral	O
medulla	O
caused	O
a	O
potent	O
hypotension	O
of	O
30	O
-	O
40	O
mm	O
Hg	O
,	O
which	O
was	O
maximal	O
2	O
-	O
3	O
h	O
after	O
administration	O
and	O
was	O
abolished	O
by	O
the	O
serotonin	B-CHED
neurotoxin	O
5	B-CHED
,	I-CHED
7	I-CHED
-	I-CHED
dihydroxytryptamine	I-CHED
(	O
5	B-CHED
,	I-CHED
7	I-CHED
-	I-CHED
DHT	I-CHED
)	O
injected	O
intracerebroventricularly	O
.	O

However	O
,	O
intraspinal	O
injection	O
of	O
5	B-CHED
,	I-CHED
7	I-CHED
-	I-CHED
DHT	I-CHED
to	O
produce	O
a	O
more	O
selective	O
lesion	O
of	O
only	O
descending	O
serotonin	B-CHED
projections	O
in	O
the	O
spinal	O
cord	O
did	O
not	O
affect	O
this	O
hypotension	O
.	O

Further	O
,	O
5	B-CHED
,	I-CHED
7	I-CHED
-	I-CHED
DHT	I-CHED
lesion	O
of	O
serotonin	B-CHED
nerves	O
travelling	O
in	O
the	O
median	O
forebrain	O
bundle	O
,	O
one	O
of	O
the	O
main	O
ascending	O
pathways	O
from	O
the	O
B3	O
serotonin	B-CHED
cells	O
,	O
did	O
not	O
affect	O
the	O
fall	O
in	O
blood	O
pressure	O
associated	O
with	O
a	O
midline	O
B3	O
serotonin	B-CHED
methyldopa	B-CHED
injection	O
.	O

It	O
is	O
concluded	O
therefore	O
that	O
,	O
unlike	O
the	O
ventrolateral	O
B3	O
cells	O
which	O
mediate	O
a	O
methyldopa	B-CHED
-	O
induced	O
hypotension	O
via	O
descending	O
projections	O
,	O
the	O
midline	O
serotonin	B-CHED
B3	O
cells	O
in	O
the	O
medulla	O
contribute	O
to	O
the	O
hypotensive	O
action	O
of	O
methyldopa	B-CHED
,	O
either	O
by	O
way	O
of	O
an	O
ascending	O
projection	O
which	O
does	O
not	O
pass	O
through	O
the	O
median	O
forebrain	O
bundle	O
,	O
or	O
through	O
a	O
projection	O
restricted	O
to	O
the	O
caudal	O
brainstem	O
.	O

Antiarrhythmic	O
plasma	O
concentrations	O
of	O
cibenzoline	B-CHED
on	O
canine	O
ventricular	O
arrhythmias	O
.	O

Using	O
two	O
-	O
stage	O
coronary	O
ligation	O
-	O
,	O
digitalis	B-CHED
-	O
,	O
and	O
adrenaline	B-CHED
-	O
induced	O
canine	O
ventricular	O
arrhythmias	O
,	O
antiarrhythmic	O
effects	O
of	O
cibenzoline	B-CHED
were	O
examined	O
and	O
the	O
minimum	O
effective	O
plasma	O
concentration	O
for	O
each	O
arrhythmia	O
model	O
was	O
determined	O
.	O

Cibenzoline	B-CHED
suppressed	O
all	O
the	O
arrhythmias	O
,	O
and	O
the	O
minimum	O
effective	O
plasma	O
concentrations	O
for	O
arrhythmias	O
induced	O
by	O
24	O
-	O
h	O
coronary	O
ligation	O
,	O
48	O
-	O
h	O
coronary	O
ligation	O
,	O
digitalis	B-CHED
,	O
and	O
adrenaline	B-CHED
were	O
1	O
.	O
9	O
+	O
/	O
-	O
0	O
.	O
9	O
(	O
by	O
8	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
,	O
1	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
5	O
(	O
by	O
8	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
,	O
0	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
2	O
(	O
by	O
2	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
,	O
and	O
3	O
.	O
5	O
+	O
/	O
-	O
1	O
.	O
3	O
(	O
by	O
5	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
micrograms	O
/	O
ml	O
,	O
respectively	O
(	O
mean	O
+	O
/	O
-	O
SDM	O
,	O
n	O
=	O
6	O
-	O
7	O
)	O
.	O

The	O
concentration	O
for	O
adrenaline	B-CHED
-	O
induced	O
arrhythmia	O
was	O
significantly	O
higher	O
than	O
those	O
for	O
the	O
other	O
types	O
of	O
arrhythmias	O
.	O

This	O
pharmacological	O
profile	O
is	O
similar	O
to	O
those	O
of	O
mexiletine	B-CHED
and	O
tocainide	B-CHED
,	O
and	O
all	O
three	O
drugs	O
have	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
stimulant	O
action	O
.	O

Because	O
cibenzoline	B-CHED
had	O
only	O
weak	O
hypotensive	O
and	O
sinus	O
node	O
depressive	O
effects	O
and	O
was	O
found	O
to	O
be	O
orally	O
active	O
when	O
given	O
to	O
coronary	O
ligation	O
arrhythmia	O
dogs	O
,	O
its	O
clinical	O
usefulness	O
is	O
expected	O
.	O

Continuous	O
ambulatory	O
ECG	O
monitoring	O
during	O
fluorouracil	B-CHED
therapy	O
:	O
a	O
prospective	O
study	O
.	O

Although	O
there	O
have	O
been	O
anecdotal	O
reports	O
of	O
cardiac	O
toxicity	O
associated	O
with	O
fluorouracil	B-CHED
(	O
5	B-CHED
-	I-CHED
FU	I-CHED
)	O
therapy	O
,	O
this	O
phenomenon	O
has	O
not	O
been	O
studied	O
in	O
a	O
systematic	O
fashion	O
.	O

We	O
prospectively	O
performed	O
continuous	O
ambulatory	O
ECG	O
monitoring	O
on	O
25	O
patients	O
undergoing	O
5	B-CHED
-	I-CHED
FU	I-CHED
infusion	O
for	O
treatment	O
of	O
solid	O
tumors	O
in	O
order	O
to	O
assess	O
the	O
incidence	O
of	O
ischemic	O
ST	O
changes	O
.	O

Patients	O
were	O
monitored	O
for	O
23	O
+	O
/	O
-	O
4	O
hours	O
before	O
5	B-CHED
-	I-CHED
FU	I-CHED
infusion	O
,	O
and	O
98	O
+	O
/	O
-	O
9	O
hours	O
during	O
5	B-CHED
-	I-CHED
FU	I-CHED
infusion	O
.	O

Anginal	O
episodes	O
were	O
rare	O
:	O
only	O
one	O
patient	O
had	O
angina	O
(	O
during	O
5	B-CHED
-	I-CHED
FU	I-CHED
infusion	O
)	O
.	O

However	O
,	O
asymptomatic	O
ST	O
changes	O
(	O
greater	O
than	O
or	O
equal	O
to	O
1	O
mm	O
ST	O
deviation	O
)	O
were	O
common	O
:	O
six	O
of	O
25	O
patients	O
(	O
24	O
%	O
)	O
had	O
ST	O
changes	O
before	O
5	B-CHED
-	I-CHED
FU	I-CHED
infusion	O
v	O
17	O
(	O
68	O
%	O
)	O
during	O
5	B-CHED
-	I-CHED
FU	I-CHED
infusion	O
(	O
P	O
less	O
than	O
.	O
002	O
)	O
.	O

The	O
incidence	O
of	O
ischemic	O
episodes	O
per	O
patient	O
per	O
hour	O
was	O
0	O
.	O
05	O
+	O
/	O
-	O
0	O
.	O
02	O
prior	O
to	O
5	B-CHED
-	I-CHED
FU	I-CHED
infusion	O
v	O
0	O
.	O
13	O
+	O
/	O
-	O
0	O
.	O
03	O
during	O
5	B-CHED
-	I-CHED
FU	I-CHED
infusion	O
(	O
P	O
less	O
than	O
.	O
001	O
)	O
;	O
the	O
duration	O
of	O
ECG	O
changes	O
was	O
0	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
3	O
minutes	O
per	O
patient	O
per	O
hour	O
before	O
5	B-CHED
-	I-CHED
FU	I-CHED
v	O
1	O
.	O
9	O
+	O
/	O
-	O
0	O
.	O
5	O
minutes	O
per	O
patient	O
per	O
hour	O
during	O
5	B-CHED
-	I-CHED
FU	I-CHED
(	O
P	O
less	O
than	O
.	O
01	O
)	O
.	O

ECG	O
changes	O
were	O
more	O
common	O
among	O
patients	O
with	O
known	O
coronary	O
artery	O
disease	O
.	O

There	O
were	O
two	O
cases	O
of	O
sudden	O
death	O
,	O
both	O
of	O
which	O
occurred	O
at	O
the	O
end	O
of	O
the	O
chemotherapy	O
course	O
.	O

We	O
conclude	O
that	O
5	B-CHED
-	I-CHED
FU	I-CHED
infusion	O
is	O
associated	O
with	O
a	O
significant	O
increase	O
in	O
silent	O
ST	O
segment	O
deviation	O
suggestive	O
of	O
ischemia	O
,	O
particularly	O
among	O
patients	O
with	O
coronary	O
artery	O
disease	O
.	O

The	O
mechanism	O
and	O
clinical	O
significance	O
of	O
these	O
ECG	O
changes	O
remain	O
to	O
be	O
determined	O
.	O

Nature	O
,	O
time	O
course	O
and	O
dose	O
dependence	O
of	O
zidovudine	B-CHED
-	O
related	O
side	O
effects	O
:	O
results	O
from	O
the	O
Multicenter	O
Canadian	O
Azidothymidine	B-CHED
Trial	O
.	O

To	O
characterize	O
the	O
nature	O
,	O
time	O
course	O
and	O
dose	O
dependency	O
of	O
zidovudine	B-CHED
-	O
related	O
side	O
effects	O
,	O
we	O
undertook	O
a	O
multicenter	O
,	O
prospective	O
,	O
dose	O
-	O
range	O
finding	O
study	O
.	O

Our	O
study	O
group	O
consisted	O
of	O
74	O
HIV	O
-	O
positive	O
homosexual	O
men	O
belonging	O
to	O
groups	O
II	O
B	O
,	O
III	O
and	O
IV	O
C2	O
from	O
the	O
Centers	O
for	O
Disease	O
Control	O
(	O
CDC	O
)	O
classification	O
of	O
HIV	O
disease	O
.	O

Following	O
a	O
3	O
-	O
week	O
observation	O
period	O
,	O
volunteers	O
were	O
treated	O
with	O
zidovudine	B-CHED
600	O
mg	O
/	O
day	O
for	O
18	O
weeks	O
,	O
900	O
mg	O
/	O
day	O
for	O
9	O
weeks	O
and	O
1200	O
mg	O
/	O
day	O
for	O
9	O
weeks	O
,	O
followed	O
by	O
a	O
washout	O
period	O
of	O
6	O
weeks	O
after	O
which	O
they	O
were	O
re	O
-	O
started	O
on	O
1200	O
mg	O
/	O
day	O
or	O
the	O
highest	O
tolerated	O
dose	O
at	O
8	O
-	O
hourly	O
intervals	O
.	O

Subjects	O
were	O
randomly	O
assigned	O
to	O
4	O
-	O
hourly	O
or	O
8	O
-	O
hourly	O
regimens	O
within	O
CDC	O
groups	O
while	O
taking	O
600	O
and	O
1200	O
mg	O
/	O
day	O
.	O

Clinical	O
and	O
laboratory	O
evaluations	O
were	O
performed	O
at	O
3	O
-	O
week	O
intervals	O
.	O

Symptomatic	O
adverse	O
effects	O
were	O
present	O
in	O
96	O
%	O
of	O
subjects	O
,	O
most	O
commonly	O
nausea	O
(	O
64	O
%	O
)	O
,	O
fatigue	O
(	O
55	O
%	O
)	O
and	O
headache	O
(	O
49	O
%	O
)	O
.	O

These	O
were	O
generally	O
self	O
-	O
limited	O
,	O
reappearing	O
briefly	O
at	O
each	O
dose	O
increment	O
.	O

A	O
decrease	O
in	O
hemoglobin	O
occurred	O
shortly	O
after	O
initiation	O
of	O
therapy	O
.	O

This	O
was	O
not	O
dose	O
dependent	O
and	O
reversed	O
rapidly	O
upon	O
discontinuation	O
of	O
treatment	O
.	O

A	O
red	O
blood	O
cell	O
count	O
decrease	O
,	O
a	O
mean	O
cell	O
volume	O
increase	O
and	O
a	O
granulocyte	O
count	O
decrease	O
developed	O
early	O
in	O
a	O
dose	O
-	O
independent	O
fashion	O
,	O
reverting	O
at	O
least	O
partially	O
during	O
the	O
washout	O
phase	O
.	O

The	O
decrease	O
in	O
reticulocyte	O
count	O
was	O
dose	O
related	O
between	O
600	O
and	O
900	O
mg	O
/	O
day	O
with	O
no	O
further	O
change	O
when	O
the	O
dose	O
was	O
escalated	O
to	O
1200	O
mg	O
/	O
day	O
.	O

Bone	O
marrow	O
changes	O
occurred	O
rapidly	O
as	O
demonstrated	O
by	O
megaloblastosis	O
in	O
95	O
%	O
of	O
65	O
specimens	O
at	O
week	O
18	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

National	O
project	O
on	O
the	O
prevention	O
of	O
mother	O
-	O
to	O
-	O
infant	O
infection	O
by	O
hepatitis	O
B	O
virus	O
in	O
Japan	O
.	O

In	O
Japan	O
,	O
a	O
nationwide	O
prevention	O
program	O
against	O
mother	O
-	O
to	O
-	O
infant	O
infection	O
by	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
started	O
in	O
1985	O
.	O

This	O
program	O
consists	O
of	O
double	O
screenings	O
of	O
pregnant	O
women	O
and	O
prophylactic	O
treatment	O
to	O
the	O
infants	O
born	O
to	O
both	O
hepatitis	B-CHED
B	I-CHED
surface	I-CHED
antigen	I-CHED
(	O
HBsAg	B-CHED
)	O
and	O
hepatitis	B-CHED
B	I-CHED
e	I-CHED
antigen	I-CHED
(	O
HBeAg	B-CHED
)	O
positive	O
mothers	O
.	O

These	O
infants	O
are	O
treated	O
with	O
two	O
injections	O
of	O
hepatitis	O
B	O
immune	O
globulin	O
(	O
HBIG	O
)	O
and	O
at	O
least	O
three	O
injections	O
of	O
plasma	O
derived	O
hepatitis	B-CHED
B	I-CHED
vaccine	I-CHED
.	O

We	O
sent	O
questionnaires	O
about	O
the	O
numbers	O
of	O
each	O
procedure	O
or	O
examination	O
during	O
nine	O
months	O
of	O
investigation	O
period	O
to	O
each	O
local	O
government	O
in	O
1986	O
and	O
1987	O
.	O

93	O
.	O
4	O
%	O
pregnant	O
women	O
had	O
the	O
chance	O
to	O
be	O
examined	O
for	O
HBsAg	B-CHED
,	O
and	O
the	O
positive	O
rate	O
was	O
1	O
.	O
4	O
to	O
1	O
.	O
5	O
%	O
.	O

The	O
HBeAg	B-CHED
positive	O
rate	O
in	O
HBsAg	B-CHED
positive	O
was	O
23	O
to	O
26	O
%	O
.	O

The	O
HBsAg	B-CHED
positive	O
rate	O
in	O
neonates	O
and	O
in	O
infants	O
before	O
two	O
months	O
were	O
3	O
%	O
and	O
2	O
%	O
respectively	O
.	O

Some	O
problems	O
may	O
arise	O
,	O
because	O
27	O
to	O
30	O
%	O
of	O
infants	O
need	O
the	O
fourth	O
vaccination	O
in	O
some	O
restricted	O
areas	O
.	O

Involvement	O
of	O
the	O
mu	O
-	O
opiate	O
receptor	O
in	O
peripheral	O
analgesia	O
.	O

The	O
intradermal	O
injection	O
of	O
mu	O
(	O
morphine	B-CHED
,	O
Tyr	B-CHED
-	I-CHED
D	I-CHED
-	I-CHED
Ala	I-CHED
-	I-CHED
Gly	I-CHED
-	I-CHED
NMe	I-CHED
-	I-CHED
Phe	I-CHED
-	I-CHED
Gly	I-CHED
-	I-CHED
ol	I-CHED
and	O
morphiceptin	B-CHED
)	O
,	O
kappa	O
(	O
trans	B-CHED
-	I-CHED
3	I-CHED
,	I-CHED
4	I-CHED
-	I-CHED
dichloro	I-CHED
-	I-CHED
N	I-CHED
-	I-CHED
methyl	I-CHED
-	I-CHED
N	I-CHED
[	I-CHED
2	I-CHED
-	I-CHED
(	I-CHED
1	I-CHED
-	I-CHED
pyrrolidinyl	I-CHED
)	I-CHED
cyclohexyl	I-CHED
]	I-CHED
benzeneactemide	I-CHED
)	O
and	O
delta	O
(	O
[	B-CHED
D	I-CHED
-	I-CHED
Pen2	I-CHED
.	I-CHED
5	I-CHED
]	I-CHED
-	I-CHED
enkephalin	I-CHED
and	O
[	B-CHED
D	I-CHED
-	I-CHED
Ser2	I-CHED
]	I-CHED
-	I-CHED
[	I-CHED
Leu	I-CHED
]	I-CHED
enkephalin	I-CHED
-	I-CHED
Thr	I-CHED
)	O
selective	O
opioid	O
-	O
agonists	O
,	O
by	O
themselves	O
,	O
did	O
not	O
significantly	O
affect	O
the	O
mechanical	O
nociceptive	O
threshold	O
in	O
the	O
hindpaw	O
of	O
the	O
rat	O
.	O

Intradermal	O
injection	O
of	O
mu	O
,	O
but	O
not	O
delta	O
or	O
kappa	O
opioid	O
-	O
agonists	O
,	O
however	O
,	O
produced	O
dose	O
-	O
dependent	O
inhibition	O
of	O
prostaglandin	B-CHED
E2	I-CHED
-	O
induced	O
hyperalgesia	O
.	O

The	O
analgesic	O
effect	O
of	O
the	O
mu	O
-	O
agonist	O
morphine	B-CHED
was	O
dose	O
-	O
dependently	O
antagonized	O
by	O
naloxone	B-CHED
and	O
prevented	O
by	O
co	O
-	O
injection	O
of	O
pertussis	O
toxin	O
.	O

Morphine	B-CHED
did	O
not	O
,	O
however	O
,	O
alter	O
the	O
hyperalgesia	O
induced	O
by	O
8	B-CHED
-	I-CHED
bromo	I-CHED
cyclic	I-CHED
adenosine	I-CHED
monophosphate	I-CHED
.	O

We	O
conclude	O
that	O
the	O
analgesic	O
action	O
of	O
opioids	O
on	O
the	O
peripheral	O
terminals	O
of	O
primary	O
afferents	O
is	O
via	O
a	O
binding	O
site	O
with	O
characteristics	O
of	O
the	O
mu	O
-	O
opioid	O
receptor	O
and	O
that	O
this	O
action	O
is	O
mediated	O
by	O
inhibition	O
of	O
the	O
cyclic	B-CHED
adenosine	I-CHED
monophosphate	I-CHED
second	O
messenger	O
system	O
.	O

Involvement	O
of	O
locus	O
coeruleus	O
and	O
noradrenergic	O
neurotransmission	O
in	O
fentanyl	B-CHED
-	O
induced	O
muscular	O
rigidity	O
in	O
the	O
rat	O
.	O

Whereas	O
muscular	O
rigidity	O
is	O
a	O
well	O
-	O
known	O
side	O
effect	O
that	O
is	O
associated	O
with	O
high	O
-	O
dose	O
fentanyl	B-CHED
anesthesia	O
,	O
a	O
paucity	O
of	O
information	O
exists	O
with	O
regard	O
to	O
its	O
underlying	O
mechanism	O
(	O
s	O
)	O
.	O

We	O
investigated	O
in	O
this	O
study	O
the	O
possible	O
engagement	O
of	O
locus	O
coeruleus	O
of	O
the	O
pons	O
in	O
this	O
phenomenon	O
,	O
using	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
anesthetized	O
with	O
ketamine	B-CHED
.	O

Under	O
proper	O
control	O
of	O
respiration	O
,	O
body	O
temperature	O
and	O
end	O
-	O
tidal	O
CO2	B-CHED
,	O
intravenous	O
administration	O
of	O
fentanyl	B-CHED
(	O
50	O
or	O
100	O
micrograms	O
/	O
kg	O
)	O
consistently	O
promoted	O
an	O
increase	O
in	O
electromyographic	O
activity	O
recorded	O
from	O
the	O
gastrocnemius	O
and	O
abdominal	O
rectus	O
muscles	O
.	O

Such	O
an	O
induced	O
muscular	O
rigidity	O
by	O
the	O
narcotic	O
agent	O
was	O
significantly	O
antagonized	O
or	O
even	O
reduced	O
by	O
prior	O
electrolytic	O
lesions	O
of	O
the	O
locus	O
coeruleus	O
or	O
pretreatment	O
with	O
the	O
alpha	O
-	O
adrenoceptor	O
blocker	O
,	O
prazosin	B-CHED
.	O

Microinjection	O
of	O
fentanyl	B-CHED
(	O
2	O
.	O
5	O
micrograms	O
/	O
50	O
nl	O
)	O
directly	O
into	O
this	O
pontine	O
nucleus	O
,	O
on	O
the	O
other	O
hand	O
,	O
elicited	O
discernible	O
electromyographic	O
excitation	O
.	O

It	O
is	O
speculated	O
that	O
the	O
induction	O
of	O
muscular	O
rigidity	O
by	O
fentanyl	B-CHED
may	O
involve	O
the	O
coerulospinal	O
noradrenergic	O
fibers	O
to	O
the	O
spinal	O
motoneurons	O
.	O

Dexmedetomidine	B-CHED
,	O
acting	O
through	O
central	O
alpha	O
-	O
2	O
adrenoceptors	O
,	O
prevents	O
opiate	O
-	O
induced	O
muscle	O
rigidity	O
in	O
the	O
rat	O
.	O

The	O
highly	O
-	O
selective	O
alpha	O
-	O
2	O
adrenergic	O
agonist	O
dexmedetomidine	B-CHED
(	O
D	B-CHED
-	I-CHED
MED	I-CHED
)	O
is	O
capable	O
of	O
inducing	O
muscle	O
flaccidity	O
and	O
anesthesia	O
in	O
rats	O
and	O
dogs	O
.	O

Intense	O
generalized	O
muscle	O
rigidity	O
is	O
an	O
undesirable	O
side	O
effect	O
of	O
potent	O
opiate	O
agonists	O
.	O

Although	O
the	O
neurochemistry	O
of	O
opiate	O
-	O
induced	O
rigidity	O
has	O
yet	O
to	O
be	O
fully	O
elucidated	O
,	O
recent	O
work	O
suggests	O
a	O
role	O
for	O
a	O
central	O
adrenergic	O
mechanism	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
authors	O
determined	O
if	O
treatment	O
with	O
D	B-CHED
-	I-CHED
MED	I-CHED
prevents	O
the	O
muscle	O
rigidity	O
caused	O
by	O
high	O
-	O
dose	O
alfentanil	B-CHED
anesthesia	O
in	O
the	O
rat	O
.	O

Animals	O
(	O
n	O
=	O
42	O
)	O
were	O
treated	O
intraperitoneally	O
with	O
one	O
of	O
the	O
following	O
six	O
regimens	O
:	O
1	O
)	O
L	O
-	O
MED	O
(	O
the	O
inactive	O
L	O
-	O
isomer	O
of	O
medetomidine	B-CHED
)	O
,	O
30	O
micrograms	O
/	O
kg	O
;	O
2	O
)	O
D	B-CHED
-	I-CHED
MED	I-CHED
,	O
10	O
micrograms	O
/	O
kg	O
;	O
3	O
)	O
D	B-CHED
-	I-CHED
MED	I-CHED
,	O
30	O
micrograms	O
/	O
kg	O
;	O
4	O
)	O
D	B-CHED
-	I-CHED
MED	I-CHED
[	O
30	O
micrograms	O
/	O
kg	O
]	O
and	O
the	O
central	O
-	O
acting	O
alpha	O
-	O
2	O
antagonist	O
,	O
idazoxan	B-CHED
[	O
10	O
mg	O
/	O
kg	O
]	O
;	O
5	O
)	O
D	B-CHED
-	I-CHED
MED	I-CHED
[	O
30	O
micrograms	O
/	O
kg	O
]	O
and	O
the	O
peripheral	O
-	O
acting	O
alpha	O
-	O
2	O
antagonist	O
DG	B-CHED
-	I-CHED
5128	I-CHED
[	O
10	O
mg	O
/	O
kg	O
]	O
,	O
or	O
;	O
6	O
)	O
saline	O
.	O

Baseline	O
electromyographic	O
activity	O
was	O
recorded	O
from	O
the	O
gastrocnemius	O
muscle	O
before	O
and	O
after	O
drug	O
treatment	O
.	O

Each	O
rat	O
was	O
then	O
injected	O
with	O
alfentanil	B-CHED
(	O
ALF	B-CHED
,	O
0	O
.	O
5	O
mg	O
/	O
kg	O
sc	O
)	O
.	O

ALF	B-CHED
injection	O
resulted	O
in	O
a	O
marked	O
increase	O
in	O
hindlimb	O
EMG	O
activity	O
in	O
the	O
L	O
-	O
MED	O
treatment	O
group	O
which	O
was	O
indistinguishable	O
from	O
that	O
seen	O
in	O
animals	O
treated	O
with	O
saline	O
.	O

In	O
contrast	O
,	O
D	B-CHED
-	I-CHED
MED	I-CHED
prevented	O
alfentanil	B-CHED
-	O
induced	O
muscle	O
rigidity	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
.	O

The	O
small	O
EMG	O
values	O
obtained	O
in	O
the	O
high	O
-	O
dose	O
D	B-CHED
-	I-CHED
MED	I-CHED
group	O
were	O
comparable	O
with	O
those	O
recorded	O
in	O
earlier	O
studies	O
from	O
control	O
animals	O
not	O
given	O
any	O
opiate	O
.	O

The	O
high	O
-	O
dose	O
D	B-CHED
-	I-CHED
MED	I-CHED
animals	O
were	O
flaccid	O
,	O
akinetic	O
,	O
and	O
lacked	O
a	O
startle	O
response	O
during	O
the	O
entire	O
experimental	O
period	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Some	O
central	O
effects	O
of	O
repeated	O
treatment	O
with	O
fluvoxamine	B-CHED
.	O

We	O
investigated	O
the	O
effect	O
of	O
repeated	O
treatment	O
with	O
fluvoxamine	B-CHED
,	O
a	O
selective	O
serotonin	B-CHED
uptake	O
inhibitor	O
,	O
on	O
behavioral	O
effects	O
of	O
dopaminomimetics	O
and	O
methoxamine	B-CHED
and	O
on	O
the	O
animal	O
behavior	O
in	O
the	O
"	O
behavioral	O
despair	O
"	O
test	O
.	O

A	O
repeated	O
treatment	O
with	O
fluvoxamine	B-CHED
(	O
twice	O
daily	O
for	O
14	O
days	O
)	O
potentiated	O
in	O
mice	O
and	O
in	O
rats	O
(	O
weaker	O
)	O
the	O
amphetamine	B-CHED
-	O
induced	O
hyperactivity	O
.	O

The	O
hyperactivity	O
induced	O
by	O
nomifensine	B-CHED
in	O
mice	O
remained	O
unaffected	O
by	O
fluvoxamine	B-CHED
.	O

The	O
stimulation	O
of	O
locomotor	O
activity	O
by	O
intracerebroventricularly	O
administered	O
methoxamine	B-CHED
was	O
not	O
affected	O
by	O
repeated	O
treatment	O
with	O
fluvoxamine	B-CHED
.	O

Given	O
three	O
times	O
fluvoxamine	B-CHED
had	O
no	O
effect	O
on	O
the	O
immobilization	O
time	O
in	O
the	O
"	O
behavioral	O
despair	O
"	O
test	O
in	O
rats	O
.	O

The	O
results	O
indicate	O
that	O
fluvoxamine	B-CHED
given	O
repeatedly	O
acts	O
differently	O
than	O
citalopram	B-CHED
,	O
another	O
selective	O
serotonin	B-CHED
uptake	O
inhibitor	O
,	O
and	O
differs	O
also	O
from	O
other	O
antidepressant	O
drugs	O
.	O

Protective	O
effect	O
of	O
a	O
specific	O
platelet	O
-	O
activating	O
factor	O
antagonist	O
,	O
BN	B-CHED
52021	I-CHED
,	O
on	O
bupivacaine	B-CHED
-	O
induced	O
cardiovascular	O
impairments	O
in	O
rats	O
.	O

Administration	O
of	O
the	O
local	O
anaesthetic	O
bupivacaine	B-CHED
(	O
1	O
.	O
5	O
or	O
2	O
mg	O
/	O
kg	O
,	O
i	O
.	O
v	O
.	O
)	O
to	O
rats	O
elicited	O
a	O
marked	O
decrease	O
of	O
mean	O
arterial	O
blood	O
pressure	O
(	O
MBP	O
)	O
and	O
heart	O
rate	O
(	O
HR	O
)	O
leading	O
to	O
death	O
(	O
in	O
67	O
%	O
or	O
90	O
%	O
of	O
animals	O
respectively	O
)	O
.	O

Intravenous	O
injection	O
of	O
the	O
specific	O
platelet	O
-	O
activating	O
factor	O
(	O
PAF	O
)	O
antagonist	O
BN	B-CHED
52021	I-CHED
(	O
10	O
mg	O
/	O
kg	O
)	O
,	O
30	O
min	O
before	O
bupivacaine	B-CHED
administration	O
(	O
2	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
suppressed	O
both	O
the	O
decrease	O
of	O
MBP	O
and	O
HR	O
.	O

In	O
contrast	O
,	O
doses	O
of	O
1	O
mg	O
/	O
kg	O
BN	B-CHED
52021	I-CHED
given	O
30	O
min	O
before	O
or	O
10	O
mg	O
/	O
kg	O
administered	O
5	O
min	O
before	O
i	O
.	O
v	O
.	O
injection	O
of	O
bupivacaine	B-CHED
were	O
ineffective	O
.	O

When	O
BN	B-CHED
52021	I-CHED
(	O
20	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
was	O
injected	O
immediately	O
after	O
bupivacaine	B-CHED
(	O
2	O
mg	O
/	O
kg	O
)	O
,	O
a	O
partial	O
reversion	O
of	O
the	O
decrease	O
of	O
MBP	O
and	O
HR	O
was	O
observed	O
,	O
whereas	O
the	O
dose	O
of	O
10	O
mg	O
/	O
kg	O
was	O
ineffective	O
.	O

A	O
partial	O
recovery	O
of	O
bupivacaine	B-CHED
-	O
induced	O
ECG	O
alterations	O
was	O
observed	O
after	O
pretreatment	O
of	O
the	O
rats	O
with	O
BN	B-CHED
52021	I-CHED
.	O

Since	O
the	O
administration	O
of	O
BN	B-CHED
52021	I-CHED
,	O
at	O
all	O
doses	O
studied	O
,	O
did	O
not	O
alter	O
MBP	O
and	O
HR	O
at	O
the	O
doses	O
used	O
,	O
the	O
bulk	O
of	O
these	O
results	O
clearly	O
demonstrate	O
a	O
protective	O
action	O
of	O
BN	B-CHED
52021	I-CHED
,	O
a	O
specific	O
antagonist	O
of	O
PAF	O
,	O
against	O
bupivacaine	B-CHED
-	O
induced	O
cardiovascular	O
toxicity	O
.	O

Thus	O
,	O
consistent	O
with	O
its	O
direct	O
effect	O
on	O
heart	O
,	O
PAF	O
appears	O
to	O
be	O
implicated	O
in	O
bupivacaine	B-CHED
-	O
induced	O
cardiovascular	O
alterations	O
.	O

The	O
epidemiology	O
of	O
the	O
acute	O
flank	O
pain	O
syndrome	O
from	O
suprofen	B-CHED
.	O

Suprofen	B-CHED
,	O
a	O
new	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drug	O
,	O
was	O
marketed	O
in	O
early	O
1986	O
as	O
an	O
analgesic	O
agent	O
.	O

Until	O
physicians	O
began	O
reporting	O
an	O
unusual	O
acute	O
flank	O
pain	O
syndrome	O
to	O
the	O
spontaneous	O
reporting	O
system	O
,	O
700	O
,	O
000	O
persons	O
used	O
the	O
drug	O
in	O
the	O
United	O
States	O
.	O

Through	O
August	O
1986	O
,	O
a	O
total	O
of	O
163	O
cases	O
of	O
this	O
syndrome	O
were	O
reported	O
.	O

To	O
elucidate	O
the	O
epidemiology	O
of	O
the	O
syndrome	O
,	O
a	O
case	O
-	O
control	O
study	O
was	O
performed	O
,	O
comparing	O
62	O
of	O
the	O
case	O
patients	O
who	O
had	O
been	O
reported	O
to	O
the	O
spontaneous	O
reporting	O
system	O
to	O
185	O
suprofen	B-CHED
-	O
exposed	O
control	O
subjects	O
who	O
did	O
not	O
have	O
the	O
syndrome	O
.	O

Case	O
patients	O
were	O
more	O
likely	O
to	O
be	O
men	O
(	O
odds	O
ratio	O
,	O
3	O
.	O
8	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
2	O
-	O
12	O
.	O
1	O
)	O
,	O
suffer	O
from	O
hay	O
fever	O
and	O
asthma	O
(	O
odds	O
ratio	O
,	O
3	O
.	O
4	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
0	O
-	O
11	O
.	O
9	O
)	O
;	O
to	O
participate	O
in	O
regular	O
exercise	O
(	O
odds	O
ratio	O
,	O
5	O
.	O
9	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
1	O
-	O
30	O
.	O
7	O
)	O
,	O
especially	O
in	O
the	O
use	O
of	O
Nautilus	O
equipment	O
(	O
p	O
=	O
0	O
.	O
02	O
)	O
;	O
and	O
to	O
use	O
alcohol	B-CHED
(	O
odds	O
ratio	O
,	O
4	O
.	O
4	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
1	O
-	O
17	O
.	O
5	O
)	O
.	O

Possible	O
risk	O
factors	O
included	O
young	O
age	O
,	O
concurrent	O
use	O
of	O
other	O
analgesic	O
agents	O
(	O
especially	O
ibuprofen	B-CHED
)	O
,	O
preexisting	O
renal	O
disease	O
,	O
a	O
history	O
of	O
kidney	O
stones	O
,	O
a	O
history	O
of	O
gout	O
,	O
a	O
recent	O
increase	O
in	O
activity	O
,	O
a	O
recent	O
increase	O
in	O
sun	O
exposure	O
,	O
and	O
residence	O
in	O
the	O
Sunbelt	O
.	O

These	O
were	O
findings	O
that	O
were	O
suggestive	O
but	O
did	O
not	O
reach	O
conventional	O
statistical	O
significance	O
.	O

These	O
findings	O
are	O
consistent	O
with	O
the	O
postulated	O
mechanism	O
for	O
this	O
unusual	O
syndrome	O
:	O
acute	O
diffuse	O
crystallization	O
of	O
uric	B-CHED
acid	I-CHED
in	O
renal	O
tubules	O
.	O

Phlorizin	B-CHED
-	O
induced	O
glycosuria	O
does	O
not	O
prevent	O
gentamicin	B-CHED
nephrotoxicity	O
in	O
rats	O
.	O

Because	O
rats	O
with	O
streptozotocin	B-CHED
-	O
induced	O
diabetes	O
mellitus	O
(	O
DM	O
)	O
have	O
a	O
high	O
solute	O
diuresis	O
(	O
glycosuria	O
of	O
10	O
to	O
12	O
g	O
/	O
day	O
)	O
,	O
we	O
have	O
suggested	O
that	O
this	O
may	O
in	O
part	O
be	O
responsible	O
for	O
their	O
resistance	O
to	O
gentamicin	B-CHED
-	O
induced	O
acute	O
renal	O
failure	O
(	O
ARF	O
)	O
.	O

The	O
protection	O
from	O
gentamicin	B-CHED
nephrotoxicity	O
was	O
studied	O
in	O
non	O
-	O
diabetic	O
rats	O
with	O
chronic	O
solute	O
diuresis	O
induced	O
by	O
blockage	O
of	O
tubular	O
glucose	B-CHED
reabsorption	O
with	O
phlorizin	B-CHED
(	O
P	B-CHED
)	O
.	O

DM	O
rats	O
with	O
mild	O
glycosuria	O
(	O
similar	O
in	O
degree	O
to	O
that	O
of	O
the	O
P	B-CHED
treated	O
animals	O
)	O
were	O
also	O
studied	O
.	O

Unanesthetized	O
adult	O
female	O
,	O
Sprague	O
-	O
Dawley	O
rats	O
were	O
divided	O
in	O
four	O
groups	O
and	O
studied	O
for	O
15	O
days	O
.	O

Group	O
1	O
(	O
P	B-CHED
alone	O
)	O
received	O
P	B-CHED
,	O
360	O
mg	O
/	O
day	O
,	O
for	O
15	O
days	O
;	O
Group	O
II	O
(	O
P	B-CHED
+	O
gentamicin	B-CHED
)	O
;	O
Group	O
III	O
(	O
gentamicin	B-CHED
alone	O
)	O
and	O
Group	O
IV	O
(	O
mild	O
DM	O
+	O
gentamicin	B-CHED
)	O
.	O

Nephrotoxic	O
doses	O
(	O
40	O
mg	O
/	O
kg	O
body	O
wt	O
/	O
day	O
)	O
of	O
gentamicin	B-CHED
were	O
injected	O
during	O
the	O
last	O
nine	O
days	O
of	O
study	O
to	O
the	O
animals	O
of	O
groups	O
II	O
to	O
IV	O
.	O

In	O
Group	O
I	O
,	O
P	B-CHED
induced	O
a	O
moderate	O
and	O
stable	O
glycosuria	O
(	O
3	O
.	O
9	O
+	O
/	O
-	O
0	O
.	O
1	O
g	O
/	O
day	O
,	O
SE	O
)	O
,	O
and	O
no	O
functional	O
or	O
morphologic	O
evidence	O
of	O
renal	O
dysfunction	O
(	O
baseline	O
CCr	O
2	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
1	O
ml	O
/	O
min	O
,	O
undetectable	O
lysozymuria	O
)	O
or	O
damage	O
(	O
tubular	O
necrosis	O
score	O
[	O
maximum	O
4	O
]	O
,	O
zero	O
)	O
.	O

In	O
Group	O
II	O
,	O
P	B-CHED
did	O
not	O
prevent	O
gentamicin	B-CHED
-	O
ARF	O
(	O
maximal	O
decrease	O
in	O
CCr	O
at	O
day	O
9	O
.	O
89	O
%	O
,	O
P	B-CHED
less	O
than	O
0	O
.	O
001	O
;	O
peak	O
lysozymuria	O
,	O
1863	O
+	O
/	O
-	O
321	O
micrograms	O
/	O
day	O
;	O
and	O
tubular	O
necrosis	O
score	O
,	O
3	O
.	O
9	O
+	O
/	O
-	O
0	O
.	O
1	O
)	O
.	O

These	O
values	O
were	O
not	O
different	O
from	O
those	O
of	O
Group	O
III	O
:	O
maximal	O
decrease	O
in	O
CCr	O
73	O
%	O
(	O
P	B-CHED
less	O
than	O
0	O
.	O
001	O
)	O
;	O
lysozymuria	O
,	O
2147	O
+	O
/	O
-	O
701	O
micrograms	O
/	O
day	O
;	O
tubular	O
necrosis	O
score	O
,	O
3	O
.	O
8	O
+	O
/	O
-	O
0	O
.	O
1	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Catalepsy	O
induced	O
by	O
combinations	O
of	O
ketamine	B-CHED
and	O
morphine	B-CHED
:	O
potentiation	O
,	O
antagonism	O
,	O
tolerance	O
and	O
cross	O
-	O
tolerance	O
in	O
the	O
rat	O
.	O

Previous	O
studies	O
demonstrated	O
that	O
both	O
ketamine	B-CHED
and	O
morphine	B-CHED
induced	O
analgesia	O
and	O
catalepsy	O
in	O
the	O
rat	O
.	O

Pre	O
-	O
treatment	O
with	O
ketamine	B-CHED
produced	O
cross	O
-	O
tolerance	O
to	O
morphine	B-CHED
,	O
whereas	O
pretreatment	O
with	O
morphine	B-CHED
did	O
not	O
induce	O
cross	O
-	O
tolerance	O
to	O
ketamine	B-CHED
but	O
rather	O
augmented	O
the	O
cataleptic	O
response	O
;	O
this	O
augmentation	O
was	O
attributed	O
to	O
residual	O
morphine	B-CHED
in	O
the	O
brain	O
.	O

The	O
present	O
studies	O
explored	O
the	O
duration	O
of	O
the	O
loss	O
of	O
righting	O
reflex	O
induced	O
by	O
sub	O
-	O
effective	O
doses	O
of	O
ketamine	B-CHED
and	O
morphine	B-CHED
,	O
administered	O
simultaneously	O
.	O

There	O
was	O
mutual	O
potentiation	O
between	O
sub	O
-	O
effective	O
doses	O
of	O
ketamine	B-CHED
and	O
morphine	B-CHED
,	O
but	O
sub	O
-	O
effective	O
doses	O
of	O
ketamine	B-CHED
partly	O
antagonized	O
fully	O
-	O
effective	O
doses	O
of	O
morphine	B-CHED
.	O

Latency	O
to	O
the	O
loss	O
of	O
righting	O
reflex	O
,	O
rigidity	O
and	O
behavior	O
on	O
recovery	O
,	O
reflected	O
the	O
relative	O
predominance	O
of	O
ketamine	B-CHED
or	O
morphine	B-CHED
in	O
each	O
combination	O
.	O

Naloxone	B-CHED
inhibited	O
the	O
induced	O
cataleptic	O
effects	O
.	O

The	O
degree	O
and	O
time	O
course	O
of	O
development	O
of	O
tolerance	O
to	O
daily	O
administration	O
of	O
sub	O
-	O
effective	O
dose	O
combinations	O
of	O
ketamine	B-CHED
and	O
morphine	B-CHED
were	O
similar	O
.	O

Rats	O
,	O
tolerant	O
to	O
ketamine	B-CHED
-	O
dominant	O
combinations	O
,	O
were	O
cross	O
-	O
tolerant	O
to	O
both	O
drugs	O
,	O
while	O
those	O
tolerant	O
to	O
morphine	B-CHED
-	O
dominant	O
combinations	O
were	O
cross	O
-	O
tolerant	O
to	O
morphine	B-CHED
but	O
showed	O
either	O
no	O
cross	O
-	O
tolerance	O
or	O
an	O
augmented	O
response	O
to	O
ketamine	B-CHED
.	O

While	O
the	O
mutual	O
potentiation	O
,	O
antagonism	O
and	O
tolerance	O
suggest	O
common	O
mechanisms	O
for	O
the	O
induced	O
catalepsy	O
,	O
differences	O
in	O
latency	O
,	O
rigidity	O
and	O
behavior	O
,	O
asymmetry	O
of	O
cross	O
-	O
tolerance	O
and	O
a	O
widely	O
-	O
different	O
ID50	O
for	O
naloxone	B-CHED
would	O
argue	O
against	O
an	O
action	O
at	O
a	O
single	O
opioid	O
site	O
.	O

Hydrocortisone	B-CHED
-	O
induced	O
hypertension	O
in	O
humans	O
:	O
pressor	O
responsiveness	O
and	O
sympathetic	O
function	O
.	O

Oral	O
hydrocortisone	B-CHED
increases	O
blood	O
pressure	O
and	O
enhances	O
pressor	O
responsiveness	O
in	O
normal	O
human	O
subjects	O
.	O

We	O
studied	O
the	O
effects	O
of	O
1	O
week	O
of	O
oral	O
hydrocortisone	B-CHED
(	O
200	O
mg	O
/	O
day	O
)	O
on	O
blood	O
pressure	O
,	O
cardiac	O
output	O
,	O
total	O
peripheral	O
resistance	O
,	O
forearm	O
vascular	O
resistance	O
,	O
and	O
norepinephrine	B-CHED
spillover	O
to	O
plasma	O
in	O
eight	O
healthy	O
male	O
volunteers	O
.	O

Although	O
diastolic	O
blood	O
pressure	O
remained	O
unchanged	O
,	O
systolic	O
blood	O
pressure	O
increased	O
from	O
119	O
to	O
135	O
mm	O
Hg	O
(	O
SED	O
+	O
/	O
-	O
3	O
.	O
4	O
,	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
,	O
associated	O
with	O
an	O
increased	O
cardiac	O
output	O
(	O
5	O
.	O
85	O
-	O
7	O
.	O
73	O
l	O
/	O
min	O
,	O
SED	O
+	O
/	O
-	O
0	O
.	O
46	O
,	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

Total	O
peripheral	O
vascular	O
resistance	O
fell	O
from	O
15	O
.	O
1	O
to	O
12	O
.	O
2	O
mm	O
Hg	O
/	O
l	O
/	O
min	O
(	O
SED	O
+	O
/	O
-	O
1	O
.	O
03	O
,	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

Resting	O
forearm	O
vascular	O
resistance	O
remained	O
unchanged	O
,	O
but	O
the	O
reflex	O
response	O
to	O
the	O
cold	O
pressor	O
test	O
was	O
accentuated	O
,	O
the	O
rise	O
in	O
resistance	O
increasing	O
from	O
10	O
.	O
5	O
mm	O
Hg	O
/	O
ml	O
/	O
100	O
ml	O
/	O
min	O
(	O
R	O
units	O
)	O
before	O
treatment	O
to	O
32	O
.	O
6	O
R	O
units	O
after	O
treatment	O
(	O
SED	O
+	O
/	O
-	O
6	O
.	O
4	O
,	O
p	O
less	O
than	O
0	O
.	O
025	O
)	O
.	O

The	O
rise	O
in	O
forearm	O
vascular	O
resistance	O
accompanying	O
intra	O
-	O
arterial	O
norepinephrine	B-CHED
(	O
25	O
,	O
50	O
,	O
and	O
100	O
ng	O
/	O
min	O
)	O
was	O
also	O
significantly	O
greater	O
after	O
hydrocortisone	B-CHED
,	O
increasing	O
from	O
an	O
average	O
of	O
14	O
.	O
9	O
+	O
/	O
-	O
2	O
.	O
4	O
R	O
units	O
before	O
treatment	O
to	O
35	O
.	O
1	O
+	O
/	O
-	O
5	O
.	O
5	O
R	O
units	O
after	O
hydrocortisone	B-CHED
(	O
SED	O
+	O
/	O
-	O
6	O
.	O
0	O
,	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

A	O
shift	O
to	O
the	O
left	O
in	O
the	O
dose	O
-	O
response	O
relation	O
and	O
fall	O
in	O
threshold	O
suggested	O
increased	O
sensitivity	O
to	O
norepinephrine	B-CHED
after	O
treatment	O
.	O

Measurement	O
of	O
resting	O
norepinephrine	B-CHED
spillover	O
rate	O
to	O
plasma	O
and	O
norepinephrine	B-CHED
uptake	O
indicated	O
that	O
overall	O
resting	O
sympathetic	O
nervous	O
system	O
activity	O
was	O
not	O
increased	O
.	O

The	O
rise	O
in	O
resting	O
blood	O
pressure	O
with	O
hydrocortisone	B-CHED
is	O
associated	O
with	O
an	O
increased	O
cardiac	O
output	O
(	O
presumably	O
due	O
to	O
increased	O
blood	O
volume	O
)	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Neuromuscular	O
blockade	O
with	O
magnesium	B-CHED
sulfate	I-CHED
and	O
nifedipine	B-CHED
.	O

A	O
patient	O
who	O
received	O
tocolysis	O
with	O
nifedipine	B-CHED
developed	O
neuromuscular	O
blockade	O
after	O
500	O
mg	O
of	O
magnesium	B-CHED
sulfate	I-CHED
was	O
administered	O
.	O

This	O
reaction	O
demonstrates	O
that	O
nifedipine	B-CHED
can	O
seriously	O
potentiate	O
the	O
toxicity	O
of	O
magnesium	B-CHED
.	O

Caution	O
should	O
be	O
exercised	O
when	O
these	O
two	O
tocolytics	O
are	O
combined	O
.	O

Chronic	O
carbamazepine	B-CHED
inhibits	O
the	O
development	O
of	O
local	O
anesthetic	O
seizures	O
kindled	O
by	O
cocaine	B-CHED
and	O
lidocaine	B-CHED
.	O

The	O
effects	O
of	O
carbamazepine	B-CHED
(	O
CBZ	B-CHED
)	O
treatment	O
on	O
local	O
anesthetic	O
-	O
kindled	O
seizures	O
and	O
lethality	O
were	O
evaluated	O
in	O
different	O
stages	O
of	O
the	O
kindling	O
process	O
and	O
under	O
different	O
methods	O
of	O
CBZ	B-CHED
administration	O
.	O

Chronic	O
oral	O
CBZ	B-CHED
inhibited	O
the	O
development	O
of	O
both	O
lidocaine	B-CHED
-	O
and	O
cocaine	B-CHED
-	O
induced	O
seizures	O
,	O
but	O
had	O
little	O
effect	O
on	O
the	O
fully	O
developed	O
local	O
anesthetic	O
seizures	O
.	O

Chronic	O
CBZ	B-CHED
also	O
decreased	O
the	O
incidence	O
of	O
seizure	O
-	O
related	O
mortality	O
in	O
the	O
cocaine	B-CHED
-	O
injected	O
rats	O
.	O

Acute	O
CBZ	B-CHED
over	O
a	O
range	O
of	O
doses	O
(	O
15	O
-	O
50	O
mg	O
/	O
kg	O
)	O
had	O
no	O
effect	O
on	O
completed	O
lidocaine	B-CHED
-	O
kindled	O
or	O
acute	O
cocaine	B-CHED
-	O
induced	O
seizures	O
.	O

Repeated	O
i	O
.	O
p	O
.	O
injection	O
of	O
CBZ	B-CHED
(	O
15	O
mg	O
/	O
kg	O
)	O
also	O
was	O
without	O
effect	O
on	O
the	O
development	O
of	O
lidocaine	B-CHED
-	O
or	O
cocaine	B-CHED
-	O
kindled	O
seizures	O
.	O

The	O
differential	O
effects	O
of	O
CBZ	B-CHED
depending	O
upon	O
stage	O
of	O
seizure	O
development	O
suggest	O
that	O
distinct	O
mechanisms	O
underlie	O
the	O
development	O
versus	O
maintenance	O
of	O
local	O
anesthetic	O
-	O
kindled	O
seizures	O
.	O

The	O
effectiveness	O
of	O
chronic	O
but	O
not	O
repeated	O
,	O
intermittent	O
injections	O
of	O
CBZ	B-CHED
suggests	O
that	O
different	O
biochemical	O
consequences	O
result	O
from	O
the	O
different	O
treatment	O
regimens	O
.	O

The	O
possible	O
utility	O
of	O
chronic	O
CBZ	B-CHED
in	O
preventing	O
the	O
development	O
of	O
toxic	O
side	O
effects	O
in	O
human	O
cocaine	B-CHED
users	O
is	O
suggested	O
by	O
these	O
data	O
,	O
but	O
remains	O
to	O
be	O
directly	O
evaluated	O
.	O

Magnetic	O
resonance	O
imaging	O
of	O
cerebral	O
venous	O
thrombosis	O
secondary	O
to	O
"	O
low	O
-	O
dose	O
"	O
birth	O
control	O
pills	O
.	O

The	O
clinical	O
and	O
radiographic	O
features	O
of	O
cerebral	O
deep	O
venous	O
thrombosis	O
in	O
a	O
21	O
-	O
year	O
-	O
old	O
white	O
woman	O
are	O
presented	O
.	O

This	O
nulliparous	O
patient	O
presented	O
with	O
relatively	O
mild	O
clinical	O
symptoms	O
and	O
progressing	O
mental	O
status	O
changes	O
.	O

The	O
only	O
known	O
risk	O
factor	O
was	O
"	O
low	O
-	O
dose	O
"	O
oral	B-CHED
contraceptive	I-CHED
pills	O
.	O

The	O
magnetic	O
resonance	O
image	O
(	O
MRI	O
)	O
showed	O
increased	O
signal	O
intensity	O
from	O
the	O
internal	O
cerebral	O
veins	O
,	O
vein	O
of	O
Galen	O
,	O
and	O
straight	O
sinus	O
.	O

The	O
diagnosis	O
was	O
confirmed	O
by	O
arterial	O
angiography	O
.	O

Beta	O
-	O
2	O
-	O
adrenoceptor	O
-	O
mediated	O
hypokalemia	O
and	O
its	O
abolishment	O
by	O
oxprenolol	B-CHED
.	O

The	O
time	O
course	O
and	O
concentration	O
-	O
effect	O
relationship	O
of	O
terbutaline	B-CHED
-	O
induced	O
hypokalemia	O
was	O
studied	O
,	O
using	O
computer	O
-	O
aided	O
pharmacokinetic	O
-	O
dynamic	O
modeling	O
.	O

Subsequently	O
we	O
investigated	O
the	O
efficacy	O
of	O
oxprenolol	B-CHED
in	O
antagonizing	O
such	O
hypokalemia	O
,	O
together	O
with	O
the	O
pharmacokinetic	O
interaction	O
between	O
both	O
drugs	O
.	O

Six	O
healthy	O
subjects	O
were	O
given	O
a	O
0	O
.	O
5	O
mg	O
subcutaneous	O
dose	O
of	O
terbutaline	B-CHED
on	O
two	O
occasions	O
:	O
1	O
hour	O
after	O
oral	O
administration	O
of	O
a	O
placebo	O
and	O
1	O
hour	O
after	O
80	O
mg	O
oxprenolol	B-CHED
orally	O
.	O

In	O
the	O
7	O
-	O
hour	O
period	O
after	O
terbutaline	B-CHED
administration	O
,	O
plasma	O
samples	O
were	O
taken	O
for	O
determination	O
of	O
plasma	O
potassium	B-CHED
levels	O
and	O
drug	O
concentrations	O
.	O

The	O
sigmoid	O
Emax	O
model	O
offered	O
a	O
good	O
description	O
of	O
the	O
relation	O
between	O
terbutaline	B-CHED
concentrations	O
and	O
potassium	B-CHED
effects	O
.	O

Oxprenolol	B-CHED
caused	O
decreases	O
of	O
65	O
%	O
and	O
56	O
%	O
of	O
terbutaline	B-CHED
volume	O
of	O
distribution	O
and	O
clearance	O
,	O
respectively	O
,	O
and	O
an	O
increase	O
of	O
130	O
%	O
of	O
its	O
AUC	O
.	O

In	O
spite	O
of	O
higher	O
terbutaline	B-CHED
concentrations	O
after	O
oxprenolol	B-CHED
pretreatment	O
,	O
the	O
hypokalemia	O
was	O
almost	O
completely	O
antagonized	O
by	O
the	O
beta	O
2	O
-	O
blocking	O
action	O
.	O

A	O
dystonia	O
-	O
like	O
syndrome	O
after	O
neuropeptide	O
(	O
MSH	B-CHED
/	O
ACTH	B-CHED
)	O
stimulation	O
of	O
the	O
rat	O
locus	O
ceruleus	O
.	O

The	O
movement	O
disorder	O
investigated	O
in	O
these	O
studies	O
has	O
some	O
features	O
in	O
common	O
with	O
human	O
idiopathic	O
dystonia	O
,	O
and	O
information	O
obtained	O
in	O
these	O
studies	O
may	O
be	O
of	O
potential	O
clinical	O
benefit	O
.	O

The	O
present	O
experimental	O
results	O
indicated	O
that	O
peptidergic	O
stimulation	O
of	O
the	O
LC	O
resulted	O
in	O
a	O
NE	O
-	O
mediated	O
inhibition	O
of	O
cerebellar	O
Purkinje	O
cells	O
located	O
at	O
terminals	O
of	O
the	O
ceruleo	O
-	O
cerebellar	O
pathway	O
.	O

However	O
,	O
it	O
is	O
not	O
certain	O
as	O
to	O
the	O
following	O
:	O
(	O
a	O
)	O
what	O
receptors	O
were	O
stimulated	O
by	O
the	O
ACTH	B-CHED
N	O
-	O
terminal	O
fragments	O
at	O
the	O
LC	O
that	O
resulted	O
in	O
this	O
disorder	O
;	O
(	O
b	O
)	O
whether	O
NE	O
,	O
released	O
onto	O
Purkinje	O
cell	O
synapses	O
located	O
at	O
terminals	O
of	O
the	O
ceruleo	O
-	O
cerebellar	O
pathway	O
,	O
did	O
indeed	O
cause	O
the	O
long	O
-	O
term	O
depression	O
at	O
Purkinje	O
cell	O
synapses	O
(	O
previously	O
described	O
by	O
others	O
)	O
that	O
resulted	O
in	O
the	O
long	O
duration	O
of	O
the	O
movement	O
disorder	O
;	O
(	O
c	O
)	O
whether	O
the	O
inhibition	O
of	O
inhibitory	O
Purkinje	O
cells	O
resulted	O
in	O
disinhibition	O
or	O
increased	O
excitability	O
of	O
the	O
unilateral	O
cerebellar	O
fastigial	O
or	O
interpositus	O
nuclei	O
,	O
the	O
output	O
targets	O
of	O
the	O
Purkinje	O
cell	O
axons	O
,	O
that	O
may	O
have	O
been	O
an	O
important	O
contributing	O
factor	O
to	O
this	O
disorder	O
.	O

These	O
questions	O
are	O
currently	O
being	O
investigated	O
.	O

Enhanced	O
stimulus	O
-	O
induced	O
neurotransmitter	O
overflow	O
in	O
epinephrine	B-CHED
-	O
induced	O
hypertensive	O
rats	O
is	O
not	O
mediated	O
by	O
prejunctional	O
beta	O
-	O
adrenoceptor	O
activation	O
.	O

The	O
present	O
study	O
examines	O
the	O
effect	O
of	O
6	O
-	O
day	O
epinephrine	B-CHED
treatment	O
(	O
100	O
micrograms	O
/	O
kg	O
per	O
h	O
,	O
s	O
.	O
c	O
.	O
)	O
on	O
stimulus	O
-	O
induced	O
(	O
1	O
Hz	O
)	O
endogenous	O
neurotransmitter	O
overflow	O
from	O
the	O
isolated	O
perfused	O
kidney	O
of	O
vehicle	O
-	O
and	O
epinephrine	B-CHED
-	O
treated	O
rats	O
.	O

Renal	O
catecholamine	B-CHED
stores	O
and	O
stimulus	O
-	O
induced	O
overflow	O
in	O
the	O
vehicle	O
-	O
treated	O
group	O
consisted	O
of	O
norepinephrine	B-CHED
only	O
.	O

However	O
,	O
epinephrine	B-CHED
treatment	O
resulted	O
in	O
the	O
incorporation	O
of	O
epinephrine	B-CHED
into	O
renal	O
catecholamine	B-CHED
stores	O
such	O
that	O
approximately	O
40	O
%	O
of	O
the	O
catecholamine	B-CHED
present	O
was	O
epinephrine	B-CHED
while	O
the	O
norepinephrine	B-CHED
content	O
was	O
reduced	O
by	O
a	O
similar	O
degree	O
.	O

Total	O
tissue	O
catecholamine	B-CHED
content	O
of	O
the	O
kidney	O
on	O
a	O
molar	O
basis	O
was	O
unchanged	O
.	O

Stimulus	O
-	O
induced	O
fractional	O
overflow	O
of	O
neurotransmitter	O
from	O
the	O
epinephrine	B-CHED
-	O
treated	O
kidneys	O
was	O
approximately	O
twice	O
normal	O
and	O
consisted	O
of	O
both	O
norepinephrine	B-CHED
and	O
epinephrine	B-CHED
in	O
proportions	O
similar	O
to	O
those	O
found	O
in	O
the	O
kidney	O
.	O

This	O
difference	O
in	O
fractional	O
overflow	O
between	O
groups	O
was	O
not	O
affected	O
by	O
neuronal	O
and	O
extraneuronal	O
uptake	O
blockade	O
.	O

Propranolol	B-CHED
had	O
no	O
effect	O
on	O
stimulus	O
-	O
induced	O
overflow	O
in	O
either	O
group	O
.	O

Phentolamine	B-CHED
increased	O
stimulus	O
-	O
induced	O
overflow	O
in	O
both	O
groups	O
although	O
the	O
increment	O
in	O
overflow	O
was	O
greater	O
in	O
the	O
epinephrine	B-CHED
-	O
treated	O
group	O
.	O

In	O
conclusion	O
,	O
chronic	O
epinephrine	B-CHED
treatment	O
results	O
in	O
enhanced	O
fractional	O
neurotransmitter	O
overflow	O
.	O

However	O
,	O
neither	O
alterations	O
in	O
prejunctional	O
beta	O
-	O
adrenoceptor	O
influences	O
nor	O
alterations	O
in	O
neuronal	O
and	O
extraneuronal	O
uptake	O
mechanisms	O
appear	O
to	O
be	O
responsible	O
for	O
this	O
alteration	O
.	O

Furthermore	O
,	O
data	O
obtained	O
with	O
phentolamine	B-CHED
alone	O
do	O
not	O
suggest	O
alpha	O
-	O
adrenoceptor	O
desensitization	O
as	O
the	O
cause	O
of	O
the	O
enhanced	O
neurotransmitter	O
overflow	O
after	O
epinephrine	B-CHED
treatment	O
.	O

GABA	B-CHED
involvement	O
in	O
naloxone	B-CHED
induced	O
reversal	O
of	O
respiratory	O
paralysis	O
produced	O
by	O
thiopental	B-CHED
.	O

No	O
agent	O
is	O
yet	O
available	O
to	O
reverse	O
respiratory	O
paralysis	O
produced	O
by	O
CNS	O
depressants	O
,	O
such	O
as	O
general	O
anesthetics	O
.	O

In	O
this	O
study	O
naloxone	B-CHED
reversed	O
respiratory	O
paralysis	O
induced	O
by	O
thiopental	B-CHED
in	O
rats	O
.	O

25	O
mg	O
/	O
kg	O
,	O
i	O
.	O
v	O
.	O
thiopental	B-CHED
produced	O
anesthesia	O
without	O
altering	O
respiratory	O
rate	O
,	O
increased	O
GABA	B-CHED
,	O
decreased	O
glutamate	B-CHED
,	O
and	O
had	O
no	O
effect	O
on	O
aspartate	B-CHED
or	O
glycine	B-CHED
levels	O
compared	O
to	O
controls	O
in	O
rat	O
cortex	O
and	O
brain	O
stem	O
.	O

Pretreatment	O
of	O
rats	O
with	O
thiosemicarbazide	B-CHED
for	O
30	O
minutes	O
abolished	O
the	O
anesthetic	O
action	O
as	O
well	O
as	O
the	O
respiratory	O
depressant	O
action	O
of	O
thiopental	B-CHED
.	O

50	O
mg	O
/	O
kg	O
,	O
i	O
.	O
v	O
.	O
thiopental	B-CHED
produced	O
respiratory	O
arrest	O
with	O
further	O
increase	O
in	O
GABA	B-CHED
and	O
decrease	O
in	O
glutamate	B-CHED
again	O
in	O
cortex	O
and	O
brain	O
stem	O
without	O
affecting	O
any	O
of	O
the	O
amino	B-CHED
acids	I-CHED
studied	O
in	O
four	O
regions	O
of	O
rat	O
brain	O
.	O

Naloxone	B-CHED
(	O
2	O
.	O
5	O
mg	O
/	O
kg	O
,	O
i	O
.	O
v	O
.	O
)	O
reversed	O
respiratory	O
paralysis	O
,	O
glutamate	B-CHED
and	O
GABA	B-CHED
levels	O
to	O
control	O
values	O
in	O
brain	O
stem	O
and	O
cortex	O
with	O
no	O
changes	O
in	O
caudate	O
or	O
cerebellum	O
.	O

These	O
data	O
suggest	O
naloxone	B-CHED
reverses	O
respiratory	O
paralysis	O
produced	O
by	O
thiopental	B-CHED
and	O
involves	O
GABA	B-CHED
in	O
its	O
action	O
.	O

Diazepam	B-CHED
facilitates	O
reflex	O
bradycardia	O
in	O
conscious	O
rats	O
.	O

The	O
effects	O
of	O
diazepam	B-CHED
on	O
cardiovascular	O
function	O
were	O
assessed	O
in	O
conscious	O
rats	O
.	O

Intravenous	O
administration	O
of	O
diazepam	B-CHED
(	O
1	O
-	O
30	O
mg	O
kg	O
-	O
1	O
)	O
produced	O
a	O
dose	O
-	O
dependent	O
decrease	O
in	O
both	O
the	O
mean	O
arterial	O
pressure	O
and	O
the	O
heart	O
rate	O
.	O

Also	O
,	O
reflex	O
bradycardia	O
was	O
produced	O
in	O
rats	O
by	O
intravenous	O
infusion	O
of	O
adrenaline	B-CHED
(	O
1	O
.	O
25	O
-	O
2	O
.	O
5	O
micrograms	O
kg	O
-	O
1	O
)	O
.	O

Intravenous	O
pretreatment	O
of	O
the	O
rats	O
with	O
diazepam	B-CHED
,	O
although	O
causing	O
no	O
change	O
in	O
the	O
adrenaline	B-CHED
-	O
induced	O
pressor	O
effect	O
,	O
did	O
enhance	O
the	O
adrenaline	B-CHED
-	O
induced	O
reflex	O
bradycardia	O
.	O

However	O
,	O
the	O
diazepam	B-CHED
enhancement	O
of	O
adrenaline	B-CHED
-	O
induced	O
reflex	O
bradycardia	O
was	O
antagonized	O
by	O
pretreatment	O
of	O
rats	O
with	O
an	O
intravenous	O
dose	O
of	O
picrotoxin	B-CHED
(	O
an	O
agent	O
blocks	O
chloride	B-CHED
channels	O
by	O
binding	O
to	O
sites	O
associated	O
with	O
the	O
benzodiazepine	B-CHED
-	O
GABA	B-CHED
-	O
chloride	B-CHED
channel	O
macromolecular	O
complex	O
)	O
.	O

The	O
data	O
indicate	O
that	O
diazepam	B-CHED
acts	O
through	O
the	O
benzodiazepine	B-CHED
-	O
GABA	B-CHED
-	O
chloride	B-CHED
channel	O
macromolecular	O
complex	O
within	O
the	O
central	O
nervous	O
system	O
to	O
facilitate	O
reflex	O
bradycardia	O
mediated	O
through	O
baroreceptor	O
reflexes	O
in	O
response	O
to	O
an	O
acute	O
increase	O
in	O
arterial	O
pressure	O
.	O

Initial	O
potassium	B-CHED
loss	O
and	O
hypokalaemia	O
during	O
chlorthalidone	B-CHED
administration	O
in	O
patients	O
with	O
essential	O
hypertension	O
:	O
the	O
influence	O
of	O
dietary	O
sodium	B-CHED
restriction	O
.	O

To	O
investigate	O
the	O
initial	O
potassium	B-CHED
loss	O
and	O
development	O
of	O
hypokalaemia	O
during	O
the	O
administration	O
of	O
an	O
oral	O
diuretic	O
,	O
metabolic	O
balance	O
studies	O
were	O
performed	O
in	O
ten	O
patients	O
with	O
essential	O
hypertension	O
who	O
had	O
shown	O
hypokalaemia	O
under	O
prior	O
oral	O
diuretic	O
treatment	O
.	O

Chlorthalidone	B-CHED
(	O
50	O
mg	O
daily	O
)	O
was	O
given	O
for	O
14	O
days	O
.	O

Six	O
patients	O
received	O
a	O
normal	O
-	O
sodium	B-CHED
diet	O
and	O
four	O
a	O
low	O
-	O
sodium	B-CHED
(	O
17	O
mmol	O
/	O
day	O
)	O
diet	O
.	O

All	O
patients	O
had	O
a	O
normal	O
initial	O
total	O
body	O
potassium	B-CHED
(	O
40K	O
)	O
.	O

The	O
electrolyte	O
balances	O
,	O
weight	O
,	O
bromide	O
space	O
,	O
plasma	O
renin	O
activity	O
,	O
and	O
aldosterone	B-CHED
secretion	O
rate	O
were	O
measured	O
.	O

In	O
both	O
groups	O
a	O
potassium	B-CHED
deficit	O
developed	O
,	O
with	O
proportionally	O
larger	O
losses	O
from	O
the	O
extracellular	O
than	O
from	O
the	O
intracellular	O
compartment	O
.	O

In	O
the	O
normal	O
-	O
sodium	B-CHED
group	O
the	O
highest	O
mean	O
potassium	B-CHED
deficit	O
was	O
176	O
mmol	O
on	O
day	O
9	O
,	O
after	O
which	O
some	O
potassium	B-CHED
was	O
regained	O
;	O
in	O
the	O
low	O
-	O
sodium	B-CHED
group	O
the	O
highest	O
deficit	O
was	O
276	O
mmol	O
on	O
day	O
13	O
.	O

The	O
normal	O
-	O
sodium	B-CHED
group	O
showed	O
an	O
immediate	O
but	O
temporary	O
rise	O
of	O
the	O
renin	O
and	O
aldosterone	B-CHED
levels	O
;	O
in	O
the	O
low	O
-	O
sodium	B-CHED
group	O
renin	O
and	O
aldosterone	B-CHED
increased	O
more	O
slowly	O
but	O
remained	O
elevated	O
.	O

It	O
is	O
concluded	O
that	O
dietary	O
sodium	B-CHED
restriction	O
increases	O
diuretic	O
-	O
induced	O
potassium	B-CHED
loss	O
,	O
presumably	O
by	O
an	O
increased	O
activity	O
of	O
the	O
renin	O
-	O
angiotensin	B-CHED
-	O
aldosterone	B-CHED
system	O
,	O
while	O
sodium	B-CHED
delivery	O
to	O
the	O
distal	O
renal	O
tubules	O
remains	O
sufficiently	O
high	O
to	O
allow	O
increased	O
potassium	B-CHED
secretion	O
.	O

Reversal	O
of	O
neuroleptic	O
-	O
induced	O
catalepsy	O
by	O
novel	O
aryl	B-CHED
-	I-CHED
piperazine	I-CHED
anxiolytic	O
drugs	O
.	O

The	O
novel	O
anxiolytic	O
drug	O
,	O
buspirone	B-CHED
,	O
reverses	O
catalepsy	O
induced	O
by	O
haloperidol	B-CHED
.	O

A	O
series	O
of	O
aryl	B-CHED
-	I-CHED
piperazine	I-CHED
analogues	O
of	O
buspirone	B-CHED
and	O
other	O
5	B-CHED
-	I-CHED
hydroxytryptaminergic	I-CHED
agonists	I-CHED
were	O
tested	O
for	O
their	O
ability	O
to	O
reverse	O
haloperidol	B-CHED
induced	O
catalepsy	O
.	O

Those	O
drugs	O
with	O
strong	O
affinity	O
for	O
5	B-CHED
-	I-CHED
hydroxytryptamine1a	I-CHED
receptors	O
were	O
able	O
to	O
reverse	O
catalepsy	O
.	O

Drugs	O
with	O
affinity	O
for	O
other	O
5	B-CHED
-	I-CHED
HT	I-CHED
receptors	O
or	O
weak	O
affinity	O
were	O
ineffective	O
.	O

However	O
,	O
inhibition	O
of	O
postsynaptic	O
5	B-CHED
-	I-CHED
HT	I-CHED
receptors	O
neither	O
inhibited	O
nor	O
potentiated	O
reversal	O
of	O
catalepsy	O
and	O
leaves	O
open	O
the	O
question	O
as	O
to	O
the	O
site	O
or	O
mechanism	O
for	O
this	O
effect	O
.	O

Glycopyrronium	B-CHED
requirements	O
for	O
antagonism	O
of	O
the	O
muscarinic	O
side	O
effects	O
of	O
edrophonium	B-CHED
.	O

We	O
have	O
compared	O
,	O
in	O
60	O
adult	O
patients	O
,	O
the	O
cardiovascular	O
effects	O
of	O
glycopyrronium	B-CHED
5	O
micrograms	O
kg	O
-	O
1	O
and	O
10	O
micrograms	O
kg	O
-	O
1	O
given	O
either	O
simultaneously	O
or	O
1	O
min	O
before	O
edrophonium	B-CHED
1	O
mg	O
kg	O
-	O
1	O
.	O

Significant	O
differences	O
between	O
the	O
four	O
groups	O
were	O
detected	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

Both	O
groups	O
receiving	O
10	O
micrograms	O
kg	O
-	O
1	O
showed	O
increases	O
in	O
heart	O
rate	O
of	O
up	O
to	O
30	O
beat	O
min	O
-	O
1	O
(	O
95	O
%	O
confidence	O
limits	O
28	O
-	O
32	O
beat	O
min	O
-	O
1	O
)	O
.	O

Use	O
of	O
glycopyrronium	B-CHED
5	O
micrograms	O
kg	O
-	O
1	O
provided	O
greater	O
cardiovascular	O
stability	O
and	O
,	O
given	O
1	O
min	O
before	O
the	O
edrophonium	B-CHED
,	O
was	O
sufficient	O
to	O
minimize	O
early	O
,	O
edrophonium	B-CHED
-	O
induced	O
bradycardias	O
.	O

This	O
low	O
dose	O
of	O
glycopyrronium	B-CHED
provided	O
good	O
control	O
of	O
oropharyngeal	O
secretions	O
.	O

Selective	O
injection	O
of	O
iopentol	B-CHED
,	O
iohexol	B-CHED
and	O
metrizoate	B-CHED
into	O
the	O
left	O
coronary	O
artery	O
of	O
the	O
dog	O
.	O

Induction	O
of	O
ventricular	O
fibrillation	O
and	O
decrease	O
of	O
aortic	O
pressure	O
.	O

In	O
twenty	O
beagle	O
dogs	O
selective	O
injections	O
were	O
made	O
into	O
the	O
left	O
coronary	O
artery	O
with	O
iopentol	B-CHED
,	O
iohexol	B-CHED
and	O
metrizoate	B-CHED
in	O
doses	O
of	O
4	O
ml	O
,	O
8	O
ml	O
and	O
16	O
ml	O
.	O

Thirty	O
-	O
six	O
iopentol	B-CHED
injections	O
,	O
35	O
iohexol	B-CHED
injections	O
and	O
37	O
metrizoate	B-CHED
injections	O
were	O
made	O
.	O

Frequencies	O
of	O
ventricular	O
fibrillation	O
were	O
significantly	O
lower	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
after	O
iopentol	B-CHED
(	O
0	O
%	O
)	O
and	O
iohexol	B-CHED
(	O
3	O
%	O
)	O
than	O
after	O
metrizoate	B-CHED
(	O
22	O
%	O
)	O
.	O

Iopentol	B-CHED
and	O
iohexol	B-CHED
also	O
produced	O
significantly	O
less	O
decrease	O
in	O
aortic	O
blood	O
pressure	O
than	O
metrizoate	B-CHED
at	O
the	O
different	O
doses	O
.	O

Thyroid	O
function	O
and	O
urine	O
-	O
concentrating	O
ability	O
during	O
lithium	B-CHED
treatment	O
.	O

It	O
has	O
been	O
suggested	O
that	O
adenylate	O
cyclase	O
inhibition	O
may	O
be	O
important	O
in	O
the	O
development	O
of	O
both	O
nephrogenic	O
diabetes	O
insipidus	O
and	O
hypothyroidism	O
during	O
lithium	B-CHED
treatment	O
.	O

We	O
measured	O
serum	O
thyroxine	B-CHED
and	O
urine	O
-	O
concentrating	O
ability	O
(	O
Umax	O
)	O
in	O
response	O
to	O
desmopressin	O
(	O
DDAVP	O
)	O
in	O
85	O
patients	O
receiving	O
lithium	B-CHED
.	O

Hypothyroidism	O
developed	O
in	O
eight	O
patients	O
while	O
they	O
were	O
taking	O
lithium	B-CHED
.	O

Impaired	O
Umax	O
was	O
found	O
in	O
both	O
euthyroid	O
and	O
hypothyroid	O
patients	O
while	O
some	O
hypothyroid	O
patients	O
concentrated	O
their	O
urine	O
well	O
.	O

It	O
is	O
concluded	O
that	O
the	O
dominant	O
mechanisms	O
by	O
which	O
lithium	B-CHED
exerts	O
these	O
two	O
effects	O
are	O
different	O
.	O

Remodelling	O
of	O
nerve	O
structure	O
in	O
experimental	O
isoniazid	B-CHED
neuropathy	O
in	O
the	O
rat	O
.	O

The	O
neuropathy	O
caused	O
by	O
a	O
single	O
dose	O
of	O
isoniazid	B-CHED
in	O
rats	O
was	O
studied	O
with	O
a	O
computer	O
-	O
assisted	O
morphometric	O
method	O
.	O

Scatter	O
diagrams	O
of	O
the	O
g	O
ratio	O
(	O
quotient	O
fibre	O
diameter	O
/	O
axon	O
diameter	O
)	O
define	O
regenerating	O
fibres	O
as	O
a	O
distinct	O
population	O
,	O
distinguishable	O
from	O
the	O
surviving	O
fibres	O
by	O
reduced	O
sheath	O
thickness	O
and	O
reduced	O
axon	O
calibre	O
.	O

There	O
was	O
also	O
evidence	O
of	O
a	O
subtle	O
direct	O
toxic	O
effect	O
on	O
the	O
entire	O
fibre	O
population	O
,	O
causing	O
axon	O
shrinkage	O
masked	O
by	O
readjustment	O
of	O
the	O
myelin	O
sheath	O
.	O

Multicenter	O
,	O
double	O
-	O
blind	O
,	O
multiple	O
-	O
dose	O
,	O
parallel	O
-	O
groups	O
efficacy	O
and	O
safety	O
trial	O
of	O
azelastine	B-CHED
,	O
chlorpheniramine	B-CHED
,	O
and	O
placebo	O
in	O
the	O
treatment	O
of	O
spring	O
allergic	O
rhinitis	O
.	O

Azelastine	B-CHED
,	O
a	O
novel	O
antiallergic	O
medication	O
,	O
was	O
compared	O
with	O
chlorpheniramine	B-CHED
maleate	I-CHED
and	O
placebo	O
for	O
efficacy	O
and	O
safety	O
in	O
the	O
treatment	O
of	O
spring	O
allergic	O
rhinitis	O
in	O
a	O
multicenter	O
,	O
double	O
-	O
blind	O
,	O
multiple	O
-	O
dose	O
,	O
parallel	O
-	O
groups	O
study	O
.	O

One	O
hundred	O
fifty	O
-	O
five	O
subjects	O
participated	O
.	O

Subjects	O
ranged	O
in	O
age	O
from	O
18	O
to	O
60	O
years	O
of	O
age	O
and	O
had	O
at	O
least	O
a	O
2	O
-	O
year	O
history	O
of	O
spring	O
allergic	O
rhinitis	O
,	O
confirmed	O
by	O
positive	O
skin	O
test	O
to	O
spring	O
aeroallergens	O
.	O

Medications	O
were	O
given	O
four	O
times	O
daily	O
;	O
the	O
azelastine	B-CHED
groups	O
received	O
0	O
.	O
5	O
,	O
1	O
.	O
0	O
,	O
or	O
2	O
.	O
0	O
mg	O
in	O
the	O
morning	O
and	O
evening	O
with	O
placebo	O
in	O
the	O
early	O
and	O
late	O
afternoon	O
;	O
the	O
chlorpheniramine	B-CHED
group	O
received	O
4	O
.	O
0	O
mg	O
four	O
times	O
daily	O
.	O

Daily	O
subject	O
symptom	O
cards	O
were	O
completed	O
during	O
a	O
screening	O
period	O
to	O
assess	O
pretreatment	O
symptoms	O
and	O
during	O
a	O
4	O
-	O
week	O
treatment	O
period	O
while	O
subjects	O
received	O
study	O
medications	O
.	O

Individual	O
symptoms	O
,	O
total	O
symptoms	O
,	O
and	O
major	O
symptoms	O
were	O
compared	O
to	O
determine	O
efficacy	O
of	O
medication	O
.	O

Elicited	O
,	O
volunteered	O
,	O
and	O
observed	O
adverse	O
experiences	O
were	O
recorded	O
for	O
each	O
subject	O
and	O
compared	O
among	O
groups	O
.	O

Vital	O
signs	O
,	O
body	O
weights	O
,	O
serum	O
chemistry	O
values	O
,	O
complete	O
blood	O
cell	O
counts	O
,	O
urine	O
studies	O
,	O
and	O
electrocardiograms	O
were	O
obtained	O
for	O
each	O
subject	O
and	O
compared	O
among	O
groups	O
.	O

Symptoms	O
relief	O
in	O
the	O
group	O
receiving	O
the	O
highest	O
concentration	O
of	O
azelastine	B-CHED
(	O
2	O
.	O
0	O
mg	O
twice	O
daily	O
)	O
was	O
statistically	O
greater	O
than	O
in	O
the	O
placebo	O
group	O
during	O
all	O
weeks	O
of	O
the	O
study	O
.	O

Lower	O
doses	O
of	O
azelastine	B-CHED
were	O
statistically	O
more	O
effective	O
than	O
placebo	O
only	O
during	O
portions	O
of	O
the	O
first	O
3	O
weeks	O
of	O
the	O
study	O
.	O

In	O
contrast	O
,	O
although	O
the	O
chlorpheniramine	B-CHED
group	O
did	O
have	O
fewer	O
symptoms	O
than	O
the	O
placebo	O
group	O
during	O
the	O
study	O
,	O
the	O
difference	O
never	O
reached	O
statistical	O
significance	O
during	O
any	O
week	O
of	O
the	O
study	O
.	O

There	O
were	O
no	O
serious	O
side	O
effects	O
in	O
any	O
of	O
the	O
treatment	O
groups	O
.	O

Drowsiness	O
and	O
altered	O
taste	O
perception	O
were	O
increased	O
significantly	O
over	O
placebo	O
only	O
in	O
the	O
high	O
-	O
dose	O
azelastine	B-CHED
group	O
.	O

Azelastine	B-CHED
appears	O
to	O
be	O
a	O
safe	O
,	O
efficacious	O
medication	O
for	O
seasonal	O
allergic	O
rhinitis	O
.	O

Toxicity	O
due	O
to	O
remission	O
inducing	O
drugs	O
in	O
rheumatoid	O
arthritis	O
.	O

Association	O
with	O
HLA	O
-	O
B35	O
and	O
Cw4	O
antigens	O
.	O

Twenty	O
-	O
five	O
patients	O
with	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
who	O
developed	O
toxicity	O
while	O
taking	O
remission	O
inducing	O
drugs	O
and	O
30	O
without	O
toxicity	O
were	O
studied	O
for	O
possible	O
associations	O
with	O
class	O
I	O
and	O
II	O
HLA	O
antigens	O
.	O

A	O
strong	O
association	O
has	O
been	O
found	O
between	O
nephritis	O
and	O
dermatitis	O
due	O
to	O
Tiopronin	B-CHED
(	O
a	O
D	B-CHED
-	I-CHED
Penicillamine	I-CHED
like	O
compound	O
)	O
and	O
class	O
I	O
antigens	O
B35	O
-	O
Cw4	O
,	O
and	O
between	O
dermatitis	O
due	O
to	O
gold	B-CHED
thiosulphate	B-CHED
and	O
B35	O
.	O

Compared	O
to	O
healthy	O
controls	O
a	O
lower	O
DR5	O
frequency	O
was	O
observed	O
in	O
patients	O
with	O
RA	O
except	O
for	O
the	O
Tiopronin	B-CHED
related	O
nephritis	O
group	O
.	O

Transient	O
contralateral	O
rotation	O
following	O
unilateral	O
substantia	O
nigra	O
lesion	O
reflects	O
susceptibility	O
of	O
the	O
nigrostriatal	O
system	O
to	O
exhaustion	O
by	O
amphetamine	B-CHED
.	O

Following	O
unilateral	O
6	B-CHED
-	I-CHED
OHDA	I-CHED
induced	O
SN	O
lesion	O
,	O
a	O
transient	O
period	O
of	O
contralateral	O
rotation	O
has	O
been	O
reported	O
to	O
precede	O
the	O
predominant	O
ipsilateral	O
circling	O
.	O

In	O
order	O
to	O
clarify	O
the	O
nature	O
of	O
this	O
initial	O
contralateral	O
rotation	O
we	O
examined	O
the	O
effect	O
of	O
the	O
duration	O
of	O
recovery	O
period	O
after	O
the	O
lesion	O
,	O
on	O
amphetamine	B-CHED
-	O
induced	O
rotational	O
behavior	O
.	O

Three	O
days	O
post	O
lesion	O
,	O
most	O
rats	O
circled	O
predominantly	O
contralaterally	O
to	O
the	O
lesion	O
.	O

Such	O
contralateral	O
rotation	O
may	O
result	O
from	O
either	O
degeneration	O
-	O
induced	O
breakdown	O
of	O
the	O
DA	O
pool	O
,	O
or	O
lesion	O
-	O
induced	O
increase	O
of	O
DA	O
turnover	O
in	O
the	O
spared	O
neurons	O
.	O

A	O
substantial	O
degree	O
of	O
contralateral	O
preference	O
was	O
still	O
evident	O
when	O
amphetamine	B-CHED
was	O
administered	O
for	O
the	O
first	O
time	O
24	O
days	O
after	O
lesioning	O
,	O
indicating	O
involvement	O
of	O
spared	O
cells	O
in	O
the	O
contralateral	O
rotation	O
.	O

However	O
,	O
regardless	O
of	O
the	O
duration	O
of	O
recovery	O
(	O
and	O
irrespective	O
of	O
either	O
lesion	O
volume	O
,	O
amphetamine	B-CHED
dose	O
,	O
or	O
post	O
-	O
lesion	O
motor	O
exercise	O
)	O
,	O
amphetamine	B-CHED
-	O
induced	O
rotation	O
tended	O
to	O
become	O
gradually	O
more	O
ipsilateral	O
as	O
the	O
observation	O
session	O
progressed	O
,	O
and	O
all	O
rats	O
circled	O
ipsilaterally	O
to	O
the	O
lesion	O
in	O
response	O
to	O
further	O
amphetamine	B-CHED
injections	O
.	O

These	O
findings	O
suggest	O
that	O
amphetamine	B-CHED
has	O
an	O
irreversible	O
effect	O
on	O
the	O
post	O
-	O
lesion	O
DA	O
pool	O
contributing	O
to	O
contralateral	O
rotation	O
.	O

Mitomycin	B-CHED
C	I-CHED
associated	O
hemolytic	O
uremic	O
syndrome	O
.	O

Mitomycin	B-CHED
C	I-CHED
associated	O
Hemolytic	O
Uremic	O
Syndrome	O
(	O
HUS	O
)	O
is	O
a	O
potentially	O
fatal	O
but	O
uncommon	O
condition	O
that	O
is	O
not	O
yet	O
widely	O
recognised	O
.	O

It	O
consists	O
of	O
microangiopathic	O
hemolytic	O
anemia	O
,	O
thrombocytopenia	O
and	O
progressive	O
renal	O
failure	O
associated	O
with	O
mitomycin	B-CHED
C	I-CHED
treatment	O
and	O
affects	O
about	O
10	O
%	O
of	O
patients	O
treated	O
with	O
this	O
agent	O
.	O

The	O
renal	O
failure	O
usually	O
develops	O
about	O
8	O
-	O
10	O
mth	O
after	O
start	O
of	O
mitomycin	B-CHED
C	I-CHED
treatment	O
and	O
the	O
mortality	O
is	O
approximately	O
60	O
%	O
from	O
renal	O
failure	O
or	O
pulmonary	O
edema	O
.	O

Renal	O
lesions	O
are	O
similar	O
to	O
those	O
seen	O
in	O
idiopathic	O
HUS	O
and	O
include	O
arteriolar	O
fibrin	O
thrombi	O
,	O
expanded	O
subendothelial	O
zones	O
in	O
glomerular	O
capillary	O
walls	O
,	O
ischemic	O
wrinkling	O
of	O
glomerular	O
basement	O
membranes	O
and	O
mesangiolysis	O
.	O

The	O
mechanism	O
of	O
action	O
is	O
postulated	O
as	O
mitomycin	B-CHED
C	I-CHED
-	O
induced	O
endothelial	O
cell	O
damage	O
.	O

We	O
describe	O
the	O
clinical	O
course	O
and	O
pathological	O
findings	O
in	O
a	O
65	O
yr	O
-	O
old	O
man	O
with	O
gastric	O
adenocarcinoma	O
who	O
developed	O
renal	O
failure	O
and	O
thrombocytopenia	O
while	O
on	O
treatment	O
with	O
mitomycin	B-CHED
C	I-CHED
and	O
died	O
in	O
pulmonary	O
edema	O
.	O

Ketanserin	B-CHED
pretreatment	O
reverses	O
alfentanil	B-CHED
-	O
induced	O
muscle	O
rigidity	O
.	O

Systemic	O
pretreatment	O
with	O
ketanserin	B-CHED
,	O
a	O
relatively	O
specific	O
type	O
-	O
2	O
serotonin	B-CHED
receptor	O
antagonist	O
,	O
significantly	O
attenuated	O
the	O
muscle	O
rigidity	O
produced	O
in	O
rats	O
by	O
the	O
potent	O
short	O
-	O
acting	O
opiate	O
agonist	O
alfentanil	B-CHED
.	O

Following	O
placement	O
of	O
subcutaneous	O
electrodes	O
in	O
each	O
animal	O
'	O
s	O
left	O
gastrocnemius	O
muscle	O
,	O
rigidity	O
was	O
assessed	O
by	O
analyzing	O
root	O
-	O
mean	O
-	O
square	O
electromyographic	O
activity	O
.	O

Intraperitoneal	O
ketanserin	B-CHED
administration	O
at	O
doses	O
of	O
0	O
.	O
63	O
and	O
2	O
.	O
5	O
mg	O
/	O
kg	O
prevented	O
the	O
alfentanil	B-CHED
-	O
induced	O
increase	O
in	O
electromyographic	O
activity	O
compared	O
with	O
animals	O
pretreated	O
with	O
saline	O
.	O

Chlordiazepoxide	B-CHED
at	O
doses	O
up	O
to	O
10	O
mg	O
/	O
kg	O
failed	O
to	O
significantly	O
influence	O
the	O
rigidity	O
produced	O
by	O
alfentanil	B-CHED
.	O

Despite	O
the	O
absence	O
of	O
rigidity	O
,	O
animals	O
that	O
received	O
ketanserin	B-CHED
(	O
greater	O
than	O
0	O
.	O
31	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
followed	O
by	O
alfentanil	B-CHED
were	O
motionless	O
,	O
flaccid	O
,	O
and	O
less	O
responsive	O
to	O
external	O
stimuli	O
than	O
were	O
animals	O
receiving	O
alfentanil	B-CHED
alone	O
.	O

Rats	O
that	O
received	O
ketanserin	B-CHED
and	O
alfentanil	B-CHED
exhibited	O
less	O
rearing	O
and	O
exploratory	O
behavior	O
at	O
the	O
end	O
of	O
the	O
60	O
-	O
min	O
recording	O
period	O
than	O
did	O
animals	O
that	O
received	O
ketanserin	B-CHED
alone	O
.	O

These	O
results	O
,	O
in	O
combination	O
with	O
previous	O
work	O
,	O
suggest	O
that	O
muscle	O
rigidity	O
,	O
a	O
clinically	O
relevant	O
side	O
-	O
effect	O
of	O
parenteral	O
narcotic	O
administration	O
,	O
may	O
be	O
partly	O
mediated	O
via	O
serotonergic	O
pathways	O
.	O

Pretreatment	O
with	O
type	O
-	O
2	O
serotonin	B-CHED
antagonists	O
may	O
be	O
clinically	O
useful	O
in	O
attenuating	O
opiate	O
-	O
induced	O
rigidity	O
,	O
although	O
further	O
studies	O
will	O
be	O
necessary	O
to	O
assess	O
the	O
interaction	O
of	O
possibly	O
enhanced	O
CNS	O
,	O
cardiovascular	O
,	O
and	O
respiratory	O
depression	O
.	O

Antagonism	O
of	O
diazepam	B-CHED
-	O
induced	O
sedative	O
effects	O
by	O
Ro15	B-CHED
-	I-CHED
1788	I-CHED
in	O
patients	O
after	O
surgery	O
under	O
lumbar	O
epidural	O
block	O
.	O

A	O
double	O
-	O
blind	O
placebo	O
-	O
controlled	O
investigation	O
of	O
efficacy	O
and	O
safety	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
efficacy	O
of	O
Ro15	B-CHED
-	I-CHED
1788	I-CHED
and	O
a	O
placebo	O
in	O
reversing	O
diazepam	B-CHED
-	O
induced	O
effects	O
after	O
surgery	O
under	O
epidural	O
block	O
,	O
and	O
to	O
evaluate	O
the	O
local	O
tolerance	O
and	O
general	O
safety	O
of	O
Ro15	B-CHED
-	I-CHED
1788	I-CHED
.	O

Fifty	O
-	O
seven	O
patients	O
were	O
sedated	O
with	O
diazepam	B-CHED
for	O
surgery	O
under	O
epidural	O
anaesthesia	O
.	O

Antagonism	O
of	O
diazepam	B-CHED
-	O
induced	O
effects	O
by	O
Ro15	B-CHED
-	I-CHED
1788	I-CHED
was	O
investigated	O
postoperatively	O
in	O
a	O
double	O
-	O
blind	O
placebo	O
-	O
controlled	O
trial	O
.	O

The	O
patient	O
'	O
s	O
subjective	O
assessment	O
of	O
mood	O
rating	O
,	O
an	O
objective	O
test	O
of	O
performance	O
,	O
a	O
test	O
for	O
amnesia	O
,	O
and	O
vital	O
signs	O
were	O
recorded	O
for	O
up	O
to	O
300	O
min	O
after	O
administration	O
of	O
the	O
trial	O
drug	O
.	O

No	O
significant	O
differences	O
between	O
the	O
two	O
groups	O
were	O
observed	O
for	O
mood	O
rating	O
,	O
amnesia	O
,	O
or	O
vital	O
signs	O
.	O

The	O
Ro15	B-CHED
-	I-CHED
1788	I-CHED
group	O
showed	O
a	O
significant	O
improvement	O
in	O
the	O
performance	O
test	O
up	O
to	O
120	O
min	O
after	O
administration	O
of	O
the	O
drug	O
.	O

There	O
was	O
no	O
evidence	O
of	O
reaction	O
at	O
the	O
injection	O
site	O
.	O

Chorea	O
associated	O
with	O
oral	B-CHED
contraception	I-CHED
.	O

Three	O
patients	O
developed	O
chorea	O
while	O
receiving	O
oral	B-CHED
contraceptives	I-CHED
.	O

Two	O
were	O
young	O
patients	O
whose	O
chorea	O
developed	O
long	O
after	O
treatment	O
had	O
been	O
started	O
and	O
disappeared	O
soon	O
after	O
it	O
had	O
been	O
discontinued	O
.	O

The	O
third	O
patient	O
had	O
acute	O
amphetamine	B-CHED
-	O
induced	O
chorea	O
after	O
prolonged	O
oral	B-CHED
contraception	I-CHED
.	O

Prolonged	O
administration	O
of	O
female	O
sex	O
hormones	O
is	O
a	O
possible	O
cause	O
of	O
chorea	O
in	O
women	O
who	O
have	O
not	O
previously	O
had	O
chorea	O
or	O
rheumatic	O
fever	O
.	O

Co	O
-	O
carcinogenic	O
effect	O
of	O
retinyl	B-CHED
acetate	I-CHED
on	O
forestomach	O
carcinogenesis	O
of	O
male	O
F344	O
rats	O
induced	O
with	O
butylated	B-CHED
hydroxyanisole	I-CHED
.	O

The	O
potential	O
modifying	O
effect	O
of	O
retinyl	B-CHED
acetate	I-CHED
(	O
RA	B-CHED
)	O
on	O
butylated	B-CHED
hydroxyanisole	I-CHED
(	O
BHA	B-CHED
)	O
-	O
induced	O
rat	O
forestomach	O
tumorigenesis	O
was	O
examined	O
.	O

Male	O
F344	O
rats	O
,	O
5	O
weeks	O
of	O
age	O
,	O
were	O
maintained	O
on	O
diet	O
containing	O
1	O
%	O
or	O
2	O
%	O
BHA	B-CHED
by	O
weight	O
and	O
simultaneously	O
on	O
drinking	O
water	O
supplemented	O
with	O
RA	B-CHED
at	O
various	O
concentrations	O
(	O
w	O
/	O
v	O
)	O
for	O
52	O
weeks	O
.	O

In	O
groups	O
given	O
2	O
%	O
BHA	B-CHED
,	O
although	O
marked	O
hyperplastic	O
changes	O
of	O
the	O
forestomach	O
epithelium	O
were	O
observed	O
in	O
all	O
animals	O
,	O
co	O
-	O
administration	O
of	O
0	O
.	O
25	O
%	O
RA	B-CHED
significantly	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
increased	O
the	O
incidence	O
of	O
forestomach	O
tumors	O
(	O
squamous	O
cell	O
papilloma	O
and	O
carcinoma	O
)	O
to	O
60	O
%	O
(	O
9	O
/	O
15	O
,	O
2	O
rats	O
with	O
carcinoma	O
)	O
from	O
15	O
%	O
(	O
3	O
/	O
20	O
,	O
one	O
rat	O
with	O
carcinoma	O
)	O
in	O
the	O
group	O
given	O
RA	B-CHED
-	O
free	O
water	O
.	O

In	O
rats	O
given	O
1	O
%	O
BHA	B-CHED
,	O
RA	B-CHED
co	O
-	O
administered	O
at	O
a	O
dose	O
of	O
0	O
.	O
05	O
,	O
0	O
.	O
1	O
,	O
0	O
.	O
2	O
or	O
0	O
.	O
25	O
%	O
showed	O
a	O
dose	O
-	O
dependent	O
enhancing	O
effect	O
on	O
the	O
development	O
of	O
the	O
BHA	B-CHED
-	O
induced	O
epithelial	O
hyperplasia	O
.	O

Tumors	O
,	O
all	O
papillomas	O
,	O
were	O
induced	O
in	O
3	O
rats	O
(	O
17	O
%	O
)	O
with	O
0	O
.	O
25	O
%	O
RA	B-CHED
and	O
in	O
one	O
rat	O
(	O
10	O
%	O
)	O
with	O
0	O
.	O
05	O
%	O
RA	B-CHED
co	O
-	O
administration	O
.	O

RA	B-CHED
alone	O
did	O
not	O
induce	O
hyperplastic	O
changes	O
in	O
the	O
forestomach	O
.	O

These	O
findings	O
indicate	O
that	O
RA	B-CHED
acted	O
as	O
a	O
co	O
-	O
carcinogen	O
in	O
the	O
BHA	B-CHED
forestomach	O
carcinogenesis	O
of	O
the	O
rat	O
.	O

A	O
prospective	O
study	O
on	O
the	O
dose	O
dependency	O
of	O
cardiotoxicity	O
induced	O
by	O
mitomycin	B-CHED
C	I-CHED
.	O

Since	O
1975	O
mitomycin	B-CHED
C	I-CHED
(	O
MMC	B-CHED
)	O
has	O
been	O
suggested	O
to	O
be	O
cardiotoxic	O
,	O
especially	O
when	O
combined	O
with	O
or	O
given	O
following	O
doxorubicin	B-CHED
.	O

Data	O
on	O
dose	O
dependency	O
or	O
incidence	O
concerning	O
this	O
side	O
effect	O
were	O
not	O
known	O
.	O

We	O
have	O
initiated	O
a	O
prospective	O
study	O
to	O
obtain	O
some	O
more	O
data	O
on	O
these	O
subjects	O
.	O

Forty	O
-	O
four	O
MMC	B-CHED
-	O
treated	O
patients	O
were	O
studied	O
,	O
37	O
of	O
them	O
could	O
be	O
evaluated	O
.	O

All	O
patients	O
were	O
studied	O
by	O
repeated	O
physical	O
examinations	O
,	O
chest	O
X	O
-	O
rays	O
,	O
electro	O
-	O
and	O
echocardiography	O
and	O
radionuclide	O
left	O
ventricular	O
ejection	O
fraction	O
(	O
EF	O
)	O
determinations	O
.	O

The	O
results	O
were	O
evaluated	O
per	O
cumulative	O
dose	O
level	O
.	O

One	O
of	O
the	O
patients	O
developed	O
cardiac	O
failure	O
after	O
30	O
mg	O
m	O
-	O
2	O
MMC	B-CHED
and	O
only	O
150	O
mg	O
m	O
-	O
2	O
doxorubicin	B-CHED
.	O

The	O
cardiac	O
failure	O
was	O
predicted	O
by	O
a	O
drop	O
in	O
EF	O
determined	O
during	O
a	O
cold	O
pressor	O
test	O
.	O

None	O
of	O
the	O
other	O
patients	O
developed	O
clinical	O
cardiotoxicity	O
,	O
nor	O
did	O
the	O
studied	O
parameters	O
change	O
.	O

The	O
literature	O
on	O
this	O
subject	O
was	O
also	O
reviewed	O
.	O

Based	O
on	O
the	O
combined	O
data	O
from	O
the	O
present	O
study	O
and	O
the	O
literature	O
,	O
we	O
suggest	O
that	O
MMC	B-CHED
-	O
related	O
cardiotoxicity	O
is	O
dose	O
dependent	O
,	O
occurring	O
at	O
cumulative	O
dose	O
levels	O
of	O
30	O
mg	O
m	O
-	O
2	O
or	O
more	O
,	O
mainly	O
in	O
patients	O
also	O
(	O
previously	O
or	O
simultaneously	O
)	O
treated	O
with	O
doxorubicin	B-CHED
.	O

The	O
incidence	O
is	O
likely	O
to	O
be	O
less	O
than	O
10	O
%	O
even	O
for	O
this	O
risk	O
group	O
.	O

Reversible	O
cerebral	O
lesions	O
associated	O
with	O
tiazofurin	B-CHED
usage	O
:	O
MR	O
demonstration	O
.	O

Tiazofurin	B-CHED
is	O
an	O
experimental	O
chemotherapeutic	O
agent	O
currently	O
undergoing	O
clinical	O
evaluation	O
.	O

We	O
report	O
our	O
results	O
with	O
magnetic	O
resonance	O
(	O
MR	O
)	O
in	O
demonstrating	O
reversible	O
cerebral	O
abnormalities	O
concurrent	O
with	O
the	O
use	O
of	O
this	O
drug	O
.	O

The	O
abnormalities	O
on	O
MR	O
were	O
correlated	O
with	O
findings	O
on	O
CT	O
as	O
well	O
as	O
with	O
cerebral	O
angiography	O
.	O

The	O
utility	O
of	O
MR	O
in	O
the	O
evaluation	O
of	O
patients	O
receiving	O
this	O
new	O
agent	O
is	O
illustrated	O
.	O

Receptor	O
mechanisms	O
of	O
nicotine	B-CHED
-	O
induced	O
locomotor	O
hyperactivity	O
in	O
chronic	O
nicotine	B-CHED
-	O
treated	O
rats	O
.	O

Rats	O
were	O
pretreated	O
with	O
saline	O
or	O
nicotine	B-CHED
(	O
1	O
.	O
5	O
mg	O
/	O
kg	O
per	O
day	O
)	O
by	O
subcutaneously	O
implanting	O
each	O
animal	O
with	O
an	O
Alzet	O
osmotic	O
mini	O
-	O
pump	O
which	O
continuously	O
released	O
saline	O
or	O
nicotine	B-CHED
for	O
1	O
,	O
5	O
and	O
14	O
days	O
.	O

At	O
the	O
end	O
of	O
each	O
pretreatment	O
period	O
,	O
animals	O
were	O
used	O
for	O
(	O
i	O
)	O
determining	O
their	O
locomotor	O
response	O
to	O
acutely	O
injected	O
nicotine	B-CHED
(	O
0	O
.	O
2	O
mg	O
/	O
kg	O
,	O
s	O
.	O
c	O
.	O
)	O
and	O
(	O
ii	O
)	O
measuring	O
the	O
density	O
of	O
L	O
-	O
[	O
3H	O
]	O
nicotine	B-CHED
and	O
[	O
3H	O
]	O
spiperone	B-CHED
binding	O
sites	O
in	O
the	O
striatum	O
.	O

We	O
observed	O
no	O
changes	O
in	O
nicotine	B-CHED
-	O
induced	O
locomotor	O
response	O
,	O
striatal	O
L	O
-	O
[	O
3H	O
]	O
nicotine	B-CHED
and	O
[	O
3H	O
]	O
spiperone	B-CHED
binding	O
in	O
the	O
animals	O
pretreated	O
with	O
nicotine	B-CHED
for	O
1	O
day	O
.	O

In	O
rats	O
which	O
were	O
pretreated	O
with	O
nicotine	B-CHED
for	O
5	O
days	O
,	O
there	O
was	O
a	O
significant	O
increase	O
in	O
the	O
nicotine	B-CHED
-	O
stimulated	O
locomotor	O
response	O
which	O
was	O
associated	O
with	O
an	O
increase	O
in	O
the	O
number	O
of	O
L	O
-	O
[	O
3H	O
]	O
nicotine	B-CHED
binding	O
sites	O
and	O
also	O
with	O
an	O
elevated	O
dopamine	B-CHED
(	O
DA	B-CHED
)	O
level	O
in	O
the	O
striatum	O
.	O

The	O
number	O
of	O
striatal	O
[	O
3H	O
]	O
spiperone	B-CHED
binding	O
sites	O
was	O
not	O
affected	O
.	O

In	O
animals	O
pretreated	O
with	O
nicotine	B-CHED
for	O
14	O
days	O
,	O
the	O
nicotine	B-CHED
-	O
induced	O
locomotor	O
response	O
remained	O
to	O
be	O
potentiated	O
.	O

However	O
,	O
this	O
response	O
was	O
correlated	O
with	O
an	O
elevated	O
number	O
of	O
striatal	O
[	O
3H	O
]	O
spiperone	B-CHED
binding	O
sites	O
,	O
whereas	O
the	O
number	O
of	O
striatal	O
L	O
-	O
[	O
3H	O
]	O
nicotine	B-CHED
binding	O
sites	O
and	O
the	O
striatal	O
DA	B-CHED
level	O
were	O
normal	O
.	O

These	O
results	O
suggest	O
that	O
chronic	O
nicotine	B-CHED
-	O
treated	O
rats	O
develop	O
locomotor	O
hyperactivity	O
in	O
response	O
to	O
nicotine	B-CHED
initially	O
due	O
to	O
increases	O
of	O
both	O
the	O
density	O
of	O
nicotinic	O
receptors	O
and	O
DA	B-CHED
concentration	O
,	O
followed	O
by	O
inducing	O
DA	B-CHED
receptor	O
supersensitivity	O
in	O
the	O
striatum	O
.	O

Amelioration	O
of	O
bendrofluazide	B-CHED
-	O
induced	O
hypokalemia	O
by	O
timolol	B-CHED
.	O

The	O
beta	O
adrenergic	O
blocking	O
drug	O
,	O
timolol	B-CHED
,	O
tended	O
to	O
correct	O
the	O
hypokalemia	O
of	O
short	O
-	O
term	O
bendrofluazide	B-CHED
treatment	O
in	O
6	O
healthy	O
male	O
subjects	O
and	O
although	O
the	O
effect	O
was	O
small	O
it	O
was	O
significant	O
.	O

Timolol	B-CHED
also	O
reduced	O
the	O
rise	O
in	O
plasma	O
aldosterone	B-CHED
and	O
urine	O
potassium	B-CHED
excretion	O
following	O
bendrofluazide	B-CHED
and	O
increased	O
the	O
urine	O
sodium	B-CHED
/	O
potassium	B-CHED
ratio	O
.	O

There	O
was	O
no	O
evidence	O
of	O
a	O
shift	O
of	O
potassium	B-CHED
from	O
the	O
intracellular	O
to	O
the	O
extracellular	O
space	O
.	O

St	O
.	O

Anthony	O
'	O
s	O
fire	O
,	O
then	O
and	O
now	O
:	O
a	O
case	O
report	O
and	O
historical	O
review	O
.	O

A	O
rare	O
case	O
of	O
morbid	O
vasospasm	O
,	O
together	O
with	O
striking	O
angiographic	O
findings	O
,	O
is	O
described	O
secondary	O
to	O
the	O
ingestion	O
of	O
methysergide	B-CHED
by	O
a	O
48	O
-	O
year	O
-	O
old	O
woman	O
.	O

A	O
brief	O
review	O
of	O
the	O
literature	O
on	O
similar	O
cases	O
is	O
presented	O
.	O

A	O
discussion	O
of	O
the	O
history	O
of	O
ergot	B-CHED
includes	O
its	O
original	O
discovery	O
,	O
the	O
epidemics	O
of	O
gangrene	O
that	O
it	O
has	O
caused	O
through	O
the	O
ages	O
and	O
its	O
past	O
and	O
present	O
role	O
in	O
the	O
management	O
of	O
migraine	O
headache	O
.	O

Despite	O
the	O
advent	O
of	O
calcium	B-CHED
channel	O
blockers	O
and	O
beta	O
-	O
adrenergic	O
antagonists	O
,	O
ergot	B-CHED
preparations	O
continue	O
to	O
play	O
a	O
major	O
role	O
in	O
migraine	O
therapy	O
,	O
so	O
that	O
the	O
danger	O
of	O
St	O
.	O

Anthony	O
'	O
s	O
fire	O
persists	O
.	O

Cardiac	O
transplantation	O
:	O
improved	O
quality	O
of	O
survival	O
with	O
a	O
modified	O
immunosuppressive	O
protocol	O
.	O

The	O
effects	O
on	O
renal	O
function	O
on	O
two	O
different	O
immunosuppressive	O
protocols	O
were	O
evaluated	O
retrospectively	O
in	O
two	O
subsequent	O
groups	O
of	O
heart	O
transplant	O
recipients	O
.	O

In	O
group	O
I	O
,	O
cyclosporine	B-CHED
was	O
given	O
before	O
the	O
procedure	O
at	O
a	O
loading	O
dose	O
of	O
17	O
.	O
5	O
mg	O
/	O
kg	O
and	O
then	O
continued	O
after	O
the	O
procedure	O
to	O
keep	O
a	O
whole	O
blood	O
level	O
about	O
1000	O
ng	O
/	O
ml	O
.	O

In	O
group	O
II	O
,	O
cyclosporine	B-CHED
was	O
started	O
only	O
after	O
the	O
procedure	O
at	O
a	O
lower	O
dosage	O
and	O
was	O
complemented	O
by	O
azathioprine	B-CHED
,	O
which	O
was	O
used	O
for	O
the	O
first	O
postoperative	O
week	O
.	O

Group	O
II	O
showed	O
a	O
better	O
perioperative	O
renal	O
function	O
as	O
determined	O
by	O
serum	O
blood	O
urea	B-CHED
nitrogen	I-CHED
and	O
serum	O
creatinine	B-CHED
levels	O
.	O

Group	O
II	O
also	O
showed	O
a	O
significant	O
decrease	O
of	O
chronic	O
nephrotoxicity	O
secondary	O
to	O
long	O
-	O
term	O
therapy	O
with	O
cyclosporine	B-CHED
.	O

Despite	O
this	O
improvement	O
in	O
late	O
renal	O
function	O
,	O
group	O
II	O
still	O
shows	O
a	O
slow	O
rise	O
in	O
serum	O
creatinine	B-CHED
.	O

We	O
think	O
that	O
even	O
these	O
lower	O
dosages	O
of	O
cyclosporine	B-CHED
can	O
cause	O
chronic	O
nephrotoxicity	O
and	O
that	O
further	O
modification	O
of	O
the	O
immunosuppressive	O
regimen	O
is	O
required	O
to	O
completely	O
abolish	O
this	O
toxic	O
side	O
effect	O
.	O

Ethopropazine	B-CHED
and	O
benztropine	B-CHED
in	O
neuroleptic	O
-	O
induced	O
parkinsonism	O
.	O

In	O
a	O
12	O
-	O
week	O
controlled	O
study	O
ethopropazine	B-CHED
was	O
compared	O
to	O
benztropine	B-CHED
in	O
the	O
treatment	O
of	O
parkinsonism	O
induced	O
by	O
fluphenazine	B-CHED
enanthate	I-CHED
in	O
60	O
schizophrenic	O
outpatients	O
.	O

Ethopropazine	B-CHED
and	O
benztropine	B-CHED
were	O
found	O
to	O
be	O
equally	O
effective	O
in	O
controlling	O
parkinsonian	O
symptoms	O
and	O
were	O
as	O
efficacious	O
as	O
procyclidine	B-CHED
,	O
their	O
previous	O
antiparkinsonian	O
drug	O
.	O

However	O
,	O
benztropine	B-CHED
treated	O
patients	O
had	O
a	O
significant	O
increase	O
in	O
tardive	O
dyskinesia	O
compared	O
to	O
their	O
condition	O
during	O
procyclindine	B-CHED
treatment	O
,	O
and	O
significantly	O
more	O
anxiety	O
and	O
depression	O
than	O
ethopropazine	B-CHED
treated	O
patients	O
.	O

This	O
suggests	O
that	O
benztropine	B-CHED
is	O
not	O
the	O
anticholinergic	O
drug	O
of	O
choice	O
in	O
the	O
treatment	O
of	O
neuroleptic	O
-	O
induced	O
parkinsonian	O
symptoms	O
,	O
because	O
of	O
its	O
more	O
toxic	O
central	O
and	O
peripheral	O
atropinic	O
effect	O
.	O

Quinidine	B-CHED
phenylethylbarbiturate	I-CHED
-	O
induced	O
fulminant	O
hepatitis	O
in	O
a	O
pregnant	O
woman	O
.	O

A	O
case	O
report	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
19	O
-	O
year	O
-	O
old	O
Laotian	O
patient	O
affected	O
by	O
fulminant	O
hepatitis	O
during	O
the	O
third	O
trimester	O
of	O
her	O
pregnancy	O
after	O
a	O
1	O
-	O
month	O
administration	O
of	O
quinidine	B-CHED
phenylethylbarbiturate	I-CHED
.	O

After	O
delivery	O
,	O
the	O
patient	O
underwent	O
orthotopic	O
liver	O
transplantation	O
.	O

The	O
patient	O
was	O
in	O
good	O
condition	O
16	O
months	O
after	O
liver	O
transplantation	O
.	O

Quinidine	B-CHED
itself	O
or	O
phenylethylbarbiturate	B-CHED
may	O
be	O
responsible	O
for	O
fulminant	O
hepatitis	O
in	O
this	O
patient	O
.	O

Mechanisms	O
of	O
myocardial	O
ischemia	O
induced	O
by	O
epinephrine	B-CHED
:	O
comparison	O
with	O
exercise	O
-	O
induced	O
ischemia	O
.	O

The	O
role	O
of	O
epinephrine	B-CHED
in	O
eliciting	O
myocardial	O
ischemia	O
was	O
examined	O
in	O
patients	O
with	O
coronary	O
artery	O
disease	O
.	O

Objective	O
signs	O
of	O
ischemia	O
and	O
factors	O
increasing	O
myocardial	O
oxygen	B-CHED
consumption	O
were	O
compared	O
during	O
epinephrine	B-CHED
infusion	O
and	O
supine	O
bicycle	O
exercise	O
.	O

Both	O
epinephrine	B-CHED
and	O
exercise	O
produced	O
myocardial	O
ischemia	O
as	O
evidenced	O
by	O
ST	O
segment	O
depression	O
and	O
angina	O
.	O

However	O
,	O
the	O
mechanisms	O
of	O
myocardial	O
ischemia	O
induced	O
by	O
epinephrine	B-CHED
were	O
significantly	O
different	O
from	O
those	O
of	O
exercise	O
.	O

Exercise	O
-	O
induced	O
myocardial	O
ischemia	O
was	O
marked	O
predominantly	O
by	O
increased	O
heart	O
rate	O
and	O
rate	O
-	O
pressure	O
product	O
with	O
a	O
minor	O
contribution	O
of	O
end	O
-	O
diastolic	O
volume	O
,	O
while	O
epinephrine	B-CHED
-	O
induced	O
ischemia	O
was	O
characterized	O
by	O
a	O
marked	O
increase	O
in	O
contractility	O
and	O
a	O
less	O
pronounced	O
increase	O
in	O
heart	O
rate	O
and	O
rate	O
-	O
pressure	O
product	O
.	O

These	O
findings	O
indicate	O
that	O
ischemia	O
produced	O
by	O
epinephrine	B-CHED
,	O
as	O
may	O
occur	O
during	O
states	O
of	O
emotional	O
distress	O
,	O
has	O
a	O
mechanism	O
distinct	O
from	O
that	O
due	O
to	O
physical	O
exertion	O
.	O

Recent	O
preclinical	O
and	O
clinical	O
studies	O
with	O
the	O
thymidylate	O
synthase	O
inhibitor	O
N10	B-CHED
-	I-CHED
propargyl	I-CHED
-	I-CHED
5	I-CHED
,	I-CHED
8	I-CHED
-	I-CHED
dideazafolic	I-CHED
acid	I-CHED
(	O
CB	B-CHED
3717	I-CHED
)	O
.	O

CB	B-CHED
3717	I-CHED
,	O
N10	B-CHED
-	I-CHED
propargyl	I-CHED
-	I-CHED
5	I-CHED
,	I-CHED
8	I-CHED
-	I-CHED
dideazafolic	I-CHED
acid	I-CHED
,	O
is	O
a	O
tight	O
-	O
binding	O
inhibitor	O
of	O
thymidylate	O
synthase	O
(	O
TS	O
)	O
whose	O
cytotoxicity	O
is	O
mediated	O
solely	O
through	O
the	O
inhibition	O
of	O
this	O
enzyme	O
.	O

Recent	O
preclinical	O
studies	O
have	O
focused	O
on	O
the	O
intracellular	O
formation	O
of	O
CB	B-CHED
3717	I-CHED
polyglutamates	O
.	O

Following	O
a	O
12	O
-	O
hour	O
exposure	O
of	O
L1210	O
cells	O
to	O
50	O
microM	O
[	O
3H	O
]	O
CB	B-CHED
3717	I-CHED
,	O
30	O
%	O
of	O
the	O
extractable	O
radioactivity	O
could	O
be	O
accounted	O
for	O
as	O
CB	B-CHED
3717	I-CHED
tetra	O
-	O
and	O
pentaglutamate	O
,	O
as	O
determined	O
by	O
high	O
-	O
pressure	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
analyses	O
.	O

As	O
inhibitors	O
of	O
isolated	O
L1210	O
TS	O
,	O
CB	O
3717	O
di	O
-	O
,	O
tri	O
-	O
,	O
tetra	O
-	O
and	O
pentaglutamate	O
are	O
26	O
-	O
,	O
87	O
-	O
,	O
119	O
-	O
and	O
114	O
-	O
fold	O
more	O
potent	O
than	O
CB	B-CHED
3717	I-CHED
,	O
respectively	O
,	O
and	O
their	O
formation	O
may	O
,	O
therefore	O
,	O
be	O
an	O
important	O
determinant	O
of	O
CB	B-CHED
3717	I-CHED
cytotoxicity	O
.	O

In	O
early	O
clinical	O
studies	O
with	O
CB	B-CHED
3717	I-CHED
,	O
activity	O
has	O
been	O
seen	O
in	O
breast	O
cancer	O
,	O
ovarian	O
cancer	O
,	O
hepatoma	O
,	O
and	O
mesothelioma	O
.	O

Toxicities	O
included	O
hepatotoxicity	O
,	O
malaise	O
,	O
and	O
dose	O
-	O
limiting	O
nephrotoxicity	O
.	O

This	O
latter	O
effect	O
is	O
thought	O
to	O
be	O
due	O
to	O
drug	O
precipitation	O
within	O
the	O
renal	O
tubule	O
as	O
a	O
result	O
of	O
the	O
poor	O
solubility	O
of	O
CB	B-CHED
3717	I-CHED
under	O
acidic	O
conditions	O
.	O

In	O
an	O
attempt	O
to	O
overcome	O
this	O
problem	O
,	O
a	O
clinical	O
trial	O
of	O
CB	B-CHED
3717	I-CHED
administered	O
with	O
alkaline	O
diuresis	O
is	O
under	O
way	O
.	O

Preliminary	O
results	O
at	O
400	O
and	O
500	O
mg	O
/	O
m2	O
suggest	O
that	O
a	O
reduction	O
in	O
nephrotoxicity	O
may	O
have	O
been	O
achieved	O
with	O
only	O
1	O
instance	O
of	O
renal	O
toxicity	O
in	O
10	O
patients	O
.	O

Hepatotoxicity	O
and	O
malaise	O
are	O
again	O
the	O
most	O
frequent	O
side	O
effects	O
.	O

Evidence	O
of	O
antitumor	O
activity	O
has	O
been	O
seen	O
in	O
3	O
patients	O
.	O

Pharmacokinetic	O
investigations	O
have	O
shown	O
that	O
alkaline	O
diuresis	O
does	O
not	O
alter	O
CB	B-CHED
3717	I-CHED
plasma	O
levels	O
or	O
urinary	O
excretion	O
and	O
that	O
satisfactory	O
urinary	O
alkalinization	O
can	O
be	O
readily	O
achieved	O
.	O

Type	O
B	O
hepatitis	O
after	O
needle	O
-	O
stick	O
exposure	O
:	O
prevention	O
with	O
hepatitis	O
B	O
immune	O
globulin	O
.	O

Final	O
report	O
of	O
the	O
Veterans	O
Administration	O
Cooperative	O
Study	O
.	O

Hepatitis	O
B	O
immune	O
globulin	O
(	O
HBIG	O
)	O
and	O
immune	O
serum	O
globulin	O
(	O
ISG	O
)	O
were	O
examined	O
in	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
trial	O
to	O
assess	O
their	O
relative	O
efficacies	O
in	O
preventing	O
type	O
B	O
hepatitis	O
after	O
needle	O
-	O
stick	O
exposure	O
to	O
hepatitis	B-CHED
B	I-CHED
surface	I-CHED
antigen	I-CHED
(	O
HBsAG	B-CHED
)	O
-	O
positive	O
donors	O
.	O

Clinical	O
hepatitis	O
developed	O
in	O
1	O
.	O
4	O
%	O
of	O
HBIG	O
and	O
in	O
5	O
.	O
9	O
%	O
of	O
ISG	O
recipients	O
(	O
P	O
=	O
0	O
.	O
016	O
)	O
,	O
and	O
seroconversion	O
(	O
anti	O
-	O
HBs	O
)	O
occurred	O
in	O
5	O
.	O
6	O
%	O
and	O
20	O
.	O
7	O
%	O
of	O
them	O
respectively	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

Mild	O
and	O
transient	O
side	O
-	O
effects	O
were	O
noted	O
in	O
3	O
.	O
0	O
%	O
of	O
ISG	O
and	O
in	O
3	O
.	O
2	O
%	O
of	O
HBIG	O
recipients	O
.	O

Available	O
donor	O
sera	O
were	O
examined	O
for	O
DNA	O
polymerase	O
(	O
DNAP	O
)	O
and	O
e	O
antigen	O
and	O
antibody	O
(	O
HBeAg	B-CHED
;	O
anti	O
-	O
HBE	O
)	O
.	O

Both	O
DNAP	O
and	O
HBeAg	B-CHED
showed	O
a	O
highly	O
statistically	O
significant	O
correlation	O
with	O
the	O
infectivity	O
of	O
HBsAg	B-CHED
-	O
positive	O
donors	O
.	O

Hepatitis	O
B	O
immune	O
globulin	O
remained	O
significantly	O
superior	O
to	O
ISG	O
in	O
preventing	O
type	O
B	O
hepatitis	O
even	O
when	O
the	O
analysis	O
was	O
confined	O
to	O
these	O
two	O
high	O
-	O
risk	O
subgroups	O
.	O

The	O
efficacy	O
of	O
ISG	O
in	O
preventing	O
type	O
B	O
hepatitis	O
cannot	O
be	O
ascertained	O
because	O
a	O
true	O
placebo	O
group	O
was	O
not	O
included	O
.	O

Production	O
of	O
autochthonous	O
prostate	O
cancer	O
in	O
Lobund	O
-	O
Wistar	O
rats	O
by	O
treatments	O
with	O
N	B-CHED
-	I-CHED
nitroso	I-CHED
-	I-CHED
N	I-CHED
-	I-CHED
methylurea	I-CHED
and	O
testosterone	B-CHED
.	O

More	O
than	O
50	O
%	O
of	O
Lobund	O
-	O
Wistar	O
(	O
L	O
-	O
W	O
)	O
strain	O
rats	O
developed	O
large	O
,	O
palpable	O
prostate	O
adenocarcinomas	O
(	O
PAs	O
)	O
following	O
treatments	O
with	O
N	B-CHED
-	I-CHED
nitroso	I-CHED
-	I-CHED
N	I-CHED
-	I-CHED
methylurea	I-CHED
(	O
CAS	O
:	O
684	O
-	O
93	O
-	O
5	O
)	O
and	O
testosterone	B-CHED
propionate	I-CHED
[	O
(	O
TP	B-CHED
)	O
CAS	O
:	O
57	O
-	O
85	O
-	O
2	O
]	O
,	O
and	O
most	O
of	O
the	O
tumor	O
-	O
bearing	O
rats	O
manifested	O
metastatic	O
lesions	O
.	O

The	O
incubation	O
periods	O
averaged	O
10	O
.	O
6	O
months	O
.	O

Within	O
the	O
same	O
timeframe	O
,	O
no	O
L	O
-	O
W	O
rat	O
developed	O
a	O
similar	O
palpable	O
PA	O
when	O
treated	O
only	O
with	O
TP	B-CHED
.	O

In	O
L	O
-	O
W	O
rats	O
,	O
TP	B-CHED
acted	O
as	O
a	O
tumor	O
enhancement	O
agent	O
,	O
with	O
primary	O
emphasis	O
on	O
the	O
development	O
of	O
prostate	O
cancer	O
.	O

Relative	O
efficacy	O
and	O
toxicity	O
of	O
netilmicin	B-CHED
and	O
tobramycin	B-CHED
in	O
oncology	O
patients	O
.	O

We	O
prospectively	O
compared	O
the	O
efficacy	O
and	O
safety	O
of	O
netilmicin	B-CHED
sulfate	I-CHED
or	O
tobramycin	B-CHED
sulfate	I-CHED
in	O
conjunction	O
with	O
piperacillin	B-CHED
sodium	I-CHED
in	O
118	O
immunocompromised	O
patients	O
with	O
presumed	O
severe	O
infections	O
.	O

The	O
two	O
treatment	O
regimens	O
were	O
equally	O
efficacious	O
.	O

Nephrotoxicity	O
occurred	O
in	O
a	O
similar	O
proportion	O
in	O
patients	O
treated	O
with	O
netilmicin	B-CHED
and	O
tobramycin	B-CHED
(	O
17	O
%	O
vs	O
11	O
%	O
)	O
.	O

Ototoxicity	O
occurred	O
in	O
four	O
(	O
9	O
.	O
5	O
%	O
)	O
of	O
42	O
netilmicin	B-CHED
and	O
piperacillin	B-CHED
and	O
in	O
12	O
(	O
22	O
%	O
)	O
of	O
54	O
tobramycin	B-CHED
and	O
piperacillin	B-CHED
-	O
treated	O
patients	O
.	O

Of	O
those	O
evaluated	O
with	O
posttherapy	O
audiograms	O
,	O
three	O
of	O
four	O
netilmicin	B-CHED
and	O
piperacillin	B-CHED
-	O
treated	O
patients	O
had	O
auditory	O
thresholds	O
return	O
to	O
baseline	O
compared	O
with	O
one	O
of	O
nine	O
tobramycin	B-CHED
and	O
piperacillin	B-CHED
-	O
treated	O
patients	O
.	O

The	O
number	O
of	O
greater	O
than	O
or	O
equal	O
to	O
15	O
-	O
dB	O
increases	O
in	O
auditory	O
threshold	O
as	O
a	O
proportion	O
of	O
total	O
greater	O
than	O
or	O
equal	O
to	O
15	O
-	O
dB	O
changes	O
(	O
increases	O
and	O
decreases	O
)	O
was	O
significantly	O
lower	O
in	O
netilmicin	B-CHED
and	O
piperacillin	B-CHED
-	O
vs	O
tobramycin	B-CHED
and	O
piperacillin	B-CHED
-	O
treated	O
patients	O
(	O
18	O
of	O
78	O
vs	O
67	O
of	O
115	O
)	O
.	O

We	O
conclude	O
that	O
aminoglycoside	B-CHED
-	O
associated	O
ototoxicity	O
was	O
less	O
severe	O
and	O
more	O
often	O
reversible	O
with	O
netilmicin	B-CHED
than	O
with	O
tobramycin	B-CHED
.	O

Urinary	O
enzymes	O
and	O
protein	O
patterns	O
as	O
indicators	O
of	O
injury	O
to	O
different	O
regions	O
of	O
the	O
kidney	O
.	O

Acute	O
experimental	O
models	O
of	O
renal	O
damage	O
to	O
the	O
proximal	O
tubular	O
,	O
glomerular	O
,	O
and	O
papillary	O
regions	O
of	O
the	O
rat	O
were	O
produced	O
by	O
administration	O
of	O
hexachloro	B-CHED
-	I-CHED
1	I-CHED
:	I-CHED
3	I-CHED
-	I-CHED
butadiene	I-CHED
(	O
HCBD	B-CHED
)	O
,	O
puromycin	B-CHED
aminonucleoside	I-CHED
(	O
PAN	B-CHED
)	O
,	O
and	O
2	B-CHED
-	I-CHED
bromoethylamine	I-CHED
(	O
BEA	B-CHED
)	O
,	O
respectively	O
.	O

Several	O
routine	O
indicators	O
of	O
nephrotoxicity	O
,	O
the	O
enzymes	O
alkaline	O
phosphatase	O
and	O
N	O
-	O
acetyl	O
-	O
beta	O
-	O
glucosaminidase	O
,	O
and	O
the	O
molecular	O
weight	O
of	O
protein	O
excretion	O
were	O
determined	O
on	O
urine	O
samples	O
.	O

Tubular	O
damage	O
produced	O
by	O
HCBD	B-CHED
or	O
BEA	B-CHED
was	O
discriminated	O
both	O
quantitatively	O
and	O
qualitatively	O
from	O
glomerular	O
damage	O
produced	O
by	O
PAN	B-CHED
.	O

The	O
latter	O
was	O
characterized	O
by	O
a	O
pronounced	O
increase	O
in	O
protein	O
excretion	O
,	O
especially	O
proteins	O
with	O
molecular	O
weight	O
greater	O
than	O
40	O
,	O
000	O
Da	O
.	O

In	O
contrast	O
,	O
protein	O
excretion	O
in	O
tubular	O
damage	O
was	O
raised	O
only	O
slightly	O
and	O
characterized	O
by	O
excretion	O
of	O
proteins	O
of	O
a	O
wide	O
range	O
of	O
molecular	O
weights	O
.	O

Proximal	O
tubular	O
damage	O
caused	O
by	O
HCBD	B-CHED
and	O
papillary	O
damage	O
caused	O
by	O
BEA	B-CHED
were	O
distinguished	O
both	O
by	O
conventional	O
urinalysis	O
(	O
volume	O
and	O
specific	O
gravity	O
)	O
and	O
by	O
measurement	O
of	O
the	O
two	O
urinary	O
enzymes	O
.	O

Alkaline	O
phosphatase	O
and	O
glucose	B-CHED
were	O
markedly	O
and	O
transiently	O
elevated	O
in	O
proximal	O
tubular	O
damage	O
and	O
N	O
-	O
acetyl	O
-	O
beta	O
-	O
glucosaminidase	O
showed	O
a	O
sustained	O
elevation	O
in	O
papillary	O
damage	O
.	O

It	O
is	O
concluded	O
that	O
both	O
selective	O
urinary	O
enzymes	O
and	O
the	O
molecular	O
weight	O
pattern	O
of	O
urinary	O
proteins	O
can	O
be	O
used	O
to	O
provide	O
diagnostic	O
information	O
about	O
the	O
possible	O
site	O
of	O
renal	O
damage	O
.	O

A	O
catch	O
in	O
the	O
Reye	O
.	O

Twenty	O
-	O
six	O
cases	O
of	O
Reye	O
syndrome	O
from	O
The	O
Children	O
'	O
s	O
Hospital	O
,	O
Camperdown	O
,	O
Australia	O
,	O
occurring	O
between	O
1973	O
and	O
1982	O
were	O
reviewed	O
.	O

Of	O
these	O
,	O
20	O
cases	O
met	O
the	O
US	O
Public	O
Health	O
Service	O
Centers	O
for	O
Disease	O
Control	O
criteria	O
for	O
the	O
diagnosis	O
of	O
Reye	O
syndrome	O
.	O

Aspirin	B-CHED
or	O
salicylate	B-CHED
ingestion	O
had	O
occurred	O
in	O
only	O
one	O
of	O
the	O
20	O
cases	O
(	O
5	O
%	O
)	O
,	O
and	O
paracetamol	B-CHED
(	O
acetaminophen	B-CHED
)	O
had	O
been	O
administered	O
in	O
only	O
six	O
of	O
the	O
cases	O
(	O
30	O
%	O
)	O
.	O

Pathologic	O
confirmation	O
of	O
the	O
diagnosis	O
of	O
Reye	O
syndrome	O
was	O
accomplished	O
in	O
90	O
%	O
of	O
the	O
cases	O
.	O

The	O
incidence	O
of	O
Reye	O
syndrome	O
in	O
New	O
South	O
Wales	O
,	O
Australia	O
,	O
is	O
estimated	O
from	O
this	O
study	O
to	O
be	O
approximately	O
nine	O
cases	O
per	O
1	O
million	O
children	O
compared	O
with	O
recent	O
US	O
data	O
of	O
ten	O
to	O
20	O
cases	O
per	O
1	O
million	O
children	O
and	O
three	O
to	O
seven	O
cases	O
per	O
1	O
million	O
children	O
in	O
Great	O
Britain	O
.	O

The	O
mortality	O
for	O
these	O
Reye	O
syndrome	O
cases	O
in	O
Australia	O
was	O
45	O
%	O
as	O
compared	O
with	O
a	O
32	O
%	O
case	O
-	O
fatality	O
rate	O
in	O
the	O
United	O
States	O
.	O

In	O
Australia	O
,	O
the	O
pediatric	O
usage	O
of	O
aspirin	B-CHED
has	O
been	O
extremely	O
low	O
for	O
the	O
past	O
25	O
years	O
(	O
less	O
than	O
1	O
%	O
of	O
total	O
dosage	O
units	O
sold	O
)	O
,	O
with	O
paracetamol	B-CHED
(	O
acetaminophen	B-CHED
)	O
dominating	O
the	O
pediatric	O
analgesic	O
and	O
antipyretic	O
market	O
.	O

Reye	O
syndrome	O
may	O
be	O
disappearing	O
from	O
Australia	O
despite	O
a	O
total	O
lack	O
of	O
association	O
with	O
salicylates	B-CHED
or	O
aspirin	B-CHED
ingestion	O
,	O
since	O
there	O
were	O
no	O
cases	O
found	O
at	O
The	O
Children	O
'	O
s	O
Hospital	O
in	O
1983	O
,	O
1984	O
,	O
or	O
1985	O
.	O

Postpartum	O
psychosis	O
induced	O
by	O
bromocriptine	B-CHED
.	O

Two	O
multigravida	O
patients	O
with	O
no	O
prior	O
psychiatric	O
history	O
were	O
seen	O
with	O
postpartum	O
psychosis	O
,	O
having	O
received	O
bromocriptine	B-CHED
for	O
inhibition	O
of	O
lactation	O
.	O

Bromocriptine	B-CHED
given	O
in	O
high	O
doses	O
has	O
been	O
associated	O
with	O
psychosis	O
in	O
patients	O
receiving	O
the	O
drug	O
for	O
Parkinson	O
'	O
s	O
disease	O
.	O

These	O
cases	O
demonstrate	O
that	O
bromocriptine	B-CHED
may	O
cause	O
psychosis	O
even	O
when	O
given	O
in	O
low	O
doses	O
.	O

Hyperglycemic	O
acidotic	O
coma	O
and	O
death	O
in	O
Kearns	O
-	O
Sayre	O
syndrome	O
.	O

This	O
paper	O
presents	O
the	O
clinical	O
and	O
metabolic	O
findings	O
in	O
two	O
young	O
boys	O
with	O
long	O
-	O
standing	O
Kearns	O
-	O
Sayre	O
syndrome	O
.	O

Following	O
short	O
exposure	O
to	O
oral	O
prednisone	B-CHED
,	O
both	O
boys	O
developed	O
lethargy	O
,	O
increasing	O
somnolence	O
,	O
polydipsia	O
,	O
polyphagia	O
,	O
and	O
polyuria	O
.	O

Both	O
presented	O
in	O
the	O
emergency	O
room	O
with	O
profound	O
coma	O
,	O
hypotension	O
,	O
severe	O
hyperglycemia	O
,	O
and	O
acidosis	O
.	O

Nonketotic	O
lactic	O
acidosis	O
was	O
present	O
in	O
one	O
and	O
ketosis	O
without	O
a	O
known	O
serum	O
lactate	B-CHED
level	O
was	O
present	O
in	O
the	O
other	O
.	O

Respiratory	O
failure	O
rapidly	O
ensued	O
and	O
both	O
patients	O
expired	O
in	O
spite	O
of	O
efforts	O
at	O
resuscitation	O
.	O

We	O
believe	O
these	O
two	O
cases	O
represent	O
a	O
newly	O
described	O
and	O
catastrophic	O
metabolic	O
-	O
endocrine	O
failure	O
in	O
the	O
Kearns	O
-	O
Sayre	O
syndrome	O
.	O

Experimental	O
cyclosporine	B-CHED
nephrotoxicity	O
:	O
risk	O
of	O
concomitant	O
chemotherapy	O
.	O

The	O
role	O
of	O
cyclosporine	B-CHED
(	O
CSA	B-CHED
)	O
alone	O
or	O
in	O
combination	O
with	O
various	O
chemotherapeutics	O
in	O
the	O
development	O
of	O
renal	O
toxicity	O
was	O
evaluated	O
in	O
rats	O
.	O

Administration	O
of	O
20	O
mg	O
/	O
kg	O
/	O
day	O
CSA	B-CHED
for	O
4	O
weeks	O
caused	O
renal	O
functional	O
and	O
structural	O
changes	O
similar	O
to	O
those	O
reported	O
in	O
man	O
.	O

The	O
combined	O
administration	O
of	O
CSA	B-CHED
and	O
various	O
chemotherapeutic	O
drugs	O
with	O
a	O
nephrotoxic	O
potential	O
,	O
such	O
as	O
gentamicin	B-CHED
(	O
at	O
therapeutic	O
doses	O
)	O
,	O
amphothericin	B-CHED
B	I-CHED
and	O
ketoconazole	B-CHED
,	O
which	O
are	O
frequently	O
used	O
in	O
immunosuppressed	O
patients	O
,	O
did	O
not	O
aggravate	O
the	O
CSA	B-CHED
induced	O
toxicity	O
in	O
the	O
rat	O
model	O
.	O

Gentamicin	B-CHED
at	O
toxic	O
doses	O
,	O
however	O
,	O
increased	O
CSA	B-CHED
nephrotoxicity	O
.	O

Thus	O
,	O
the	O
nephrotoxicity	O
induced	O
by	O
CSA	B-CHED
has	O
a	O
different	O
pathogenetic	O
mechanism	O
.	O

Diuretics	O
,	O
potassium	B-CHED
and	O
arrhythmias	O
in	O
hypertensive	O
coronary	O
disease	O
.	O

It	O
has	O
been	O
proposed	O
that	O
modest	O
changes	O
in	O
plasma	O
potassium	B-CHED
can	O
alter	O
the	O
tendency	O
towards	O
cardiac	O
arrhythmias	O
.	O

If	O
this	O
were	O
so	O
,	O
patients	O
with	O
coronary	O
artery	O
disease	O
might	O
be	O
especially	O
susceptible	O
.	O

Thus	O
,	O
myocardial	O
electrical	O
excitability	O
was	O
measured	O
in	O
patients	O
with	O
mild	O
essential	O
hypertension	O
and	O
known	O
coronary	O
artery	O
disease	O
after	O
8	O
weeks	O
of	O
treatment	O
with	O
a	O
potassium	B-CHED
-	O
conserving	O
diuretic	O
(	O
amiloride	B-CHED
)	O
and	O
a	O
similar	O
period	O
on	O
a	O
potassium	B-CHED
-	O
losing	O
diuretic	O
(	O
chlorthalidone	B-CHED
)	O
in	O
a	O
randomised	O
study	O
.	O

Plasma	O
potassium	B-CHED
concentrations	O
were	O
on	O
average	O
1	O
mmol	O
/	O
L	O
lower	O
during	O
the	O
chlorthalidone	B-CHED
phase	O
compared	O
to	O
amiloride	B-CHED
therapy	O
.	O

Blood	O
pressure	O
and	O
volume	O
states	O
as	O
assessed	O
by	O
bodyweight	O
,	O
plasma	O
renin	O
and	O
noradrenaline	B-CHED
(	O
norepinephrine	B-CHED
)	O
concentrations	O
were	O
similar	O
on	O
the	O
2	O
regimens	O
.	O

Compared	O
to	O
amiloride	B-CHED
treatment	O
,	O
the	O
chlorthalidone	B-CHED
phase	O
was	O
associated	O
with	O
an	O
increased	O
frequency	O
of	O
ventricular	O
ectopic	O
beats	O
(	O
24	O
-	O
hour	O
Holter	O
monitoring	O
)	O
and	O
a	O
higher	O
Lown	O
grading	O
,	O
increased	O
upslope	O
and	O
duration	O
of	O
the	O
monophasic	O
action	O
potential	O
,	O
prolonged	O
ventricular	O
effective	O
refractory	O
period	O
,	O
and	O
increased	O
electrical	O
instability	O
during	O
programmed	O
ventricular	O
stimulation	O
.	O

The	O
above	O
results	O
indicate	O
that	O
because	O
potassium	B-CHED
-	O
losing	O
diuretic	O
therapy	O
can	O
increase	O
myocardial	O
electrical	O
excitability	O
in	O
patients	O
with	O
ischaemic	O
heart	O
disease	O
,	O
even	O
minor	O
falls	O
in	O
plasma	O
potassium	B-CHED
concentrations	O
are	O
probably	O
best	O
avoided	O
in	O
such	O
patients	O
.	O

Transketolase	O
abnormality	O
in	O
tolazamide	B-CHED
-	O
induced	O
Wernicke	O
'	O
s	O
encephalopathy	O
.	O

We	O
studied	O
a	O
thiamine	B-CHED
-	O
dependent	O
enzyme	O
,	O
transketolase	O
,	O
from	O
fibroblasts	O
of	O
a	O
diabetic	O
patient	O
who	O
developed	O
Wernicke	O
'	O
s	O
encephalopathy	O
when	O
treated	O
with	O
tolazamide	B-CHED
,	O
in	O
order	O
to	O
delineate	O
if	O
this	O
patient	O
also	O
had	O
transketolase	O
abnormality	O
[	O
high	O
Km	O
for	O
thiamine	B-CHED
pyrophosphate	I-CHED
(	O
TPP	B-CHED
)	O
]	O
,	O
as	O
previously	O
reported	O
in	O
postalcoholic	O
Wernicke	O
-	O
Korsakoff	O
syndrome	O
.	O

In	O
addition	O
to	O
this	O
patient	O
,	O
we	O
also	O
studied	O
this	O
enzyme	O
from	O
three	O
diabetic	O
kindreds	O
without	O
any	O
history	O
of	O
Wernicke	O
'	O
s	O
encephalopathy	O
and	O
from	O
four	O
normal	O
controls	O
.	O

We	O
found	O
that	O
the	O
above	O
-	O
mentioned	O
patient	O
and	O
one	O
of	O
the	O
diabetic	O
kindreds	O
with	O
no	O
history	O
of	O
Wernicke	O
'	O
s	O
encephalopathy	O
had	O
abnormal	O
transketolase	O
as	O
determined	O
by	O
its	O
Km	O
for	O
TPP	B-CHED
.	O

These	O
data	O
suggest	O
a	O
similarity	O
between	O
postalcoholic	O
Wernicke	O
-	O
Korsakoff	O
syndrome	O
and	O
the	O
patient	O
with	O
tolazamide	B-CHED
-	O
induced	O
Wernicke	O
'	O
s	O
encephalopathy	O
from	O
the	O
standpoint	O
of	O
transketolase	O
abnormality	O
.	O

Bradycardia	O
due	O
to	O
trihexyphenidyl	B-CHED
hydrochloride	I-CHED
.	O

A	O
chronic	O
schizophrenic	O
patient	O
was	O
treated	O
with	O
an	O
anticholinergic	O
drug	O
,	O
trihexyphenidyl	B-CHED
hydrochloride	I-CHED
.	O

The	O
patient	O
developed	O
,	O
paradoxically	O
,	O
sinus	O
bradycardia	O
.	O

The	O
reaction	O
was	O
specific	O
to	O
trihexyphenidyl	B-CHED
and	O
not	O
to	O
other	O
anticholinergic	O
drugs	O
.	O

This	O
antidyskinetic	O
drug	O
is	O
widely	O
used	O
in	O
clinical	O
psychiatric	O
practice	O
and	O
physicians	O
should	O
be	O
aware	O
of	O
this	O
side	O
effect	O
.	O

Post	O
-	O
operative	O
rigidity	O
after	O
fentanyl	B-CHED
administration	O
.	O

A	O
case	O
of	O
thoraco	O
-	O
abdominal	O
rigidity	O
leading	O
to	O
respiratory	O
failure	O
is	O
described	O
in	O
the	O
post	O
-	O
operative	O
period	O
in	O
an	O
elderly	O
patient	O
who	O
received	O
a	O
moderate	O
dose	O
of	O
fentanyl	B-CHED
.	O

This	O
was	O
successfully	O
reversed	O
by	O
naloxone	B-CHED
.	O

The	O
mechanisms	O
possibly	O
implicated	O
in	O
this	O
accident	O
are	O
discussed	O
.	O

Anti	O
-	O
carcinogenic	O
action	O
of	O
phenobarbital	B-CHED
given	O
simultaneously	O
with	O
diethylnitrosamine	B-CHED
in	O
the	O
rat	O
.	O

The	O
present	O
work	O
has	O
been	O
planned	O
in	O
order	O
to	O
elucidate	O
the	O
effect	O
of	O
phenobarbital	B-CHED
(	O
PB	B-CHED
:	O
15	O
mg	O
per	O
rat	O
of	O
ingested	O
dose	O
)	O
on	O
carcinogenesis	O
when	O
it	O
is	O
administered	O
simultaneously	O
with	O
diethylnitrosamine	B-CHED
(	O
DEN	B-CHED
:	O
10	O
mg	O
/	O
kg	O
/	O
day	O
)	O
.	O

Wistar	O
rats	O
(	O
180	O
g	O
)	O
were	O
treated	O
by	O
DEN	B-CHED
alone	O
or	O
by	O
DEN	B-CHED
+	O
PB	B-CHED
during	O
2	O
,	O
4	O
and	O
6	O
weeks	O
according	O
to	O
our	O
schedule	O
for	O
hepatocarcinogenesis	O
.	O

After	O
the	O
end	O
of	O
the	O
treatment	O
,	O
the	O
number	O
and	O
the	O
size	O
of	O
induced	O
PAS	O
positive	O
preneoplastic	O
foci	O
was	O
significantly	O
reduced	O
when	O
PB	B-CHED
was	O
given	O
simultaneously	O
with	O
DEN	B-CHED
for	O
4	O
and	O
6	O
weeks	O
.	O

The	O
mitotic	O
inhibition	O
and	O
the	O
production	O
of	O
micronuclei	O
normally	O
observed	O
after	O
partial	O
hepatectomy	O
in	O
DEN	B-CHED
treated	O
rats	O
were	O
also	O
significantly	O
decreased	O
in	O
DEN	B-CHED
+	O
PB	B-CHED
treated	O
rats	O
.	O

When	O
the	O
treatment	O
last	O
only	O
2	O
weeks	O
,	O
the	O
presence	O
of	O
PB	B-CHED
did	O
not	O
change	O
significantly	O
the	O
last	O
parameters	O
.	O

In	O
DEN	B-CHED
+	O
PB	B-CHED
treated	O
rats	O
,	O
the	O
survival	O
was	O
prolonged	O
and	O
the	O
tumor	O
incidence	O
decreased	O
as	O
compared	O
with	O
the	O
results	O
obtained	O
by	O
DEN	B-CHED
alone	O
.	O

It	O
is	O
concluded	O
that	O
PB	B-CHED
,	O
which	O
promotes	O
carcinogenesis	O
when	O
administered	O
after	O
the	O
DEN	B-CHED
treatment	O
,	O
reduces	O
the	O
carcinogen	O
effect	O
when	O
given	O
simultaneously	O
with	O
DEN	B-CHED
.	O

This	O
'	O
anti	O
-	O
carcinogen	O
'	O
effect	O
acts	O
on	O
the	O
initiation	O
as	O
well	O
as	O
on	O
the	O
promotion	O
of	O
the	O
precancerous	O
lesions	O
.	O

Biochemical	O
investigations	O
are	O
in	O
progress	O
to	O
obtain	O
more	O
information	O
about	O
this	O
'	O
paradoxical	O
'	O
PB	B-CHED
effect	O
.	O

Bilateral	O
optic	O
neuropathy	O
due	O
to	O
combined	O
ethambutol	B-CHED
and	O
isoniazid	B-CHED
treatment	O
.	O

The	O
case	O
of	O
a	O
40	O
-	O
year	O
-	O
old	O
patient	O
who	O
underwent	O
an	O
unsuccessful	O
cadaver	O
kidney	O
transplantation	O
and	O
was	O
treated	O
with	O
ethambutol	B-CHED
and	O
isoniazid	B-CHED
is	O
reported	O
.	O

A	O
bilateral	O
retrobulbar	O
neuropathy	O
with	O
an	O
unusual	O
central	O
bitemporal	O
hemianopic	O
scotoma	O
was	O
found	O
.	O

Ethambutol	B-CHED
was	O
stopped	O
and	O
only	O
small	O
improvement	O
of	O
the	O
visual	O
acuity	O
followed	O
.	O

Isoniazid	B-CHED
was	O
discontinued	O
later	O
,	O
followed	O
by	O
a	O
dramatic	O
improvement	O
in	O
the	O
visual	O
acuity	O
.	O

The	O
hazards	O
of	O
optic	O
nerve	O
toxicity	O
due	O
to	O
ethambutol	B-CHED
are	O
known	O
.	O

We	O
emphasize	O
the	O
potential	O
danger	O
in	O
the	O
use	O
of	O
ethambutol	B-CHED
and	O
isoniazid	B-CHED
.	O

A	O
prospective	O
study	O
of	O
adverse	O
reactions	O
associated	O
with	O
vancomycin	B-CHED
therapy	O
.	O

A	O
prospective	O
evaluation	O
of	O
the	O
efficacy	O
and	O
safety	O
of	O
vancomycin	B-CHED
was	O
conducted	O
in	O
54	O
consecutive	O
patients	O
over	O
a	O
16	O
-	O
month	O
period	O
.	O

Vancomycin	B-CHED
was	O
curative	O
in	O
95	O
%	O
of	O
43	O
patients	O
with	O
proven	O
infection	O
.	O

Drugs	O
were	O
ceased	O
in	O
six	O
patients	O
because	O
of	O
adverse	O
reactions	O
;	O
in	O
three	O
of	O
these	O
vancomycin	B-CHED
was	O
considered	O
the	O
likely	O
cause	O
.	O

Reactions	O
included	O
thrombophlebitis	O
(	O
20	O
of	O
54	O
patients	O
)	O
,	O
rash	O
(	O
4	O
of	O
54	O
)	O
,	O
nephrotoxicity	O
(	O
4	O
of	O
50	O
)	O
,	O
proteinuria	O
(	O
1	O
of	O
50	O
)	O
and	O
ototoxicity	O
(	O
1	O
of	O
11	O
patients	O
tested	O
by	O
audiometry	O
)	O
.	O

Thrombophlebitis	O
occurred	O
only	O
with	O
infusion	O
through	O
peripheral	O
cannulae	O
;	O
nephrotoxicity	O
and	O
ototoxicity	O
were	O
confined	O
to	O
patients	O
receiving	O
an	O
aminoglycoside	B-CHED
plus	O
vancomycin	B-CHED
.	O

We	O
conclude	O
that	O
vancomycin	B-CHED
,	O
administered	O
appropriately	O
,	O
constitutes	O
safe	O
,	O
effective	O
therapy	O
for	O
infections	O
caused	O
by	O
susceptible	O
bacteria	O
.	O

Factors	O
associated	O
with	O
nephrotoxicity	O
and	O
clinical	O
outcome	O
in	O
patients	O
receiving	O
amikacin	B-CHED
.	O

Data	O
from	O
60	O
patients	O
treated	O
with	O
amikacin	B-CHED
were	O
analyzed	O
for	O
factors	O
associated	O
with	O
nephrotoxicity	O
.	O

In	O
42	O
of	O
these	O
patients	O
,	O
data	O
were	O
examined	O
for	O
factors	O
associated	O
with	O
clinical	O
outcome	O
.	O

Variables	O
evaluated	O
included	O
patient	O
weight	O
,	O
age	O
,	O
sex	O
,	O
serum	O
creatinine	B-CHED
level	O
,	O
creatinine	B-CHED
clearance	O
,	O
duration	O
of	O
therapy	O
,	O
total	O
dose	O
,	O
mean	O
daily	O
dose	O
,	O
organism	O
minimum	O
inhibitory	O
concentration	O
(	O
MIC	O
)	O
,	O
mean	O
peak	O
levels	O
,	O
mean	O
trough	O
levels	O
,	O
mean	O
area	O
under	O
the	O
serum	O
concentration	O
-	O
time	O
curve	O
(	O
AUC	O
)	O
,	O
total	O
AUC	O
,	O
mean	O
AUC	O
greater	O
than	O
MIC	O
,	O
total	O
AUC	O
greater	O
than	O
MIC	O
,	O
mean	O
Schumacher	O
'	O
s	O
intensity	O
factor	O
(	O
IF	O
)	O
,	O
total	O
IF	O
,	O
In	O
(	O
mean	O
maximum	O
concentration	O
[	O
Cmax	O
]	O
/	O
MIC	O
)	O
.	O

Model	O
-	O
dependent	O
pharmacokinetic	O
parameters	O
were	O
calculated	O
by	O
computer	O
based	O
on	O
a	O
one	O
-	O
compartment	O
model	O
.	O

When	O
the	O
parameters	O
were	O
examined	O
individually	O
,	O
duration	O
of	O
therapy	O
and	O
total	O
AUC	O
correlated	O
significantly	O
(	O
P	O
less	O
than	O
.	O
05	O
)	O
with	O
nephrotoxicity	O
.	O

In	O
contrast	O
,	O
a	O
stepwise	O
discriminant	O
function	O
analysis	O
identified	O
only	O
duration	O
of	O
therapy	O
(	O
P	O
less	O
than	O
.	O
001	O
)	O
as	O
an	O
important	O
factor	O
.	O

Based	O
on	O
this	O
model	O
and	O
on	O
Bayes	O
'	O
theorem	O
,	O
the	O
predictive	O
accuracy	O
of	O
identifying	O
"	O
nephrotoxic	O
"	O
patients	O
increased	O
from	O
0	O
.	O
17	O
to	O
0	O
.	O
39	O
.	O

When	O
examined	O
individually	O
,	O
mean	O
IF	O
,	O
MIC	O
,	O
total	O
dose	O
,	O
mean	O
daily	O
dose	O
,	O
and	O
ln	O
(	O
mean	O
Cmax	O
/	O
MIC	O
)	O
correlated	O
significantly	O
(	O
P	O
less	O
than	O
.	O
05	O
)	O
with	O
cure	O
.	O

In	O
contrast	O
,	O
a	O
simultaneous	O
multivariable	O
analysis	O
identified	O
IF	O
,	O
MIC	O
,	O
and	O
total	O
dose	O
according	O
to	O
one	O
model	O
and	O
ln	O
(	O
mean	O
Cmax	O
/	O
MIC	O
)	O
according	O
to	O
a	O
second	O
statistical	O
model	O
of	O
parameters	O
selected	O
to	O
have	O
the	O
greatest	O
prospective	O
value	O
.	O

Based	O
on	O
Bayes	O
'	O
theorem	O
and	O
the	O
first	O
model	O
,	O
the	O
predictive	O
accuracy	O
of	O
identifying	O
patients	O
not	O
cured	O
increased	O
from	O
0	O
.	O
19	O
to	O
0	O
.	O
83	O
.	O

For	O
the	O
second	O
model	O
,	O
the	O
predictive	O
accuracy	O
increased	O
from	O
0	O
.	O
19	O
to	O
0	O
.	O
50	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Cardiac	O
toxicity	O
of	O
5	B-CHED
-	I-CHED
fluorouracil	I-CHED
.	O

Report	O
of	O
a	O
case	O
of	O
spontaneous	O
angina	O
.	O

We	O
report	O
a	O
case	O
of	O
a	O
patient	O
with	O
colon	O
carcinoma	O
and	O
liver	O
metastasis	O
who	O
presented	O
chest	O
pain	O
after	O
5	B-CHED
-	I-CHED
fluorouracil	I-CHED
(	O
5	B-CHED
-	I-CHED
FU	I-CHED
)	O
administration	O
.	O

Clinical	O
electrocardiographic	O
evolution	O
was	O
similar	O
to	O
that	O
observed	O
in	O
Prinzmetal	O
'	O
s	O
angina	O
,	O
and	O
chest	O
pain	O
promptly	O
resolved	O
with	O
nifedipine	B-CHED
.	O

These	O
data	O
suggest	O
that	O
coronary	O
spasm	O
may	O
be	O
the	O
cause	O
of	O
cardiotoxicity	O
due	O
to	O
5	B-CHED
-	I-CHED
FU	I-CHED
,	O
and	O
that	O
calcium	B-CHED
antagonists	O
may	O
probably	O
be	O
used	O
in	O
the	O
prevention	O
or	O
treatment	O
of	O
5	B-CHED
-	I-CHED
FU	I-CHED
cardiotoxicity	O
.	O

Dose	O
-	O
related	O
beneficial	O
and	O
adverse	O
effects	O
of	O
dietary	O
corticosterone	B-CHED
on	O
organophosphorus	B-CHED
-	O
induced	O
delayed	O
neuropathy	O
in	O
chickens	O
.	O

Tri	B-CHED
-	I-CHED
ortho	I-CHED
-	I-CHED
tolyl	I-CHED
phosphate	I-CHED
(	O
TOTP	B-CHED
)	O
,	O
360	O
mg	O
/	O
kg	O
,	O
po	O
,	O
and	O
0	B-CHED
,	I-CHED
0	I-CHED
'	I-CHED
-	I-CHED
diisopropyl	I-CHED
phosphorofluoridate	I-CHED
(	O
DFP	B-CHED
)	O
,	O
1	O
mg	O
/	O
kg	O
sc	O
,	O
were	O
administered	O
to	O
adult	O
White	O
Leghorn	O
chickens	O
24	O
hr	O
after	O
they	O
were	O
placed	O
on	O
diets	O
containing	O
0	O
to	O
300	O
ppm	O
corticosterone	B-CHED
.	O

Supplemented	O
diets	O
were	O
continued	O
until	O
clinical	O
signs	O
and	O
lesions	O
of	O
delayed	O
neuropathy	O
appeared	O
.	O

Although	O
low	O
concentrations	O
(	O
less	O
than	O
or	O
equal	O
to	O
50	O
ppm	O
)	O
of	O
corticosterone	B-CHED
had	O
beneficial	O
effects	O
on	O
TOTP	B-CHED
-	O
induced	O
neuropathy	O
,	O
greater	O
than	O
or	O
equal	O
to	O
200	O
ppm	O
exacerbated	O
clinical	O
signs	O
in	O
chickens	O
given	O
either	O
TOTP	B-CHED
or	O
DFP	B-CHED
.	O

Neurotoxic	O
esterase	O
activities	O
24	O
hr	O
after	O
TOTP	B-CHED
or	O
DFP	B-CHED
were	O
less	O
than	O
20	O
%	O
of	O
values	O
measured	O
in	O
chickens	O
not	O
given	O
organophosphorous	B-CHED
compounds	O
.	O

Chickens	O
given	O
200	O
ppm	O
corticosterone	B-CHED
without	O
TOTP	B-CHED
or	O
DFP	B-CHED
had	O
significantly	O
elevated	O
activity	O
of	O
plasma	O
cholinesterase	O
and	O
significantly	O
inhibited	O
activity	O
of	O
liver	O
carboxylesterase	O
.	O

Degenerating	O
myelinated	O
fibers	O
were	O
also	O
evident	O
in	O
distal	O
levels	O
of	O
the	O
peripheral	O
nerves	O
of	O
chickens	O
given	O
TOTP	B-CHED
or	O
DFP	B-CHED
.	O

Hepatotoxicity	O
of	O
amiodarone	B-CHED
.	O

Amiodarone	B-CHED
has	O
proved	O
very	O
effective	O
in	O
the	O
treatment	O
of	O
otherwise	O
resistant	O
cardiac	O
tachyarrhythmias	O
.	O

The	O
use	O
of	O
amiodarone	B-CHED
has	O
,	O
however	O
,	O
been	O
limited	O
due	O
to	O
its	O
serious	O
side	O
-	O
effects	O
.	O

A	O
patient	O
with	O
cholestatic	O
hepatitis	O
due	O
to	O
amiodarone	B-CHED
treatment	O
is	O
presented	O
below	O
and	O
a	O
review	O
of	O
the	O
hepatotoxicity	O
of	O
amiodarone	B-CHED
is	O
given	O
.	O

It	O
is	O
concluded	O
that	O
solid	O
evidence	O
exists	O
of	O
hepatic	O
injury	O
due	O
to	O
amiodarone	B-CHED
treatment	O
,	O
including	O
steatosis	O
,	O
alterations	O
resembling	O
alcoholic	O
hepatitis	O
,	O
cholestatic	O
hepatitis	O
and	O
micronodular	O
cirrhosis	O
of	O
the	O
liver	O
.	O

Patients	O
receiving	O
amiodarone	B-CHED
should	O
be	O
regularly	O
screened	O
with	O
respect	O
to	O
hepatic	O
enzyme	O
levels	O
.	O

Therapy	O
should	O
be	O
discontinued	O
on	O
the	O
suspicion	O
of	O
cholestatic	O
injury	O
or	O
hepatomegaly	O
.	O

Promotional	O
effects	O
of	O
testosterone	B-CHED
and	O
dietary	O
fat	O
on	O
prostate	O
carcinogenesis	O
in	O
genetically	O
susceptible	O
rats	O
.	O

Germfree	O
(	O
GF	O
)	O
Lobund	O
strain	O
Wistar	O
(	O
LW	O
)	O
rats	O
,	O
fed	O
vegetable	O
diet	O
L	O
-	O
485	O
,	O
have	O
developed	O
prostate	O
adenocarcinomas	O
spontaneously	O
(	O
10	O
%	O
incidence	O
)	O
at	O
average	O
age	O
34	O
months	O
.	O

Conventional	O
LW	O
rats	O
,	O
implanted	O
with	O
testosterone	B-CHED
at	O
age	O
4	O
months	O
,	O
developed	O
a	O
higher	O
incidence	O
of	O
prostate	O
cancer	O
after	O
an	O
average	O
interval	O
of	O
14	O
months	O
:	O
24	O
%	O
had	O
developed	O
gross	O
tumors	O
,	O
and	O
40	O
%	O
when	O
it	O
included	O
microscopic	O
tumors	O
.	O

Preliminary	O
results	O
indicate	O
that	O
testosterone	B-CHED
-	O
treated	O
LW	O
rats	O
that	O
were	O
fed	O
the	O
same	O
diet	O
,	O
which	O
was	O
supplemented	O
with	O
corn	O
oil	O
up	O
to	O
20	O
%	O
fat	O
,	O
developed	O
prostate	O
cancer	O
after	O
intervals	O
of	O
6	O
-	O
12	O
months	O
.	O

Aged	O
GF	O
Sprague	O
-	O
Dawley	O
(	O
SD	O
)	O
rats	O
have	O
not	O
developed	O
prostate	O
cancer	O
spontaneously	O
.	O

Conventional	O
SD	O
rats	O
fed	O
diet	O
L	O
-	O
485	O
and	O
treated	O
with	O
testosterone	B-CHED
developed	O
only	O
prostatitis	O
.	O

Experimental	O
designs	O
should	O
consider	O
genetic	O
susceptibility	O
as	O
a	O
basic	O
prerequisite	O
for	O
studies	O
on	O
experimental	O
prostate	O
cancer	O
.	O

Time	O
course	O
alterations	O
of	O
QTC	O
interval	O
due	O
to	O
hypaque	B-CHED
76	I-CHED
.	O

Sequential	O
measurement	O
of	O
QT	O
interval	O
during	O
left	O
ventricular	O
angiography	O
was	O
made	O
30	O
seconds	O
and	O
one	O
,	O
three	O
,	O
five	O
and	O
ten	O
minutes	O
after	O
injection	O
of	O
hypaque	B-CHED
76	I-CHED
.	O

The	O
subjects	O
were	O
ten	O
patients	O
found	O
to	O
have	O
normal	O
left	O
ventricles	O
and	O
coronary	O
arteries	O
.	O

Significant	O
QTC	O
prolongation	O
occurred	O
in	O
30	O
seconds	O
to	O
one	O
minute	O
in	O
association	O
with	O
marked	O
hypotension	O
and	O
elevation	O
of	O
cardiac	O
output	O
.	O

Rat	O
extraocular	O
muscle	O
regeneration	O
.	O

Repair	O
of	O
local	O
anesthetic	O
-	O
induced	O
damage	O
.	O

Local	O
anesthetics	O
that	O
are	O
commonly	O
used	O
in	O
ophthalmic	O
surgery	O
(	O
0	O
.	O
75	O
%	O
bupivacaine	B-CHED
hydrochloride	I-CHED
,	O
2	O
.	O
0	O
%	O
mepivacaine	B-CHED
hydrochloride	I-CHED
,	O
and	O
2	O
.	O
0	O
%	O
lidocaine	B-CHED
hydrochloride	I-CHED
plus	O
1	O
:	O
100	O
,	O
000	O
epinephrine	B-CHED
)	O
were	O
injected	O
into	O
the	O
retrobulbar	O
area	O
of	O
rat	O
eyes	O
.	O

Controls	O
were	O
injected	O
with	O
physiological	O
saline	O
.	O

All	O
three	O
anesthetics	O
produced	O
massive	O
degeneration	O
of	O
the	O
extraocular	O
muscles	O
.	O

Muscle	O
degeneration	O
is	O
followed	O
by	O
regeneration	O
of	O
the	O
damaged	O
muscle	O
fibers	O
.	O

In	O
addition	O
to	O
muscle	O
damage	O
,	O
severe	O
damage	O
was	O
also	O
seen	O
in	O
harderian	O
glands	O
,	O
especially	O
after	O
exposure	O
to	O
mepivacaine	B-CHED
and	O
lidocaine	B-CHED
plus	O
epinephrine	B-CHED
.	O

With	O
these	O
findings	O
in	O
rats	O
,	O
it	O
is	O
hypothesized	O
that	O
the	O
temporary	O
diplopia	O
sometimes	O
seen	O
in	O
patients	O
after	O
ophthalmic	O
surgery	O
might	O
be	O
due	O
to	O
anesthetic	O
-	O
induced	O
damage	O
to	O
the	O
extraocular	O
muscles	O
.	O

Gentamicin	B-CHED
nephropathy	O
in	O
a	O
neonate	O
.	O

The	O
clinical	O
and	O
autopsy	O
findings	O
in	O
a	O
premature	O
baby	O
who	O
died	O
of	O
acute	O
renal	O
failure	O
after	O
therapy	O
with	O
gentamicin	B-CHED
(	O
5	O
mg	O
/	O
kg	O
/	O
day	O
)	O
and	O
penicillin	B-CHED
are	O
presented	O
.	O

The	O
serum	O
gentamicin	B-CHED
concentration	O
had	O
reached	O
toxic	O
levels	O
when	O
anuria	O
developed	O
.	O

Numerous	O
periodic	B-CHED
acid	I-CHED
Schiff	O
(	O
PAS	O
)	O
positive	O
,	O
diastase	O
resistant	O
cytoplasmic	O
inclusion	O
bodies	O
which	O
appeared	O
as	O
myelin	O
figures	O
in	O
cytosegresomes	O
under	O
the	O
electron	O
microscope	O
were	O
identified	O
in	O
the	O
proximal	O
convoluted	O
tubules	O
.	O

The	O
pathological	O
changes	O
induced	O
by	O
gentamicin	B-CHED
in	O
the	O
human	O
neonatal	O
kidneys	O
have	O
not	O
been	O
previously	O
reported	O
.	O

Induction	O
by	O
paracetamol	B-CHED
of	O
bladder	O
and	O
liver	O
tumours	O
in	O
the	O
rat	O
.	O

Effects	O
on	O
hepatocyte	O
fine	O
structure	O
.	O

Groups	O
of	O
male	O
and	O
female	O
inbred	O
Leeds	O
strain	O
rats	O
were	O
fed	O
diets	O
containing	O
either	O
0	O
.	O
5	O
%	O
or	O
1	O
.	O
0	O
%	O
paracetamol	B-CHED
by	O
weight	O
for	O
up	O
to	O
18	O
months	O
.	O

At	O
the	O
1	O
.	O
0	O
%	O
dosage	O
level	O
,	O
20	O
%	O
of	O
rats	O
of	O
both	O
sexes	O
developed	O
neoplastic	O
nodules	O
of	O
the	O
liver	O
,	O
a	O
statistically	O
significant	O
incidence	O
.	O

These	O
rats	O
also	O
showed	O
gross	O
enlargement	O
of	O
their	O
livers	O
and	O
an	O
increase	O
in	O
foci	O
of	O
cellular	O
alteration	O
,	O
the	O
latter	O
also	O
being	O
observed	O
in	O
the	O
low	O
dosage	O
male	O
rats	O
.	O

Papillomas	O
of	O
the	O
transitional	O
epithelium	O
of	O
the	O
bladder	O
developed	O
in	O
all	O
paracetamol	B-CHED
-	O
treated	O
groups	O
,	O
and	O
three	O
rats	O
bore	O
bladder	O
carcinomas	O
.	O

However	O
,	O
significant	O
yields	O
of	O
bladder	O
tumours	O
were	O
only	O
obtained	O
from	O
low	O
dosage	O
females	O
and	O
high	O
dosage	O
males	O
.	O

Additionally	O
,	O
20	O
to	O
25	O
%	O
of	O
paracetamol	B-CHED
-	O
treated	O
rats	O
developed	O
hyperplasia	O
of	O
the	O
bladder	O
epithelium	O
,	O
which	O
was	O
not	O
coincident	O
with	O
the	O
presence	O
of	O
bladder	O
calculi	O
.	O

A	O
low	O
yield	O
of	O
tumours	O
at	O
various	O
other	O
sites	O
also	O
arose	O
following	O
paracetamol	B-CHED
feeding	O
.	O

An	O
electron	O
microscope	O
study	O
of	O
the	O
livers	O
of	O
paracetamol	B-CHED
-	O
treated	O
rats	O
revealed	O
ultrastructural	O
changes	O
in	O
the	O
hepatocytes	O
that	O
resemble	O
those	O
that	O
result	O
from	O
exposure	O
to	O
a	O
variety	O
of	O
known	O
hepatocarcinogens	O
.	O

Transient	O
hemiparesis	O
:	O
a	O
rare	O
manifestation	O
of	O
diphenylhydantoin	B-CHED
toxicity	O
.	O

Report	O
of	O
two	O
cases	O
.	O

Among	O
the	O
common	O
side	O
effects	O
of	O
diphenylhydantoin	B-CHED
(	O
DPH	B-CHED
)	O
overdose	O
,	O
the	O
most	O
frequently	O
encountered	O
neurological	O
signs	O
are	O
those	O
of	O
cerebellar	O
dysfunction	O
.	O

Very	O
rarely	O
,	O
the	O
toxic	O
neurological	O
manifestations	O
of	O
this	O
drug	O
are	O
of	O
cerebral	O
origin	O
.	O

Two	O
patients	O
are	O
presented	O
who	O
suffered	O
progressive	O
hemiparesis	O
due	O
to	O
DPH	B-CHED
overdose	O
.	O

Both	O
had	O
brain	O
surgery	O
before	O
DPH	B-CHED
treatment	O
.	O

It	O
is	O
assumed	O
that	O
patients	O
with	O
some	O
cerebral	O
damage	O
are	O
liable	O
to	O
manifest	O
DPH	B-CHED
toxicity	O
as	O
focal	O
neurological	O
signs	O
.	O

Tiapride	B-CHED
in	O
levodopa	B-CHED
-	O
induced	O
involuntary	O
movements	O
.	O

Tiapride	B-CHED
,	O
a	O
substituted	O
benzamide	B-CHED
derivative	O
closely	O
related	O
to	O
metoclopramide	B-CHED
,	O
reduced	O
levodopa	B-CHED
-	O
induced	O
peak	O
dose	O
involuntary	O
movements	O
in	O
16	O
patients	O
with	O
idiopathic	O
Parkinson	O
'	O
s	O
disease	O
.	O

However	O
,	O
an	O
unacceptable	O
increase	O
in	O
disability	O
from	O
Parkinsonism	O
with	O
aggravation	O
of	O
end	O
-	O
of	O
-	O
dose	O
akinesia	O
led	O
to	O
its	O
cessation	O
in	O
14	O
patients	O
.	O

Tiapride	B-CHED
had	O
no	O
effect	O
on	O
levodopa	B-CHED
-	O
induced	O
early	O
morning	O
of	O
"	O
off	O
-	O
period	O
"	O
segmental	O
dystonia	O
.	O

These	O
results	O
fail	O
to	O
support	O
the	O
notion	O
that	O
levodopa	B-CHED
-	O
induced	O
dyskinesias	O
are	O
caused	O
by	O
overstimulation	O
of	O
a	O
separate	O
group	O
of	O
dopamine	B-CHED
receptors	O
.	O

Quinidine	B-CHED
hepatitis	O
.	O

Long	O
-	O
term	O
administration	O
of	O
quinidine	B-CHED
was	O
associated	O
with	O
persistent	O
elevation	O
of	O
serum	O
concentrations	O
of	O
SGOT	O
,	O
lactic	B-CHED
acid	I-CHED
dehydrogenase	O
,	O
and	O
alkaline	O
phosphatase	O
.	O

Liver	O
biopsy	O
showed	O
active	O
hepatitis	O
.	O

Discontinuance	O
of	O
quinidine	B-CHED
therapy	O
led	O
to	O
normalization	O
of	O
liver	O
function	O
tests	O
.	O

A	O
challenge	O
dose	O
of	O
quinidine	B-CHED
caused	O
clinical	O
symptoms	O
and	O
abrupt	O
elevation	O
of	O
SGOT	O
,	O
alkaline	O
phosphatase	O
,	O
and	O
lactic	B-CHED
acid	I-CHED
dehydrogenase	O
values	O
.	O

We	O
concluded	O
that	O
this	O
patient	O
had	O
quinidine	B-CHED
hepatotoxicity	O
and	O
believe	O
that	O
this	O
is	O
the	O
first	O
case	O
reported	O
with	O
liver	O
biopsy	O
documentation	O
.	O

This	O
report	O
also	O
suggests	O
that	O
,	O
even	O
after	O
long	O
-	O
term	O
administration	O
,	O
the	O
hepatic	O
toxicity	O
is	O
reversible	O
.	O

Arterial	O
thromboembolism	O
in	O
patients	O
receiving	O
systemic	O
heparin	B-CHED
therapy	O
:	O
a	O
complication	O
associated	O
with	O
heparin	B-CHED
-	O
induced	O
thrombocytopenia	O
.	O

Arterial	O
thromboembolism	O
is	O
a	O
recognized	O
complication	O
of	O
systemic	O
heparin	B-CHED
therapy	O
.	O

Characteristic	O
of	O
the	O
entity	O
is	O
arterial	O
occlusion	O
by	O
platelet	O
-	O
fibrin	O
thrombi	O
with	O
distal	O
ischemia	O
occurring	O
four	O
to	O
twenty	O
days	O
after	O
the	O
initiation	O
of	O
heparin	B-CHED
therapy	O
,	O
preceded	O
by	O
profound	O
thrombocytopenia	O
with	O
platelet	O
counts	O
in	O
the	O
range	O
of	O
30	O
,	O
000	O
to	O
40	O
,	O
000	O
per	O
cubic	O
millimeter	O
.	O

The	O
clinically	O
apparent	O
occlusion	O
may	O
be	O
preceded	O
by	O
gastrointestinal	O
and	O
musculoskeletal	O
symptoms	O
that	O
appear	O
to	O
be	O
ischemic	O
in	O
origin	O
,	O
and	O
might	O
serve	O
to	O
warn	O
the	O
clinician	O
of	O
these	O
complications	O
.	O

Previous	O
reports	O
of	O
these	O
phenomena	O
as	O
well	O
as	O
recent	O
studies	O
of	O
the	O
effect	O
of	O
heparin	B-CHED
are	O
reviewed	O
.	O

The	O
common	O
factor	O
relating	O
thromboembolism	O
and	O
thrombocytopenia	O
is	O
heparin	B-CHED
-	O
induced	O
platelet	O
aggregation	O
.	O

Appropriate	O
treatment	O
consists	O
of	O
discontinuation	O
of	O
heparin	B-CHED
,	O
and	O
anticoagulation	O
with	O
sodium	B-CHED
warfarin	I-CHED
if	O
necessary	O
.	O

Vascular	O
procedures	O
are	O
performed	O
as	O
indicated	O
.	O

Pharmacology	O
of	O
GYKI	B-CHED
-	I-CHED
41	I-CHED
099	I-CHED
(	O
chlorpropanol	B-CHED
,	O
Tobanum	B-CHED
)	O
a	O
new	O
potent	O
beta	O
-	O
adrenergic	O
antagonist	O
.	O

The	O
compound	O
GYKI	B-CHED
-	I-CHED
41	I-CHED
099	I-CHED
,	O
as	O
a	O
beta	O
-	O
adrenergic	O
antagonist	O
,	O
is	O
3	O
-	O
8	O
times	O
more	O
potent	O
than	O
propranolol	B-CHED
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Its	O
antiarrhythmic	O
effectiveness	O
surpasses	O
that	O
of	O
propranolol	B-CHED
and	O
pindolol	B-CHED
inhibiting	O
the	O
ouabain	B-CHED
arrhythmia	O
in	O
dogs	O
and	O
cats	O
.	O

GYKI	B-CHED
-	I-CHED
41	I-CHED
900	I-CHED
has	O
a	O
negligible	O
cardiodepressant	O
activity	O
;	O
it	O
is	O
not	O
cardioselective	O
.	O

The	O
compound	O
shows	O
a	O
rapid	O
and	O
long	O
lasting	O
effect	O
.	O

There	O
was	O
a	O
prolonged	O
elimination	O
of	O
the	O
radioactivity	O
after	O
the	O
injection	O
of	O
14C	B-CHED
-	I-CHED
41	I-CHED
099	I-CHED
to	O
rats	O
and	O
dogs	O
.	O

The	O
half	O
life	O
of	O
the	O
unlabeled	O
substance	O
in	O
humans	O
was	O
more	O
than	O
10	O
hours	O
.	O

Adverse	O
reactions	O
to	O
bendrofluazide	B-CHED
and	O
propranolol	B-CHED
for	O
the	O
treatment	O
of	O
mild	O
hypertension	O
.	O

Report	O
of	O
Medical	O
Research	O
Council	O
Working	O
Party	O
on	O
Mild	O
to	O
Moderate	O
Hypertension	O
.	O

Participants	O
in	O
the	O
Medical	O
Research	O
Council	O
treatment	O
trial	O
for	O
mild	O
hypertension	O
are	O
randomly	O
allocated	O
to	O
one	O
of	O
four	O
treatment	O
groups	O
:	O
bendrofluazide	B-CHED
,	O
propranolol	B-CHED
,	O
or	O
a	O
placebo	O
for	O
either	O
of	O
these	O
drugs	O
.	O

The	O
trial	O
is	O
single	O
-	O
blind	O
.	O

23	O
582	O
patient	O
-	O
years	O
of	O
observation	O
have	O
been	O
completed	O
so	O
far	O
,	O
10	O
684	O
on	O
active	O
drugs	O
and	O
12	O
898	O
on	O
placebos	O
.	O

The	O
results	O
show	O
an	O
association	O
between	O
bendrofluazide	B-CHED
treatment	O
and	O
impotence	O
,	O
and	O
impotence	O
also	O
occurred	O
more	O
frequently	O
in	O
patients	O
taking	O
propranolol	B-CHED
than	O
in	O
those	O
taking	O
placebos	O
.	O

Other	O
adverse	O
reactions	O
significantly	O
linked	O
with	O
active	O
drugs	O
include	O
impaired	O
glucose	O
tolerance	O
in	O
men	O
and	O
women	O
and	O
gout	O
in	O
men	O
,	O
associated	O
with	O
bendrofluazide	B-CHED
treatment	O
,	O
and	O
Raynaud	O
'	O
s	O
phenomenon	O
and	O
dyspnoea	O
in	O
men	O
and	O
women	O
taking	O
propranolol	B-CHED
.	O

No	O
corneal	O
disease	O
is	O
known	O
to	O
have	O
occurred	O
in	O
the	O
propranolol	B-CHED
group	O
.	O

Mean	O
serum	O
potassium	B-CHED
level	O
fell	O
,	O
and	O
urea	B-CHED
and	O
uric	B-CHED
acid	I-CHED
levels	O
rose	O
,	O
in	O
men	O
and	O
women	O
taking	O
bendrofluazide	B-CHED
.	O

In	O
the	O
propranolol	B-CHED
group	O
,	O
serum	O
potassium	B-CHED
and	O
uric	B-CHED
acid	I-CHED
levels	O
rose	O
in	O
both	O
sexes	O
,	O
but	O
the	O
urea	B-CHED
level	O
rose	O
significantly	O
in	O
women	O
only	O
.	O

Serotonergic	O
drugs	O
,	O
benzodiazepines	B-CHED
and	O
baclofen	B-CHED
block	O
muscimol	B-CHED
-	O
induced	O
myoclonic	O
jerks	O
in	O
a	O
strain	O
of	O
mice	O
.	O

In	O
male	O
Swiss	O
mice	O
,	O
muscimol	B-CHED
produced	O
myoclonic	O
jerks	O
.	O

A	O
3	O
mg	O
/	O
kg	O
(	O
i	O
.	O
p	O
.	O
)	O
dose	O
induced	O
this	O
response	O
in	O
all	O
of	O
the	O
mice	O
tested	O
and	O
the	O
peak	O
response	O
of	O
73	O
jerks	O
per	O
min	O
was	O
observed	O
between	O
27	O
and	O
45	O
min	O
.	O

Increasing	O
the	O
brain	O
serotonin	B-CHED
levels	O
by	O
the	O
administration	O
of	O
5	B-CHED
-	I-CHED
hydroxytryptophan	I-CHED
(	O
80	O
-	O
160	O
mg	O
/	O
kg	O
)	O
in	O
combination	O
with	O
a	O
peripheral	O
decarboxylase	O
inhibitor	O
resulted	O
in	O
an	O
inhibition	O
of	O
the	O
muscimol	B-CHED
effect	O
.	O

However	O
,	O
in	O
a	O
similar	O
experiment	O
l	B-CHED
-	I-CHED
dopa	I-CHED
(	O
80	O
-	O
160	O
mg	O
/	O
kg	O
)	O
was	O
without	O
effect	O
.	O

In	O
doses	O
of	O
3	O
-	O
10	O
mg	O
/	O
kg	O
,	O
the	O
serotonin	B-CHED
receptor	O
agonist	O
MK	B-CHED
-	I-CHED
212	I-CHED
caused	O
a	O
dose	O
-	O
dependent	O
blockade	O
of	O
the	O
response	O
of	O
muscimol	B-CHED
.	O

Of	O
the	O
benzodiazepines	B-CHED
,	O
clonazepam	B-CHED
(	O
0	O
.	O
1	O
-	O
0	O
.	O
3	O
mg	O
/	O
kg	O
)	O
was	O
found	O
to	O
be	O
several	O
fold	O
more	O
potent	O
than	O
diazepam	B-CHED
(	O
0	O
.	O
3	O
-	O
3	O
mg	O
/	O
kg	O
)	O
in	O
blocking	O
the	O
myoclonic	O
jerks	O
.	O

While	O
(	O
-	O
)	O
-	O
baclofen	B-CHED
(	O
1	O
-	O
3	O
mg	O
/	O
kg	O
)	O
proved	O
to	O
be	O
an	O
effective	O
antagonist	O
of	O
muscimol	B-CHED
,	O
its	O
(	O
+	O
)	O
-	O
isomer	O
(	O
5	O
-	O
20	O
mg	O
/	O
kg	O
)	O
lacked	O
this	O
property	O
.	O

Considering	O
the	O
fact	O
that	O
5	B-CHED
-	I-CHED
HTP	I-CHED
and	O
the	O
benzodiazepines	B-CHED
have	O
been	O
found	O
to	O
be	O
beneficial	O
in	O
the	O
management	O
of	O
clinical	O
myoclonus	O
,	O
the	O
muscimol	B-CHED
-	O
induced	O
myoclonus	O
seems	O
to	O
be	O
a	O
satisfactory	O
animal	O
model	O
that	O
may	O
prove	O
useful	O
for	O
the	O
development	O
of	O
new	O
drug	O
treatments	O
for	O
this	O
condition	O
.	O

Our	O
present	O
study	O
indicated	O
the	O
possible	O
value	O
of	O
MK	B-CHED
-	I-CHED
212	I-CHED
and	O
(	O
-	O
)	O
-	O
baclofen	B-CHED
in	O
the	O
management	O
of	O
clinical	O
myoclonus	O
.	O

Adverse	O
interaction	O
between	O
beta	B-CHED
-	I-CHED
adrenergic	I-CHED
blocking	I-CHED
drugs	I-CHED
and	O
verapamil	B-CHED
-	O
-	O
report	O
of	O
three	O
cases	O
.	O

Three	O
patients	O
with	O
ischaemic	O
heart	O
disease	O
developed	O
profound	O
cardiac	O
failure	O
,	O
hypotension	O
and	O
bradycardia	O
during	O
combined	O
therapy	O
with	O
verapamil	B-CHED
and	O
beta	B-CHED
-	I-CHED
adrenergic	I-CHED
blocking	I-CHED
drugs	I-CHED
.	O

This	O
clinical	O
picture	O
resolved	O
completely	O
with	O
cessation	O
of	O
the	O
combined	O
therapy	O
.	O

Baseline	O
left	O
ventricular	O
function	O
,	O
assessed	O
by	O
cardiac	O
catheterisation	O
or	O
nuclear	O
angiography	O
,	O
was	O
normal	O
in	O
two	O
patients	O
and	O
only	O
mildly	O
reduced	O
in	O
the	O
other	O
.	O

Simultaneously	O
administration	O
of	O
beta	B-CHED
-	I-CHED
adrenergic	I-CHED
blocking	I-CHED
drugs	I-CHED
and	O
verapamil	B-CHED
may	O
result	O
in	O
profound	O
adverse	O
interactions	O
and	O
should	O
only	O
be	O
administered	O
with	O
great	O
caution	O
.	O

Comparison	O
of	O
the	O
effectiveness	O
of	O
ranitidine	B-CHED
and	O
cimetidine	B-CHED
in	O
inhibiting	O
acid	O
secretion	O
in	O
patients	O
with	O
gastric	O
hypersecretory	O
states	O
.	O

The	O
H2	O
-	O
histamine	B-CHED
receptor	O
antagonists	O
ranitidine	B-CHED
and	O
cimetidine	B-CHED
were	O
compared	O
for	O
their	O
abilities	O
to	O
control	O
gastric	O
acid	O
hypersecretion	O
on	O
a	O
short	O
-	O
and	O
long	O
-	O
term	O
basis	O
in	O
22	O
patients	O
with	O
gastric	O
acid	O
hypersecretory	O
states	O
.	O

Nineteen	O
patients	O
had	O
Zollinger	O
-	O
Ellison	O
syndrome	O
,	O
one	O
patient	O
had	O
systemic	O
mastocytosis	O
,	O
and	O
two	O
patients	O
had	O
idiopathic	O
hypersecretion	O
.	O

The	O
rates	O
of	O
onset	O
of	O
the	O
action	O
of	O
cimetidine	B-CHED
and	O
ranitidine	B-CHED
were	O
the	O
same	O
.	O

The	O
actions	O
of	O
both	O
drugs	O
were	O
increased	O
by	O
anticholinergic	O
agents	O
,	O
and	O
there	O
was	O
a	O
close	O
correlation	O
between	O
the	O
daily	O
maintenance	O
dose	O
of	O
each	O
drug	O
needed	O
to	O
control	O
acid	O
secretion	O
.	O

However	O
,	O
ranitidine	B-CHED
was	O
threefold	O
more	O
potent	O
than	O
cimetidine	B-CHED
both	O
in	O
acute	O
inhibition	O
studies	O
and	O
in	O
the	O
median	O
maintenance	O
dose	O
needed	O
(	O
1	O
.	O
2	O
g	O
per	O
day	O
for	O
ranitidine	B-CHED
and	O
3	O
.	O
6	O
g	O
per	O
day	O
for	O
cimetidine	B-CHED
)	O
.	O

Sixty	O
percent	O
of	O
the	O
males	O
developed	O
breast	O
changes	O
or	O
impotence	O
while	O
taking	O
cimetidine	B-CHED
and	O
in	O
all	O
cases	O
these	O
changes	O
disappeared	O
when	O
cimetidine	B-CHED
was	O
replaced	O
by	O
ranitidine	B-CHED
.	O

Treatment	O
with	O
high	O
doses	O
of	O
cimetidine	B-CHED
(	O
one	O
to	O
60	O
months	O
;	O
median	O
,	O
11	O
months	O
)	O
or	O
ranitidine	B-CHED
(	O
two	O
to	O
31	O
months	O
;	O
median	O
,	O
14	O
months	O
)	O
was	O
not	O
associated	O
with	O
hepatic	O
or	O
hematologic	O
toxicity	O
or	O
alterations	O
of	O
serum	O
gastrin	O
concentrations	O
,	O
but	O
ranitidine	B-CHED
therapy	O
was	O
associated	O
with	O
a	O
significantly	O
lower	O
serum	O
creatinine	B-CHED
level	O
than	O
seen	O
with	O
cimetidine	B-CHED
therapy	O
.	O

The	O
results	O
show	O
that	O
both	O
drugs	O
can	O
adequately	O
inhibit	O
acid	O
secretion	O
in	O
patients	O
with	O
gastric	O
hypersecretory	O
states	O
.	O

Both	O
are	O
safe	O
at	O
high	O
doses	O
,	O
but	O
ranitidine	B-CHED
is	O
threefold	O
more	O
potent	O
and	O
does	O
not	O
cause	O
the	O
antiandrogen	O
side	O
effects	O
frequently	O
seen	O
with	O
high	O
doses	O
of	O
cimetidine	B-CHED
.	O

Epileptogenic	O
properties	O
of	O
enflurane	B-CHED
and	O
their	O
clinical	O
interpretation	O
.	O

Three	O
cases	O
of	O
EEG	O
changes	O
induced	O
by	O
single	O
exposure	O
to	O
enflurane	B-CHED
anesthesia	O
are	O
reported	O
.	O

In	O
one	O
patient	O
,	O
enflurane	B-CHED
administered	O
during	O
a	O
donor	O
nephrectomy	O
resulted	O
in	O
unexpected	O
partial	O
motor	O
seizures	O
.	O

Until	O
the	O
cause	O
of	O
the	O
seizures	O
was	O
correctly	O
identified	O
,	O
the	O
patient	O
was	O
inappropriately	O
treated	O
with	O
anticonvulsants	O
.	O

Two	O
other	O
patients	O
suffered	O
from	O
partial	O
,	O
complex	O
and	O
generalized	O
seizures	O
uncontrolled	O
by	O
medication	O
.	O

Epileptic	O
foci	O
delineated	O
and	O
activated	O
by	O
enflurane	B-CHED
were	O
surgically	O
ablated	O
and	O
the	O
patients	O
are	O
now	O
seizure	O
-	O
free	O
.	O

Previous	O
exposures	O
to	O
enflurane	B-CHED
have	O
to	O
be	O
disclosed	O
to	O
avoid	O
mistakes	O
in	O
clinical	O
interpretation	O
of	O
the	O
EEG	O
.	O

On	O
the	O
other	O
hand	O
,	O
enflurane	B-CHED
may	O
prove	O
to	O
be	O
a	O
safe	O
fast	O
acting	O
activator	O
of	O
epileptic	O
foci	O
during	O
corticography	O
or	O
depth	O
electrode	O
intraoperative	O
recordings	O
.	O

Development	O
of	O
isoproterenol	B-CHED
-	O
induced	O
cardiac	O
hypertrophy	O
.	O

The	O
development	O
of	O
cardiac	O
hypertrophy	O
was	O
studied	O
in	O
adult	O
female	O
Wistar	O
rats	O
following	O
daily	O
subcutaneous	O
injections	O
of	O
isoproterenol	B-CHED
(	O
ISO	B-CHED
)	O
(	O
0	O
.	O
3	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
.	O

A	O
time	O
course	O
was	O
established	O
for	O
the	O
change	O
in	O
tissue	O
mass	O
,	O
RNA	O
and	O
DNA	O
content	O
,	O
as	O
well	O
as	O
hydroxyproline	B-CHED
content	O
.	O

Heart	O
weight	O
increased	O
44	O
%	O
after	O
8	O
days	O
of	O
treatment	O
with	O
a	O
half	O
time	O
of	O
3	O
.	O
4	O
days	O
.	O

Ventricular	O
RNA	O
content	O
was	O
elevated	O
26	O
%	O
after	O
24	O
h	O
of	O
a	O
single	O
injection	O
and	O
reached	O
a	O
maximal	O
level	O
following	O
8	O
days	O
of	O
therapy	O
.	O

The	O
half	O
time	O
for	O
RNA	O
accumulation	O
was	O
2	O
.	O
0	O
days	O
.	O

The	O
total	O
content	O
of	O
hydroxyproline	B-CHED
remained	O
stable	O
during	O
the	O
first	O
2	O
days	O
of	O
treatment	O
but	O
increased	O
46	O
%	O
after	O
4	O
days	O
of	O
therapy	O
.	O

Ventricular	O
DNA	O
content	O
was	O
unchanged	O
during	O
the	O
early	O
stage	O
(	O
1	O
-	O
4	O
days	O
)	O
of	O
hypertrophic	O
growth	O
but	O
increased	O
to	O
a	O
new	O
steady	O
-	O
state	O
level	O
19	O
%	O
above	O
the	O
controls	O
after	O
8	O
days	O
of	O
treatment	O
.	O

Intraventricular	O
pressures	O
and	O
coronary	O
flow	O
measures	O
were	O
similar	O
for	O
control	O
and	O
experimental	O
animals	O
following	O
4	O
days	O
of	O
developed	O
hypertrophy	O
.	O

However	O
,	O
dP	O
/	O
dt	O
in	O
the	O
ISO	B-CHED
-	O
treated	O
hearts	O
was	O
slightly	O
but	O
significantly	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
elevated	O
.	O

These	O
data	O
indicate	O
that	O
the	O
adaptive	O
response	O
to	O
ISO	B-CHED
shows	O
an	O
early	O
hypertrophic	O
phase	O
(	O
1	O
-	O
4	O
days	O
)	O
characterized	O
by	O
a	O
substantial	O
increase	O
in	O
RNA	O
content	O
and	O
cardiac	O
mass	O
in	O
the	O
absence	O
of	O
changes	O
in	O
DNA	O
.	O

However	O
,	O
prolonged	O
stimulation	O
(	O
8	O
-	O
12	O
days	O
)	O
appears	O
to	O
represent	O
a	O
complex	O
integration	O
of	O
both	O
cellular	O
hypertrophy	O
and	O
hyperplasia	O
within	O
the	O
heart	O
.	O

Multiple	O
side	O
effects	O
of	O
penicillamine	B-CHED
therapy	O
in	O
one	O
patient	O
with	O
rheumatoid	O
arthritis	O
.	O

Skin	O
rashes	O
,	O
proteinuria	O
,	O
systemic	O
lupus	O
erythematosus	O
,	O
polymyositis	O
and	O
myasthenia	O
gravis	O
have	O
all	O
been	O
recorded	O
as	O
complications	O
of	O
penicillamine	B-CHED
therapy	O
in	O
patients	O
with	O
rheumatoid	O
arthritis	O
.	O

A	O
patient	O
who	O
had	O
developed	O
all	O
5	O
is	O
now	O
described	O
.	O

The	O
skin	O
lesion	O
resembled	O
elastosis	O
perforans	O
serpiginosa	O
,	O
which	O
has	O
been	O
reported	O
as	O
a	O
rare	O
side	O
effect	O
in	O
patients	O
with	O
Wilson	O
'	O
s	O
disease	O
but	O
not	O
in	O
patients	O
with	O
rheumatoid	O
arthritis	O
treated	O
with	O
penicillamine	B-CHED
.	O

Obsolete	O
but	O
dangerous	O
antacid	O
preparations	O
.	O

One	O
case	O
of	O
acute	O
hypercalcaemia	O
and	O
two	O
of	O
recurrent	O
nephrolithiasis	O
are	O
reported	O
in	O
patients	O
who	O
had	O
regularly	O
consumed	O
large	O
amounts	O
of	O
calcium	B-CHED
carbon	I-CHED
-	I-CHED
ate	I-CHED
-	O
sodium	B-CHED
bicarbonate	I-CHED
powders	O
for	O
more	O
than	O
20	O
years	O
.	O

The	O
powders	O
had	O
been	O
obtained	O
from	O
pharmacists	O
unknown	O
to	O
the	O
patients	O
'	O
medical	O
practitioners	O
.	O

It	O
is	O
suggested	O
that	O
these	O
preparations	O
were	O
responsible	O
for	O
the	O
patient	O
'	O
s	O
problems	O
,	O
and	O
that	O
such	O
powders	O
should	O
no	O
longer	O
be	O
freely	O
obtainable	O
.	O

Doxorubicin	B-CHED
cardiomyopathy	O
in	O
children	O
with	O
left	O
-	O
sided	O
Wilms	O
tumor	O
.	O

Two	O
children	O
with	O
Wilms	O
tumor	O
of	O
the	O
left	O
kidney	O
experienced	O
severe	O
anthracycline	B-CHED
cardiomyopathy	O
after	O
irradiation	O
to	O
the	O
tumor	O
bed	O
and	O
conventional	O
dosage	O
of	O
doxorubicin	B-CHED
.	O

The	O
cardiomyopathy	O
is	O
attributed	O
1	O
)	O
to	O
the	O
fact	O
that	O
radiation	O
fields	O
for	O
left	O
Wilms	O
tumor	O
include	O
the	O
lower	O
portion	O
of	O
the	O
heart	O
and	O
2	O
)	O
to	O
the	O
interaction	O
of	O
doxorubicin	B-CHED
and	O
irradiation	O
on	O
cardiac	O
muscle	O
.	O

It	O
is	O
recommended	O
that	O
doxorubicin	B-CHED
dosage	O
be	O
sharply	O
restricted	O
in	O
children	O
with	O
Wilms	O
tumor	O
of	O
the	O
left	O
kidney	O
who	O
receive	O
postoperative	O
irradiation	O
.	O

Effects	O
of	O
calcitonin	O
on	O
rat	O
extrapyramidal	O
motor	O
system	O
:	O
behavioral	O
and	O
biochemical	O
data	O
.	O

The	O
effects	O
of	O
i	O
.	O
v	O
.	O
c	O
.	O
injection	O
of	O
human	O
and	O
salmon	O
calcitonin	O
on	O
biochemical	O
and	O
behavioral	O
parameters	O
related	O
to	O
the	O
extrapyramidal	O
motor	O
system	O
,	O
were	O
investigated	O
in	O
male	O
rats	O
.	O

Calcitonin	O
injection	O
resulted	O
in	O
a	O
potentiation	O
of	O
haloperidol	B-CHED
-	O
induced	O
catalepsy	O
and	O
a	O
partial	O
prevention	O
of	O
apomorphine	B-CHED
-	O
induced	O
hyperactivity	O
.	O

Moreover	O
calcitonin	O
induced	O
a	O
significant	O
decrease	O
in	O
nigral	O
GAD	O
activity	O
but	O
no	O
change	O
in	O
striatal	O
DA	B-CHED
and	O
DOPAC	B-CHED
concentration	O
or	O
GAD	O
activity	O
.	O

The	O
results	O
are	O
discussed	O
in	O
view	O
of	O
a	O
primary	O
action	O
of	O
calcitonin	O
on	O
the	O
striatonigral	O
GABAergic	O
pathway	O
mediating	O
the	O
DA	B-CHED
-	O
related	O
behavioral	O
messages	O
of	O
striatal	O
origin	O
.	O

Naloxazone	B-CHED
pretreatment	O
modifies	O
cardiorespiratory	O
,	O
temperature	O
,	O
and	O
behavioral	O
effects	O
of	O
morphine	B-CHED
.	O

Behavioral	O
and	O
cardiorespiratory	O
responses	O
to	O
a	O
lethal	O
dose	O
of	O
morphine	B-CHED
were	O
evaluated	O
in	O
rats	O
pretreated	O
with	O
saline	O
or	O
naloxazone	B-CHED
,	O
an	O
antagonist	O
of	O
high	O
-	O
affinity	O
mu	O
1	O
opioid	O
receptors	O
.	O

Pretreatment	O
with	O
naloxazone	B-CHED
significantly	O
blocked	O
morphine	B-CHED
analgesia	O
,	O
catalepsy	O
and	O
hypothermia	O
at	O
a	O
dose	O
which	O
completely	O
eliminated	O
high	O
-	O
affinity	O
binding	O
in	O
brain	O
membranes	O
.	O

Moreover	O
,	O
naloxazone	B-CHED
significantly	O
attenuated	O
the	O
morphine	B-CHED
-	O
induced	O
hypotension	O
and	O
respiratory	O
depression	O
,	O
whereas	O
morphine	B-CHED
-	O
induced	O
bradycardia	O
was	O
less	O
affected	O
.	O

Results	O
indicate	O
that	O
subpopulations	O
of	O
mu	O
receptors	O
may	O
mediate	O
selective	O
behavioral	O
and	O
cardiorespiratory	O
responses	O
to	O
morphine	B-CHED
.	O

Modification	O
of	O
drug	O
action	O
by	O
hyperammonemia	O
.	O

Pretreatment	O
with	O
ammonium	B-CHED
acetate	I-CHED
(	O
NH4Ac	B-CHED
)	O
(	O
6	O
mmol	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
approximately	O
doubled	O
the	O
time	O
morphine	B-CHED
-	O
treated	O
mice	O
remained	O
on	O
a	O
hot	O
surface	O
and	O
similarly	O
increased	O
muscular	O
incoordination	O
by	O
diazepam	B-CHED
,	O
but	O
NH4Ac	B-CHED
treatment	O
alone	O
had	O
no	O
effect	O
.	O

Thus	O
,	O
hyperammonemia	O
is	O
capable	O
of	O
altering	O
drug	O
action	O
and	O
must	O
be	O
considered	O
along	O
with	O
impaired	O
drug	O
metabolism	O
in	O
enhanced	O
drug	O
responses	O
associated	O
with	O
liver	O
disease	O
.	O

Experiments	O
in	O
vitro	O
showed	O
that	O
acetylcholine	B-CHED
-	O
induced	O
catecholamine	B-CHED
release	O
from	O
bovine	O
adrenal	O
medulla	O
is	O
depressed	O
as	O
much	O
as	O
50	O
%	O
by	O
0	O
.	O
3	O
mM	O
NH4Ac	B-CHED
and	O
KCl	B-CHED
-	O
induced	O
contractions	O
of	O
guinea	O
-	O
pig	O
ileum	O
were	O
inhibited	O
20	O
%	O
by	O
5	O
mM	O
NH4Ac	B-CHED
.	O

Addition	O
of	O
excess	O
calcium	B-CHED
reversed	O
the	O
depression	O
in	O
both	O
tissues	O
,	O
but	O
calcium	B-CHED
-	O
independent	O
catecholamine	B-CHED
release	O
by	O
acetaldehyde	B-CHED
was	O
not	O
blocked	O
by	O
NH4Ac	B-CHED
.	O

These	O
results	O
suggested	O
that	O
ammonia	B-CHED
blocks	O
calcium	B-CHED
channels	O
.	O

Parallels	O
in	O
the	O
actions	O
of	O
NH4Ac	B-CHED
and	O
the	O
calcium	B-CHED
channel	O
blocker	O
verapamil	B-CHED
support	O
this	O
concept	O
.	O

Both	O
verapamil	B-CHED
(	O
10	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
and	O
NH4Ac	B-CHED
pretreatment	O
enhanced	O
morphine	B-CHED
analgesia	O
-	O
and	O
diazepam	B-CHED
-	O
induced	O
muscular	O
incoordination	O
and	O
antagonized	O
amphetamine	B-CHED
-	O
induced	O
motor	O
activity	O
,	O
and	O
neither	O
verapamil	B-CHED
nor	O
NH4Ac	B-CHED
affected	O
the	O
convulsant	O
action	O
of	O
metrazol	B-CHED
.	O

The	O
data	O
suggest	O
that	O
hyperammonemia	O
exerts	O
a	O
calcium	B-CHED
channel	O
blocking	O
action	O
which	O
enhances	O
the	O
effects	O
of	O
central	O
nervous	O
system	O
depressants	O
and	O
certain	O
opioid	O
analgesics	O
.	O

Levodopa	B-CHED
-	O
induced	O
dyskinesia	O
and	O
thalamotomy	O
.	O

Levodopa	B-CHED
-	O
induced	O
dyskinesia	O
of	O
the	O
limbs	O
in	O
thirteen	O
cases	O
of	O
Parkinsonism	O
,	O
which	O
was	O
choreic	O
,	O
ballistic	O
or	O
dystonic	O
in	O
type	O
,	O
was	O
alleviated	O
almost	O
completely	O
by	O
stereotaxic	O
surgery	O
using	O
a	O
microelectrode	O
technique	O
for	O
the	O
ventralis	O
oralis	O
anterior	O
and	O
posterior	O
nuclei	O
of	O
the	O
thalamus	O
,	O
but	O
much	O
less	O
by	O
the	O
ventralis	O
intermedius	O
nucleus	O
.	O

Control	O
of	O
levodopa	B-CHED
-	O
induced	O
dyskinesias	O
by	O
thalamic	O
lesions	O
in	O
the	O
course	O
of	O
routine	O
treatment	O
of	O
Parkinsonism	O
is	O
discussed	O
.	O

Treatment	O
of	O
ifosfamide	B-CHED
-	O
induced	O
urothelial	O
toxicity	O
by	O
oral	O
administration	O
of	O
sodium	B-CHED
2	I-CHED
-	I-CHED
mercaptoethane	I-CHED
sulphonate	I-CHED
(	O
MESNA	B-CHED
)	O
to	O
patients	O
with	O
inoperable	O
lung	O
cancer	O
.	O

The	O
protective	O
effect	O
of	O
oral	O
administration	O
of	O
the	O
thiol	B-CHED
compound	O
sodium	B-CHED
2	I-CHED
-	I-CHED
mercaptoethane	I-CHED
sulphonate	I-CHED
(	O
MESNA	B-CHED
)	O
against	O
urothelial	O
toxicity	O
induced	O
by	O
ifosfamide	B-CHED
(	O
IF	B-CHED
)	O
was	O
tested	O
in	O
a	O
group	O
of	O
45	O
patients	O
with	O
inoperable	O
lung	O
cancer	O
under	O
treatment	O
with	O
IF	B-CHED
(	O
2250	O
mg	O
/	O
m2	O
on	O
days	O
2	O
-	O
5	O
)	O
as	O
part	O
of	O
a	O
polychemotherapy	O
regimen	O
repeated	O
in	O
a	O
4	O
-	O
week	O
cycle	O
.	O

MESNA	B-CHED
was	O
given	O
orally	O
on	O
the	O
days	O
of	O
treatment	O
with	O
IF	B-CHED
in	O
3	O
doses	O
of	O
840	O
mg	O
/	O
m2	O
,	O
each	O
administered	O
at	O
0	O
hr	O
(	O
=	O
injection	O
of	O
IF	B-CHED
)	O
,	O
4	O
hr	O
and	O
8	O
hr	O
p	O
.	O
i	O
.	O

Out	O
of	O
a	O
total	O
of	O
88	O
courses	O
of	O
this	O
treatment	O
we	O
observed	O
10	O
episodes	O
of	O
asymptomatic	O
microscopic	O
haematuria	O
and	O
no	O
episodes	O
of	O
gross	O
haematuria	O
.	O

In	O
this	O
group	O
of	O
45	O
patients	O
under	O
protection	O
with	O
MESNA	B-CHED
there	O
were	O
5	O
complete	O
remissions	O
and	O
9	O
partial	O
remissions	O
(	O
total	O
31	O
%	O
)	O
.	O

A	O
further	O
group	O
of	O
25	O
patients	O
under	O
polychemotherapy	O
with	O
IF	B-CHED
were	O
treated	O
by	O
conventional	O
prophylactic	O
measures	O
(	O
raised	O
fluid	O
intake	O
and	O
forced	O
diuresis	O
)	O
.	O

In	O
this	O
group	O
there	O
were	O
1	O
complete	O
and	O
5	O
partial	O
remissions	O
(	O
total	O
24	O
%	O
)	O
,	O
but	O
nearly	O
all	O
patients	O
developed	O
either	O
gross	O
haematuria	O
and	O
/	O
or	O
symptoms	O
of	O
bladder	O
irritation	O
(	O
cystitis	O
and	O
pollakisuria	O
)	O
.	O

There	O
were	O
no	O
appreciable	O
differences	O
between	O
the	O
MESNA	B-CHED
series	O
and	O
the	O
conventional	O
prophylaxis	O
series	O
with	O
respect	O
to	O
either	O
haematological	O
or	O
systemic	O
toxicity	O
of	O
the	O
cytostatic	O
treatment	O
.	O

Our	O
results	O
support	O
the	O
view	O
that	O
MESNA	B-CHED
,	O
given	O
orally	O
in	O
conjunction	O
with	O
combined	O
cytostatic	O
regimens	O
which	O
include	O
IF	B-CHED
,	O
simplifies	O
the	O
treatment	O
and	O
provides	O
optimum	O
protection	O
for	O
the	O
urinary	O
epithelium	O
.	O

Protection	O
with	O
oral	O
MESNA	B-CHED
is	O
particularly	O
suitable	O
for	O
outpatients	O
.	O

Myoclonic	O
,	O
atonic	O
,	O
and	O
absence	O
seizures	O
following	O
institution	O
of	O
carbamazepine	B-CHED
therapy	O
in	O
children	O
.	O

Five	O
children	O
,	O
aged	O
3	O
to	O
11	O
years	O
,	O
treated	O
with	O
carbamazepine	B-CHED
for	O
epilepsy	O
,	O
had	O
an	O
acute	O
aberrant	O
reaction	O
characterized	O
by	O
the	O
onset	O
of	O
myoclonic	O
,	O
atypical	O
absence	O
and	O
/	O
or	O
atonic	O
(	O
minor	O
motor	O
)	O
seizures	O
within	O
a	O
few	O
days	O
.	O

When	O
the	O
carbamazepine	B-CHED
was	O
discontinued	O
,	O
two	O
of	O
the	O
children	O
returned	O
to	O
their	O
former	O
state	O
very	O
quickly	O
,	O
two	O
had	O
the	O
minor	O
motor	O
seizures	O
resolve	O
in	O
3	O
and	O
6	O
months	O
,	O
and	O
one	O
had	O
the	O
seizures	O
persist	O
.	O

The	O
child	O
in	O
whom	O
the	O
seizures	O
persisted	O
was	O
later	O
found	O
to	O
have	O
ceroid	O
lipofuscinosis	O
.	O

The	O
other	O
children	O
are	O
doing	O
well	O
on	O
other	O
anticonvulsants	O
.	O

Effect	O
of	O
prostaglandin	B-CHED
synthetase	O
inhibitors	O
on	O
experimentally	O
induced	O
convulsions	O
in	O
rats	O
.	O

To	O
investigate	O
the	O
relationship	O
of	O
prostaglandins	B-CHED
(	O
PGs	B-CHED
)	O
to	O
seizure	O
induction	O
,	O
the	O
effects	O
of	O
six	O
PG	O
synthetase	O
inhibitors	O
on	O
convulsions	O
induced	O
by	O
flurothyl	B-CHED
,	O
picrotoxin	B-CHED
,	O
pentetrazol	B-CHED
(	O
PTZ	B-CHED
)	O
,	O
electroshock	O
or	O
bicuculline	B-CHED
were	O
evaluated	O
.	O

Ibuprofen	B-CHED
,	O
sulindac	B-CHED
,	O
mefenamic	B-CHED
acid	I-CHED
,	O
and	O
low	O
dose	O
meclofenamic	B-CHED
acid	I-CHED
increased	O
the	O
latency	O
-	O
to	O
-	O
onset	O
in	O
the	O
flurothyl	B-CHED
and	O
/	O
or	O
PTZ	B-CHED
models	O
;	O
the	O
electroshock	O
,	O
picrotoxin	B-CHED
and	O
bicuculline	B-CHED
models	O
were	O
not	O
significantly	O
affected	O
by	O
any	O
of	O
the	O
pretreatment	O
agents	O
.	O

These	O
results	O
suggest	O
that	O
PGs	B-CHED
are	O
involved	O
in	O
the	O
mechanism	O
(	O
s	O
)	O
underlying	O
fluorthyl	B-CHED
-	O
and	O
PTZ	B-CHED
-	O
induced	O
convulsions	O
,	O
but	O
not	O
picrotoxin	B-CHED
-	O
,	O
electroshock	O
-	O
,	O
or	O
bicuculline	B-CHED
-	O
induced	O
convulsions	O
.	O

Acute	O
changes	O
of	O
blood	O
ammonia	B-CHED
may	O
predict	O
short	O
-	O
term	O
adverse	O
effects	O
of	O
valproic	B-CHED
acid	I-CHED
.	O

Valproic	B-CHED
acid	I-CHED
(	O
VPA	B-CHED
)	O
was	O
given	O
to	O
24	O
epileptic	O
patients	O
who	O
were	O
already	O
being	O
treated	O
with	O
other	O
antiepileptic	O
drugs	O
.	O

A	O
standardized	O
loading	O
dose	O
of	O
VPA	B-CHED
was	O
administered	O
,	O
and	O
venous	O
blood	O
was	O
sampled	O
at	O
0	O
,	O
1	O
,	O
2	O
,	O
3	O
,	O
and	O
4	O
hours	O
.	O

Ammonia	B-CHED
(	O
NH3	B-CHED
)	O
was	O
higher	O
in	O
patients	O
who	O
,	O
during	O
continuous	O
therapy	O
,	O
complained	O
of	O
drowsiness	O
(	O
7	O
patients	O
)	O
than	O
in	O
those	O
who	O
were	O
symptom	O
-	O
free	O
(	O
17	O
patients	O
)	O
,	O
although	O
VPA	B-CHED
plasma	O
levels	O
were	O
similar	O
in	O
both	O
groups	O
.	O

By	O
measuring	O
VPA	B-CHED
-	O
induced	O
changes	O
of	O
blood	O
NH3	B-CHED
content	O
,	O
it	O
may	O
be	O
possible	O
to	O
identify	O
patients	O
at	O
higher	O
risk	O
of	O
obtundation	O
when	O
VPA	B-CHED
is	O
given	O
chronically	O
.	O

Effect	O
of	O
captopril	B-CHED
on	O
pre	O
-	O
existing	O
and	O
aminonucleoside	B-CHED
-	O
induced	O
proteinuria	O
in	O
spontaneously	O
hypertensive	O
rats	O
.	O

Proteinuria	O
is	O
a	O
side	O
effect	O
of	O
captopril	B-CHED
treatment	O
in	O
hypertensive	O
patients	O
.	O

The	O
possibility	O
of	O
reproducing	O
the	O
same	O
renal	O
abnormality	O
with	O
captopril	B-CHED
was	O
examined	O
in	O
SHR	O
.	O

Oral	O
administration	O
of	O
captopril	B-CHED
at	O
100	O
mg	O
/	O
kg	O
for	O
14	O
days	O
failed	O
to	O
aggravate	O
proteinuria	O
pre	O
-	O
existing	O
in	O
SHR	O
.	O

Also	O
,	O
captopril	B-CHED
treatment	O
failed	O
to	O
potentiate	O
or	O
facilitate	O
development	O
of	O
massive	O
proteinuria	O
invoked	O
by	O
puromycin	B-CHED
aminonucleoside	I-CHED
in	O
SHR	O
.	O

Captopril	B-CHED
had	O
little	O
or	O
no	O
demonstrable	O
effects	O
on	O
serum	O
electrolyte	O
concentrations	O
,	O
excretion	O
of	O
urine	O
,	O
sodium	B-CHED
and	O
potassium	B-CHED
,	O
endogenous	O
creatinine	B-CHED
clearance	O
,	O
body	O
weight	O
,	O
and	O
food	O
and	O
water	O
consumption	O
.	O

However	O
,	O
ketone	B-CHED
bodies	O
were	O
consistently	O
present	O
in	O
urine	O
and	O
several	O
lethalities	O
occurred	O
during	O
multiple	O
dosing	O
of	O
captopril	B-CHED
in	O
SHR	O
.	O

Complete	O
heart	O
block	O
following	O
a	O
single	O
dose	O
of	O
trazodone	B-CHED
.	O

Forty	O
minutes	O
after	O
receiving	O
a	O
single	O
starting	O
dose	O
of	O
trazodone	B-CHED
,	O
a	O
patient	O
developed	O
complete	O
heart	O
block	O
.	O

The	O
case	O
illustrates	O
that	O
,	O
despite	O
the	O
results	O
of	O
earlier	O
studies	O
,	O
trazodone	B-CHED
'	O
s	O
effect	O
on	O
cardiac	O
conduction	O
may	O
be	O
severe	O
in	O
individuals	O
at	O
risk	O
for	O
conduction	O
delay	O
.	O

Phenobarbital	B-CHED
-	O
induced	O
dyskinesia	O
in	O
a	O
neurologically	O
-	O
impaired	O
child	O
.	O

A	O
2	O
-	O
year	O
-	O
old	O
child	O
with	O
known	O
neurologic	O
impairment	O
developed	O
a	O
dyskinesia	O
soon	O
after	O
starting	O
phenobarbital	B-CHED
therapy	O
for	O
seizures	O
.	O

Known	O
causes	O
of	O
movement	O
disorders	O
were	O
eliminated	O
after	O
evaluation	O
.	O

On	O
repeat	O
challenge	O
with	O
phenobarbital	B-CHED
,	O
the	O
dyskinesia	O
recurred	O
.	O

Phenobarbital	B-CHED
should	O
be	O
added	O
to	O
the	O
list	O
of	O
anticonvulsant	O
drugs	O
that	O
can	O
cause	O
movement	O
disorders	O
.	O

Effects	O
of	O
amine	B-CHED
pretreatment	O
on	O
ketamine	B-CHED
catatonia	O
in	O
pinealectomized	O
or	O
hypophysectomized	O
animals	O
.	O

The	O
present	O
studies	O
were	O
designed	O
to	O
clarify	O
the	O
role	O
of	O
catecholamines	B-CHED
and	O
pineal	O
idolamines	O
on	O
ketamine	B-CHED
-	O
induced	O
catatonia	O
in	O
the	O
intact	O
,	O
pinealectomized	O
or	O
hypophysectomized	O
chick	O
and	O
rat	O
.	O

In	O
the	O
pinealectomized	O
chick	O
,	O
pretreatment	O
with	O
dopamine	B-CHED
increased	O
the	O
duration	O
of	O
catatonia	O
(	O
DOC	O
)	O
after	O
ketamine	B-CHED
,	O
but	O
pretreatment	O
with	O
norepinephrine	B-CHED
did	O
not	O
.	O

The	O
pineal	O
indolamines	O
exhibited	O
mixed	O
actions	O
.	O

Serotonin	B-CHED
and	O
N	B-CHED
-	I-CHED
acetyl	I-CHED
serotonin	I-CHED
which	O
augmented	O
ketamine	B-CHED
DOC	O
,	O
did	O
not	O
do	O
so	O
in	O
the	O
absence	O
of	O
the	O
pineal	O
gland	O
,	O
whereas	O
melatonin	B-CHED
potentiated	O
the	O
ketamine	B-CHED
DOC	O
in	O
both	O
the	O
intact	O
and	O
pinealectomized	O
chick	O
.	O

Ketamine	B-CHED
was	O
more	O
potent	O
in	O
the	O
hypophysectomized	O
chick	O
and	O
the	O
circadian	O
rhythm	O
noted	O
in	O
the	O
intact	O
chick	O
was	O
absent	O
;	O
furthermore	O
,	O
melatonin	B-CHED
did	O
not	O
augment	O
the	O
ketamine	B-CHED
DOC	O
whereas	O
dopamine	B-CHED
continued	O
to	O
do	O
so	O
.	O

This	O
study	O
did	O
not	O
demonstrate	O
a	O
species	O
difference	O
regarding	O
the	O
role	O
of	O
the	O
amines	B-CHED
on	O
the	O
pineal	O
in	O
spite	O
of	O
the	O
immature	O
blood	O
-	O
brain	O
barrier	O
in	O
the	O
young	O
chick	O
and	O
the	O
intact	O
barrier	O
in	O
the	O
rat	O
.	O

In	O
addition	O
,	O
these	O
data	O
indicate	O
a	O
direct	O
role	O
of	O
the	O
pituitary	O
in	O
the	O
augmentation	O
of	O
ketamine	B-CHED
DOC	O
induced	O
by	O
melatonin	B-CHED
.	O

Furthermore	O
,	O
dopamine	B-CHED
appeared	O
to	O
act	O
on	O
systems	O
more	O
closely	O
involved	O
with	O
the	O
induction	O
of	O
ketamine	B-CHED
catatonia	O
rather	O
than	O
directly	O
on	O
the	O
pituitary	O
.	O

Heparin	B-CHED
-	O
induced	O
thrombocytopenia	O
,	O
thrombosis	O
,	O
and	O
hemorrhage	O
.	O

Sixty	O
-	O
two	O
patients	O
with	O
a	O
heparin	B-CHED
-	O
induced	O
thrombocytopenia	O
are	O
reported	O
.	O

Clinical	O
manifestations	O
of	O
this	O
disorder	O
include	O
hemorrhage	O
or	O
,	O
more	O
frequently	O
,	O
thromboembolic	O
events	O
in	O
patients	O
receiving	O
heparin	B-CHED
.	O

Laboratory	O
testing	O
has	O
revealed	O
a	O
falling	O
platelet	O
count	O
,	O
increased	O
resistance	O
to	O
heparin	B-CHED
,	O
and	O
aggregation	O
of	O
platelets	O
by	O
the	O
patient	O
'	O
s	O
plasma	O
when	O
heparin	B-CHED
is	O
added	O
.	O

Immunologic	O
testing	O
has	O
demonstrated	O
the	O
presence	O
of	O
a	O
heparin	B-CHED
-	O
dependent	O
platelet	O
membrane	O
antibody	O
.	O

The	O
20	O
deaths	O
,	O
52	O
hemorrhagic	O
and	O
thromboembolic	O
complications	O
,	O
and	O
21	O
surgical	O
procedures	O
to	O
manage	O
the	O
complications	O
confirm	O
the	O
seriousness	O
of	O
the	O
disorder	O
.	O

Specific	O
risk	O
factors	O
have	O
not	O
been	O
identified	O
;	O
therefore	O
,	O
all	O
patients	O
receiving	O
heparin	B-CHED
should	O
be	O
monitored	O
.	O

If	O
the	O
platelet	O
count	O
falls	O
to	O
less	O
than	O
100	O
,	O
000	O
/	O
mm3	O
,	O
while	O
the	O
patient	O
is	O
receiving	O
heparin	B-CHED
,	O
platelet	O
aggregation	O
testing	O
,	O
using	O
the	O
patient	O
'	O
s	O
plasma	O
,	O
is	O
indicated	O
.	O

Management	O
consists	O
of	O
cessation	O
of	O
heparin	B-CHED
,	O
platelet	O
anti	O
-	O
aggregating	O
agents	O
,	O
and	O
alternate	O
forms	O
of	O
anticoagulation	O
when	O
indicated	O
.	O

Ventricular	O
fibrillation	O
from	O
diatrizoate	B-CHED
with	O
and	O
without	O
chelating	O
agents	O
.	O

The	O
toxicity	O
of	O
Renografin	B-CHED
76	I-CHED
%	I-CHED
was	O
compared	O
with	O
that	O
of	O
Hypaque	B-CHED
76	I-CHED
%	I-CHED
by	O
selective	O
injection	O
of	O
each	O
into	O
the	O
right	O
coronary	O
artery	O
of	O
dogs	O
.	O

Renografin	B-CHED
contains	O
the	O
chelating	O
agents	O
sodium	B-CHED
citrate	I-CHED
and	O
disodium	B-CHED
edetate	I-CHED
,	O
while	O
Hypaque	B-CHED
contains	O
calcium	B-CHED
disodium	I-CHED
edetate	I-CHED
and	O
no	O
sodium	B-CHED
citrate	I-CHED
.	O

Ventricular	O
fibrillation	O
occurred	O
significantly	O
more	O
often	O
with	O
Renografin	B-CHED
,	O
suggesting	O
that	O
chelating	O
agents	O
contribute	O
to	O
toxicity	O
in	O
coronary	O
angiography	O
.	O

Long	O
-	O
term	O
efficacy	O
and	O
toxicity	O
of	O
high	O
-	O
dose	O
amiodarone	B-CHED
therapy	O
for	O
ventricular	O
tachycardia	O
or	O
ventricular	O
fibrillation	O
.	O

Amiodarone	B-CHED
was	O
administered	O
to	O
154	O
patients	O
who	O
had	O
sustained	O
,	O
symptomatic	O
ventricular	O
tachycardia	O
(	O
VT	O
)	O
(	O
n	O
=	O
118	O
)	O
or	O
a	O
cardiac	O
arrest	O
(	O
n	O
=	O
36	O
)	O
and	O
who	O
were	O
refractory	O
to	O
conventional	O
antiarrhythmic	O
drugs	O
.	O

The	O
loading	O
dose	O
was	O
800	O
mg	O
/	O
day	O
for	O
6	O
weeks	O
and	O
the	O
maintenance	O
dose	O
was	O
600	O
mg	O
/	O
day	O
.	O

Sixty	O
-	O
nine	O
percent	O
of	O
patients	O
continued	O
treatment	O
with	O
amiodarone	B-CHED
and	O
had	O
no	O
recurrence	O
of	O
symptomatic	O
VT	O
or	O
ventricular	O
fibrillation	O
(	O
VF	O
)	O
over	O
a	O
follow	O
-	O
up	O
of	O
6	O
to	O
52	O
months	O
(	O
mean	O
+	O
/	O
-	O
standard	O
deviation	O
14	O
.	O
2	O
+	O
/	O
-	O
8	O
.	O
2	O
)	O
.	O

Six	O
percent	O
of	O
the	O
patients	O
had	O
a	O
nonfatal	O
recurrence	O
of	O
VT	O
and	O
were	O
successfully	O
managed	O
by	O
continuing	O
amiodarone	B-CHED
at	O
a	O
higher	O
dose	O
or	O
by	O
the	O
addition	O
of	O
a	O
conventional	O
antiarrhythmic	O
drug	O
.	O

One	O
or	O
more	O
adverse	O
drug	O
reactions	O
occurred	O
in	O
51	O
%	O
of	O
patients	O
.	O

Adverse	O
effects	O
forced	O
a	O
reduction	O
in	O
the	O
dose	O
of	O
amiodarone	B-CHED
in	O
41	O
%	O
and	O
discontinuation	O
of	O
amiodarone	B-CHED
in	O
10	O
%	O
of	O
patients	O
.	O

The	O
most	O
common	O
symptomatic	O
adverse	O
reactions	O
were	O
tremor	O
or	O
ataxia	O
(	O
35	O
%	O
)	O
,	O
nausea	O
and	O
anorexia	O
(	O
8	O
%	O
)	O
,	O
visual	O
halos	O
or	O
blurring	O
(	O
6	O
%	O
)	O
,	O
thyroid	O
function	O
abnormalities	O
(	O
6	O
%	O
)	O
and	O
pulmonary	O
interstitial	O
infiltrates	O
(	O
5	O
%	O
)	O
.	O

Although	O
large	O
-	O
dose	O
amiodarone	B-CHED
is	O
highly	O
effective	O
in	O
the	O
long	O
-	O
term	O
treatment	O
of	O
VT	O
or	O
VF	O
refractory	O
to	O
conventional	O
antiarrhythmic	O
drugs	O
,	O
it	O
causes	O
significant	O
toxicity	O
in	O
approximately	O
50	O
%	O
of	O
patients	O
.	O

However	O
,	O
when	O
the	O
dose	O
is	O
adjusted	O
based	O
on	O
clinical	O
response	O
or	O
the	O
development	O
of	O
adverse	O
effects	O
,	O
75	O
%	O
of	O
patients	O
with	O
VT	O
or	O
VF	O
can	O
be	O
successfully	O
managed	O
with	O
amiodarone	B-CHED
.	O

Why	O
may	O
epsilon	B-CHED
-	I-CHED
aminocaproic	I-CHED
acid	I-CHED
(	O
EACA	B-CHED
)	O
induce	O
myopathy	O
in	O
man	O
?	O

Report	O
of	O
a	O
case	O
and	O
literature	O
review	O
.	O

A	O
case	O
of	O
necrotizing	O
myopathy	O
due	O
to	O
a	O
short	O
epsilon	B-CHED
-	I-CHED
aminocaproic	I-CHED
acid	I-CHED
(	O
EACA	B-CHED
)	O
treatment	O
in	O
a	O
72	O
year	O
-	O
old	O
patient	O
with	O
subarachnoid	O
haemorrhage	O
(	O
SAH	O
)	O
is	O
described	O
.	O

Pathogenetic	O
hypotheses	O
are	O
discussed	O
.	O

Cerebral	O
hemorrhage	O
associated	O
with	O
phenylpropanolamine	B-CHED
in	O
combination	O
with	O
caffeine	B-CHED
.	O

Phenylpropanolamine	B-CHED
(	O
PPA	B-CHED
)	O
is	O
a	O
drug	O
that	O
has	O
been	O
associated	O
with	O
serious	O
side	O
effects	O
including	O
stroke	O
.	O

It	O
is	O
often	O
combined	O
with	O
caffeine	B-CHED
in	O
diet	O
preparations	O
and	O
"	O
look	O
-	O
alike	O
"	O
pills	O
.	O

In	O
order	O
to	O
determine	O
if	O
PPA	B-CHED
/	O
caffeine	B-CHED
can	O
lead	O
to	O
stroke	O
in	O
normotensive	O
and	O
/	O
or	O
hypertensive	O
rats	O
,	O
we	O
administered	O
the	O
combination	O
in	O
six	O
times	O
the	O
allowed	O
human	O
dose	O
calculated	O
on	O
a	O
per	O
weight	O
basis	O
for	O
the	O
rats	O
two	O
times	O
per	O
day	O
for	O
five	O
days	O
.	O

Subarachnoid	O
and	O
cerebral	O
hemorrhage	O
was	O
noted	O
in	O
18	O
%	O
of	O
the	O
hypertensive	O
rats	O
.	O

A	O
single	O
PPA	B-CHED
/	O
caffeine	B-CHED
administration	O
(	O
same	O
dose	O
)	O
lead	O
to	O
acute	O
hypertension	O
in	O
both	O
the	O
normotensive	O
and	O
hypertensive	O
animals	O
.	O

These	O
results	O
suggest	O
that	O
PPA	B-CHED
/	O
caffeine	B-CHED
can	O
lead	O
to	O
cerebral	O
hemorrhage	O
in	O
previously	O
hypertensive	O
animals	O
when	O
administered	O
in	O
greater	O
than	O
the	O
allowed	O
dosage	O
.	O

An	O
acute	O
elevation	O
in	O
blood	O
pressure	O
may	O
be	O
a	O
contributing	O
factor	O
.	O

Renal	O
papillary	O
necrosis	O
due	O
to	O
naproxen	B-CHED
.	O

A	O
31	O
-	O
year	O
-	O
old	O
man	O
with	O
rheumatoid	O
arthritis	O
,	O
who	O
had	O
previously	O
been	O
treated	O
with	O
sulindac	B-CHED
,	O
fenoprofen	B-CHED
calcium	I-CHED
,	O
high	O
dose	O
salicylates	B-CHED
and	O
gold	B-CHED
salts	O
,	O
developed	O
renal	O
papillary	O
necrosis	O
(	O
RPN	O
)	O
4	O
months	O
after	O
institution	O
of	O
naproxen	B-CHED
therapy	O
.	O

No	O
other	O
factor	O
predisposing	O
to	O
RPN	O
could	O
be	O
discovered	O
.	O

Sulindac	B-CHED
was	O
substituted	O
for	O
naproxen	B-CHED
and	O
no	O
further	O
adverse	O
renal	O
effects	O
occurred	O
over	O
the	O
next	O
12	O
months	O
.	O

We	O
review	O
previous	O
reports	O
linking	O
RPN	O
to	O
antiinflammatory	O
drug	O
use	O
and	O
discuss	O
possible	O
advantages	O
of	O
sulindac	B-CHED
in	O
patients	O
who	O
have	O
experienced	O
renal	O
toxicity	O
from	O
other	O
antiinflammatory	O
agents	O
.	O

Nephrotoxic	O
effects	O
of	O
aminoglycoside	B-CHED
treatment	O
on	O
renal	O
protein	O
reabsorption	O
and	O
accumulation	O
.	O

To	O
quantify	O
the	O
effects	O
of	O
gentamicin	B-CHED
,	O
kanamycin	B-CHED
and	O
netilmicin	B-CHED
on	O
renal	O
protein	O
reabsorption	O
and	O
accumulation	O
,	O
these	O
drugs	O
were	O
administered	O
to	O
rats	O
intraperitoneally	O
(	O
30	O
mg	O
/	O
kg	O
/	O
day	O
)	O
for	O
7	O
,	O
14	O
or	O
21	O
days	O
.	O

Scanning	O
electron	O
microscopy	O
of	O
the	O
glomerular	O
endothelia	O
,	O
urinary	O
measurements	O
of	O
sodium	B-CHED
,	O
potassium	B-CHED
,	O
endogenous	O
lysozyme	O
,	O
N	O
-	O
acetyl	O
-	O
beta	O
-	O
D	O
-	O
glucosaminidase	O
(	O
NAG	O
)	O
as	O
well	O
as	O
clearance	O
and	O
accumulation	O
experiments	O
after	O
i	O
.	O
v	O
.	O
administration	O
of	O
egg	O
-	O
white	O
lysozyme	O
and	O
measurements	O
of	O
inulin	O
clearance	O
(	O
GFR	O
)	O
were	O
done	O
in	O
each	O
treatment	O
group	O
.	O

Gentamicin	B-CHED
administration	O
decreased	O
diameter	O
,	O
density	O
and	O
shape	O
of	O
endothelial	O
fenestrae	O
.	O

Kanamycin	B-CHED
and	O
netilmicin	B-CHED
appeared	O
to	O
have	O
no	O
effect	O
at	O
the	O
dose	O
used	O
.	O

All	O
three	O
aminoglycosides	B-CHED
decreased	O
GFR	O
and	O
increased	O
urinary	O
excretion	O
of	O
sodium	B-CHED
and	O
potassium	B-CHED
.	O

While	O
gentamicin	B-CHED
and	O
kanamycin	B-CHED
decreased	O
the	O
percentage	O
reabsorption	O
and	O
accumulation	O
of	O
lysozyme	O
after	O
i	O
.	O
v	O
.	O
administration	O
of	O
egg	O
-	O
white	O
lysozyme	O
netilmicin	B-CHED
had	O
no	O
effect	O
.	O

Daily	O
excretion	O
of	O
total	O
protein	O
,	O
endogenous	O
lysozyme	O
and	O
NAG	O
increased	O
only	O
after	O
treatment	O
with	O
kanamycin	B-CHED
and	O
gentamicin	B-CHED
.	O

Thus	O
,	O
aminoglycosides	B-CHED
may	O
act	O
as	O
nephrotoxicants	O
at	O
glomerular	O
and	O
/	O
or	O
tubular	O
level	O
inducing	O
impairment	O
of	O
renal	O
reabsorption	O
and	O
accumulation	O
of	O
proteins	O
.	O

Induction	O
of	O
the	O
obstructive	O
sleep	O
apnea	O
syndrome	O
in	O
a	O
woman	O
by	O
exogenous	O
androgen	B-CHED
administration	O
.	O

We	O
documented	O
airway	O
occlusion	O
during	O
sleep	O
and	O
an	O
abnormally	O
high	O
supraglottic	O
resistance	O
while	O
awake	O
in	O
a	O
54	O
-	O
yr	O
-	O
old	O
woman	O
who	O
had	O
developed	O
physical	O
changes	O
and	O
the	O
syndrome	O
of	O
obstructive	O
sleep	O
apnea	O
while	O
being	O
administered	O
exogenous	O
androgens	B-CHED
.	O

When	O
the	O
androgens	B-CHED
were	O
withdrawn	O
,	O
the	O
patient	O
'	O
s	O
physical	O
changes	O
,	O
symptoms	O
,	O
sleep	O
study	O
,	O
and	O
supraglottic	O
resistance	O
all	O
returned	O
to	O
normal	O
.	O

A	O
rechallenge	O
with	O
androgen	B-CHED
produced	O
symptoms	O
of	O
obstructive	O
sleep	O
apnea	O
that	O
abated	O
upon	O
withdrawal	O
of	O
the	O
hormone	O
.	O

Previous	O
reports	O
have	O
favored	O
a	O
role	O
of	O
androgens	B-CHED
in	O
the	O
pathogenesis	O
of	O
sleep	O
apnea	O
.	O

Our	O
report	O
provides	O
direct	O
evidence	O
for	O
this	O
role	O
.	O

Structural	O
and	O
functional	O
measurements	O
indicate	O
that	O
androgens	B-CHED
exert	O
a	O
permissive	O
or	O
necessary	O
action	O
on	O
the	O
structural	O
configuration	O
of	O
the	O
oropharynx	O
that	O
predisposes	O
to	O
obstruction	O
during	O
sleep	O
.	O

Development	O
of	O
the	O
obstructive	O
sleep	O
apnea	O
syndrome	O
must	O
be	O
considered	O
a	O
possible	O
side	O
effect	O
of	O
androgen	B-CHED
therapy	O
.	O

Cardiotoxic	O
and	O
possible	O
leukemogenic	O
effects	O
of	O
adriamycin	B-CHED
in	O
nonhuman	O
primates	O
.	O

10	O
monkeys	O
(	O
macaques	O
)	O
received	O
adriamycin	B-CHED
by	O
monthly	O
intravenous	O
injections	O
at	O
12	O
mg	O
/	O
m2	O
(	O
1	O
mg	O
/	O
kg	O
)	O
.	O

8	O
of	O
the	O
10	O
monkeys	O
developed	O
congestive	O
heart	O
failure	O
at	O
an	O
average	O
cumulative	O
adriamycin	B-CHED
dose	O
(	O
310	O
mg	O
/	O
m2	O
)	O
well	O
below	O
that	O
considered	O
the	O
safe	O
upper	O
limit	O
(	O
550	O
mg	O
/	O
m2	O
)	O
in	O
man	O
.	O

Histologically	O
,	O
the	O
myocardial	O
lesions	O
resembled	O
those	O
found	O
in	O
human	O
anthracycline	B-CHED
-	O
induced	O
cardiomyopathy	O
.	O

1	O
of	O
the	O
10	O
monkeys	O
developed	O
acute	O
myeloblastic	O
leukemia	O
after	O
receiving	O
324	O
mg	O
/	O
m2	O
of	O
adriamycin	B-CHED
;	O
the	O
10th	O
monkey	O
is	O
alive	O
and	O
well	O
26	O
months	O
after	O
the	O
last	O
dose	O
of	O
drug	O
.	O

Our	O
results	O
suggest	O
that	O
adriamycin	B-CHED
is	O
a	O
more	O
potent	O
cardiotoxin	O
in	O
monkeys	O
than	O
in	O
man	O
,	O
and	O
that	O
leukemia	O
may	O
be	O
a	O
consequence	O
of	O
prolonged	O
treatment	O
with	O
this	O
drug	O
.	O

Tricuspid	O
valve	O
regurgitation	O
and	O
lithium	B-CHED
carbonate	I-CHED
toxicity	O
in	O
a	O
newborn	O
infant	O
.	O

A	O
newborn	O
with	O
massive	O
tricuspid	O
regurgitation	O
,	O
atrial	O
flutter	O
,	O
congestive	O
heart	O
failure	O
,	O
and	O
a	O
high	O
serum	O
lithium	B-CHED
level	O
is	O
described	O
.	O

This	O
is	O
the	O
first	O
patient	O
to	O
initially	O
manifest	O
tricuspid	O
regurgitation	O
and	O
atrial	O
flutter	O
,	O
and	O
the	O
11th	O
described	O
patient	O
with	O
cardiac	O
disease	O
among	O
infants	O
exposed	O
to	O
lithium	B-CHED
compounds	O
in	O
the	O
first	O
trimester	O
of	O
pregnancy	O
.	O

Sixty	O
-	O
three	O
percent	O
of	O
these	O
infants	O
had	O
tricuspid	O
valve	O
involvement	O
.	O

Lithium	B-CHED
carbonate	I-CHED
may	O
be	O
a	O
factor	O
in	O
the	O
increasing	O
incidence	O
of	O
congenital	O
heart	O
disease	O
when	O
taken	O
during	O
early	O
pregnancy	O
.	O

It	O
also	O
causes	O
neurologic	O
depression	O
,	O
cyanosis	O
,	O
and	O
cardiac	O
arrhythmia	O
when	O
consumed	O
prior	O
to	O
delivery	O
.	O

Effects	O
of	O
the	O
novel	O
compound	O
aniracetam	B-CHED
(	O
Ro	B-CHED
13	I-CHED
-	I-CHED
5057	I-CHED
)	O
upon	O
impaired	O
learning	O
and	O
memory	O
in	O
rodents	O
.	O

The	O
effect	O
of	O
aniracetam	B-CHED
(	O
Ro	B-CHED
13	I-CHED
-	I-CHED
5057	I-CHED
,	O
1	B-CHED
-	I-CHED
anisoyl	I-CHED
-	I-CHED
2	I-CHED
-	I-CHED
pyrrolidinone	I-CHED
)	O
was	O
studied	O
on	O
various	O
forms	O
of	O
experimentally	O
impaired	O
cognitive	O
functions	O
(	O
learning	O
and	O
memory	O
)	O
in	O
rodents	O
and	O
produced	O
the	O
following	O
effects	O
:	O
(	O
1	O
)	O
almost	O
complete	O
prevention	O
of	O
the	O
incapacity	O
to	O
learn	O
a	O
discrete	O
escape	O
response	O
in	O
rats	O
exposed	O
to	O
sublethal	O
hypercapnia	O
immediately	O
before	O
the	O
acquisition	O
session	O
;	O
(	O
2	O
)	O
partial	O
(	O
rats	O
)	O
or	O
complete	O
(	O
mice	O
)	O
prevention	O
of	O
the	O
scopolamine	B-CHED
-	O
induced	O
short	O
-	O
term	O
amnesia	O
for	O
a	O
passive	O
avoidance	O
task	O
;	O
(	O
3	O
)	O
complete	O
protection	O
against	O
amnesia	O
for	O
a	O
passive	O
avoidance	O
task	O
in	O
rats	O
submitted	O
to	O
electroconvulsive	O
shock	O
immediately	O
after	O
avoidance	O
acquisition	O
;	O
(	O
4	O
)	O
prevention	O
of	O
the	O
long	O
-	O
term	O
retention	O
-	O
or	O
retrieval	O
-	O
deficit	O
for	O
a	O
passive	O
avoidance	O
task	O
induced	O
in	O
rats	O
and	O
mice	O
by	O
chloramphenicol	B-CHED
or	O
cycloheximide	B-CHED
administered	O
immediately	O
after	O
acquisition	O
;	O
(	O
5	O
)	O
reversal	O
,	O
when	O
administered	O
as	O
late	O
as	O
1	O
h	O
before	O
the	O
retention	O
test	O
,	O
of	O
the	O
deficit	O
in	O
retention	O
or	O
retrieval	O
of	O
a	O
passive	O
avoidance	O
task	O
induced	O
by	O
cycloheximide	B-CHED
injected	O
2	O
days	O
previously	O
;	O
(	O
6	O
)	O
prevention	O
of	O
the	O
deficit	O
in	O
the	O
retrieval	O
of	O
an	O
active	O
avoidance	O
task	O
induced	O
in	O
mice	O
by	O
subconvulsant	O
electroshock	O
or	O
hypercapnia	O
applied	O
immediately	O
before	O
retrieval	O
testing	O
(	O
24	O
h	O
after	O
acquisition	O
)	O
.	O

These	O
improvements	O
or	O
normalizations	O
of	O
impaired	O
cognitive	O
functions	O
were	O
seen	O
at	O
oral	O
aniracetam	B-CHED
doses	O
of	O
10	O
-	O
100	O
mg	O
/	O
kg	O
.	O

Generally	O
,	O
the	O
dose	O
-	O
response	O
curves	O
were	O
bell	O
-	O
shaped	O
.	O

The	O
mechanisms	O
underlying	O
the	O
activity	O
of	O
aniracetam	B-CHED
and	O
its	O
'	O
therapeutic	O
window	O
'	O
are	O
unknown	O
.	O

Piracetam	B-CHED
,	O
another	O
pyrrolidinone	B-CHED
derivative	O
was	O
used	O
for	O
comparison	O
.	O

It	O
was	O
active	O
only	O
in	O
six	O
of	O
nine	O
tests	O
and	O
had	O
about	O
one	O
-	O
tenth	O
the	O
potency	O
of	O
aniracetam	B-CHED
.	O

The	O
results	O
indicate	O
that	O
aniracetam	B-CHED
improves	O
cognitive	O
functions	O
which	O
are	O
impaired	O
by	O
different	O
procedure	O
and	O
in	O
different	O
phases	O
of	O
the	O
learning	O
and	O
memory	O
process	O
.	O

Effect	O
of	O
calcium	B-CHED
chloride	I-CHED
on	O
gross	O
behavioural	O
changes	O
produced	O
by	O
carbachol	B-CHED
and	O
eserine	B-CHED
in	O
cats	O
.	O

The	O
effect	O
of	O
calcium	B-CHED
chloride	I-CHED
injected	O
into	O
the	O
cerebral	O
ventricles	O
of	O
group	O
-	O
housed	O
unanaesthetized	O
cats	O
upon	O
vocalization	O
(	O
rage	O
,	O
hissing	O
and	O
snarling	O
)	O
,	O
fighting	O
(	O
attack	O
with	O
paws	O
and	O
claws	O
,	O
defense	O
with	O
paws	O
and	O
claws	O
and	O
biting	O
)	O
,	O
mydriasis	O
,	O
tremor	O
and	O
clonic	O
-	O
tonic	O
convulsions	O
produced	O
by	O
carbachol	B-CHED
and	O
eserine	B-CHED
injected	O
similarly	O
was	O
investigated	O
.	O

Calcium	B-CHED
chloride	I-CHED
depressed	O
or	O
almost	O
completely	O
abolished	O
the	O
vocalization	O
and	O
fighting	O
due	O
to	O
carbachol	B-CHED
and	O
eserine	B-CHED
.	O

On	O
the	O
other	O
hand	O
,	O
mydriasis	O
,	O
tremor	O
and	O
clonic	O
-	O
tonic	O
convulsions	O
evoked	O
by	O
carbachol	B-CHED
and	O
eserine	B-CHED
were	O
not	O
significantly	O
changed	O
by	O
calcium	B-CHED
chloride	I-CHED
.	O

It	O
is	O
apparent	O
that	O
calcium	B-CHED
chloride	I-CHED
can	O
"	O
dissociate	O
"	O
vocalization	O
and	O
fighting	O
from	O
autonomic	O
and	O
motor	O
phenomena	O
such	O
as	O
mydriasis	O
,	O
tremor	O
and	O
clonic	O
-	O
tonic	O
convulsions	O
caused	O
by	O
carbachol	B-CHED
and	O
eserine	B-CHED
.	O

Calcium	B-CHED
chloride	I-CHED
inhibited	O
the	O
vocalization	O
and	O
fighting	O
produced	O
by	O
carbachol	B-CHED
and	O
eserine	B-CHED
most	O
probably	O
by	O
a	O
nonspecific	O
stabilizing	O
action	O
on	O
central	O
muscarinic	O
cholinoceptive	O
sites	O
.	O

These	O
results	O
further	O
support	O
the	O
view	O
that	O
calcium	B-CHED
ions	O
in	O
excess	O
have	O
an	O
atropine	B-CHED
-	O
like	O
action	O
also	O
in	O
the	O
central	O
nervous	O
system	O
.	O

Thiazide	B-CHED
diuretics	O
,	O
hypokalemia	O
and	O
cardiac	O
arrhythmias	O
.	O

Thiazide	B-CHED
diuretics	O
are	O
widely	O
accepted	O
as	O
the	O
cornerstone	O
of	O
antihypertensive	O
treatment	O
programs	O
.	O

Hypokalemia	O
is	O
a	O
commonly	O
encountered	O
metabolic	O
consequence	O
of	O
chronic	O
thiazide	B-CHED
therapy	O
.	O

We	O
treated	O
38	O
patients	O
(	O
22	O
low	O
renin	O
,	O
16	O
normal	O
renin	O
)	O
with	O
moderate	O
diastolic	O
hypertension	O
with	O
hydrochlorothiazide	B-CHED
(	O
HCTC	B-CHED
)	O
administered	O
on	O
a	O
twice	O
daily	O
schedule	O
.	O

Initial	O
dose	O
was	O
50	O
mg	O
and	O
the	O
dose	O
was	O
increased	O
at	O
monthly	O
intervals	O
to	O
100	O
mg	O
,	O
150	O
mg	O
and	O
200	O
mg	O
daily	O
until	O
blood	O
pressure	O
normalized	O
.	O

The	O
serum	O
K	B-CHED
during	O
the	O
control	O
period	O
was	O
4	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
2	O
mEq	O
/	O
l	O
an	O
on	O
50	O
,	O
100	O
,	O
150	O
and	O
200	O
mg	O
HCTZ	B-CHED
daily	O
3	O
.	O
9	O
+	O
/	O
-	O
0	O
.	O
3	O
,	O
3	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
2	O
,	O
2	O
.	O
9	O
+	O
/	O
-	O
0	O
.	O
2	O
,	O
and	O
2	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
3	O
mEq	O
/	O
l	O
,	O
respectively	O
.	O

Corresponding	O
figures	O
for	O
whole	O
body	O
K	B-CHED
were	O
4107	O
+	O
/	O
-	O
208	O
,	O
3722	O
+	O
/	O
-	O
319	O
,	O
3628	O
+	O
/	O
-	O
257	O
,	O
3551	O
+	O
/	O
-	O
336	O
,	O
and	O
3269	O
+	O
/	O
-	O
380	O
mEq	O
,	O
respectively	O
.	O

In	O
13	O
patients	O
we	O
observed	O
the	O
effects	O
of	O
HCTZ	B-CHED
therapy	O
(	O
100	O
mg	O
daily	O
)	O
on	O
the	O
occurrence	O
of	O
PVC	O
'	O
s	O
during	O
rest	O
as	O
well	O
as	O
during	O
static	O
and	O
dynamic	O
exercise	O
.	O

During	O
rest	O
we	O
observed	O
0	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
08	O
PVC	O
beats	O
/	O
min	O
+	O
/	O
-	O
SEM	O
and	O
during	O
static	O
and	O
dynamic	O
exercise	O
0	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
06	O
and	O
0	O
.	O
8	O
+	O
/	O
-	O
0	O
.	O
15	O
,	O
respectively	O
.	O

Corresponding	O
figures	O
during	O
HCTZ	B-CHED
therapy	O
100	O
mg	O
daily	O
were	O
1	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
1	O
,	O
3	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
7	O
and	O
5	O
.	O
7	O
4	O
/	O
-	O
0	O
.	O
8	O
,	O
respectively	O
.	O

The	O
occurrence	O
of	O
PVC	O
'	O
s	O
correlated	O
significantly	O
with	O
the	O
fall	O
in	O
serum	O
K	B-CHED
+	O
observed	O
r	O
=	O
0	O
.	O
72	O
,	O
p	O
less	O
than	O
0	O
.	O
001	O
.	O

In	O
conclusion	O
we	O
found	O
that	O
thiazide	B-CHED
diuretics	O
cause	O
hypokalemia	O
and	O
depletion	O
of	O
body	O
potassium	B-CHED
.	O

The	O
more	O
profound	O
hypokalemia	O
,	O
the	O
greater	O
the	O
propensity	O
for	O
the	O
occurrence	O
of	O
PVC	O
'	O
s	O
.	O

Circulating	O
lysosomal	O
enzymes	O
and	O
acute	O
hepatic	O
necrosis	O
.	O

The	O
activities	O
of	O
the	O
lysosomal	O
enzymes	O
acid	O
and	O
neutral	O
protease	O
,	O
N	O
-	O
acetylglucosaminidase	O
,	O
and	O
acid	O
phosphatase	O
were	O
measured	O
in	O
the	O
serum	O
of	O
patients	O
with	O
fulminant	O
hepatic	O
failure	O
.	O

Acid	O
protease	O
(	O
cathepsin	O
D	O
)	O
activity	O
was	O
increased	O
about	O
tenfold	O
in	O
patients	O
who	O
died	O
and	O
nearly	O
fourfold	O
in	O
those	O
who	O
survived	O
fulminant	O
hepatic	O
failure	O
after	O
paracetamol	B-CHED
overdose	O
,	O
whereas	O
activities	O
were	O
increased	O
equally	O
in	O
patients	O
with	O
fulminant	O
hepatic	O
failure	O
due	O
to	O
viral	O
hepatitis	O
whether	O
or	O
not	O
they	O
survived	O
.	O

A	O
correlation	O
was	O
found	O
between	O
serum	O
acid	O
protease	O
activity	O
and	O
prothrombin	O
time	O
,	O
and	O
the	O
increase	O
in	O
cathepsin	O
D	O
activity	O
was	O
sustained	O
over	O
several	O
days	O
compared	O
with	O
aspartate	B-CHED
aminotransferase	O
,	O
which	O
showed	O
a	O
sharp	O
early	O
peak	O
and	O
then	O
a	O
fall	O
.	O

Circulating	O
lysosomal	O
proteases	O
can	O
damage	O
other	O
organs	O
,	O
and	O
measurement	O
of	O
their	O
activity	O
may	O
therefore	O
be	O
of	O
added	O
value	O
in	O
assessing	O
prognosis	O
in	O
this	O
condition	O
.	O

Hepatic	O
veno	O
-	O
occlusive	O
disease	O
caused	O
by	O
6	B-CHED
-	I-CHED
thioguanine	I-CHED
.	O

Clinically	O
reversible	O
veno	O
-	O
occlusive	O
disease	O
of	O
the	O
liver	O
developed	O
in	O
a	O
23	O
-	O
year	O
-	O
old	O
man	O
with	O
acute	O
lymphocytic	O
leukemia	O
after	O
10	O
months	O
of	O
maintenance	O
therapy	O
with	O
6	B-CHED
-	I-CHED
thioguanine	I-CHED
.	O

Serial	O
liver	O
biopsies	O
showed	O
the	O
development	O
and	O
resolution	O
of	O
intense	O
sinusoidal	O
engorgement	O
.	O

Although	O
this	O
disease	O
was	O
clinically	O
reversible	O
,	O
some	O
subintimal	O
fibrosis	O
about	O
the	O
terminal	O
hepatic	O
veins	O
persisted	O
.	O

This	O
case	O
presented	O
a	O
unique	O
opportunity	O
to	O
observe	O
the	O
histologic	O
features	O
of	O
clinically	O
reversible	O
hepatic	O
veno	O
-	O
occlusive	O
disease	O
over	O
time	O
,	O
and	O
may	O
be	O
the	O
first	O
case	O
of	O
veno	O
-	O
occlusive	O
related	O
solely	O
to	O
6	B-CHED
-	I-CHED
thioguanine	I-CHED
.	O

Chlorpropamide	B-CHED
-	O
induced	O
optic	O
neuropathy	O
.	O

A	O
65	O
-	O
year	O
-	O
old	O
woman	O
with	O
adult	O
-	O
onset	O
diabetes	O
treated	O
with	O
chlorpropamide	B-CHED
(	O
Diabenese	B-CHED
)	O
had	O
a	O
toxic	O
optic	O
neuropathy	O
that	O
resolved	O
with	O
discontinuation	O
of	O
chlorpropamide	B-CHED
therapy	O
.	O

Visual	O
loss	O
occurs	O
in	O
diabetics	O
for	O
a	O
variety	O
of	O
reasons	O
,	O
and	O
accurate	O
diagnosis	O
is	O
necessary	O
to	O
institute	O
appropriate	O
therapy	O
.	O

The	O
possibility	O
of	O
a	O
drug	O
-	O
induced	O
optic	O
neuropathy	O
should	O
be	O
considered	O
in	O
the	O
differential	O
diagnosis	O
of	O
visual	O
loss	O
in	O
diabetics	O
.	O

Plasma	O
and	O
urinary	O
lipids	O
and	O
lipoproteins	O
during	O
the	O
development	O
of	O
nephrotic	O
syndrome	O
induced	O
in	O
the	O
rat	O
by	O
puromycin	B-CHED
aminonucleoside	I-CHED
.	O

This	O
study	O
was	O
undertaken	O
to	O
ascertain	O
whether	O
the	O
alterations	O
of	O
plasma	O
lipoproteins	O
found	O
in	O
nephrotic	O
syndrome	O
induced	O
by	O
puromycin	B-CHED
aminonucleoside	I-CHED
were	O
due	O
to	O
nephrotic	O
syndrome	O
per	O
se	O
,	O
or	O
,	O
at	O
least	O
in	O
part	O
,	O
to	O
the	O
aminonucleoside	B-CHED
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
changes	O
in	O
plasma	O
and	O
urinary	O
lipoproteins	O
during	O
the	O
administration	O
of	O
puromycin	B-CHED
aminonucleoside	I-CHED
(	O
20	O
mg	O
/	O
kg	O
for	O
7	O
days	O
)	O
and	O
the	O
subsequent	O
development	O
of	O
nephrotic	O
syndrome	O
.	O

Since	O
massive	O
albuminuria	O
occurred	O
after	O
6	O
days	O
of	O
treatment	O
,	O
the	O
time	O
-	O
course	O
study	O
was	O
divided	O
into	O
two	O
stages	O
:	O
pre	O
-	O
nephrotic	O
stage	O
(	O
day	O
1	O
-	O
5	O
)	O
and	O
nephrotic	O
stage	O
(	O
day	O
6	O
-	O
11	O
)	O
.	O

In	O
pre	O
-	O
nephrotic	O
stage	O
the	O
plasma	O
level	O
of	O
fatty	B-CHED
acids	I-CHED
,	O
triacylglycerol	B-CHED
and	O
VLDL	O
decreased	O
while	O
that	O
of	O
phospholipid	O
,	O
cholesteryl	B-CHED
esters	I-CHED
and	O
HDL	O
remained	O
constant	O
.	O

Plasma	O
apolipoprotein	O
A	O
-	O
I	O
tended	O
to	O
increase	O
(	O
40	O
%	O
increase	O
at	O
day	O
5	O
)	O
.	O

At	O
the	O
beginning	O
of	O
nephrotic	O
stage	O
(	O
day	O
6	O
)	O
the	O
concentration	O
of	O
plasma	O
albumin	O
dropped	O
to	O
a	O
very	O
low	O
level	O
,	O
while	O
that	O
of	O
apolipoprotein	O
A	O
-	O
I	O
increased	O
abruptly	O
(	O
4	O
-	O
fold	O
increase	O
)	O
and	O
continued	O
to	O
rise	O
,	O
although	O
less	O
steeply	O
,	O
in	O
the	O
following	O
days	O
.	O

The	O
plasma	O
concentration	O
of	O
HDL	O
followed	O
the	O
same	O
pattern	O
.	O

Plasma	O
VLDL	O
and	O
LDL	O
increased	O
at	O
a	O
later	O
stage	O
(	O
day	O
9	O
)	O
.	O

Plasma	O
apolipoprotein	O
A	O
-	O
I	O
was	O
found	O
not	O
only	O
in	O
HDL	O
(	O
1	O
.	O
063	O
-	O
1	O
.	O
210	O
g	O
/	O
ml	O
)	O
but	O
also	O
in	O
the	O
LDL	O
density	O
class	O
(	O
1	O
.	O
025	O
-	O
1	O
.	O
050	O
g	O
/	O
ml	O
)	O
.	O

In	O
the	O
pre	O
-	O
nephrotic	O
stage	O
lipoproteinuria	O
was	O
negligible	O
,	O
while	O
in	O
the	O
early	O
nephrotic	O
stage	O
the	O
urinary	O
loss	O
of	O
plasma	O
lipoproteins	O
consisted	O
mainly	O
of	O
HDL	O
.	O

These	O
observations	O
indicate	O
that	O
puromycin	B-CHED
aminonucleoside	I-CHED
alters	O
plasma	O
lipoproteins	O
by	O
lowering	O
VLDL	O
and	O
increasing	O
HDL	O
.	O

It	O
is	O
likely	O
that	O
the	O
early	O
and	O
striking	O
increase	O
of	O
plasma	O
HDL	O
found	O
in	O
nephrotic	O
rats	O
is	O
related	O
to	O
a	O
direct	O
effect	O
of	O
the	O
drug	O
on	O
HDL	O
metabolism	O
.	O

Fatal	O
aplastic	O
anemia	O
following	O
topical	O
administration	O
of	O
ophthalmic	O
chloramphenicol	B-CHED
.	O

A	O
73	O
-	O
year	O
-	O
old	O
woman	O
died	O
of	O
aplastic	O
anemia	O
less	O
than	O
two	O
months	O
after	O
undergoing	O
cataract	O
extraction	O
and	O
beginning	O
topical	O
therapy	O
with	O
chloramphenicol	B-CHED
.	O

The	O
first	O
signs	O
of	O
pancytopenia	O
began	O
within	O
one	O
month	O
of	O
the	O
surgery	O
.	O

The	O
pattern	O
of	O
the	O
aplastic	O
anemia	O
was	O
associated	O
with	O
an	O
idiosyncratic	O
response	O
to	O
chloramphenicol	B-CHED
.	O

This	O
was	O
the	O
second	O
report	O
of	O
fatal	O
aplastic	O
anemia	O
after	O
topical	O
treatment	O
with	O
chloramphenicol	B-CHED
for	O
ocular	O
conditions	O
,	O
although	O
two	O
cases	O
of	O
reversible	O
bone	O
marrow	O
hypoplasia	O
have	O
also	O
been	O
reported	O
.	O

Any	O
other	O
suspected	O
cases	O
of	O
ocular	O
toxicity	O
associated	O
with	O
topically	O
applied	O
chloramphenicol	B-CHED
should	O
be	O
reported	O
to	O
the	O
National	O
Registry	O
of	O
Drug	O
-	O
Induced	O
Ocular	O
Side	O
Effects	O
,	O
Oregon	O
Health	O
Sciences	O
University	O
,	O
Portland	O
,	O
OR	O
97201	O
.	O

Midazolam	B-CHED
compared	O
with	O
thiopentone	B-CHED
as	O
an	O
induction	O
agent	O
.	O

In	O
patients	O
premedicated	O
with	O
scopolamine	B-CHED
+	O
morphine	B-CHED
(	O
+	O
5	O
mg	O
nitrazepam	B-CHED
the	O
evening	O
before	O
surgery	O
)	O
,	O
the	O
sleep	O
-	O
inducing	O
effect	O
of	O
midazolam	B-CHED
0	O
.	O
15	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
was	O
clearly	O
slower	O
in	O
onset	O
than	O
that	O
of	O
thiopentone	B-CHED
4	O
.	O
67	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
Somewhat	O
fewer	O
cardiovascular	O
and	O
local	O
sequelae	O
were	O
found	O
in	O
the	O
midazolam	B-CHED
group	O
,	O
but	O
,	O
although	O
apnoea	O
occurred	O
less	O
often	O
in	O
the	O
midazolam	B-CHED
group	O
it	O
lasted	O
longer	O
.	O

On	O
the	O
whole	O
,	O
the	O
differences	O
between	O
midazolam	B-CHED
and	O
thiopentone	B-CHED
had	O
no	O
apparent	O
clinical	O
consequences	O
.	O

Midazolam	B-CHED
is	O
a	O
new	O
alternative	O
agent	O
for	O
induction	O
in	O
combination	O
anaesthesia	O
.	O

Extrapyramidal	O
side	O
effects	O
and	O
oral	O
haloperidol	B-CHED
:	O
an	O
analysis	O
of	O
explanatory	O
patient	O
and	O
treatment	O
characteristics	O
.	O

The	O
incidence	O
of	O
extrapyramidal	O
side	O
effects	O
(	O
EPS	O
)	O
was	O
evaluated	O
in	O
98	O
patients	O
treated	O
with	O
haloperidol	B-CHED
.	O

The	O
incidence	O
of	O
parkinsonism	O
was	O
higher	O
at	O
higher	O
doses	O
of	O
haloperidol	B-CHED
and	O
in	O
younger	O
patients	O
.	O

Prophylactic	O
antiparkinsonian	O
medication	O
was	O
effective	O
in	O
younger	O
but	O
not	O
in	O
older	O
patients	O
.	O

However	O
,	O
these	O
medications	O
were	O
more	O
effective	O
in	O
both	O
young	O
and	O
old	O
patients	O
when	O
given	O
after	O
parkinsonism	O
developed	O
.	O

Akathisia	O
was	O
controlled	O
by	O
the	O
benzodiazepine	B-CHED
lorazepam	B-CHED
in	O
14	O
out	O
of	O
16	O
patients	O
,	O
while	O
prophylactic	O
antiparkinsonians	O
were	O
ineffective	O
.	O

The	O
present	O
study	O
points	O
to	O
patient	O
characteristics	O
that	O
may	O
be	O
of	O
significance	O
in	O
the	O
development	O
of	O
EPS	O
due	O
to	O
haloperidol	B-CHED
.	O

Deaths	O
from	O
local	O
anesthetic	O
-	O
induced	O
convulsions	O
in	O
mice	O
.	O

Median	O
convulsant	O
(	O
CD50	O
)	O
and	O
median	O
lethal	O
(	O
LD50	O
)	O
doses	O
of	O
three	O
representative	O
local	O
anesthetics	O
were	O
determined	O
in	O
adult	O
mice	O
to	O
evaluate	O
the	O
threat	O
to	O
life	O
of	O
local	O
anesthetic	O
-	O
induced	O
convulsions	O
.	O

The	O
CD50	O
and	O
LD50	O
,	O
respectively	O
,	O
were	O
57	O
.	O
7	O
and	O
58	O
.	O
7	O
mg	O
/	O
kg	O
for	O
bupivacaine	B-CHED
,	O
111	O
.	O
0	O
and	O
133	O
.	O
1	O
mg	O
/	O
kg	O
for	O
lidocaine	B-CHED
,	O
and	O
243	O
.	O
4	O
and	O
266	O
.	O
5	O
mg	O
/	O
kg	O
for	O
chloroprocaine	B-CHED
.	O

When	O
given	O
intraperitoneally	O
,	O
bupivacaine	B-CHED
thus	O
was	O
only	O
about	O
twice	O
as	O
toxic	O
as	O
lidocaine	B-CHED
and	O
four	O
times	O
as	O
toxic	O
as	O
chloroprocaine	B-CHED
.	O

Convulsions	O
always	O
preceded	O
death	O
,	O
except	O
after	O
precipitous	O
cardiopulmonary	O
arrest	O
from	O
extreme	O
doses	O
.	O

A	O
CD50	O
dose	O
of	O
local	O
anesthetic	O
(	O
causing	O
convulsions	O
in	O
50	O
%	O
of	O
mice	O
)	O
was	O
fatal	O
in	O
90	O
%	O
of	O
bupivacaine	B-CHED
-	O
induced	O
seizures	O
,	O
in	O
57	O
%	O
of	O
the	O
chloroprocaine	B-CHED
group	O
,	O
and	O
in	O
6	O
%	O
of	O
the	O
lidocaine	B-CHED
group	O
.	O

The	O
narrow	O
gap	O
between	O
convulsant	O
and	O
lethal	O
doses	O
of	O
local	O
anesthetics	O
indicates	O
that	O
untreated	O
convulsions	O
present	O
much	O
more	O
of	O
a	O
threat	O
to	O
life	O
than	O
heretofore	O
appreciated	O
.	O

REM	O
sleep	O
deprivation	O
changes	O
behavioral	O
response	O
to	O
catecholaminergic	O
and	O
serotonergic	O
receptor	O
activation	O
in	O
rats	O
.	O

The	O
effects	O
of	O
REM	O
sleep	O
deprivation	O
(	O
REMD	O
)	O
on	O
apomorphine	B-CHED
-	O
induced	O
aggressiveness	O
and	O
quipazine	B-CHED
-	O
induced	O
head	O
twitches	O
in	O
rats	O
were	O
determined	O
.	O

Forty	O
-	O
eight	O
hr	O
of	O
REMD	O
increased	O
apomorphine	B-CHED
-	O
induced	O
aggressiveness	O
,	O
and	O
reduced	O
(	O
immediately	O
after	O
completing	O
of	O
REMD	O
)	O
or	O
increased	O
(	O
96	O
hr	O
after	O
completing	O
of	O
REMD	O
)	O
quipazine	B-CHED
-	O
induced	O
head	O
twitches	O
.	O

Results	O
are	O
discussed	O
in	O
terms	O
of	O
similarity	O
to	O
pharmacological	O
effects	O
of	O
other	O
antidepressive	O
treatments	O
.	O

Fatal	O
aplastic	O
anemia	O
due	O
to	O
indomethacin	B-CHED
-	O
-	O
lymphocyte	O
transformation	O
tests	O
in	O
vitro	O
.	O

Although	O
indomethacin	B-CHED
has	O
been	O
implicated	O
as	O
a	O
possible	O
cause	O
of	O
aplastic	O
anemia	O
on	O
the	O
basis	O
of	O
a	O
few	O
clinical	O
observations	O
,	O
its	O
role	O
has	O
not	O
been	O
definitely	O
established	O
.	O

A	O
case	O
of	O
fatal	O
aplastic	O
anemia	O
is	O
described	O
in	O
which	O
no	O
drugs	O
other	O
than	O
allopurinol	B-CHED
and	O
indomethacin	B-CHED
were	O
given	O
.	O

Indomethacin	B-CHED
was	O
first	O
given	O
four	O
weeks	O
prior	O
to	O
the	O
onset	O
of	O
symptoms	O
.	O

A	O
positive	O
lymphocyte	O
transformation	O
test	O
with	O
indomethacin	B-CHED
in	O
vitro	O
further	O
substantiates	O
the	O
potential	O
role	O
of	O
this	O
drug	O
in	O
causing	O
aplastic	O
anemia	O
in	O
a	O
susceptible	O
patient	O
.	O

Fortunately	O
,	O
this	O
seems	O
to	O
be	O
a	O
very	O
rare	O
complication	O
.	O

Dose	O
-	O
effect	O
and	O
structure	O
-	O
function	O
relationships	O
in	O
doxorubicin	B-CHED
cardiomyopathy	O
.	O

The	O
cardiomyopathy	O
(	O
CM	O
)	O
produced	O
by	O
the	O
anticancer	O
drug	O
doxorubicin	B-CHED
(	O
DXR	B-CHED
)	O
(	O
Adriamycin	B-CHED
)	O
provides	O
a	O
unique	O
opportunity	O
to	O
analyze	O
dose	O
-	O
effect	O
and	O
structure	O
-	O
function	O
relationships	O
during	O
development	O
of	O
myocardial	O
disease	O
.	O

We	O
measured	O
the	O
degree	O
of	O
morphologic	O
damage	O
by	O
ultrastructural	O
examination	O
of	O
endomyocardial	O
biopsy	O
and	O
the	O
degree	O
of	O
performance	O
abnormally	O
by	O
right	O
heart	O
catheterization	O
in	O
patients	O
receiving	O
DXR	B-CHED
.	O

Morphologic	O
damage	O
was	O
variable	O
but	O
was	O
proportional	O
to	O
the	O
total	O
cumulative	O
DXR	B-CHED
dose	O
between	O
100	O
and	O
600	O
mg	O
/	O
m2	O
.	O

Performance	O
abnormalities	O
correlated	O
weakly	O
with	O
dose	O
,	O
exhibited	O
a	O
curvilinear	O
relationship	O
,	O
and	O
had	O
a	O
"	O
threshold	O
"	O
for	O
expression	O
.	O

Catheterization	O
abnormalities	O
correlated	O
well	O
with	O
morphologic	O
damage	O
(	O
r	O
=	O
0	O
.	O
57	O
to	O
0	O
.	O
78	O
)	O
in	O
a	O
subgroup	O
of	O
patients	O
in	O
whom	O
exercise	O
hemodynamics	O
were	O
measured	O
,	O
and	O
this	O
relationship	O
also	O
exhibited	O
a	O
curvilinear	O
,	O
threshold	O
configuration	O
.	O

In	O
DXR	B-CHED
-	O
CM	O
myocardial	O
damage	O
is	O
proportional	O
to	O
the	O
degree	O
of	O
cytotoxic	O
insult	O
(	O
DXR	B-CHED
dose	O
)	O
while	O
myocardial	O
function	O
is	O
preserved	O
until	O
a	O
critical	O
dose	O
or	O
degree	O
of	O
damage	O
is	O
reached	O
,	O
after	O
which	O
myocardial	O
performance	O
deteriorates	O
rapidly	O
.	O

Massive	O
cerebral	O
edema	O
associated	O
with	O
fulminant	O
hepatic	O
failure	O
in	O
acetaminophen	B-CHED
overdose	O
:	O
possible	O
role	O
of	O
cranial	O
decompression	O
.	O

Cerebral	O
edema	O
may	O
complicate	O
the	O
course	O
of	O
fulminant	O
hepatic	O
failure	O
.	O

Response	O
to	O
conventional	O
therapy	O
has	O
been	O
disappointing	O
.	O

We	O
present	O
a	O
patient	O
with	O
fatal	O
acetaminophen	B-CHED
-	O
induced	O
fulminant	O
hepatic	O
failure	O
,	O
with	O
signs	O
and	O
symptoms	O
of	O
cerebral	O
edema	O
,	O
unresponsive	O
to	O
conventional	O
medical	O
therapy	O
.	O

Cranial	O
decompression	O
was	O
carried	O
out	O
.	O

A	O
justification	O
of	O
the	O
need	O
for	O
further	O
evaluation	O
of	O
cranial	O
decompression	O
in	O
such	O
patients	O
is	O
presented	O
.	O

Subjective	O
assessment	O
of	O
sexual	O
dysfunction	O
of	O
patients	O
on	O
long	O
-	O
term	O
administration	O
of	O
digoxin	B-CHED
.	O

Various	O
data	O
suggest	O
that	O
male	O
patients	O
who	O
have	O
received	O
digoxin	B-CHED
on	O
a	O
longterm	O
basis	O
have	O
increased	O
levels	O
of	O
serum	O
estrogen	B-CHED
and	O
decreased	O
levels	O
of	O
plasma	O
testosterone	B-CHED
and	O
luteinizing	O
hormone	O
(	O
LH	O
)	O
.	O

This	O
study	O
was	O
undertaken	O
to	O
investigate	O
the	O
links	O
between	O
the	O
long	O
-	O
term	O
administration	O
of	O
digoxin	B-CHED
therapy	O
and	O
sexual	O
behavior	O
,	O
and	O
the	O
effect	O
of	O
digoxin	B-CHED
on	O
plasma	O
levels	O
of	O
estradiol	B-CHED
,	O
testosterone	B-CHED
,	O
and	O
LH	O
.	O

The	O
patients	O
of	O
the	O
study	O
and	O
control	O
group	O
(	O
without	O
digoxin	B-CHED
)	O
were	O
of	O
similar	O
cardiac	O
functional	O
capacity	O
and	O
age	O
(	O
25	O
-	O
40	O
years	O
)	O
and	O
were	O
randomly	O
selected	O
from	O
the	O
rheumatic	O
heart	O
disease	O
patients	O
.	O

A	O
subjective	O
assessment	O
of	O
sexual	O
behavior	O
in	O
the	O
study	O
and	O
control	O
groups	O
was	O
carried	O
out	O
,	O
using	O
parameters	O
such	O
as	O
sexual	O
desire	O
,	O
sexual	O
excitement	O
,	O
and	O
frequency	O
of	O
sexual	O
relations	O
.	O

Personal	O
interviews	O
and	O
a	O
questionnaire	O
were	O
also	O
used	O
for	O
the	O
evaluation	O
of	O
sexual	O
behavior	O
.	O

The	O
findings	O
support	O
the	O
reports	O
concerning	O
digoxin	B-CHED
effect	O
on	O
plasma	O
estradiol	B-CHED
,	O
testosterone	B-CHED
,	O
and	O
LH	O
.	O

The	O
differences	O
in	O
the	O
means	O
were	O
significant	O
.	O

Tests	O
used	O
to	O
evaluate	O
the	O
changes	O
in	O
sexual	O
behavior	O
showed	O
a	O
significant	O
decrease	O
in	O
sexual	O
desire	O
,	O
sexual	O
excitement	O
phase	O
(	O
erection	O
)	O
,	O
and	O
frequency	O
of	O
sexual	O
relations	O
in	O
the	O
study	O
group	O
.	O

Endometrial	O
carcinoma	O
after	O
Hodgkin	O
disease	O
in	O
childhood	O
.	O

A	O
34	O
-	O
year	O
-	O
old	O
patient	O
developed	O
metastic	O
endometrial	O
carcinoma	O
after	O
Hodgkin	O
disease	O
in	O
childhood	O
.	O

She	O
had	O
ovarian	O
failure	O
after	O
abdominal	O
irradiation	O
and	O
chemotherapy	O
for	O
Hodgkin	O
disease	O
,	O
and	O
received	O
exogenous	O
estrogens	B-CHED
,	O
a	O
treatment	O
implicated	O
in	O
the	O
development	O
of	O
endometrial	O
cancer	O
in	O
menopausal	O
women	O
.	O

Young	O
women	O
on	O
replacement	O
estrogens	B-CHED
for	O
ovarian	O
failure	O
after	O
cancer	O
therapy	O
may	O
also	O
have	O
increased	O
risk	O
of	O
endometrial	O
carcinoma	O
and	O
should	O
be	O
examined	O
periodically	O
.	O

Long	O
-	O
term	O
lithium	B-CHED
treatment	O
and	O
the	O
kidney	O
.	O

Interim	O
report	O
on	O
fifty	O
patients	O
.	O

This	O
is	O
a	O
report	O
on	O
the	O
first	O
part	O
of	O
our	O
study	O
of	O
the	O
effects	O
of	O
long	O
-	O
term	O
lithium	B-CHED
treatment	O
on	O
the	O
kidney	O
.	O

Creatinine	B-CHED
clearance	O
,	O
maximum	O
urinary	O
osmolality	O
and	O
24	O
hour	O
urine	O
volume	O
have	O
been	O
tested	O
in	O
50	O
affectively	O
ill	O
patients	O
who	O
have	O
been	O
on	O
long	O
-	O
term	O
lithium	B-CHED
for	O
more	O
than	O
one	O
year	O
.	O

These	O
findings	O
have	O
been	O
compared	O
with	O
norms	O
and	O
with	O
values	O
of	O
the	O
same	O
tests	O
from	O
screening	O
prior	O
to	O
lithium	B-CHED
,	O
available	O
for	O
most	O
of	O
our	O
patients	O
.	O

No	O
evidence	O
was	O
found	O
for	O
any	O
reduction	O
of	O
glomerular	O
filtration	O
during	O
lithium	B-CHED
treatment	O
.	O

Low	O
clearance	O
values	O
found	O
in	O
several	O
patients	O
could	O
be	O
accounted	O
for	O
by	O
their	O
age	O
and	O
their	O
pre	O
-	O
lithium	B-CHED
values	O
.	O

Urinary	O
concentration	O
defect	O
appeared	O
frequent	O
but	O
the	O
extent	O
of	O
the	O
impairment	O
is	O
difficult	O
to	O
assess	O
because	O
of	O
the	O
uncertainty	O
about	O
the	O
norms	O
applicable	O
to	O
this	O
group	O
of	O
patients	O
.	O

The	O
concentration	O
defect	O
appeared	O
reversible	O
,	O
at	O
least	O
in	O
part	O
.	O

Polyuria	O
above	O
3	O
litres	O
/	O
24	O
hours	O
was	O
found	O
in	O
10	O
%	O
of	O
patients	O
.	O

An	O
attempt	O
is	O
made	O
to	O
draw	O
practical	O
conclusions	O
from	O
the	O
preliminary	O
findings	O
.	O

Nephrotoxicity	O
of	O
cyclosporin	B-CHED
A	I-CHED
and	O
FK506	B-CHED
:	O
inhibition	O
of	O
calcineurin	O
phosphatase	O
.	O

Cyclosporin	B-CHED
A	I-CHED
(	O
CsA	B-CHED
;	O
50	O
mg	O
/	O
kg	O
)	O
and	O
Fujimycine	B-CHED
(	O
FK506	B-CHED
;	O
5	O
mg	O
/	O
kg	O
)	O
,	O
but	O
not	O
the	O
related	O
macrolide	B-CHED
immunosuppressant	O
rapamycin	B-CHED
(	O
5	O
mg	O
/	O
kg	O
)	O
,	O
caused	O
a	O
reduction	O
of	O
glomerular	O
filtration	O
rate	O
,	O
degenerative	O
changes	O
of	O
proximal	O
tubular	O
epithelium	O
,	O
and	O
hypertrophy	O
of	O
the	O
juxtaglomerular	O
apparatus	O
in	O
male	O
Wistar	O
rats	O
when	O
given	O
for	O
10	O
days	O
.	O

The	O
molecular	O
mechanisms	O
of	O
CsA	B-CHED
and	O
FK506	B-CHED
toxicity	O
were	O
investigated	O
.	O

Cyclophilin	O
A	O
and	O
FK506	B-CHED
-	O
binding	O
protein	O
,	O
the	O
main	O
intracytoplasmic	O
receptors	O
for	O
CsA	B-CHED
and	O
FK506	B-CHED
,	O
respectively	O
,	O
were	O
each	O
detected	O
in	O
renal	O
tissue	O
extract	O
.	O

In	O
the	O
kidney	O
,	O
high	O
levels	O
of	O
immunoreactive	O
and	O
enzymatically	O
active	O
calcineurin	O
were	O
found	O
which	O
were	O
inhibited	O
by	O
the	O
immunosuppressants	O
CsA	B-CHED
and	O
FK506	B-CHED
,	O
but	O
not	O
by	O
rapamycin	B-CHED
.	O

Finally	O
,	O
specific	O
immunophilin	O
-	O
drug	O
-	O
calcineurin	O
complexes	O
formed	O
only	O
in	O
the	O
presence	O
of	O
CsA	B-CHED
and	O
FK506	B-CHED
,	O
but	O
not	O
rapamycin	B-CHED
.	O

These	O
results	O
suggest	O
that	O
the	O
nephrotoxic	O
effects	O
of	O
CsA	B-CHED
and	O
FK506	B-CHED
is	O
likely	O
mediated	O
through	O
binding	O
to	O
renal	O
immunophilin	O
and	O
inhibiting	O
calcineurin	O
phosphatase	O
.	O

Acute	O
renal	O
failure	O
in	O
high	O
dose	O
carboplatin	B-CHED
chemotherapy	O
.	O

Carboplatin	B-CHED
has	O
been	O
reported	O
to	O
cause	O
acute	O
renal	O
failure	O
when	O
administered	O
in	O
high	O
doses	O
to	O
adult	O
patients	O
.	O

We	O
report	O
a	O
4	O
1	O
/	O
2	O
-	O
year	O
-	O
old	O
girl	O
who	O
was	O
treated	O
with	O
high	O
-	O
dose	O
carboplatin	B-CHED
for	O
metastatic	O
parameningeal	O
embryonal	O
rhabdomyosarcoma	O
.	O

Acute	O
renal	O
failure	O
developed	O
followed	O
by	O
a	O
slow	O
partial	O
recovery	O
of	O
renal	O
function	O
.	O

Possible	O
contributing	O
factors	O
are	O
discussed	O
.	O

Clinical	O
evaluation	O
on	O
combined	O
administration	O
of	O
oral	O
prostacyclin	B-CHED
analogue	O
beraprost	B-CHED
and	O
phosphodiesterase	O
inhibitor	O
cilostazol	B-CHED
.	O

Among	O
various	O
oral	O
antiplatelets	O
,	O
a	O
combination	O
of	O
a	O
novel	O
prostacyclin	B-CHED
analogue	O
beraprost	B-CHED
(	O
BPT	B-CHED
)	O
and	O
a	O
potent	O
phosphodiesterase	O
inhibitor	O
cilostazol	B-CHED
(	O
CLZ	B-CHED
)	O
may	O
result	O
in	O
untoward	O
clinical	O
effects	O
due	O
to	O
possible	O
synergistic	O
elevation	O
of	O
intracellular	O
cAMP	B-CHED
(	O
cyclic	B-CHED
adenosine	I-CHED
3	I-CHED
'	I-CHED
,	I-CHED
5	I-CHED
'	I-CHED
-	I-CHED
monophosphate	I-CHED
)	O
.	O

Thereby	O
,	O
a	O
clinical	O
study	O
of	O
the	O
combined	O
administration	O
of	O
the	O
two	O
agents	O
was	O
attempted	O
.	O

Twelve	O
healthy	O
volunteers	O
were	O
assigned	O
to	O
take	O
BPT	B-CHED
/	O
CLZ	B-CHED
in	O
the	O
following	O
schedule	O
;	O
BPT	B-CHED
:	O
40	O
micrograms	O
at	O
day	O
1	O
and	O
120	O
micrograms	O
t	O
.	O
i	O
.	O
d	O
.	O
from	O
day	O
7	O
to	O
14	O
,	O
CLZ	B-CHED
:	O
200	O
mg	O
t	O
.	O
i	O
.	O
d	O
.	O
from	O
day	O
3	O
to	O
14	O
.	O

At	O
various	O
time	O
intervals	O
,	O
physical	O
examination	O
and	O
blood	O
collection	O
for	O
ex	O
vivo	O
platelet	O
aggregation	O
and	O
determination	O
of	O
intraplatelet	O
cAMP	B-CHED
were	O
performed	O
.	O

Throughout	O
the	O
observation	O
period	O
,	O
no	O
significant	O
alteration	O
in	O
vital	O
signs	O
was	O
observed	O
.	O

Seven	O
out	O
of	O
12	O
subjects	O
experienced	O
headache	O
of	O
a	O
short	O
duration	O
accompanying	O
facial	O
flush	O
in	O
one	O
and	O
nausea	O
in	O
one	O
,	O
especially	O
after	O
ingestion	O
of	O
CLZ	B-CHED
.	O

All	O
of	O
these	O
symptoms	O
,	O
probably	O
caused	O
by	O
the	O
vasodilating	O
effect	O
of	O
the	O
two	O
agents	O
,	O
were	O
of	O
mild	O
degree	O
and	O
no	O
special	O
treatment	O
was	O
required	O
.	O

Intraplatelet	O
cAMP	B-CHED
content	O
was	O
gradually	O
but	O
significantly	O
increased	O
to	O
9	O
.	O
84	O
+	O
/	O
-	O
4	O
.	O
59	O
pmol	O
per	O
10	O
(	O
9	O
)	O
platelets	O
at	O
day	O
14	O
in	O
comparison	O
with	O
the	O
initial	O
value	O
(	O
6	O
.	O
87	O
+	O
/	O
-	O
2	O
.	O
25	O
pmol	O
)	O
.	O

The	O
platelet	O
aggregability	O
was	O
significantly	O
suppressed	O
at	O
various	O
time	O
intervals	O
but	O
no	O
additive	O
or	O
synergistic	O
inhibitory	O
effect	O
by	O
the	O
combined	O
administration	O
was	O
noted	O
.	O

In	O
conclusion	O
,	O
the	O
combined	O
administration	O
of	O
BPT	B-CHED
/	O
CLZ	B-CHED
is	O
safe	O
at	O
doses	O
used	O
in	O
the	O
study	O
,	O
though	O
the	O
beneficial	O
clinical	O
effect	O
of	O
the	O
combined	O
administration	O
has	O
yet	O
to	O
be	O
elucidated	O
.	O

Pravastatin	B-CHED
-	O
associated	O
myopathy	O
.	O

Report	O
of	O
a	O
case	O
.	O

A	O
case	O
of	O
acute	O
inflammatory	O
myopathy	O
associated	O
with	O
the	O
use	O
of	O
pravastatin	B-CHED
,	O
a	O
new	O
hydrophilic	O
3	O
-	O
hydroxy	O
-	O
3	O
methylglutaril	O
coenzyme	O
A	O
reductase	O
inhibitor	O
,	O
is	O
reported	O
.	O

The	O
patient	O
,	O
a	O
69	O
-	O
year	O
-	O
old	O
man	O
was	O
affected	O
by	O
non	O
-	O
insulin	O
-	O
dependent	O
diabetes	O
mellitus	O
and	O
hypertension	O
.	O

He	O
assumed	O
pravastatin	B-CHED
(	O
20	O
mg	O
/	O
day	O
)	O
because	O
of	O
hypercholesterolemia	O
.	O

He	O
was	O
admitted	O
with	O
acute	O
myopathy	O
of	O
the	O
lower	O
limbs	O
which	O
resolved	O
in	O
a	O
few	O
days	O
after	O
pravastatin	B-CHED
discontinuation	O
.	O

A	O
previously	O
unknown	O
hypothyroidism	O
,	O
probably	O
due	O
to	O
chronic	O
autoimmune	O
thyroiditis	O
,	O
was	O
evidenced	O
.	O

Muscle	O
biopsy	O
(	O
left	O
gastrocnemius	O
)	O
revealed	O
a	O
perimysial	O
and	O
endomysial	O
inflammatory	O
infiltrate	O
with	O
a	O
prevalence	O
of	O
CD4	O
+	O
lymphocytes	O
.	O

While	O
lovastatin	B-CHED
and	O
simvastatin	B-CHED
have	O
been	O
associated	O
with	O
toxic	O
myopathy	O
,	O
pravastatin	B-CHED
-	O
associated	O
myopathy	O
could	O
represent	O
a	O
distinct	O
,	O
inflammatory	O
entity	O
.	O

Reversal	O
of	O
ammonia	B-CHED
coma	O
in	O
rats	O
by	O
L	B-CHED
-	I-CHED
dopa	I-CHED
:	O
a	O
peripheral	O
effect	O
.	O

Ammonia	B-CHED
coma	O
was	O
produced	O
in	O
rats	O
within	O
10	O
to	O
15	O
minutes	O
of	O
an	O
intraperitonealinjection	O
of	O
1	O
.	O
7	O
mmol	O
NH4CL	B-CHED
.	O

This	O
coma	O
was	O
prevented	O
with	O
1	O
.	O
68	O
mmol	O
L	B-CHED
-	I-CHED
dopa	I-CHED
given	O
by	O
gastric	O
intubation	O
15	O
minutes	O
before	O
the	O
ammonium	B-CHED
salt	I-CHED
injection	O
.	O

The	O
effect	O
of	O
L	B-CHED
-	I-CHED
dopa	I-CHED
was	O
correlated	O
with	O
a	O
decrease	O
in	O
blood	O
and	O
brain	O
ammonia	B-CHED
,	O
an	O
increase	O
in	O
brain	O
dopamine	B-CHED
,	O
and	O
an	O
increase	O
in	O
renal	O
excretion	O
of	O
ammonia	B-CHED
and	O
urea	B-CHED
.	O

Intraventricular	O
infusion	O
of	O
dopamine	B-CHED
sufficient	O
to	O
raise	O
the	O
brain	O
dopamine	B-CHED
to	O
the	O
same	O
extent	O
did	O
not	O
prevent	O
the	O
ammonia	B-CHED
coma	O
nor	O
affect	O
the	O
blood	O
and	O
brain	O
ammonia	B-CHED
concentrations	O
.	O

Bilateral	O
nephrectomy	O
eliminated	O
the	O
beneficial	O
effect	O
of	O
L	B-CHED
-	I-CHED
dopa	I-CHED
on	O
blood	O
and	O
brain	O
ammonia	B-CHED
and	O
the	O
ammonia	B-CHED
coma	O
was	O
not	O
prevented	O
.	O

Thus	O
,	O
the	O
reduction	O
in	O
blood	O
and	O
brain	O
ammonia	B-CHED
and	O
the	O
prevention	O
of	O
ammonia	B-CHED
coma	O
after	O
L	B-CHED
-	I-CHED
dopa	I-CHED
,	O
can	O
be	O
accounted	O
for	O
by	O
the	O
peripheral	O
effect	O
of	O
dopamine	B-CHED
on	O
renal	O
function	O
rather	O
than	O
its	O
central	O
action	O
.	O

These	O
results	O
provide	O
a	O
reasonable	O
explanation	O
for	O
the	O
beneficial	O
effects	O
observed	O
in	O
some	O
encephalopathic	O
patients	O
receiving	O
L	B-CHED
-	I-CHED
dopa	I-CHED
.	O

Etoposide	B-CHED
-	O
related	O
myocardial	O
infarction	O
.	O

The	O
occurrence	O
of	O
a	O
myocardial	O
infarction	O
is	O
reported	O
after	O
chemotherapy	O
containing	O
etoposide	B-CHED
,	O
in	O
a	O
man	O
with	O
no	O
risk	O
factors	O
for	O
coronary	O
heart	O
disease	O
.	O

Possible	O
causal	O
mechanisms	O
are	O
discussed	O
.	O

Halogenated	O
anesthetics	O
form	O
liver	O
adducts	O
and	O
antigens	O
that	O
cross	O
-	O
react	O
with	O
halothane	B-CHED
-	O
induced	O
antibodies	O
.	O

Two	O
halogenated	O
anesthetics	O
,	O
enflurane	B-CHED
and	O
isoflurane	B-CHED
,	O
have	O
been	O
associated	O
with	O
an	O
allergic	O
-	O
type	O
hepatic	O
injury	O
both	O
alone	O
and	O
following	O
previous	O
exposure	O
to	O
halothane	B-CHED
.	O

Halothane	B-CHED
hepatitis	O
appears	O
to	O
involve	O
an	O
aberrant	O
immune	O
response	O
.	O

An	O
antibody	O
response	O
to	O
a	O
protein	O
-	O
bound	O
biotransformation	O
product	O
(	O
trifluoroacetyl	B-CHED
adduct	O
)	O
has	O
been	O
detected	O
on	O
halothane	B-CHED
hepatitis	O
patients	O
.	O

This	O
study	O
was	O
performed	O
to	O
determine	O
cross	O
-	O
reactivity	O
between	O
enflurane	B-CHED
and	O
isoflurane	B-CHED
with	O
the	O
hypersensitivity	O
induced	O
by	O
halothane	B-CHED
.	O

The	O
subcellular	O
and	O
lobular	O
production	O
of	O
hepatic	O
neoantigens	O
recognized	O
by	O
halothane	B-CHED
-	O
induced	O
antibodies	O
following	O
enflurane	B-CHED
and	O
isoflurane	B-CHED
,	O
and	O
the	O
biochemical	O
nature	O
of	O
these	O
neoantigens	O
was	O
investigated	O
in	O
two	O
animal	O
models	O
.	O

Enflurane	B-CHED
administration	O
resulted	O
in	O
neoantigens	O
detected	O
in	O
both	O
the	O
microsomal	O
and	O
cytosolic	O
fraction	O
of	O
liver	O
homogenates	O
and	O
in	O
the	O
centrilobular	O
region	O
of	O
the	O
liver	O
.	O

In	O
the	O
same	O
liver	O
,	O
biochemical	O
analysis	O
detected	O
fluorinated	O
liver	O
adducts	O
that	O
were	O
up	O
to	O
20	O
-	O
fold	O
greater	O
in	O
guinea	O
pigs	O
than	O
in	O
rats	O
.	O

This	O
supports	O
and	O
extends	O
previous	O
evidence	O
for	O
a	O
mechanism	O
by	O
which	O
enflurane	B-CHED
and	O
/	O
or	O
isoflurane	B-CHED
could	O
produce	O
a	O
hypersensitivity	O
condition	O
similar	O
to	O
that	O
of	O
halothane	B-CHED
hepatitis	O
either	O
alone	O
or	O
subsequent	O
to	O
halothane	B-CHED
administration	O
.	O

The	O
guinea	O
pig	O
would	O
appear	O
to	O
be	O
a	O
useful	O
model	O
for	O
further	O
investigations	O
of	O
the	O
immunological	O
response	O
to	O
these	O
antigens	O
.	O

Cholinergic	O
toxicity	O
resulting	O
from	O
ocular	O
instillation	O
of	O
echothiophate	B-CHED
iodide	I-CHED
eye	O
drops	O
.	O

A	O
patient	O
developed	O
a	O
severe	O
cholinergic	O
syndrome	O
from	O
the	O
use	O
of	O
echothiophate	B-CHED
iodide	I-CHED
ophthalmic	O
drops	O
,	O
presented	O
with	O
profound	O
muscle	O
weakness	O
and	O
was	O
initially	O
given	O
the	O
diagnosis	O
of	O
myasthenia	O
gravis	O
.	O

Red	O
blood	O
cell	O
and	O
serum	O
cholinesterase	O
levels	O
were	O
severely	O
depressed	O
and	O
symptoms	O
resolved	O
spontaneously	O
following	O
discontinuation	O
of	O
the	O
eye	O
drops	O
.	O

Seizure	O
after	O
flumazenil	B-CHED
administration	O
in	O
a	O
pediatric	O
patient	O
.	O

Flumazenil	B-CHED
is	O
a	O
benzodiazepine	B-CHED
receptor	O
antagonist	O
used	O
to	O
reverse	O
sedation	O
and	O
respiratory	O
depression	O
induced	O
by	O
benzodiazepines	B-CHED
.	O

Seizures	O
and	O
cardiac	O
arrhythmias	O
have	O
complicated	O
its	O
use	O
in	O
adult	O
patients	O
.	O

Overdose	O
patients	O
who	O
have	O
coingested	O
tricyclic	O
antidepressants	O
have	O
a	O
higher	O
risk	O
of	O
these	O
complications	O
.	O

Little	O
information	O
exists	O
concerning	O
adverse	O
effects	O
of	O
flumazenil	B-CHED
in	O
children	O
.	O

We	O
report	O
the	O
occurrence	O
of	O
a	O
generalized	O
tonic	O
-	O
clonic	O
seizure	O
in	O
a	O
pediatric	O
patient	O
following	O
the	O
administration	O
of	O
flumazenil	B-CHED
.	O

Phase	O
I	O
trial	O
of	O
13	B-CHED
-	I-CHED
cis	I-CHED
-	I-CHED
retinoic	I-CHED
acid	I-CHED
in	O
children	O
with	O
neuroblastoma	O
following	O
bone	O
marrow	O
transplantation	O
.	O

PURPOSE	O
:	O
Treatment	O
of	O
neuroblastoma	O
cell	O
lines	O
with	O
13	B-CHED
-	I-CHED
cis	I-CHED
-	I-CHED
retinoic	I-CHED
acid	I-CHED
(	O
cis	B-CHED
-	I-CHED
RA	I-CHED
)	O
can	O
cause	O
sustained	O
inhibition	O
of	O
proliferation	O
.	O

Since	O
cis	B-CHED
-	I-CHED
RA	I-CHED
has	O
demonstrated	O
clinical	O
responses	O
in	O
neuroblastoma	O
patients	O
,	O
it	O
may	O
be	O
effective	O
in	O
preventing	O
relapse	O
after	O
cytotoxic	O
therapy	O
.	O

This	O
phase	O
I	O
trial	O
was	O
designed	O
to	O
determine	O
the	O
maximal	O
-	O
tolerated	O
dosage	O
(	O
MTD	O
)	O
,	O
toxicities	O
,	O
and	O
pharmacokinetics	O
of	O
cis	B-CHED
-	I-CHED
RA	I-CHED
administered	O
on	O
an	O
intermittent	O
schedule	O
in	O
children	O
with	O
neuroblastoma	O
following	O
bone	O
marrow	O
transplantation	O
(	O
BMT	O
)	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Fifty	O
-	O
one	O
assessable	O
patients	O
,	O
2	O
to	O
12	O
years	O
of	O
age	O
,	O
were	O
treated	O
with	O
oral	O
cis	B-CHED
-	I-CHED
RA	I-CHED
administered	O
in	O
two	O
equally	O
divided	O
doses	O
daily	O
for	O
2	O
weeks	O
,	O
followed	O
by	O
a	O
2	O
-	O
week	O
rest	O
period	O
,	O
for	O
up	O
to	O
12	O
courses	O
.	O

The	O
dose	O
was	O
escalated	O
from	O
100	O
to	O
200	O
mg	O
/	O
m2	O
/	O
d	O
until	O
dose	O
-	O
limiting	O
toxicity	O
(	O
DLT	O
)	O
was	O
observed	O
.	O

A	O
single	O
intrapatient	O
dose	O
escalation	O
was	O
permitted	O
.	O

RESULTS	O
:	O
The	O
MTD	O
of	O
cis	B-CHED
-	I-CHED
RA	I-CHED
was	O
160	O
mg	O
/	O
m2	O
/	O
d	O
.	O

Dose	O
-	O
limiting	O
toxicities	O
in	O
six	O
of	O
nine	O
patients	O
at	O
200	O
mg	O
/	O
m2	O
/	O
d	O
included	O
hypercalcemia	O
(	O
n	O
=	O
3	O
)	O
,	O
rash	O
(	O
n	O
=	O
2	O
)	O
,	O
and	O
anemia	O
/	O
thrombocytopenia	O
/	O
emesis	O
/	O
rash	O
(	O
n	O
=	O
1	O
)	O
.	O

All	O
toxicities	O
resolved	O
after	O
cis	B-CHED
-	I-CHED
RA	I-CHED
was	O
discontinued	O
.	O

Three	O
complete	O
responses	O
were	O
observed	O
in	O
marrow	O
metastases	O
.	O

Serum	O
levels	O
of	O
7	O
.	O
4	O
+	O
/	O
-	O
3	O
.	O
0	O
mumol	O
/	O
L	O
(	O
peak	O
)	O
and	O
4	O
.	O
0	O
+	O
/	O
-	O
2	O
.	O
8	O
mumol	O
/	O
L	O
(	O
trough	O
)	O
at	O
the	O
MTD	O
were	O
maintained	O
during	O
14	O
days	O
of	O
therapy	O
.	O

The	O
DLT	O
correlated	O
with	O
serum	O
levels	O
>	O
or	O
=	O
10	O
mumol	O
/	O
L	O
.	O

CONCLUSION	O
:	O
The	O
MTD	O
of	O
cis	B-CHED
-	I-CHED
RA	I-CHED
given	O
on	O
this	O
intermittent	O
schedule	O
was	O
160	O
mg	O
/	O
m2	O
/	O
d	O
.	O

Serum	O
levels	O
known	O
to	O
be	O
effective	O
against	O
neuroblastoma	O
in	O
vitro	O
were	O
achieved	O
at	O
this	O
dose	O
.	O

The	O
DLT	O
included	O
hypercalcemia	O
,	O
and	O
may	O
be	O
predicted	O
by	O
serum	O
cis	B-CHED
-	I-CHED
RA	I-CHED
levels	O
.	O

Monitoring	O
of	O
serum	O
calcium	B-CHED
and	O
cis	B-CHED
-	I-CHED
RA	I-CHED
levels	O
is	O
indicated	O
in	O
future	O
trials	O
.	O

Time	O
dependence	O
of	O
plasma	O
malondialdehyde	B-CHED
,	O
oxypurines	B-CHED
,	O
and	O
nucleosides	B-CHED
during	O
incomplete	O
cerebral	O
ischemia	O
in	O
the	O
rat	O
.	O

Incomplete	O
cerebral	O
ischemia	O
(	O
30	O
min	O
)	O
was	O
induced	O
in	O
the	O
rat	O
by	O
bilaterally	O
clamping	O
the	O
common	O
carotid	O
arteries	O
.	O

Peripheral	O
venous	O
blood	O
samples	O
were	O
withdrawn	O
from	O
the	O
femoral	O
vein	O
four	O
times	O
(	O
once	O
every	O
5	O
min	O
)	O
before	O
ischemia	O
(	O
0	O
time	O
)	O
and	O
5	O
,	O
15	O
,	O
and	O
30	O
min	O
after	O
ischemia	O
.	O

Plasma	O
extracts	O
were	O
analyzed	O
by	O
a	O
highly	O
sensitive	O
high	O
-	O
performance	O
liquid	O
chromatographic	O
method	O
for	O
the	O
direct	O
determination	O
of	O
malondialdehyde	B-CHED
,	O
oxypurines	B-CHED
,	O
and	O
nucleosides	B-CHED
.	O

During	O
ischemia	O
,	O
a	O
time	O
-	O
dependent	O
increase	O
of	O
plasma	O
oxypurines	B-CHED
and	O
nucleosides	B-CHED
was	O
observed	O
.	O

Plasma	O
malondialdehyde	B-CHED
,	O
which	O
was	O
present	O
in	O
minimal	O
amount	O
at	O
zero	O
time	O
(	O
0	O
.	O
058	O
mumol	O
/	O
liter	O
plasma	O
;	O
SD	O
0	O
.	O
015	O
)	O
,	O
increased	O
after	O
5	O
min	O
of	O
ischemia	O
,	O
resulting	O
in	O
a	O
fivefold	O
increase	O
after	O
30	O
min	O
of	O
carotid	O
occlusion	O
(	O
0	O
.	O
298	O
mumol	O
/	O
liter	O
plasma	O
;	O
SD	O
0	O
.	O
078	O
)	O
.	O

Increased	O
plasma	O
malondialdehyde	B-CHED
was	O
also	O
recorded	O
in	O
two	O
other	O
groups	O
of	O
animals	O
subjected	O
to	O
the	O
same	O
experimental	O
model	O
,	O
one	O
receiving	O
20	O
mg	O
/	O
kg	O
b	O
.	O
w	O
.	O
of	O
the	O
cyclooxygenase	O
inhibitor	O
acetylsalicylate	B-CHED
intravenously	O
immediately	O
before	O
ischemia	O
,	O
the	O
other	O
receiving	O
650	O
micrograms	O
/	O
kg	O
b	O
.	O
w	O
.	O
of	O
the	O
hypotensive	O
drug	O
nitroprusside	B-CHED
at	O
a	O
flow	O
rate	O
of	O
103	O
microliters	O
/	O
min	O
intravenously	O
during	O
ischemia	O
,	O
although	O
in	O
this	O
latter	O
group	O
malondialdehyde	B-CHED
was	O
significantly	O
higher	O
.	O

The	O
present	O
data	O
indicate	O
that	O
the	O
determination	O
of	O
malondialdehyde	B-CHED
,	O
oxypurines	B-CHED
,	O
and	O
nucleosides	B-CHED
in	O
peripheral	O
blood	O
,	O
may	O
be	O
used	O
to	O
monitor	O
the	O
metabolic	O
alterations	O
of	O
tissues	O
occurring	O
during	O
ischemic	O
phenomena	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Acute	O
renal	O
toxicity	O
of	O
doxorubicin	B-CHED
(	O
adriamycin	B-CHED
)	O
-	O
loaded	O
cyanoacrylate	B-CHED
nanoparticles	O
.	O

Acute	O
doxorubicin	B-CHED
-	O
loaded	O
nanoparticle	O
(	O
DXNP	O
)	O
renal	O
toxicity	O
was	O
explored	O
in	O
both	O
normal	O
rats	O
and	O
rats	O
with	O
experimental	O
glomerulonephritis	O
.	O

In	O
normal	O
rats	O
,	O
2	O
/	O
6	O
rats	O
given	O
free	O
doxorubicin	B-CHED
(	O
DX	B-CHED
)	O
(	O
5	O
mg	O
/	O
kg	O
)	O
died	O
within	O
one	O
week	O
,	O
whereas	O
all	O
control	O
animals	O
and	O
all	O
rats	O
having	O
received	O
free	O
NP	O
or	O
DXNP	O
survived	O
.	O

A	O
3	O
times	O
higher	O
proteinuria	O
appeared	O
in	O
animals	O
treated	O
with	O
DXNP	O
than	O
in	O
those	O
treated	O
with	O
DX	B-CHED
.	O

Free	O
NP	O
did	O
not	O
provoke	O
any	O
proteinuria	O
.	O

Two	O
hr	O
post	O
-	O
injection	O
,	O
DXNP	O
was	O
2	O
.	O
7	O
times	O
more	O
concentrated	O
in	O
kidneys	O
than	O
free	O
DX	B-CHED
(	O
p	O
<	O
0	O
.	O
025	O
)	O
.	O

In	O
rats	O
with	O
immune	O
experimental	O
glomerulonephritis	O
,	O
5	O
/	O
6	O
rats	O
given	O
DX	B-CHED
died	O
within	O
7	O
days	O
,	O
in	O
contrast	O
to	O
animals	O
treated	O
by	O
DXNP	O
,	O
NP	O
,	O
or	O
untreated	O
,	O
which	O
all	O
survived	O
.	O

Proteinuria	O
appeared	O
in	O
all	O
series	O
,	O
but	O
was	O
2	O
-	O
5	O
times	O
more	O
intense	O
(	O
p	O
>	O
0	O
.	O
001	O
)	O
and	O
prolonged	O
after	O
doxorubicin	B-CHED
treatment	O
(	O
400	O
-	O
700	O
mg	O
/	O
day	O
)	O
,	O
without	O
significant	O
difference	O
between	O
DXNP	O
and	O
DX	B-CHED
.	O

Rats	O
treated	O
by	O
unloaded	O
NP	O
behaved	O
as	O
controls	O
.	O

These	O
results	O
demonstrate	O
that	O
,	O
in	O
these	O
experimental	O
conditions	O
,	O
DXNP	O
killed	O
less	O
animals	O
than	O
free	O
DX	B-CHED
,	O
despite	O
of	O
an	O
enhanced	O
renal	O
toxicity	O
of	O
the	O
former	O
.	O

Both	O
effects	O
(	O
better	O
survival	O
and	O
nephrosis	O
)	O
are	O
most	O
probably	O
related	O
to	O
an	O
enhanced	O
capture	O
of	O
DXNP	O
by	O
cells	O
of	O
the	O
mononuclear	O
phagocyte	O
system	O
,	O
including	O
mesangial	O
cells	O
.	O

Prostaglandin	B-CHED
E2	I-CHED
-	O
induced	O
bladder	O
hyperactivity	O
in	O
normal	O
,	O
conscious	O
rats	O
:	O
involvement	O
of	O
tachykinins	B-CHED
?	O

In	O
normal	O
conscious	O
rats	O
investigated	O
by	O
continuous	O
cystometry	O
,	O
intravesically	O
instilled	O
prostaglandin	B-CHED
(	I-CHED
PG	I-CHED
)	I-CHED
E2	I-CHED
facilitated	O
micturition	O
and	O
increased	O
basal	O
intravesical	O
pressure	O
.	O

The	O
effect	O
was	O
attenuated	O
by	O
both	O
the	O
NK1	O
receptor	O
selective	O
antagonist	O
RP	B-CHED
67	I-CHED
,	I-CHED
580	I-CHED
and	O
the	O
NK2	O
receptor	O
selective	O
antagonist	O
SR	B-CHED
48	I-CHED
,	I-CHED
968	I-CHED
,	O
given	O
intra	O
-	O
arterially	O
,	O
suggesting	O
that	O
it	O
was	O
mediated	O
by	O
stimulation	O
of	O
both	O
NK1	O
and	O
NK2	O
receptors	O
.	O

Intra	O
-	O
arterially	O
given	O
PGE2	B-CHED
produced	O
a	O
distinct	O
increase	O
in	O
bladder	O
pressure	O
before	O
initiating	O
a	O
micturition	O
reflex	O
,	O
indicating	O
that	O
the	O
PG	B-CHED
had	O
a	O
direct	O
contractant	O
effect	O
on	O
the	O
detrusor	O
smooth	O
muscle	O
.	O

The	O
effect	O
of	O
intra	O
-	O
arterial	O
PGE2	B-CHED
could	O
not	O
be	O
blocked	O
by	O
intra	O
-	O
arterial	O
RP	B-CHED
67	I-CHED
,	I-CHED
580	I-CHED
or	O
SR	B-CHED
48	I-CHED
,	I-CHED
968	I-CHED
,	O
which	O
opens	O
the	O
possibility	O
that	O
the	O
micturition	O
reflex	O
elicited	O
by	O
intra	O
-	O
arterial	O
PGE2	B-CHED
was	O
mediated	O
by	O
pathways	O
other	O
than	O
the	O
reflex	O
initiated	O
when	O
the	O
PG	B-CHED
was	O
given	O
intravesically	O
.	O

The	O
present	O
results	O
thus	O
suggest	O
that	O
intra	O
-	O
arterial	O
PGE2	B-CHED
,	O
given	O
near	O
the	O
bladder	O
,	O
may	O
initiate	O
micturition	O
in	O
the	O
normal	O
rat	O
chiefly	O
by	O
directly	O
contracting	O
the	O
smooth	O
muscle	O
of	O
the	O
detrusor	O
.	O

However	O
,	O
when	O
given	O
intravesically	O
,	O
PGE2	B-CHED
may	O
stimulate	O
micturition	O
by	O
releasing	O
tachykinins	B-CHED
from	O
nerves	O
in	O
and	O
/	O
or	O
immediately	O
below	O
the	O
urothelium	O
.	O

These	O
tachykinins	B-CHED
,	O
in	O
turn	O
,	O
initiate	O
a	O
micturition	O
reflex	O
by	O
stimulating	O
NK1	O
and	O
NK2	O
receptors	O
.	O

Prostanoids	B-CHED
may	O
,	O
via	O
release	O
of	O
tachykinins	B-CHED
,	O
contribute	O
to	O
both	O
urge	O
and	O
bladder	O
hyperactivity	O
seen	O
in	O
inflammatory	O
conditions	O
of	O
the	O
lower	O
urinary	O
tract	O
.	O

Refractory	O
cardiogenic	O
shock	O
and	O
complete	O
heart	O
block	O
after	O
verapamil	B-CHED
SR	O
and	O
metoprolol	B-CHED
treatment	O
.	O

A	O
case	O
report	O
.	O

A	O
seventy	O
-	O
eight	O
-	O
year	O
-	O
old	O
woman	O
presented	O
with	O
complete	O
heart	O
block	O
and	O
refractory	O
hypotension	O
two	O
days	O
after	O
a	O
therapeutic	O
dose	O
of	O
sustained	O
-	O
release	O
verapamil	B-CHED
with	O
concomitant	O
use	O
of	O
metoprolol	B-CHED
.	O

The	O
patient	O
continued	O
to	O
remain	O
hypotensive	O
with	O
complete	O
heart	O
block	O
,	O
even	O
with	O
multiple	O
uses	O
of	O
intravenous	O
atropine	B-CHED
as	O
well	O
as	O
high	O
doses	O
of	O
pressor	O
agents	O
such	O
as	O
dopamine	B-CHED
and	O
dobutamine	B-CHED
.	O

However	O
,	O
shortly	O
after	O
the	O
use	O
of	O
intravenous	O
calcium	B-CHED
chloride	I-CHED
,	O
the	O
refractory	O
hypotension	O
and	O
complete	O
heart	O
block	O
resolved	O
.	O

Protective	O
effect	O
of	O
misoprostol	B-CHED
on	O
indomethacin	B-CHED
induced	O
renal	O
dysfunction	O
in	O
elderly	O
patients	O
.	O

OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
possible	O
protective	O
effects	O
of	O
misoprostol	B-CHED
on	O
renal	O
function	O
in	O
hospitalized	O
elderly	O
patients	O
treated	O
with	O
indomethacin	B-CHED
.	O

METHODS	O
:	O
Forty	O
-	O
five	O
hospitalized	O
elderly	O
patients	O
(	O
>	O
65	O
years	O
old	O
)	O
who	O
required	O
therapy	O
with	O
nonsteroidal	O
antiinflammatory	O
drugs	O
(	O
NSAID	O
)	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
indomethacin	B-CHED
,	O
150	O
mg	O
/	O
day	O
(	O
Group	O
A	O
)	O
,	O
or	O
indomethacin	B-CHED
150	O
mg	O
/	O
day	O
plus	O
misoprostol	B-CHED
at	O
0	O
.	O
6	O
mg	O
/	O
day	O
(	O
Group	O
B	O
)	O
.	O

Laboratory	O
variables	O
of	O
renal	O
function	O
[	O
serum	O
creatinine	B-CHED
,	O
blood	B-CHED
urea	I-CHED
nitrogen	I-CHED
(	O
BUN	B-CHED
)	O
and	O
electrolytes	O
]	O
were	O
evaluated	O
before	O
initiation	O
of	O
therapy	O
and	O
every	O
2	O
days	O
,	O
until	O
termination	O
of	O
the	O
study	O
(	O
a	O
period	O
of	O
at	O
least	O
6	O
days	O
)	O
.	O

Response	O
to	O
treatment	O
was	O
estimated	O
by	O
the	O
visual	O
analog	O
scale	O
for	O
severity	O
of	O
pain	O
.	O

RESULTS	O
:	O
Forty	O
-	O
two	O
patients	O
completed	O
the	O
study	O
,	O
22	O
in	O
Group	O
A	O
and	O
20	O
in	O
Group	O
B	O
.	O

BUN	B-CHED
and	O
creatinine	B-CHED
increased	O
by	O
>	O
50	O
%	O
of	O
baseline	O
levels	O
in	O
54	O
and	O
45	O
%	O
of	O
Group	O
A	O
patients	O
,	O
respectively	O
,	O
compared	O
to	O
only	O
20	O
and	O
10	O
%	O
of	O
Group	O
B	O
patients	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Potassium	B-CHED
(	O
K	B-CHED
)	O
increment	O
of	O
0	O
.	O
6	O
mEq	O
/	O
l	O
or	O
more	O
was	O
observed	O
in	O
50	O
%	O
of	O
Group	O
A	O
,	O
but	O
in	O
only	O
15	O
%	O
of	O
Group	O
B	O
patients	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
mean	O
increments	O
in	O
BUN	B-CHED
,	O
creatinine	B-CHED
,	O
and	O
K	B-CHED
were	O
reduced	O
by	O
63	O
,	O
80	O
,	O
and	O
42	O
%	O
,	O
respectively	O
,	O
in	O
Group	O
B	O
patients	O
compared	O
to	O
Group	O
A	O
.	O
Response	O
to	O
treatment	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
2	O
groups	O
.	O

CONCLUSION	O
:	O
Hospitalized	O
elderly	O
patients	O
are	O
at	O
risk	O
for	O
developing	O
indomethacin	B-CHED
related	O
renal	O
dysfunction	O
.	O

Addition	O
of	O
misoprostol	B-CHED
can	O
minimize	O
this	O
renal	O
impairment	O
without	O
affecting	O
pain	O
control	O
.	O

Cognitive	O
deterioration	O
from	O
long	O
-	O
term	O
abuse	O
of	O
dextromethorphan	B-CHED
:	O
a	O
case	O
report	O
.	O

Dextromethorphan	B-CHED
(	O
DM	B-CHED
)	O
,	O
the	O
dextrorotatory	O
isomer	O
of	O
3	B-CHED
-	I-CHED
hydroxy	I-CHED
-	I-CHED
N	I-CHED
-	I-CHED
methylmorphinan	I-CHED
,	O
is	O
the	O
main	O
ingredient	O
in	O
a	O
number	O
of	O
widely	O
available	O
,	O
over	O
-	O
the	O
-	O
counter	O
antitussives	O
.	O

Initial	O
studies	O
(	O
Bornstein	O
1968	O
)	O
showed	O
that	O
it	O
possessed	O
no	O
respiratory	O
suppressant	O
effects	O
and	O
no	O
addiction	O
liability	O
.	O

Subsequently	O
,	O
however	O
,	O
several	O
articles	O
reporting	O
abuse	O
of	O
this	O
drug	O
have	O
appeared	O
in	O
the	O
literature	O
.	O

The	O
drug	O
is	O
known	O
to	O
cause	O
a	O
variety	O
of	O
acute	O
toxic	O
effects	O
,	O
ranging	O
from	O
nausea	O
,	O
restlessness	O
,	O
insomnia	O
,	O
ataxia	O
,	O
slurred	O
speech	O
and	O
nystagmus	O
to	O
mood	O
changes	O
,	O
perceptual	O
alterations	O
,	O
inattention	O
,	O
disorientation	O
and	O
aggressive	O
behavior	O
(	O
Rammer	O
et	O
al	O
1988	O
;	O
Katona	O
and	O
Watson	O
1986	O
;	O
Isbell	O
and	O
Fraser	O
1953	O
;	O
Devlin	O
et	O
al	O
1985	O
;	O
McCarthy	O
1971	O
;	O
Dodds	O
and	O
Revai	O
1967	O
;	O
Degkwitz	O
1964	O
;	O
Hildebrand	O
et	O
al	O
1989	O
)	O
.	O

There	O
have	O
also	O
been	O
two	O
reported	O
fatalities	O
from	O
DM	B-CHED
overdoses	O
(	O
Fleming	O
1986	O
)	O
.	O

However	O
,	O
there	O
are	O
no	O
reports	O
describing	O
the	O
effects	O
of	O
chronic	O
abuse	O
.	O

This	O
report	O
describes	O
a	O
case	O
of	O
cognitive	O
deterioration	O
resulting	O
from	O
prolonged	O
use	O
of	O
DM	B-CHED
.	O

Effects	O
of	O
ouabain	B-CHED
on	O
myocardial	O
oxygen	B-CHED
supply	O
and	O
demand	O
in	O
patients	O
with	O
chronic	O
coronary	O
artery	O
disease	O
.	O

A	O
hemodynamic	O
,	O
volumetric	O
,	O
and	O
metabolic	O
study	O
in	O
patients	O
without	O
heart	O
failure	O
.	O

The	O
effects	O
of	O
digitalis	B-CHED
glycosides	I-CHED
on	O
myocardial	O
oxygen	B-CHED
supply	O
and	O
demand	O
are	O
of	O
particular	O
interest	O
in	O
the	O
presence	O
of	O
obstructive	O
coronary	O
artery	O
disease	O
,	O
but	O
have	O
not	O
been	O
measured	O
previously	O
in	O
man	O
.	O

We	O
assessed	O
the	O
effects	O
of	O
ouabain	B-CHED
(	O
0	O
.	O
015	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
on	O
hemodynamic	O
,	O
volumetric	O
,	O
and	O
metabolic	O
parameters	O
in	O
11	O
patients	O
with	O
severe	O
chronic	O
coronary	O
artery	O
disease	O
without	O
clinical	O
congestive	O
heart	O
failure	O
.	O

Because	O
the	O
protocol	O
was	O
long	O
and	O
involved	O
interventions	O
which	O
might	O
affect	O
the	O
determinations	O
,	O
we	O
also	O
studied	O
in	O
nine	O
patients	O
using	O
an	O
identical	O
protocol	O
except	O
that	O
ouabain	B-CHED
administration	O
was	O
omitted	O
.	O

Left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
and	O
left	O
ventricular	O
end	O
-	O
diastolic	O
volume	O
fell	O
in	O
each	O
patient	O
given	O
ouabain	B-CHED
,	O
even	O
though	O
they	O
were	O
initially	O
elevated	O
in	O
only	O
two	O
patients	O
.	O

Left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
fell	O
from	O
11	O
.	O
5	O
+	O
/	O
-	O
1	O
.	O
4	O
(	O
mean	O
+	O
/	O
-	O
SE	O
)	O
to	O
5	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
9	O
mm	O
Hg	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
and	O
left	O
ventricular	O
end	O
-	O
diastolic	O
volume	O
fell	O
from	O
100	O
+	O
/	O
-	O
17	O
to	O
82	O
+	O
/	O
-	O
12	O
ml	O
/	O
m2	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
1	O
h	O
after	O
ouabain	B-CHED
infusion	O
was	O
completed	O
.	O

The	O
maximum	O
velocity	O
of	O
contractile	O
element	O
shortening	O
increased	O
from	O
1	O
.	O
68	O
+	O
/	O
-	O
0	O
.	O
11	O
ml	O
/	O
s	O
to	O
2	O
.	O
18	O
+	O
/	O
-	O
0	O
.	O
21	O
muscle	O
-	O
lengths	O
/	O
s	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
and	O
is	O
consistent	O
with	O
an	O
increase	O
in	O
contractility	O
.	O

No	O
significant	O
change	O
in	O
these	O
parameters	O
occurred	O
in	O
the	O
control	O
patients	O
.	O

No	O
significant	O
change	O
in	O
myocardial	O
oxygen	B-CHED
consumption	O
occurred	O
after	O
ouabain	B-CHED
administration	O
but	O
this	O
may	O
be	O
related	O
to	O
a	O
greater	O
decrease	O
in	O
mean	O
arterial	O
pressure	O
in	O
the	O
ouabain	B-CHED
patients	O
than	O
in	O
the	O
control	O
patients	O
.	O

We	O
conclude	O
that	O
in	O
patients	O
with	O
chronic	O
coronary	O
artery	O
disease	O
who	O
are	O
not	O
in	O
clinical	O
congestive	O
heart	O
failure	O
left	O
ventricular	O
end	O
-	O
diastolic	O
volume	O
falls	O
after	O
ouabain	B-CHED
administration	O
even	O
when	O
it	O
is	O
initially	O
normal	O
.	O

Though	O
this	O
fall	O
would	O
be	O
associated	O
with	O
a	O
decrease	O
in	O
wall	O
tension	O
,	O
and	O
,	O
therefore	O
,	O
of	O
myocardial	O
oxygen	B-CHED
consumption	O
,	O
it	O
may	O
not	O
be	O
of	O
sufficient	O
magnitude	O
to	O
prevent	O
a	O
net	O
increase	O
in	O
myocardial	O
oxygen	B-CHED
consumption	O
.	O

Nevertheless	O
,	O
compensatory	O
mechanisms	O
prevent	O
a	O
deterioration	O
of	O
resting	O
myocardial	O
metabolism	O
.	O

Dexamethasone	B-CHED
-	O
induced	O
ocular	O
hypertension	O
in	O
perfusion	O
-	O
cultured	O
human	O
eyes	O
.	O

PURPOSE	O
:	O
Glucocorticoid	O
administration	O
can	O
lead	O
to	O
the	O
development	O
of	O
ocular	O
hypertension	O
and	O
corticosteroid	O
glaucoma	O
in	O
a	O
subset	O
of	O
the	O
population	O
through	O
a	O
decrease	O
in	O
the	O
aqueous	O
humor	O
outflow	O
facility	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
glucocorticoid	O
treatment	O
can	O
directly	O
affect	O
the	O
outflow	O
facility	O
of	O
isolated	O
,	O
perfusion	O
-	O
cultured	O
human	O
eyes	O
.	O

METHODS	O
:	O
The	O
anterior	O
segments	O
of	O
human	O
donor	O
eyes	O
from	O
regional	O
eye	O
banks	O
were	O
placed	O
in	O
a	O
constant	O
flow	O
,	O
variable	O
pressure	O
perfusion	O
culture	O
system	O
.	O

Paired	O
eyes	O
were	O
perfused	O
in	O
serum	O
-	O
free	O
media	O
with	O
or	O
without	O
10	O
(	O
-	O
7	O
)	O
M	O
dexamethasone	B-CHED
for	O
12	O
days	O
.	O

Intraocular	O
pressure	O
was	O
monitored	O
daily	O
.	O

After	O
incubation	O
,	O
the	O
eyes	O
were	O
morphologically	O
characterized	O
by	O
light	O
microscopy	O
,	O
transmission	O
and	O
scanning	O
electron	O
microscopy	O
,	O
and	O
scanning	O
laser	O
confocal	O
microscopy	O
.	O

RESULTS	O
:	O
A	O
significant	O
increase	O
in	O
intraocular	O
pressure	O
developed	O
in	O
13	O
of	O
the	O
44	O
pairs	O
of	O
eyes	O
perfused	O
with	O
dexamethasone	B-CHED
with	O
an	O
average	O
pressure	O
rise	O
of	O
17	O
.	O
5	O
+	O
/	O
-	O
3	O
.	O
8	O
mm	O
Hg	O
after	O
12	O
days	O
of	O
dexamethasone	B-CHED
exposure	O
.	O

The	O
contralateral	O
control	O
eyes	O
,	O
which	O
did	O
not	O
receive	O
dexamethasone	B-CHED
,	O
maintained	O
a	O
stable	O
intraocular	O
pressure	O
during	O
the	O
same	O
period	O
.	O

The	O
outflow	O
pathway	O
of	O
the	O
untreated	O
eyes	O
appeared	O
morphologically	O
normal	O
.	O

In	O
contrast	O
,	O
the	O
dexamethasone	B-CHED
-	O
treated	O
hypertensive	O
eyes	O
had	O
thickened	O
trabecular	O
beams	O
,	O
decreased	O
intertrabecular	O
spaces	O
,	O
thickened	O
juxtacanalicular	O
tissue	O
,	O
activated	O
trabecular	O
meshwork	O
cells	O
,	O
and	O
increased	O
amounts	O
of	O
amorphogranular	O
extracellular	O
material	O
,	O
especially	O
in	O
the	O
juxtacanalicular	O
tissue	O
and	O
beneath	O
the	O
endothelial	O
lining	O
of	O
the	O
canal	O
of	O
Schlemm	O
.	O

The	O
dexamethasone	B-CHED
-	O
treated	O
nonresponder	O
eyes	O
appeared	O
to	O
be	O
morphologically	O
similar	O
to	O
the	O
untreated	O
eyes	O
,	O
although	O
several	O
subtle	O
dexamethasone	B-CHED
-	O
induced	O
morphologic	O
changes	O
were	O
evident	O
.	O

CONCLUSION	O
:	O
Dexamethasone	B-CHED
treatment	O
of	O
isolated	O
,	O
perfusion	O
-	O
cultured	O
human	O
eyes	O
led	O
to	O
the	O
generation	O
of	O
ocular	O
hypertension	O
in	O
approximately	O
30	O
%	O
of	O
the	O
dexamethasone	B-CHED
-	O
treated	O
eyes	O
.	O

Steroid	B-CHED
treatment	O
resulted	O
in	O
morphologic	O
changes	O
in	O
the	O
trabecular	O
meshwork	O
similar	O
to	O
those	O
reported	O
for	O
corticosteroid	O
glaucoma	O
and	O
open	O
angle	O
glaucoma	O
.	O

This	O
system	O
may	O
provide	O
an	O
acute	O
model	O
in	O
which	O
to	O
study	O
the	O
pathogenic	O
mechanisms	O
involved	O
in	O
steroid	O
glaucoma	O
and	O
primary	O
open	O
angle	O
glaucoma	O
.	O

Auditory	O
disturbance	O
associated	O
with	O
interscalene	O
brachial	O
plexus	O
block	O
.	O

We	O
performed	O
an	O
audiometric	O
study	O
in	O
20	O
patients	O
who	O
underwent	O
surgery	O
of	O
the	O
shoulder	O
region	O
under	O
an	O
interscalene	O
brachial	O
plexus	O
block	O
(	O
IBPB	O
)	O
.	O

Bupivacaine	B-CHED
0	O
.	O
75	O
%	O
with	O
adrenaline	B-CHED
was	O
given	O
followed	O
by	O
a	O
24	O
-	O
hr	O
continuous	O
infusion	O
of	O
0	O
.	O
25	O
%	O
bupivacaine	B-CHED
.	O

Three	O
audiometric	O
threshold	O
measurements	O
(	O
0	O
.	O
25	O
-	O
18	O
kHz	O
)	O
were	O
made	O
:	O
the	O
first	O
before	O
IBPB	O
,	O
the	O
second	O
2	O
-	O
6	O
h	O
after	O
surgery	O
and	O
the	O
third	O
on	O
the	O
first	O
day	O
after	O
operation	O
.	O

In	O
four	O
patients	O
hearing	O
impairment	O
on	O
the	O
side	O
of	O
the	O
block	O
was	O
demonstrated	O
after	O
operation	O
,	O
in	O
three	O
measurements	O
on	O
the	O
day	O
of	O
surgery	O
and	O
in	O
one	O
on	O
the	O
following	O
day	O
.	O

The	O
frequencies	O
at	O
which	O
the	O
impairment	O
occurred	O
varied	O
between	O
patients	O
;	O
in	O
one	O
only	O
low	O
frequencies	O
(	O
0	O
.	O
25	O
-	O
0	O
.	O
5	O
kHz	O
)	O
were	O
involved	O
.	O

The	O
maximum	O
change	O
in	O
threshold	O
was	O
35	O
dB	O
at	O
6	O
kHz	O
measured	O
at	O
the	O
end	O
of	O
the	O
continuous	O
infusion	O
of	O
bupivacaine	B-CHED
.	O

This	O
patient	O
had	O
hearing	O
threshold	O
changes	O
(	O
15	O
-	O
20	O
dB	O
)	O
at	O
6	O
-	O
10	O
kHz	O
on	O
the	O
opposite	O
side	O
also	O
.	O

IBPB	O
may	O
cause	O
transient	O
auditory	O
dysfunction	O
in	O
the	O
ipsilateral	O
ear	O
,	O
possibly	O
via	O
an	O
effect	O
on	O
sympathetic	O
innervation	O
.	O

The	O
safety	O
and	O
efficacy	O
of	O
combination	O
N	B-CHED
-	I-CHED
butyl	I-CHED
-	I-CHED
deoxynojirimycin	I-CHED
(	O
SC	B-CHED
-	I-CHED
48334	I-CHED
)	O
and	O
zidovudine	B-CHED
in	O
patients	O
with	O
HIV	O
-	O
1	O
infection	O
and	O
200	O
-	O
500	O
CD4	O
cells	O
/	O
mm3	O
.	O

We	O
conducted	O
a	O
double	O
-	O
blind	O
,	O
randomized	O
phase	O
II	O
study	O
to	O
evaluate	O
the	O
safety	O
and	O
activity	O
of	O
combination	O
therapy	O
with	O
N	B-CHED
-	I-CHED
butyl	I-CHED
-	I-CHED
deoxynojirimycin	I-CHED
(	O
SC	B-CHED
-	I-CHED
48334	I-CHED
)	O
(	O
an	O
alpha	O
-	O
glucosidase	O
I	O
inhibitor	O
)	O
and	O
zidovudine	B-CHED
versus	O
zidovudine	B-CHED
alone	O
.	O

Patients	O
with	O
200	O
to	O
500	O
CD4	O
cells	O
/	O
mm3	O
who	O
tolerated	O
<	O
or	O
=	O
12	O
weeks	O
of	O
prior	O
zidovudine	B-CHED
therapy	O
received	O
SC	B-CHED
-	I-CHED
48334	I-CHED
(	O
1000	O
mg	O
every	O
8	O
h	O
)	O
and	O
zidovudine	B-CHED
(	O
100	O
mg	O
every	O
8	O
h	O
)	O
or	O
zidovudine	B-CHED
and	O
placebo	O
.	O

Sixty	O
patients	O
received	O
combination	O
therapy	O
and	O
58	O
,	O
zidovudine	B-CHED
and	O
placebo	O
.	O

Twenty	O
-	O
three	O
patients	O
(	O
38	O
%	O
)	O
and	O
15	O
(	O
26	O
%	O
)	O
,	O
in	O
the	O
combination	O
and	O
zidovudine	B-CHED
groups	O
,	O
respectively	O
,	O
discontinued	O
therapy	O
(	O
p	O
=	O
0	O
.	O
15	O
)	O
.	O

The	O
mean	O
SC	B-CHED
-	I-CHED
48334	I-CHED
steady	O
-	O
state	O
trough	O
level	O
(	O
4	O
.	O
04	O
+	O
/	O
-	O
0	O
.	O
99	O
micrograms	O
/	O
ml	O
)	O
was	O
below	O
the	O
in	O
vitro	O
inhibitory	O
concentration	O
for	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
.	O

The	O
mean	O
increase	O
in	O
CD4	O
cells	O
at	O
week	O
4	O
was	O
73	O
.	O
8	O
cells	O
/	O
mm3	O
and	O
52	O
.	O
4	O
cells	O
/	O
mm3	O
for	O
the	O
combination	O
and	O
zidovudine	B-CHED
groups	O
,	O
respectively	O
(	O
p	O
>	O
0	O
.	O
36	O
)	O
.	O

For	O
patients	O
with	O
prior	O
zidovudine	B-CHED
therapy	O
,	O
the	O
mean	O
change	O
in	O
CD4	O
cells	O
in	O
the	O
combination	O
and	O
zidovudine	B-CHED
groups	O
was	O
63	O
.	O
7	O
cells	O
/	O
mm3	O
and	O
4	O
.	O
9	O
cells	O
/	O
mm3	O
at	O
week	O
8	O
and	O
6	O
.	O
8	O
cells	O
/	O
mm3	O
and	O
-	O
45	O
.	O
1	O
cells	O
/	O
mm3	O
at	O
week	O
16	O
,	O
respectively	O
.	O

The	O
number	O
of	O
patients	O
with	O
suppression	O
of	O
HIV	O
p24	O
antigenemia	O
in	O
the	O
combination	O
and	O
zidovudine	B-CHED
groups	O
was	O
six	O
(	O
40	O
%	O
)	O
and	O
two	O
(	O
11	O
%	O
)	O
at	O
week	O
4	O
(	O
p	O
=	O
0	O
.	O
10	O
)	O
and	O
five	O
(	O
45	O
%	O
)	O
and	O
two	O
(	O
14	O
%	O
)	O
at	O
week	O
24	O
(	O
p	O
=	O
0	O
.	O
08	O
)	O
,	O
respectively	O
.	O

Diarrhea	O
,	O
flatulence	O
,	O
abdominal	O
pain	O
,	O
and	O
weight	O
loss	O
were	O
common	O
for	O
combination	O
recipients	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Prolonged	O
paralysis	O
due	O
to	O
nondepolarizing	B-CHED
neuromuscular	I-CHED
blocking	I-CHED
agents	I-CHED
and	O
corticosteroids	B-CHED
.	O

The	O
long	O
-	O
term	O
use	O
of	O
nondepolarizing	B-CHED
neuromuscular	I-CHED
blocking	I-CHED
agents	I-CHED
(	O
ND	B-CHED
-	I-CHED
NMBA	I-CHED
)	O
has	O
recently	O
been	O
implicated	O
as	O
a	O
cause	O
of	O
prolonged	O
muscle	O
weakness	O
,	O
although	O
the	O
site	O
of	O
the	O
lesion	O
and	O
the	O
predisposing	O
factors	O
have	O
been	O
unclear	O
.	O

We	O
report	O
3	O
patients	O
(	O
age	O
37	O
-	O
52	O
years	O
)	O
with	O
acute	O
respiratory	O
insufficiency	O
who	O
developed	O
prolonged	O
weakness	O
following	O
the	O
discontinuation	O
of	O
ND	B-CHED
-	I-CHED
NMBAs	I-CHED
.	O

Two	O
patients	O
also	O
received	O
intravenous	O
corticosteroids	B-CHED
.	O

Renal	O
function	O
was	O
normal	O
but	O
hepatic	O
function	O
was	O
impaired	O
in	O
all	O
patients	O
,	O
and	O
all	O
had	O
acidosis	O
.	O

Electrophysiologic	O
studies	O
revealed	O
low	O
amplitude	O
compound	O
motor	O
action	O
potentials	O
,	O
normal	O
sensory	O
studies	O
,	O
and	O
fibrillations	O
.	O

Repetitive	O
stimulation	O
at	O
2	O
Hz	O
showed	O
a	O
decremental	O
response	O
in	O
2	O
patients	O
.	O

The	O
serum	O
vecuronium	B-CHED
level	O
measured	O
in	O
1	O
patient	O
14	O
days	O
after	O
the	O
drug	O
had	O
been	O
discontinued	O
was	O
172	O
ng	O
/	O
mL	O
.	O

A	O
muscle	O
biopsy	O
in	O
this	O
patient	O
showed	O
loss	O
of	O
thick	O
,	O
myosin	O
filaments	O
.	O

The	O
weakness	O
in	O
these	O
patients	O
is	O
due	O
to	O
pathology	O
at	O
both	O
the	O
neuromuscular	O
junction	O
(	O
most	O
likely	O
due	O
to	O
ND	B-CHED
-	I-CHED
NMBA	I-CHED
)	O
and	O
muscle	O
(	O
most	O
likely	O
due	O
to	O
corticosteroids	B-CHED
)	O
.	O

Hepatic	O
dysfunction	O
and	O
acidosis	O
are	O
contributing	O
risk	O
factors	O
.	O

Failure	O
of	O
ancrod	O
in	O
the	O
treatment	O
of	O
heparin	B-CHED
-	O
induced	O
arterial	O
thrombosis	O
.	O

The	O
morbidity	O
and	O
mortality	O
associated	O
with	O
heparin	B-CHED
-	O
induced	O
thrombosis	O
remain	O
high	O
despite	O
numerous	O
empirical	O
therapies	O
.	O

Ancrod	O
has	O
been	O
used	O
successfully	O
for	O
prophylaxis	O
against	O
development	O
of	O
thrombosis	O
in	O
patients	O
with	O
heparin	B-CHED
induced	O
platelet	O
aggregation	O
who	O
require	O
brief	O
reexposure	O
to	O
heparin	B-CHED
,	O
but	O
its	O
success	O
in	O
patients	O
who	O
have	O
developed	O
the	O
thrombosis	O
syndrome	O
is	O
not	O
well	O
defined	O
.	O

The	O
authors	O
present	O
a	O
case	O
of	O
failure	O
of	O
ancrod	O
treatment	O
in	O
a	O
patient	O
with	O
heparin	B-CHED
-	O
induced	O
thrombosis	O
.	O

Water	O
intoxication	O
associated	O
with	O
oxytocin	B-CHED
administration	O
during	O
saline	O
-	O
induced	O
abortion	O
.	O

Four	O
cases	O
of	O
water	O
intoxication	O
in	O
connection	O
with	O
oxytocin	B-CHED
administration	O
during	O
saline	O
-	O
induced	O
abortions	O
are	O
described	O
.	O

The	O
mechanism	O
of	O
water	O
intoxication	O
is	O
discussed	O
in	O
regard	O
to	O
these	O
cases	O
.	O

Oxytocin	B-CHED
administration	O
during	O
midtrimester	O
-	O
induced	O
abortions	O
is	O
advocated	O
only	O
if	O
it	O
can	O
be	O
carried	O
out	O
under	O
careful	O
observations	O
of	O
an	O
alert	O
nursing	O
staff	O
,	O
aware	O
of	O
the	O
symptoms	O
of	O
water	O
intoxication	O
and	O
instructed	O
to	O
watch	O
the	O
diuresis	O
and	O
report	O
such	O
early	O
signs	O
of	O
the	O
syndrome	O
as	O
asthenia	O
,	O
muscular	O
irritability	O
,	O
or	O
headaches	O
.	O

The	O
oxytocin	B-CHED
should	O
be	O
given	O
only	O
in	O
Ringers	O
lactate	B-CHED
or	O
,	O
alternately	O
,	O
in	O
Ringers	O
lactate	B-CHED
and	O
a	O
5	O
per	O
cent	O
dextrose	B-CHED
and	O
water	O
solutions	O
.	O

The	O
urinary	O
output	O
should	O
be	O
monitored	O
and	O
the	O
oxytocin	B-CHED
administration	O
discontinued	O
and	O
the	O
serum	O
electrolytes	O
checked	O
if	O
the	O
urinary	O
output	O
decreases	O
.	O

The	O
oxytocin	B-CHED
should	O
not	O
be	O
administered	O
in	O
excess	O
of	O
36	O
hours	O
.	O

If	O
the	O
patient	O
has	O
not	O
aborted	O
by	O
then	O
the	O
oxytocin	B-CHED
should	O
be	O
discontinued	O
for	O
10	O
to	O
12	O
hours	O
in	O
order	O
to	O
perform	O
electrolyte	O
determinations	O
and	O
correct	O
any	O
electrolyte	O
imbalance	O
.	O

Light	O
chain	O
proteinuria	O
and	O
cellular	O
mediated	O
immunity	O
in	O
rifampin	B-CHED
treated	O
patients	O
with	O
tuberculosis	O
.	O

Light	O
chain	O
proteinuria	O
was	O
found	O
in	O
9	O
of	O
17	O
tuberculosis	O
patients	O
treated	O
with	O
rifampin	B-CHED
.	O

Concomitant	O
assay	O
of	O
cellular	O
mediated	O
immunity	O
in	O
these	O
patients	O
using	O
skin	O
test	O
antigen	O
and	O
a	O
lymphokine	O
in	O
vitro	O
test	O
provided	O
results	O
that	O
were	O
different	O
.	O

Response	O
to	O
Varidase	O
skin	O
test	O
antigen	O
was	O
negative	O
for	O
all	O
eight	O
tuberculosis	O
patients	O
tested	O
,	O
but	O
there	O
occurred	O
a	O
hyper	O
-	O
responsiveness	O
of	O
the	O
lymphocytes	O
of	O
these	O
eight	O
patients	O
to	O
phytomitogen	O
(	O
PHA	O
-	O
P	O
)	O
.	O
as	O
well	O
as	O
of	O
those	O
of	O
seven	O
other	O
tuberculous	O
patients	O
.	O

This	O
last	O
finding	O
may	O
be	O
related	O
to	O
time	O
of	O
testing	O
and	O
/	O
or	O
endogenous	O
serum	O
binding	O
of	O
rifampin	B-CHED
which	O
could	O
have	O
inhibited	O
mitogen	O
activity	O
for	O
the	O
lymphocyte	O
.	O

KF17837	B-CHED
:	O
a	O
novel	O
selective	O
adenosine	B-CHED
A2A	O
receptor	O
antagonist	O
with	O
anticataleptic	O
activity	O
.	O

KF17837	B-CHED
is	O
a	O
novel	O
selective	O
adenosine	B-CHED
A2A	O
receptor	O
antagonist	O
.	O

Oral	O
administration	O
of	O
KF17837	B-CHED
(	O
2	O
.	O
5	O
,	O
10	O
.	O
0	O
and	O
30	O
.	O
0	O
mg	O
/	O
kg	O
)	O
significantly	O
ameliorated	O
the	O
cataleptic	O
responses	O
induced	O
by	O
intracerebroventricular	O
administration	O
of	O
an	O
adenosine	B-CHED
A2A	O
receptor	O
agonist	O
,	O
CGS	B-CHED
21680	I-CHED
(	O
10	O
micrograms	O
)	O
,	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

KF17837	B-CHED
also	O
reduced	O
the	O
catalepsy	O
induced	O
by	O
haloperidol	B-CHED
(	O
1	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
and	O
by	O
reserpine	B-CHED
(	O
5	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
.	O

These	O
anticataleptic	O
effects	O
were	O
exhibited	O
dose	O
dependently	O
at	O
doses	O
from	O
0	O
.	O
625	O
and	O
2	O
.	O
5	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O
,	O
respectively	O
.	O

Moreover	O
,	O
KF17837	B-CHED
(	O
0	O
.	O
625	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O
)	O
potentiated	O
the	O
anticataleptic	O
effects	O
of	O
a	O
subthreshold	O
dose	O
of	O
L	B-CHED
-	I-CHED
3	I-CHED
,	I-CHED
4	I-CHED
-	I-CHED
dihydroxyphenylalanine	I-CHED
(	O
L	B-CHED
-	I-CHED
DOPA	I-CHED
;	O
25	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
plus	O
benserazide	B-CHED
(	O
6	O
.	O
25	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
.	O

These	O
results	O
suggested	O
that	O
KF17837	B-CHED
is	O
a	O
centrally	O
active	O
adenosine	B-CHED
A2A	O
receptor	O
antagonist	O
and	O
that	O
the	O
dopaminergic	O
function	O
of	O
the	O
nigrostriatal	O
pathway	O
is	O
potentiated	O
by	O
adenosine	B-CHED
A2A	O
receptor	O
antagonists	O
.	O

Furthermore	O
,	O
KF17837	B-CHED
may	O
be	O
a	O
useful	O
drug	O
in	O
the	O
treatment	O
of	O
parkinsonism	O
.	O

Effect	O
of	O
nondopaminergic	O
drugs	O
on	O
L	B-CHED
-	I-CHED
dopa	I-CHED
-	O
induced	O
dyskinesias	O
in	O
MPTP	B-CHED
-	O
treated	O
monkeys	O
.	O

A	O
group	O
of	O
four	O
monkeys	O
was	O
rendered	O
parkinsonian	O
with	O
the	O
toxin	O
MPTP	B-CHED
.	O

They	O
were	O
then	O
treated	O
chronically	O
with	O
L	B-CHED
-	I-CHED
DOPA	I-CHED
/	I-CHED
benserazide	I-CHED
50	O
/	O
12	O
.	O
5	O
mg	O
/	O
kg	O
given	O
orally	O
daily	O
for	O
2	O
months	O
.	O

This	O
dose	O
produced	O
a	O
striking	O
antiparkinsonian	O
effect	O
,	O
but	O
all	O
animals	O
manifested	O
dyskinesia	O
.	O

A	O
series	O
of	O
agents	O
acting	O
primarily	O
on	O
neurotransmitters	O
other	O
than	O
dopamine	B-CHED
were	O
then	O
tested	O
in	O
combination	O
with	O
L	B-CHED
-	I-CHED
DOPA	I-CHED
to	O
see	O
if	O
the	O
dyskinetic	O
movements	O
would	O
be	O
modified	O
.	O

Several	O
drugs	O
,	O
including	O
clonidine	B-CHED
,	O
physostigmine	B-CHED
,	O
methysergide	B-CHED
,	O
5	B-CHED
-	I-CHED
MDOT	I-CHED
,	O
propranolol	B-CHED
,	O
and	O
MK	B-CHED
-	I-CHED
801	I-CHED
,	O
markedly	O
reduced	O
the	O
dyskinetic	O
movements	O
but	O
at	O
the	O
cost	O
of	O
a	O
return	O
of	O
parkinsonian	O
symptomatology	O
.	O

However	O
,	O
yohimbine	B-CHED
and	O
meperidine	B-CHED
reduced	O
predominantly	O
the	O
dyskinetic	O
movements	O
.	O

Baclofen	B-CHED
was	O
also	O
useful	O
in	O
one	O
monkey	O
against	O
a	O
more	O
dystonic	O
form	O
of	O
dyskinesia	O
.	O

Atropine	B-CHED
converted	O
the	O
dystonic	O
movements	O
into	O
chorea	O
.	O

Hallucinations	O
and	O
ifosfamide	B-CHED
-	O
induced	O
neurotoxicity	O
.	O

BACKGROUND	O
:	O
Hallucinations	O
as	O
a	O
symptom	O
of	O
central	O
neurotoxicity	O
are	O
a	O
known	O
but	O
poorly	O
described	O
side	O
effect	O
of	O
ifosfamide	B-CHED
.	O

Most	O
cases	O
of	O
ifosfamide	B-CHED
-	O
induced	O
hallucinations	O
have	O
been	O
reported	O
with	O
other	O
mental	O
status	O
changes	O
.	O

METHODS	O
:	O
The	O
authors	O
interviewed	O
six	O
persons	O
with	O
ifosfamide	B-CHED
-	O
induced	O
hallucinations	O
in	O
the	O
presence	O
of	O
a	O
clear	O
sensorium	O
.	O

All	O
patients	O
were	O
receiving	O
high	O
-	O
dose	O
ifosfamide	B-CHED
as	O
part	O
of	O
their	O
bone	O
marrow	O
transplant	O
procedure	O
.	O

RESULTS	O
:	O
Hallucinations	O
occurred	O
only	O
when	O
the	O
patient	O
'	O
s	O
eyes	O
were	O
closed	O
and	O
,	O
in	O
all	O
but	O
one	O
case	O
,	O
were	O
reported	O
as	O
disturbing	O
or	O
frightening	O
.	O

Underreporting	O
of	O
these	O
hallucinations	O
by	O
patients	O
is	O
likely	O
.	O

CONCLUSIONS	O
:	O
Hallucinations	O
may	O
be	O
the	O
sole	O
or	O
first	O
manifestation	O
of	O
neurotoxicity	O
.	O

The	O
incidence	O
may	O
be	O
dose	O
and	O
infusion	O
-	O
time	O
related	O
.	O

The	O
clinician	O
should	O
be	O
alerted	O
for	O
possible	O
ifosfamide	B-CHED
-	O
induced	O
hallucinations	O
,	O
which	O
may	O
occur	O
without	O
other	O
signs	O
of	O
neurotoxicity	O
.	O

"	O
Eyes	O
-	O
closed	O
"	O
hallucinatory	O
experiences	O
appear	O
to	O
be	O
an	O
unusual	O
feature	O
of	O
this	O
presentation	O
.	O

Patients	O
anxious	O
about	O
this	O
experience	O
respond	O
well	O
to	O
support	O
and	O
education	O
about	O
this	O
occurrence	O
.	O

Optimal	O
pharmacologic	O
management	O
of	O
disturbed	O
patients	O
is	O
unclear	O
.	O

If	O
agitation	O
becomes	O
marked	O
,	O
high	O
-	O
potency	O
neuroleptics	O
(	O
i	O
.	O
e	O
.	O
,	O
haloperidol	B-CHED
)	O
may	O
be	O
effective	O
.	O

Photodistributed	O
nifedipine	B-CHED
-	O
induced	O
facial	O
telangiectasia	O
.	O

Five	O
months	O
after	O
starting	O
nifedipine	B-CHED
(	O
Adalat	B-CHED
)	O
,	O
two	O
patients	O
developed	O
photodistributed	O
facial	O
telangiectasia	O
,	O
which	O
became	O
more	O
noticeable	O
with	O
time	O
.	O

Neither	O
patient	O
complained	O
of	O
photosensitivity	O
or	O
flushing	O
.	O

Both	O
patients	O
reported	O
a	O
significant	O
cosmetic	O
improvement	O
after	O
discontinuing	O
the	O
drug	O
.	O

One	O
commenced	O
the	O
closely	O
related	O
drug	O
amlodipine	B-CHED
3	O
years	O
later	O
,	O
with	O
recurrence	O
of	O
telangiectasia	O
.	O

The	O
photodistribution	O
of	O
the	O
telangiectasia	O
suggests	O
a	O
significant	O
drug	O
/	O
light	O
interaction	O
.	O

Penicillamine	B-CHED
-	O
induced	O
rapidly	O
progressive	O
glomerulonephritis	O
in	O
a	O
patient	O
with	O
rheumatoid	O
arthritis	O
.	O

A	O
67	O
-	O
year	O
-	O
old	O
woman	O
with	O
rheumatoid	O
arthritis	O
presented	O
rapidly	O
progressive	O
glomerulonephritis	O
(	O
RPGN	O
)	O
after	O
5	O
months	O
of	O
D	B-CHED
-	I-CHED
penicillamine	I-CHED
(	O
250	O
mg	O
/	O
day	O
)	O
treatment	O
.	O

Light	O
microscopy	O
study	O
showed	O
severe	O
glomerulonephritis	O
with	O
crescent	O
formation	O
in	O
60	O
%	O
of	O
the	O
glomeruli	O
and	O
infiltration	O
of	O
inflammatory	O
cells	O
in	O
the	O
wall	O
of	O
an	O
arteriole	O
.	O

Immunofluorescence	O
revealed	O
scanty	O
granular	O
IgG	O
,	O
IgA	O
and	O
C3	O
deposits	O
along	O
the	O
capillary	O
walls	O
and	O
mesangium	O
.	O

The	O
patient	O
was	O
treated	O
with	O
steroid	B-CHED
pulse	O
,	O
plasmapheresis	O
,	O
cyclophosphamide	B-CHED
and	O
antiplatelet	B-CHED
agents	I-CHED
.	O

A	O
complete	O
recovery	O
of	O
renal	O
function	O
was	O
achieved	O
in	O
a	O
few	O
weeks	O
.	O

This	O
new	O
case	O
of	O
RPGN	O
in	O
the	O
course	O
of	O
D	B-CHED
-	I-CHED
penicillamine	I-CHED
treatment	O
emphasizes	O
the	O
need	O
for	O
frequent	O
monitoring	O
of	O
renal	O
function	O
and	O
evaluation	O
of	O
urinary	O
sediment	O
and	O
proteinuria	O
in	O
these	O
patients	O
.	O

The	O
prompt	O
discontinuation	O
of	O
D	B-CHED
-	I-CHED
penicillamine	I-CHED
and	O
vigorous	O
treatment	O
measures	O
could	O
allow	O
for	O
a	O
good	O
prognosis	O
as	O
in	O
this	O
case	O
.	O

A	O
case	O
of	O
polymyositis	O
in	O
a	O
patient	O
with	O
primary	O
biliary	O
cirrhosis	O
treated	O
with	O
D	B-CHED
-	I-CHED
penicillamine	I-CHED
.	O

Although	O
D	B-CHED
-	I-CHED
penicillamine	I-CHED
has	O
been	O
used	O
for	O
many	O
rheumatologic	O
diseases	O
,	O
toxicity	O
limits	O
its	O
usefulness	O
in	O
many	O
patients	O
.	O

Polymyositis	O
/	O
dermatomyositis	O
can	O
develop	O
as	O
one	O
of	O
the	O
autoimmune	O
complications	O
of	O
D	B-CHED
-	I-CHED
penicillamine	I-CHED
treatment	O
,	O
but	O
its	O
exact	O
pathogenesis	O
remains	O
unclear	O
.	O

We	O
report	O
a	O
patient	O
with	O
primary	O
biliary	O
cirrhosis	O
,	O
who	O
developed	O
polymyositis	O
while	O
receiving	O
D	B-CHED
-	I-CHED
penicillamine	I-CHED
therapy	O
.	O

We	O
described	O
the	O
special	O
clinical	O
course	O
of	O
the	O
patient	O
.	O

Patients	O
receiving	O
D	B-CHED
-	I-CHED
penicillamine	I-CHED
therapy	O
should	O
be	O
followed	O
carefully	O
for	O
the	O
development	O
of	O
autoimmune	O
complications	O
like	O
polymyositis	O
/	O
dermatomyositis	O
.	O

Hyperalgesia	O
and	O
myoclonus	O
in	O
terminal	O
cancer	O
patients	O
treated	O
with	O
continuous	O
intravenous	O
morphine	B-CHED
.	O

Eight	O
cancer	O
patients	O
in	O
the	O
terminal	O
stages	O
of	O
the	O
disease	O
treated	O
with	O
high	O
doses	O
of	O
intravenous	O
morphine	B-CHED
developed	O
hyperalgesia	O
.	O

All	O
cases	O
were	O
retrospectively	O
sampled	O
from	O
three	O
different	O
hospitals	O
in	O
Copenhagen	O
.	O

Five	O
patients	O
developed	O
universal	O
hyperalgesia	O
and	O
hyperesthesia	O
which	O
in	O
2	O
cases	O
were	O
accompanied	O
by	O
myoclonus	O
.	O

In	O
3	O
patients	O
a	O
pre	O
-	O
existing	O
neuralgia	O
increased	O
to	O
excruciating	O
intensity	O
and	O
in	O
2	O
of	O
these	O
cases	O
myoclonus	O
occurred	O
simultaneously	O
.	O

Although	O
only	O
few	O
clinical	O
descriptions	O
of	O
the	O
relationship	O
between	O
hyperalgesia	O
/	O
myoclonus	O
and	O
high	O
doses	O
of	O
morphine	B-CHED
are	O
available	O
,	O
experimental	O
support	O
from	O
animal	O
studies	O
indicates	O
that	O
morphine	B-CHED
,	O
or	O
its	O
metabolites	O
,	O
plays	O
a	O
causative	O
role	O
for	O
the	O
observed	O
behavioural	O
syndrome	O
.	O

The	O
possible	O
mechanisms	O
are	O
discussed	O
and	O
treatment	O
proposals	O
given	O
suggesting	O
the	O
use	O
of	O
more	O
efficacious	O
opioids	O
with	O
less	O
excitatory	O
potency	O
in	O
these	O
situations	O
.	O

Liposomal	O
daunorubicin	B-CHED
in	O
advanced	O
Kaposi	O
'	O
s	O
sarcoma	O
:	O
a	O
phase	O
II	O
study	O
.	O

We	O
report	O
a	O
non	O
-	O
randomized	O
Phase	O
II	O
clinical	O
trial	O
to	O
assess	O
the	O
efficacy	O
and	O
safety	O
of	O
liposomal	O
daunorubicin	B-CHED
(	O
DaunoXome	O
)	O
in	O
the	O
treatment	O
of	O
AIDS	O
related	O
Kaposi	O
'	O
s	O
sarcoma	O
.	O

Eleven	O
homosexual	O
men	O
with	O
advanced	O
Kaposi	O
'	O
s	O
sarcoma	O
were	O
entered	O
in	O
the	O
trial	O
.	O

Changes	O
in	O
size	O
,	O
colour	O
and	O
associated	O
oedema	O
of	O
selected	O
'	O
target	O
'	O
lesions	O
were	O
measured	O
.	O

Clinical	O
,	O
biochemical	O
and	O
haematological	O
toxicities	O
were	O
assessed	O
.	O

Ten	O
subjects	O
were	O
evaluated	O
.	O

A	O
partial	O
response	O
was	O
achieved	O
in	O
four	O
,	O
of	O
whom	O
two	O
subsequently	O
relapsed	O
.	O

Stabilization	O
of	O
Kaposi	O
'	O
s	O
sarcoma	O
occurred	O
in	O
the	O
remaining	O
six	O
,	O
maintained	O
until	O
the	O
end	O
of	O
the	O
trial	O
period	O
in	O
four	O
.	O

The	O
drug	O
was	O
generally	O
well	O
tolerated	O
,	O
with	O
few	O
mild	O
symptoms	O
of	O
toxicity	O
.	O

The	O
main	O
problem	O
encountered	O
was	O
haematological	O
toxicity	O
,	O
with	O
three	O
subjects	O
experiencing	O
severe	O
neutropenia	O
(	O
neutrophil	O
count	O
<	O
0	O
.	O
5	O
x	O
10	O
(	O
9	O
)	O
/	O
l	O
)	O
.	O

There	O
was	O
no	O
evidence	O
of	O
cardiotoxicity	O
.	O

In	O
this	O
small	O
patient	O
sample	O
,	O
liposomal	O
daunorubicin	B-CHED
was	O
an	O
effective	O
and	O
well	O
tolerated	O
agent	O
in	O
the	O
treatment	O
of	O
Kaposi	O
'	O
s	O
sarcoma	O
.	O

Long	O
-	O
term	O
effects	O
of	O
vincristine	B-CHED
on	O
the	O
peripheral	O
nervous	O
system	O
.	O

Forty	O
patients	O
with	O
Non	O
-	O
Hodgkin	O
'	O
s	O
Lymphoma	O
treated	O
with	O
vincristine	B-CHED
between	O
1984	O
and	O
1990	O
(	O
cumulative	O
dose	O
12	O
mg	O
in	O
18	O
-	O
24	O
weeks	O
)	O
were	O
investigated	O
in	O
order	O
to	O
evaluate	O
the	O
long	O
term	O
effects	O
of	O
vincristine	B-CHED
on	O
the	O
peripheral	O
nervous	O
system	O
.	O

The	O
patients	O
were	O
interviewed	O
with	O
emphasis	O
on	O
neuropathic	O
symptoms	O
.	O

Physical	O
and	O
quantitative	O
sensory	O
examination	O
with	O
determination	O
of	O
vibratory	O
perception	O
and	O
thermal	O
discrimination	O
thresholds	O
were	O
performed	O
,	O
four	O
to	O
77	O
months	O
(	O
median	O
34	O
months	O
)	O
after	O
vincristine	B-CHED
treatment	O
.	O

Twenty	O
-	O
seven	O
patients	O
reported	O
neuropathic	O
symptoms	O
.	O

In	O
13	O
of	O
these	O
27	O
patients	O
symptoms	O
were	O
still	O
present	O
at	O
the	O
time	O
of	O
examination	O
.	O

In	O
these	O
patients	O
sensory	O
signs	O
and	O
symptoms	O
predominated	O
.	O

In	O
the	O
other	O
14	O
patients	O
symptoms	O
had	O
been	O
present	O
in	O
the	O
past	O
.	O

Symptoms	O
persisted	O
maximally	O
40	O
months	O
since	O
cessation	O
of	O
therapy	O
.	O

There	O
was	O
no	O
age	O
difference	O
between	O
patients	O
with	O
and	O
without	O
complaints	O
at	O
the	O
time	O
of	O
examination	O
.	O

Normal	O
reflexes	O
were	O
found	O
in	O
two	O
third	O
of	O
patients	O
.	O

Neuropathic	O
complaints	O
were	O
not	O
very	O
troublesome	O
on	O
the	O
long	O
term	O
.	O

It	O
is	O
concluded	O
that	O
with	O
the	O
above	O
mentioned	O
vincristine	B-CHED
dose	O
schedule	O
signs	O
and	O
symptoms	O
of	O
vincristine	B-CHED
neuropathy	O
are	O
reversible	O
for	O
a	O
great	O
deal	O
and	O
prognosis	O
is	O
fairly	O
good	O
.	O

Hepatic	O
adenomas	O
and	O
focal	O
nodular	O
hyperplasia	O
of	O
the	O
liver	O
in	O
young	O
women	O
on	O
oral	B-CHED
contraceptives	I-CHED
:	O
case	O
reports	O
.	O

Two	O
cases	O
of	O
hepatic	O
adenoma	O
and	O
one	O
of	O
focal	O
nodular	O
hyperplasia	O
presumably	O
associated	O
with	O
the	O
use	O
of	O
oral	B-CHED
contraceptives	I-CHED
,	O
are	O
reported	O
.	O

Special	O
reference	O
is	O
made	O
to	O
their	O
clinical	O
presentation	O
,	O
which	O
may	O
be	O
totally	O
asymptomatic	O
.	O

Liver	O
-	O
function	O
tests	O
are	O
of	O
little	O
diagnostic	O
value	O
,	O
but	O
valuable	O
information	O
may	O
be	O
obtained	O
from	O
both	O
liver	O
scanning	O
and	O
hepatic	O
angiography	O
.	O

Histologic	O
differences	O
and	O
clinical	O
similarities	O
between	O
hepatic	O
adenoma	O
and	O
focal	O
nodular	O
hyperplasia	O
of	O
the	O
liver	O
are	O
discussed	O
.	O

Loss	O
of	O
glutamate	B-CHED
decarboxylase	O
mRNA	O
-	O
containing	O
neurons	O
in	O
the	O
rat	O
dentate	O
gyrus	O
following	O
pilocarpine	B-CHED
-	O
induced	O
seizures	O
.	O

In	O
situ	O
hybridization	O
methods	O
were	O
used	O
to	O
determine	O
if	O
glutamic	B-CHED
acid	I-CHED
decarboxylase	O
(	O
GAD	O
)	O
mRNA	O
-	O
containing	O
neurons	O
within	O
the	O
hilus	O
of	O
the	O
dentate	O
gyrus	O
are	O
vulnerable	O
to	O
seizure	O
-	O
induced	O
damage	O
in	O
a	O
model	O
of	O
chronic	O
seizures	O
.	O

Sprague	O
-	O
Dawley	O
rats	O
were	O
injected	O
intraperitoneally	O
with	O
pilocarpine	B-CHED
,	O
and	O
the	O
hippocampal	O
formation	O
was	O
studied	O
histologically	O
at	O
1	O
,	O
2	O
,	O
4	O
,	O
and	O
8	O
week	O
intervals	O
after	O
pilocarpine	B-CHED
-	O
induced	O
seizures	O
.	O

In	O
situ	O
hybridization	O
histochemistry	O
,	O
using	O
a	O
digoxigenin	B-CHED
-	O
labeled	O
GAD	O
cRNA	O
probe	O
,	O
demonstrated	O
a	O
substantial	O
decrease	O
in	O
the	O
number	O
of	O
GAD	O
mRNA	O
-	O
containing	O
neurons	O
in	O
the	O
hilus	O
of	O
the	O
dentate	O
gyrus	O
in	O
the	O
pilocarpine	B-CHED
-	O
treated	O
rats	O
as	O
compared	O
to	O
controls	O
at	O
all	O
time	O
intervals	O
.	O

Additional	O
neuronanatomical	O
studies	O
,	O
including	O
cresyl	B-CHED
violet	I-CHED
staining	O
,	O
neuronal	O
degeneration	O
methods	O
,	O
and	O
histochemical	O
localization	O
of	O
glial	O
fibrillary	O
acidic	O
protein	O
,	O
suggested	O
that	O
the	O
decrease	O
in	O
the	O
number	O
of	O
GAD	O
mRNA	O
-	O
containing	O
neurons	O
was	O
related	O
to	O
neuronal	O
loss	O
rather	O
than	O
to	O
a	O
decrease	O
in	O
GAD	O
mRNA	O
levels	O
.	O

The	O
loss	O
of	O
GAD	O
mRNA	O
-	O
containing	O
neurons	O
in	O
the	O
hilus	O
contrasted	O
with	O
the	O
relative	O
preservation	O
of	O
labeled	O
putative	O
basket	O
cells	O
along	O
the	O
inner	O
margin	O
of	O
the	O
granule	O
cell	O
layer	O
.	O

Quantitative	O
analyses	O
of	O
labeled	O
neurons	O
in	O
three	O
regions	O
of	O
the	O
dentate	O
gyrus	O
in	O
the	O
1	O
and	O
2	O
week	O
groups	O
showed	O
statistically	O
significant	O
decreases	O
in	O
the	O
mean	O
number	O
of	O
GAD	O
mRNA	O
-	O
containing	O
neurons	O
in	O
the	O
hilus	O
of	O
both	O
groups	O
of	O
experimental	O
animals	O
.	O

No	O
significant	O
differences	O
were	O
found	O
in	O
the	O
molecular	O
layer	O
or	O
the	O
granule	O
cell	O
layer	O
,	O
which	O
included	O
labeled	O
neurons	O
along	O
the	O
lower	O
margin	O
of	O
the	O
granule	O
cell	O
layer	O
.	O

The	O
results	O
indicate	O
that	O
,	O
in	O
this	O
model	O
,	O
a	O
subpopulation	O
of	O
GAD	O
mRNA	O
-	O
containing	O
neurons	O
within	O
the	O
dentate	O
gyrus	O
is	O
selectively	O
vulnerable	O
to	O
seizure	O
-	O
induced	O
damage	O
.	O

Such	O
differential	O
vulnerability	O
appears	O
to	O
be	O
another	O
indication	O
of	O
the	O
heterogeneity	O
of	O
GABA	B-CHED
neurons	O
.	O

Effects	O
of	O
deliberate	O
hypotension	O
induced	O
by	O
labetalol	B-CHED
with	O
isoflurane	B-CHED
on	O
neuropsychological	O
function	O
.	O

The	O
effect	O
of	O
deliberate	O
hypotension	O
on	O
brain	O
function	O
measured	O
by	O
neuropsychological	O
tests	O
was	O
studied	O
in	O
41	O
adult	O
patients	O
.	O

Twenty	O
-	O
four	O
patients	O
were	O
anaesthetized	O
for	O
middle	O
-	O
ear	O
surgery	O
with	O
deliberate	O
hypotension	O
induced	O
by	O
labetalol	B-CHED
with	O
isoflurane	B-CHED
(	O
hypotensive	O
group	O
)	O
.	O

Seventeen	O
patients	O
without	O
hypotension	O
served	O
as	O
a	O
control	O
group	O
.	O

The	O
mean	O
arterial	O
pressure	O
was	O
77	O
+	O
/	O
-	O
2	O
mmHg	O
(	O
10	O
.	O
3	O
+	O
/	O
-	O
0	O
.	O
3	O
kPa	O
)	O
before	O
hypotension	O
and	O
50	O
+	O
/	O
-	O
0	O
mmHg	O
(	O
6	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
0	O
kPa	O
)	O
during	O
hypotension	O
in	O
the	O
hypotensive	O
group	O
,	O
and	O
86	O
+	O
/	O
-	O
2	O
mmHg	O
(	O
11	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
3	O
kPa	O
)	O
during	O
anaesthesia	O
in	O
the	O
control	O
group	O
.	O

The	O
following	O
psychological	O
tests	O
were	O
performed	O
:	O
four	O
subtests	O
of	O
the	O
Wechsler	O
Adult	O
Intelligence	O
Scale	O
(	O
similarities	O
,	O
digit	O
span	O
,	O
vocabulary	O
and	O
digit	O
symbol	O
)	O
,	O
Trail	O
-	O
Making	O
tests	O
A	O
and	O
B	O
,	O
Zung	O
tests	O
(	O
self	O
-	O
rating	O
anxiety	O
scale	O
and	O
self	O
-	O
rating	O
depression	O
scale	O
)	O
and	O
two	O
-	O
part	O
memory	O
test	O
battery	O
with	O
immediate	O
and	O
delayed	O
recall	O
.	O

The	O
tests	O
were	O
performed	O
preoperatively	O
and	O
2	O
days	O
postoperatively	O
.	O

There	O
were	O
no	O
statistically	O
significant	O
differences	O
between	O
the	O
groups	O
in	O
any	O
of	O
the	O
tests	O
in	O
the	O
changes	O
from	O
preoperative	O
value	O
to	O
postoperative	O
value	O
.	O

The	O
results	O
indicate	O
that	O
hypotension	O
induced	O
by	O
labetalol	B-CHED
with	O
isoflurane	B-CHED
has	O
no	O
significant	O
harmful	O
effects	O
on	O
mental	O
functions	O
compared	O
to	O
normotensive	O
anaesthesia	O
.	O

Apparent	O
cure	O
of	O
rheumatoid	O
arthritis	O
by	O
bone	O
marrow	O
transplantation	O
.	O

We	O
describe	O
the	O
induction	O
of	O
sustained	O
remissions	O
and	O
possible	O
cure	O
of	O
severe	O
erosive	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
by	O
bone	O
marrow	O
transplantation	O
(	O
BMT	O
)	O
in	O
2	O
patients	O
.	O

BMT	O
was	O
used	O
to	O
treat	O
severe	O
aplastic	O
anemia	O
which	O
was	O
caused	O
by	O
gold	B-CHED
in	O
one	O
case	O
and	O
D	B-CHED
-	I-CHED
penicillamine	I-CHED
in	O
the	O
other	O
.	O

In	O
the	O
8	O
and	O
6	O
years	O
since	O
the	O
transplants	O
(	O
representing	O
8	O
and	O
4	O
years	O
since	O
cessation	O
of	O
all	O
immunosuppressive	O
therapy	O
,	O
respectively	O
)	O
,	O
the	O
RA	O
in	O
each	O
case	O
has	O
been	O
completely	O
quiescent	O
.	O

Although	O
short	O
term	O
remission	O
of	O
severe	O
RA	O
following	O
BMT	O
has	O
been	O
reported	O
,	O
these	O
are	O
the	O
first	O
cases	O
for	O
which	O
prolonged	O
followup	O
has	O
been	O
available	O
.	O

This	O
experience	O
raises	O
the	O
question	O
of	O
the	O
role	O
of	O
BMT	O
itself	O
as	O
a	O
therapeutic	O
option	O
for	O
patients	O
with	O
uncontrolled	O
destructive	O
synovitis	O
.	O

Seizures	O
induced	O
by	O
combined	O
levomepromazine	B-CHED
-	O
fluvoxamine	B-CHED
treatment	O
.	O

We	O
report	O
a	O
case	O
of	O
combined	O
levomepromazine	B-CHED
-	O
fluvoxamine	B-CHED
treatment	O
-	O
induced	O
seizures	O
.	O

It	O
seems	O
that	O
combined	O
treatment	O
of	O
fluvoxamine	B-CHED
with	O
phenothiazines	B-CHED
may	O
possess	O
proconvulsive	O
activity	O
.	O

Case	O
report	O
:	O
pentamidine	B-CHED
and	O
polymorphic	O
ventricular	O
tachycardia	O
revisited	O
.	O

Pentamidine	B-CHED
isethionate	I-CHED
has	O
been	O
associated	O
with	O
ventricular	O
tachyarrhythmias	O
,	O
including	O
torsade	O
de	O
pointes	O
.	O

This	O
article	O
reports	O
two	O
cases	O
of	O
this	O
complication	O
and	O
reviews	O
all	O
reported	O
cases	O
to	O
date	O
.	O

Pentamidine	B-CHED
-	O
induced	O
torsade	O
de	O
pointes	O
may	O
be	O
related	O
to	O
serum	O
magnesium	B-CHED
levels	O
and	O
hypomagnesemia	O
may	O
synergistically	O
induce	O
torsade	O
.	O

Torsade	O
de	O
pointes	O
occurred	O
after	O
an	O
average	O
of	O
10	O
days	O
of	O
treatment	O
with	O
pentamidine	B-CHED
.	O

In	O
these	O
patients	O
,	O
no	O
other	O
acute	O
side	O
effects	O
of	O
pentamidine	B-CHED
were	O
observed	O
.	O

Torsade	O
de	O
pointes	O
can	O
be	O
treated	O
when	O
recognized	O
early	O
,	O
possibly	O
without	O
discontinuation	O
of	O
pentamidine	B-CHED
.	O

When	O
QTc	O
interval	O
prolongation	O
is	O
observed	O
,	O
early	O
magnesium	B-CHED
supplementation	O
is	O
advocated	O
.	O

Efficacy	O
and	O
tolerability	O
of	O
lovastatin	B-CHED
in	O
3390	O
women	O
with	O
moderate	O
hypercholesterolemia	O
.	O

OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
lovastatin	B-CHED
in	O
women	O
with	O
moderate	O
hypercholesterolemia	O
.	O

DESIGN	O
:	O
The	O
Expanded	O
Clinical	O
Evaluation	O
of	O
Lovastatin	B-CHED
(	O
EXCEL	O
)	O
Study	O
,	O
a	O
multicenter	O
,	O
double	O
-	O
blind	O
,	O
diet	O
-	O
and	O
placebo	O
-	O
controlled	O
trial	O
,	O
in	O
which	O
participants	O
were	O
randomly	O
assigned	O
to	O
receive	O
placebo	O
or	O
lovastatin	B-CHED
at	O
doses	O
of	O
20	O
or	O
40	O
mg	O
once	O
daily	O
,	O
or	O
20	O
or	O
40	O
mg	O
twice	O
daily	O
for	O
48	O
weeks	O
.	O

SETTING	O
:	O
Ambulatory	O
patients	O
recruited	O
by	O
362	O
participating	O
centers	O
throughout	O
the	O
United	O
States	O
.	O

PATIENTS	O
:	O
Women	O
(	O
n	O
=	O
3390	O
)	O
from	O
the	O
total	O
cohort	O
of	O
8245	O
volunteers	O
.	O

MEASUREMENTS	O
:	O
Plasma	O
total	O
,	O
low	O
-	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
,	O
and	O
high	O
-	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
cholesterol	B-CHED
,	O
and	O
triglycerides	B-CHED
;	O
and	O
laboratory	O
and	O
clinical	O
evidence	O
of	O
adverse	O
events	O
monitored	O
periodically	O
throughout	O
the	O
study	O
.	O

RESULTS	O
:	O
Among	O
women	O
,	O
lovastatin	B-CHED
(	O
20	O
to	O
80	O
mg	O
/	O
d	O
)	O
produced	O
sustained	O
(	O
12	O
-	O
to	O
48	O
-	O
week	O
)	O
,	O
dose	O
-	O
related	O
changes	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
:	O
decreases	O
in	O
LDL	O
cholesterol	B-CHED
(	O
24	O
%	O
to	O
40	O
%	O
)	O
and	O
triglycerides	B-CHED
(	O
9	O
%	O
to	O
18	O
%	O
)	O
,	O
and	O
increases	O
in	O
HDL	O
cholesterol	B-CHED
(	O
6	O
.	O
7	O
%	O
to	O
8	O
.	O
6	O
%	O
)	O
.	O

Depending	O
on	O
the	O
dose	O
,	O
from	O
82	O
%	O
to	O
95	O
%	O
of	O
lovastatin	B-CHED
-	O
treated	O
women	O
achieved	O
the	O
National	O
Cholesterol	B-CHED
Education	O
Program	O
goal	O
of	O
LDL	O
cholesterol	B-CHED
levels	O
less	O
than	O
4	O
.	O
14	O
mmol	O
/	O
L	O
(	O
160	O
mg	O
/	O
dL	O
)	O
,	O
and	O
40	O
%	O
to	O
87	O
%	O
achieved	O
the	O
goal	O
of	O
3	O
.	O
36	O
mmol	O
/	O
L	O
(	O
130	O
mg	O
/	O
dL	O
)	O
.	O

Successive	O
transaminase	O
elevations	O
greater	O
than	O
three	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
occurred	O
in	O
0	O
.	O
1	O
%	O
of	O
women	O
and	O
were	O
dose	O
dependent	O
above	O
the	O
20	O
-	O
mg	O
dose	O
.	O

Myopathy	O
,	O
defined	O
as	O
muscle	O
symptoms	O
with	O
creatine	B-CHED
kinase	O
elevations	O
greater	O
than	O
10	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
,	O
was	O
rare	O
and	O
associated	O
with	O
the	O
highest	O
recommended	O
daily	O
dose	O
of	O
lovastatin	B-CHED
(	O
80	O
mg	O
)	O
.	O

Estrogen	O
-	O
replacement	O
therapy	O
appeared	O
to	O
have	O
no	O
effect	O
on	O
either	O
the	O
efficacy	O
or	O
safety	O
profile	O
of	O
lovastatin	B-CHED
.	O

CONCLUSION	O
:	O
Lovastatin	B-CHED
is	O
highly	O
effective	O
and	O
generally	O
well	O
tolerated	O
as	O
therapy	O
for	O
primary	O
hypercholesterolemia	O
in	O
women	O
.	O

Tetany	O
and	O
rhabdomyolysis	O
due	O
to	O
surreptitious	O
furosemide	B-CHED
-	O
-	O
importance	O
of	O
magnesium	B-CHED
supplementation	O
.	O

Diuretics	O
may	O
induce	O
hypokalemia	O
,	O
hypocalcemia	O
and	O
hypomagnesemia	O
.	O

While	O
severe	O
hypokalemia	O
may	O
cause	O
muscle	O
weakness	O
,	O
severe	O
hypomagnesemia	O
is	O
associated	O
with	O
muscle	O
spasms	O
and	O
tetany	O
which	O
cannot	O
be	O
corrected	O
by	O
potassium	B-CHED
and	O
calcium	B-CHED
supplementation	O
alone	O
(	O
1	O
,	O
2	O
)	O
.	O

Surreptitious	O
diuretic	O
ingestion	O
has	O
been	O
described	O
,	O
mainly	O
in	O
women	O
who	O
are	O
concerned	O
that	O
they	O
are	O
obese	O
or	O
edematous	O
.	O

Symptomatic	O
hypokalemia	O
has	O
been	O
reported	O
in	O
such	O
patients	O
(	O
3	O
-	O
7	O
)	O
and	O
in	O
one	O
case	O
hypocalcemia	O
was	O
observed	O
(	O
8	O
)	O
,	O
but	O
the	O
effects	O
of	O
magnesium	B-CHED
depletion	O
were	O
not	O
noted	O
in	O
these	O
patients	O
.	O

Ciprofloxacin	B-CHED
-	O
induced	O
nephrotoxicity	O
in	O
patients	O
with	O
cancer	O
.	O

Nephrotoxicity	O
associated	O
with	O
ciprofloxacin	B-CHED
is	O
uncommon	O
.	O

Five	O
patients	O
with	O
cancer	O
who	O
developed	O
acute	O
renal	O
failure	O
that	O
followed	O
treatment	O
with	O
ciprofloxacin	B-CHED
are	O
described	O
and	O
an	O
additional	O
15	O
cases	O
reported	O
in	O
the	O
literature	O
are	O
reviewed	O
.	O

Other	O
than	O
elevation	O
of	O
serum	O
creatinine	B-CHED
levels	O
,	O
characteristic	O
clinical	O
manifestations	O
and	O
abnormal	O
laboratory	O
findings	O
are	O
not	O
frequently	O
present	O
.	O

Allergic	O
interstitial	O
nephritis	O
is	O
believed	O
to	O
be	O
the	O
underlying	O
pathological	O
-	O
process	O
.	O

Definitive	O
diagnosis	O
requires	O
performance	O
of	O
renal	O
biopsy	O
,	O
although	O
this	O
is	O
not	O
always	O
feasible	O
.	O

An	O
improvement	O
in	O
renal	O
function	O
that	O
followed	O
the	O
discontinuation	O
of	O
the	O
offending	O
antibiotic	O
supports	O
the	O
presumptive	O
diagnosis	O
of	O
ciprofloxacin	B-CHED
-	O
induced	O
acute	O
renal	O
failure	O
.	O

Venous	O
complications	O
of	O
midazolam	B-CHED
versus	O
diazepam	B-CHED
.	O

Although	O
some	O
studies	O
have	O
suggested	O
fewer	O
venous	O
complications	O
are	O
associated	O
with	O
midazolam	B-CHED
than	O
with	O
diazepam	B-CHED
for	O
endoscopic	O
procedures	O
,	O
this	O
variable	O
has	O
not	O
been	O
well	O
documented	O
.	O

We	O
prospectively	O
evaluated	O
the	O
incidence	O
of	O
venous	O
complications	O
after	O
intravenous	O
injection	O
of	O
diazepam	B-CHED
or	O
midazolam	B-CHED
in	O
122	O
consecutive	O
patients	O
undergoing	O
colonoscopy	O
and	O
esophagogastroduodenoscopy	O
.	O

Overall	O
,	O
venous	O
complications	O
were	O
more	O
frequent	O
with	O
diazepam	B-CHED
(	O
22	O
of	O
62	O
patients	O
)	O
than	O
with	O
midazolam	B-CHED
(	O
4	O
of	O
60	O
patients	O
)	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

A	O
palpable	O
venous	O
cord	O
was	O
present	O
in	O
23	O
%	O
(	O
14	O
of	O
62	O
)	O
of	O
patients	O
in	O
the	O
diazepam	B-CHED
group	O
,	O
compared	O
with	O
2	O
%	O
(	O
1	O
of	O
60	O
patients	O
)	O
in	O
the	O
midazolam	B-CHED
group	O
(	O
p	O
<	O
0	O
.	O
002	O
)	O
.	O

Pain	O
at	O
the	O
injection	O
site	O
occurred	O
in	O
35	O
%	O
(	O
22	O
of	O
62	O
)	O
of	O
patients	O
in	O
the	O
diazepam	B-CHED
group	O
compared	O
with	O
7	O
%	O
(	O
4	O
of	O
60	O
patients	O
)	O
in	O
the	O
midazolam	B-CHED
group	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Swelling	O
and	O
warmth	O
at	O
the	O
injection	O
site	O
were	O
not	O
significantly	O
different	O
between	O
the	O
two	O
groups	O
.	O

Smoking	O
,	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drug	O
use	O
,	O
intravenous	O
catheter	O
site	O
,	O
dwell	O
time	O
of	O
the	O
needle	O
,	O
alcohol	B-CHED
use	O
,	O
and	O
pain	O
during	O
the	O
injection	O
had	O
no	O
effect	O
on	O
the	O
incidence	O
of	O
venous	O
complications	O
.	O

Clarithromycin	B-CHED
-	O
associated	O
visual	O
hallucinations	O
in	O
a	O
patient	O
with	O
chronic	O
renal	O
failure	O
on	O
continuous	O
ambulatory	O
peritoneal	O
dialysis	O
.	O

Visual	O
hallucinations	O
are	O
a	O
rare	O
event	O
in	O
chronic	O
renal	O
failure	O
and	O
not	O
related	O
to	O
uremia	O
per	O
se	O
.	O

Unreported	O
in	O
the	O
literature	O
is	O
visual	O
hallucinations	O
occurring	O
in	O
association	O
with	O
the	O
new	O
macrolide	B-CHED
antibiotic	O
,	O
clarithromycin	B-CHED
.	O

We	O
describe	O
such	O
a	O
case	O
in	O
a	O
patient	O
with	O
end	O
-	O
stage	O
renal	O
disease	O
(	O
ESRD	O
)	O
maintained	O
on	O
continuous	O
ambulatory	O
peritoneal	O
dialysis	O
(	O
CAPD	O
)	O
.	O

The	O
combination	O
of	O
a	O
relatively	O
high	O
dose	O
of	O
clarithromycin	B-CHED
in	O
face	O
of	O
chronic	O
renal	O
failure	O
in	O
a	O
functionally	O
anephric	O
patient	O
,	O
with	O
underlying	O
aluminum	B-CHED
intoxication	O
,	O
may	O
have	O
facilitated	O
the	O
appearance	O
of	O
this	O
neurotoxic	O
side	O
effect	O
.	O

It	O
is	O
important	O
to	O
understand	O
the	O
pharmacokinetics	O
of	O
medications	O
in	O
face	O
of	O
chronic	O
renal	O
failure	O
,	O
the	O
possibility	O
of	O
drug	O
interactions	O
,	O
and	O
how	O
these	O
factors	O
should	O
help	O
guide	O
medication	O
therapy	O
in	O
the	O
ESRD	O
patient	O
.	O

Changes	O
in	O
peroxisomes	O
in	O
preneoplastic	O
liver	O
and	O
hepatoma	O
of	O
mice	O
induced	O
by	O
alpha	B-CHED
-	I-CHED
benzene	I-CHED
hexachloride	I-CHED
.	O

Peroxisomes	O
in	O
hepatomas	O
and	O
hyperplastic	O
preneoplastic	O
liver	O
lesions	O
induced	O
in	O
mice	O
by	O
500	O
ppm	O
alpha	B-CHED
-	I-CHED
benzene	I-CHED
hexachloride	I-CHED
were	O
examined	O
histochemically	O
and	O
electron	O
microscopically	O
.	O

Although	O
most	O
of	O
the	O
hepatomas	O
were	O
well	O
-	O
differentiated	O
tumors	O
and	O
contained	O
a	O
considerable	O
number	O
of	O
peroxisomes	O
,	O
the	O
tumor	O
cells	O
did	O
not	O
respond	O
to	O
ethyl	B-CHED
-	I-CHED
alpha	I-CHED
-	I-CHED
p	I-CHED
-	I-CHED
chlorophenoxyisobutyrate	I-CHED
with	O
proliferation	O
of	O
peroxisomes	O
.	O

At	O
the	O
16th	O
week	O
of	O
carcinogen	O
feeding	O
,	O
hyperplastic	O
nodules	O
appeared	O
and	O
advanced	O
to	O
further	O
stages	O
.	O

A	O
majority	O
of	O
the	O
nodules	O
showed	O
a	O
considerable	O
number	O
of	O
peroxisomes	O
and	O
the	O
inductive	O
proliferation	O
of	O
peroxisomes	O
.	O

Within	O
the	O
nodules	O
,	O
foci	O
of	O
proliferation	O
of	O
the	O
cells	O
that	O
showed	O
no	O
inducibility	O
of	O
proliferation	O
of	O
peroxisomes	O
appeared	O
.	O

These	O
cells	O
proliferated	O
further	O
,	O
replacing	O
the	O
most	O
part	O
of	O
the	O
nodules	O
,	O
and	O
with	O
this	O
process	O
hepatomas	O
appeared	O
to	O
have	O
been	O
formed	O
.	O

No	O
abnormal	O
matrical	O
inclusions	O
of	O
peroxisomes	O
were	O
formed	O
in	O
the	O
cells	O
of	O
hyperplastic	O
nodules	O
by	O
ethyl	B-CHED
-	I-CHED
alpha	I-CHED
-	I-CHED
p	I-CHED
-	I-CHED
chlorophenoxyisobutyrate	I-CHED
unlike	O
in	O
the	O
case	O
of	O
rats	O
.	O

Contribution	O
of	O
the	O
sympathetic	O
nervous	O
system	O
to	O
salt	O
-	O
sensitivity	O
in	O
lifetime	O
captopril	B-CHED
-	O
treated	O
spontaneously	O
hypertensive	O
rats	O
.	O

OBJECTIVE	O
:	O
To	O
test	O
the	O
hypothesis	O
that	O
,	O
in	O
lifetime	O
captopril	B-CHED
-	O
treated	O
spontaneously	O
hypertensive	O
rats	O
(	O
SHR	O
)	O
,	O
the	O
sympathetic	O
nervous	O
system	O
contributes	O
importantly	O
to	O
the	O
hypertensive	O
effect	O
of	O
dietary	B-CHED
sodium	I-CHED
chloride	I-CHED
supplementation	O
.	O

METHODS	O
:	O
Male	O
SHR	O
(	O
aged	O
6	O
weeks	O
)	O
that	O
had	O
been	O
treated	O
from	O
conception	O
onward	O
with	O
either	O
captopril	B-CHED
or	O
vehicle	O
remained	O
on	O
a	O
basal	O
sodium	B-CHED
chloride	I-CHED
diet	O
or	O
were	O
fed	O
a	O
high	O
sodium	B-CHED
chloride	I-CHED
diet	O
.	O

After	O
2	O
weeks	O
,	O
the	O
rats	O
were	O
subjected	O
to	O
ganglionic	O
blockade	O
and	O
2	O
days	O
later	O
,	O
an	O
infusion	O
of	O
clonidine	B-CHED
.	O

RESULTS	O
:	O
Lifetime	O
captopril	B-CHED
treatment	O
significantly	O
lowered	O
mean	O
arterial	O
pressure	O
in	O
both	O
groups	O
.	O

Intravenous	O
infusion	O
of	O
the	O
ganglionic	O
blocker	O
hexamethonium	B-CHED
resulted	O
in	O
a	O
rapid	O
decline	O
in	O
MAP	O
that	O
eliminated	O
the	O
dietary	B-CHED
sodium	I-CHED
chloride	I-CHED
-	O
induced	O
increase	O
in	O
MAP	O
in	O
both	O
groups	O
.	O

Infusion	O
of	O
the	O
central	O
nervous	O
system	O
alpha2	B-CHED
-	I-CHED
adrenergic	I-CHED
receptor	I-CHED
agonist	I-CHED
clonidine	B-CHED
also	O
resulted	O
in	O
a	O
greater	O
reduction	O
in	O
MAP	O
in	O
both	O
groups	O
of	O
SHR	O
that	O
were	O
fed	O
the	O
high	O
(	O
compared	O
with	O
the	O
basal	O
)	O
sodium	B-CHED
chloride	I-CHED
diet	O
.	O

CONCLUSIONS	O
:	O
In	O
both	O
lifetime	O
captopril	B-CHED
-	O
treated	O
and	O
control	O
SHR	O
,	O
the	O
sympathetic	O
nervous	O
system	O
contributes	O
to	O
the	O
pressor	O
effects	O
of	O
a	O
high	O
sodium	B-CHED
chloride	I-CHED
diet	O
.	O

Angioedema	O
associated	O
with	O
droperidol	B-CHED
administration	O
.	O

Angioedema	O
,	O
also	O
known	O
as	O
angioneurotic	O
edema	O
or	O
Quincke	O
'	O
s	O
disease	O
,	O
is	O
a	O
well	O
-	O
demarcated	O
,	O
localized	O
edema	O
involving	O
the	O
subcutaneous	O
tissues	O
that	O
may	O
cause	O
upper	O
-	O
airway	O
obstruction	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
previously	O
healthy	O
19	O
-	O
year	O
-	O
old	O
man	O
with	O
no	O
known	O
drug	O
allergies	O
in	O
whom	O
angioedema	O
with	O
significant	O
tongue	O
swelling	O
and	O
protrusion	O
developed	O
within	O
10	O
minutes	O
of	O
the	O
administration	O
of	O
a	O
single	O
IV	O
dose	O
of	O
droperidol	B-CHED
.	O

Late	O
cardiotoxicity	O
after	O
treatment	O
for	O
a	O
malignant	O
bone	O
tumor	O
.	O

Cardiac	O
function	O
was	O
assessed	O
in	O
long	O
-	O
term	O
survivors	O
of	O
malignant	O
bone	O
tumors	O
who	O
were	O
treated	O
according	O
to	O
Rosen	B-CHED
'	I-CHED
s	I-CHED
T5	I-CHED
or	I-CHED
T10	I-CHED
protocol	I-CHED
,	O
both	O
including	O
doxorubicin	B-CHED
.	O

Thirty	O
-	O
one	O
patients	O
,	O
age	O
10	O
-	O
45	O
years	O
(	O
median	O
age	O
17	O
.	O
8	O
years	O
)	O
were	O
evaluated	O
2	O
.	O
3	O
-	O
14	O
.	O
1	O
years	O
(	O
median	O
8	O
.	O
9	O
years	O
)	O
following	O
completion	O
of	O
treatment	O
.	O

Cumulative	O
doses	O
of	O
doxorubicin	B-CHED
were	O
225	O
-	O
550	O
mg	O
/	O
m2	O
(	O
median	O
dose	O
360	O
)	O
.	O

The	O
evaluation	O
consisted	O
of	O
a	O
history	O
,	O
physical	O
examination	O
,	O
electrocardiogram	O
(	O
ECG	O
)	O
,	O
signal	O
averaged	O
ECG	O
,	O
24	O
-	O
hour	O
ambulatory	O
ECG	O
,	O
echocardiography	O
and	O
radionuclide	O
angiography	O
.	O

Eighteen	O
of	O
31	O
(	O
58	O
%	O
)	O
patients	O
showed	O
cardiac	O
toxicity	O
,	O
defined	O
as	O
having	O
one	O
or	O
more	O
of	O
the	O
following	O
abnormalities	O
:	O
late	O
potentials	O
,	O
complex	O
ventricular	O
arrhythmias	O
,	O
left	O
ventricular	O
dilation	O
,	O
decreased	O
shortening	O
fraction	O
,	O
or	O
decreased	O
ejection	O
fraction	O
.	O

The	O
incidence	O
of	O
cardiac	O
abnormalities	O
increased	O
with	O
length	O
of	O
follow	O
-	O
up	O
(	O
P	O
<	O
or	O
=	O
.	O
05	O
)	O
.	O

No	O
correlation	O
could	O
be	O
demonstrated	O
between	O
cumulative	O
dose	O
of	O
doxorubicin	B-CHED
and	O
cardiac	O
status	O
,	O
except	O
for	O
heart	O
rate	O
variability	O
.	O

When	O
adjusted	O
to	O
body	O
surface	O
area	O
,	O
the	O
left	O
ventricular	O
posterior	O
wall	O
thickness	O
(	O
LVPW	O
index	O
)	O
was	O
decreased	O
in	O
all	O
patients	O
.	O

The	O
incidence	O
of	O
doxorubicin	B-CHED
-	O
induced	O
cardiotoxicity	O
is	O
high	O
and	O
increases	O
with	O
follow	O
-	O
up	O
,	O
irrespective	O
of	O
cumulative	O
dose	O
.	O

Life	O
-	O
long	O
cardiac	O
follow	O
-	O
up	O
in	O
these	O
patients	O
is	O
warranted	O
.	O

The	O
results	O
of	O
our	O
study	O
suggest	O
that	O
heart	O
rate	O
variability	O
and	O
LVPW	O
index	O
could	O
be	O
sensitive	O
indicators	O
for	O
cardiotoxicity	O
.	O

Acute	O
blood	O
pressure	O
elevations	O
with	O
caffeine	B-CHED
in	O
men	O
with	O
borderline	O
systemic	O
hypertension	O
.	O

Whether	O
the	O
vasoconstrictive	O
actions	O
of	O
caffeine	B-CHED
are	O
enhanced	O
in	O
hypertensive	O
persons	O
has	O
not	O
been	O
demonstrated	O
.	O

Thus	O
,	O
caffeine	B-CHED
(	O
3	O
.	O
3	O
mg	O
/	O
kg	O
)	O
versus	O
placebo	O
was	O
tested	O
in	O
48	O
healthy	O
men	O
(	O
aged	O
20	O
to	O
35	O
years	O
)	O
selected	O
after	O
screening	O
on	O
2	O
separate	O
occasions	O
.	O

Borderline	O
hypertensive	O
men	O
(	O
n	O
=	O
24	O
)	O
were	O
selected	O
with	O
screening	O
systolic	O
blood	O
pressure	O
(	O
BP	O
)	O
of	O
140	O
to	O
160	O
mm	O
Hg	O
and	O
/	O
or	O
diastolic	O
BP	O
90	O
to	O
99	O
mm	O
Hg	O
.	O

Low	O
-	O
risk	O
controls	O
(	O
n	O
=	O
24	O
)	O
reported	O
no	O
parental	O
history	O
of	O
hypertension	O
and	O
had	O
screening	O
BP	O
<	O
130	O
/	O
85	O
mm	O
Hg	O
.	O

Participants	O
were	O
then	O
tested	O
on	O
2	O
occasions	O
after	O
12	O
-	O
hour	O
abstinence	O
from	O
caffeine	B-CHED
in	O
each	O
of	O
2	O
protocols	O
;	O
this	O
required	O
a	O
total	O
of	O
4	O
laboratory	O
visits	O
.	O

Caffeine	B-CHED
-	O
induced	O
changes	O
in	O
diastolic	O
BP	O
were	O
2	O
to	O
3	O
times	O
larger	O
in	O
borderline	O
subjects	O
than	O
in	O
controls	O
(	O
+	O
8	O
.	O
4	O
vs	O
+	O
3	O
.	O
8	O
mm	O
Hg	O
,	O
p	O
<	O
0	O
.	O
0001	O
)	O
,	O
and	O
were	O
attributable	O
to	O
larger	O
changes	O
in	O
impedance	O
-	O
derived	O
measures	O
of	O
systemic	O
vascular	O
resistance	O
(	O
+	O
135	O
vs	O
+	O
45	O
dynes	O
.	O
s	O
.	O
cm	O
-	O
5	O
,	O
p	O
<	O
0	O
.	O
004	O
)	O
.	O

These	O
findings	O
were	O
consistent	O
and	O
reached	O
significance	O
in	O
both	O
protocols	O
.	O

The	O
percentage	O
of	O
borderline	O
subjects	O
in	O
whom	O
diastolic	O
BP	O
changes	O
exceeded	O
the	O
median	O
control	O
response	O
was	O
96	O
%	O
.	O

Consequently	O
,	O
whereas	O
all	O
participants	O
exhibited	O
normotensive	O
levels	O
during	O
the	O
resting	O
predrug	O
baseline	O
,	O
33	O
%	O
of	O
borderline	O
subjects	O
achieved	O
hypertensive	O
BP	O
levels	O
after	O
caffeine	B-CHED
ingestion	O
.	O

Thus	O
,	O
in	O
borderline	O
hypertensive	O
men	O
,	O
exaggerated	O
responses	O
to	O
caffeine	B-CHED
were	O
:	O
selective	O
for	O
diastolic	O
BP	O
,	O
consistent	O
with	O
greater	O
vasoconstriction	O
,	O
replicated	O
in	O
2	O
protocols	O
,	O
and	O
representative	O
of	O
nearly	O
all	O
borderline	O
hypertensives	O
.	O

We	O
suspect	O
that	O
the	O
potential	O
for	O
caffeine	B-CHED
to	O
stabilize	O
high	O
resistance	O
states	O
in	O
susceptible	O
persons	O
suggests	O
that	O
its	O
use	O
may	O
facilitate	O
their	O
disease	O
progression	O
,	O
as	O
well	O
as	O
hinder	O
accurate	O
diagnosis	O
and	O
treatment	O
.	O

Absence	O
of	O
effect	O
of	O
sertraline	B-CHED
on	O
time	O
-	O
based	O
sensitization	O
of	O
cognitive	O
impairment	O
with	O
haloperidol	B-CHED
.	O

This	O
double	O
-	O
blind	O
,	O
randomized	O
,	O
placebo	O
-	O
controlled	O
study	O
evaluated	O
the	O
effects	O
of	O
haloperidol	B-CHED
alone	O
and	O
haloperidol	B-CHED
plus	O
sertraline	B-CHED
on	O
cognitive	O
and	O
psychomotor	O
function	O
in	O
24	O
healthy	O
male	O
subjects	O
.	O

METHOD	O
:	O
All	O
subjects	O
received	O
placebo	O
on	O
Day	O
1	O
and	O
haloperidol	B-CHED
2	O
mg	O
on	O
Days	O
2	O
and	O
25	O
.	O

From	O
Days	O
9	O
to	O
25	O
,	O
subjects	O
were	O
randomly	O
assigned	O
to	O
either	O
sertraline	B-CHED
(	O
12	O
subjects	O
)	O
or	O
placebo	O
(	O
12	O
subjects	O
)	O
;	O
the	O
sertraline	B-CHED
dose	O
was	O
titrated	O
from	O
50	O
to	O
200	O
mg	O
/	O
day	O
from	O
Days	O
9	O
to	O
16	O
,	O
and	O
remained	O
at	O
200	O
mg	O
/	O
day	O
for	O
the	O
final	O
10	O
days	O
of	O
the	O
drug	O
administration	O
period	O
.	O

Cognitive	O
function	O
testing	O
was	O
performed	O
before	O
dosing	O
and	O
over	O
a	O
24	O
-	O
hour	O
period	O
after	O
dosing	O
on	O
Days	O
1	O
,	O
2	O
,	O
and	O
25	O
.	O

RESULTS	O
:	O
Impairment	O
of	O
cognitive	O
function	O
was	O
observed	O
6	O
to	O
8	O
hours	O
after	O
administration	O
of	O
haloperidol	B-CHED
on	O
Day	O
2	O
but	O
was	O
not	O
evident	O
23	O
hours	O
after	O
dosing	O
.	O

When	O
single	O
-	O
dose	O
haloperidol	B-CHED
was	O
given	O
again	O
25	O
days	O
later	O
,	O
greater	O
impairment	O
with	O
earlier	O
onset	O
was	O
noted	O
in	O
several	O
tests	O
in	O
both	O
treatment	O
groups	O
,	O
suggesting	O
enhancement	O
of	O
this	O
effect	O
.	O

There	O
was	O
no	O
indication	O
that	O
sertraline	B-CHED
exacerbated	O
the	O
impairment	O
produced	O
by	O
haloperidol	B-CHED
since	O
an	O
equivalent	O
effect	O
also	O
occurred	O
in	O
the	O
placebo	O
group	O
.	O

Three	O
subjects	O
(	O
2	O
on	O
sertraline	B-CHED
and	O
1	O
on	O
placebo	O
)	O
withdrew	O
from	O
the	O
study	O
because	O
of	O
side	O
effects	O
.	O

Ten	O
subjects	O
in	O
each	O
group	O
reported	O
side	O
effects	O
related	O
to	O
treatment	O
.	O

The	O
side	O
effect	O
profiles	O
of	O
sertraline	B-CHED
and	O
of	O
placebo	O
were	O
similar	O
.	O

CONCLUSION	O
:	O
Haloperidol	B-CHED
produced	O
a	O
clear	O
profile	O
of	O
cognitive	O
impairment	O
that	O
was	O
not	O
worsened	O
by	O
concomitant	O
sertraline	B-CHED
administration	O
.	O

Coexistence	O
of	O
cerebral	O
venous	O
sinus	O
and	O
internal	O
carotid	O
artery	O
thrombosis	O
associated	O
with	O
exogenous	O
sex	O
hormones	O
.	O

A	O
case	O
report	O
.	O

A	O
forty	O
-	O
six	O
year	O
-	O
old	O
premenopausal	O
woman	O
developed	O
headache	O
,	O
nausea	O
and	O
vomiting	O
,	O
left	O
hemiparesis	O
and	O
seizure	O
two	O
days	O
after	O
parenteral	O
use	O
of	O
progesterone	B-CHED
and	O
estradiol	B-CHED
.	O

Diabetes	O
mellitus	O
(	O
DM	O
)	O
was	O
found	O
during	O
admission	O
.	O

Computed	O
tomography	O
showed	O
a	O
hemorrhagic	O
infarct	O
in	O
the	O
right	O
frontal	O
lobe	O
and	O
increased	O
density	O
in	O
the	O
superior	O
sagittal	O
sinus	O
(	O
SSS	O
)	O
.	O

Left	O
carotid	O
angiography	O
found	O
occlusion	O
of	O
the	O
left	O
internal	O
carotid	O
artery	O
(	O
ICA	O
)	O
.	O

Right	O
carotid	O
angiograms	O
failed	O
to	O
show	O
the	O
SSS	O
and	O
inferior	O
sagittal	O
sinus	O
,	O
suggestive	O
of	O
venous	O
sinus	O
thrombosis	O
.	O

Coexistence	O
of	O
the	O
cerebral	O
artery	O
and	O
the	O
venous	O
sinus	O
occlusion	O
has	O
been	O
described	O
infrequently	O
.	O

In	O
this	O
case	O
,	O
the	O
authors	O
postulate	O
that	O
the	O
use	O
of	O
estradiol	B-CHED
and	O
progesterone	B-CHED
and	O
the	O
underlying	O
DM	O
increased	O
vascular	O
thrombogenicity	O
,	O
which	O
provided	O
a	O
common	O
denominator	O
for	O
thrombosis	O
of	O
both	O
the	O
ICA	O
and	O
the	O
venous	O
sinus	O
.	O

Chemotherapy	O
of	O
advanced	O
inoperable	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
with	O
paclitaxel	B-CHED
:	O
a	O
phase	O
II	O
trial	O
.	O

Paclitaxel	B-CHED
(	O
Taxol	B-CHED
;	O
Bristol	O
-	O
Myers	O
Squibb	O
Company	O
,	O
Princeton	O
,	O
NJ	O
)	O
has	O
demonstrated	O
significant	O
antineoplastic	O
activity	O
against	O
different	O
tumor	O
types	O
,	O
notably	O
ovarian	O
and	O
breast	O
carcinoma	O
.	O

Two	O
phase	O
II	O
trials	O
of	O
24	O
-	O
hour	O
paclitaxel	B-CHED
infusions	O
in	O
chemotherapy	O
-	O
naive	O
patients	O
with	O
stage	O
IIIB	O
or	O
IV	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
reported	O
response	O
rates	O
of	O
21	O
%	O
and	O
24	O
%	O
.	O

Leukopenia	O
was	O
dose	O
limiting	O
:	O
as	O
many	O
as	O
62	O
.	O
5	O
%	O
of	O
patients	O
experienced	O
grade	O
4	O
leukopenia	O
.	O

We	O
investigated	O
the	O
efficacy	O
and	O
toxicity	O
of	O
a	O
3	O
-	O
hour	O
paclitaxel	B-CHED
infusion	O
in	O
a	O
phase	O
II	O
trial	O
in	O
patients	O
with	O
inoperable	O
stage	O
IIIB	O
or	O
IV	O
NSCLC	O
.	O

The	O
58	O
patients	O
treated	O
(	O
41	O
men	O
and	O
17	O
women	O
)	O
had	O
a	O
median	O
age	O
of	O
59	O
years	O
(	O
age	O
range	O
,	O
25	O
to	O
75	O
)	O
and	O
a	O
performance	O
status	O
of	O
0	O
through	O
2	O
.	O

Most	O
patients	O
(	O
72	O
.	O
4	O
%	O
)	O
had	O
stage	O
IV	O
NSCLC	O
.	O

Paclitaxel	B-CHED
225	O
mg	O
/	O
m2	O
was	O
infused	O
over	O
3	O
hours	O
every	O
3	O
weeks	O
with	O
standard	O
prophylactic	O
premedication	O
.	O

Of	O
50	O
patients	O
evaluable	O
for	O
response	O
,	O
12	O
(	O
24	O
%	O
)	O
had	O
partial	O
remission	O
,	O
26	O
(	O
52	O
%	O
)	O
had	O
no	O
change	O
,	O
and	O
12	O
had	O
disease	O
progression	O
(	O
24	O
%	O
)	O
.	O

Hematologic	O
toxicities	O
were	O
mild	O
:	O
only	O
one	O
patient	O
(	O
2	O
%	O
)	O
developed	O
grade	O
3	O
or	O
4	O
neutropenia	O
,	O
while	O
29	O
%	O
had	O
grade	O
1	O
or	O
2	O
.	O

Grade	O
1	O
or	O
2	O
polyneuropathy	O
affected	O
56	O
%	O
of	O
patients	O
while	O
only	O
one	O
(	O
2	O
%	O
)	O
experienced	O
severe	O
polyneuropathy	O
.	O

Similarly	O
,	O
grade	O
1	O
or	O
2	O
myalgia	O
/	O
arthralgia	O
was	O
observed	O
in	O
63	O
.	O
2	O
%	O
of	O
patients	O
,	O
but	O
only	O
14	O
.	O
3	O
%	O
experienced	O
grade	O
3	O
or	O
4	O
.	O

Nausea	O
and	O
vomiting	O
were	O
infrequent	O
,	O
with	O
14	O
%	O
of	O
patients	O
experiencing	O
grade	O
1	O
or	O
2	O
and	O
only	O
2	O
%	O
experiencing	O
grade	O
3	O
or	O
4	O
.	O

Paclitaxel	B-CHED
is	O
thus	O
an	O
active	O
single	O
agent	O
in	O
this	O
patient	O
population	O
,	O
with	O
a	O
3	O
-	O
hour	O
infusion	O
proving	O
comparably	O
effective	O
to	O
a	O
24	O
-	O
hour	O
infusion	O
and	O
superior	O
in	O
terms	O
of	O
the	O
incidence	O
of	O
hematologic	O
and	O
nonhematologic	O
toxicity	O
.	O

Further	O
phase	O
II	O
studies	O
with	O
paclitaxel	B-CHED
combined	O
with	O
other	O
drugs	O
active	O
against	O
NSCLC	O
are	O
indicated	O
,	O
and	O
phase	O
III	O
studies	O
comparing	O
paclitaxel	B-CHED
with	O
standard	O
chemotherapy	O
remain	O
to	O
be	O
completed	O
.	O

Paclitaxel	B-CHED
combined	O
with	O
carboplatin	B-CHED
in	O
the	O
first	O
-	O
line	O
treatment	O
of	O
advanced	O
ovarian	O
cancer	O
.	O

In	O
a	O
phase	O
I	O
study	O
to	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
of	O
paclitaxel	B-CHED
(	O
Taxol	B-CHED
;	O
Bristol	O
-	O
Myers	O
Squibb	O
Company	O
,	O
Princeton	O
,	O
NJ	O
)	O
given	O
as	O
a	O
3	O
-	O
hour	O
infusion	O
in	O
combination	O
with	O
carboplatin	B-CHED
administered	O
every	O
21	O
days	O
to	O
women	O
with	O
advanced	O
ovarian	O
cancer	O
,	O
paclitaxel	B-CHED
doses	O
were	O
escalated	O
as	O
follows	O
:	O
level	O
1	O
,	O
135	O
mg	O
/	O
m2	O
;	O
level	O
2	O
,	O
160	O
mg	O
/	O
m2	O
;	O
level	O
3	O
,	O
185	O
mg	O
/	O
m2	O
;	O
and	O
level	O
4	O
,	O
210	O
mg	O
/	O
m2	O
.	O

The	O
fixed	O
dose	O
of	O
carboplatin	B-CHED
at	O
levels	O
1	O
through	O
4	O
was	O
given	O
to	O
achieve	O
an	O
area	O
under	O
the	O
concentration	O
-	O
time	O
curve	O
(	O
AUC	O
)	O
of	O
5	O
using	O
the	O
Calvert	O
formula	O
.	O

In	O
levels	O
5	O
and	O
6	O
the	O
carboplatin	B-CHED
dose	O
was	O
targeted	O
at	O
AUCs	O
of	O
6	O
and	O
7	O
.	O
5	O
,	O
respectively	O
,	O
combined	O
with	O
a	O
fixed	O
paclitaxel	B-CHED
dose	O
of	O
185	O
mg	O
/	O
m2	O
.	O

To	O
date	O
,	O
30	O
previously	O
untreated	O
patients	O
,	O
all	O
with	O
a	O
good	O
performance	O
status	O
(	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
0	O
to	O
2	O
)	O
have	O
been	O
entered	O
into	O
this	O
ongoing	O
study	O
.	O

The	O
dose	O
-	O
limiting	O
toxicity	O
of	O
the	O
combination	O
was	O
myelosuppression	O
(	O
leukopenia	O
,	O
granulocytopenia	O
,	O
and	O
thrombocytopenia	O
)	O
.	O

Neurotoxicity	O
was	O
largely	O
moderate	O
.	O

So	O
far	O
,	O
14	O
patients	O
are	O
evaluable	O
for	O
response	O
;	O
of	O
these	O
,	O
eight	O
(	O
57	O
%	O
)	O
showed	O
objective	O
(	O
complete	O
or	O
partial	O
)	O
response	O
and	O
disease	O
stabilized	O
in	O
six	O
patients	O
.	O

No	O
patient	O
had	O
disease	O
progression	O
.	O

We	O
conclude	O
that	O
the	O
combination	O
of	O
paclitaxel	B-CHED
185	O
mg	O
/	O
m2	O
administered	O
as	O
a	O
3	O
-	O
hour	O
infusion	O
followed	O
immediately	O
by	O
a	O
1	O
-	O
hour	O
infusion	O
of	O
carboplatin	B-CHED
at	O
an	O
AUC	O
of	O
6	O
can	O
be	O
administered	O
safely	O
in	O
a	O
21	O
-	O
day	O
schedule	O
in	O
the	O
outpatient	O
setting	O
.	O

The	O
recommended	O
dose	O
for	O
phase	O
III	O
studies	O
is	O
paclitaxel	B-CHED
185	O
mg	O
/	O
m2	O
and	O
carboplatin	B-CHED
AUC	O
6	O
.	O

Effects	O
of	O
acute	O
steroid	B-CHED
administration	O
on	O
ventilatory	O
and	O
peripheral	O
muscles	O
in	O
rats	O
.	O

Occasional	O
case	O
reports	O
have	O
shown	O
that	O
acute	O
myopathy	O
may	O
occur	O
in	O
patients	O
treated	O
with	O
massive	O
doses	O
of	O
corticosteroids	B-CHED
.	O

The	O
mechanism	O
of	O
this	O
myopathy	O
is	O
poorly	O
understood	O
.	O

Therefore	O
,	O
60	O
male	O
rats	O
were	O
randomly	O
assigned	O
to	O
receive	O
daily	O
injection	O
of	O
saline	O
(	O
C	O
)	O
,	O
methylprednisolone	B-CHED
(	O
M	B-CHED
)	O
,	O
or	O
triamcinolone	B-CHED
(	O
T	B-CHED
)	O
80	O
mg	O
/	O
kg	O
/	O
d	O
for	O
5	O
d	O
.	O

Nutritional	O
intake	O
,	O
measured	O
daily	O
in	O
15	O
animals	O
,	O
showed	O
a	O
significant	O
reduction	O
of	O
food	O
intake	O
in	O
the	O
steroid	B-CHED
-	O
treated	O
groups	O
(	O
-	O
50	O
and	O
-	O
79	O
%	O
in	O
M	B-CHED
and	O
T	B-CHED
,	O
respectively	O
)	O
.	O

This	O
was	O
associated	O
with	O
a	O
similar	O
loss	O
in	O
body	O
weight	O
.	O

In	O
the	O
45	O
remaining	O
animals	O
,	O
diaphragm	O
contractility	O
and	O
histopathologic	O
features	O
of	O
several	O
muscles	O
were	O
studied	O
.	O

Weights	O
of	O
respiratory	O
and	O
peripheral	O
muscles	O
were	O
similarly	O
decreased	O
after	O
steroid	B-CHED
treatment	O
.	O

Maximal	O
twitches	O
of	O
the	O
diaphragm	O
were	O
lower	O
in	O
the	O
C	O
group	O
(	O
653	O
+	O
/	O
-	O
174	O
g	O
/	O
cm	O
(	O
2	O
)	O
)	O
than	O
in	O
the	O
M	B-CHED
group	O
(	O
837	O
+	O
/	O
-	O
171	O
g	O
/	O
cm	O
(	O
2	O
)	O
;	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
the	O
T	B-CHED
group	O
(	O
765	O
+	O
/	O
-	O
145	O
g	O
/	O
cm	O
(	O
2	O
)	O
,	O
NS	O
)	O
.	O

Half	O
-	O
relaxation	O
time	O
was	O
prolonged	O
in	O
both	O
steroid	B-CHED
groups	O
,	O
and	O
time	O
to	O
peak	O
tension	O
was	O
longer	O
with	O
M	B-CHED
,	O
whereas	O
tetanic	O
tensions	O
were	O
similar	O
.	O

Steroid	B-CHED
treatment	O
also	O
induced	O
a	O
leftward	O
shift	O
of	O
the	O
force	O
-	O
frequency	O
curve	O
at	O
25	O
and	O
50	O
Hz	O
when	O
compared	O
with	O
saline	O
treatment	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

ATPase	O
staining	O
of	O
the	O
diaphragm	O
,	O
scalenus	O
medius	O
,	O
and	O
gastrocnemius	O
showed	O
type	O
IIb	O
fiber	O
atrophy	O
in	O
the	O
steroid	B-CHED
groups	O
and	O
also	O
diaphragmatic	O
type	O
IIa	O
atrophy	O
with	O
T	B-CHED
,	O
whereas	O
histologic	O
examinations	O
revealed	O
a	O
normal	O
muscular	O
pattern	O
with	O
absence	O
of	O
necrosis	O
.	O

Finally	O
,	O
a	O
pair	O
-	O
fed	O
(	O
PF	O
)	O
study	O
,	O
performed	O
in	O
18	O
rats	O
(	O
C	O
,	O
T	B-CHED
,	O
and	O
PF	O
)	O
,	O
showed	O
that	O
muscle	O
atrophy	O
was	O
considerably	O
less	O
pronounced	O
in	O
PF	O
animals	O
than	O
in	O
T	B-CHED
-	O
treated	O
animals	O
.	O

We	O
conclude	O
that	O
(	O
1	O
)	O
short	O
-	O
term	O
treatment	O
with	O
massive	O
doses	O
of	O
steroids	B-CHED
induced	O
severe	O
respiratory	O
and	O
limb	O
muscle	O
wasting	O
;	O
(	O
2	O
)	O
both	O
types	O
of	O
steroids	B-CHED
induced	O
predominantly	O
type	O
IIb	O
atrophy	O
,	O
resulting	O
in	O
the	O
expected	O
alterations	O
in	O
diaphragm	O
contractile	O
properties	O
;	O
(	O
3	O
)	O
neither	O
steroid	B-CHED
caused	O
muscle	O
necrosis	O
;	O
(	O
4	O
)	O
type	O
IIb	O
atrophy	O
was	O
not	O
caused	O
by	O
acute	O
nutritional	O
deprivation	O
alone	O
.	O

Continuous	O
subcutaneous	O
administration	O
of	O
mesna	B-CHED
to	O
prevent	O
ifosfamide	B-CHED
-	O
induced	O
hemorrhagic	O
cystitis	O
.	O

Hemorrhagic	O
cystitis	O
is	O
a	O
major	O
potential	O
toxicity	O
of	O
ifosfamide	B-CHED
that	O
can	O
be	O
prevented	O
by	O
administering	O
mesna	B-CHED
along	O
with	O
the	O
cytotoxic	O
agent	O
.	O

Mesna	B-CHED
is	O
generally	O
administered	O
by	O
the	O
intravenous	O
route	O
,	O
although	O
experience	O
with	O
oral	O
delivery	O
of	O
the	O
drug	O
has	O
increased	O
.	O

The	O
continuous	O
subcutaneous	O
administration	O
of	O
mesna	B-CHED
has	O
the	O
advantage	O
of	O
not	O
requiring	O
intravenous	O
access	O
.	O

In	O
addition	O
,	O
subcutaneous	O
delivery	O
of	O
the	O
neutralizing	O
agent	O
will	O
not	O
be	O
associated	O
with	O
the	O
risk	O
of	O
inadequate	O
urinary	O
mesna	B-CHED
concentrations	O
,	O
such	O
as	O
in	O
a	O
patient	O
taking	O
oral	O
mesna	B-CHED
who	O
experiences	O
severe	O
ifosfamide	B-CHED
-	O
induced	O
emesis	O
and	O
is	O
unable	O
to	O
absorb	O
the	O
drug	O
.	O

Limited	O
clinical	O
experience	O
with	O
continuous	O
subcutaneous	O
mesna	B-CHED
administration	O
suggests	O
it	O
is	O
a	O
safe	O
,	O
practical	O
,	O
and	O
economic	O
method	O
of	O
drug	O
delivery	O
that	O
permits	O
ifosfamide	B-CHED
to	O
be	O
administered	O
successfully	O
in	O
the	O
outpatient	O
setting	O
.	O

Leg	O
and	O
back	O
pain	O
after	O
spinal	O
anaesthesia	O
involving	O
hyperbaric	O
5	O
%	O
lignocaine	B-CHED
.	O

Fifty	O
-	O
four	O
patients	O
,	O
aged	O
27	O
-	O
90	O
years	O
,	O
who	O
were	O
given	O
lignocaine	B-CHED
5	O
%	O
in	O
6	O
.	O
8	O
%	O
glucose	B-CHED
solution	O
for	O
spinal	O
anaesthesia	O
were	O
studied	O
.	O

Thirteen	O
of	O
these	O
patients	O
experienced	O
pain	O
in	O
the	O
legs	O
and	O
/	O
or	O
back	O
after	O
recovery	O
from	O
anaesthesia	O
.	O

The	O
patients	O
affected	O
were	O
younger	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
the	O
site	O
of	O
the	O
dural	O
puncture	O
was	O
higher	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
than	O
those	O
individuals	O
without	O
pain	O
.	O

Five	O
of	O
the	O
13	O
patients	O
(	O
38	O
%	O
)	O
with	O
pain	O
and	O
seven	O
of	O
the	O
41	O
patients	O
(	O
17	O
%	O
)	O
without	O
pain	O
admitted	O
to	O
a	O
high	O
alcohol	B-CHED
intake	O
,	O
which	O
might	O
be	O
a	O
contributing	O
factor	O
.	O

Leg	O
and	O
/	O
or	O
back	O
pain	O
is	O
associated	O
with	O
the	O
intrathecal	O
use	O
of	O
hyperbaric	O
5	O
%	O
lignocaine	B-CHED
.	O

The	O
use	O
of	O
serum	O
cholinesterase	O
in	O
succinylcholine	B-CHED
apnoea	O
.	O

Fifteen	O
patients	O
demonstrating	O
unexpected	O
prolonged	O
apnoea	O
lasting	O
several	O
hours	O
after	O
succinylcholine	B-CHED
have	O
been	O
treated	O
by	O
a	O
new	O
preparation	O
of	O
human	O
serum	O
cholinesterase	O
.	O

Adequate	O
spontaneous	O
respiration	O
was	O
re	O
-	O
established	O
in	O
an	O
average	O
period	O
of	O
ten	O
minutes	O
after	O
the	O
injection	O
.	O

In	O
12	O
patients	O
biochemical	O
genetic	O
examinations	O
confirmed	O
the	O
presence	O
of	O
an	O
atypical	O
serum	O
cholinesterase	O
.	O

In	O
three	O
patients	O
none	O
of	O
the	O
usual	O
variants	O
were	O
found	O
.	O

It	O
is	O
therefore	O
supposed	O
that	O
other	O
unknown	O
variants	O
of	O
serum	O
cholinesterase	O
exist	O
which	O
cannot	O
hydrolyze	O
succinylcholine	B-CHED
.	O

The	O
use	O
of	O
serum	O
cholinesterase	O
in	O
succinylcholine	B-CHED
apnoea	O
provided	O
considerable	O
relief	O
to	O
both	O
patient	O
and	O
anaesthetist	O
.	O

Increased	O
sulfation	O
and	O
decreased	O
7alpha	O
-	O
hydroxylation	O
of	O
deoxycholic	B-CHED
acid	I-CHED
in	O
ethinyl	B-CHED
estradiol	I-CHED
-	O
induced	O
cholestasis	O
in	O
rats	O
.	O

Deoxycholic	B-CHED
acid	I-CHED
conjugation	O
,	O
transport	O
capacity	O
,	O
and	O
metabolism	O
were	O
compared	O
in	O
control	O
and	O
ethinyl	B-CHED
estradiol	I-CHED
-	O
treated	O
rats	O
.	O

Control	O
rats	O
were	O
found	O
to	O
have	O
a	O
lower	O
capacity	O
to	O
transport	O
deoxycholic	B-CHED
acid	I-CHED
than	O
taurodeoxycholic	B-CHED
acid	I-CHED
,	O
and	O
both	O
were	O
decreased	O
by	O
ethinyl	B-CHED
estradiol	I-CHED
treatment	O
.	O

During	O
[	O
24	O
-	O
14C	O
]	O
sodium	B-CHED
deoxycholate	I-CHED
infusion	O
,	O
[	O
14C	O
]	O
biliary	O
bile	B-CHED
acid	I-CHED
secretion	O
increased	O
,	O
but	O
bile	O
flow	O
did	O
not	O
change	O
significantly	O
in	O
either	O
control	O
or	O
ethinyl	B-CHED
estradiol	I-CHED
-	O
treated	O
rats	O
.	O

Ethinyl	B-CHED
estradiol	I-CHED
-	O
treated	O
animals	O
excreted	O
significantly	O
less	O
14C	O
as	O
taurocholic	B-CHED
acid	I-CHED
than	O
did	O
control	O
animals	O
,	O
consistent	O
with	O
an	O
impairment	O
of	O
7alpha	O
-	O
hydroxylation	O
of	O
taurodeoxycholic	B-CHED
acid	I-CHED
.	O

Ethinyl	B-CHED
estradiol	I-CHED
treatment	O
did	O
not	O
impair	O
conjugation	O
of	O
deoxycholic	B-CHED
acid	I-CHED
,	O
but	O
did	O
result	O
in	O
an	O
increase	O
in	O
sulfation	O
of	O
taurodeoxycholic	B-CHED
acid	I-CHED
from	O
1	O
.	O
5	O
%	O
in	O
controls	O
to	O
nearly	O
4	O
.	O
0	O
%	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

These	O
results	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
the	O
rat	O
has	O
a	O
poorer	O
tolerance	O
for	O
deoxycholic	B-CHED
acid	I-CHED
than	O
do	O
certain	O
other	O
species	O
.	O

Furthermore	O
,	O
the	O
rat	O
converts	O
deoxycholic	B-CHED
acid	I-CHED
,	O
a	O
poor	O
choleretic	O
,	O
to	O
taurocholic	B-CHED
acid	I-CHED
,	O
a	O
good	O
choleretic	O
.	O

When	O
this	O
conversion	O
is	O
impaired	O
with	O
ethinyl	B-CHED
estradiol	I-CHED
treatment	O
,	O
sulfation	O
may	O
be	O
an	O
important	O
alternate	O
pathway	O
for	O
excretion	O
of	O
this	O
potentially	O
harmful	O
bile	B-CHED
acid	I-CHED
.	O

Influence	O
of	O
diet	O
free	O
of	O
NAD	B-CHED
-	O
precursors	O
on	O
acetaminophen	B-CHED
hepatotoxicity	O
in	O
mice	O
.	O

Recently	O
,	O
we	O
demonstrated	O
the	O
hepatoprotective	O
effects	O
of	O
nicotinic	B-CHED
acid	I-CHED
amide	I-CHED
,	O
a	O
selective	O
inhibitor	O
of	O
poly	B-CHED
(	I-CHED
ADP	I-CHED
-	I-CHED
ribose	I-CHED
)	I-CHED
polymerase	O
(	O
PARP	O
;	O
EC	O
2	O
.	O
4	O
.	O
2	O
.	O
30	O
)	O
on	O
mice	O
suffering	O
from	O
acetaminophen	B-CHED
(	O
AAP	B-CHED
)	O
-	O
hepatitis	O
,	O
suggesting	O
that	O
the	O
AAP	B-CHED
-	O
induced	O
liver	O
injury	O
involves	O
a	O
step	O
which	O
depends	O
on	O
adenoribosylation	O
.	O

The	O
present	O
study	O
investigates	O
the	O
effects	O
of	O
a	O
diet	O
free	O
of	O
precursors	O
of	O
NAD	B-CHED
,	O
the	O
substrate	O
on	O
which	O
PARP	O
acts	O
,	O
in	O
female	O
NMRI	O
mice	O
with	O
AAP	B-CHED
hepatitis	O
and	O
evaluates	O
the	O
influence	O
of	O
simultaneous	O
ethanol	B-CHED
consumption	O
in	O
these	O
animals	O
.	O

Liver	O
injuries	O
were	O
quantified	O
as	O
serum	O
activities	O
of	O
glutamate	B-CHED
-	O
oxaloacetate	B-CHED
transaminase	O
(	O
GOT	O
)	O
and	O
glutamate	B-CHED
-	O
pyruvate	B-CHED
transaminase	O
(	O
GPT	O
)	O
.	O

While	O
AAP	B-CHED
caused	O
a	O
117	O
-	O
fold	O
elevation	O
of	O
serum	O
transaminase	O
activities	O
in	O
mice	O
kept	O
on	O
a	O
standard	O
laboratory	O
diet	O
,	O
which	O
was	O
significantly	O
exacerbated	O
by	O
ethanol	B-CHED
and	O
inhibited	O
by	O
nicotinic	B-CHED
acid	I-CHED
amide	I-CHED
(	O
NAA	B-CHED
)	O
,	O
adverse	O
effects	O
were	O
noted	O
in	O
animals	O
fed	O
a	O
diet	O
free	O
of	O
precursors	O
of	O
NAD	B-CHED
.	O

In	O
these	O
animals	O
,	O
only	O
minor	O
increases	O
of	O
serum	O
transaminase	O
activities	O
were	O
measured	O
in	O
the	O
presence	O
of	O
AAP	B-CHED
,	O
and	O
unlike	O
the	O
exacerbation	O
caused	O
by	O
ethanol	B-CHED
in	O
mice	O
on	O
a	O
standard	O
diet	O
,	O
the	O
liver	O
damage	O
was	O
inhibited	O
by	O
50	O
%	O
by	O
ethanol	B-CHED
.	O

A	O
further	O
64	O
%	O
reduction	O
of	O
hepatitis	O
was	O
observed	O
,	O
when	O
NAA	B-CHED
was	O
given	O
to	O
ethanol	B-CHED
/	O
AAP	B-CHED
-	O
mice	O
.	O

Our	O
results	O
provide	O
evidence	O
that	O
the	O
AAP	B-CHED
-	O
induced	O
hepatitis	O
and	O
its	O
exacerbation	O
by	O
ethanol	B-CHED
can	O
either	O
be	O
reduced	O
by	O
end	O
-	O
product	O
inhibition	O
of	O
PARP	O
by	O
NAA	B-CHED
or	O
by	O
dietary	O
depletion	O
of	O
the	O
enzyme	O
'	O
s	O
substrate	O
NAD	B-CHED
.	O

We	O
see	O
the	O
main	O
application	O
of	O
NAA	B-CHED
as	O
for	O
the	O
combinational	O
use	O
in	O
pharmaceutical	O
preparations	O
of	O
acetaminophen	B-CHED
in	O
order	O
to	O
avoid	O
hepatic	O
damage	O
in	O
patients	O
treated	O
with	O
this	O
widely	O
used	O
analgesic	O
.	O

Nightmares	O
and	O
hallucinations	O
after	O
long	O
-	O
term	O
intake	O
of	O
tramadol	B-CHED
combined	O
with	O
antidepressants	O
.	O

Tramadol	B-CHED
is	O
a	O
weak	O
opioid	O
with	O
effects	O
on	O
adrenergic	O
and	O
serotonergic	O
neurotransmission	O
that	O
is	O
used	O
to	O
treat	O
cancer	O
pain	O
and	O
chronic	O
non	O
malignant	O
pain	O
.	O

This	O
drug	O
was	O
initiated	O
in	O
association	O
with	O
paroxetine	B-CHED
and	O
dosulepine	B-CHED
hydrochloride	I-CHED
in	O
a	O
tetraparetic	O
patient	O
with	O
chronic	O
pain	O
.	O

Fifty	O
-	O
six	O
days	O
after	O
initiation	O
of	O
the	O
treatment	O
the	O
patient	O
presented	O
hallucinations	O
that	O
only	O
stopped	O
after	O
the	O
withdrawal	O
of	O
psycho	O
-	O
active	O
drugs	O
and	O
tramadol	B-CHED
.	O

The	O
case	O
report	O
questions	O
the	O
long	O
term	O
use	O
of	O
pain	O
killers	O
combined	O
with	O
psycho	O
-	O
active	O
drugs	O
in	O
chronic	O
non	O
malignant	O
pain	O
,	O
especially	O
if	O
pain	O
is	O
under	O
control	O
.	O

Effect	O
of	O
calcium	B-CHED
chloride	I-CHED
and	O
4	B-CHED
-	I-CHED
aminopyridine	I-CHED
therapy	O
on	O
desipramine	B-CHED
toxicity	O
in	O
rats	O
.	O

BACKGROUND	O
:	O
Hypotension	O
is	O
a	O
major	O
contributor	O
to	O
mortality	O
in	O
tricyclic	O
antidepressant	O
overdose	O
.	O

Recent	O
data	O
suggest	O
that	O
tricyclic	O
antidepressants	O
inhibit	O
calcium	B-CHED
influx	O
in	O
some	O
tissues	O
.	O

This	O
study	O
addressed	O
the	O
potential	O
role	O
of	O
calcium	B-CHED
channel	O
blockade	O
in	O
tricyclic	O
antidepressant	O
-	O
induced	O
hypotension	O
.	O

METHODS	O
:	O
Two	O
interventions	O
were	O
studied	O
that	O
have	O
been	O
shown	O
previously	O
to	O
improve	O
blood	O
pressure	O
with	O
calcium	B-CHED
channel	O
blocker	O
overdose	O
.	O

CaCl2	B-CHED
and	O
4	B-CHED
-	I-CHED
aminopyridine	I-CHED
.	O

Anesthetized	O
rats	O
received	O
the	O
tricyclic	O
antidepressant	O
desipramine	B-CHED
IP	O
to	O
produce	O
hypotension	O
,	O
QRS	O
prolongation	O
,	O
and	O
bradycardia	O
.	O

Fifteen	O
min	O
later	O
,	O
animals	O
received	O
CaCl2	B-CHED
,	O
NaHCO3	B-CHED
,	O
or	O
saline	O
.	O

In	O
a	O
second	O
experiment	O
,	O
rats	O
received	O
tricyclic	O
antidepressant	O
desipramine	B-CHED
IP	O
followed	O
in	O
15	O
min	O
by	O
4	B-CHED
-	I-CHED
aminopyridine	I-CHED
or	O
saline	O
.	O

RESULTS	O
:	O
NaHCO3	B-CHED
briefly	O
(	O
5	O
min	O
)	O
reversed	O
hypotension	O
and	O
QRS	O
prolongation	O
.	O

CaCl2	B-CHED
and	O
4	B-CHED
-	I-CHED
aminopyridine	I-CHED
failed	O
to	O
improve	O
blood	O
pressure	O
.	O

The	O
incidence	O
of	O
ventricular	O
arrhythmias	O
(	O
p	O
=	O
0	O
.	O
004	O
)	O
and	O
seizures	O
(	O
p	O
=	O
0	O
.	O
03	O
)	O
in	O
the	O
CaCl2	B-CHED
group	O
was	O
higher	O
than	O
the	O
other	O
groups	O
.	O

CONCLUSION	O
:	O
The	O
administration	O
of	O
CaCl2	B-CHED
or	O
4	B-CHED
-	I-CHED
aminopyridine	I-CHED
did	O
not	O
reverse	O
tricyclic	O
antidepressant	O
-	O
induced	O
hypotension	O
in	O
rats	O
.	O

CaCl2	B-CHED
therapy	O
may	O
possibly	O
worsen	O
both	O
cardiovascular	O
and	O
central	O
nervous	O
system	O
toxicity	O
.	O

These	O
findings	O
do	O
not	O
support	O
a	O
role	O
for	O
calcium	B-CHED
channel	O
inhibition	O
in	O
the	O
pathogenesis	O
of	O
tricyclic	O
antidepressant	O
-	O
induced	O
hypotension	O
.	O

Valsartan	B-CHED
,	O
a	O
new	O
angiotensin	B-CHED
II	I-CHED
antagonist	O
for	O
the	O
treatment	O
of	O
essential	O
hypertension	O
:	O
a	O
comparative	O
study	O
of	O
the	O
efficacy	O
and	O
safety	O
against	O
amlodipine	B-CHED
.	O

OBJECTIVE	O
:	O
To	O
compare	O
the	O
antihypertensive	O
efficacy	O
of	O
a	O
new	O
angiotensin	B-CHED
II	I-CHED
antagonist	O
,	O
valsartan	B-CHED
,	O
with	O
a	O
reference	O
therapy	O
,	O
amlodipine	B-CHED
.	O

METHODS	O
:	O
One	O
hundred	O
sixty	O
-	O
eight	O
adult	O
outpatients	O
with	O
mild	O
to	O
moderate	O
hypertension	O
were	O
randomly	O
allocated	O
in	O
double	O
-	O
blind	O
fashion	O
and	O
equal	O
number	O
to	O
receive	O
80	O
mg	O
valsartan	B-CHED
or	O
5	O
mg	O
amlodipine	B-CHED
for	O
12	O
weeks	O
.	O

After	O
8	O
weeks	O
of	O
therapy	O
,	O
in	O
patients	O
whose	O
blood	O
pressure	O
remained	O
uncontrolled	O
,	O
5	O
mg	O
amlodipine	B-CHED
was	O
added	O
to	O
the	O
initial	O
therapy	O
.	O

Patients	O
were	O
assessed	O
at	O
4	O
,	O
8	O
,	O
and	O
12	O
weeks	O
.	O

The	O
primary	O
efficacy	O
variable	O
was	O
change	O
from	O
baseline	O
in	O
mean	O
sitting	O
diastolic	O
blood	O
pressure	O
at	O
8	O
weeks	O
.	O

Secondary	O
variables	O
included	O
change	O
in	O
sitting	O
systolic	O
blood	O
pressure	O
and	O
responder	O
rates	O
.	O

RESULTS	O
:	O
Both	O
valsartan	B-CHED
and	O
amlodipine	B-CHED
were	O
effective	O
at	O
lowering	O
blood	O
pressure	O
at	O
4	O
,	O
8	O
,	O
and	O
12	O
weeks	O
.	O

Similar	O
decreases	O
were	O
observed	O
in	O
both	O
groups	O
,	O
with	O
no	O
statistically	O
significant	O
differences	O
between	O
the	O
groups	O
for	O
any	O
variable	O
analyzed	O
.	O

For	O
the	O
primary	O
variable	O
the	O
difference	O
was	O
0	O
.	O
5	O
mm	O
Hg	O
in	O
favor	O
of	O
valsartan	B-CHED
(	O
p	O
=	O
0	O
.	O
68	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
-	O
2	O
.	O
7	O
to	O
1	O
.	O
7	O
)	O
.	O

Responder	O
rates	O
at	O
8	O
weeks	O
were	O
66	O
.	O
7	O
%	O
for	O
valsartan	B-CHED
and	O
60	O
.	O
2	O
%	O
for	O
amlodipine	B-CHED
(	O
p	O
=	O
0	O
.	O
39	O
)	O
.	O

Both	O
treatments	O
were	O
well	O
tolerated	O
.	O

The	O
incidence	O
of	O
drug	O
-	O
related	O
dependent	O
edema	O
was	O
somewhat	O
higher	O
in	O
the	O
amlodipine	B-CHED
group	O
,	O
particularly	O
at	O
a	O
dose	O
of	O
10	O
mg	O
per	O
day	O
(	O
2	O
.	O
4	O
%	O
for	O
80	O
mg	O
valsartan	B-CHED
;	O
3	O
.	O
6	O
%	O
for	O
5	O
mg	O
amlodipine	B-CHED
;	O
0	O
%	O
for	O
valsartan	B-CHED
plus	O
5	O
mg	O
amlodipine	B-CHED
;	O
14	O
.	O
3	O
%	O
for	O
10	O
mg	O
amlodipine	B-CHED
)	O
.	O

CONCLUSIONS	O
:	O
The	O
data	O
show	O
that	O
valsartan	B-CHED
is	O
at	O
least	O
as	O
effective	O
as	O
amlodipine	B-CHED
in	O
the	O
treatment	O
of	O
mild	O
to	O
moderate	O
hypertension	O
.	O

The	O
results	O
also	O
show	O
valsartan	B-CHED
to	O
be	O
well	O
tolerated	O
and	O
suggest	O
that	O
it	O
is	O
not	O
associated	O
with	O
side	O
effects	O
characteristic	O
of	O
this	O
comparator	O
class	O
,	O
dihydropyridine	B-CHED
calcium	B-CHED
antagonists	O
.	O

A	O
measure	O
of	O
pupillary	O
oscillation	O
as	O
a	O
marker	O
of	O
cocaine	B-CHED
-	O
induced	O
paranoia	O
.	O

Cocaine	B-CHED
-	O
induced	O
paranoia	O
(	O
CIP	O
)	O
remains	O
an	O
important	O
drug	O
-	O
induced	O
model	O
of	O
idiopathic	O
paranoia	O
for	O
which	O
no	O
psychophysiologic	O
marker	O
has	O
yet	O
emerged	O
.	O

Measures	O
of	O
pupillary	O
oscillation	O
were	O
able	O
to	O
significantly	O
distinguish	O
a	O
group	O
of	O
abstinent	O
crack	B-CHED
cocaine	I-CHED
abusers	O
endorsing	O
past	O
CIP	O
(	O
n	O
=	O
32	O
)	O
from	O
another	O
group	O
of	O
crack	B-CHED
addicts	O
who	O
denied	O
past	O
CIP	O
(	O
n	O
=	O
29	O
)	O
.	O

Serotonin	O
syndrome	O
from	O
venlafaxine	B-CHED
-	O
tranylcypromine	B-CHED
interaction	O
.	O

Excessive	O
stimulation	O
of	O
serotonin	B-CHED
5HT1A	O
receptors	O
causes	O
a	O
syndrome	O
of	O
serotonin	B-CHED
excess	O
that	O
consists	O
of	O
shivering	O
,	O
muscle	O
rigidity	O
,	O
salivation	O
,	O
confusion	O
,	O
agitation	O
and	O
hyperthermia	O
.	O

The	O
most	O
common	O
cause	O
of	O
this	O
syndrome	O
is	O
an	O
interaction	O
between	O
a	O
monoamine	O
oxidase	O
inhibitor	O
(	O
MAOI	O
)	O
and	O
a	O
specific	O
serotonin	B-CHED
reuptake	O
inhibitor	O
.	O

Venlafaxine	B-CHED
is	O
a	O
new	O
antidepressant	O
agent	O
that	O
inhibits	O
the	O
reuptake	O
of	O
serotonin	B-CHED
and	O
norepinephrine	B-CHED
.	O

We	O
report	O
a	O
venlafaxine	B-CHED
-	O
MAOI	O
interaction	O
that	O
resulted	O
in	O
the	O
serotonin	O
syndrome	O
in	O
a	O
23	O
-	O
y	O
-	O
old	O
male	O
who	O
was	O
taking	O
tranylcypromine	B-CHED
for	O
depression	O
.	O

He	O
had	O
been	O
well	O
until	O
the	O
morning	O
of	O
presentation	O
when	O
he	O
took	O
1	O
/	O
2	O
tab	O
of	O
venlafaxine	B-CHED
.	O

Within	O
2	O
h	O
he	O
became	O
confused	O
with	O
jerking	O
movements	O
of	O
his	O
extremities	O
,	O
tremors	O
and	O
rigidity	O
.	O

He	O
was	O
brought	O
directly	O
to	O
a	O
hospital	O
where	O
he	O
was	O
found	O
to	O
be	O
agitated	O
and	O
confused	O
with	O
shivering	O
,	O
myoclonic	O
jerks	O
,	O
rigidity	O
,	O
salivation	O
and	O
diaphoresis	O
.	O

His	O
pupils	O
were	O
7	O
mm	O
and	O
sluggishly	O
reactive	O
to	O
light	O
.	O

Vital	O
signs	O
were	O
:	O
blood	O
pressure	O
120	O
/	O
67	O
mm	O
Hg	O
,	O
heart	O
rate	O
127	O
/	O
min	O
,	O
respiratory	O
rate	O
28	O
/	O
min	O
,	O
and	O
temperature	O
97	O
F	O
.	O

After	O
180	O
mg	O
of	O
diazepam	B-CHED
i	O
.	O
v	O
.	O
he	O
remained	O
tremulous	O
with	O
muscle	O
rigidity	O
and	O
clenched	O
jaws	O
.	O

He	O
was	O
intubated	O
for	O
airway	O
protection	O
and	O
because	O
of	O
hypoventilation	O
,	O
and	O
was	O
paralyzed	O
to	O
control	O
muscle	O
rigidity	O
.	O

His	O
subsequent	O
course	O
was	O
remarkable	O
for	O
non	O
-	O
immune	O
thrombocytopenia	O
which	O
resolved	O
.	O

The	O
patient	O
'	O
s	O
maximal	O
temperature	O
was	O
101	O
.	O
2	O
F	O
and	O
his	O
CPK	O
remained	O
<	O
500	O
units	O
/	O
L	O
with	O
no	O
other	O
evidence	O
of	O
rhabdomyolysis	O
.	O

His	O
mental	O
status	O
normalized	O
and	O
he	O
was	O
transferred	O
to	O
a	O
psychiatry	O
ward	O
.	O

This	O
patient	O
survived	O
without	O
sequelae	O
due	O
to	O
the	O
aggressive	O
sedation	O
and	O
neuromuscular	O
paralysis	O
.	O

Cyclophosphamide	B-CHED
associated	O
bladder	O
cancer	O
-	O
-	O
a	O
highly	O
aggressive	O
disease	O
:	O
analysis	O
of	O
12	O
cases	O
.	O

PURPOSE	O
:	O
We	O
gained	O
knowledge	O
of	O
the	O
etiology	O
,	O
treatment	O
and	O
prevention	O
of	O
cyclophosphamide	B-CHED
associated	O
urothelial	O
cancer	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
The	O
medical	O
records	O
of	O
6	O
men	O
and	O
6	O
women	O
(	O
mean	O
age	O
55	O
years	O
)	O
with	O
cyclophosphamide	B-CHED
associated	O
bladder	O
cancer	O
were	O
reviewed	O
.	O

RESULTS	O
:	O
All	O
tumors	O
were	O
grade	O
3	O
or	O
4	O
transitional	O
cell	O
carcinoma	O
.	O

Of	O
the	O
5	O
patients	O
initially	O
treated	O
with	O
endoscopic	O
resection	O
alone	O
only	O
1	O
is	O
alive	O
without	O
disease	O
.	O

Of	O
the	O
6	O
patients	O
who	O
underwent	O
early	O
cystectomy	O
4	O
were	O
alive	O
at	O
24	O
to	O
111	O
months	O
.	O

The	O
remaining	O
patient	O
with	O
extensive	O
cancer	O
underwent	O
partial	O
cystectomy	O
for	O
palliation	O
and	O
died	O
3	O
months	O
later	O
.	O

CONCLUSIONS	O
:	O
Cyclophosphamide	B-CHED
associated	O
bladder	O
tumor	O
is	O
an	O
aggressive	O
disease	O
.	O

However	O
,	O
long	O
-	O
term	O
survival	O
is	O
possible	O
when	O
radical	O
cystectomy	O
is	O
performed	O
for	O
bladder	O
tumors	O
with	O
any	O
sign	O
of	O
invasion	O
and	O
for	O
recurrent	O
high	O
grade	O
disease	O
,	O
even	O
when	O
noninvasive	O
.	O

A	O
phase	O
I	O
clinical	O
study	O
of	O
the	O
antipurine	B-CHED
antifolate	O
lometrexol	B-CHED
(	O
DDATHF	B-CHED
)	O
given	O
with	O
oral	O
folic	B-CHED
acid	I-CHED
.	O

Lometrexol	B-CHED
is	O
an	O
antifolate	O
which	O
inhibits	O
glycinamide	B-CHED
ribonucleotide	I-CHED
formyltransferase	O
(	O
GARFT	O
)	O
,	O
an	O
enzyme	O
essential	O
for	O
de	O
novo	O
purine	B-CHED
synthesis	O
.	O

Extensive	O
experimental	O
and	O
limited	O
clinical	O
data	O
have	O
shown	O
that	O
lometrexol	B-CHED
has	O
activity	O
against	O
tumours	O
which	O
are	O
refractory	O
to	O
other	O
drugs	O
,	O
notably	O
methotrexate	B-CHED
.	O

However	O
,	O
the	O
initial	O
clinical	O
development	O
of	O
lometrexol	B-CHED
was	O
curtailed	O
because	O
of	O
severe	O
and	O
cumulative	O
antiproliferative	O
toxicities	O
.	O

Preclinical	O
murine	O
studies	O
demonstrated	O
that	O
the	O
toxicity	O
of	O
lometrexol	B-CHED
can	O
be	O
prevented	O
by	O
low	O
dose	O
folic	B-CHED
acid	I-CHED
administration	O
,	O
i	O
.	O
e	O
.	O
for	O
7	O
days	O
prior	O
to	O
and	O
7	O
days	O
following	O
a	O
single	O
bolus	O
dose	O
.	O

This	O
observation	O
prompted	O
a	O
Phase	O
I	O
clinical	O
study	O
of	O
lometrexol	B-CHED
given	O
with	O
folic	B-CHED
acid	I-CHED
supplementation	O
which	O
has	O
confirmed	O
that	O
the	O
toxicity	O
of	O
lometrexol	B-CHED
can	O
be	O
markedly	O
reduced	O
by	O
folic	B-CHED
acid	I-CHED
supplementation	O
.	O

Thrombocytopenia	O
and	O
mucositis	O
were	O
the	O
major	O
toxicities	O
.	O

There	O
was	O
no	O
clear	O
relationship	O
between	O
clinical	O
toxicity	O
and	O
the	O
extent	O
of	O
plasma	O
folate	B-CHED
elevation	O
.	O

Associated	O
studies	O
demonstrated	O
that	O
lometrexol	B-CHED
plasma	O
pharmacokinetics	O
were	O
not	O
altered	O
by	O
folic	B-CHED
acid	I-CHED
administration	O
indicating	O
that	O
supplementation	O
is	O
unlikely	O
to	O
reduce	O
toxicity	O
by	O
enhancing	O
lometrexol	B-CHED
plasma	O
clearance	O
.	O

The	O
work	O
described	O
in	O
this	O
report	O
has	O
identified	O
for	O
the	O
first	O
time	O
a	O
clinically	O
acceptable	O
schedule	O
for	O
the	O
administration	O
of	O
a	O
GARFT	O
inhibitor	O
.	O

This	O
information	O
will	O
facilitate	O
the	O
future	O
evaluation	O
of	O
this	O
class	O
of	O
compounds	O
in	O
cancer	O
therapy	O
.	O

Fatal	O
excited	O
delirium	O
following	O
cocaine	B-CHED
use	O
:	O
epidemiologic	O
findings	O
provide	O
new	O
evidence	O
for	O
mechanisms	O
of	O
cocaine	B-CHED
toxicity	O
.	O

We	O
describe	O
an	O
outbreak	O
of	O
deaths	O
from	O
cocaine	B-CHED
-	O
induced	O
excited	O
delirium	O
(	O
EDDs	O
)	O
in	O
Dade	O
County	O
,	O
Florida	O
between	O
1979	O
and	O
1990	O
.	O

From	O
a	O
registry	O
of	O
all	O
cocaine	B-CHED
-	O
related	O
deaths	O
in	O
Dade	O
County	O
,	O
Florida	O
,	O
from	O
1969	O
-	O
1990	O
,	O
58	O
EDDs	O
were	O
compared	O
with	O
125	O
victims	O
of	O
accidental	O
cocaine	B-CHED
overdose	O
without	O
excited	O
delirium	O
.	O

Compared	O
with	O
controls	O
,	O
EDDs	O
were	O
more	O
frequently	O
black	O
,	O
male	O
,	O
and	O
younger	O
.	O

They	O
were	O
less	O
likely	O
to	O
have	O
a	O
low	O
body	O
mass	O
index	O
,	O
and	O
more	O
likely	O
to	O
have	O
died	O
in	O
police	O
custody	O
,	O
to	O
have	O
received	O
medical	O
treatment	O
immediately	O
before	O
death	O
,	O
to	O
have	O
survived	O
for	O
a	O
longer	O
period	O
,	O
to	O
have	O
developed	O
hyperthermia	O
,	O
and	O
to	O
have	O
died	O
in	O
summer	O
months	O
.	O

EDDs	O
had	O
concentrations	O
of	O
cocaine	B-CHED
and	O
benzoylecgonine	B-CHED
in	O
autopsy	O
blood	O
that	O
were	O
similar	O
to	O
those	O
for	O
controls	O
.	O

The	O
epidemiologic	O
findings	O
are	O
most	O
consistent	O
with	O
the	O
hypothesis	O
that	O
chronic	O
cocaine	B-CHED
use	O
disrupts	O
dopaminergic	O
function	O
and	O
,	O
when	O
coupled	O
with	O
recent	O
cocaine	B-CHED
use	O
,	O
may	O
precipitate	O
agitation	O
,	O
delirium	O
,	O
aberrant	O
thermoregulation	O
,	O
rhabdomyolysis	O
,	O
and	O
sudden	O
death	O
.	O

Pemoline	B-CHED
induced	O
acute	O
choreoathetosis	O
:	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

BACKGROUND	O
:	O
Pemoline	B-CHED
is	O
an	O
oxazolidine	B-CHED
derivative	O
that	O
is	O
structurally	O
different	O
from	O
amphetamines	B-CHED
and	O
used	O
in	O
the	O
treatment	O
of	O
attention	O
deficit	O
disorder	O
.	O

Pemoline	B-CHED
has	O
not	O
been	O
commonly	O
associated	O
in	O
the	O
literature	O
as	O
a	O
cause	O
of	O
acute	O
movement	O
disorders	O
.	O

The	O
following	O
case	O
describes	O
two	O
children	O
acutely	O
poisoned	O
with	O
pemoline	B-CHED
who	O
experienced	O
profound	O
choreoathetosis	O
.	O

CASE	O
REPORT	O
:	O
Two	O
,	O
3	O
-	O
year	O
-	O
old	O
male	O
,	O
identical	O
twin	O
siblings	O
presented	O
to	O
the	O
emergency	O
department	O
after	O
found	O
playing	O
with	O
a	O
an	O
empty	O
bottle	O
of	O
pemoline	B-CHED
originally	O
containing	O
59	O
tablets	O
.	O

The	O
children	O
had	O
a	O
medical	O
history	O
significant	O
for	O
attention	O
deficit	O
disorder	O
previously	O
treated	O
with	O
methylphenidate	B-CHED
without	O
success	O
.	O

This	O
was	O
their	O
first	O
day	O
of	O
pemoline	B-CHED
therapy	O
.	O

The	O
choreoathetoid	O
movements	O
began	O
45	O
min	O
to	O
1	O
h	O
after	O
ingestion	O
.	O

The	O
children	O
gave	O
no	O
history	O
of	O
prior	O
movement	O
disorders	O
and	O
there	O
was	O
no	O
family	O
history	O
of	O
movement	O
disorders	O
.	O

The	O
children	O
received	O
gastrointestinal	O
decontamination	O
and	O
high	O
doses	O
of	O
intravenous	O
benzodiazepines	B-CHED
in	O
an	O
attempt	O
to	O
control	O
the	O
choreoathetoid	O
movements	O
.	O

Despite	O
treatment	O
,	O
the	O
children	O
continued	O
to	O
have	O
choreoathetosis	O
for	O
approximately	O
24	O
hours	O
.	O

Forty	O
-	O
eight	O
hours	O
after	O
admission	O
,	O
the	O
children	O
appeared	O
to	O
be	O
at	O
their	O
baseline	O
and	O
were	O
discharged	O
home	O
.	O

CONCLUSION	O
:	O
Pemoline	B-CHED
associated	O
movement	O
disorder	O
has	O
been	O
rarely	O
reported	O
in	O
the	O
acute	O
toxicology	O
literature	O
.	O

The	O
possibility	O
of	O
choreoathetoid	O
movements	O
should	O
be	O
considered	O
in	O
patients	O
presenting	O
after	O
pemoline	B-CHED
overdose	O
.	O

Effect	O
of	O
myopic	O
excimer	O
laser	O
photorefractive	O
keratectomy	O
on	O
the	O
electrophysiologic	O
function	O
of	O
the	O
retina	O
and	O
optic	O
nerve	O
.	O

PURPOSE	O
:	O
To	O
assess	O
by	O
electrophysiologic	O
testing	O
the	O
effect	O
of	O
photorefractive	O
keratectomy	O
(	O
PRK	O
)	O
on	O
the	O
retina	O
and	O
optic	O
nerve	O
.	O

SETTING	O
:	O
Eye	O
Clinic	O
,	O
S	O
.	O

Salvatore	O
Hospital	O
,	O
L	O
'	O
Aquila	O
University	O
,	O
Italy	O
.	O

METHODS	O
:	O
Standard	O
pattern	O
electroretinograms	O
(	O
P	O
-	O
ERGs	O
)	O
and	O
standard	O
pattern	O
visual	O
evoked	O
potentials	O
(	O
P	O
-	O
VEPs	O
)	O
were	O
done	O
in	O
25	O
eyes	O
of	O
25	O
patients	O
who	O
had	O
myopic	O
PRK	O
for	O
an	O
attempted	O
correction	O
between	O
5	O
.	O
00	O
and	O
15	O
.	O
00	O
diopters	O
(	O
D	O
)	O
(	O
mean	O
8	O
.	O
00	O
D	O
)	O
.	O

Testing	O
was	O
done	O
preoperatively	O
and	O
3	O
,	O
6	O
,	O
12	O
,	O
and	O
18	O
months	O
postoperatively	O
.	O

The	O
contralateral	O
eyes	O
served	O
as	O
controls	O
.	O

During	O
the	O
follow	O
-	O
up	O
,	O
3	O
patients	O
(	O
12	O
%	O
)	O
developed	O
steroid	B-CHED
-	O
induced	O
elevated	O
intraocular	O
pressure	O
(	O
IOP	O
)	O
that	O
resolved	O
after	O
corticosteroid	B-CHED
therapy	O
was	O
discontinued	O
.	O

RESULTS	O
:	O
No	O
statistically	O
significant	O
differences	O
were	O
seen	O
between	O
treated	O
and	O
control	O
eyes	O
nor	O
between	O
treated	O
eyes	O
preoperatively	O
and	O
postoperatively	O
.	O

CONCLUSION	O
:	O
Myopic	O
excimer	O
laser	O
PRK	O
did	O
not	O
seem	O
to	O
affect	O
the	O
posterior	O
segment	O
.	O

The	O
transient	O
steroid	B-CHED
-	O
induced	O
IOP	O
rise	O
did	O
not	O
seem	O
to	O
cause	O
functional	O
impairment	O
.	O

Neutrophil	O
superoxide	B-CHED
and	O
hydrogen	B-CHED
peroxide	I-CHED
production	O
in	O
patients	O
with	O
acute	O
liver	O
failure	O
.	O

Defects	O
in	O
superoxide	B-CHED
and	O
hydrogen	B-CHED
peroxide	I-CHED
production	O
may	O
be	O
implicated	O
in	O
the	O
high	O
incidence	O
of	O
bacterial	O
infections	O
in	O
patients	O
with	O
acute	O
liver	O
failure	O
(	O
ALF	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
oxygen	B-CHED
radical	O
production	O
in	O
patients	O
with	O
ALF	O
due	O
to	O
paracetamol	B-CHED
overdose	O
was	O
compared	O
with	O
that	O
of	O
healthy	O
volunteers	O
.	O

Neutrophils	O
from	O
14	O
ALF	O
patients	O
were	O
stimulated	O
via	O
the	O
complement	O
receptors	O
using	O
zymosan	O
opsonized	O
with	O
ALF	O
or	O
control	O
serum	O
.	O

Superoxide	B-CHED
and	O
hydrogen	B-CHED
peroxide	I-CHED
production	O
by	O
ALF	O
neutrophils	O
stimulated	O
with	O
zymosan	O
opsonized	O
with	O
ALF	O
serum	O
was	O
significantly	O
reduced	O
compared	O
with	O
the	O
control	O
subjects	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

This	O
defect	O
persisted	O
when	O
zymosan	O
opsonized	O
by	O
control	O
serum	O
was	O
used	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Superoxide	B-CHED
and	O
hydrogen	B-CHED
peroxide	I-CHED
production	O
in	O
neutrophils	O
stimulated	O
with	O
formyl	B-CHED
-	I-CHED
methionyl	I-CHED
-	I-CHED
leucyl	I-CHED
-	I-CHED
phenylalanine	I-CHED
(	O
fMLP	B-CHED
)	O
from	O
a	O
further	O
18	O
ALF	O
patients	O
was	O
unaffected	O
compared	O
with	O
control	O
neutrophils	O
.	O

Serum	O
C3	O
complement	O
levels	O
were	O
significantly	O
reduced	O
in	O
ALF	O
patients	O
compared	O
with	O
control	O
subjects	O
(	O
P	O
<	O
0	O
.	O
0005	O
)	O
.	O

These	O
results	O
demonstrate	O
a	O
neutrophil	O
defect	O
in	O
ALF	O
due	O
to	O
paracetamol	B-CHED
overdose	O
,	O
that	O
is	O
complement	O
dependent	O
but	O
independent	O
of	O
serum	O
complement	O
,	O
possibly	O
connected	O
to	O
the	O
complement	O
receptor	O
.	O

Cholesteryl	B-CHED
hemisuccinate	I-CHED
treatment	O
protects	O
rodents	O
from	O
the	O
toxic	O
effects	O
of	O
acetaminophen	B-CHED
,	O
adriamycin	B-CHED
,	O
carbon	B-CHED
tetrachloride	I-CHED
,	O
chloroform	B-CHED
and	O
galactosamine	B-CHED
.	O

In	O
addition	O
to	O
its	O
use	O
as	O
a	O
stabilizer	O
/	O
rigidifier	O
of	O
membranes	O
,	O
cholesteryl	B-CHED
hemisuccinate	I-CHED
,	O
tris	B-CHED
salt	I-CHED
(	O
CS	B-CHED
)	O
administration	O
has	O
also	O
been	O
shown	O
to	O
protect	O
rats	O
from	O
the	O
hepatotoxic	O
effects	O
of	O
carbon	B-CHED
tetrachloride	I-CHED
(	O
CCl4	B-CHED
)	O
.	O

To	O
further	O
our	O
understanding	O
of	O
the	O
mechanism	O
of	O
CS	B-CHED
cytoprotection	O
,	O
we	O
examined	O
in	O
rats	O
and	O
mice	O
the	O
protective	O
abilities	O
of	O
CS	B-CHED
and	O
the	O
non	O
-	O
hydrolyzable	O
ether	O
form	O
of	O
CS	B-CHED
,	O
gamma	B-CHED
-	I-CHED
cholesteryloxybutyric	I-CHED
acid	I-CHED
,	O
tris	B-CHED
salt	I-CHED
(	O
CSE	B-CHED
)	O
against	O
acetaminophen	B-CHED
-	O
,	O
adriamycin	B-CHED
-	O
,	O
carbon	B-CHED
tetrachloride	I-CHED
-	O
,	O
chloroform	B-CHED
-	O
and	O
galactosamine	B-CHED
-	O
induced	O
toxicity	O
.	O

The	O
results	O
of	O
these	O
studies	O
demonstrated	O
that	O
CS	B-CHED
-	O
mediated	O
protection	O
is	O
not	O
selective	O
for	O
a	O
particular	O
species	O
,	O
organ	O
system	O
or	O
toxic	O
chemical	O
.	O

A	O
24	O
-	O
h	O
pretreatment	O
of	O
both	O
rats	O
and	O
mice	O
with	O
a	O
single	O
dose	O
of	O
CS	B-CHED
(	O
100mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
,	O
resulted	O
in	O
significant	O
protection	O
against	O
the	O
hepatotoxic	O
effects	O
of	O
CCl4	B-CHED
,	O
CHCl3	B-CHED
,	O
acetaminophen	B-CHED
and	O
galactosamine	B-CHED
and	O
against	O
the	O
lethal	O
(	O
and	O
presumably	O
cardiotoxic	O
)	O
effect	O
of	O
adriamycin	B-CHED
administration	O
.	O

Maximal	O
CS	B-CHED
-	O
mediated	O
protection	O
was	O
observed	O
in	O
experimental	O
animals	O
pretreated	O
24	O
h	O
prior	O
to	O
the	O
toxic	O
insult	O
.	O

These	O
data	O
suggest	O
that	O
CS	B-CHED
intervenes	O
in	O
a	O
critical	O
cellular	O
event	O
that	O
is	O
an	O
important	O
common	O
pathway	O
to	O
toxic	O
cell	O
death	O
.	O

The	O
mechanism	O
of	O
CS	B-CHED
protection	O
does	O
not	O
appear	O
to	O
be	O
dependent	O
on	O
the	O
inhibition	O
of	O
chemical	O
bioactivation	O
to	O
a	O
toxic	O
reactive	O
intermediate	O
(	O
in	O
light	O
of	O
the	O
protection	O
observed	O
against	O
galactosamine	B-CHED
hepatotoxicity	O
)	O
.	O

However	O
,	O
based	O
on	O
the	O
data	O
presented	O
,	O
we	O
can	O
not	O
exclude	O
the	O
possibility	O
that	O
CS	B-CHED
administration	O
inhibits	O
chemical	O
bioactivation	O
.	O

Our	O
findings	O
do	O
suggest	O
that	O
CS	B-CHED
-	O
mediated	O
protection	O
is	O
dependent	O
on	O
the	O
action	O
of	O
the	O
intact	O
anionic	O
CS	B-CHED
molecule	O
(	O
non	O
-	O
hydrolyzable	O
CSE	B-CHED
was	O
as	O
protective	O
as	O
CS	B-CHED
)	O
,	O
whose	O
mechanism	O
has	O
yet	O
to	O
be	O
defined	O
.	O

A	O
murine	O
model	O
of	O
adenomyosis	O
:	O
the	O
effects	O
of	O
hyperprolactinemia	O
induced	O
by	O
fluoxetine	B-CHED
hydrochloride	I-CHED
,	O
a	O
selective	O
serotonin	B-CHED
reuptake	O
inhibitor	O
,	O
on	O
adenomyosis	O
induction	O
in	O
Wistar	O
albino	O
rats	O
.	O

OBJECTIVE	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
fluoxetine	B-CHED
given	O
to	O
castrated	O
and	O
noncastrated	O
rats	O
caused	O
hyperprolactinemia	O
and	O
its	O
effects	O
with	O
respect	O
to	O
adenomyosis	O
.	O

DESIGN	O
:	O
Fluoxetine	B-CHED
,	O
a	O
serotonin	B-CHED
reuptake	O
inhibitor	O
,	O
was	O
given	O
to	O
Wistar	O
Albino	O
rats	O
for	O
98	O
days	O
to	O
produce	O
hyperprolactinemia	O
.	O

The	O
drug	O
was	O
given	O
to	O
two	O
groups	O
consisting	O
of	O
castrated	O
and	O
noncastrated	O
rats	O
and	O
compared	O
to	O
two	O
groups	O
of	O
castrated	O
and	O
noncastrated	O
controls	O
.	O

Prolactin	O
levels	O
were	O
measured	O
and	O
the	O
uteri	O
of	O
the	O
rats	O
were	O
removed	O
for	O
histopathological	O
analysis	O
at	O
the	O
end	O
of	O
98	O
days	O
.	O

SETTING	O
:	O
Marmara	O
University	O
School	O
of	O
Medicine	O
,	O
Department	O
of	O
Histology	O
and	O
Embryology	O
,	O
Zeynep	O
Kamil	O
Women	O
and	O
Children	O
'	O
s	O
Hospital	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
:	O
Serum	O
prolactin	O
levels	O
,	O
uterine	O
histopathology	O
.	O

RESULTS	O
:	O
The	O
prolactin	O
levels	O
of	O
castrated	O
and	O
noncastrated	O
groups	O
treated	O
with	O
fluoxetine	B-CHED
were	O
statistically	O
significantly	O
higher	O
when	O
compared	O
to	O
their	O
respective	O
control	O
groups	O
.	O

Histological	O
studies	O
revealed	O
11	O
cases	O
of	O
adenomyosis	O
,	O
all	O
within	O
the	O
noncastrated	O
group	O
receiving	O
fluoxetine	B-CHED
.	O

CONCLUSION	O
:	O
It	O
was	O
suggested	O
that	O
high	O
serum	O
prolactin	O
levels	O
cause	O
degeneration	O
of	O
myometrial	O
cells	O
in	O
the	O
presence	O
of	O
ovarian	O
steroids	B-CHED
that	O
results	O
in	O
a	O
myometrial	O
invasion	O
by	O
endometrial	O
stroma	O
.	O

This	O
invasion	O
eventually	O
progresses	O
to	O
adenomyosis	O
.	O

Postinfarction	O
ventricular	O
septal	O
defect	O
associated	O
with	O
long	O
-	O
term	O
steroid	B-CHED
therapy	O
.	O

Two	O
cases	O
of	O
postinfarction	O
ventricular	O
septal	O
rupture	O
in	O
patients	O
on	O
long	O
-	O
term	O
steroid	B-CHED
therapy	O
are	O
presented	O
and	O
the	O
favourable	O
outcome	O
in	O
both	O
cases	O
described	O
.	O

A	O
possible	O
association	O
between	O
steroid	B-CHED
therapy	O
and	O
subsequent	O
postinfarction	O
septal	O
rupture	O
is	O
discussed	O
.	O

Neuroactive	O
steroids	B-CHED
protect	O
against	O
pilocarpine	B-CHED
-	O
and	O
kainic	B-CHED
acid	I-CHED
-	O
induced	O
limbic	O
seizures	O
and	O
status	O
epilepticus	O
in	O
mice	O
.	O

Several	O
structurally	O
related	O
metabolites	O
of	O
progesterone	B-CHED
(	O
3	B-CHED
alpha	I-CHED
-	I-CHED
hydroxy	I-CHED
pregnane	I-CHED
-	I-CHED
20	I-CHED
-	I-CHED
ones	I-CHED
)	O
and	O
deoxycorticosterone	B-CHED
(	O
3	B-CHED
alpha	I-CHED
-	I-CHED
hydroxy	I-CHED
pregnane	I-CHED
-	I-CHED
21	I-CHED
-	I-CHED
diol	I-CHED
-	I-CHED
20	I-CHED
-	I-CHED
ones	I-CHED
)	O
and	O
their	O
3	O
beta	O
-	O
epimers	O
were	O
evaluated	O
for	O
protective	O
activity	O
against	O
pilocarpine	B-CHED
-	O
,	O
kainic	B-CHED
acid	I-CHED
-	O
and	O
N	B-CHED
-	I-CHED
methyl	I-CHED
-	I-CHED
D	I-CHED
-	I-CHED
aspartate	I-CHED
(	O
NMDA	B-CHED
)	O
-	O
induced	O
seizures	O
in	O
mice	O
.	O

Steroids	B-CHED
with	O
the	O
3	O
-	O
hydroxy	O
group	O
in	O
the	O
alpha	O
-	O
position	O
and	O
5	O
-	O
H	O
in	O
the	O
alpha	O
-	O
or	O
beta	O
-	O
configurations	O
were	O
highly	O
effective	O
in	O
protecting	O
against	O
pilocarpine	B-CHED
(	O
416	O
mg	O
/	O
kg	O
,	O
s	O
.	O
c	O
.	O
)	O
-	O
induced	O
limbic	O
motor	O
seizures	O
and	O
status	O
epilepticus	O
(	O
ED50	O
values	O
,	O
7	O
.	O
0	O
-	O
18	O
.	O
7	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
.	O

The	O
corresponding	O
epimers	O
with	O
the	O
3	O
-	O
hydroxy	O
group	O
in	O
the	O
beta	O
-	O
position	O
were	O
also	O
effective	O
but	O
less	O
potent	O
(	O
ED50	O
values	O
,	O
33	O
.	O
8	O
-	O
63	O
.	O
5	O
,	O
i	O
.	O
p	O
.	O
)	O
.	O

Although	O
the	O
neuroactive	O
steroids	B-CHED
were	O
considerably	O
less	O
potent	O
than	O
the	O
benzodiazepine	B-CHED
clonazepam	B-CHED
in	O
protecting	O
against	O
pilocarpine	B-CHED
seizures	O
,	O
steroids	B-CHED
with	O
the	O
5	O
alpha	O
,	O
3	O
alpha	O
-	O
configuration	O
had	O
comparable	O
or	O
higher	O
protective	O
index	O
values	O
(	O
TD50	O
for	O
motor	O
impairment	O
divided	O
by	O
ED50	O
for	O
seizure	O
protection	O
)	O
than	O
clonazepam	B-CHED
,	O
indicating	O
that	O
some	O
neuroactive	O
steroids	B-CHED
may	O
have	O
lower	O
relative	O
toxicity	O
.	O

Steroids	B-CHED
with	O
the	O
5	O
alpha	O
,	O
3	O
alpha	O
-	O
or	O
5	O
beta	O
,	O
3	O
alpha	O
-	O
configurations	O
also	O
produced	O
a	O
dose	O
-	O
dependent	O
delay	O
in	O
the	O
onset	O
of	O
limbic	O
seizures	O
induced	O
by	O
kainic	B-CHED
acid	I-CHED
(	O
32	O
mg	O
/	O
kg	O
,	O
s	O
.	O
c	O
.	O
)	O
,	O
but	O
did	O
not	O
completely	O
protect	O
against	O
the	O
seizures	O
.	O

However	O
,	O
when	O
a	O
second	O
dose	O
of	O
the	O
steroid	B-CHED
was	O
administered	O
1	O
hr	O
after	O
the	O
first	O
dose	O
,	O
complete	O
protection	O
from	O
the	O
kainic	B-CHED
acid	I-CHED
-	O
induced	O
limbic	O
seizures	O
and	O
status	O
epilepticus	O
was	O
obtained	O
.	O

The	O
steroids	B-CHED
also	O
caused	O
a	O
dose	O
-	O
dependent	O
delay	O
in	O
NMDA	B-CHED
(	O
257	O
mg	O
/	O
kg	O
,	O
s	O
.	O
c	O
.	O
)	O
-	O
induced	O
lethality	O
,	O
but	O
did	O
not	O
completely	O
protect	O
against	O
NMDA	B-CHED
seizures	O
or	O
lethality	O
.	O

We	O
conclude	O
that	O
neuroactive	O
steroids	B-CHED
are	O
highly	O
effective	O
in	O
protecting	O
against	O
pilocarpine	B-CHED
-	O
and	O
kainic	B-CHED
acid	I-CHED
-	O
induced	O
seizures	O
and	O
status	O
epilepticus	O
in	O
mice	O
,	O
and	O
may	O
be	O
of	O
utility	O
in	O
the	O
treatment	O
of	O
some	O
forms	O
of	O
status	O
epilepticus	O
in	O
humans	O
.	O

Hepatic	O
and	O
extrahepatic	O
angiotensinogen	O
gene	O
expression	O
in	O
rats	O
with	O
acute	O
nephrotic	O
syndrome	O
.	O

Plasma	O
concentration	O
and	O
urine	O
excretion	O
of	O
the	O
renin	O
-	O
angiotensin	B-CHED
system	O
proteins	O
are	O
altered	O
in	O
rats	O
with	O
nephrotic	O
syndrome	O
(	O
NS	O
)	O
.	O

In	O
this	O
work	O
the	O
messenger	O
ribonucleic	O
acid	O
(	O
mRNA	O
)	O
levels	O
of	O
angiotensinogen	O
(	O
Ao	O
)	O
were	O
analyzed	O
with	O
the	O
slot	O
-	O
blot	O
hybridization	O
technique	O
in	O
liver	O
and	O
other	O
extrahepatic	O
tissues	O
:	O
kidney	O
,	O
heart	O
,	O
brain	O
,	O
and	O
adrenal	O
gland	O
from	O
control	O
,	O
nephrotic	O
,	O
and	O
pair	O
-	O
fed	O
(	O
PF	O
)	O
rats	O
.	O

NS	O
was	O
induced	O
by	O
a	O
single	O
injection	O
of	O
puromycin	B-CHED
amino	I-CHED
-	I-CHED
nucleoside	I-CHED
(	O
PAN	B-CHED
)	O
.	O

Although	O
a	O
great	O
urinary	O
excretion	O
and	O
half	O
-	O
normal	O
plasma	O
levels	O
of	O
Ao	O
were	O
observed	O
on	O
day	O
6	O
after	O
PAN	B-CHED
injection	O
,	O
when	O
NS	O
was	O
clearly	O
established	O
,	O
hepatic	O
Ao	O
mRNA	O
levels	O
did	O
not	O
change	O
.	O

Furthermore	O
,	O
the	O
Ao	O
mRNA	O
levels	O
did	O
not	O
change	O
in	O
any	O
of	O
the	O
extrahepatic	O
tissues	O
studied	O
on	O
day	O
6	O
,	O
nor	O
did	O
its	O
hepatic	O
levels	O
at	O
days	O
1	O
,	O
3	O
,	O
5	O
,	O
or	O
7	O
after	O
PAN	B-CHED
injection	O
.	O

These	O
data	O
suggest	O
that	O
the	O
hepatic	O
and	O
extrahepatic	O
Ao	O
mRNA	O
levels	O
are	O
unaltered	O
during	O
the	O
development	O
of	O
the	O
acute	O
NS	O
induced	O
by	O
PAN	B-CHED
.	O

Neuroleptic	O
malignant	O
syndrome	O
with	O
risperidone	B-CHED
.	O

Neuroleptic	O
malignant	O
syndrome	O
is	O
thought	O
to	O
be	O
a	O
result	O
of	O
dopamine	B-CHED
D2	O
receptor	O
blockade	O
in	O
the	O
striatum	O
of	O
the	O
basal	O
ganglia	O
.	O

Risperidone	B-CHED
,	O
a	O
benzisoxazole	B-CHED
derivative	O
antipsychotic	O
,	O
has	O
high	O
serotonin	B-CHED
5	O
-	O
HT2	O
receptor	O
blockade	O
and	O
dose	O
-	O
related	O
D2	O
receptor	O
blockade	O
.	O

The	O
high	O
ratio	O
is	O
believed	O
to	O
impart	O
the	O
low	O
frequency	O
of	O
extrapyramidal	O
symptoms	O
with	O
risperidone	B-CHED
at	O
low	O
dosages	O
.	O

With	O
this	O
low	O
frequency	O
of	O
extrapyramidal	O
symptoms	O
,	O
it	O
was	O
thought	O
the	O
frequency	O
of	O
neuroleptic	O
malignant	O
syndrome	O
might	O
also	O
be	O
lowered	O
.	O

A	O
73	O
-	O
year	O
-	O
old	O
woman	O
developed	O
neuroleptic	O
malignant	O
syndrome	O
after	O
monotherapy	O
with	O
risperidone	B-CHED
.	O

The	O
syndrome	O
reversed	O
after	O
discontinuing	O
risperidone	B-CHED
and	O
starting	O
treatment	O
with	O
dantrolene	B-CHED
and	O
bromocriptine	B-CHED
.	O

It	O
appears	O
that	O
the	O
protection	O
from	O
extrapyramidal	O
side	O
effects	O
observed	O
with	O
risperidone	B-CHED
does	O
not	O
ensure	O
protection	O
from	O
neuroleptic	O
malignant	O
syndrome	O
.	O

The	O
attenuating	O
effect	O
of	O
carteolol	B-CHED
hydrochloride	I-CHED
,	O
a	O
beta	O
-	O
adrenoceptor	O
antagonist	O
,	O
on	O
neuroleptic	O
-	O
induced	O
catalepsy	O
in	O
rats	O
.	O

It	O
is	O
known	O
that	O
beta	O
-	O
adrenoceptor	O
antagonists	O
are	O
effective	O
in	O
the	O
treatment	O
of	O
akathisia	O
,	O
one	O
of	O
the	O
extrapyramidal	O
side	O
effects	O
that	O
occur	O
during	O
neuroleptic	O
treatment	O
.	O

Neuroleptic	O
-	O
induced	O
catalepsy	O
,	O
a	O
model	O
of	O
neuroleptic	O
-	O
induced	O
extrapyramidal	O
side	O
effects	O
,	O
was	O
considered	O
suitable	O
as	O
a	O
model	O
for	O
predicting	O
neuroleptic	O
-	O
induced	O
akathisia	O
in	O
humans	O
,	O
although	O
neuroleptic	O
-	O
induced	O
catalepsy	O
was	O
not	O
considered	O
a	O
specific	O
test	O
for	O
neuroleptic	O
-	O
induced	O
akathisia	O
.	O

Therefore	O
,	O
the	O
effects	O
of	O
carteolol	B-CHED
,	O
a	O
beta	O
-	O
adrenoceptor	O
antagonist	O
,	O
on	O
haloperidol	B-CHED
-	O
induced	O
catalepsy	O
in	O
rats	O
were	O
behaviorally	O
studied	O
and	O
compared	O
with	O
those	O
of	O
propranolol	B-CHED
and	O
biperiden	B-CHED
,	O
a	O
muscarinic	O
receptor	O
antagonist	O
.	O

Carteolol	B-CHED
,	O
as	O
well	O
as	O
propranolol	B-CHED
and	O
biperiden	B-CHED
,	O
inhibited	O
the	O
haloperidol	B-CHED
-	O
induced	O
catalepsy	O
.	O

The	O
inhibitory	O
effect	O
of	O
carteolol	B-CHED
was	O
almost	O
comparable	O
to	O
that	O
of	O
propranolol	B-CHED
,	O
but	O
was	O
weaker	O
than	O
that	O
of	O
biperiden	B-CHED
.	O

Carteolol	B-CHED
did	O
not	O
evoke	O
postsynaptic	O
dopamine	B-CHED
receptor	O
-	O
stimulating	O
behavioral	O
signs	O
such	O
as	O
stereotypy	O
and	O
hyperlocomotion	O
in	O
rats	O
.	O

Carteolol	B-CHED
did	O
not	O
antagonize	O
the	O
inhibitory	O
effects	O
of	O
haloperidol	B-CHED
on	O
apomorphine	B-CHED
-	O
induced	O
stereotypy	O
and	O
locomotor	O
activity	O
in	O
rats	O
.	O

In	O
addition	O
,	O
carteolol	B-CHED
did	O
not	O
evoke	O
5	O
-	O
HT1A	O
receptor	O
-	O
stimulating	O
behavioral	O
signs	O
such	O
as	O
flat	O
body	O
posture	O
and	O
forepaw	O
treading	O
and	O
did	O
not	O
inhibit	O
5	B-CHED
-	I-CHED
hydroxytryptophan	I-CHED
-	O
induced	O
head	O
twitch	O
in	O
rats	O
.	O

Finally	O
,	O
carteolol	B-CHED
did	O
not	O
inhibit	O
physostigmine	B-CHED
-	O
induced	O
lethality	O
in	O
rats	O
.	O

These	O
results	O
strongly	O
suggest	O
that	O
carteolol	B-CHED
improves	O
haloperidol	B-CHED
-	O
induced	O
catalepsy	O
via	O
its	O
beta	O
-	O
adrenoceptor	O
antagonistic	O
activity	O
and	O
is	O
expected	O
to	O
be	O
effective	O
in	O
the	O
treatment	O
of	O
akathisia	O
without	O
attenuating	O
neuroleptic	O
-	O
induced	O
antipsychotic	O
effects	O
due	O
to	O
its	O
postsynaptic	O
dopamine	B-CHED
receptor	O
antagonistic	O
activity	O
.	O

Granulosa	O
cell	O
tumor	O
of	O
the	O
ovary	O
associated	O
with	O
antecedent	O
tamoxifen	B-CHED
use	O
.	O

BACKGROUND	O
:	O
Increased	O
attention	O
has	O
been	O
focused	O
recently	O
on	O
the	O
estrogenic	O
effects	O
of	O
tamoxifen	B-CHED
.	O

Review	O
of	O
the	O
literature	O
reveals	O
an	O
association	O
between	O
tamoxifen	B-CHED
use	O
and	O
gynecologic	O
tumors	O
.	O

CASE	O
:	O
A	O
52	O
-	O
year	O
-	O
old	O
postmenopausal	O
woman	O
was	O
treated	O
with	O
tamoxifen	B-CHED
for	O
stage	O
II	O
estrogen	B-CHED
receptor	O
-	O
positive	O
breast	O
carcinoma	O
.	O

Her	O
aspartate	B-CHED
transaminase	O
and	O
alanine	B-CHED
transaminase	O
levels	O
increase	O
markedly	O
after	O
6	O
months	O
of	O
tamoxifen	B-CHED
use	O
.	O

After	O
an	O
additional	O
17	O
months	O
of	O
elevated	O
serum	O
transaminases	O
,	O
the	O
patient	O
was	O
found	O
to	O
have	O
a	O
stage	O
Ic	O
granulosa	O
cell	O
tumor	O
of	O
the	O
ovary	O
.	O

CONCLUSION	O
:	O
Patients	O
with	O
tamoxifen	B-CHED
-	O
induced	O
liver	O
dysfunction	O
may	O
be	O
at	O
increased	O
risk	O
for	O
granulosa	O
cell	O
tumors	O
because	O
of	O
alterations	O
in	O
tamoxifen	B-CHED
metabolism	O
.	O

Lifetime	O
treatment	O
of	O
mice	O
with	O
azidothymidine	B-CHED
(	O
AZT	B-CHED
)	O
produces	O
myelodysplasia	O
.	O

AZT	B-CHED
has	O
induced	O
a	O
macrocytic	O
anemia	O
in	O
AIDS	O
patients	O
on	O
long	O
term	O
AZT	B-CHED
therapy	O
.	O

It	O
is	O
generally	O
assumed	O
that	O
DNA	O
elongation	O
is	O
stopped	O
by	O
the	O
insertion	O
of	O
AZT	B-CHED
into	O
the	O
chain	O
in	O
place	O
of	O
thymidine	B-CHED
thus	O
preventing	O
the	O
phosphate	B-CHED
hydroxyl	O
linkages	O
and	O
therefore	O
suppresses	O
hemopoietic	O
progenitor	O
cell	O
proliferation	O
in	O
an	O
early	O
stage	O
of	O
differentiation	O
.	O

CBA	O
/	O
Ca	O
male	O
mice	O
started	O
on	O
AZT	B-CHED
0	O
.	O
75	O
mg	O
/	O
ml	O
H2O	O
at	O
84	O
days	O
of	O
age	O
and	O
kept	O
on	O
it	O
for	O
687	O
days	O
when	O
dosage	O
reduced	O
to	O
0	O
.	O
5	O
mg	O
/	O
ml	O
H2O	O
for	O
a	O
group	O
,	O
another	O
group	O
removed	O
from	O
AZT	B-CHED
to	O
see	O
recovery	O
,	O
and	O
third	O
group	O
remained	O
on	O
0	O
.	O
75	O
mg	O
.	O

At	O
687	O
days	O
mice	O
that	O
had	O
been	O
on	O
0	O
.	O
75	O
mg	O
had	O
average	O
platelet	O
counts	O
of	O
2	O
.	O
5	O
x	O
10	O
(	O
6	O
)	O
.	O

Histological	O
examination	O
on	O
9	O
of	O
10	O
mice	O
with	O
such	O
thrombocytopenia	O
showed	O
changes	O
compatible	O
with	O
myelodysplastic	O
syndrome	O
(	O
MDS	O
)	O
.	O

A	O
variety	O
of	O
histological	O
patterns	O
was	O
observed	O
.	O

There	O
were	O
two	O
cases	O
of	O
hypocellular	O
myelodysplasia	O
,	O
two	O
cases	O
of	O
hypersegmented	O
myelodysplastic	O
granulocytosis	O
,	O
two	O
cases	O
of	O
hypercellular	O
marrow	O
with	O
abnormal	O
megakaryocytes	O
with	O
bizarre	O
nuclei	O
,	O
one	O
case	O
of	O
megakaryocytic	O
myelosis	O
associated	O
with	O
a	O
hyperplastic	O
marrow	O
,	O
dysmyelopoiesis	O
and	O
a	O
hypocellular	O
marrow	O
and	O
two	O
cases	O
of	O
myelodysplasia	O
with	O
dyserythropoiesis	O
,	O
hemosiderosis	O
and	O
a	O
hypocellular	O
marrow	O
.	O

Above	O
mentioned	O
AZT	B-CHED
incorporation	O
may	O
have	O
induced	O
an	O
ineffective	O
hemopoiesis	O
in	O
the	O
primitive	O
hemopoietic	O
progenitor	O
cells	O
,	O
which	O
is	O
known	O
to	O
be	O
seen	O
commonly	O
in	O
the	O
myelodysplastic	O
syndrome	O
.	O

Biphasic	O
response	O
of	O
the	O
SA	O
node	O
of	O
the	O
dog	O
heart	O
in	O
vivo	O
to	O
selective	O
administration	O
of	O
ketamine	B-CHED
.	O

Effect	O
of	O
ketamine	B-CHED
on	O
the	O
SA	O
node	O
of	O
the	O
dog	O
heart	O
was	O
studied	O
in	O
vivo	O
using	O
a	O
selective	O
perfusion	O
technique	O
of	O
the	O
SA	O
node	O
artery	O
.	O

Injections	O
of	O
ketamine	B-CHED
in	O
doses	O
from	O
100	O
microgram	O
to	O
3	O
mg	O
into	O
the	O
artery	O
produced	O
a	O
depression	O
of	O
the	O
SA	O
nodal	O
activity	O
by	O
a	O
direct	O
action	O
.	O

This	O
depression	O
was	O
followed	O
by	O
the	O
sudden	O
appearance	O
of	O
a	O
stimulatory	O
phase	O
.	O

Bilateral	O
vagotomy	O
and	O
sympathectomy	O
or	O
prior	O
administration	O
of	O
a	O
ganglion	O
blocker	O
failed	O
to	O
inhibit	O
the	O
occurrence	O
of	O
the	O
ketamine	B-CHED
-	O
induced	O
tachycardia	O
,	O
while	O
it	O
was	O
completely	O
abolished	O
in	O
the	O
reserpinized	O
dogs	O
or	O
by	O
a	O
prior	O
injection	O
of	O
a	O
beta	O
-	O
blocking	O
agent	O
into	O
the	O
SA	O
node	O
artery	O
.	O

This	O
may	O
indicate	O
that	O
an	O
activation	O
of	O
the	O
peripheral	O
adrenergic	O
mechanism	O
plays	O
an	O
important	O
role	O
in	O
the	O
induction	O
of	O
the	O
excitatory	O
effect	O
of	O
ketamine	B-CHED
injected	O
in	O
the	O
SA	O
node	O
artery	O
.	O

Over	O
expression	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
and	O
its	O
receptor	O
during	O
the	O
development	O
of	O
estrogen	B-CHED
-	O
induced	O
rat	O
pituitary	O
tumors	O
may	O
mediate	O
estrogen	B-CHED
-	O
initiated	O
tumor	O
angiogenesis	O
.	O

Estrogens	B-CHED
,	O
which	O
have	O
been	O
associated	O
with	O
several	O
types	O
of	O
human	O
and	O
animal	O
cancers	O
,	O
can	O
induce	O
tumor	O
angiogenesis	O
in	O
the	O
pituitary	O
of	O
Fischer	O
344	O
rats	O
.	O

The	O
mechanistic	O
details	O
of	O
tumor	O
angiogenesis	O
induction	O
,	O
during	O
estrogen	B-CHED
carcinogenesis	O
,	O
are	O
still	O
unknown	O
.	O

To	O
elucidate	O
the	O
role	O
of	O
estrogen	B-CHED
in	O
the	O
regulation	O
of	O
tumor	O
angiogenesis	O
in	O
the	O
pituitary	O
of	O
female	O
rats	O
,	O
the	O
density	O
of	O
blood	O
vessels	O
was	O
analysed	O
using	O
factor	O
VIII	O
related	O
antigen	O
(	O
FVIIIRAg	O
)	O
immunohistochemistry	O
and	O
the	O
expression	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
/	O
vascular	O
permeability	O
factor	O
(	O
VEGF	O
/	O
VPF	O
)	O
was	O
examined	O
by	O
Western	O
blot	O
and	O
immunohistochemical	O
analysis	O
.	O

The	O
expression	O
of	O
VEGF	O
receptor	O
(	O
VEGFR	O
-	O
2	O
/	O
Flk	O
-	O
1	O
/	O
KDR	O
)	O
was	O
also	O
examined	O
by	O
immunohistochemistry	O
.	O

The	O
results	O
demonstrated	O
that	O
17beta	B-CHED
-	I-CHED
estradiol	I-CHED
(	O
E2	B-CHED
)	O
induces	O
neovascularization	O
,	O
as	O
well	O
as	O
the	O
growth	O
and	O
enlargement	O
of	O
blood	O
vessels	O
after	O
7	O
days	O
of	O
exposure	O
.	O

The	O
high	O
tumor	O
angiogenic	O
potential	O
was	O
associated	O
with	O
an	O
elevated	O
VEGF	O
/	O
VPF	O
protein	O
expression	O
in	O
the	O
E2	B-CHED
exposed	O
pituitary	O
of	O
ovariectomized	O
(	O
OVEX	O
)	O
rats	O
.	O

VEGF	O
/	O
VPF	O
and	O
FVIIIRAg	O
immunohistochemistry	O
and	O
endothelial	O
specific	O
lectin	O
(	O
UEA1	O
)	O
binding	O
studies	O
,	O
indicate	O
that	O
the	O
elevation	O
of	O
VEGF	O
protein	O
expression	O
initially	O
occurred	O
in	O
both	O
blood	O
vessels	O
and	O
non	O
-	O
endothelial	O
cells	O
.	O

After	O
15	O
days	O
of	O
E2	B-CHED
exposure	O
,	O
VEGF	O
/	O
VPF	O
protein	O
expression	O
,	O
in	O
the	O
non	O
-	O
endothelial	O
cell	O
population	O
,	O
sharply	O
declined	O
and	O
was	O
restricted	O
to	O
the	O
blood	O
vessels	O
.	O

The	O
function	O
of	O
non	O
-	O
endothelial	O
-	O
derived	O
VEGF	O
is	O
not	O
clear	O
.	O

Furthermore	O
,	O
immunohistochemical	O
studies	O
demonstrated	O
that	O
VEGFR	O
-	O
2	O
(	O
flk	O
-	O
1	O
/	O
KDR	O
)	O
,	O
expression	O
was	O
elevated	O
significantly	O
in	O
the	O
endothelial	O
cells	O
of	O
microblood	O
vessels	O
after	O
7	O
days	O
of	O
E2	B-CHED
exposure	O
.	O

These	O
findings	O
suggest	O
that	O
over	O
expression	O
of	O
VEGF	O
and	O
its	O
receptor	O
(	O
VEGFR	O
-	O
2	O
)	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
initial	O
step	O
of	O
the	O
regulation	O
of	O
estrogen	B-CHED
induced	O
tumor	O
angiogenesis	O
in	O
the	O
rat	O
pituitary	O
.	O

Persistent	O
nephrogenic	O
diabetes	O
insipidus	O
following	O
lithium	B-CHED
therapy	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
patient	O
who	O
developed	O
severe	O
hypernatraemic	O
dehydration	O
following	O
a	O
head	O
injury	O
.	O

Ten	O
years	O
previously	O
he	O
had	O
been	O
diagnosed	O
to	O
have	O
lithium	B-CHED
-	O
induced	O
nephrogenic	O
diabetes	O
insipidus	O
,	O
and	O
lithium	B-CHED
therapy	O
had	O
been	O
discontinued	O
.	O

He	O
remained	O
thirsty	O
and	O
polyuric	O
despite	O
cessation	O
of	O
lithium	B-CHED
and	O
investigations	O
on	O
admission	O
showed	O
him	O
to	O
have	O
normal	O
osmoregulated	O
thirst	O
and	O
vasopressin	B-CHED
secretion	O
,	O
with	O
clear	O
evidence	O
of	O
nephrogenic	O
diabetes	O
insipidus	O
.	O

Lithium	B-CHED
induced	O
nephrogenic	O
diabetes	O
insipidus	O
is	O
considered	O
to	O
be	O
reversible	O
on	O
cessation	O
of	O
therapy	O
but	O
polyuria	O
persisted	O
in	O
this	O
patient	O
for	O
ten	O
years	O
after	O
lithium	B-CHED
was	O
stopped	O
.	O

We	O
discuss	O
the	O
possible	O
renal	O
mechanisms	O
and	O
the	O
implications	O
for	O
management	O
of	O
patients	O
with	O
lithium	B-CHED
-	O
induced	O
nephrogenic	O
diabetes	O
insipidus	O
.	O

Effects	O
of	O
NIK	B-CHED
-	I-CHED
247	I-CHED
on	O
cholinesterase	O
and	O
scopolamine	B-CHED
-	O
induced	O
amnesia	O
.	O

The	O
effects	O
of	O
NIK	B-CHED
-	I-CHED
247	I-CHED
on	O
cholinesterase	O
,	O
scopolamine	B-CHED
-	O
induced	O
amnesia	O
and	O
spontaneous	O
movement	O
were	O
examined	O
and	O
compared	O
with	O
those	O
of	O
the	O
well	O
-	O
known	O
cholinesterase	O
inhibitors	O
tacrine	B-CHED
and	O
E	B-CHED
-	I-CHED
2020	I-CHED
.	O

NIK	B-CHED
-	I-CHED
247	I-CHED
,	O
tacrine	B-CHED
and	O
E	B-CHED
-	I-CHED
2020	I-CHED
all	O
strongly	O
inhibited	O
acetylcholinesterase	O
(	O
AChE	O
)	O
in	O
human	O
red	O
blood	O
cells	O
(	O
IC50s	O
=	O
1	O
.	O
0	O
x	O
10	O
(	O
-	O
6	O
)	O
,	O
2	O
.	O
9	O
x	O
10	O
(	O
-	O
7	O
)	O
and	O
3	O
.	O
7	O
x	O
10	O
(	O
-	O
8	O
)	O
M	O
,	O
respectively	O
)	O
.	O

In	O
addition	O
,	O
NIK	B-CHED
-	I-CHED
247	I-CHED
and	O
tacrine	B-CHED
,	O
but	O
not	O
E	B-CHED
-	I-CHED
2020	I-CHED
,	O
strongly	O
inhibited	O
butyrylcholinestrase	O
(	O
BuChE	O
)	O
in	O
human	O
serum	O
.	O

All	O
three	O
drugs	O
produced	O
mixed	O
inhibition	O
of	O
AChE	O
activity	O
.	O

Moreover	O
,	O
the	O
inhibitory	O
effect	O
of	O
NIK	B-CHED
-	I-CHED
247	I-CHED
on	O
AChE	O
was	O
reversible	O
.	O

All	O
compounds	O
at	O
0	O
.	O
1	O
-	O
1	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O
significantly	O
improved	O
the	O
amnesia	O
induced	O
by	O
scopolamine	B-CHED
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
in	O
rats	O
performing	O
a	O
passive	O
avoidance	O
task	O
.	O

The	O
three	O
compounds	O
at	O
1	O
and	O
3	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O
did	O
not	O
significantly	O
decrease	O
spontaneous	O
movement	O
by	O
rats	O
.	O

These	O
findings	O
suggest	O
that	O
NIK	B-CHED
-	I-CHED
247	I-CHED
at	O
a	O
low	O
dose	O
(	O
0	O
.	O
1	O
-	O
1	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O
)	O
improves	O
scopolamine	B-CHED
-	O
induced	O
amnesia	O
but	O
does	O
not	O
affect	O
spontaneous	O
movement	O
.	O

The	O
findings	O
suggest	O
that	O
NIK	B-CHED
-	I-CHED
247	I-CHED
may	O
be	O
a	O
useful	O
drug	O
for	O
the	O
treatment	O
of	O
Alzheimer	O
'	O
s	O
disease	O
.	O

Potential	O
therapeutic	O
use	O
of	O
the	O
selective	O
dopamine	B-CHED
D1	O
receptor	O
agonist	O
,	O
A	B-CHED
-	I-CHED
86929	I-CHED
:	O
an	O
acute	O
study	O
in	O
parkinsonian	O
levodopa	B-CHED
-	O
primed	O
monkeys	O
.	O

The	O
clinical	O
utility	O
of	O
dopamine	B-CHED
(	O
DA	B-CHED
)	O
D1	O
receptor	O
agonists	O
in	O
the	O
treatment	O
of	O
Parkinson	O
'	O
s	O
disease	O
(	O
PD	O
)	O
is	O
still	O
unclear	O
.	O

The	O
therapeutic	O
use	O
of	O
selective	O
DA	B-CHED
D1	O
receptor	O
agonists	O
such	O
as	O
SKF	B-CHED
-	I-CHED
82958	I-CHED
(	O
6	B-CHED
-	I-CHED
chloro	I-CHED
-	I-CHED
7	I-CHED
,	I-CHED
8	I-CHED
-	I-CHED
dihydroxy	I-CHED
-	I-CHED
3	I-CHED
-	I-CHED
allyl	I-CHED
-	I-CHED
1	I-CHED
-	I-CHED
phenyl	I-CHED
-	I-CHED
2	I-CHED
,	I-CHED
3	I-CHED
,	I-CHED
4	I-CHED
,	I-CHED
5	I-CHED
-	I-CHED
tetrahydro	I-CHED
-	I-CHED
1H	I-CHED
-	I-CHED
3	I-CHED
-	I-CHED
benzaze	I-CHED
pine	I-CHED
hydrobromide	I-CHED
)	O
and	O
A	B-CHED
-	I-CHED
77636	I-CHED
(	O
[	B-CHED
1R	I-CHED
,	I-CHED
3S	I-CHED
]	I-CHED
3	I-CHED
-	I-CHED
[	I-CHED
1	I-CHED
'	I-CHED
-	I-CHED
admantyl	I-CHED
]	I-CHED
-	I-CHED
1	I-CHED
-	I-CHED
aminomethyl	I-CHED
-	I-CHED
3	I-CHED
,	I-CHED
4	I-CHED
-	I-CHED
dihydro	I-CHED
-	I-CHED
5	I-CHED
,	I-CHED
6	I-CHED
-	I-CHED
dihydroxy	I-CHED
-	I-CHED
1H	I-CHED
-	I-CHED
2	I-CHED
-	I-CHED
benzo	I-CHED
pyran	I-CHED
hydrochloride	I-CHED
)	O
seems	O
limited	O
because	O
of	O
their	O
duration	O
of	O
action	O
,	O
which	O
is	O
too	O
short	O
for	O
SKF	B-CHED
-	I-CHED
82958	I-CHED
(	O
<	O
1	O
hr	O
)	O
and	O
too	O
long	O
for	O
A	B-CHED
-	I-CHED
77636	I-CHED
(	O
>	O
20	O
hr	O
,	O
leading	O
to	O
behavioral	O
tolerance	O
)	O
.	O

We	O
therefore	O
conducted	O
the	O
present	O
acute	O
dose	O
-	O
response	O
study	O
in	O
four	O
1	B-CHED
-	I-CHED
methyl	I-CHED
-	I-CHED
4	I-CHED
-	I-CHED
phenyl	I-CHED
-	I-CHED
1	I-CHED
,	I-CHED
2	I-CHED
,	I-CHED
3	I-CHED
,	I-CHED
6	I-CHED
-	I-CHED
tetrahydropyridine	I-CHED
(	O
MPTP	B-CHED
)	O
-	O
exposed	O
cynomolgus	O
monkeys	O
primed	O
to	O
exhibit	O
levodopa	B-CHED
-	O
induced	O
dyskinesias	O
to	O
evaluate	O
the	O
locomotor	O
and	O
dyskinetic	O
effects	O
on	O
challenge	O
with	O
four	O
doses	O
(	O
from	O
0	O
.	O
03	O
to	O
1	O
.	O
0	O
mg	O
/	O
kg	O
)	O
of	O
A	B-CHED
-	I-CHED
86929	I-CHED
(	O
[	B-CHED
-	I-CHED
]	I-CHED
-	I-CHED
[	I-CHED
5aR	I-CHED
,	I-CHED
11bS	I-CHED
]	I-CHED
-	I-CHED
4	I-CHED
,	I-CHED
5	I-CHED
,	I-CHED
5a	I-CHED
,	I-CHED
6	I-CHED
,	I-CHED
7	I-CHED
,	I-CHED
11b	I-CHED
-	I-CHED
hexahydro	I-CHED
-	I-CHED
2	I-CHED
-	I-CHED
propyl	I-CHED
-	I-CHED
3	I-CHED
-	I-CHED
thia	I-CHED
-	I-CHED
5	I-CHED
-	I-CHED
+	I-CHED
+	I-CHED
+	I-CHED
azacyclopent	I-CHED
-	I-CHED
1	I-CHED
-	I-CHED
ena	I-CHED
[	I-CHED
c	I-CHED
]	I-CHED
phenathrene	I-CHED
-	I-CHED
9	I-CHED
-	I-CHED
10	I-CHED
-	I-CHED
diol	I-CHED
)	O
,	O
a	O
selective	O
and	O
full	O
DA	B-CHED
D1	O
-	O
like	O
receptor	O
agonist	O
with	O
an	O
intermediate	O
duration	O
of	O
action	O
.	O

Levodopa	B-CHED
and	O
the	O
DA	B-CHED
D2	O
-	O
like	O
receptor	O
agonist	O
,	O
LY	B-CHED
-	I-CHED
171555	I-CHED
(	O
[	B-CHED
4aR	I-CHED
-	I-CHED
trans	I-CHED
]	I-CHED
-	I-CHED
4	I-CHED
,	I-CHED
4a	I-CHED
,	I-CHED
5	I-CHED
,	I-CHED
6	I-CHED
,	I-CHED
7	I-CHED
,	I-CHED
8	I-CHED
,	I-CHED
8a	I-CHED
,	I-CHED
9	I-CHED
-	I-CHED
o	I-CHED
-	I-CHED
dihydro	I-CHED
-	I-CHED
5n	I-CHED
-	I-CHED
propyl	I-CHED
-	I-CHED
2H	I-CHED
-	I-CHED
pyrazo	I-CHED
lo	I-CHED
-	I-CHED
3	I-CHED
-	I-CHED
4	I-CHED
-	I-CHED
quinoline	I-CHED
hydrochloride	I-CHED
)	O
were	O
also	O
used	O
for	O
comparison	O
.	O

Acute	O
administration	O
of	O
A	B-CHED
-	I-CHED
86929	I-CHED
was	O
as	O
efficacious	O
in	O
alleviating	O
MPTP	B-CHED
-	O
induced	O
parkinsonism	O
as	O
levodopa	B-CHED
and	O
LY	B-CHED
-	I-CHED
171555	I-CHED
,	O
but	O
was	O
less	O
likely	O
to	O
reproduce	O
the	O
levodopa	B-CHED
-	O
induced	O
dyskinesias	O
in	O
these	O
animals	O
than	O
with	O
either	O
LY	B-CHED
-	I-CHED
171555	I-CHED
or	O
subsequent	O
challenge	O
of	O
levodopa	B-CHED
.	O

Selective	O
stimulation	O
of	O
the	O
DA	B-CHED
D1	O
receptor	O
may	O
provide	O
better	O
integration	O
of	O
neural	O
inputs	O
transmitted	O
to	O
the	O
internal	O
segment	O
of	O
the	O
globus	O
pallidus	O
(	O
referred	O
to	O
as	O
the	O
basal	O
ganglia	O
output	O
)	O
compared	O
with	O
levodopa	B-CHED
and	O
selective	O
DA	B-CHED
D2	O
receptor	O
agonist	O
.	O

Potent	O
DA	B-CHED
D1	O
receptor	O
agents	O
with	O
an	O
intermediate	O
duration	O
of	O
efficacy	O
such	O
as	O
A	B-CHED
-	I-CHED
86929	I-CHED
(	O
approximately	O
4	O
hr	O
at	O
higher	O
doses	O
tested	O
)	O
are	O
potential	O
therapeutic	O
tools	O
in	O
PD	O
and	O
merit	O
further	O
attention	O
.	O

Neuropeptide	O
-	O
Y	O
immunoreactivity	O
in	O
the	O
pilocarpine	B-CHED
model	O
of	O
temporal	O
lobe	O
epilepsy	O
.	O

Neuropeptide	O
-	O
Y	O
(	O
NPY	O
)	O
is	O
expressed	O
by	O
granule	O
cells	O
and	O
mossy	O
fibres	O
of	O
the	O
hippocampal	O
dentate	O
gyrus	O
during	O
experimental	O
temporal	O
lobe	O
epilepsy	O
(	O
TLE	O
)	O
.	O

This	O
expression	O
may	O
represent	O
an	O
endogenous	O
damping	O
mechanism	O
since	O
NPY	O
has	O
been	O
shown	O
to	O
block	O
seizure	O
-	O
like	O
events	O
following	O
high	O
-	O
frequency	O
stimulation	O
in	O
hippocampal	O
slices	O
.	O

The	O
pilocarpine	B-CHED
(	O
PILO	B-CHED
)	O
model	O
of	O
epilepsy	O
is	O
characterized	O
by	O
an	O
acute	O
period	O
of	O
status	O
epilepticus	O
followed	O
by	O
spontaneous	O
recurrent	O
seizures	O
and	O
related	O
brain	O
damage	O
.	O

We	O
report	O
peroxidase	O
-	O
antiperoxidase	O
immunostaining	O
for	O
NPY	O
in	O
several	O
brain	O
regions	O
in	O
this	O
model	O
.	O

PILO	B-CHED
-	O
injected	O
animals	O
exhibited	O
NPY	O
immunoreactivity	O
in	O
the	O
region	O
of	O
the	O
mossy	O
fibre	O
terminals	O
,	O
in	O
the	O
dentate	O
gyrus	O
inner	O
molecular	O
layer	O
and	O
,	O
in	O
a	O
few	O
cases	O
,	O
within	O
presumed	O
granule	O
cells	O
.	O

NPY	O
immunoreactivity	O
was	O
also	O
dramatically	O
changed	O
in	O
the	O
entorhinal	O
cortex	O
,	O
amygdala	O
and	O
sensorimotor	O
areas	O
.	O

In	O
addition	O
,	O
PILO	B-CHED
injected	O
animals	O
exhibited	O
a	O
reduction	O
in	O
the	O
number	O
of	O
NPY	O
-	O
immunoreactive	O
interneurons	O
compared	O
with	O
controls	O
.	O

The	O
results	O
demonstrate	O
that	O
changes	O
in	O
NPY	O
expression	O
,	O
including	O
expression	O
in	O
the	O
granule	O
cells	O
and	O
mossy	O
fibres	O
and	O
the	O
loss	O
of	O
vulnerable	O
NPY	O
neurons	O
,	O
are	O
present	O
in	O
the	O
PILO	B-CHED
model	O
of	O
TLE	O
.	O

However	O
,	O
the	O
significance	O
of	O
this	O
changed	O
synthesis	O
of	O
NPY	O
remains	O
to	O
be	O
determined	O
.	O

Posteroventral	O
medial	O
pallidotomy	O
in	O
advanced	O
Parkinson	O
'	O
s	O
disease	O
.	O

BACKGROUND	O
:	O
Posteroventral	O
medial	O
pallidotomy	O
sometimes	O
produces	O
striking	O
improvement	O
in	O
patients	O
with	O
advanced	O
Parkinson	O
'	O
s	O
disease	O
,	O
but	O
the	O
studies	O
to	O
date	O
have	O
involved	O
small	O
numbers	O
of	O
patients	O
and	O
short	O
-	O
term	O
follow	O
-	O
up	O
.	O

METHODS	O
:	O
Forty	O
patients	O
with	O
Parkinson	O
'	O
s	O
disease	O
underwent	O
serial	O
,	O
detailed	O
assessments	O
both	O
after	O
drug	O
withdrawal	O
(	O
"	O
off	O
"	O
period	O
)	O
and	O
while	O
taking	O
their	O
optimal	O
medical	O
regimens	O
(	O
"	O
on	O
"	O
period	O
)	O
.	O

All	O
patients	O
were	O
examined	O
preoperatively	O
and	O
39	O
were	O
examined	O
at	O
six	O
months	O
;	O
27	O
of	O
the	O
patients	O
were	O
also	O
examined	O
at	O
one	O
year	O
,	O
and	O
11	O
at	O
two	O
years	O
.	O

RESULTS	O
:	O
The	O
percent	O
improvements	O
at	O
six	O
months	O
were	O
as	O
follows	O
:	O
off	O
-	O
period	O
score	O
for	O
overall	O
motor	O
function	O
,	O
28	O
percent	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
19	O
to	O
38	O
percent	O
)	O
,	O
with	O
most	O
of	O
the	O
improvement	O
in	O
the	O
contralateral	O
limbs	O
;	O
off	O
-	O
period	O
score	O
for	O
activities	O
of	O
daily	O
living	O
,	O
29	O
percent	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
19	O
to	O
39	O
percent	O
)	O
;	O
on	O
-	O
period	O
score	O
for	O
contralateral	O
dyskinesias	O
,	O
82	O
percent	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
72	O
to	O
91	O
percent	O
)	O
;	O
and	O
on	O
-	O
period	O
score	O
for	O
ipsilateral	O
dyskinesias	O
,	O
44	O
percent	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
29	O
to	O
59	O
percent	O
)	O
.	O

The	O
improvements	O
in	O
dyskinesias	O
and	O
the	O
total	O
scores	O
for	O
off	O
-	O
period	O
parkinsonism	O
,	O
contralateral	O
bradykinesia	O
,	O
and	O
rigidity	O
were	O
sustained	O
in	O
the	O
11	O
patients	O
examined	O
at	O
two	O
years	O
.	O

The	O
improvement	O
in	O
ipsilateral	O
dyskinesias	O
was	O
lost	O
after	O
one	O
year	O
,	O
and	O
the	O
improvements	O
in	O
postural	O
stability	O
and	O
gait	O
lasted	O
only	O
three	O
to	O
six	O
months	O
.	O

Approximately	O
half	O
the	O
patients	O
who	O
had	O
been	O
dependent	O
on	O
assistance	O
in	O
activities	O
of	O
daily	O
living	O
in	O
the	O
off	O
period	O
before	O
surgery	O
became	O
independent	O
after	O
surgery	O
.	O

The	O
complications	O
of	O
surgery	O
were	O
generally	O
well	O
tolerated	O
,	O
and	O
there	O
were	O
no	O
significant	O
changes	O
in	O
the	O
use	O
of	O
medication	O
.	O

CONCLUSIONS	O
:	O
In	O
late	O
-	O
stage	O
Parkinson	O
'	O
s	O
disease	O
,	O
pallidotomy	O
significantly	O
reduces	O
levodopa	B-CHED
-	O
induced	O
dyskinesias	O
and	O
off	O
-	O
period	O
disability	O
.	O

Much	O
of	O
the	O
benefit	O
is	O
sustained	O
at	O
two	O
years	O
,	O
although	O
some	O
improvements	O
,	O
such	O
as	O
those	O
on	O
the	O
ipsilateral	O
side	O
and	O
in	O
axial	O
symptoms	O
,	O
wane	O
within	O
the	O
first	O
year	O
.	O

The	O
on	O
-	O
period	O
symptoms	O
that	O
are	O
resistant	O
to	O
dopaminergic	O
therapy	O
do	O
not	O
respond	O
to	O
pallidotomy	O
.	O

Clarithromycin	B-CHED
-	O
induced	O
ventricular	O
tachycardia	O
.	O

Clarithromycin	B-CHED
is	O
a	O
relatively	O
new	O
macrolide	B-CHED
antibiotic	O
that	O
offers	O
twice	O
-	O
daily	O
dosing	O
.	O

It	O
differs	O
from	O
erythromycin	B-CHED
only	O
in	O
the	O
methylation	O
of	O
the	O
hydroxyl	O
group	O
at	O
position	O
6	O
.	O

Although	O
the	O
side	O
-	O
effect	O
profile	O
of	O
erythromycin	B-CHED
is	O
established	O
,	O
including	O
gastroenteritis	O
and	O
interactions	O
with	O
other	O
drugs	O
subject	O
to	O
hepatic	O
mixed	O
-	O
function	O
oxidase	O
metabolism	O
,	O
experience	O
with	O
the	O
newer	O
macrolides	B-CHED
is	O
still	O
being	O
recorded	O
.	O

Cardiotoxicity	O
has	O
been	O
demonstrated	O
after	O
both	O
intravenous	O
and	O
oral	O
administration	O
of	O
erythromycin	B-CHED
but	O
has	O
never	O
been	O
reported	O
with	O
the	O
newer	O
macrolides	B-CHED
.	O

We	O
report	O
a	O
case	O
of	O
ventricular	O
dysrhythmias	O
that	O
occurred	O
after	O
six	O
therapeutic	O
doses	O
of	O
clarithromycin	B-CHED
.	O

The	O
dysrhythmias	O
resolved	O
after	O
discontinuation	O
of	O
the	O
drug	O
.	O

Effect	O
of	O
glyceryl	B-CHED
trinitrate	I-CHED
on	O
the	O
sphincter	O
of	O
Oddi	O
spasm	O
evoked	O
by	O
prostigmine	B-CHED
-	O
morphine	B-CHED
administration	O
.	O

OBJECTIVE	O
:	O
In	O
this	O
study	O
the	O
effect	O
of	O
glyceryl	B-CHED
trinitrate	I-CHED
on	O
the	O
prostigmine	B-CHED
-	O
morphine	B-CHED
-	O
induced	O
sphincter	O
of	O
Oddi	O
spasm	O
was	O
evaluated	O
in	O
nine	O
female	O
patients	O
with	O
sphincter	O
of	O
Oddi	O
dyskinesia	O
.	O

METHOD	O
:	O
Sphincter	O
of	O
Oddi	O
spasm	O
was	O
induced	O
by	O
prostigmine	B-CHED
-	O
morphine	B-CHED
administration	O
(	O
0	O
.	O
5	O
mg	O
prostigmine	B-CHED
intramuscularly	O
and	O
10	O
mg	O
morphine	B-CHED
subcutaneously	O
)	O
and	O
visualized	O
by	O
quantitative	O
hepatobiliary	O
scintigraphy	O
.	O

The	O
entire	O
procedure	O
was	O
repeated	O
during	O
glyceryl	B-CHED
trinitrate	I-CHED
infusion	O
(	O
Nitrolingual	B-CHED
1	O
microg	O
/	O
kg	O
/	O
min	O
for	O
120	O
min	O
)	O
.	O

RESULTS	O
:	O
Prostigmine	B-CHED
-	O
morphine	B-CHED
provocation	O
caused	O
significant	O
increases	O
in	O
the	O
time	O
to	O
peak	O
activity	O
(	O
Tmax	O
)	O
over	O
the	O
hepatic	O
hilum	O
(	O
HH	O
:	O
34	O
.	O
33	O
+	O
/	O
-	O
5	O
.	O
05	O
vs	O
.	O
22	O
.	O
77	O
+	O
/	O
-	O
3	O
.	O
26	O
)	O
and	O
the	O
common	O
bile	O
duct	O
(	O
CBD	O
:	O
60	O
.	O
44	O
+	O
/	O
-	O
5	O
.	O
99	O
vs	O
.	O
40	O
.	O
0	O
+	O
/	O
-	O
2	O
.	O
88	O
)	O
and	O
in	O
the	O
half	O
-	O
time	O
of	O
excretion	O
(	O
T1	O
/	O
2	O
)	O
over	O
the	O
liver	O
parenchyma	O
(	O
LP	O
:	O
120	O
.	O
04	O
+	O
/	O
-	O
16	O
.	O
01	O
vs	O
.	O
27	O
.	O
37	O
+	O
/	O
-	O
2	O
.	O
19	O
)	O
,	O
HH	O
(	O
117	O
.	O
61	O
+	O
/	O
-	O
14	O
.	O
71	O
vs	O
.	O
31	O
.	O
85	O
+	O
/	O
-	O
3	O
.	O
99	O
)	O
and	O
CBD	O
(	O
158	O
.	O
11	O
+	O
/	O
-	O
9	O
.	O
18	O
vs	O
.	O
40	O
.	O
1	O
+	O
/	O
-	O
6	O
.	O
24	O
)	O
,	O
indicating	O
a	O
complete	O
spasm	O
at	O
the	O
level	O
of	O
the	O
sphincter	O
of	O
Oddi	O
.	O

Glyceryl	B-CHED
trinitrate	I-CHED
infusion	O
completely	O
normalized	O
the	O
prostigmine	B-CHED
-	O
morphine	B-CHED
-	O
induced	O
alterations	O
in	O
these	O
quantitative	O
parameters	O
(	O
TmaX	O
over	O
the	O
LP	O
:	O
11	O
.	O
33	O
+	O
/	O
-	O
1	O
.	O
13	O
;	O
over	O
the	O
HH	O
:	O
18	O
.	O
88	O
+	O
/	O
-	O
1	O
.	O
48	O
;	O
and	O
over	O
the	O
CBD	O
:	O
36	O
.	O
22	O
+	O
/	O
-	O
1	O
.	O
92	O
;	O
and	O
T1	O
/	O
2	O
over	O
the	O
LP	O
:	O
28	O
.	O
21	O
+	O
/	O
-	O
1	O
.	O
83	O
;	O
over	O
the	O
HH	O
:	O
33	O
.	O
42	O
+	O
/	O
-	O
3	O
.	O
10	O
;	O
and	O
over	O
the	O
CBD	O
:	O
41	O
.	O
66	O
+	O
/	O
-	O
6	O
.	O
33	O
)	O
,	O
suggesting	O
an	O
effective	O
sphincter	O
-	O
relaxing	O
effect	O
of	O
glyceryl	B-CHED
trinitrate	I-CHED
.	O

CONCLUSION	O
:	O
These	O
results	O
provide	O
the	O
first	O
evidence	O
of	O
the	O
effectiveness	O
of	O
glyceryl	B-CHED
trinitrate	I-CHED
on	O
the	O
morphine	B-CHED
-	O
induced	O
sphincter	O
of	O
Oddi	O
spasm	O
in	O
humans	O
.	O

Since	O
glyceryl	B-CHED
trinitrate	I-CHED
is	O
able	O
to	O
overcome	O
even	O
the	O
drastic	O
effect	O
of	O
morphine	B-CHED
,	O
it	O
might	O
be	O
of	O
relevance	O
in	O
the	O
treatment	O
of	O
sphincter	O
of	O
Oddi	O
dyskinesia	O
.	O

Immunopathology	O
of	O
penicillamine	B-CHED
-	O
induced	O
glomerular	O
disease	O
.	O

Four	O
patients	O
with	O
rheumatoid	O
arthritis	O
developed	O
heavy	O
proteinuria	O
after	O
five	O
to	O
12	O
months	O
of	O
treatment	O
with	O
D	B-CHED
-	I-CHED
penicillamine	I-CHED
.	O

Light	O
microscopy	O
of	O
renal	O
biopsy	O
samples	O
showed	O
minimal	O
glomerular	O
capillary	O
wall	O
thickening	O
and	O
mesangial	O
matrix	O
increase	O
,	O
or	O
no	O
departure	O
from	O
normal	O
.	O

Electron	O
microscopy	O
,	O
however	O
,	O
revealed	O
subepithelial	O
electron	O
-	O
dense	O
deposits	O
,	O
fusion	O
of	O
epithelial	O
cell	O
foot	O
processes	O
,	O
and	O
evidence	O
of	O
mesangial	O
cell	O
hyperactivity	O
.	O

Immunofluorescence	O
microscopy	O
demonstrated	O
granular	O
capillary	O
wall	O
deposits	O
of	O
IgG	O
and	O
C3	O
.	O

The	O
findings	O
were	O
similar	O
to	O
those	O
in	O
early	O
membranous	O
glomerulonephritis	O
,	O
differences	O
being	O
observed	O
however	O
in	O
the	O
results	O
of	O
staining	O
for	O
the	O
early	O
-	O
acting	O
complement	O
components	O
C1q	O
and	O
C4	O
.	O

It	O
is	O
tentatively	O
concluded	O
that	O
complement	O
was	O
activated	O
by	O
the	O
classical	O
pathway	O
.	O

Experimental	O
cranial	O
pain	O
elicited	O
by	O
capsaicin	B-CHED
:	O
a	O
PET	O
study	O
.	O

Using	O
a	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
study	O
it	O
was	O
shown	O
recently	O
that	O
in	O
migraine	O
without	O
aura	O
certain	O
areas	O
in	O
the	O
brain	O
stem	O
were	O
activated	O
during	O
the	O
headache	O
state	O
,	O
but	O
not	O
in	O
the	O
headache	O
free	O
interval	O
.	O

It	O
was	O
suggested	O
that	O
this	O
brain	O
stem	O
activation	O
is	O
inherent	O
to	O
the	O
migraine	O
attack	O
itself	O
and	O
represents	O
the	O
so	O
called	O
'	O
migraine	O
generator	O
'	O
.	O

To	O
test	O
this	O
hypothesis	O
we	O
performed	O
an	O
experimental	O
pain	O
study	O
in	O
seven	O
healthy	O
volunteers	O
,	O
using	O
the	O
same	O
positioning	O
in	O
the	O
PET	O
scanner	O
as	O
in	O
the	O
migraine	O
patients	O
.	O

A	O
small	O
amount	O
of	O
capsaicin	B-CHED
was	O
administered	O
subcutaneously	O
in	O
the	O
right	O
forehead	O
to	O
evoke	O
a	O
burning	O
painful	O
sensation	O
in	O
the	O
first	O
division	O
of	O
the	O
trigeminal	O
nerve	O
.	O

Increases	O
of	O
regional	O
cerebral	O
blood	O
flow	O
(	O
rCBF	O
)	O
were	O
found	O
bilaterally	O
in	O
the	O
insula	O
,	O
in	O
the	O
anterior	O
cingulate	O
cortex	O
,	O
the	O
cavernous	O
sinus	O
and	O
the	O
cerebellum	O
.	O

Using	O
the	O
same	O
stereotactic	O
space	O
limits	O
as	O
in	O
the	O
above	O
mentioned	O
migraine	O
study	O
no	O
brain	O
stem	O
activation	O
was	O
found	O
in	O
the	O
acute	O
pain	O
state	O
compared	O
to	O
the	O
pain	O
free	O
state	O
.	O

The	O
increase	O
of	O
activation	O
in	O
the	O
region	O
of	O
the	O
cavernous	O
sinus	O
however	O
,	O
suggests	O
that	O
this	O
structure	O
is	O
more	O
likely	O
to	O
be	O
involved	O
in	O
trigeminal	O
transmitted	O
pain	O
as	O
such	O
,	O
rather	O
than	O
in	O
a	O
specific	O
type	O
of	O
headache	O
as	O
was	O
suggested	O
for	O
cluster	O
headache	O
.	O

Value	O
of	O
methylprednisolone	B-CHED
in	O
prevention	O
of	O
the	O
arthralgia	O
-	O
myalgia	O
syndrome	O
associated	O
with	O
the	O
total	O
dose	O
infusion	O
of	O
iron	B-CHED
dextran	I-CHED
:	O
a	O
double	O
blind	O
randomized	O
trial	O
.	O

The	O
safety	O
and	O
efficacy	O
of	O
total	O
dose	O
infusion	O
(	O
TDI	O
)	O
of	O
iron	B-CHED
dextran	I-CHED
has	O
been	O
well	O
documented	O
.	O

In	O
40	O
%	O
of	O
treated	O
patients	O
,	O
an	O
arthralgia	O
-	O
myalgia	O
syndrome	O
develops	O
.	O

The	O
purpose	O
of	O
this	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
prospective	O
study	O
was	O
to	O
investigate	O
whether	O
intravenous	O
(	O
i	O
.	O
v	O
.	O
)	O
administration	O
of	O
methylprednisolone	B-CHED
(	O
MP	B-CHED
)	O
prevents	O
this	O
complication	O
.	O

Sixty	O
-	O
five	O
patients	O
,	O
34	O
women	O
and	O
31	O
men	O
,	O
ages	O
36	O
to	O
80	O
years	O
,	O
received	O
either	O
normal	O
saline	O
before	O
and	O
after	O
TDI	O
(	O
group	O
1	O
)	O
,	O
125	O
mg	O
i	O
.	O
v	O
.	O
MP	B-CHED
before	O
and	O
saline	O
after	O
TDI	O
(	O
group	O
2	O
)	O
,	O
or	O
125	O
mg	O
i	O
.	O
v	O
.	O
MP	B-CHED
before	O
and	O
after	O
TDI	O
(	O
group	O
3	O
)	O
.	O

Patients	O
were	O
observed	O
for	O
72	O
hours	O
and	O
reactions	O
were	O
recorded	O
and	O
graded	O
according	O
to	O
severity	O
.	O

Fifty	O
-	O
eight	O
percent	O
of	O
group	O
1	O
patients	O
,	O
33	O
%	O
of	O
group	O
2	O
,	O
and	O
26	O
%	O
of	O
group	O
3	O
had	O
reactions	O
to	O
TDI	O
.	O

The	O
severity	O
of	O
reactions	O
(	O
minimal	O
,	O
mild	O
,	O
and	O
moderate	O
,	O
respectively	O
)	O
was	O
as	O
follows	O
:	O
group	O
1	O
-	O
-	O
6	O
,	O
6	O
,	O
and	O
2	O
;	O
group	O
2	O
-	O
-	O
1	O
,	O
5	O
,	O
and	O
0	O
;	O
group	O
3	O
-	O
-	O
5	O
,	O
1	O
,	O
and	O
0	O
.	O

Data	O
were	O
analyzed	O
by	O
the	O
two	O
-	O
sided	O
Fisher	O
'	O
s	O
exact	O
test	O
using	O
95	O
%	O
confidence	O
intervals	O
with	O
the	O
approximation	O
of	O
Woolf	O
.	O

These	O
data	O
demonstrate	O
that	O
administration	O
of	O
MP	B-CHED
before	O
and	O
after	O
TDI	O
reduces	O
the	O
frequency	O
and	O
severity	O
of	O
the	O
arthralgia	O
-	O
myalgia	O
syndrome	O
.	O

We	O
conclude	O
that	O
125	O
mg	O
i	O
.	O
v	O
.	O
MP	B-CHED
should	O
be	O
given	O
routinely	O
before	O
and	O
after	O
TDI	O
of	O
iron	B-CHED
dextran	I-CHED
.	O

Prolongation	O
of	O
the	O
QT	O
interval	O
related	O
to	O
cisapride	B-CHED
-	O
diltiazem	B-CHED
interaction	O
.	O

Cisapride	B-CHED
,	O
a	O
cytochrome	O
P450	O
3A4	O
(	O
CYP3A4	O
)	O
substrate	O
,	O
is	O
widely	O
prescribed	O
for	O
the	O
treatment	O
of	O
gastrointestinal	O
motility	O
disorders	O
.	O

Prolongation	O
of	O
QT	O
interval	O
,	O
torsades	O
de	O
pointes	O
,	O
and	O
sudden	O
cardiac	O
death	O
have	O
been	O
reported	O
after	O
concomitant	O
administration	O
with	O
erythromycin	B-CHED
or	O
azole	B-CHED
antifungal	O
agents	O
,	O
but	O
not	O
with	O
other	O
CYP3A4	O
inhibitors	O
.	O

A	O
possible	O
drug	O
interaction	O
occurred	O
in	O
a	O
45	O
-	O
year	O
-	O
old	O
woman	O
who	O
was	O
taking	O
cisapride	B-CHED
for	O
gastroesophageal	O
reflux	O
disorder	O
and	O
diltiazem	B-CHED
,	O
an	O
agent	O
that	O
has	O
inhibitory	O
effect	O
on	O
CYP3A4	O
,	O
for	O
hypertension	O
.	O

The	O
patient	O
was	O
in	O
near	O
syncope	O
and	O
had	O
QT	O
-	O
interval	O
prolongation	O
.	O

After	O
discontinuing	O
cisapride	B-CHED
,	O
the	O
QT	O
interval	O
returned	O
to	O
normal	O
and	O
symptoms	O
did	O
not	O
recur	O
.	O

We	O
suggest	O
that	O
caution	O
be	O
taken	O
when	O
cisapride	B-CHED
is	O
prescribed	O
with	O
any	O
potent	O
inhibitor	O
of	O
CYP3A4	O
,	O
including	O
diltiazem	B-CHED
.	O

Cortical	O
motor	O
overactivation	O
in	O
parkinsonian	O
patients	O
with	O
L	B-CHED
-	I-CHED
dopa	I-CHED
-	O
induced	O
peak	O
-	O
dose	O
dyskinesia	O
.	O

We	O
have	O
studied	O
the	O
regional	O
cerebral	O
blood	O
flow	O
(	O
rCBF	O
)	O
changes	O
induced	O
by	O
the	O
execution	O
of	O
a	O
finger	O
-	O
to	O
-	O
thumb	O
opposition	O
motor	O
task	O
in	O
the	O
supplementary	O
and	O
primary	O
motor	O
cortex	O
of	O
two	O
groups	O
of	O
parkinsonian	O
patients	O
on	O
L	B-CHED
-	I-CHED
dopa	I-CHED
medication	O
,	O
the	O
first	O
one	O
without	O
L	B-CHED
-	I-CHED
dopa	I-CHED
induced	O
dyskinesia	O
(	O
n	O
=	O
23	O
)	O
and	O
the	O
other	O
with	O
moderate	O
peak	O
-	O
dose	O
dyskinesia	O
(	O
n	O
=	O
15	O
)	O
,	O
and	O
of	O
a	O
group	O
of	O
14	O
normal	O
subjects	O
.	O

Single	O
photon	O
emission	O
tomography	O
with	O
i	O
.	O
v	O
.	O
133Xe	O
was	O
used	O
to	O
measure	O
the	O
rCBF	O
changes	O
.	O

The	O
dyskinetic	O
parkinsonian	O
patients	O
exhibited	O
a	O
pattern	O
of	O
response	O
which	O
was	O
markedly	O
different	O
from	O
those	O
of	O
the	O
normal	O
subjects	O
and	O
non	O
-	O
dyskinetic	O
parkinsonian	O
patients	O
,	O
with	O
a	O
significant	O
overactivation	O
in	O
the	O
supplementary	O
motor	O
area	O
and	O
the	O
ipsi	O
-	O
and	O
contralateral	O
primary	O
motor	O
areas	O
.	O

These	O
results	O
are	O
compatible	O
with	O
the	O
hypothesis	O
that	O
an	O
hyperkinetic	O
abnormal	O
involuntary	O
movement	O
,	O
like	O
L	B-CHED
-	I-CHED
dopa	I-CHED
-	O
induced	O
peak	O
dose	O
dyskinesia	O
,	O
is	O
due	O
to	O
a	O
disinhibition	O
of	O
the	O
primary	O
and	O
associated	O
motor	O
cortex	O
secondary	O
to	O
an	O
excessive	O
outflow	O
of	O
the	O
pallidothalamocortical	O
motor	O
loop	O
.	O

Open	O
-	O
label	O
assessment	O
of	O
levofloxacin	B-CHED
for	O
the	O
treatment	O
of	O
acute	O
bacterial	O
sinusitis	O
in	O
adults	O
.	O

PURPOSE	O
:	O
To	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
levofloxacin	B-CHED
(	O
500	O
mg	O
orally	O
once	O
daily	O
for	O
10	O
to	O
14	O
days	O
)	O
in	O
treating	O
adult	O
outpatients	O
with	O
acute	O
bacterial	O
sinusitis	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
A	O
total	O
of	O
329	O
patients	O
enrolled	O
in	O
the	O
study	O
at	O
24	O
centers	O
.	O

All	O
patients	O
had	O
a	O
pre	O
-	O
therapy	O
Gram	O
'	O
s	O
stain	O
and	O
culture	O
of	O
sinus	O
exudate	O
obtained	O
by	O
antral	O
puncture	O
or	O
nasal	O
endoscopy	O
.	O

Clinical	O
response	O
was	O
assessed	O
on	O
the	O
basis	O
of	O
signs	O
and	O
symptoms	O
and	O
sinus	O
radiograph	O
or	O
computed	O
tomography	O
results	O
.	O

Microbiologic	O
cure	O
rates	O
were	O
determined	O
on	O
the	O
basis	O
of	O
presumed	O
plus	O
documented	O
eradication	O
of	O
the	O
pre	O
-	O
therapy	O
pathogen	O
(	O
s	O
)	O
.	O

RESULTS	O
:	O
The	O
most	O
common	O
pathogens	O
were	O
Haemophilus	O
influenzae	O
,	O
Streptococcus	O
pneumoniae	O
,	O
Staphylococcus	O
aureus	O
,	O
and	O
Moraxella	O
catarrhalis	O
.	O

Of	O
300	O
clinically	O
evaluable	O
patients	O
,	O
175	O
(	O
58	O
%	O
)	O
were	O
cured	O
and	O
90	O
(	O
30	O
%	O
)	O
were	O
improved	O
at	O
the	O
post	O
-	O
therapy	O
evaluation	O
,	O
resulting	O
in	O
a	O
clinical	O
success	O
rate	O
of	O
88	O
%	O
.	O

Thirty	O
-	O
five	O
patients	O
(	O
12	O
%	O
)	O
clinically	O
failed	O
treatment	O
.	O

The	O
microbiologic	O
eradication	O
rate	O
(	O
presumed	O
plus	O
documented	O
)	O
among	O
138	O
microbiologically	O
evaluable	O
patients	O
was	O
92	O
%	O
.	O

Microbiologic	O
eradication	O
rates	O
(	O
presumed	O
plus	O
documented	O
)	O
of	O
the	O
most	O
common	O
pathogens	O
ranged	O
from	O
93	O
%	O
(	O
M	O
.	O
catarrhalis	O
)	O
to	O
100	O
%	O
(	O
S	O
.	O
pneumoniae	O
)	O
at	O
the	O
post	O
-	O
therapy	O
visit	O
.	O

All	O
but	O
one	O
of	O
the	O
265	O
patients	O
who	O
were	O
cured	O
or	O
improved	O
at	O
post	O
-	O
therapy	O
returned	O
for	O
a	O
long	O
-	O
term	O
follow	O
-	O
up	O
visit	O
;	O
243	O
(	O
92	O
%	O
)	O
remained	O
well	O
4	O
to	O
6	O
weeks	O
after	O
therapy	O
;	O
and	O
21	O
(	O
8	O
%	O
)	O
had	O
a	O
relapse	O
of	O
symptoms	O
.	O

Adverse	O
events	O
considered	O
to	O
be	O
related	O
to	O
levofloxacin	B-CHED
administration	O
were	O
reported	O
by	O
29	O
patients	O
(	O
9	O
%	O
)	O
.	O

The	O
most	O
common	O
drug	O
-	O
related	O
adverse	O
events	O
were	O
diarrhea	O
,	O
flatulence	O
,	O
and	O
nausea	O
;	O
most	O
adverse	O
events	O
were	O
mild	O
to	O
moderate	O
in	O
severity	O
.	O

CONCLUSION	O
:	O
The	O
results	O
of	O
this	O
study	O
indicate	O
that	O
levofloxacin	B-CHED
500	O
mg	O
once	O
daily	O
is	O
an	O
effective	O
and	O
safe	O
treatment	O
for	O
acute	O
bacterial	O
sinusitis	O
.	O

Iatrogenic	O
risks	O
of	O
endometrial	O
carcinoma	O
after	O
treatment	O
for	O
breast	O
cancer	O
in	O
a	O
large	O
French	O
case	O
-	O
control	O
study	O
.	O

F	O
d	O
ration	O
Nationale	O
des	O
Centres	O
de	O
Lutte	O
Contre	O
le	O
Cancer	O
(	O
FNCLCC	O
)	O
.	O

Since	O
tamoxifen	B-CHED
is	O
widely	O
used	O
in	O
breast	O
cancer	O
treatment	O
and	O
has	O
been	O
proposed	O
for	O
the	O
prevention	O
of	O
breast	O
cancer	O
,	O
its	O
endometrial	O
iatrogenic	O
effects	O
must	O
be	O
carefully	O
examined	O
.	O

We	O
have	O
investigated	O
the	O
association	O
between	O
endometrial	O
cancer	O
and	O
tamoxifen	B-CHED
use	O
or	O
other	O
treatments	O
in	O
women	O
treated	O
for	O
breast	O
cancer	O
in	O
a	O
case	O
-	O
control	O
study	O
.	O

Cases	O
of	O
endometrial	O
cancer	O
diagnosed	O
after	O
breast	O
cancer	O
(	O
n	O
=	O
135	O
)	O
and	O
467	O
controls	O
matched	O
for	O
age	O
,	O
year	O
of	O
diagnosis	O
of	O
breast	O
cancer	O
and	O
hospital	O
and	O
survival	O
time	O
with	O
an	O
intact	O
uterus	O
were	O
included	O
.	O

Women	O
who	O
had	O
received	O
tamoxifen	B-CHED
were	O
significantly	O
more	O
likely	O
to	O
have	O
endometrial	O
cancer	O
diagnosed	O
than	O
those	O
who	O
had	O
not	O
(	O
crude	O
relative	O
risk	O
=	O
4	O
.	O
9	O
,	O
p	O
=	O
0	O
.	O
0001	O
)	O
.	O

Univariate	O
and	O
adjusted	O
analyses	O
showed	O
that	O
the	O
risk	O
increased	O
with	O
the	O
length	O
of	O
treatment	O
(	O
p	O
=	O
0	O
.	O
0001	O
)	O
or	O
the	O
cumulative	O
dose	O
of	O
tamoxifen	B-CHED
received	O
(	O
p	O
=	O
0	O
.	O
0001	O
)	O
,	O
irrespective	O
of	O
the	O
daily	O
dose	O
.	O

Women	O
who	O
had	O
undergone	O
pelvic	O
radiotherapy	O
also	O
had	O
a	O
higher	O
risk	O
(	O
crude	O
relative	O
risk	O
=	O
7	O
.	O
8	O
,	O
p	O
=	O
0	O
.	O
0001	O
)	O
.	O

After	O
adjusting	O
for	O
confounding	O
factors	O
,	O
the	O
risk	O
was	O
higher	O
for	O
tamoxifen	B-CHED
users	O
(	O
p	O
=	O
0	O
.	O
0012	O
)	O
,	O
treatment	O
for	O
more	O
than	O
3	O
years	O
(	O
all	O
p	O
<	O
0	O
.	O
03	O
)	O
and	O
pelvic	O
radiotherapy	O
(	O
p	O
=	O
0	O
.	O
012	O
)	O
.	O

Women	O
who	O
had	O
endometrial	O
cancer	O
and	O
had	O
received	O
tamoxifen	B-CHED
had	O
more	O
advanced	O
disease	O
and	O
poorer	O
prognosis	O
than	O
those	O
with	O
endometrial	O
cancer	O
who	O
had	O
not	O
received	O
this	O
treatment	O
.	O

Our	O
results	O
suggest	O
a	O
causal	O
role	O
of	O
tamoxifen	B-CHED
in	O
endometrial	O
cancer	O
,	O
particularly	O
when	O
used	O
as	O
currently	O
proposed	O
for	O
breast	O
cancer	O
prevention	O
.	O

Pelvic	O
radiotherapy	O
may	O
be	O
an	O
additional	O
iatrogenic	O
factor	O
for	O
women	O
with	O
breast	O
cancer	O
.	O

Endometrial	O
cancers	O
diagnosed	O
in	O
women	O
treated	O
with	O
tamoxifen	B-CHED
have	O
poorer	O
prognosis	O
.	O

Women	O
who	O
receive	O
tamoxifen	B-CHED
for	O
breast	O
cancer	O
should	O
be	O
offered	O
gynaecological	O
surveillance	O
during	O
and	O
after	O
treatment	O
.	O

A	O
long	O
-	O
term	O
evaluation	O
of	O
the	O
risk	O
-	O
benefit	O
ratio	O
of	O
tamoxifen	B-CHED
as	O
a	O
preventive	O
treatment	O
for	O
breast	O
cancer	O
is	O
clearly	O
warranted	O
.	O

Contribution	O
of	O
the	O
glycine	B-CHED
site	O
of	O
NMDA	B-CHED
receptors	O
in	O
rostral	O
and	O
intermediate	O
-	O
caudal	O
parts	O
of	O
the	O
striatum	O
to	O
the	O
regulation	O
of	O
muscle	O
tone	O
in	O
rats	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
assess	O
the	O
contribution	O
of	O
the	O
glycine	B-CHED
site	O
of	O
NMDA	B-CHED
receptors	O
in	O
the	O
striatum	O
to	O
the	O
regulation	O
of	O
muscle	O
tone	O
.	O

Muscle	O
tone	O
was	O
examined	O
using	O
a	O
combined	O
mechanoand	O
electromyographic	O
method	O
,	O
which	O
measured	O
simultaneously	O
the	O
muscle	O
resistance	O
(	O
MMG	O
)	O
of	O
the	O
rat	O
'	O
s	O
hind	O
foot	O
to	O
passive	O
extension	O
and	O
flexion	O
in	O
the	O
ankle	O
joint	O
and	O
the	O
electromyographic	O
activity	O
(	O
EMG	O
)	O
of	O
the	O
antagonistic	O
muscles	O
of	O
that	O
joint	O
:	O
gastrocnemius	O
and	O
tibialis	O
anterior	O
.	O

Muscle	O
rigidity	O
was	O
induced	O
by	O
haloperidol	B-CHED
(	O
2	O
.	O
5	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
.	O

5	B-CHED
,	I-CHED
7	I-CHED
-	I-CHED
dichlorokynurenic	I-CHED
acid	I-CHED
(	O
5	B-CHED
,	I-CHED
7	I-CHED
-	I-CHED
DCKA	I-CHED
)	O
,	O
a	O
selective	O
glycine	B-CHED
site	O
antagonist	O
,	O
injected	O
in	O
doses	O
of	O
2	O
.	O
5	O
and	O
4	O
.	O
5	O
microg	O
/	O
0	O
.	O
5	O
microl	O
bilaterally	O
,	O
into	O
the	O
rostral	O
region	O
of	O
the	O
striatum	O
,	O
decreased	O
both	O
the	O
haloperidol	B-CHED
-	O
induced	O
muscle	O
rigidity	O
(	O
MMG	O
)	O
and	O
the	O
enhanced	O
electromyographic	O
activity	O
(	O
EMG	O
)	O
.	O

5	B-CHED
,	I-CHED
7	I-CHED
-	I-CHED
DCKA	I-CHED
injected	O
bilaterally	O
in	O
a	O
dose	O
of	O
4	O
.	O
5	O
microg	O
/	O
0	O
.	O
5	O
microl	O
into	O
the	O
intermediate	O
-	O
caudal	O
region	O
of	O
the	O
striatum	O
of	O
rats	O
not	O
pretreated	O
with	O
haloperidol	B-CHED
had	O
no	O
effect	O
on	O
the	O
muscle	O
tone	O
.	O

The	O
present	O
results	O
suggest	O
that	O
blockade	O
of	O
the	O
glycine	B-CHED
site	O
of	O
NMDA	B-CHED
receptors	O
in	O
the	O
rostral	O
part	O
of	O
the	O
striatum	O
may	O
be	O
mainly	O
responsible	O
for	O
the	O
antiparkinsonian	O
action	O
of	O
this	O
drug	O
.	O

Carboplatin	B-CHED
toxic	O
effects	O
on	O
the	O
peripheral	O
nervous	O
system	O
of	O
the	O
rat	O
.	O

BACKGROUND	O
:	O
The	O
most	O
striking	O
of	O
carboplatin	B-CHED
'	O
s	O
advantages	O
(	O
CBDCA	B-CHED
)	O
over	O
cisplatin	B-CHED
(	O
CDDP	B-CHED
)	O
is	O
its	O
markedly	O
reduced	O
rate	O
of	O
neurotoxic	O
effects	O
.	O

However	O
,	O
the	O
use	O
of	O
CBDCA	B-CHED
higher	O
-	O
intensity	O
schedules	O
and	O
the	O
association	O
with	O
other	O
neurotoxic	O
drugs	O
in	O
polychemotherapy	O
may	O
cause	O
some	O
concern	O
about	O
its	O
safety	O
with	O
respect	O
to	O
peripheral	O
nervous	O
system	O
damage	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Two	O
different	O
schedules	O
of	O
CBDCA	B-CHED
administration	O
(	O
10	O
mg	O
/	O
kg	O
and	O
15	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
twice	O
a	O
week	O
for	O
nine	O
times	O
)	O
were	O
evaluated	O
in	O
Wistar	O
rats	O
.	O

Neurotoxicity	O
was	O
assessed	O
for	O
behavioral	O
(	O
tail	O
-	O
flick	O
test	O
)	O
,	O
neurophysiological	O
(	O
nerve	O
conduction	O
velocity	O
in	O
the	O
tail	O
nerve	O
)	O
,	O
morphological	O
,	O
morphometrical	O
and	O
analytical	O
effects	O
.	O

RESULTS	O
:	O
CBDCA	B-CHED
administration	O
induced	O
dose	O
-	O
dependent	O
peripheral	O
neurotoxicity	O
.	O

Pain	O
perception	O
and	O
nerve	O
conduction	O
velocity	O
in	O
the	O
tail	O
were	O
significantly	O
impaired	O
,	O
particularly	O
after	O
the	O
high	O
-	O
dose	O
treatment	O
.	O

The	O
dorsal	O
root	O
ganglia	O
sensory	O
neurons	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
satellite	O
cells	O
showed	O
the	O
same	O
changes	O
as	O
those	O
induced	O
by	O
CDDP	B-CHED
,	O
mainly	O
affecting	O
the	O
nucleus	O
and	O
nucleolus	O
of	O
ganglionic	O
sensory	O
neurons	O
.	O

Moreover	O
,	O
significant	O
amounts	O
of	O
platinum	B-CHED
were	O
detected	O
in	O
the	O
dorsal	O
root	O
ganglia	O
and	O
kidney	O
after	O
CBDCA	B-CHED
treatment	O
.	O

CONCLUSIONS	O
:	O
CBDCA	B-CHED
is	O
neurotoxic	O
in	O
our	O
model	O
,	O
and	O
the	O
type	O
of	O
pathological	O
changes	O
it	O
induces	O
are	O
so	O
closely	O
similar	O
to	O
those	O
caused	O
by	O
CDDP	B-CHED
that	O
it	O
is	O
probable	O
that	O
neurotoxicity	O
is	O
induced	O
in	O
the	O
two	O
drugs	O
by	O
the	O
same	O
mechanism	O
.	O

This	O
model	O
can	O
be	O
used	O
alone	O
or	O
in	O
combination	O
with	O
other	O
drugs	O
to	O
explore	O
the	O
effect	O
of	O
CBDCA	B-CHED
on	O
the	O
peripheral	O
nervous	O
system	O
.	O

Effects	O
of	O
cisapride	B-CHED
on	O
symptoms	O
and	O
postcibal	O
small	O
-	O
bowel	O
motor	O
function	O
in	O
patients	O
with	O
irritable	O
bowel	O
syndrome	O
.	O

BACKGROUND	O
:	O
Irritable	O
bowel	O
syndrome	O
is	O
a	O
common	O
cause	O
of	O
abdominal	O
pain	O
and	O
discomfort	O
and	O
may	O
be	O
related	O
to	O
disordered	O
gastrointestinal	O
motility	O
.	O

Our	O
aim	O
was	O
to	O
assess	O
the	O
effects	O
of	O
long	O
-	O
term	O
treatment	O
with	O
a	O
prokinetic	O
agent	O
,	O
cisapride	B-CHED
,	O
on	O
postprandial	O
jejunal	O
motility	O
and	O
symptoms	O
in	O
the	O
irritable	O
bowel	O
syndrome	O
(	O
IBS	O
)	O
.	O

METHODS	O
:	O
Thirty	O
-	O
eight	O
patients	O
with	O
IBS	O
(	O
constipation	O
-	O
predominant	O
,	O
n	O
=	O
17	O
;	O
diarrhoea	O
-	O
predominant	O
,	O
n	O
=	O
21	O
)	O
underwent	O
24	O
-	O
h	O
ambulatory	O
jejunal	O
manometry	O
before	O
and	O
after	O
12	O
week	O
'	O
s	O
treatment	O
[	O
cisapride	B-CHED
,	O
5	O
mg	O
three	O
times	O
daily	O
(	O
n	O
=	O
19	O
)	O
or	O
placebo	O
(	O
n	O
=	O
19	O
)	O
]	O
.	O

RESULTS	O
:	O
In	O
diarrhoea	O
-	O
predominant	O
patients	O
significant	O
differences	O
in	O
contraction	O
characteristics	O
were	O
observed	O
between	O
the	O
cisapride	B-CHED
and	O
placebo	O
groups	O
.	O

In	O
cisapride	B-CHED
-	O
treated	O
diarrhoea	O
-	O
predominant	O
patients	O
the	O
mean	O
contraction	O
amplitude	O
was	O
higher	O
(	O
29	O
.	O
3	O
+	O
/	O
-	O
3	O
.	O
2	O
versus	O
24	O
.	O
9	O
+	O
/	O
-	O
2	O
.	O
6	O
mm	O
Hg	O
,	O
cisapride	B-CHED
versus	O
placebo	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
;	O
pretreatment	O
,	O
25	O
.	O
7	O
+	O
/	O
-	O
6	O
.	O
0	O
mm	O
Hg	O
)	O
,	O
the	O
mean	O
contraction	O
duration	O
longer	O
(	O
3	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
2	O
versus	O
3	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
2	O
sec	O
,	O
cisapride	B-CHED
versus	O
placebo	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
;	O
pretreatment	O
,	O
3	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
5	O
sec	O
)	O
,	O
and	O
the	O
mean	O
contraction	O
frequency	O
lower	O
(	O
2	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
2	O
versus	O
2	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
4	O
cont	O
.	O
/	O
min	O
,	O
cisapride	B-CHED
versus	O
placebo	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
;	O
pretreatment	O
,	O
2	O
.	O
5	O
+	O
/	O
-	O
1	O
.	O
1	O
cont	O
.	O
/	O
min	O
]	O
than	O
patients	O
treated	O
with	O
placebo	O
.	O

No	O
significant	O
differences	O
in	O
jejunal	O
motility	O
were	O
found	O
in	O
the	O
constipation	O
-	O
predominant	O
IBS	O
group	O
.	O

Symptoms	O
were	O
assessed	O
by	O
using	O
a	O
visual	O
analogue	O
scale	O
before	O
and	O
after	O
treatment	O
.	O

Symptom	O
scores	O
relating	O
to	O
the	O
severity	O
of	O
constipation	O
were	O
lower	O
in	O
cisapride	B-CHED
-	O
treated	O
constipation	O
-	O
predominant	O
IBS	O
patients	O
[	O
score	O
,	O
54	O
+	O
/	O
-	O
5	O
versus	O
67	O
+	O
/	O
-	O
14	O
mm	O
,	O
cisapride	B-CHED
versus	O
placebo	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
;	O
pretreatment	O
,	O
62	O
+	O
/	O
-	O
19	O
mm	O
]	O
.	O

Diarrhoea	O
-	O
predominant	O
IBS	O
patients	O
had	O
a	O
higher	O
pain	O
score	O
after	O
cisapride	B-CHED
therapy	O
[	O
score	O
,	O
55	O
+	O
/	O
-	O
15	O
versus	O
34	O
+	O
/	O
-	O
12	O
mm	O
,	O
cisapride	B-CHED
versus	O
placebo	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
;	O
pretreatment	O
,	O
67	O
+	O
/	O
-	O
19	O
mm	O
]	O
.	O

CONCLUSION	O
:	O
Cisapride	B-CHED
affects	O
jejunal	O
contraction	O
characteristics	O
and	O
some	O
symptoms	O
in	O
IBS	O
.	O

Prevention	O
of	O
breast	O
cancer	O
with	O
tamoxifen	B-CHED
:	O
preliminary	O
findings	O
from	O
the	O
Italian	O
randomised	O
trial	O
among	O
hysterectomised	O
women	O
.	O

Italian	O
Tamoxifen	B-CHED
Prevention	O
Study	O
.	O

BACKGROUND	O
:	O
Tamoxifen	B-CHED
is	O
a	O
candidate	O
chemopreventive	O
agent	O
in	O
breast	O
cancer	O
,	O
although	O
the	O
drug	O
may	O
be	O
associated	O
with	O
the	O
development	O
of	O
endometrial	O
cancer	O
.	O

Therefore	O
we	O
did	O
a	O
trial	O
in	O
hysterectomised	O
women	O
of	O
tamoxifen	B-CHED
as	O
a	O
chemopreventive	O
.	O

METHODS	O
:	O
In	O
October	O
,	O
1992	O
,	O
we	O
started	O
a	O
double	O
-	O
blind	O
placebo	O
-	O
controlled	O
,	O
randomised	O
trial	O
of	O
tamoxifen	B-CHED
in	O
women	O
(	O
mainly	O
in	O
Italy	O
)	O
who	O
did	O
not	O
have	O
breast	O
cancer	O
and	O
who	O
had	O
had	O
a	O
hysterectomy	O
.	O

Women	O
were	O
randomised	O
to	O
receive	O
tamoxifen	B-CHED
20	O
mg	O
per	O
day	O
or	O
placebo	O
,	O
both	O
orally	O
for	O
5	O
years	O
.	O

The	O
original	O
plan	O
was	O
to	O
follow	O
the	O
intervention	O
phase	O
by	O
5	O
years	O
'	O
follow	O
-	O
up	O
.	O

In	O
June	O
,	O
1997	O
,	O
the	O
trialists	O
and	O
the	O
data	O
-	O
monitoring	O
committee	O
decided	O
to	O
end	O
recruitment	O
primarily	O
because	O
of	O
the	O
number	O
of	O
women	O
dropping	O
out	O
of	O
the	O
study	O
.	O

Recruitment	O
ended	O
on	O
July	O
11	O
,	O
1997	O
,	O
and	O
the	O
study	O
will	O
continue	O
as	O
planned	O
.	O

The	O
primary	O
endpoints	O
are	O
the	O
occurrence	O
of	O
and	O
deaths	O
from	O
breast	O
cancer	O
.	O

This	O
preliminary	O
interim	O
analysis	O
is	O
based	O
on	O
intention	O
-	O
to	O
-	O
treat	O
.	O

FINDINGS	O
:	O
5408	O
women	O
were	O
randomised	O
;	O
participating	O
women	O
have	O
a	O
median	O
follow	O
-	O
up	O
of	O
46	O
months	O
for	O
major	O
endpoints	O
.	O

41	O
cases	O
of	O
breast	O
cancer	O
occurred	O
so	O
far	O
;	O
there	O
have	O
been	O
no	O
deaths	O
from	O
breast	O
cancer	O
.	O

There	O
is	O
no	O
difference	O
in	O
breast	O
-	O
cancer	O
frequency	O
between	O
the	O
placebo	O
(	O
22	O
cases	O
)	O
and	O
tamoxifen	B-CHED
(	O
19	O
)	O
arms	O
.	O

There	O
is	O
a	O
statistically	O
significant	O
reduction	O
of	O
breast	O
cancer	O
among	O
women	O
receiving	O
tamoxifen	B-CHED
who	O
also	O
used	O
hormone	O
-	O
replacement	O
therapy	O
during	O
the	O
trial	O
:	O
among	O
390	O
women	O
on	O
such	O
therapy	O
and	O
allocated	O
to	O
placebo	O
,	O
we	O
found	O
eight	O
cases	O
of	O
breast	O
cancer	O
compared	O
with	O
one	O
case	O
among	O
362	O
women	O
allocated	O
to	O
tamoxifen	B-CHED
.	O

Compared	O
with	O
the	O
placebo	O
group	O
,	O
there	O
was	O
a	O
significantly	O
increased	O
risk	O
of	O
vascular	O
events	O
and	O
hypertriglyceridaemia	O
among	O
women	O
on	O
tamoxifen	B-CHED
.	O

INTERPRETATION	O
:	O
Although	O
this	O
preliminary	O
analysis	O
has	O
low	O
power	O
,	O
in	O
this	O
cohort	O
of	O
women	O
at	O
low	O
-	O
to	O
-	O
normal	O
risk	O
of	O
breast	O
cancer	O
,	O
the	O
postulated	O
protective	O
effects	O
of	O
tamoxifen	B-CHED
are	O
not	O
yet	O
apparent	O
.	O

Women	O
using	O
hormone	O
-	O
replacement	O
therapy	O
appear	O
to	O
have	O
benefited	O
from	O
use	O
of	O
tamoxifen	B-CHED
.	O

There	O
were	O
no	O
deaths	O
from	O
breast	O
cancer	O
recorded	O
in	O
women	O
in	O
the	O
study	O
.	O

It	O
is	O
essential	O
to	O
continue	O
follow	O
-	O
up	O
to	O
quantify	O
the	O
long	O
-	O
term	O
risks	O
and	O
benefits	O
of	O
tamoxifen	B-CHED
therapy	O
.	O

Epileptogenic	O
activity	O
of	O
folic	B-CHED
acid	I-CHED
after	O
drug	O
induces	O
SLE	O
(	O
folic	B-CHED
acid	I-CHED
and	O
epilepsy	O
)	O

OBJECTIVE	O
:	O
To	O
study	O
the	O
effect	O
of	O
folic	B-CHED
acid	I-CHED
-	O
containing	O
multivitamin	O
supplementation	O
in	O
epileptic	O
women	O
before	O
and	O
during	O
pregnancy	O
in	O
order	O
to	O
determine	O
the	O
rate	O
of	O
structural	O
birth	O
defects	O
and	O
epilepsy	O
-	O
related	O
side	O
effects	O
.	O

STUDY	O
DESIGN	O
:	O
First	O
a	O
randomised	O
trial	O
,	O
later	O
periconception	O
care	O
including	O
in	O
total	O
12225	O
females	O
.	O

RESULTS	O
:	O
Of	O
60	O
epileptic	O
women	O
with	O
periconceptional	O
folic	B-CHED
acid	I-CHED
(	O
0	O
.	O
8	O
mg	O
)	O
-	O
containing	O
multivitamin	O
supplementation	O
,	O
no	O
one	O
developed	O
epilepsy	O
-	O
related	O
side	O
effects	O
during	O
the	O
periconception	O
period	O
.	O

One	O
epileptic	O
woman	O
delivered	O
a	O
newborn	O
with	O
cleft	O
lip	O
and	O
palate	O
.	O

Another	O
patient	O
exhibited	O
with	O
a	O
cluster	O
of	O
seizures	O
after	O
the	O
periconception	O
period	O
using	O
another	O
multivitamin	O
.	O

This	O
22	O
-	O
year	O
-	O
old	O
epileptic	O
woman	O
was	O
treated	O
continuously	O
by	O
carbamazepine	B-CHED
and	O
a	O
folic	B-CHED
acid	I-CHED
(	O
1	O
mg	O
)	O
-	O
containing	O
multivitamin	O
from	O
the	O
20th	O
week	O
of	O
gestation	O
.	O

She	O
developed	O
status	O
epilepticus	O
and	O
later	O
symptoms	O
of	O
systemic	O
lupus	O
erythematodes	O
.	O

Her	O
pregnancy	O
ended	O
with	O
stillbirth	O
.	O

CONCLUSIONS	O
:	O
The	O
epileptic	O
pregnant	O
patient	O
'	O
s	O
autoimmune	O
disease	O
(	O
probably	O
drug	O
-	O
induced	O
lupus	O
)	O
could	O
damage	O
the	O
blood	O
-	O
brain	O
barrier	O
,	O
therefore	O
the	O
therapeutic	O
dose	O
(	O
>	O
or	O
=	O
1	O
mg	O
)	O
of	O
folic	B-CHED
acid	I-CHED
triggered	O
a	O
cluster	O
of	O
seizures	O
.	O

Physiological	O
dose	O
(	O
<	O
1	O
mg	O
)	O
of	O
folic	B-CHED
acid	I-CHED
both	O
in	O
healthy	O
and	O
60	O
epileptic	O
women	O
,	O
all	O
without	O
any	O
autoimmune	O
disease	O
,	O
did	O
not	O
increase	O
the	O
risk	O
for	O
epileptic	O
seizures	O
.	O

Stroke	O
and	O
cocaine	B-CHED
or	O
amphetamine	B-CHED
use	O
.	O

The	O
association	O
of	O
cocaine	B-CHED
and	O
amphetamine	B-CHED
use	O
with	O
hemorrhagic	O
and	O
ischemic	O
stroke	O
is	O
based	O
almost	O
solely	O
on	O
data	O
from	O
case	O
series	O
.	O

The	O
limited	O
number	O
of	O
epidemiologic	O
studies	O
of	O
stroke	O
and	O
use	O
of	O
cocaine	B-CHED
and	O
/	O
or	O
amphetamine	B-CHED
have	O
been	O
done	O
in	O
settings	O
that	O
serve	O
mostly	O
the	O
poor	O
and	O
/	O
or	O
minorities	O
.	O

This	O
case	O
-	O
control	O
study	O
was	O
conducted	O
in	O
the	O
defined	O
population	O
comprising	O
members	O
of	O
Kaiser	O
Permanente	O
of	O
Northern	O
and	O
Southern	O
California	O
.	O

We	O
attempted	O
to	O
identify	O
all	O
incident	O
strokes	O
in	O
women	O
ages	O
15	O
-	O
44	O
years	O
during	O
a	O
3	O
-	O
year	O
period	O
using	O
hospital	O
admission	O
and	O
discharge	O
records	O
,	O
emergency	O
department	O
logs	O
,	O
and	O
payment	O
requests	O
for	O
out	O
-	O
of	O
-	O
plan	O
hospitalizations	O
.	O

We	O
selected	O
controls	O
,	O
matched	O
on	O
age	O
and	O
facility	O
of	O
usual	O
care	O
,	O
at	O
random	O
from	O
healthy	O
members	O
of	O
the	O
health	O
plan	O
.	O

We	O
obtained	O
information	O
in	O
face	O
-	O
to	O
-	O
face	O
interviews	O
.	O

There	O
were	O
347	O
confirmed	O
stroke	O
cases	O
and	O
1	O
,	O
021	O
controls	O
.	O

The	O
univariate	O
matched	O
odds	O
ratio	O
for	O
stroke	O
in	O
women	O
who	O
admitted	O
to	O
using	O
cocaine	B-CHED
and	O
/	O
or	O
amphetamine	B-CHED
was	O
8	O
.	O
5	O
(	O
95	O
%	O
confidence	O
interval	O
=	O
3	O
.	O
6	O
-	O
20	O
.	O
0	O
)	O
.	O

After	O
further	O
adjustment	O
for	O
potential	O
confounders	O
,	O
the	O
odds	O
ratio	O
in	O
women	O
who	O
reported	O
using	O
cocaine	B-CHED
and	O
/	O
or	O
amphetamine	B-CHED
was	O
7	O
.	O
0	O
(	O
95	O
%	O
confidence	O
interval	O
=	O
2	O
.	O
8	O
-	O
17	O
.	O
9	O
)	O
.	O

The	O
use	O
of	O
cocaine	B-CHED
and	O
/	O
or	O
amphetamine	B-CHED
is	O
a	O
strong	O
risk	O
factor	O
for	O
stroke	O
in	O
this	O
socioeconomically	O
heterogeneous	O
,	O
insured	O
urban	O
population	O
.	O

Acute	O
renal	O
failure	O
subsequent	O
to	O
the	O
administration	O
of	O
rifampicin	B-CHED
.	O

A	O
follow	O
-	O
up	O
study	O
of	O
cases	O
reported	O
earlier	O
.	O

A	O
clinical	O
presentation	O
is	O
made	O
of	O
a	O
2	O
-	O
3	O
year	O
follow	O
-	O
up	O
of	O
six	O
cases	O
of	O
acute	O
renal	O
failure	O
that	O
have	O
been	O
reported	O
earlier	O
.	O

The	O
patients	O
had	O
developed	O
transient	O
renal	O
failure	O
after	O
the	O
intermittent	O
administration	O
of	O
rifampicin	B-CHED
.	O

The	O
stage	O
of	O
olig	O
-	O
anuria	O
lasted	O
for	O
1	O
-	O
3	O
weeks	O
,	O
and	O
five	O
of	O
the	O
patients	O
were	O
treated	O
by	O
hemodialysis	O
.	O

Two	O
of	O
the	O
patients	O
died	O
due	O
to	O
unrelated	O
causes	O
during	O
the	O
follow	O
-	O
up	O
period	O
.	O

The	O
four	O
patients	O
re	O
-	O
examined	O
were	O
clinically	O
cured	O
.	O

Pathologic	O
findings	O
by	O
light	O
microscopy	O
and	O
immunofluorescence	O
at	O
biopsy	O
were	O
scarce	O
.	O

Nothing	O
abnormal	O
was	O
seen	O
by	O
electron	O
microscopy	O
in	O
two	O
of	O
the	O
cases	O
studied	O
.	O

Renal	O
function	O
was	O
normal	O
.	O

In	O
three	O
cases	O
the	O
excretion	O
at	O
131I	O
-	O
hippuran	O
renography	O
was	O
slightly	O
slowed	O
.	O

Although	O
in	O
the	O
acute	O
stage	O
the	O
renal	O
lesions	O
histologically	O
appeared	O
toxic	O
,	O
evidence	O
suggestive	O
of	O
an	O
immunological	O
mechanism	O
cannot	O
be	O
excluded	O
.	O

Chronic	O
effects	O
of	O
a	O
novel	O
synthetic	O
anthracycline	B-CHED
derivative	O
(	O
SM	B-CHED
-	I-CHED
5887	I-CHED
)	O
on	O
normal	O
heart	O
and	O
doxorubicin	B-CHED
-	O
induced	O
cardiomyopathy	O
in	O
beagle	O
dogs	O
.	O

This	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
chronic	O
cardiotoxic	O
potential	O
of	O
SM	B-CHED
-	I-CHED
5887	I-CHED
and	O
a	O
possible	O
deteriorating	O
effect	O
of	O
SM	B-CHED
-	I-CHED
5887	I-CHED
on	O
low	O
-	O
grade	O
cardiotoxicity	O
pre	O
-	O
induced	O
by	O
doxorubicin	B-CHED
in	O
beagle	O
dogs	O
.	O

In	O
the	O
chronic	O
treatment	O
,	O
beagle	O
dogs	O
of	O
each	O
sex	O
were	O
given	O
intravenously	O
once	O
every	O
3	O
weeks	O
,	O
either	O
a	O
sublethal	O
dose	O
of	O
doxorubicin	B-CHED
(	O
1	O
.	O
5	O
mg	O
/	O
kg	O
)	O
or	O
SM	B-CHED
-	I-CHED
5887	I-CHED
(	O
2	O
.	O
5	O
mg	O
/	O
kg	O
)	O
.	O

The	O
experiment	O
was	O
terminated	O
3	O
weeks	O
after	O
the	O
ninth	O
dosing	O
.	O

Animals	O
which	O
received	O
over	O
six	O
courses	O
of	O
doxorubicin	B-CHED
demonstrated	O
the	O
electrocardiogram	O
(	O
ECG	O
)	O
changes	O
,	O
decrease	O
of	O
blood	O
pressure	O
and	O
high	O
-	O
grade	O
histopathological	O
cardiomyopathy	O
,	O
while	O
animals	O
which	O
were	O
terminally	O
sacrificed	O
after	O
the	O
SM	B-CHED
-	I-CHED
5887	I-CHED
administration	O
did	O
not	O
show	O
any	O
changes	O
in	O
ECG	O
,	O
blood	O
pressure	O
and	O
histopathological	O
examinations	O
.	O

To	O
examine	O
a	O
possibly	O
deteriorating	O
cardiotoxic	O
effect	O
of	O
SM	B-CHED
-	I-CHED
5887	I-CHED
,	O
low	O
-	O
grade	O
cardiomyopathy	O
was	O
induced	O
in	O
dogs	O
by	O
four	O
courses	O
of	O
doxorubicin	B-CHED
(	O
1	O
.	O
5	O
mg	O
/	O
kg	O
)	O
.	O

Nine	O
weeks	O
after	O
pre	O
-	O
treatment	O
,	O
dogs	O
were	O
given	O
four	O
courses	O
of	O
either	O
doxorubicin	B-CHED
(	O
1	O
.	O
5	O
mg	O
/	O
kg	O
)	O
or	O
SM	B-CHED
-	I-CHED
5887	I-CHED
(	O
2	O
.	O
5	O
mg	O
/	O
kg	O
)	O
once	O
every	O
3	O
weeks	O
.	O

The	O
low	O
-	O
grade	O
cardiotoxic	O
changes	O
were	O
enhanced	O
by	O
the	O
additional	O
doxorubicin	B-CHED
treatment	O
.	O

On	O
the	O
contrary	O
,	O
the	O
SM	B-CHED
-	I-CHED
5887	I-CHED
treatment	O
did	O
not	O
progress	O
the	O
grade	O
of	O
cardiomyopathy	O
.	O

In	O
conclusion	O
,	O
SM	B-CHED
-	I-CHED
5887	I-CHED
does	O
not	O
have	O
any	O
potential	O
of	O
chronic	O
cardiotoxicity	O
and	O
deteriorating	O
effect	O
on	O
doxorubicin	B-CHED
-	O
induced	O
cardiotoxicity	O
in	O
dogs	O
.	O

Risk	O
for	O
valvular	O
heart	O
disease	O
among	O
users	O
of	O
fenfluramine	B-CHED
and	O
dexfenfluramine	B-CHED
who	O
underwent	O
echocardiography	O
before	O
use	O
of	O
medication	O
.	O

BACKGROUND	O
:	O
Because	O
uncontrolled	O
echocardiographic	O
surveys	O
suggested	O
that	O
up	O
to	O
30	O
%	O
to	O
38	O
%	O
of	O
users	O
of	O
fenfluramine	B-CHED
and	O
dexfenfluramine	B-CHED
had	O
valvular	O
disease	O
,	O
these	O
drugs	O
were	O
withdrawn	O
from	O
the	O
market	O
.	O

OBJECTIVE	O
:	O
To	O
determine	O
the	O
risk	O
for	O
new	O
or	O
worsening	O
valvular	O
abnormalities	O
among	O
users	O
of	O
fenfluramine	B-CHED
or	O
dexfenfluramine	B-CHED
who	O
underwent	O
echocardiography	O
before	O
they	O
began	O
to	O
take	O
these	O
medications	O
.	O

DESIGN	O
:	O
Cohort	O
study	O
.	O

SETTING	O
:	O
Academic	O
primary	O
care	O
practices	O
.	O

PATIENTS	O
:	O
46	O
patients	O
who	O
used	O
fenfluramine	B-CHED
or	O
dexfenfluramine	B-CHED
for	O
14	O
days	O
or	O
more	O
and	O
had	O
echocardiograms	O
obtained	O
before	O
therapy	O
.	O

MEASUREMENTS	O
:	O
Follow	O
-	O
up	O
echocardiography	O
.	O

The	O
primary	O
outcome	O
was	O
new	O
or	O
worsening	O
valvulopathy	O
,	O
defined	O
as	O
progression	O
of	O
either	O
aortic	O
or	O
mitral	O
regurgitation	O
by	O
at	O
least	O
one	O
degree	O
of	O
severity	O
and	O
disease	O
that	O
met	O
U	O
.	O
S	O
.	O

Food	O
and	O
Drug	O
Administration	O
criteria	O
(	O
at	O
least	O
mild	O
aortic	O
regurgitation	O
or	O
moderate	O
mitral	O
regurgitation	O
)	O
.	O

RESULTS	O
:	O
Two	O
patients	O
(	O
4	O
.	O
3	O
%	O
[	O
95	O
%	O
CI	O
,	O
0	O
.	O
6	O
%	O
to	O
14	O
.	O
8	O
%	O
]	O
)	O
receiving	O
fenfluramine	B-CHED
-	O
phentermine	B-CHED
developed	O
valvular	O
heart	O
disease	O
.	O

One	O
had	O
baseline	O
bicuspid	O
aortic	O
valve	O
and	O
mild	O
aortic	O
regurgitation	O
that	O
progressed	O
to	O
moderate	O
regurgitation	O
.	O

The	O
second	O
patient	O
developed	O
new	O
moderate	O
aortic	O
insufficiency	O
.	O

CONCLUSION	O
:	O
Users	O
of	O
diet	O
medications	O
are	O
at	O
risk	O
for	O
valvular	O
heart	O
disease	O
.	O

However	O
,	O
the	O
incidence	O
may	O
be	O
lower	O
than	O
that	O
reported	O
previously	O
.	O

Therapeutic	O
drug	O
monitoring	O
of	O
tobramycin	B-CHED
:	O
once	O
-	O
daily	O
versus	O
twice	O
-	O
daily	O
dosage	O
schedules	O
.	O

OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
effect	O
of	O
dosage	O
regimen	O
(	O
once	O
-	O
daily	O
vs	O
.	O
twice	O
-	O
daily	O
)	O
of	O
tobramicyn	B-CHED
on	O
steady	O
-	O
state	O
serum	O
concentrations	O
and	O
toxicity	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Patients	O
undergoing	O
treatment	O
with	O
i	O
.	O
v	O
.	O
tobramycin	B-CHED
(	O
4	O
mg	O
/	O
kg	O
/	O
day	O
)	O
were	O
randomised	O
to	O
two	O
groups	O
.	O

Group	O
OD	O
(	O
n	O
=	O
22	O
)	O
received	O
a	O
once	O
-	O
daily	O
dose	O
of	O
tobramycin	B-CHED
and	O
group	O
TD	O
(	O
n	O
=	O
21	O
)	O
received	O
the	O
same	O
dose	O
divided	O
into	O
two	O
doses	O
daily	O
.	O

Tobramycin	B-CHED
serum	O
concentrations	O
(	O
peak	O
and	O
trough	O
)	O
were	O
measured	O
by	O
enzyme	O
multiplied	O
immunoassay	O
.	O

The	O
renal	O
and	O
auditory	O
functions	O
of	O
the	O
patients	O
were	O
monitored	O
before	O
,	O
during	O
and	O
immediately	O
after	O
treatment	O
.	O

RESULTS	O
:	O
The	O
two	O
groups	O
were	O
comparable	O
with	O
respect	O
to	O
sex	O
,	O
age	O
,	O
body	O
weight	O
and	O
renal	O
function	O
.	O

No	O
statistically	O
significant	O
differences	O
were	O
found	O
in	O
mean	O
daily	O
dose	O
,	O
duration	O
of	O
treatment	O
,	O
or	O
cumulative	O
dose	O
.	O

Trough	O
concentrations	O
were	O
<	O
2	O
g	O
/	O
ml	O
in	O
the	O
two	O
groups	O
(	O
100	O
%	O
)	O
.	O

Peak	O
concentrations	O
were	O
>	O
6	O
microg	O
/	O
ml	O
in	O
100	O
%	O
of	O
the	O
OD	O
group	O
and	O
in	O
67	O
%	O
of	O
the	O
TD	O
group	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

Mean	O
peak	O
concentrations	O
were	O
markedly	O
different	O
:	O
11	O
.	O
00	O
+	O
/	O
-	O
2	O
.	O
89	O
microg	O
/	O
ml	O
in	O
OD	O
vs	O
.	O
6	O
.	O
53	O
+	O
/	O
-	O
1	O
.	O
45	O
microg	O
/	O
ml	O
in	O
TD	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

The	O
pharmacokinetics	O
parameters	O
were	O
:	O
Ke	O
,	O
(	O
0	O
.	O
15	O
+	O
/	O
-	O
0	O
.	O
03	O
/	O
h	O
in	O
OD	O
vs	O
.	O
0	O
.	O
24	O
+	O
/	O
-	O
0	O
.	O
06	O
/	O
h	O
in	O
TD	O
)	O
,	O
t1	O
/	O
2	O
,	O
(	O
4	O
.	O
95	O
+	O
/	O
-	O
1	O
.	O
41	O
h	O
in	O
OD	O
vs	O
.	O
3	O
.	O
07	O
+	O
/	O
-	O
0	O
.	O
71	O
h	O
in	O
TD	O
)	O
,	O
Vd	O
(	O
0	O
.	O
35	O
+	O
/	O
-	O
0	O
.	O
11	O
l	O
/	O
kg	O
in	O
OD	O
vs	O
.	O
0	O
.	O
33	O
+	O
/	O
-	O
0	O
.	O
09	O
l	O
/	O
kg	O
in	O
TD	O
)	O
,	O
Cl	O
(	O
0	O
.	O
86	O
+	O
/	O
-	O
0	O
.	O
29	O
ml	O
/	O
min	O
/	O
kg	O
in	O
OD	O
vs	O
.	O
1	O
.	O
28	O
+	O
/	O
-	O
0	O
.	O
33	O
ml	O
/	O
min	O
/	O
kg	O
in	O
TD	O
)	O
.	O

Increased	O
serum	O
creatinine	B-CHED
was	O
observed	O
in	O
73	O
%	O
of	O
patients	O
in	O
OD	O
versus	O
57	O
%	O
of	O
patients	O
in	O
TD	O
,	O
without	O
evidence	O
of	O
nephrotoxicity	O
.	O

In	O
TD	O
group	O
,	O
three	O
patients	O
developed	O
decreased	O
auditory	O
function	O
,	O
of	O
which	O
one	O
presented	O
with	O
an	O
auditory	O
loss	O
of	O
-	O
30	O
dB	O
,	O
whereas	O
in	O
the	O
OD	O
group	O
only	O
one	O
patient	O
presented	O
decreased	O
auditory	O
function	O
.	O

CONCLUSION	O
:	O
This	O
small	O
study	O
suggests	O
that	O
a	O
once	O
-	O
daily	O
dosing	O
regimen	O
of	O
tobramycin	B-CHED
is	O
at	O
least	O
as	O
effective	O
as	O
and	O
is	O
no	O
more	O
and	O
possibly	O
less	O
toxic	O
than	O
the	O
twice	O
-	O
daily	O
regimen	O
.	O

Using	O
a	O
single	O
-	O
dose	O
therapy	O
,	O
peak	O
concentration	O
determination	O
is	O
not	O
necessary	O
,	O
only	O
trough	O
samples	O
should	O
be	O
monitored	O
to	O
ensure	O
levels	O
below	O
2	O
microg	O
/	O
ml	O
.	O

Enhanced	O
bradycardia	O
induced	O
by	O
beta	O
-	O
adrenoceptor	O
antagonists	O
in	O
rats	O
pretreated	O
with	O
isoniazid	B-CHED
.	O

High	O
doses	O
of	O
isoniazid	B-CHED
increase	O
hypotension	O
induced	O
by	O
vasodilators	O
and	O
change	O
the	O
accompanying	O
reflex	O
tachycardia	O
to	O
bradycardia	O
,	O
an	O
interaction	O
attributed	O
to	O
decreased	O
synthesis	O
of	O
brain	O
gamma	B-CHED
-	I-CHED
aminobutyric	I-CHED
acid	I-CHED
(	O
GABA	B-CHED
)	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
possible	O
enhancement	O
by	O
isoniazid	B-CHED
of	O
bradycardia	O
induced	O
by	O
beta	O
-	O
adrenoceptor	O
antagonists	O
was	O
determined	O
in	O
rats	O
anaesthetised	O
with	O
chloralose	B-CHED
-	O
urethane	B-CHED
.	O

Isoniazid	B-CHED
significantly	O
increased	O
bradycardia	O
after	O
propranolol	B-CHED
,	O
pindolol	B-CHED
,	O
labetalol	B-CHED
and	O
atenolol	B-CHED
,	O
as	O
well	O
as	O
after	O
clonidine	B-CHED
,	O
but	O
not	O
after	O
hexamethonium	B-CHED
or	O
carbachol	B-CHED
.	O

Enhancement	O
was	O
not	O
observed	O
in	O
rats	O
pretreated	O
with	O
methylatropine	B-CHED
or	O
previously	O
vagotomised	O
.	O

These	O
results	O
are	O
compatible	O
with	O
interference	O
by	O
isoniazid	B-CHED
with	O
GABAergic	O
inhibition	O
of	O
cardiac	O
parasympathetic	O
tone	O
.	O

Such	O
interference	O
could	O
be	O
exerted	O
centrally	O
,	O
possibly	O
at	O
the	O
nucleus	O
ambiguus	O
,	O
or	O
peripherally	O
at	O
the	O
sinus	O
node	O
.	O

Structural	O
and	O
functional	O
impairment	O
of	O
mitochondria	O
in	O
adriamycin	B-CHED
-	O
induced	O
cardiomyopathy	O
in	O
mice	O
:	O
suppression	O
of	O
cytochrome	O
c	O
oxidase	O
II	O
gene	O
expression	O
.	O

The	O
use	O
of	O
adriamycin	B-CHED
(	O
ADR	B-CHED
)	O
in	O
cancer	O
chemotherapy	O
has	O
been	O
limited	O
due	O
to	O
its	O
cumulative	O
cardiovascular	O
toxicity	O
.	O

Earlier	O
observations	O
that	O
ADR	B-CHED
interacts	O
with	O
mitochondrial	O
cytochrome	O
c	O
oxidase	O
(	O
COX	O
)	O
and	O
suppresses	O
its	O
enzyme	O
activity	O
led	O
us	O
to	O
investigate	O
ADR	B-CHED
'	O
s	O
action	O
on	O
the	O
cardiovascular	O
functions	O
and	O
heart	O
mitochondrial	O
morphology	O
in	O
Balb	O
-	O
c	O
mice	O
i	O
.	O
p	O
.	O
treated	O
with	O
ADR	B-CHED
for	O
several	O
weeks	O
.	O

At	O
various	O
times	O
during	O
treatment	O
,	O
the	O
animals	O
were	O
assessed	O
for	O
cardiovascular	O
functions	O
by	O
electrocardiography	O
and	O
for	O
heart	O
tissue	O
damage	O
by	O
electron	O
microscopy	O
.	O

In	O
parallel	O
,	O
total	O
RNA	O
was	O
extracted	O
from	O
samples	O
of	O
dissected	O
heart	O
and	O
analyzed	O
by	O
Northern	O
blot	O
hybridization	O
to	O
determine	O
the	O
steady	O
-	O
state	O
level	O
of	O
three	O
RNA	O
transcripts	O
encoded	O
by	O
the	O
COXII	O
,	O
COXIII	O
,	O
and	O
COXIV	O
genes	O
.	O

Similarly	O
,	O
samples	O
obtained	O
from	O
the	O
liver	O
of	O
the	O
same	O
animals	O
were	O
analyzed	O
for	O
comparative	O
studies	O
.	O

Our	O
results	O
indicated	O
that	O
1	O
)	O
treatment	O
of	O
mice	O
with	O
ADR	B-CHED
caused	O
cardiovascular	O
arrhythmias	O
characterized	O
by	O
bradycardia	O
,	O
extension	O
of	O
ventricular	O
depolarization	O
time	O
(	O
tQRS	O
)	O
,	O
and	O
failure	O
of	O
QRS	O
at	O
high	O
concentrations	O
(	O
10	O
-	O
14	O
mg	O
/	O
kg	O
body	O
weight	O
cumulative	O
dose	O
)	O
;	O
2	O
)	O
the	O
heart	O
mitochondria	O
underwent	O
swelling	O
,	O
fusion	O
,	O
dissolution	O
,	O
and	O
/	O
or	O
disruption	O
of	O
mitochondrial	O
cristae	O
after	O
several	O
weeks	O
of	O
treatment	O
.	O

Such	O
abnormalities	O
were	O
not	O
observed	O
in	O
the	O
mitochondria	O
of	O
liver	O
tissue	O
;	O
and	O
3	O
)	O
among	O
the	O
three	O
genes	O
of	O
COX	O
enzyme	O
examined	O
,	O
only	O
COXII	O
gene	O
expression	O
was	O
suppressed	O
by	O
ADR	B-CHED
treatment	O
,	O
mainly	O
after	O
8	O
weeks	O
in	O
both	O
heart	O
and	O
liver	O
.	O

Knowing	O
that	O
heart	O
mitochondria	O
represent	O
almost	O
40	O
%	O
of	O
heart	O
muscle	O
by	O
weight	O
,	O
we	O
conclude	O
that	O
the	O
deteriorating	O
effects	O
of	O
ADR	B-CHED
on	O
cardiovascular	O
function	O
involve	O
mitochondrial	O
structural	O
and	O
functional	O
impairment	O
.	O

